-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 DYQyvgumaP1Gu4n4/5exgjVMXhlExbmEjil24B11WxhPbIg67sXNSp1AipxUrU6F
 48Q0wdSAw54NgbOckvYjrw==

<SEC-DOCUMENT>0001144204-10-002167.txt : 20100115
<SEC-HEADER>0001144204-10-002167.hdr.sgml : 20100115
<ACCEPTANCE-DATETIME>20100115105432
ACCESSION NUMBER:		0001144204-10-002167
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20100115
FILED AS OF DATE:		20100115
DATE AS OF CHANGE:		20100115

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		10529222

	BUSINESS ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
		BUSINESS PHONE:		972-8-930-4440

	MAIL ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v171490_6k.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!--Licensed to: trackball-->
    <!--Document Created using EDGARizer 4.0.6.4-->
    <!--Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved-->
    </head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNITED
STATES</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES
AND EXCHANGE COMMISSION</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Washington,
D.C. 20549</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
6-K</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Report
of Foreign Private Issuer</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to Rule 13a-16 or 15d-16</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of
the Securities Exchange Act of 1934</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the
month of January, 2010</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
File Number: <font style="DISPLAY: inline; FONT-WEIGHT: bold">000-51310</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">XTL Biopharmaceuticals Ltd. </font></font>

      <div>
        <hr style="COLOR: black" align="center" noshade size="1" width="30%">
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Translation
of registrant's name into English)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Kiryat
Weizmann Science Park</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3
Hasapir Street, Building 3, PO Box 370</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Rehovot 76100, Israel </font></font>

      <div>
        <hr style="COLOR: black" align="center" noshade size="1" width="30%">
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;(Address
of principal executive offices)</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
20-F&#160;<font style="DISPLAY: inline;" face="Wingdings">x&#160;
</font>Form 40-F <font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): ____</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): ____</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether by furnishing the information contained in this Form, the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes&#160;<font style="DISPLAY: inline;" face="Wingdings">o&#160; </font>No <font style="DISPLAY: inline;" face="Wingdings">x</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If &#8220;Yes&#8221;
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-<font style="DISPLAY: inline; TEXT-DECORATION: underline">N/A</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><br></div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
      <div>&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporation
by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated January 15,
2010 is hereby incorporated by reference into the registration statements on
Form F-3 (File No. 333-141529, File No. 333-147024 and File No. 333-153055)
filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission
on March 23, 2007, October 30, 2007 and August 15, 2008, respectively, and the
registration statements on Form S-8 (File No. 333-148085, File No. 333-148754
and File No. 333-154795) filed by XTL Biopharmaceuticals Ltd. with the
Securities and Exchange Commission on December 14, 2007, January 18, 2008, and
October 28, 2008, respectively.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
Biopharmaceuticals convenes an Extraordinary Shareholder Meeting for the
Approval of the XTL &#8211; Bio-Gal Agreement (via Xtepo Ltd.) and Share
Allocation</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Attached&#160;is
an English translation (from Hebrew) of the announcement and documents submitted
on the Tel Aviv Stock Exchange for convening an extraordinary shareholder
meeting, which includes the following:&#160;&#160;(a) <font style="DISPLAY: inline; FONT-STYLE: italic">A</font><font style="DISPLAY: inline; FONT-STYLE: italic">llocation Report</font>; (b) <font style="DISPLAY: inline; FONT-STYLE: italic">Transaction Outline</font>; and (c)
<font style="DISPLAY: inline; FONT-STYLE: italic">Fairness
Opinion</font>.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 2
- -</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">DOCUMENT
INDEX</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">(A)
Allocation Report</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">(B)
Transaction Outline</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">(C)
Fairness Opinion</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 3
- -</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">(A)
Allocation Report</font><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">XTL
Biopharmaceuticals Ltd.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">("The
Company")</font><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">January
14, 2010</font><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <div align="left">
        <div align="left">
          <div align="left">
            <table cellpadding="0" cellspacing="0" width="100%">
                <tr>
                  <td align="left" valign="bottom" width="36%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">To</font></div>
                  </td>
                  <td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td valign="bottom" width="47%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">To</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="bottom" width="36%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The
      Israel Securities Authority Ltd.</font></div>
                  </td>
                  <td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td valign="bottom" width="47%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The
      Tel-Aviv Securities Stock Exchange Ltd. ("TASE")</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="bottom" width="36%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Through the Magna</font></font></div>
                  </td>
                  <td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="bottom" width="47%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Through the Magna</font></font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="bottom" width="36%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #0000ff; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #0000ff; FONT-FAMILY: times new roman">www.isa.co.il</font></font></font></div>
                  </td>
                  <td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="bottom" width="47%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #0000ff; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #0000ff; FONT-FAMILY: times new roman">www.tase.co.il</font></font></font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div align="left">&#160;</div>
        <div align="left">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">An immediate report
regarding an extraordinary private placement in accordance with the Israeli
Securities Regulations (Private Placement of Securities in a Listed Company),
2000, and in accordance with Regulation 36 of the Israeli Securities Regulations
(Periodic and Immediate Reports), 1970, with respect to convening an
extraordinary general meeting of the Company whose agenda consists, among other
things, of approving an extraordinary private placement pursuant to the share
swap agreement signed with Xtepo Ltd. (a company that was established by Bio-Gal
Ltd. shareholders for the purpose of the execution of the transaction), all as
specified in the immediate report</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Introduction</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
furtherance to the immediate report issued by the Company on March 19, 2009
(reference No. 2009-02-061491), in accordance with the Israeli Securities
Regulations (Private Placement of Securities in a Listed Company), 2000,
Regulation 36 of the Israeli Securities Regulations (Periodic and Immediate
Reports), 1970, and in accordance with the decision of the Company's board of
directors of December 31<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">st</font>, 2009,
the Company hereby announces the convening of an extraordinary general meeting
whose agenda includes approving the extraordinary private placement as specified
in this immediate report ("<font style="DISPLAY: inline; FONT-WEIGHT: bold">the
meeting</font>").</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Condensed
      information of the transaction's nature and main
    terms</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 44pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.1</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
      December 31<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">st</font>,
      2009, the Company's Board approved the Company's engagement in an
      agreement to acquire 100% of the shares of Xtepo Ltd. ("<font style="DISPLAY: inline; FONT-WEIGHT: bold">Xtepo</font>"), a private
      company incorporated in Israel on November 9, 2009, which holds an
      exclusive license to use a patent for the Erythropoietin drug ("<font style="DISPLAY: inline; FONT-WEIGHT: bold">EPO</font>"), by way of issuing
      new shares of the Company in an extraordinary private placement pursuant
      to the Israeli Securities Regulations (Private Placement of Securities in
      a Listed Company), 2000 ("<font style="DISPLAY: inline; FONT-WEIGHT: bold">the Regulations</font>") to the
      shareholders of Xtepo <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">1</font>
      ("<font style="DISPLAY: inline; FONT-WEIGHT: bold">the share swap
      agreement</font>"), such that after consummating the share swap agreement
      as above, Xtepo's shareholders (together with their stake in the Company
      prior to the share swap) will hold about 70.64% <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">2</font> of
      the Company's issued and outstanding share capital and the balance of
      about 29.36% will be held by the Company's shareholders (excluding Xtepo
      shareholders). For details of Xtepo, see <font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Appendix
      A</font> to this report.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div>
      <hr style="COLOR: black" align="left" noshade size="1" width="15%">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 35px">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">1</font></font></div>
            </td>
            <td width="842">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      more details of the shareholders in Xtepo, see paragraph 11
      below.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 35px">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">2</font></font></div>
            </td>
            <td width="842">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Xtepo's
      shareholders were granted a right to invest in Xtepo pro rata to their
      holdings.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div id="PGBRK" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Allocation
Report</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A-1</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 44pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.2</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      execution of the share swap agreement as above is contingent, among other
      things, on obtaining the approval of the Company's general shareholders'
      meeting for the execution of the extraordinary private placement as above
      and on obtaining the approval of the Israeli Tax Authorities as detailed
      below ("<font style="DISPLAY: inline; FONT-WEIGHT: bold">the record
      date</font>"). For more details of the share swap agreement's
      prerequisites, see paragraph 13.1.1
below.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">The
      extraordinary private placement optionees and their status as interested
      parties</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
optionees in the extraordinary private placement at hand are Xtepo's
shareholders ("<font style="DISPLAY: inline; FONT-WEIGHT: bold">the
optionees</font>"). For details of the optionees who will become interested
parties in the Company following the completion of the transaction, see
paragraph 14.4 below.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
optionee, Mr. Alex Rabinovitch <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">3</font>, who is
a controlling shareholder in Xtepo, holds about 30.81% of Xtepo's shares and
will hold about 22.25% of the Company's shares following the share swap
transaction (including his stake in the Company prior to the completion of the
transaction, see paragraph 14.4 below).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">The
      terms, number and percentage of the Company's share capital of the offered
      securities following the
allocation</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 44pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.1</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
      the record date, the optionees will be allocated - 133,063,688 Ordinary
      shares of NIS&#160;0.1 par value each of the Company representing after
      their allocation 69.44% of the Company's issued and outstanding share
      capital after the completion of the
transaction.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 44pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.2</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      allocated shares will have rights that are equal in all respects to the
      rights of existing Ordinary shares in the Company on the date of the
      publication of this report and that confer upon their holders, among other
      things, equal rights in participating and voting in the Company's general
      meetings, receiving dividends or any other distribution and participating
      in excess assets of the Company in the event of
    liquidation.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">The
      consideration for the offered
securities</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In return
for the allocation of 133,063,688&#160;&#160;Ordinary shares
of&#160;&#160;NIS&#160;0.1 par value each of the Company to the optionees, the
optionees will assign to the Company all the Xteposhares held by them,
representing 100% of Xtepo's issued share capital. Consequently, after the
completion of the transaction, the optionees (together with their stake in the
Company prior to the share swap) will hold about 70.64% of the Company's issued
and outstanding share capital and the Company will hold 100% of Xtepo's issued
and outstanding share capital.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">The
      price of the Company's shares in the extraordinary private placement and
      their quoted market price</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 44pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.1</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      price of the Company's share in the private placement is appox.
      NIS&#160;0.10 <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">4</font>.
      The quoted market price of the Company's share as of March 18, 2009 (the
      original transaction date) is NIS&#160;0.205, which is 111% higher than
      the price of the Company's share in the private
  placement.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div>
      <hr style="COLOR: black" align="left" noshade size="1" width="15%">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 27pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">3</font></font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mr.
      Alex Rabinovitch holds shares of Xtepoboth directly and through a company
      controlled by him.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 27pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">4</font></font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">It
      should be mentioned that the investors in Xtepoprior to the transaction
      make their investments in U.S. dollars. Accordingly, the transaction is
      according to a share price in U.S. dollars equivalent to $&#160;0.0262. As
      of the date of this report, in relation to the foreign currency exchange
      rate at January 14, 2009, this price reflects NIS&#160;0.097 per
      share.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Allocation
Report</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A-2</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 44pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.2</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">It
      should be mentioned that the price of the Company's share according to the
      private placement is identical to the exercise price of the options
      allocated to several investors in Xtepo<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">5</font>
      which will be exercised after the prerequisites specified in paragraph
      13.1.1 to this report are met, based, among other things, on a fairness
      opinion attached as <font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Appendix
      B</font> to this report which established that the swap ratios reflected
      in the Company's share prices in the private placement are
      fair.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 44pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.3</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company shares' quoted market price at January 14, 2009 is
      NIS&#160;0.287.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">The
      names of the controlling shareholders in the Company, the interested
      parties, the directors and/or officers in the Company with personal
      interest in the private placement and the nature of the personal
      interest</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To the
best of the Company's knowledge, as of the date of this report, the Company has
no controlling shareholders. Furthermore, to the best of the Company's
knowledge, none of the officers or interested parties in the Company has
personal interest in the private placement.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Announcement
      of convening an extraordinary general meeting of the Company's
      shareholders</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 44pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.1</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the Companies Law, 1999 ("<font style="DISPLAY: inline; FONT-WEIGHT: bold">the Companies Law</font>"), an
      announcement is hereby provided of the convening of an extraordinary
      general meeting of the Company's shareholders to be held on Tuesday
      February 23<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">rd</font>,
      2010 at 10:00 am at the law offices of Kantor &amp; Co. on 14 Abba Hillel
      Silver, 12<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">th</font>
      floor, Ramat-Gan, Israel under the following
  agenda:</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 88pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 63pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.1.1</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      approval of the share swap agreement including the extraordinary private
      placement.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 44pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.2</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">The meeting's venue
      and date</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 88pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 63pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.2.1</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      extraordinary general meeting will convene on Tuesday February 23, 2010 at
      10:00 at the law offices of Kantor &amp; Co. on 14 Abba Hillel Silver,
      12<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">th</font>
      floor, Ramat-Gan, Israel. A deferred meeting, if necessary, will convene
      on Tuesday March 2<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">nd</font>,
      2010 at the same place and time.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 88pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 63pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.2.2</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      the extraordinary general meeting, a legal quorum will constitute the
      presence of at least two (2) shareholders, represented by themselves or by
      their proxies, who hold or represent together at least 33.33% of the
      voting rights in the Company. If at the elapse of thirty minutes from the
      meeting's scheduled date, the legal quorum is not achieved, the meeting
      will be automatically deferred to the same day of the following week, at
      the same time and place as scheduled for the original meeting; or to a
      different time or place as decided by the board of directors in an
      announcement to the shareholders. If in such deferred meeting no legal
      quorum is obtained within thirty minutes from the scheduled date, two
      shareholders that are present by themselves or by a proxy will form a
      legal quorum and the meeting will be entitled to discuss the issues on the
      agenda.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div>
      <hr style="COLOR: black" align="left" noshade size="1" width="15%">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 27pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">5</font></font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      details of the options granted to investors in Xtepo, see paragraph 13.1.1
      to this report.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Allocation
Report</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A-3</font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">
            </div><br></div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 88pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 63pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.2.3</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      date for establishing the shareholders' right to vote in the general
      meeting, as stipulated in Section 182 to the Companies Law, is Sunday
      January 24<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">th</font>,
      2010 ("<font style="DISPLAY: inline; FONT-WEIGHT: bold">the meeting
      participation record date</font>").</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 88pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 63pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.2.4</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any
      existing shareholder of the Company on the record date, whether or not the
      shares are registered in its name or are held by it through a member of
      the Stock Exchange, is entitled to participate in the meeting by itself or
      via a proxy. Pursuant to the Companies Regulations (Proof of Share
      Ownership for Voting in General Meetings), 2000, a Company shareholder
      whose shares are held by a member of the Stock Exchange will be able to
      participate in said meeting by itself or via a proxy provided that an
      original proof of Company share ownership on the meeting participation
      record date is delivered to the Company before the meeting (to be obtained
      by that member of the Stock Exchange). Any documents appointing proxies
      ("<font style="DISPLAY: inline; FONT-WEIGHT: bold">the letters of
      appointment</font>") as well as the original authorizations under which
      the letters of appointment (if any) were signed must be deposited with the
      Company's registered headquarters 48 hours prior to the date of the
      meeting.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 88pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 63pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.2.5</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
      written format of the voting paper and statements of position, if any, can
      be found at the Israel Securities Authority's site at <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.magna.isa.gov.il</font>
      and at the TASE's site at <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.tase.co.il</font>.
      In addition, a shareholder may apply to the Company directly for receiving
      the written format of the voting paper and statements of position, if any.
      A member of the Stock Exchange will send, at no consideration, via e-mail,
      a link to the written format of the voting paper and statements of
      position, if any, to each shareholder that is not registered with the
      Company's shareholders' registrar and whose shares are listed with that
      member of the Stock Exchange, if the shareholder has notified the member
      of the Stock Exchange of its wish and provided that the notice was made
      with respect to a certain securities account and prior to the record date.
      Any shareholder whose shares are listed with a member of the Stock
      Exchange is entitled to receive proof of ownership from the relevant
      member of the Stock Exchange at the member of the Stock Exchange's branch
      or by mail to their address in return for payment of delivery fees only,
      if so requested, and this application will be granted in advance to the
      relevant securities account. Pursuant to the Companies Regulations (Voting
      Paper and Statements of Position), 2005, that shareholder will vote on the
      second part of the voting paper and specify the manner of voting and
      deliver it to the Company or mail it via registered mail whereby the proof
      of ownership must reach the Company's headquarters no later than 72 hours
      prior to the meeting date.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 88pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 63pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.2.6</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company does not allow voting via the
internet.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 88pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 63pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.2.7</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">One
      or more shareholders that hold at least 5% of total voting rights and also
      hold such rate of total voting rights that are not held by the controlling
      shareholder in the Company, as defined in Section 286 to the Companies
      Law, are entitled to review the voting papers as detailed in Regulation 10
      to the Companies Regulations (Voting Paper and Statements of Position),
      2005.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Allocation
Report</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A-4</font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">
            </div><br></div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 88pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 63pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.2.8</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      last date for producing statements of position is within ten days after
      the meeting participation record date ("<font style="DISPLAY: inline; FONT-WEIGHT: bold">the last statement of position
      date of delivery</font>"), namely: Wednesday, February 3<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">rd</font>,,
      2010 and the last date for producing the board of directors' response to
      the statements of position is five days after the last statement of
      position date of delivery, namely Monday, February 8<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">th</font>,
      2010.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 44pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.3</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">The required decision
      passing majority</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 88pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 63pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.3.1</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      passing of the decision mentioned in paragraph 8.1.1 above requires an
      ordinary majority of the voting
participants.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Review
      of documents</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
documents pertaining to this report may be reviewed at the law offices of Kantor
&amp; Co. on 14 Abba Hillel Silver, 12<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">th</font> floor,
Ramat-Gan, Israel during standard work hours and after advance coordination at
+972-3-613 3371.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Allocation
Report</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A-5</font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">
            </div>
          </div>
          <div>&#160;</div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">XTL
Biopharmaceuticals Ltd.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">("The
Company")</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">January
14, 2010</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <div align="left">
        <div align="left">
          <div align="left">
            <table cellpadding="0" cellspacing="0" width="100%">
                <tr>
                  <td align="left" valign="bottom" width="36%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">To</font></div>
                  </td>
                  <td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td valign="bottom" width="47%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">To</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="bottom" width="36%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The
      Israel Securities Authority Ltd.</font></div>
                  </td>
                  <td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td valign="bottom" width="47%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The
      Tel-Aviv Securities Stock Exchange Ltd. ("TASE")</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="bottom" width="36%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Through the Magna</font></font></div>
                  </td>
                  <td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="bottom" width="47%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Through the Magna</font></font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="bottom" width="36%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #0000ff; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #0000ff; FONT-FAMILY: times new roman">www.isa.co.il</font></font></font></div>
                  </td>
                  <td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="bottom" width="47%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #0000ff; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #0000ff; FONT-FAMILY: times new roman">www.tase.co.il</font></font></font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">An immediate report
regarding an extraordinary private placement in accordance with the Israeli
Securities Regulations (Private Placement of Securities in a Listed Company),
2000, and in accordance with Regulation 36 of the Israeli Securities Regulations
(Periodic and Immediate Reports), 1970, with respect to convening an
extraordinary general meeting of the Company whose agenda consists, among other
things, of approving an extraordinary private placement pursuant to the share
swap agreement signed with XtepoLtd., all as specified in the immediate
report</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Introduction</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 44pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.1</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
      December 31, 2009 the Company's Board approved the Company's engagement in
      an agreement to acquire 100% of the shares of Xtepo Ltd. ("<font style="DISPLAY: inline; FONT-WEIGHT: bold">Xtepo</font>" <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">6</font>),
      a private Israeli company, which following the execution of the
      transaction at hand will hold an exclusive license to use a patent for the
      Erythropoietin drug ("<font style="DISPLAY: inline; FONT-WEIGHT: bold">EPO</font>"), by way of issuing
      133,063,688&#160;&#160;Ordinary shares of NIS&#160;0.1 par value each of
      the Company ("<font style="DISPLAY: inline; FONT-WEIGHT: bold">the
      allocated shares</font>") in an extraordinary private placement pursuant
      to the Israeli Securities Regulations (Private Placement of Securities in
      a Listed Company), 2000 ("<font style="DISPLAY: inline; FONT-WEIGHT: bold">the Regulations</font>") to the
      shareholders of Xtepo<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">7</font>
      ("<font style="DISPLAY: inline; FONT-WEIGHT: bold">the share swap
      agreement</font>"), such that after consummating the share swap agreement
      as above, Xtepo's shareholders (together with their stake in the Company
      prior to the share swap) will hold about 70.64% <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">8</font> of
      the Company's issued and outstanding share capital (disregarding the
      holdings of the optionees in the Company prior to the transaction) and the
      balance of about 29.36% will be held by the Company's shareholders
      (excluding Xtepo shareholders). For details of Xtepo, see <font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Appendix
      A</font> to this report.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 44pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.2</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      execution of the share swap agreement as above is contingent, among other
      things, on obtaining the approval of the Company's general shareholders'
      meeting for the execution of the extraordinary private placement as above
      and on obtaining the approval of the Israeli Tax Authorities as detailed
      below ("<font style="DISPLAY: inline; FONT-WEIGHT: bold">the record
      date</font>"). For more details of the share swap agreement's
      prerequisites, see paragraph 13.1
below.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div>
      <hr style="COLOR: black" align="left" noshade size="1" width="15%">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 27pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">6</font></font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
      company incorporated and registered in Israel on November 9,
      2009.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 27pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">7</font></font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      more details of the shareholders in Xtepo, see paragraph 14.4
      below.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 27pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">8</font></font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Xtepo<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>'s shareholders were
      granted a right to invest in Xtepo<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>pro rata to their
      holdings.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Allocation
Report</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A-6</font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">11.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Details
      of the optionees</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
optionees in the extraordinary private placement are 33 shareholders of Xtepo, a
private company established in Israel ("<font style="DISPLAY: inline; FONT-WEIGHT: bold">the optionees</font>"). For details
of the optionees who will become interested parties in the Company after the
completion of the transaction, see paragraph 14.4 to this report.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">The
      terms, number and percentage of the Company's share capital of the offered
      securities following the
allocation</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 44pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12.1</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">According
      to the terms of the extraordinary private placement and subject to the
      fulfillment of the share swap agreement's prerequisites as specified
      below, the optionees will be allocated 133,063,688&#160;&#160;Ordinary
      shares of NIS&#160;0.1 par value each of the Company representing after
      their allocation 69.44% of the Company's issued and outstanding share
      capital and about 65.71% of the Company's issued and outstanding share
      capital on a fully diluted basis <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">9</font>.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 44pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12.2</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      allocated shares as above will have rights that are equal in all respects
      to the rights of existing Ordinary shares of NIS&#160;0.1 par value each
      of the Company on the date of the publication of this report and that
      confer upon their holders, among other things, equal rights in
      participating and voting in the Company's general meetings, receiving
      dividends or any other distribution and participating in excess assets of
      the Company in the event of
liquidation.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">13.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">The
      overall transaction relating to the private
    placement</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 44pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">13.1</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">The
      Share Swap Agreement</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 90pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
December 31<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">st</font>, 2010
the Company entered into a share swap agreement with the optionees in the
context of which the optionees committed that on the record date, they will
assign to the Company 133,063,688&#160;&#160;shares of Xtepoheld by them,
representing 100% of their holdings in Xtepoin return for the allocation of
133,063,688 ordinary shares of NIS&#160;0.1 par value each of the Company
representing 69.44% of the Company's issued and outstanding share capital
following the completion of the transaction. Simultaneously with the fulfillment
of the prerequisites as detailed below and prior to the completion of the
transaction,&#160;&#160;56,202,290 stock options that had been granted to
several investors in Xtepowill be converted into 56,202,290&#160;&#160;shares of
Xtepoin consideration of approximately $&#160;1.5 million, reflecting a price
per share of $&#160;0.0262. The share swap agreement stipulates that performance
is also contingent on the fulfillment of the following
prerequisites:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 88pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 63pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      issuance of an extraordinary private placement report with respect to the
      allocated shares;</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 88pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 63pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      approval of the share swap agreement by the Company's general
      meeting;</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 88pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 63pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      approval of the transaction by the Israeli Tax Authorities. For more
      details, see paragraph 13.2 below;</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 88pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 63pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      approval of the TASE for listing the shares allocated to the
      optionees;</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 88pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 63pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(e)</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any
      other legally required approval for executing the share swap
      agreement;</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 117px">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td width="760">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(collectively,
      "<font style="DISPLAY: inline; FONT-WEIGHT: bold">the
      prerequisites</font>").</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div>
      <hr style="COLOR: black" align="left" noshade size="1" width="15%">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 27pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">9</font></font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Assuming
      the exercise of all of the Company's convertible stock options and
      securities.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Allocation
Report</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A-7</font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 44pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">13.2</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">The
      tax aspects relating to the
transaction</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 88pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      optionees have applied to the Israeli Income Tax Authority for a tax
      exemption according to Sections 104b and 103t to the Israeli Income Tax
      Ordinance. The optionees have committed towards each other to act to
      achieve said tax exemption. As of the date of this report, said exemption
      has not yet been obtained. The restrictions applicable pursuant to Section
      104b to the Income Tax Ordinance currently prescribe as
      follows:</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 88pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 63pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      optionees will not transfer more than 10% of the Company's shares held by
      them for a period of two years from the allocation date ("<font style="DISPLAY: inline; FONT-WEIGHT: bold">the restriction
      period</font>").</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 88pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 63pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">b.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Through
      the end of the restriction period, the Company will not make a private
      placement of shares or share rights at a rate of 25% or more of the
      Company's share capital as of the allocation
  date.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 88pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 63pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">c.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Through
      the end of the restriction period, the Company will not make any private
      placements of public offerings of shares resulting in a cumulative holding
      rate of less than 51% of each of the optionees compared to their holdings
      on the allocation date.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 88pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to Section 103t to the Income Tax Ordinance, the parties will not be
      subject to any tax liability whatsoever for the execution of the share
      swap agreement. The tax exemption will be granted subject to obtaining a
      pre-ruling from the Israeli Tax Authorities, to meeting the conditions and
      restrictions as determined in the income tax pre-ruling and the conditions
      and restrictions prescribed by the Income Tax Ordinance. The restriction
      period will be two years from the end of the tax year in which the swap
      transaction was carried out ("<font style="DISPLAY: inline; FONT-WEIGHT: bold">the restriction
      period</font>").</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 88pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      main conditions and restrictions prescribed by Section 103t to the Income
      Tax Ordinance are as follows:</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 88pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 63pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      main economic activities of each company participating in the swap
      transaction will continue as they were prior to the
      transaction.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 88pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 63pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">b.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Most
      of the assets (over 50%) that were held by the companies participating in
      the swap transaction will not be sold (excluding an involuntary sale) and
      will be used as customary in the companies' ordinary course of business.
      For this purpose, those assets will be fixed assets. As for the intangible
      asset to be assigned to Xtepo pursuant to the provisions of Section
      104b(f) to the Income Tax Ordinance, this asset will not be sold for a
      period of two years from the date of
transfer.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 88pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 63pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">c.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Each
      of the right owners in the companies participating in the swap transaction
      holds during the restriction period all the rights it owned immediately
      after the transaction and the right owners holding quoted rights will not
      be included in the right owner quorum for the purpose of this paragraph
      unless they were on the date of the transaction the controlling
      shareholders in the Company/transferred company. Moreover, after the swap
      transaction and during the restriction period, the Company will hold all
      the rights in the transferred company (Xtepo) which it held on the swap
      transaction date.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Allocation
Report</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A-8</font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 88pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 63pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">d.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Despite
      the abovementioned, upon the occurrence of any of the events specified
      below, it will not be viewed as a change in rights provided that at no
      time during the restriction period were the rights of the Company's right
      owners lower than 51% in each of the rights in the Company and that the
      Company's rights will not be lower than 51% in each of the rights in the
      transferred company:</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 201px">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 74px">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.</font></div>
            </td>
            <td width="602">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Securities
      were offered to the public based on a
  prospectus;</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 201px">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 74px">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.</font></div>
            </td>
            <td width="602">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
      sale of up to 10% of the total rights in the Company/transferred company
      to non former right owners on the swap transaction date, subject to the
      provisions of the Income Tax
Ordinance;</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 201px">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 74px">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.</font></div>
            </td>
            <td width="602">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Allocation
      of shares in the Company/transferred company to non former right owners in
      the Company/transferred company prior to the allocation at a rate not
      exceeding 25% of the Company's share capital prior to the
      allocation.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 88pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 63pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">13.2.1</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
      the record date and subject to the fulfillment of the share swap
      agreement's prerequisites as specified above, the optionees will assign
      <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">10</font>
      their holdings in Xtepoto the Company in return for and against the
      allocation of shares in the Company representing after their allocation
      69.44% of the Company's issued and outstanding share
    capital.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 88pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 63pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">13.2.2</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      table below provides information of the interested parties in Xtepo prior
      to the transaction:</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
        <div style="DISPLAY: block; MARGIN-LEFT: 153pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left">
          <table cellpadding="3" cellspacing="0" width="75%">
              <tr>
                <td valign="top" width="50%" style="BORDER-TOP: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Interested
      party</font></div>
                </td>
                <td valign="top" width="50%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-TOP: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stake
      in Xtepo (including rights owners)</font></div>
                </td>
              </tr>
              <tr>
                <td valign="top" width="50%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Alex
      Rabinovitch <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">11</font></font></div>
                </td>
                <td valign="top" width="50%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">30.81%</font></div>
                </td>
              </tr>
              <tr>
                <td valign="top" width="50%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">David
      Bassa <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">12</font></font></div>
                </td>
                <td valign="top" width="50%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16.31%</font></div>
                </td>
              </tr>
              <tr>
                <td valign="top" width="50%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Shalom
      Manova</font></div>
                </td>
                <td valign="top" width="50%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12.91%</font></div>
                </td>
              </tr>
              <tr>
                <td valign="top" width="50%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pinchas
      Ben Eliezer <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">13</font></font></div>
                </td>
                <td valign="top" width="50%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7.01%</font></div>
                </td>
              </tr>
              <tr>
                <td valign="top" width="50%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="50%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
          </table>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 88pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 63pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">13.2.3</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      convenience purposes, the holding structure in the Company and in Xtepo
      before and after the execution of the share swap transaction is presented
      in the sketch below*:</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div>
      <hr style="COLOR: black" align="left" noshade size="1" width="15%">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 27pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">10</font></font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      optionees' entire shares in Xtepo as of the date of this report are held
      in trust by Ronen Kantor Trustees Ltd. ("<font style="DISPLAY: inline; FONT-WEIGHT: bold">the share trustee</font>") for
      the optionees. Upon the completion of the transaction at hand, the share
      trustee will assign the Xtepo shares to the Company against the allocation
      of the shares to Eyal Rubin, CPA, Partner and Head of Tax Division at BDO
      ("<font style="DISPLAY: inline; FONT-WEIGHT: bold">the optionee
      trustee</font>") who will hold them for the optionees pursuant to the
      provisions of Sections 104b and 103t to the Income Tax
      Ordinance.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 27pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">11</font></font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mr.
      Alex Rabinovitch holds shares of Xtepo both directly and through a company
      under his control.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 27pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">12</font></font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      shares are held for Messrs. David Bassa and Shlomo Bassa in equal parts
      through a company controlled by them and/or directly
  held.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 27pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">13</font></font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By
      himself or through a company controlled by
him.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Allocation
Report</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A-9</font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Before the share swap
transaction</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><img src="graph1.jpg" alt=""><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">After the share swap
transaction </font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super; TEXT-DECORATION: underline">14</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><img src="graph2.jpg" alt=""></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(*) Note
that due to the fact that the transaction according to this report does not
fulfill the definition of business combination, the accounting treatment in the
transaction as aforesaid is treated as purchase of intellectual property against
placement of shares, thus after the completion of the transaction the
intellectual property will be recorded based on its fair value and according to
a valuation report from an independent assessor.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">14.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">The
      Company's issued share capital, number and percentage of optionees' and
      public holdings in the
Company</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 44pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">14.1</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company's authorized share capital as of the date of this report is NIS
      70,000,000 million and consists of 700,000,000 Ordinary shares of
      NIS&#160;0.1 par value each.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 44pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">14.2</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company's issued and outstanding share capital as of the date of this
      report amounts to NIS&#160;5.9 million, consisting of 58,561,065 Ordinary
      shares of NIS&#160;0.1 par value
each.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 44pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">14.3</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Immediately
      following the private placement as detailed in paragraph 13 above, the
      Company's issued and outstanding share capital will amount to
      NIS&#160;19,153 thousand, consisting of&#160;&#160;191,624,753 Ordinary
      shares of NIS&#160;0.1 par value
each.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div>
      <hr style="COLOR: black" align="left" noshade size="1" width="15%">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 27pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">14</font></font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">It
      should be emphasized that the transfer of the holdings of the shareholders
      in Xtepo to the Company and the allocation of Company shares to Xtepo
      shareholders in return will be effected simultaneously subject to the
      fulfillment of the prerequisites.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Allocation
Report</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A-10</font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 44pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">14.4</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
      the best of the Company's knowledge, the holdings of the public and the
      interested parties in the Company as of the date of this immediate report
      and following the allocation of shares as above are as
      follows:</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
              <table cellpadding="3" cellspacing="0" width="100%">
                  <tr>
                    <td valign="bottom" width="20%" style="BORDER-TOP: black 1.5pt solid; BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Shareholder
      name</font></div>
                    </td>
                    <td colspan="4" valign="bottom" width="40%" style="BORDER-TOP: black 1.5pt solid; BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Before
      the allocation</font></div>
                    </td>
                    <td colspan="4" valign="bottom" width="40%" style="BORDER-RIGHT: black 1.5pt solid; BORDER-TOP: black 1.5pt solid; BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">After
      the allocation</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td valign="bottom" width="20%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">No.
      of shares</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Options</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Holding
      rate</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fully
      diluted</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">No.
      of shares</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Options</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Holding
      rate</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-RIGHT: black 1.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fully
      diluted</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td valign="bottom" width="20%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-RIGHT: black 1.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  </tr>
                  <tr>
                    <td valign="bottom" width="20%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Interested parties</font></font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-RIGHT: black 1.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  </tr>
                  <tr>
                    <td valign="bottom" width="20%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Alex
      Rabinovitch <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">15</font></font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,643,592
      *</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.81%</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.37%</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">42,641,209</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">22.25%</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-RIGHT: black 1.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">21.06%</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td valign="bottom" width="20%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">David
      Bassa <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">16</font></font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">21,705,987</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11.33%</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-RIGHT: black 1.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.72%</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td valign="bottom" width="20%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Shalom
      Manova</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">17,175,573</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8.96%</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-RIGHT: black 1.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8.49%</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td valign="bottom" width="20%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Xtepo shareholders that are </font></font></div>
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"><font style="TEXT-DECORATION: underline">not
      </font></font></font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"><font style="TEXT-DECORATION: underline">interested
      parties</font></font></font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">664,000
      &#160;</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0&#160;</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.13%&#160;</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.96%&#160;</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">53,848,512</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;27.75%</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-RIGHT: black 1.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">26.27%</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td valign="bottom" width="20%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-RIGHT: black 1.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  </tr>
                  <tr>
                    <td valign="bottom" width="20%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Public</font></font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">56,253,473</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,863,611</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">96.06%</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">96.67%</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">56,253,473</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,863,611</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">29.36%</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-RIGHT: black 1.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">33.15%</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td valign="bottom" width="20%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="10%" style="BORDER-RIGHT: black 1.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  </tr>
                  <tr>
                    <td valign="bottom" width="20%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">58,561,065</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,863,611</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">100%</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">100%</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">191,624,753</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,863,611</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">100%</font></div>
                    </td>
                    <td valign="bottom" width="10%" style="BORDER-RIGHT: black 1.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">100%</font></div>
                    </td>
                  </tr>
              </table>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 78px">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 55px">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(*)</font></div>
            </td>
            <td width="744">
              <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Together
      with a relative.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div>
      <hr style="COLOR: black" align="left" noshade size="1" width="15%">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 27pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">15</font></font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Directly
      or through a company wholly owned by
him.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 27pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">16</font></font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      shares are held for Messrs. David Bassa and Shlomo Bassa in equal parts
      through a company controlled by them and/or
  directly.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
          <div style="DISPLAY: block; TEXT-INDENT: 0pt">
            <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div id="FTR">
                <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Allocation
Report</font></div>
              </div>
              <div id="PN" style="PAGE-BREAK-AFTER: always">
                <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A-11</font></div>
                <div style="WIDTH: 100%; TEXT-ALIGN: center">
                  <hr style="COLOR: black" noshade size="2">
                </div>
              </div>
              <div id="HDR">
                <div id="GLHDR" style="WIDTH: 100%" align="right">
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div>&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">15.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">The
      consideration for the offered securities and its
      determination</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 44pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">15.1</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Subject
      to the fulfillment of all the share swap agreement prerequisites, as
      stated in paragraph 13.1.1 above, the Company will allocate the optionees
      on the record date 133,063,688 &#160;Ordinary shares of NIS&#160;0.1 par
      value each of the Company representing 69.44% of the Company's issued and
      outstanding share capital in return for and against all the Extipo shares
      held by the optionees that represent 100% of Xtepo's issued and
      outstanding share capital.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 44pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">15.2</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      share price was determined after negotiations between the Company's
      management and the optionees and is identical to the exercise price of the
      options allocated to several investors in Xtepo<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: super">18</font>. It should be
      stated that the share price is based, among other things, on a fairness
      opinion attached as <font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Appendix
      B</font> to this report which established that the swap ratios reflected
      in the Company's share prices are
fair.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 45pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">16.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">The
      price of the Company's shares in the extraordinary private placement and
      their quoted market price</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 44pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 45pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                  <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">16.1&#160;&#160;</font></div>
                </div>
              </td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">It
      should be stated that according to the conditions of the share swap
      transaction, the allocated shares will be allocated to the optionees in
      consideration for their total holdings in Xtepo, reflecting NIS an amount
      of 0.10 per share<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: super">19</font>.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
          <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 44pt">
                  <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
                </td>
                <td style="WIDTH: 45pt">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">16.2</font></div>
                  </div>
                </td>
                <td>
                  <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      average rate of the Company&#8217;s shares in the four months preceding the
      publication date of the immediate report regarding the original
      transaction signed on March 18, 2009 is NIS 0.18, approximately 85.6%
      higher than the share price in the special private
    offering.</font></div>
                </td>
              </tr>
          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">17.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Names
      of controlling shareholders in the Company, material shareholders,
      directors and/or position holders and officers in the Company with
      personal interest in the private allocation and substance of their
      personal interest</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
      the best of the Company&#8217;s knowledge, as of the date of this report, the
      Company has no controlling shareholders. Also, to the best of the
      Company&#8217;s knowledge, no position holder, officer or interested party in
      the Company has a personal interest in the private allocation relating to
      this report.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">18.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Required
      contingent approvals and
conditions</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      share swap transaction determines that its implementation is subject,
      <font style="DISPLAY: inline; FONT-STYLE: italic">inter alia</font>, to
      fulfillment of the following contingent
  conditions:</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Publication
      of a report on the special private offering regarding allocation of the
      allocated shares;</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Approval
      of share swap transaction by the general shareholder meeting of the
      Company;</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Approval
      by the Israel Tax Authority for implementation of the transaction; for
      details see paragraph 13.2 above;</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div>
      <hr style="COLOR: black" align="left" noshade size="1" width="15%">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
        <div>
          <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 36pt">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">18<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;</font></font></div>
                </td>
                <td>
                  <div><font size="2">For details of the options granted to investors in
      Xtepo, see paragraph 13.1 to this
report.</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">19</font></font></div>
              </td>
              <td>
                <div style="TEXT-ALIGN: justify" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      investors in Xtepo prior to the transaction invest in United States
      dollars. Accordingly, the transaction relating to the present report is
      stated in according to the share price in United States dollars, which is
      equivalent to US$ 0.0262. As of the date of this report, regarding the
      conversion rate as of January 14, 20109, this price reflects NIS 0.097 per
      share.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
            <div style="DISPLAY: block; TEXT-INDENT: 0pt">
              <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div id="FTR">
                  <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Allocation
Report</font></div>
                </div>
                <div id="PN" style="PAGE-BREAK-AFTER: always">
                  <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A-12</font></div>
                  <div style="WIDTH: 100%; TEXT-ALIGN: center">
                    <hr style="COLOR: black" noshade size="2">
                  </div>
                </div>
                <div id="HDR">
                  <div id="GLHDR" style="WIDTH: 100%" align="right">
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Approval
      by the Stock Exchange for registration of the allocated shares to the
      optionees;</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(e)</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any
      other approval required for implementation of the share swap transaction
      in accordance with relevant
legislation.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">19.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Details
      of transactions of the kind of the proposed agreement or transactions
      similar thereto, between the Company and the controlling shareholders, or
      in which the controlling shareholders held a personal interest, in the
      last two years</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
      the best of the Company&#8217;s knowledge, the Company has no controlling
      shareholder. Also, to the best of the Company&#8217;s knowledge, there were no
      similar transactions to the proposed agreement according to this immediate
      report, in the two years preceding the date of approval of the proposed
      agreement by the Company&#8217;s board of directors, between the Company and
      between the controlling shareholders or in which the controlling
      shareholders held a personal
interest.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">20.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Limitations
      or restrictions in implementation of transactions in respect of allocation
      of shares to optionees</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">According
      to Section 15C of the Securities Law, 1968, and the Securities Regulations
      (Details Regarding Sections 15A &#8211; 15C of the Law), 2000, a public offering
      will be deemed:</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">20.1</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An
      offering concurrently with trading on the stock exchange of the allocated
      shares in the framework of this share swap transaction (&#8220;the shares&#8221;), not
      exceeding six months from the date of the allocation (&#8220;the definitive
      restricted period&#8221;).</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">20.2</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An
      offering concurrently with trading on the stock exchange of the shares,
      not exceeding six continuous quarters, commencing as from the end of the
      period stated in paragraph (a) above (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">the drizzling period</font>&#8221;),
      subject to fulfillment of one of the following in each of the additional
      periods in the drizzling period:</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
            </td>
            <td style="WIDTH: 72pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">20.2.1</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      number of shares offered in each day of trading on the stock exchange
      exceeded the average daily volume of trading on the stock exchange of the
      Company&#8217;s shares in the period of eight weeks preceding the offering
      date.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
            </td>
            <td style="WIDTH: 72pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">20.2.2</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      proposed number of the proposed shares, in each quarter exceeded 1% of the
      Company&#8217;s issued and paid up share
capital.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Issued and
      paid up share capital</font>&#8221; &#8211; except shares derived from realization or
      conversion of convertible securities allocated until the date of the
      offering and not yet realized or
converted.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
            </td>
            <td style="WIDTH: 72pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">20.2..3</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      above will apply also in respect of shares that will be acquired from the
      optionee during the definitive restricted period or the drizzling period,
      as stated, not according to a prospectus and not in the course of trading
      on the stock exchange.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">21.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Discussion
      of board of directors regarding approval of offering, value determined for
      shares and value of consideration in respect
  thereof</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company&#8217;s board of directors approved this report at its meeting on
      January 14<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">th</font>,
      2010, in accordance with the
following:</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table cellpadding="0" cellspacing="0" id="list" width="100%">
          <tr valign="top">
            <td align="right" style="WIDTH: 95px">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a.&#160;&#160;</font></div>
            </td>
            <td width="782">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Xtepo&#8217;s
      activity is in the sector of the Company&#8217;s traditional activity and
      enables the Company to commence Stage 2 clinical trials of a drug with
      material market potential.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table cellpadding="0" cellspacing="0" id="list" width="100%">
          <tr valign="top">
            <td align="right" style="WIDTH: 72pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">b.&#160;&#160;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Xtepo
      completed a capital raise so that the share swap transaction will enable
      material improvement of the Company&#8217;s financial position and will enable
      the Company&#8217;s continued business activity, including clinical
      trials.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
          <div style="DISPLAY: block; TEXT-INDENT: 0pt">
            <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div id="FTR">
                <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Allocation
Report</font></div>
              </div>
              <div id="PN" style="PAGE-BREAK-AFTER: always">
                <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A-13</font></div>
                <div style="WIDTH: 100%; TEXT-ALIGN: center">
                  <hr style="COLOR: black" noshade size="2">
                </div>
              </div>
              <div id="HDR">
                <div id="GLHDR" style="WIDTH: 100%" align="right">
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table cellpadding="0" cellspacing="0" id="list" width="100%">
          <tr valign="top">
            <td align="right" style="WIDTH: 72pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">c.&#160;&#160;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Since
      the Company&#8217;s securities are no longer traded on the Nasdaq,
      implementation of an integrated transaction (activity and financing),
      enabling the Company to focus on development of drugs, is attractive,
      taking into account the financial position of relevant markets,
      specifically in companies in the Company&#8217;s
  sector.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table cellpadding="0" cellspacing="0" id="list" width="100%">
          <tr valign="top">
            <td align="right" style="WIDTH: 72pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">d.&#160;&#160;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      transaction is based on a professional opinion received by the Company
      from an external appraiser, determining that &#8220;allocation of XTL shares to
      Xtepo shareholders, after transfer of shares and IP assets &#8211; of Xtepo to
      XTL &#8211; is reasonable and
appropriate&#8221;.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table cellpadding="0" cellspacing="0" id="list" width="100%">
          <tr valign="top">
            <td align="right" style="WIDTH: 72pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">e.&#160;&#160;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      accordance with the transaction scenario detailed in this report, a
      liability in the amount of US$ 10 million was waived, compared to the
      original transaction scenario signed in March 2009, and furthermore,
      despite the fact that the Company&#8217;s shares were delisted from trading on
      the Nasdaq, the current transaction scenario improves the Company's
      situation compared to the original transaction
  structure.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table cellpadding="0" cellspacing="0" id="list" width="100%">
          <tr valign="top">
            <td align="right" style="WIDTH: 72pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">f.&#160;&#160;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      light of the Company&#8217;s position immediately prior to implementation of the
      transaction and lack of other viable alternatives, non-implementation of
      the transaction may lead to the Company&#8217;s inability to operate and to
      cessation of activity.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">22.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Names
      of directors that approved the special private
    offering</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At
      the meeting of the Company&#8217;s board of directors convened on December
      31<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">st</font>,
      2009, at which submission of this report was approved, Amit Yonay
      (chairman of the board of directors), David Grossman (director and CEO),
      Boaz Shweiger (director), Marc Allouche (director), Dafna Cohen (director
      for the public) and Jaron Diament (director for the public),
      participated.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">23.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Date
      of implementation of special private
  offering</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      of the determining date, and subject to fulfillment of the contingent
      conditions, the Company will allocate to the optionees the allocated
      shares concurrently with transfer of the optionees&#8217; total holdings in
      Xtepo to the Company.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">24.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Announcement
      regarding special general meeting of the Company&#8217;s
      shareholders</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">24.1</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      accordance with the Companies Ordinance, announcement is hereby
      transmitted regarding convention of an extraordinary meeting of the
      Company&#8217;s shareholders, to be held on February 23<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">rd</font>,
      2010, at 10:00, in the offices of Kantor &amp; Co. Law Offices, Abba
      Hillel Silver Street 14, Floor 12, Ramat Gan, Israel, with the following
      agenda:</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
            </td>
            <td style="WIDTH: 72pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">24.1.1</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Approval
      of share swap agreement including special private offering in accordance
      therewith.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">24.2</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Location and date of
      meeting</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
            </td>
            <td style="WIDTH: 72pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">24.2.1</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      special general meeting will be convened on February 23<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">rd</font>,
      2010,, at 10:00, in the offices of Kantor &amp; Co. Law Offices, Abba
      Hillel Silver Street 14, Floor 12, Ramat Gan, Israel. A deferred meeting
      will be convened, if required, on Tuesday, March 2<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">nd</font>,
      2010, at the same location and at the same
time.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
            </td>
            <td style="WIDTH: 72pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">24.2.2</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
      legal quorum participating in the special general meeting, themselves or
      by legal proxies, will constitute at least two (2) shareholders holding or
      representing together at least 33.33% of the voting rights in the Company.
      If, after 30 minutes from the date and time determined for the meeting a
      legal quorum is not present, the meeting will be deferred automatically
      until the dame day in the following week, at the same time and in the same
      location determined for the original meeting; or to another day, hour or
      location as determined by the board of directors in an announcement to the
      shareholders. In the event that no legal quorum is present at the deferred
      meeting, within 30 minutes from the date and time determined for the
      deferred meeting, two shareholders present by themselves or by their legal
      proxy will constitute a legal quorum and the extraordinary meeting will be
      entitled to consider issues for which purpose the meeting was
      convened.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
          <div style="DISPLAY: block; TEXT-INDENT: 0pt">
            <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div id="FTR">
                <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Allocation
Report</font></div>
              </div>
              <div id="PN" style="PAGE-BREAK-AFTER: always">
                <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A-14</font></div>
                <div style="WIDTH: 100%; TEXT-ALIGN: center">
                  <hr style="COLOR: black" noshade size="2">
                </div>
              </div>
              <div id="HDR">
                <div id="GLHDR" style="WIDTH: 100%" align="right">
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
            </td>
            <td style="WIDTH: 72pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">24.2.3</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      determining date for entitlement of the shareholders to vote at the
      general meeting, as stated in Section 182 of the Companies Law is January
      24<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">th</font>,
      2010 (&#8220;the determining date for entitlement to participate in the
      meeting&#8221;).</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
            </td>
            <td style="WIDTH: 72pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">24.2.4</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All
      shareholders in the Company as of the determining date for entitlement to
      participate in the meeting, whether the shares are registered in the
      holder&#8217;s name or whether the shareholder holds the shares through a stock
      exchange member, are entitled to participate in the meeting, individually
      or through a voting representative. In accordance with the Companies
      Regulations (Determination of Share Holding for Purposes of Voting at
      General Meeting), 2000, a shareholder in the Company holding shares
      through a member of the stock exchange may participate in the general
      meeting individually or through a voting representative, only in the event
      that original confirmation is transmitted to the Company, prior to the
      meeting, regarding ownership of the Company&#8217;s shares as of the determining
      date for entitlement to participate in the meeting (such confirmation is
      receivable from the stock exchange member). A document appointing a voting
      representative (&#8220;the appointment document&#8221;), and original power of
      attorney in accordance with which the appointment document was signed (if
      such exists) should be transmitted to the Company&#8217;s registered offices up
      to 48 hours prior to the date of the
meeting.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
            </td>
            <td style="WIDTH: 72pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">24.2.5</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      format of the voting document and the position announcement, if such
      exist, may be found on the website of the Securities Authority, <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.magna.isa.gov.il</font>
      and on the website of the Tel Aviv Stock Exchange, <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.tase.co.il</font>.
      Also, a shareholder is entitled to contact the Company directly in order
      to receive the format of the voting document and the position
      announcement, if such exist. A stock exchange member will transmit,
      without consideration, by electronic mail, a link to the format of the
      voting document and position announcement, if such exist, to any
      shareholder not registered in the listing of the Company&#8217;s shareholders
      and whose shares are registered with the same stock exchange member, if
      the shareholder informs the stock exchange member of his interest therein,
      subject to transmission of the announcement regarding a specific
      securities account and prior to the determining date. A shareholders whose
      shares are registered with a stock exchange member is entitled to receive
      confirmation of ownership from the stock exchange member through which the
      shareholder&#8217;s shares are held, at a branch of the stock exchange member or
      by post to the shareholder&#8217;s address, in consideration for postage fees
      only, subject to the shareholder&#8217;s request, and submission of such request
      in advance to a specific securities account. In accordance with the
      Companies Regulations (Voting in Writing and Position Announcement), 2005,
      shareholders will vote on Part 2 of the voting document, detailing the
      method of the voting, and will transmit the document to the Company or
      will send the document by registered mail, wherein the document will reach
      the Company&#8217;s offices not later than 72 hours prior to the date of
      convention of the general meeting.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
            </td>
            <td style="WIDTH: 72pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">24.2.6</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company does not enable voting by
Internet.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
            </td>
            <td style="WIDTH: 72pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">24.2.7</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">One
      or more shareholders holding shares at a rate of 5% or more of total
      voting rights, and holders of such rate out of the total voting rights not
      held by controlling shareholders in the Company, As defined in Section 286
      of the Companies Law, are entitled to review the voting documents as
      detailed in Regulation 10 of the Companies Regulations (Voting in Writing
      and Position Announcement), 2005.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
          <div style="DISPLAY: block; TEXT-INDENT: 0pt">
            <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div id="FTR">
                <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Allocation
Report</font></div>
              </div>
              <div id="PN" style="PAGE-BREAK-AFTER: always">
                <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A-15</font></div>
                <div style="WIDTH: 100%; TEXT-ALIGN: center">
                  <hr style="COLOR: black" noshade size="2">
                </div>
              </div>
              <div id="HDR">
                <div id="GLHDR" style="WIDTH: 100%" align="right">
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
            </td>
            <td style="WIDTH: 72pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">24.2.8</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      final date for transmission of a position announcement is up to ten days
      after the determining date for entitlement to participate in the
      extraordinary meeting (&#8220;the final date for transmission of position
      announcements&#8221;), i.e. Wednesday, February 3<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">rd</font>,
      2010, and the final date for transmission of the board of directors&#8217;
      response to the position announcements is five days after the final date
      for transmission of position announcements, i.e. Monday, February 8<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">rd</font>,
      2010.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">24.3</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Required majority for
      decision</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      required majority for approval of the decision stated in paragraph 24.1.1
      above is a regular majority of the participants in the
    voting.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">25.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Securities
      Authority</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Within
      21 days from the date of submission of this issued report, the Israel
      Securities Authority (&#8220;the Authority&#8221;) is entitled to instruct the Company
      to provide, by a certain date, explanation, details, information, data and
      documents regarding the agreement for the transaction relating to this
      mediate report, and to instruct the Company to amend this immediate
      report, in such manner and as such time as
  determined.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      the event of such instruction for amendment, the Authority or an employee
      thereof is entitled to determine deferral of the date of the general
      meeting until a date not earlier than three business days and not later
      than 21 days from the date of publication of the amendment to the
      immediate report.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">26.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Review
      of documents</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Documents
      relating to this immediate report may be reviewed at the offices of Kantor
      &amp; Co. Law Offices, Abba Hillel Silver Street 14, Floor 12, Ramat Gan,
      Israel, during regular work hours and after advance coordination at
      telephone 03-6133371.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">27.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Company
      representatives</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company&#8217;s representatives responsible for the immediate report are
      Advocate Giora Gutman and/or Ronen Kantor, of Kantor &amp; Co. Law
      Offices, Abba Hillel Silver Street 14, Floor 12, Ramat Gan, Israel,
      telephone 03-6133371.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yours
sincerely</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">XTL
Biopharmaceuticals Ltd.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
          <div style="DISPLAY: block; TEXT-INDENT: 0pt">
            <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div id="FTR">
                <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Allocation
Report</font></div>
              </div>
              <div id="PN" style="PAGE-BREAK-AFTER: always">
                <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A-16</font></div>
                <div style="WIDTH: 100%; TEXT-ALIGN: center">
                  <hr style="COLOR: black" noshade size="2">
                </div>
              </div>
              <div id="HDR">
                <div id="GLHDR" style="WIDTH: 100%" align="right">
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">(B)
Transaction Outline</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman">Xtepo
Ltd. ("Xtepo")</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">First
Part &#8211; Description of the General Development of Xtepo Business
Activities</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 27pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.</font></div>
              </td>
              <td>
                <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Xtepo&#8217;s activity and
      description of its business
development</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36px">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 40px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.1</font></font></div>
              </td>
              <td width="801">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Terminology</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">For the sake of convenience,
the meaning of the terms used in this section will be as
follows</font>:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div>
        <div align="left">
          <div align="left">
            <div align="left">
              <div align="left">
                <div align="left">
                  <div align="left">
                    <div align="left">
                      <div align="left">
                        <div align="left">
                          <div align="left">
                            <div align="left">
                              <div align="left">
                                <div align="left">
                                  <div align="left">
                                    <div align="left">
                                      <div align="left">
                                        <div align="left">
                                          <div align="left">
                                            <div align="left">
                                              <div align="left">
                                                <div align="left">
                                                  <div align="left">
                                                    <div align="left">
                                                      <div align="left">
                                                        <table cellpadding="0" cellspacing="0" width="100%">
                                                            <tr>
                                                              <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="15%">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Multiple
      myeloma</font></div>
                                                              </td>
                                                              <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="73%">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Multiple
      myeloma is a hematological cancer accounting for about 10% of all
      hematological cancers and about 1% of all malignant diseases. This disease
      is characterized by uncontrolled proliferation of plasma cells, a type of
      white blood cells, in the bone marrow, thus leading to the formation of
      malignant cell foci causing damage and partial bone
      destruction&#160;&#160;This disease has a multi-focal (multiple) nature,
      reflected by formation of multiple malignant cell foci. The malignant
      cells and the proteins secreted by them are responsible for a series of
      clinical manifestations and complications, including damage to the bones,
      accompanied by pain and fractures, damage to the bone marrow and anemia,
      susceptibility to infections, weakening of the immune system, nervous
      system impairment, renal insufficiency, coagulation defects,
      etc.&#160;&#160;Multiple myeloma is an incurable disease, with mean life
      expectancy of the patients being about 3-5 years.</font></div>
                                                              </td>
                                                            </tr>
                                                            <tr>
                                                              <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="73%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                            </tr>
                                                            <tr>
                                                              <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="15%">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Plasma
      cells</font></div>
                                                              </td>
                                                              <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="73%">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">A
      group of cells constituting about 2-5% of all white blood cells in the
      human body. Plasma cells produce immunoglobulins, which are immune system
      proteins serving as antibodies.</font></div>
                                                              </td>
                                                            </tr>
                                                            <tr>
                                                              <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="73%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                            </tr>
                                                            <tr>
                                                              <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="15%">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Erythropoietin-
      EPO</font></div>
                                                              </td>
                                                              <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="73%">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">A
      hormone produced by the kidneys, the known function of which is
      stimulation of red blood cell production in the bone
    marrow.</font></div>
                                                              </td>
                                                            </tr>
                                                            <tr>
                                                              <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="73%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                            </tr>
                                                            <tr>
                                                              <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="15%">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Recombinant
      Erythropoietin (Recombinant EPO)</font></div>
                                                              </td>
                                                              <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="73%">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">A
      genetically &#8211; engineered hormone usually designed for treatment of various
      types of anemia, mainly anemia affecting patients suffering from renal
      insufficiency (and treated with hemodialysis), as well as patients with
      various types of malignant diseases accompanied by
  anemia.</font></div>
                                                              </td>
                                                            </tr>
                                                            <tr>
                                                              <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="73%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                            </tr>
                                                            <tr>
                                                              <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="15%">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Autologous
      stem cells</font></div>
                                                              </td>
                                                              <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="73%">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stem
      cells are undifferentiated cells, out of which the three types of blood
      cells are formed. Most stem cells reside in the bone marrow; however, some
      of them- called peripheral blood stem cells (PBSC)- are collected from the
      bloodstream.</font></div>
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Autologous
      transplantation &#8211; the patient receives stem cells from his own bone marrow
      or peripheral blood.</font></div>
                                                              </td>
                                                            </tr>
                                                            <tr>
                                                              <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="73%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                            </tr>
                                                            <tr>
                                                              <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="15%">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Neuropathy/
      Peripheral neuropathy</font></div>
                                                              </td>
                                                              <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="73%">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Functional
      impairment of the nerves responsible for transmitting sensation from the
      tips of the hands and feet. In mild cases, peripheral neuropathy may cause
      tingling in hands and feet, while in severe cases, it may cause pain and
      pricking sensation in all parts of the body, up to difficulties in limb
      function and movement.</font></div>
                                                              </td>
                                                            </tr>
                                                            <tr>
                                                              <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="73%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                            </tr>
                                                            <tr>
                                                              <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="15%">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">T-
      Lymphocytes</font></div>
                                                              </td>
                                                              <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="73%">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">White
      blood cells, which are an important component of the immune system. These
      cells act in various ways, and are responsible for assisting the body in
      its fight against infections, malignant cells,
  etc.</font></div>
                                                              </td>
                                                            </tr>
                                                        </table>
                                                      </div>
                                                    </div>
                                                  </div>
                                                </div>
                                              </div>
                                            </div>
                                          </div>
                                        </div>
                                      </div>
                                    </div>
                                  </div>
                                </div>
                              </div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Transaction
Outline</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B-1</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div>
          <div align="left">
            <div align="left">
              <div align="left">
                <div align="left">
                  <div align="left">
                    <div align="left">
                      <div align="left">
                        <div align="left">
                          <div align="left">
                            <div align="left">
                              <div align="left">
                                <div align="left">
                                  <table cellpadding="0" cellspacing="0" width="100%">
                                      <tr>
                                        <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td align="left" valign="top" width="15%">
                                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Anti-
      cancer effect</font></div>
                                        </td>
                                        <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td valign="top" width="73%">
                                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Anti-
      cancer effect is any effect causing the cancer cells to stop dividing and
      multiplying, destroying the cells or &#8220;freezing&#8221; their growth and
      spread.</font></div>
                                        </td>
                                      </tr>
                                      <tr>
                                        <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td valign="top" width="73%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      </tr>
                                      <tr>
                                        <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td align="left" valign="top" width="15%">
                                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Helsinki
      committee</font></div>
                                        </td>
                                        <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td valign="top" width="73%">
                                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">A
      committee acting in accordance with People&#8217;s Health Regulations (Clinical
      trials in human subjects), 1980, responsible for approving and supervising
      clinical trials - for more information, see paragraph 2.10.1
      below.</font></div>
                                        </td>
                                      </tr>
                                      <tr>
                                        <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td valign="top" width="73%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      </tr>
                                      <tr>
                                        <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td align="left" valign="top" width="15%">
                                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">IRB</font></div>
                                        </td>
                                        <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td valign="top" width="73%">
                                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Institutional
      Review Board &#8211; A committee equivalent to the Helsinki committee in the US
      and other world countries.</font></div>
                                        </td>
                                      </tr>
                                      <tr>
                                        <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td valign="top" width="73%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      </tr>
                                      <tr>
                                        <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td align="left" valign="top" width="15%">
                                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">FDA</font></div>
                                        </td>
                                        <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td valign="top" width="73%">
                                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Food
      and Drug Administration &#8211; The US authority responsible for control and
      regulation of drug development and registration in the
  US.</font></div>
                                        </td>
                                      </tr>
                                      <tr>
                                        <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td valign="top" width="73%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      </tr>
                                      <tr>
                                        <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td align="left" valign="top" width="15%">
                                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">EMEA</font></div>
                                        </td>
                                        <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td valign="top" width="73%">
                                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">European
      Medicines Agency &#8211; The European authority responsible for control and
      regulation of drug development and registration in European Union
      countries. EMEA currently includes about 30 member - countries.<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: super">1</font></font></div>
                                        </td>
                                      </tr>
                                      <tr>
                                        <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td valign="top" width="73%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      </tr>
                                      <tr>
                                        <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td align="left" valign="top" width="15%">
                                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Serious
      Adverse Events (SEA) or Serious Adverse Drug Reaction</font></div>
                                        </td>
                                        <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td valign="top" width="73%">
                                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Any
      disturbing medical event, at any dose, which is either life threatening or
      fatal, or requiring hospitalization or extension of current
      hospitalization, or causing permanent disability or permanent functional
      impairment.</font></div>
                                        </td>
                                      </tr>
                                      <tr>
                                        <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td valign="top" width="73%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      </tr>
                                      <tr>
                                        <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td align="left" valign="top" width="15%">
                                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Activity</font></div>
                                        </td>
                                        <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td valign="top" width="73%">
                                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Laboratory
      or clinical results indicating clinical efficacy of the
    drug.</font></div>
                                        </td>
                                      </tr>
                                      <tr>
                                        <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td valign="top" width="73%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      </tr>
                                      <tr>
                                        <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td align="left" valign="top" width="15%">
                                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Efficacy</font></div>
                                        </td>
                                        <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td valign="top" width="73%">
                                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proof
      of clinical effect of a drug in a human clinical trial.</font></div>
                                        </td>
                                      </tr>
                                      <tr>
                                        <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td valign="top" width="73%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      </tr>
                                      <tr>
                                        <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td align="left" valign="top" width="15%">
                                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Orphan
      drug</font></div>
                                        </td>
                                        <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td valign="top" width="73%">
                                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">A
      special pathway for approval and marketing of medicinal agents by the FDA.
      This pathway is designed to fulfill the need for the development of drugs
      for unique populations, as well as for the treatment of relatively rare
      and incurable diseases (in the US &#8211; diseases affecting 200,000 patients
      (maximal number), in the European Union - diseases with an incidence of up
      to 5 per 10,000 people). Recognition of a certain drug as an orphan drug
      grants the manufacturer regulatory marketing exclusivity for a period of 7
      years in the US and 10 years in the European Union.</font></div>
                                        </td>
                                      </tr>
                                      <tr>
                                        <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td valign="top" width="73%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      </tr>
                                      <tr>
                                        <td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td align="left" valign="top" width="15%">
                                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Ethical
      drug</font></div>
                                        </td>
                                        <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                        <td valign="top" width="73%">
                                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">A
      patented drug; only its developer is authorized to manufacture and sell
      it.</font></div>
                                        </td>
                                      </tr>
                                  </table>
                                </div>
                              </div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>&#160;</div>
      </div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 28px">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 48px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.2</font></font></div>
              </td>
              <td width="801">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">General</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Xtepo
Ltd. (hereafter:&#160;&#160;&#8220;Xtepo&#8221;) is a private company incorporated and
registered in Israel since November 9, 2009, according to the Corporations Law
1999 (hereafter Corporations Law).</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Together
with fulfillment of all the prerequisites for executing the transaction, as
detailed in paragraph 18 of this report, Xtepo will receive an exclusive license
for using the patent for the treatment of multiple myeloma patients with
recombinant EPO, based on a series of studies including, among others, an
empirical observation in patients treated with recombinant EPO by Prof. Moshe
Mittelman. Prof. Moshe Mittelman is an internationally recognized hematologist,
who proved by empirical observations that treatment with recombinant EPO may
prolong survival in multiple myeloma patients, along with a significant quality
of life improvement, and with reduced side effects, as compared to the currently
available medications. Please see paragraph 6.1 below for details of the license
agreement.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <hr style="COLOR: black" align="left" noshade size="1" width="25%">
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div><a name="ref.ID0EAH"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;According
to the information present in the website of EMEA:
http://www.emea.europa.eu/htms/aboutus/emeaoverview.htm</font></a></div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Transaction
Outline</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B-2</font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">
            </div>
          </div>
        </div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      </div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 21.25pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 36pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.3</font></font></div>
              </td>
              <td>
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Xtepo&#8217;s
      drugs</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">EPO</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Recombinant
EPO (hereafter: &#8220;The EPO drug&#8221;) is a drug currently used for the treatment of
anemia caused by renal insufficiency and various types of cancer, in view of the
fact that chemotherapy may exacerbate and accelerate the development and
progression of anemia in cancer patients.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 28px">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 48px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.4</font></font></div>
              </td>
              <td width="801">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Drug development
      procedure &#8211; General
description</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Drug
development is a complex procedure usually including the following major
phases<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: super">2</font>; in order to
move from one phase to the next one, it is necessary to fulfill the criteria
defined by the health authority for every phase, as follows:</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 77px">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 37px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font></div>
              </td>
              <td width="763">
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Pre-clinical
      phase</font> &#8211; This phase includes animal studies designed to demonstrate
      efficacy of the drug in animal models of the disease for which the drug is
      indicated. The pre-clinical phase also includes experiments, performed
      under stringent conditions, designed to examine whether the drug exerts
      toxic side effects, and to evaluate its various features in animals. In
      addition, the pre-clinical phase includes development of Good
      Manufacturing Practice methods (GMP- a set of manufacturing requirements
      with which the drug has to comply in order to be approved for future
      administration to the patients).</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 76px">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 38px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font></div>
              </td>
              <td width="763">
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Phase I</font> &#8211; This
      is the first clinical phase of drug development, during which a
      preliminary examination is performed in human subjects, with the aim of
      evaluating the safety and the maximal safe dosage of the drug. Tests of
      drug distribution and duration of its retention in the bloodstream may
      also be performed during this phase; these tests enable evaluation of the
      bioavailability of the drug and other parameters. Phase I studies may be
      carried out in either healthy volunteers or in
  patients.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 76px">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 38px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c
      )</font></div>
              </td>
              <td width="763">
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Phase II</font> &#8211; This
      phase involves preliminary examination of drug efficacy in patients. In
      addition, one of the aims of this phase is to determine the optimal
      therapeutic dose of the drug. Its safety evaluations are ongoing
      simultaneously. In many cases, several Phase II studies are performed:
      Phase IIa study, the objective of which is proof of concept, and a more
      extensive Phase IIb study, including a larger number of patients and study
      centers, as compared to Phase IIa
study.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div>
        <hr style="COLOR: black" align="left" noshade size="1" width="25%">
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Description of the phases is general; changes may sometimes occur with respect
to various drugs. For example, in certain cases, phases I and II or II and III
may be combined.</font></div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">
          <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div id="FTR">
              <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Transaction
Outline</font></div>
            </div>
            <div id="PN" style="PAGE-BREAK-AFTER: always">
              <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B-3</font></div>
              <div style="WIDTH: 100%; TEXT-ALIGN: center">
                <hr style="COLOR: black" noshade size="2">
              </div>
            </div>
            <div id="HDR">
              <div id="GLHDR" style="WIDTH: 100%" align="right">
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 75px">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 39px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)</font></div>
              </td>
              <td width="763">
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Phase III</font> &#8211; The
      most important phase of multinational, multicenter, randomized, placebo-
      controlled and double- blind studies. This phase involves a larger number
      of subjects (hundreds and even thousands), and is carried out in a large
      number of medical centers worldwide, using a single dosage. The objective
      of this phase is to prove the safety and efficacy of the drug in a large
      number of patients in order to enable a more accurate simulation (compared
      to earlier phases) of its use by physicians in clinical practice.
      Following successful completion of this phase, applications for approval
      of drug registration may be submitted to the relevant health
      authorities.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">It must
be emphasized that performance of clinical trials in human subjects during each
phase, Phase I, II and III, requires preliminary approval by the Helsinki
committee /IRB and by the regulatory authorities of the countries involved in
the clinical trials. It must be noted that obtaining successful results in the
early phases is absolutely required for the transition from one phase to the
next one.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Following
successful completion of all the above phases (including completion of Phase
III), Xtepo will be able to submit an application for approval of registration
of the drug by the relevant health authority, e.g. US FDA.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
demonstrated above, drug development is a long process requiring significant
funding in view of the prolonged duration of the trials, approval processes and
analysis of information and results obtained from the studies, the completion of
which will enable Xtepo to submit an application for approval of registration of
the drug by the FDA or any equivalent regulatory authority in another country.
Clinical development, including performance of clinical trials, is frequently
assisted by expert subcontractors, qualified for working under stringent
professional standards required by the regulatory authorities.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 27pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.</font></div>
              </td>
              <td>
                <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Xtepo&#8217;s field of
      activity</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Xtepo,
together with or through its mother company, will be involved in one field of
activity, in accordance with the license agreement for exclusive use of the EPO
drug patent, with the aim of commercializing a new indication for the above
drug, which is treatment of multiple myeloma patients, based on the studies
performed by Prof. Moshe Mittelman.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
addition, Xtepo will take action to receive a status of an orphan drug for the
EPO drug in order to obtain marketing exclusivity for a limited period and
reduced regulatory constraints during the development process.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
company&#8217;s assessments with respect to receiving a status of an orphan drug
include a forward- looking statement. This statement is uncertain, and is based
on the information available to the company at the time of preparing this
outline. It should be emphasized that it is possible that an orphan drug status
will not be granted to the EPO drug, and it will be entitled to neither an
accelerated regulatory pathway nor to limited marketing exclusivity
period</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">
          <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div id="FTR">
              <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Transaction
Outline</font></div>
            </div>
            <div id="PN" style="PAGE-BREAK-AFTER: always">
              <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B-4</font></div>
              <div style="WIDTH: 100%; TEXT-ALIGN: center">
                <hr style="COLOR: black" noshade size="2">
              </div>
            </div>
            <div id="HDR">
              <div id="GLHDR" style="WIDTH: 100%" align="right">
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">Second
part &#8211; Other information</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 27pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.</font></div>
              </td>
              <td>
                <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Financial information
      with respect to Xtepo&#8217;s field of
activity</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Since
Xtepo was founded on November 9, 2009, no financial reports have been published
up to the date of this outline.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 27pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.</font></div>
              </td>
              <td>
                <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">General environment
      and effect of external factors on Xtepo&#8217;s
  activity</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
market of anti- cancer drugs in general, and the market of drugs for the
treatment of multiple myeloma in particular, for which Xtepo&#8217;s drug is intended,
is characterized by an increasing need for new developments in the field of
treatment of various cancer types. In spite of the general progress in the field
of pharmaceuticals, and the impressive achievements observed in this field
during the last years, up to the date of this outline, there are still numerous
diseases, including various cancers, for which the currently available
medication treatments are insufficient due to either limited activity range or
insufficient efficacy, as well as due to severe adverse events. The increasing
mean population age, paralleled by increasing number of cancer patients in
general, and multiple myeloma patients in particular, emphasizes the ever
increasing need for new therapeutic agents aimed at treatment of these
diseases.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There is
no drug, even the most efficient one in reducing disease symptoms, which can be
efficient in all the patients. In many cases, for certain populations of
patients, there is no efficient drug for treating their disease or the stage of
their disease. Furthermore, in many cases, a certain drug may be efficient for a
certain period of time, followed by cessation of its positive effect. In
addition, many drugs cause severe side effects, thus sometimes preventing the
patients from taking the drugs.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
target market of Xtepo's drug is unique (for further details, see paragraph 5
below), and according to the opinions of Xtepo's experts, the capacity of any
drug to bite into a market share depends on its short- term and long- term
efficacy, as well as its side effects, including absolute effects and effects
relative to those caused by the competing drugs.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In view
of the fact that Xtepo is developing a new indication for the EPO drug, which is
an established and approved drug for the treatment of anemia, Xtepo expects to
receive exemptions from performing pre- clinical and Phase I clinical studies.
At present, Xtepo has a preliminary design for initiating a Phase II clinical
study in multiple myeloma patients. It should be noted that in view of the fact
that the above design was provided to the company as part of the license
agreement for patent use, and considering the long time period that had elapsed
since the date of study design preparation, it is conceivable that Xtepo will be
required to introduce changes into the design and to submit them for additional
approval by the health authorities prior to study initiation.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Prof.
Mittelman's studies indicate that treatment of multiple myeloma patients with
the EPO drug leads to significant suppression of disease symptoms, improves
their immune system function, stabilizes their health status, prolongs their
survival and induces a marked improvement in their quality of life, without
causing severe side effects. These features make this drug superior in most of
its therapeutic aspects. Provided that these features are apparent in additional
clinical studies, as required by the regulatory authorities for drug
registration, Xtepo may foresee that the drug will conquer a large market share
in the market of drugs designed for the treatment of multiple myeloma, including
treatment of patients with advanced/ terminal disease not responding well enough
to the currently available therapies. In addition, Xtepo foresees another market
share for the above drug, based on combinations of the EPO drug with the
currently available therapies. If these predictions turn out to be true, the
drug will have an estimated market share of millions of USD per year.<font style="DISPLAY: inline; FONT-WEIGHT: bold"> However, it must be emphasized that
clinical research is associated with numerous elements of uncertainty.
Therefore, the possibility that Xtepo will not succeed in continuous
demonstration of the safety and efficacy of the drug, or that the actual drug
efficacy will be lower than expected, cannot be excluded. In addition, possible
development of competing drugs by Exstipo's competitors cannot be
excluded</font>.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">
          <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div id="FTR">
              <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Transaction
Outline</font></div>
            </div>
            <div id="PN" style="PAGE-BREAK-AFTER: always">
              <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B-5</font></div>
              <div style="WIDTH: 100%; TEXT-ALIGN: center">
                <hr style="COLOR: black" noshade size="2">
              </div>
            </div>
            <div id="HDR">
              <div id="GLHDR" style="WIDTH: 100%" align="right">
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
above Xtepo's estimates with respect to the potential capacity of Xtepo's drug
to conquer a large market share in the market of drugs designed for the
treatment of multiple myeloma include a forward looking statement. This
statement is uncertain, and is based on the information available to the company
at the time of preparing this outline. It should be emphasized that the actual
results of the advanced clinical trial phases may be significantly different
from the estimates implied by this statement, thus there is no certainty
regarding further successful development of the EPO drug by Xtepo.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">
          <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div id="FTR">
              <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Transaction
Outline</font></div>
            </div>
            <div id="PN" style="PAGE-BREAK-AFTER: always">
              <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B-6</font></div>
              <div style="WIDTH: 100%; TEXT-ALIGN: center">
                <hr style="COLOR: black" noshade size="2">
              </div>
            </div>
            <div id="HDR">
              <div id="GLHDR" style="WIDTH: 100%" align="right">
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">Third
Part &#8211; Description of Xtepo&#8217;s Business Activities</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 27pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.</font></div>
              </td>
              <td>
                <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">General information on
      the field of activity</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
following is a detailed description of Xtepo&#8217;s business activities, including
trends, events and developments in the macro- economic environment of Xtepo,
which significantly affect, or may significantly affect Xtepo&#8217;s business
activities. It should be noted that at present, the company has no independent
activity. Activity, to be carried out together with or through Xtepo&#8217;s mother
company, will be initiated following completion of the transaction discussed in
this report, as follows:</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36px">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 40px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">5.1</font></font></div>
              </td>
              <td width="801">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Introduction</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 76px">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 44px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">5.1.1</font></font></div>
              </td>
              <td width="757">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Prof. Mittelman&#8217;s
      research study</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 90pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Analysis
of the clinical findings observed by Prof. Mittelman in multiple myeloma
patients revealed that treatment with recombinant EPO has prolonged the survival
of some patients beyond that predicted for them, based on their condition,
without this treatment. The results and conclusions drawn from the above
observations were further tested in murine models of multiple myeloma,
demonstrating that recombinant EPO has anti- cancer activity, based on its
effect on the activation of T- lymphocytes.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 90pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">These
observations have led to the assumption that recombinant EPO affects the immune
system regardless of malignant tumors. Another study performed by Prof.
Mittelman&#8217;s research team revealed that patients with advanced multiple myeloma
demonstrate prominent changes in various immune system parameters, and that
treatment of these patients with recombinant EPO results in improvement of the
immune system status in terms of its various components, as well as its
function, which may significantly contribute to the prolonged survival of these
patients.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 35px">
              </td>
              <td style="WIDTH: 49px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">5.2</font></font></div>
              </td>
              <td width="793">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Structure of Xtepo&#8217;s
      field of activity and the changes occurring within
    it</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 83px">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 37px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">5.2.1</font></font></div>
              </td>
              <td width="757">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Multiple Myeloma
      (MM)</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 90pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Multiple
myeloma is a hematological cancer characterized by uncontrolled proliferation of
plasma cells in the bone marrow, thus leading to the formation of malignant cell
foci causing damage and partial bone destruction. This disease has a multi-focal
(multiple) nature, reflected by formation of multiple malignant cell foci. The
malignant cells and the proteins secreted by them are responsible for a series
of clinical manifestations and complications, including damage to the bones,
accompanied by pain and fractures, damage to the bone marrow and anemia,
susceptibility to infections, weakening of the immune system, nervous system
impairment, renal insufficiency, coagulation defects, etc. Multiple myeloma is
an incurable disease, with mean life expectancy of the patients being about 3-5
years.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div style="DISPLAY: block; TEXT-INDENT: 0pt">
            <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div id="FTR">
                <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Transaction
Outline</font></div>
              </div>
              <div id="PN" style="PAGE-BREAK-AFTER: always">
                <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B-7</font></div>
                <div style="WIDTH: 100%; TEXT-ALIGN: center">
                  <hr style="COLOR: black" noshade size="2">
                </div>
              </div>
              <div id="HDR">
                <div id="GLHDR" style="WIDTH: 100%" align="right">
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 90pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In the US
alone, the total number of new cancer cases diagnosed in 2005 was about 1.4
million (about 0.4% of the population), with the number of deaths due to cancer
approaching 0.6 million (about 0.2% of the population)<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: super">3</font>. Out of the overall known
cancer types, the most common types are colon cancer (about 100,000 new
patients), lung cancer (about 170,000 new patients), breast cancer in women
(about 210,000 new patients) and prostate cancer in men (about 230,000 new
patients). In the US alone, the number of patients diagnosed with any type of
cancer is estimated to be several millions.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 90pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Multiple
myeloma is a common hematological cancer accounting for about 10% of all
hematological cancers, with 60,000 multiple myeloma patients currently living in
the US alone. 16,000 new cases are diagnosed in the US annually, and this number
is increasing with the increasing average life expectancy worldwide. In general,
multiple myeloma is considered to be a disease of advanced age, with typical
onset at the age of 65- 70 years, although cases of multiple myeloma diagnosed
in people in their fifties are not rare. In addition, multiple myeloma accounts
for about 1% of overall cancer cases of all types, and for about 2% of all
deaths due to cancer<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: super">4</font>. It should be noted that
multiple myeloma is more common in men, and the risk of developing the disease
is twofold higher in men of African origin, as compared to white
men.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 90pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At
present, numerous medications and treatments are available for multiple myeloma
patients at various disease stages. Sometimes combination therapy is given,
including chemotherapy, radiotherapy, medication therapy and bone marrow
transplantation. It should be noted that the most common treatment given to
multiple myeloma patients is chemotherapy, which destroys cancer cells, but also
causes damage to normal cells in the patients&#8217; body, mainly active cells e.g.
mucous membrane cells, connective tissue cells, as well as blood cells,
including cells of the immune system, cells of the reproductive organs, etc. The
damage caused to normal cells leads to the development of side effects including
nausea, hair loss, severe pain, etc. In addition, biological drugs are
available, which are more specific to cancer cells and known to cause less side
effects, as compared to chemotherapeutic agents. Examples of such drugs are
Thalidomide(R) marketed by Celgene Corporation (hereafter: Thalidomide) and
Velcade(R) developed by Millennium Pharmaceuticals (hereafter: Velcade). These
biological drugs are very expensive and have to be administered, at least in
part, by injection.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 90pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In the
Western world, drugs available on the market of anti- cancer drugs in general,
and on the market of anti- myeloma drugs in particular, are usually approved for
a strictly specific indication. For example, a drug indicated for treatment of
multiple myeloma may only be given to patients complying with the precise
definition of patients eligible for such treatment, based on the disease stage,
previous treatments, etc. This situation leads to an anti- cancer drug market
comprised of multiple patient populations. One of the challenges inherent in
anti- cancer drug development is definition of the filed for which the drug is
intended, since there are numerous types of cancer, each with several disease
stages, and any approved drug is designed to be used during a specific stage of
a specific cancer. There are many patient populations suffering from diseases
for which no appropriate treatments are available.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <hr style="COLOR: black" align="left" noshade size="1" width="25%">
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt"> The data were taken from the NCI
(National Cancer Institute) website </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #0000ff; FONT-FAMILY: Times New Roman; TEXT-DECORATION: underline">http://seer.cancer.gov.csr/1975_2002/results_merged/sect_01_overview.pdf</font></font><a name="ref.ID0EB4AE">&#160; </a></div>
        <div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The
data were taken from the website of Multiple Myeloma Association
http://www.amen.org.il/site_files/index.he.1024.html</font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div style="DISPLAY: block; TEXT-INDENT: 0pt">
            <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div id="FTR">
                <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Transaction
Outline</font></div>
              </div>
              <div id="PN" style="PAGE-BREAK-AFTER: always">
                <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B-8</font></div>
                <div style="WIDTH: 100%; TEXT-ALIGN: center">
                  <hr style="COLOR: black" noshade size="2">
                </div>
              </div>
              <div id="HDR">
                <div id="GLHDR" style="WIDTH: 100%" align="right">
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 90pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Furthermore,
the efficacy of currently available drugs is limited. For each of the available
drugs, there is a considerable percentage of non- responders. In addition, in
many patients considered to be responders, the response to the drug is merely
partial, and drug combination is required in order to achieve the desired
clinical outcome. Malignant tumors are sometimes so aggressive, that a mean
prolongation of survival by several months, or sometimes a slight improvement in
quality of life, is sufficient to define the drug as effective. In view of the
above, there is a clinical need for drugs designed for the treatment of multiple
myeloma, which would be efficient on one hand, and would have a minimal number
of side effects on the other. The new indication for the EPO drug, which Xtepo
intends to develop<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: super">5</font>,
i.e. treatment of multiple myeloma patients, attempts to fulfill this need. That
is: an effective drug not causing significant side effects.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 77px">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 43px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">5.2.2</font></font></div>
              </td>
              <td width="757">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Drug development
      processes</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 90pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
process of drug development is a multi- phase process, composed of the following
phases: pre- clinical phase, Phase I, Phase II and&#160;&#160;Phase III clinical
studies (see paragraph 1.4 above for further details).</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 90pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In view
of Xtepo&#8217;s intention<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: super">6</font>
to develop a new indication for the EPO drug, which is already approved for
another indication, and in view of the fact that the pre- clinical phase and
Phase I clinical studies are aimed at evaluating drug toxicity and safety,
respectively, Xtepo&#8217;s experts believe that the company will receive an exemption
from performing the above clinical studies, and that the drug development
process will begin with a Phase II clinical study.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 90pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
above Xtepo's estimates with respect to the phases of drug development and the
exemption from performing the pre- clinical phase and Phase I clinical studies
include a forward looking statement. This statement is uncertain, and is based
on the information available to the company at the time of preparing this
outline. It should be emphasized that the actual results may be significantly
different from the estimates implied by this statement, thus there is no
certainty with respect to receiving an exemption from performing a certain phase
and/or with respect to the results of the drug trials performed by
Xtepo.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 21.25pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 36pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">5.3</font></font></div>
              </td>
              <td>
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Critical success
      determinants in this field of
activity</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Successful
development of a medical product requires basic knowledge and technology
enabling the development of effective products, long- term investments of both
financial funds and high quality personnel experienced in the specific field of
activity, as well as capacities of commercialization following the completion of
development and approval for marketing. In addition, ownership of intellectual
property is required in order to enable further development and upgrading of the
future product.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <hr style="COLOR: black" align="left" noshade size="1" width="25%">
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Together
with or through its mother company, following completion of the transaction
discussed in this report.</font><a name="ref.ID0EUCAG">&#160; </a></div>
        </div>
        <div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Together
with or through its mother company, following completion of the transaction
discussed in this report.</font></div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div style="DISPLAY: block; TEXT-INDENT: 0pt">
            <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div id="FTR">
                <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Transaction
Outline</font></div>
              </div>
              <div id="PN" style="PAGE-BREAK-AFTER: always">
                <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B-9</font></div>
                <div style="WIDTH: 100%; TEXT-ALIGN: center">
                  <hr style="COLOR: black" noshade size="2">
                </div>
              </div>
              <div id="HDR">
                <div id="GLHDR" style="WIDTH: 100%" align="right">
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Upon
completion of the transaction as detailed in paragraph 13 of the report, Xtepo
will have an exclusive patent license for using the EPO drug for the treatment
of multiple myeloma, based on the research performed by Prof. Moshe Mittleman,
an internationally recognized hematologist, Director of Internal Medicine
Department at Ichilov Hospital, who is also the Principal Investigator at
Xtepo.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 28px">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 48px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">5.4</font></font></div>
              </td>
              <td width="801">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Barriers at the
      entrance to the field of
activity</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The major
barrier at the entrance to the field of drug development is the fact that drug
development is a long- term process, a sequential, accurate and cumulative
procedure lasting for several years. That is, lack of success at any stage of
the development process precludes moving forward to the next stage. Needless to
say, such a long process requires allocation of significant financial resources
in order to cover the ongoing development costs.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
mentioned above, ensuring ownership of intellectual property is of crucial
importance, since no use and development of certain materials and products will
be possible without it, thus precluding any progress in development. In
addition, ensuring ownership of intellectual property is required in order to
benefit from the product developed, and to ensure that the developed product is
not protected by another patent. Without patent protection, anyone would be able
to benefit from the research and development products without covering any
costs, as the original developer, Xtepo in this case, has covered them.
Similarly, if the development extends into the field of another patent, the
patent owner will be able to block any commercial activity of the developer. In
order to ensure commercialization freedom for the development products, the
relevant licenses have to be obtained for product development. In addition to
the above, qualified and professional personnel, experienced in the relevant
field, is required.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 28px">
              </td>
              <td style="WIDTH: 47px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">5.5</font></font></div>
              </td>
              <td width="802">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Alternatives to the
      development product and changes occurring in
  them</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At
present, there are no drugs competing with the EPO drug, which Xtepo<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: super">7</font> intends to develop, in
view of the fact that the EPO drug is designed for treating multiple myeloma
patients already treated with all the currently available treatment options. At
this disease stage, terminal patients are treated with analgesics
only.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In spite
of the above, Xtepo&#8217;s EPO drug may be found effective for non- terminal patients
in the future, if given in combination with other currently available drugs. If
the above prediction turns out to be true, the EPO drug may become useful as an
alternative and/or adjuvant therapy to drugs available on the market and/or
drugs under development. However, approved drugs are available for non- terminal
multiple myeloma patients, which may cause difficulties in penetration into this
market. It must be noted that development of a new indication for an existing
drug is superior to development of a new product, in view of Xtepo&#8217;s estimate
that certain drug development phases will actually become obsolete (mainly Phase
I clinical trial, which has already been performed for the original indication).
However, development of the new indication is expected to be a long lasting
process.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div>
        <hr style="COLOR: black" align="left" noshade size="1" width="25%">
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">7</font> Together
with or through its mother company, following completion of the transaction
discussed in this report.</font></div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div style="DISPLAY: block; TEXT-INDENT: 0pt">
              <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div id="FTR">
                  <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Transaction
Outline</font></div>
                </div>
                <div id="PN" style="PAGE-BREAK-AFTER: always">
                  <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B-10</font></div>
                  <div style="WIDTH: 100%; TEXT-ALIGN: center">
                    <hr style="COLOR: black" noshade size="2">
                  </div>
                </div>
                <div id="HDR">
                  <div id="GLHDR" style="WIDTH: 100%" align="right">
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">It must
be noted that during the last years<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: super">8</font>, the preferred treatment
given to multiple myeloma patients, at various disease stages, is composed of
chemotherapy combined with autologous stem cell transplantation, or a
combination of Thalidomide, dexamethasone (a type of steroid) and Velcade,
depending on the patient&#8217;s condition. If stem cell transplantation is performed,
the patients receive initial high- dose chemotherapy (relevant for patients
younger than 65 years of age).</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
patients older than 65 years of age, the physical condition of which does not
enable autologous stem cell transplantation, the standard chemotherapy is a
combination of two anti- cancer drugs (not specifically indicated for multiple
myeloma treatment), sometimes including Thalidomide.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The above
treatments result in overall survival of about 30 months in 83% of the patients
undergoing autologous stem cell transplantation (below age 65), and in overall
survival of about 24 months in 90% of the patients (above age 65).</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">It must
be clarified that the treatments and medications currently used to
treat&#160;&#160;multiple myeloma are associated with severe side effects, e.g.
neuropathy &#8211; peripheral neuropathy, which may sometimes be irreversible,
requiring treatment discontinuation for prolonged periods of time.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The drug
currently given to terminal patients is Velcade (Bortezomib), approved by the
FDA in 2003. This treatment results in prolongation of survival, with 33% of the
patients achieving the survival period of 5 years; the mean survival period
observed in patients treated with this drug is about 33 months. The EPO drug
developed by Xtepo<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: super">9</font>
may become an alternative to this drug.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 21.25pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 36pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">5.6</font></font></div>
              </td>
              <td>
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Structure of the
      competition in the field of activity and changes occurring in
      it</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 76px">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 44px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">5.6.1</font></font></div>
              </td>
              <td width="757">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">General</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 90pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
competitors in this field of activity are a broad range of companies worldwide,
including small bio- pharmaceutical companies, up to huge international
companies. International marketing of a drug requires access to worldwide
marketing channels, which usually forces small companies to cooperate with large
companies in the field. On one hand, this is a limiting factor
for&#160;&#160;small companies, and on the other- these huge companies are
always searching for new drugs in order to enrich the range of products marketed
by them, or their &#8220;drug development pipeline&#8221;. During certain periods, the need
for new drugs leads the huge multi- national companies to make very high
investments in order to purchase rights for drug development and marketing,
which may provide an opportunity for companies developing drugs.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div>
        <hr style="COLOR: black" align="left" noshade size="1" width="25%">
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">8</font> The
above information with respect to the treatment of multiple myeloma patients and
their survival periods was taken from the paper by Prof. Ben-Ami Sela, Director
of the Institute of Pathological Chemistry, Sheba Medical Center, Tel Hashomer,
published online: www.tevalife.com</font><a name="ref.ID0E3NAG">&#160;
</a></div>
        </div>
        <div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">9</font> Together
with or through its mother company, following completion of the transaction
discussed in this report.</font></div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div style="DISPLAY: block; TEXT-INDENT: 0pt">
              <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div id="FTR">
                  <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Transaction
Outline</font></div>
                </div>
                <div id="PN" style="PAGE-BREAK-AFTER: always">
                  <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B-11</font></div>
                  <div style="WIDTH: 100%; TEXT-ALIGN: center">
                    <hr style="COLOR: black" noshade size="2">
                  </div>
                </div>
                <div id="HDR">
                  <div id="GLHDR" style="WIDTH: 100%" align="right">
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 90pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
company<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: super">10</font> has a
preliminary design for a Phase II clinical trial, including enrolment of about
50 patients<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: super">11</font>.
Development of numerous drugs at the time of Xtepo&#8217;s trial may impose
difficulties on patient enrolment for Phase II and III clinical trials. The need
for a significant number of patients during the advanced phases of clinical
trials may become a considerable obstacle in drug development, which may affect
the chances and the schedule of Xtepo&#8217;s EPO drug development. In many cases,
this problem may be solved by using a development strategy including, among
others: correct definition of study subjects (by disease severity grade, by
types of previous treatments received, by types of concomitant medications
received together with the study drug, etc.); optimal selection of study centers
(for example, performing some trials in countries where other treatment
alternatives are not yet offered to the patients, or choosing study centers
famous for their relatively rapid enrolment capacity, etc.); use of companies
specializing in performance of clinical studies<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: super">12</font>; interest of the
investigators participating in the study with respect to the drug and its
mechanism of action; providing financial contribution to the research funds of
departments participating in the study (this incentive is indirectly designed to
improve hospitalization conditions for the patients) in order to ensure referral
of patients to Xtepo&#8217;s clinical trial, rather than referral to other clinical
trials. Xtepo intends to use such strategies in order to ensure rapid patient
enrolment and compliance with the predetermined schedule, although this cannot
be guaranteed.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 26.65pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 63pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">5.6.2</font></font></div>
              </td>
              <td>
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Competition in the
      cancer market</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 90pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
market of anti- cancer drugs is a huge market. In 2003, the overall volume of
sales of anti- cancer drugs had reached 28 billion USD, out of which about 15
billion USD were attributed to drugs against multiple myeloma, while the
remaining sum included supportive care drugs (e.g. drugs for regeneration of the
immune and blood systems damaged by chemotherapy, anti- emetic drugs, etc.).
During 2003- 2004, Velcade, a new anti- cancer drug indicated for the treatment
of multiple myeloma, was approved and introduced into the market. For details on
other drugs competing with Xtepo&#8217;s drug, see paragraph 5.5 above.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 26.65pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 63pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">5.6.3</font></font></div>
              </td>
              <td>
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Ways of coping with
      competition</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 90pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In order
to successfully cope with the expected competition, Xtepo<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: super">13</font> must position its drug
on the market while emphasizing its superiority over the competing drugs.
According to Xtepo&#8217;s estimates, the expected advantages of its drug, subject to
approval, are based on the assumption that it will prolong survival, and improve
the patients&#8217; quality of life with minimal side effects. According to Xtepo&#8217;s
estimates, the fact that its drug may be effective when given in combination
with other available drugs, or after treatment with other drugs, will reinforce
its position and provide the company with a marketing advantage. Thus, provided
that the drug is approved, these advantages are expected to grant the company
significant superiority, which will ensure a great advantage in the market of
multiple myeloma treatments, based on the right marketing efforts.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <hr style="COLOR: black" align="left" noshade size="1" width="25%">
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">10</font>
Together with or through its mother company, following completion of the
transaction discussed in this report.</font><a name="ref.ID0E5RAG">&#160;
</a></div>
        </div>
        <div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">11</font> This
assumption is based on the number of patients required for clinical trials with
other drugs designed for the treatment of multiple myeloma and cancer in
general. No comprehensive statistical design has yet been planned, and Xtepo had
not yet discussed the clinical design with the regulatory authorities, the FDA
and others, thus the actual number of patients required may differ from the
above assumption.</font><a name="ref.ID0ESSAG">&#160; </a></div>
        </div>
        <div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">12</font> These
companies are known as CRO &#8211; Clinical Research Organization</font><a name="ref.ID0E6VAG">&#160; </a></div>
        </div>
        <div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">13</font>
Together with or through its mother company, following completion of the
transaction discussed in this report.</font></div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div style="DISPLAY: block; TEXT-INDENT: 0pt">
              <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div id="FTR">
                  <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Transaction
Outline</font></div>
                </div>
                <div id="PN" style="PAGE-BREAK-AFTER: always">
                  <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B-12</font></div>
                  <div style="WIDTH: 100%; TEXT-ALIGN: center">
                    <hr style="COLOR: black" noshade size="2">
                  </div>
                </div>
                <div id="HDR">
                  <div id="GLHDR" style="WIDTH: 100%" align="right">
                  </div>
                </div>
                <div>&#160;</div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 90pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
addition, the clinical advantages of the product and the ability to protect the
intellectual property are crucial factors influencing the ability to introduce a
new product into the market and to cope with competition. In view of the fact
that the company has an exclusive patent license to use recombinant EPO for the
treatment of multiple myeloma patients, the company believes that the drug has
the right qualities suitable for coping with the expected
competition.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 90pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Several
years are required for Xtepo&#8217;s product to reach the market. However, until that
stage is reached, one of the huge companies in this field may wish to cooperate
with Xtepo<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: super"><a href="#ref.ID0EWXAG">14</a></font> in the development and/ or marketing of the
EPO drug.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 90pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Xtepo's
estimates with respect to adjustment of the product and its introduction into
the market include a forward looking statement. This statement is uncertain, and
is based on the information available to the company at the time of preparing
this outline. The actual results may be significantly different from the
estimates implied by this statement, thus there is no certainty with respect to
the results of the drug trials performed by Xtepo.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 27pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.</font></div>
              </td>
              <td>
                <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Intangible
      assets</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36px">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 40px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.1</font></font></div>
              </td>
              <td width="801">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Patent licensing
      agrrements</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
December, 2009, Xtepo had signed an agreement with Bio- Gal Limited (hereafter:
Bio &#8211; Gal) for purchasing a patent license for using recombinant EPO to treat
terminal multiple myeloma patients and to improve their quality of life. The
said transaction is subject to the prerequisites detailed in paragraph 18 of
this report. For further details on the license agreement, see paragraph 8.1
below.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 27pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.</font></div>
              </td>
              <td>
                <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Restrictions, valid
      legislation and special constraints relevant to the field of
      activity</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 37px">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 39px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.1</font></font></div>
              </td>
              <td width="801">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Helsinki
      committee</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Approval
of clinical trials in human subjects by the relevant authorities (in each of the
countries where Xtepo<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: super"><a href="#ref.ID0EL4AG">15</a></font> intends to conduct a trial) is a prerequisite
for performing clinical trials sponsored by Xtepo. The trials have to comply
with the principles of the Declaration of Helsinki, and be approved by the
ethics committee at every institution participating in the trial. The physician
and/or physician&#8217;s committee, with whom Xtepo will collaborate, will submit the
study protocol to the institutional ethics committee. Following discussion,
including examination of the ethical aspects of the study, subject to protocol
approval, the trial may be initiated. Any protocol change requires updating and
resubmission for approval by the ethics committee.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <hr style="COLOR: black" align="left" noshade size="1" width="25%">
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">14</font>
Together with or through its mother company, following completion of the
transaction discussed in this report.</font><a name="ref.ID0EL4AG">&#160;
</a></div>
        <div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">15</font>
Together with or through its mother company, following completion of the
transaction discussed in this report.</font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div style="DISPLAY: block; TEXT-INDENT: 0pt">
              <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div id="FTR">
                  <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Transaction
Outline</font></div>
                </div>
                <div id="PN" style="PAGE-BREAK-AFTER: always">
                  <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B-13</font></div>
                  <div style="WIDTH: 100%; TEXT-ALIGN: center">
                    <hr style="COLOR: black" noshade size="2">
                  </div>
                </div>
                <div id="HDR">
                  <div id="GLHDR" style="WIDTH: 100%" align="right">
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Approval
by Helsinki committee &#8211; as discussed above, is a prerequisite for approving the
use of medicinal products by Western health authorities, including the Israel
Ministry of Health; it enables proof of safety and efficacy of medicinal
products by clinical trials. In order to perform clinical trials in Israel,
approval of the protocol has to be obtained (hereafter: authorization) from the
committee (the above Helsinki committee), acting in accordance with People&#8217;s
Health Regulations (Clinical trials in human subjects), 1980) (hereafter:
People&#8217;s Health Regulations).</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Authorization
is subject to submission of the application for approval by a licensed
physician, who will be the investigator responsible for the study; the
investigator participating in the human clinical trial will have the skills and
the relevant expertise required for conducting the trial under the following
conditions:</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 49.65pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 27pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a)</font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      expected advantages, for the subject and the company, justify the risk and
      discomfort associated with the trial for the
  subject;</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 49.65pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 27pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">b)</font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      existing scientific and medical information justify performance of the
      requested clinical trial;</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 49.65pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 27pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">c)</font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      clinical study design is scientifically valid, enabling it to provide
      answers to the question under investigation; it is presented in a clear,
      detailed and accurate manner in the study
  protocol;</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 49.65pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 27pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">d)</font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      risk for the study subject is minimal, due to the use of correct methods,
      and use of procedures already performed in humans or tested in animals, as
      much as possible;</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 49.65pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 27pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">e)</font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      study subjects will be chosen in accordance with inclusion/ exclusion
      criteria specified in the study
protocol;</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 49.65pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 27pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">f)</font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Informed
      consent form for the study including all the required information, as
      specified in the procedure;</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 49.65pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 27pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">g)</font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Study
      design including instructions with respect to patient&#8217;s privacy protection
      and confidentiality of the data
collected;</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 49.65pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 27pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">h)</font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      study design includes a proper mechanism of study
    monitoring;</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 49.65pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 27pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">i)</font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      sponsored has ensured proper insurance coverage for the study
      subjects;</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 49.65pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 27pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">j)</font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      sponsor and the investigator are capable of allocating the resources
      required for adequate performance of the study, including qualified
      personnel and the necessary
equipment;</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 49.65pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 27pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">k)</font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Adequate
      performance of the study will not be harmed by the nature of commercial
      agreement with the investigator and the institution in which the study is
      performed;</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 49.65pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 27pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">l)</font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      the study subjects, some or all, may be exposed to inadequate pressure or
      influence in order to convince them to participate in the study &#8211;
      appropriate measures were taken in order to prevent the above pressure or
      to minimize the above influence.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div style="DISPLAY: block; TEXT-INDENT: 0pt">
              <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div id="FTR">
                  <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Transaction
Outline</font></div>
                </div>
                <div id="PN" style="PAGE-BREAK-AFTER: always">
                  <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B-14</font></div>
                  <div style="WIDTH: 100%; TEXT-ALIGN: center">
                    <hr style="COLOR: black" noshade size="2">
                  </div>
                </div>
                <div id="HDR">
                  <div id="GLHDR" style="WIDTH: 100%" align="right">
                  </div><a name="ref.ID0EWXAG" /></div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36px">
              </td>
              <td style="WIDTH: 38px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.2</font></font></div>
              </td>
              <td width="803">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Approval by FDA and
      EMEA</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
product to be developed by Xtepo<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: super">16</font> is a medicinal product.
Thus, its production, sale and marketing are dependent on its approval in every
country where it is intended for marketing. In order to receive the above
approval, Xtepo has to comply with the approval requirements, including safety
and quality control standards, as required in each of the
countries.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
requirements for approval of the drug for sale, as well as the duration of the
approval process and the costs associated with it, vary from one country to
another. Lack of approval of Xtepo&#8217;s product in a certain country will preclude
its sale, thus reducing Xtepo&#8217;s income. The major markets where Xtepo intends to
act are the US and the European Union.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Having
completed the product development process, Xtepo<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: super">17</font> intends to receive
approvals by FDA and EMEA for its marketing and sale. It must be clarified that
these approvals are separate and independent. Such approval will be required in
the future for any product change to be approved or for extension of the
existing applications.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Following
approval by FDA and EMEA, Xtepo will be authorized to market the product only
for the approved indication. The FDA and EMEA may perform audits and
investigations in order to verify that Xtepo meets the requirements determined
by law and regulation. In addition, Xtepo may act to monitor its compliance with
FDA requirements using a system of quality control, thus significantly reducing
the chances of failures and enabling warning of failures in advance, if
discovered. Failure to comply with the requirements may lead to sanctions
against Xtepo, including publication of a Black box warning with respect to the
product, imposition of penalties and civil compensations, refusal to approve new
products of the company or cancellation of existing product
approval.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">It must
be noted that at present, FDA is the most stringent authority; therefore FDA
approval is a significant indication for approval by other regulatory
authorities.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 27pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.</font></div>
              </td>
              <td>
                <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Essential
      agreements</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 37px">
              </td>
              <td style="WIDTH: 36px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.1</font></font></div>
              </td>
              <td width="804">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">License agreement with
      Bio- Gal</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
December 31<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">st</font>, 2009,
Xtepo had signed a transfer of rights agreement for exclusive patent license (as
defined below) with Bio- Gal, which was originally signed between Bio- Gal and
Yeda Research and Development Ltd. (hereafter: Yeda) and Mor Research
Applications Ltd. (hereafter: Mor) (Yeda and Mor together are &#8220;license owners&#8221;)
in 2002 (hereafter: original license agreement), for exclusive use of the
registered patent of the EPO drug license owners, in order to develop a new
indication intended to prolong the survival and improve the quality of life of
multiple myeloma patients (hereafter: the patent). It must be noted that the
transfer of rights according to the original license agreement was dependent on
consent of the license owners, who gave their consent, thus enabling Xtepo to
replace Bio- Gal as a valid license owner.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div>
        <hr style="COLOR: black" align="left" noshade size="1" width="25%">
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">16</font>
Together with or through its mother company, following completion of the
transaction discussed in this report.</font><a name="ref.ID0ELLBG">&#160;
</a></div>
        <div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">17</font>
Together with or through its mother company, following completion of the
transaction discussed in this report.</font></div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div style="DISPLAY: block; TEXT-INDENT: 0pt">
              <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div id="FTR">
                  <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Transaction
Outline</font></div>
                </div>
                <div id="PN" style="PAGE-BREAK-AFTER: always">
                  <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B-15</font></div>
                  <div style="WIDTH: 100%; TEXT-ALIGN: center">
                    <hr style="COLOR: black" noshade size="2">
                  </div>
                </div>
                <div id="HDR">
                  <div id="GLHDR" style="WIDTH: 100%" align="right">
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">According
to the terms of the original license agreement, Bio Gal is committed to conduct
the research for further development of the patents owned by the license owners,
including full financing of the research, and will be the owner of an exclusive
license for the development, use, marketing, distribution and sale of drugs for
the treatment of multiple myeloma and other types of cancer, as permitted by the
research. According to the license agreement, Bio- Gal will bear all the costs
associated with the preparation, completion, maintenance and protection of any
patent registered as a result of the research. The exclusive license given to
the above company will be effective for 15 years from the day of the first
commercial sale of the drug by Bio- Gal, or until expiration of the patent in
the countries where the patent is registered (the latest of the events). It
should be noted that the patent is registered in the US since 1999, as well as
in Europe, Israel and Hong Kong. In addition, patent applications were submitted
in Canada and Japan. The patent will expire in 2019 in those countries where it
was registered.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In return
for the transfer of the above license, and in accordance with modifications
introduced into the original license agreement (the last one was introduced in
April 2008), Xtepo will pay to Yeda, with guarantee of the mother
company:</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 72px">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 30px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.</font></div>
              </td>
              <td width="775">
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Annual
      license fee of one percent (1%) of the net sales of Xtepo and its
      subcontractors.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 72px">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 30px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.</font></div>
              </td>
              <td width="775">
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
      single payment upon the following conditions: (1) Sale of 50% or more of
      Xtepo&#8217;s shares to a third party (2) Merging of Xtepo with a third party
      (3) Sale or transfer of Xtepo&#8217;s strategic assets (hereafter: realization
      event), with a value of&#160;&#160;250,000 USD or 2.5% of the gross profit
      of Xtepo from this event (the lowest of the
  two).</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 72px">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 30px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.</font></div>
              </td>
              <td width="775">
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      spite of the above, the parties have decided to agree that although
      performance of the transaction according to this report is a realization
      event, the appropriate payments will be postponed until the successful
      completion of Phase II clinical trial, following which Xtepo will pay Yeda
      a single sum of 250,000 USD, and additional 100,000 USD in case of raising
      at least 2 million USD, and subject to successful completion of Phase II
      clinical trial.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 27pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.</font></div>
              </td>
              <td>
                <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Human
      resources</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36px">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 40px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">9.1</font></font></div>
              </td>
              <td width="801">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Organizational
      structure</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Since
Xtepo was founded on November 9, 2009, at the date of preparing this outline,
the company had no employees.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.</font></div>
              </td>
              <td width="841">
                <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Taxation</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 35px">
              </td>
              <td style="WIDTH: 40px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">10.1</font></font></div>
              </td>
              <td width="802">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Tax rates applicable
      to Xtepo as an Israeli
company</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In June
2004, correction of the income tax law was accepted by the Knesset (no. 140),
2004, and on July 25, 2005, correction of the income tax law was accepted by the
Knesset (no. 147), 2005 (published in the records on August 10, 2005), stating,
among others, that corporation tax will be gradually reduced as follows: year
2005 &#8211; 34%, year 2006- 31%, year 2007 &#8211; 29%, year 2008 &#8211; 27%, year 2009 &#8211; 26%,
year 2010 and on &#8211; 25%.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div style="DISPLAY: block; TEXT-INDENT: 0pt">
              <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div id="FTR">
                  <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Transaction
Outline</font></div>
                </div>
                <div id="PN" style="PAGE-BREAK-AFTER: always">
                  <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B-16</font></div>
                  <div style="WIDTH: 100%; TEXT-ALIGN: center">
                    <hr style="COLOR: black" noshade size="2">
                  </div>
                </div>
                <div id="HDR">
                  <div id="GLHDR" style="WIDTH: 100%" align="right">
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
February 2008, correction of the income tax law was accepted by the Knesset
(adjustments for inflation),1985, which limits the application of the
adjustments law from 2008 and on. Since 2008, the results for taxation are
measured in nominal values, except for certain adjustments due to changes in the
consumer price index up to December 31, 2007. The correction of the law
includes, among others, cancellation of the addition and deduction due to
inflation and the additional deduction due to depreciation since
2008.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Since
Xtepo was founded on November 9, 2009, the company has not yet paid
taxes.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">11.</font></div>
              </td>
              <td>
                <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Aims and business
      strategy</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Xtepo
intends to continue developing<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: super">18</font> the EPO drug for
treatment of multiple myeloma patients, and to initiate Phase II clinical trial,
thus enhancing the value of the company and the EPO drug.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Xtepo's
estimates with respect to the aims and business strategy include a forward
looking statement. This statement is uncertain, and is based on the information
available to the company at the time of preparing this outline. The actual
results may be significantly different from the estimates implied by this
statement. This is a clinical drug development, which is a process associated
with a high degree of uncertainty, thus there is no certainty with respect to
the development schedule and obtaining preliminary clinical results for the EPO
drug as expected by Xtepo&#8217;s management.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12.</font></div>
              </td>
              <td>
                <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Expected development
      over the next year</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During
the next year, Xtepo intends to collect long- term clinical data on patients,
and to perform Phase II clinical trials, which will demonstrate the benefits of
the EPO drugs in multiple myeloma patients.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Xtepo's estimates with respect to
development over the next year</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">include a forward looking statement.
This statement is uncertain, and is based on the information available to the
company at the time of preparing this outline. The actual results may be
significantly different from the estimates implied by this statement, since
there is no certainty with respect to the continuation and the results of the
clinical trials to be performed by Xtepo.</font></font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">13.</font></div>
              </td>
              <td>
                <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Discussion of risk
      factors</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
following are details on risk factors, which may significantly affect Xtepo&#8217;s
activity and its business outcomes:</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 49px">
              </td>
              <td style="WIDTH: 35px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">13.1</font></font></div>
              </td>
              <td width="793">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Risks of the
      field</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 83px">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 62px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">13.1.1</font></font></div>
              </td>
              <td width="732">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Exposure to the
      effects of regulation</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As any
company acting in the medical field, Xtepo&#8217;s activity is subject to approvals,
licenses and supervision of government and worldwide authorities associated with
environmental control, toxins, medicine, etc. Changes in laws and regulations
associated with Xtepo&#8217;s activity may require heavy expenses, and may even lead
to discontinuation of the EPO drug development.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div>
        <hr style="COLOR: black" align="left" noshade size="1" width="25%">
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">18</font>
Together with or through its mother company, following completion of the
transaction discussed in this report.</font></div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div style="DISPLAY: block; TEXT-INDENT: 0pt">
              <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div id="FTR">
                  <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Transaction
Outline</font></div>
                </div>
                <div id="PN" style="PAGE-BREAK-AFTER: always">
                  <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B-17</font></div>
                  <div style="WIDTH: 100%; TEXT-ALIGN: center">
                    <hr style="COLOR: black" noshade size="2">
                  </div>
                </div>
                <div id="HDR">
                  <div id="GLHDR" style="WIDTH: 100%" align="right">
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 83px">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 63px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">13.1.2</font></font></div>
              </td>
              <td width="731">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Dependence on external
      funding</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Being a
biotechnological company, Xtepo<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: super">19</font> is dependent on external
funding, since it has no income, while the expenses associated with the EPO drug
development are high. Xtepo&#8217;s financial resources may be depleted at a certain
stage, which will disable further funding of development of the above
drug.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 83px">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 63px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">13.1.3</font></font></div>
              </td>
              <td width="731">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Dependence on highly
      professional and skilled
personnel</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Being a
biotechnological company, Xtepo needs highly professional and skilled personnel,
capable of performing the tasks required for Xtepo&#8217;s activity with high level of
proficiency in order to achieve maximal results with maximal
supervision.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 82px">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 64px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">13.1.4</font></font></div>
              </td>
              <td width="731">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Dependence on
      volunteers for the trial</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Being a
biotechnological company performing clinical trials, Xtepo needs healthy
volunteers and patients for its trials. There are often difficulties associated
with enrolment of patients, due to the high competition for recruitment of these
patients (especially terminally ill patients), as well as due to treatment of
these patients with other drugs, which excludes them from the
study.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 82px">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 64px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">13.1.5</font></font></div>
              </td>
              <td width="731">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Exposure to
      lawsuits</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In view
of its activity in the field of medicine, Xtepo may be exposed to legal
procedures due to possible side effects of the EPO drug. Drug side effects are
known phenomena, especially during development stages. The company cannot
exclude with certainty discovery of a possible side effect of EPO, which may
expose Xtepo to various lawsuits.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 81px">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 64px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">13.1.6</font></font></div>
              </td>
              <td width="732">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Competitors</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Xtepo is
exposed to the risk of possible development of a similar drug&#160;&#160;- for
further details on competition and products competing with Xtepo&#8217;s product, see
paragraph 5.6 above.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
addition, it must be noted that following patent expiration in 2019, the drug
will become a generic drug. Of note, the patent for the use of Erythropoietin
for the treatment of anemia is about to expire soon, and there is a risk of off-
label use of&#160;&#160;Erythropoietin in certain countries. However, such risk
may be limited by the fact that the EPO drug is accompanied by a Black box
warning, which may reduce its off- label use.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div>
        <hr style="COLOR: black" align="left" noshade size="1" width="25%">
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">19</font>
Together with its mother company, following completion of the transaction
discussed in this report</font></div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">
                <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                  <div id="FTR">
                    <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Transaction
Outline</font></div>
                  </div>
                  <div id="PN" style="PAGE-BREAK-AFTER: always">
                    <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B-18</font></div>
                    <div style="WIDTH: 100%; TEXT-ALIGN: center">
                      <hr style="COLOR: black" noshade size="2">
                    </div>
                  </div>
                  <div id="HDR">
                    <div id="GLHDR" style="WIDTH: 100%" align="right">
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 81px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">13.2</font></div>
              </td>
              <td width="796">
                <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Risks
      unique to the company</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 81px">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 62px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">13.2.1</font></font></div>
              </td>
              <td width="734">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Development
      failure</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Being a
biotechnological company, Xtepo relies on the potential development of the EPO
drug<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: super">20</font>, while
currently it has no income at all. If the company&#8217;s expectations with respect to
the EPO drug development do not lead to a product of marketing feasibility, then
the existence of Xtepo as an independent company will become questionable. Since
the company is involved in drug development, there is no guarantee for
successful outcomes of the clinical trials with Xtepo&#8217;s drug. If these trials
fail, then the very existence of Xtepo will become questionable. It must be
noted that medical research is associated with a high degree of uncertainty, and
the possibility that Xtepo will not be able to demonstrate the expected efficacy
and safety of the EPO drug cannot be excluded. In addition, development of other
drugs by competitors, competing with Xtepo for the same market share, cannot be
excluded as well.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 81px">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 62px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">13.2.2</font></font></div>
              </td>
              <td width="734">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Relative dependence on
      a key person</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
company is dependent on Prof. Moshe Mittelman as the Medical Director<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: super">21</font> of the company.
Development of the indication for the EPO drug is based on his research. If, for
any reason, Prof. Mittelman does not support the scientific/ medical aspects
and/or does not perform his duties at the company, damage to the company may be
expected<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: super">22</font>. If Prof.
Mittelman stops his activity at the company, finding a person capable of
replacing him at Xtepo may take a lot of time. It must be emphasized that Prof.
Mittelman&#8217;s absence will not significantly affect the ongoing performance of the
clinical trials with the EPO drug.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 81px">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 61px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">13.2.3</font></font></div>
              </td>
              <td width="735">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Protection of
      intellectual property</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Being a
biotechnological company, Xtepo heavily relies on the potential maintenance and
protection of its intellectual property. Impairment of its intellectual property
by violation of the patent granted to the company may severely damage Xtepo&#8217;s
business activity, since without appropriate protection, any company may use
Xtepo&#8217;s product without being required to make heavy investments in development.
In addition, it is possible that the patent granted to the company will not be
able to withstand a legal process attacking the claims included in
it.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 80px">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 62px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">13.2.4</font></font></div>
              </td>
              <td width="735">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Marketing and
      sales</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Xtepo has
no manufacturing, marketing and sales capacities. If the EPO drug reaches the
stage of its commercialization by Xtepo, Xtepo will have to collaborate with
another company in order to develop manufacturing, marketing and sales
activities and to realize the marketing potential of the drug. It must be noted
that upon completion of the transaction discussed in this report, Xtepo is
expected to act together with or through its mother company to execute
development, marketing, commercialization and sale of the drug.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 77px">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 65px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">13.2.5</font></div>
              </td>
              <td width="735">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      following table summarizes the risk factors, which may affect Xtepo&#8217;s
      business activity and business outcomes, and Xtepo&#8217;s estimate of the
      extent of effect for each risk
factor</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
        <div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
            <hr style="COLOR: black" align="left" noshade size="1" width="25%">
          </div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">20</font>
Together with or through its mother company, following completion of the
transaction discussed in this report.</font><a name="ref.ID0EGNAI">&#160;
</a></div>
        </div>
        <div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">21</font> Of
note, following completion of the transaction discussed in this report, Prof.
Mittelman will serve as the Medical Director at Extipo&#8217;s mother
company.</font><a name="ref.ID0E1NAI">&#160; </a></div>
        </div>
        <div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">22</font>
Together with its mother company, following completion of the transaction
discussed in this report.</font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">
          <div style="DISPLAY: block; TEXT-INDENT: 0pt">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div style="DISPLAY: block; TEXT-INDENT: 0pt">
                  <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                    <div id="FTR">
                      <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Transaction
Outline</font></div>
                    </div>
                    <div id="PN" style="PAGE-BREAK-AFTER: always">
                      <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B-19</font></div>
                      <div style="WIDTH: 100%; TEXT-ALIGN: center">
                        <hr style="COLOR: black" noshade size="2">
                      </div>
                    </div>
                    <div id="HDR">
                      <div id="GLHDR" style="WIDTH: 100%" align="right">
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
      <div>
        <div align="left">
          <table cellpadding="3" cellspacing="0" width="100%">
              <tr>
                <td align="left" valign="top" width="13%" style="BORDER-TOP: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Type
      of risk</font></div>
                </td>
                <td align="left" valign="top" width="44%" style="BORDER-TOP: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Brief
      description</font></div>
                </td>
                <td colspan="3" valign="top" width="43%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-TOP: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Extent
      of effect on Xtepo&#8217;s business activity</font></div>
                </td>
              </tr>
              <tr>
                <td valign="top" width="13%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="44%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="15%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">High</font></div>
                </td>
                <td valign="top" width="15%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Moderate</font></div>
                </td>
                <td valign="top" width="13%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Low</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" rowspan="5" valign="top" width="13%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Risks
      of the field</font></div>
                </td>
                <td align="left" valign="top" width="44%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Being
      subjected to law and regulation</font></div>
                </td>
                <td valign="middle" width="15%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">V</font></div>
                </td>
                <td valign="middle" width="15%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></div>
                </td>
                <td valign="middle" width="13%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr>
                <td align="left" valign="top" width="44%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Dependence
      on external funding</font></div>
                </td>
                <td valign="middle" width="15%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">V</font></div>
                </td>
                <td valign="middle" width="15%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></div>
                </td>
                <td valign="middle" width="13%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr>
                <td align="left" valign="top" width="44%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Dependence
      on professional and skilled personnel</font></div>
                </td>
                <td valign="middle" width="15%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></div>
                </td>
                <td valign="middle" width="15%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">V</font></div>
                </td>
                <td valign="middle" width="13%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr>
                <td align="left" valign="top" width="44%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Dependence
      on recruitment of study subjects</font></div>
                </td>
                <td valign="middle" width="15%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">V</font></div>
                </td>
                <td valign="middle" width="15%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></div>
                </td>
                <td valign="middle" width="13%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr>
                <td align="left" valign="top" width="44%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Possible
      side effects of the drug, certainly during development &#8211; potential
      lawsuits</font></div>
                </td>
                <td valign="middle" width="15%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></div>
                </td>
                <td valign="middle" width="15%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">V</font></div>
                </td>
                <td valign="middle" width="13%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr>
                <td valign="top" width="13%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td align="left" valign="top" width="44%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Development
      of competing drugs</font></div>
                </td>
                <td valign="middle" width="15%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></div>
                </td>
                <td valign="middle" width="15%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">V</font></div>
                </td>
                <td valign="middle" width="13%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr>
                <td align="left" rowspan="3" valign="top" width="13%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Risks
      unique to the company</font></div>
                </td>
                <td align="left" valign="top" width="44%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Numerous
      elements of uncertainty &#8211; insufficient results, delay or failure of the
      drug &#8211; no guarantee of successful trial or absence of side
      effects</font></div>
                </td>
                <td valign="middle" width="15%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">V</font></div>
                </td>
                <td valign="middle" width="15%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></div>
                </td>
                <td valign="middle" width="13%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr>
                <td align="left" valign="top" width="44%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Due
      to the high dependence on patents and maintenance of intellectual
      property, there may be potential violation of existing
      patents.</font></div>
                </td>
                <td valign="middle" width="15%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></div>
                </td>
                <td valign="middle" width="15%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">V</font></div>
                </td>
                <td valign="middle" width="13%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr>
                <td align="left" valign="top" width="44%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In
      the future, when Xtepo&#8217;s drugs reach the stage of manufacture, Xtepo will
      be dependent on manufacturing facilities of other companies, since it has
      no capacity of mass production of the drug.</font></div>
                </td>
                <td valign="middle" width="15%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></div>
                </td>
                <td valign="middle" width="15%" style="BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">V</font></div>
                </td>
                <td valign="middle" width="13%" style="BORDER-RIGHT: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
          <div style="DISPLAY: block; TEXT-INDENT: 0pt">
            <div style="DISPLAY: block; TEXT-INDENT: 0pt">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                  <div style="DISPLAY: block; TEXT-INDENT: 0pt">
                    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                      <div id="FTR">
                        <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Transaction
Outline</font></div>
                      </div>
                      <div id="PN" style="PAGE-BREAK-AFTER: always">
                        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B-20</font></div>
                        <div style="WIDTH: 100%; TEXT-ALIGN: center">
                          <hr style="COLOR: black" noshade size="2">
                        </div>
                      </div>
                      <div id="HDR">
                        <div id="GLHDR" style="WIDTH: 100%" align="right">
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">(C)
Fairness Opinion</font></div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><img src="logo1.jpg" alt=""></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 36pt; FONT-FAMILY: Times New Roman">Fairness
opinion</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><br>&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 36pt; FONT-FAMILY: Times New Roman">XTL -
Bio-Gal</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><br>&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman">December
2009</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-1</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Introduction</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.1</font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">General</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have
been requested by the Management of XTL Biopharmaceuticals Ltd. (hereafter:
&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">XTL&#8221; </font>or &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">the Company&#8221;) </font>to express an
opinion on the fairness of the ratios derived from the merger transaction and
the share swap contemplated therein (hereafter: &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">the Transaction</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8221;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">) </font>between<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>XTL and Bio-Gal Ltd.
(hereafter &#8211; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Bio-Gal</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8221;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">), </font>pursuant to which
approximately 70% of XTL&#8217;s shares will be allotted to the shareholders of
Bio-Gal and the New Investors, as detailed below.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In the
context of the review, we performed the following activities:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      read, analyzed and examined the data, records, legal memoranda and
      documentation furnished to us in regard to the Transaction, Bio-Gal and
      the Company.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      reviewed public data, including inter alia the evolvement process of the
      Company&#8217;s share price.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      performed various calculations as detailed and required for assessing the
      reasonableness of the merged companies&#8217; value derived from the
      Transaction.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      held talks with the Company&#8217;s CEO, Mr. David Grossman and with the CFO,
      Mr. Ronen Twito, who provided us with the data used in this
      Opinion.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      prepared a reasonableness test to examine the assumptions underlying the
      value of the subject Transaction.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
information contained herein does not necessarily cover all the data that a
shareholder might require. A fairness opinions (hereafter: &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">the Opinion&#8221;) </font>is not intended
for a specific investor, because his considerations in determining value are
likely to be influenced by additional factors, which we have not taken into
account. This report does not include accounting, legal or physical due
diligence reviews, nor does it purport to contain all the information, tests,
assessments or any other data covered by the due diligence process.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
assumed that the financial data, diverse information and the presentations on
which we relied, are complete and fair, and we have not independently verified
them. To perform the review, we presumed that the information is accurate and/or
complete and/or fair, and there was no reason to infer that the data on which we
relied is inaccurate or incomplete or unfair, and we have therefore not tested
the information independently. Reliance on it neither substantiates nor confirms
its correctness. If it transpires that the financial and other data, together
with the documentation delivered to us, are inaccurate and/or incomplete and/or
unfair, the reasonableness review will change accordingly.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-2</font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
fairness test performed for the Transaction is correct up to November 2009 and
is based, inter alia, on XTL&#8217;s financial statements for the first 6 months of
2009.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We agree
that our Opinion be included and/or cited in the report to be filed by XTL with
respect to the Transaction, in conformity with the disclosure requirements
applicable to XTL under the Securities Law or any other legislation, including
any amended reported which the Company may be required to file.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Details
of the Assessing Company and of Person Performing the Review</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ziv Haft
Consulting and Management Ltd. is part of the BDO worldwide network, providing
corporate consulting and management services in a wide range of subjects to
companies operating in diverse sectors.&#160;&#160;The Company has wide
expertise and experience in providing the following services: performing
valuations, due diligence reviews (economic and accounting), valuations of
goodwill and intangible assets, economic analyses, current analyses of Israeli
public companies engaged in the hi-tech and communication sectors, business
plans, presentations for potential investors, financial management and analysis
of BOT and PFI projects, receiverships, liquidations and appointment as special
administrator, assisting companies in distress, developing plans for corporate
recovery, business and corporate management, overseeing mergers and split-ups,
planning transactions, and more.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div id="FTR">
              <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
            </div>
            <div id="PN" style="PAGE-BREAK-AFTER: always">
              <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-3</font></div>
              <div style="WIDTH: 100%; TEXT-ALIGN: center">
                <hr style="COLOR: black" noshade size="2">
              </div>
            </div>
            <div id="HDR">
              <div id="GLHDR" style="WIDTH: 100%" align="right">
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">2.&#160;
&#160;&#160;&#160;&#160;&#160;&#160;&#160;General Company <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">Profile</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.1</font></div>
              </td>
              <td>
                <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Description
      of XTL Biopharmaceuticals Ltd.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL&#8217;s
principal activity is the acquisition and development of therapeutics for the
treatment of diseases and medical conditions for which no cure has yet been
found, as well as improve current treatments. The Company was established in
Israel on March 9, 1993 and its shares were first listed on the main London
Stock Exchange in 2000, where they were traded until 2007.&#160;&#160;In July
2005 the Company&#8217;s securities began to be traded on the NASDAQ and in 2005 they
were dual-listed for trading on the Tel Aviv Stock Exchange.&#160;&#160;In July
2009, the NASDAQ authorities suspended trading in the Company&#8217;s ADR, and since
then, the ADRs have been quoted by brokers on Pink Sheets under the symbol:
XTLBY.PK.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
December 2008, the Company implemented a reorganization plan after failure of
the clinical trials in its leading medication, Bicifadine, developed as an
analgesic for the treatment of neuropathic pain among diabetic patients. The
failure in clinical trials led to a sharp drop in the Company&#8217;s shares on the
Tel Aviv Stock Exchange &#8211; where they fell from NIS 5.3 to NIS 0.3 per share in
one day (reflecting a decline in the Company&#8217;s value from NIS 311 m. to NIS 20
m.), and also to a minimum price of NIS 0.08 per share (reflecting a value of
NIS 4.7 m.) &#8211; the minimum price since the failure in the Bicifadine clinical
trials.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Furthermore,
under the above-mentioned reorganization plan, the Company dismissed its staff,
with the exception of the CEO and CFO, who maintained their functions until
April 7 and May 11, 2009 respectively. Upon their departure from the Company, a
new CEO and CFO were appointed in their stead, currently engaged in implementing
and finalizing the subject Transaction and in seeking business opportunities for
acquiring assets and merging operations into the Company. At present, the
Company is not actively engaged in product development.&#160;&#160;However, it
maintains certain rights in the DOS program sub-licensed in 2008 to Presidio
Pharmaceuticals Inc. (a U.S. biotechnological company focused on developing
drugs in the field of viral infections, including Hepatitis C and HIV) together
with rights in the Bicifadine pain medication, as outlined above.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div id="FTR">
                <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
              </div>
              <div id="PN" style="PAGE-BREAK-AFTER: always">
                <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-4</font></div>
                <div style="WIDTH: 100%; TEXT-ALIGN: center">
                  <hr style="COLOR: black" noshade size="2">
                </div>
              </div>
              <div id="HDR">
                <div id="GLHDR" style="WIDTH: 100%" align="right">
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Description of
Bio-Gal</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bio-Gal
was set up in 2000 as a company in Gibraltar, to engage in patent
commercialization (hereafter: &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">the Patent&#8221;) </font>for use of the
Erythropoietin drug therapy (hereafter: &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">EPO</font>&#8221;) to treat patients with
blood cancer type Multiple Myeloma. The EPO has been approved by the relevant
authorities for the treatment of anemia and is currently sold for billions of
dollars by leading drug companies such as Johnson &amp; Johnson, Roche and
Amgen.&#160;&#160;However, it is intended for use in anemia, which is not the
application proposed by Bio-Gal, as outlined above.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
patent is jointly owned by Yeda Research &amp; Development Ltd. (55%), the
Weizmann Institute&#8217;s commercialization company (hereafter &#8211; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Yeda&#8221;) </font>and Mor Research
Applications Ltd. (hereafter &#8211; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Mor&#8221;)</font> Clalit Health Services&#8217;
commercialization company (45%). The Patent is based on research conducted by
Professor Moshe Mittelman, an international hematologist who runs Ichilov
Hospital&#8217;s Internal Department.&#160;&#160;Bio-Gal obtained a licence to use the
Patent (hereafter: &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">the Patent
Agreement&#8221;) </font>for commercialization purposes.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We drew a
comparison between the Patent owned by Bio-Gal&#8217;s and other patents in similar
maturity phases, to assess the ability of using the equivalent rights and range
priced by an active market.&#160;&#160;It emerged that the price range of a
patent in similar maturity phases, i.e. prior to Phase II trial, varies between
$ 3 m. to $40 m.&#160;&#160;(See detailed analysis under Item 4.5).</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under the
Patent Agreement, Bio-Gal undertook to pay royalties amounting to 1% of net
sales of the patented drug to be developed. Furthermore, Bio-Gal undertook to
transfer to Yeda (provided the transaction takes place and, if successful, that
Phase II EPO clinical tests are performed), the lower of 2.5% of net receivables
to be transferred to Bio-Gal&#8217;s shareholders upon executing the Transaction. This
constitutes a significant change in the composition of shareholders, or
$250,000.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div id="FTR">
                <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
              </div>
              <div id="PN" style="PAGE-BREAK-AFTER: always">
                <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-5</font></div>
                <div style="WIDTH: 100%; TEXT-ALIGN: center">
                  <hr style="COLOR: black" noshade size="2">
                </div>
              </div>
              <div id="HDR">
                <div id="GLHDR" style="WIDTH: 100%" align="right">
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Up until
the year 2004, Bio-Gal had raised approximately $1.5 m., applied primarily for
laboratory experiments, licences and various tests relating to the patent and
its underlying technology, including worldwide registration thereof. From 2004,
owing to lack of resources to fund ongoing development and commercialization,
Bio-Gal ceased the laboratory experiments and other development activities and
concentrated on continued patent maintenance globally and preserving their
regulatory status.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bio-Gal
has a preliminary plan to commence Phase II Clinical Trials with EPO medication
in Multiple Myeloma cancer patients.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bio-Gal
has recently decided to raise funds from its shareholders and New Investors, to
enable performance of Phase II experiment, as described above, as well as
implementation of the Transaction signed with XTL, mutatis mutandis<font style="DISPLAY: inline; FONT-STYLE: italic"> (</font>see Section
3).&#160;&#160;Below is a description of the capital to be raised by Bio-Gal and
the subsequent restructuring that will be required:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.</font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bio-Gal&#8217;s
      shareholders are to establish a new company incorporated in Israel
      (hereafter: &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Xtepo</font>&#8221;), to which
      Bio-Gal would assign its intellectual property (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">IP</font>&#8221;).&#160;&#160;The
      shareholders&#8217; holdings in Xtepo would be identical to those in Bio-Gal,
      (in conformity with the exemption prescribed under Section 104B of the
      Income Tax Ordinance).</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.</font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Xtepo
      will raise capital from New Investors by way of issuingof warrants, when
      the capital to be raised will be approximately $1.5 m. Once the capital
      has been raised, the new investors (hereafter: &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">the New Investors&#8221;) </font>will
      hold a 42% stake in Xtepo, while Bio-Gal&#8217;s original investors (hereafter:
      &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">the Original Investors&#8221;)
      </font>will hold a 58% stake in Xtepo.&#160;&#160;(The Investors and
      Original Investors will hereafter be referred to as &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Xtepo&#8217;s
      Shareholders</font>&#8221;).</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exercising
      of the warrants depends on the approval of the shareholder
      meeting.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div id="FTR">
                <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
              </div>
              <div id="PN" style="PAGE-BREAK-AFTER: always">
                <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-6</font></div>
                <div style="WIDTH: 100%; TEXT-ALIGN: center">
                  <hr style="COLOR: black" noshade size="2">
                </div>
              </div>
              <div id="HDR">
                <div id="GLHDR" style="WIDTH: 100%" align="right">
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div>&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.</font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Description
      of XTL&#8211; Bio-Gal Transaction (through
Xtepo):</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On March
18, 2009, XTL published a report describing its engagement with Bio-Gal, under
an agreement to acquire Bio-Gal along with the intellectual property relating
thereto, including the Patent, and the program for conducting clinical trials
with this drug (hereafter: <font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;IP&#8221;</font>). The agreement includes
certain conditions precedent such as funding and payments according to
milestones (a summary of the original transaction is contained in the Company&#8217;s
financial statements and in the outline plan).</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Recently,
the parties resolved to update the summary of the original transaction as
described in the Company&#8217;s report of March this year, as detailed
below:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.</font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
      will purchase 100% of Xtepo by way of issuing new Company shares under a
      private placement to Xtepo&#8217;s shareholders (hereafter: &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Share Swap Transaction&#8221;).
      </font>After completing the Share Swap Transaction, Xtepo&#8217;s shareholders
      would control about 70% of XTL&#8217;s share capital, whilst the balance would
      be held by the Company&#8217;s existing shareholders whose holdings in the
      Company, subsequent to the Share Swap Transaction and share allotment,
      would be diluted.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 48px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.</font></div>
              </td>
              <td width="829">
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      cash payment of $10 m. would be cancelled in accordance with the
      milestones (based on development progress) as stipulated in the original
      agreement.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.</font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Furthermore,
      pursuant to the Transaction, the Patent usage rights would be assigned to
      Xtepo. In the context of assigning the Patent rights, XTL has undertaken
      to guarantee all of Xtepo&#8217;s debts to Yeda and Mor (including a commitment
      to maintain information secrecy as well as payment of 1% royalties on net
      sales of the drug developed on the basis of the Patent), derived as a
      result of the Patent Agreement, should the Transaction with Xtepo indeed
      materialize.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 48px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.</font></div>
              </td>
              <td width="829">
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">According
      to a binding clause in the Agreement, Xtepo is under an obligation, should
      Phase II of the EPO Clinical Trial succeed, to transfer to Yeda a lump sum
      of $250 thousand, as well as a lump sum of $120 thousand, upon occurrence
      of two events in the following
order:</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 18pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Success
      of EPO Phase II Clinical Trial</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 18pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      earlier of the Company raising $2 m. at least, or 180 days from date of
      success of Phase II clinical trial, as
above.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>&#160;</div>
      <div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div id="FTR">
                <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
              </div>
              <div id="PN" style="PAGE-BREAK-AFTER: always">
                <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-7</font></div>
                <div style="WIDTH: 100%; TEXT-ALIGN: center">
                  <hr style="COLOR: black" noshade size="2">
                </div>
              </div>
              <div id="HDR">
                <div id="GLHDR" style="WIDTH: 100%" align="right">
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div>&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Summary
and Conclusions for Assessment of Transaction Fairness</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In order
to assess the fairness of the merger ratios (70% for Xtepo&#8217;s Shareholders and
30% for XTL&#8217;s Shareholders), we performed the following analysis:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 18pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      analyzed the value of Xtepo prior to the merger, based on a $1.5 m.
      capital infusion, against which 42.2% of Xtepo&#8217;s shares were allotted to
      the New Investors (through the allotment of warrants). This allotment
      reflects an aggregate Company value of approximately $3.5 m. The IP value
      derived from this Transaction is $2.0
m.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 18pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Since,
      according to the proposed Transaction, Xtepo&#8217;s shareholders are entitled
      to 70% of XTL&#8217;s shares, the value of the new merged company (XTL + Xtepo)
      is $5 m.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 18pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Thus,
      the value of XTL obtained prior to the merger was $1.5 m. XTL&#8217;s equity as
      of 31.3.2009 (close to the original transaction date) amounted to $0.6 m.,
      composed mostly of a cash balance. Thus, in our opinion, given that this
      concerns a public company traded in Tel Aviv and in the U.S. and bearing
      in mind its equity, a value of $1.5 m. is reasonable and
    fair.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Attached
is a detailed calculation showing the value of Xtepo and XTL prior to the
merger, bearing in mind the proposed merger ratios.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <div align="left">
          <div align="right">
            <div align="left">
              <table cellpadding="0" cellspacing="0" width="75%">
                  <tr>
                    <td valign="bottom" width="82%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td align="right" colspan="2" valign="bottom" width="16%" style="BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$ millions</font></font></div>
                    </td>
                    <td align="left" nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                  </tr>
                  <tr bgcolor="#ccffcc">
                    <td valign="bottom" width="82%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash
      investments in Xtepo</font></div>
                    </td>
                    <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td align="right" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.4725</font></td>
                    <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                  </tr>
                  <tr bgcolor="white">
                    <td valign="bottom" width="82%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proportion
      of shares obtained</font></div>
                    </td>
                    <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td align="right" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">42.24</font></td>
                    <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
                  </tr>
                  <tr bgcolor="#ccffcc">
                    <td valign="bottom" width="82%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Company
      value derived from $1.5 m. infusion in Xtepo</font></font></font></div>
                    </td>
                    <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td align="right" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.5</font></font></font></td>
                    <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                  </tr>
                  <tr bgcolor="white">
                    <td valign="bottom" width="82%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">IP
      value obtained (company value less cash investment</font></div>
                    </td>
                    <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td align="right" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.0</font></td>
                    <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                  </tr>
                  <tr bgcolor="#ccffcc">
                    <td valign="bottom" width="82%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td align="right" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                  </tr>
                  <tr bgcolor="white">
                    <td valign="bottom" width="82%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">XTL
      value prior to merger</font></font></font></div>
                    </td>
                    <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td align="right" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.534</font></font></font></td>
                    <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                  </tr>
                  <tr bgcolor="#ccffcc">
                    <td valign="bottom" width="82%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Merged
      company value</font></div>
                    </td>
                    <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td align="right" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5.021</font></td>
                    <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                  </tr>
                  <tr bgcolor="white">
                    <td valign="bottom" width="82%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proportional
      part for Xtepo&#8217;s shareholders</font></div>
                    </td>
                    <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td align="right" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">69.44</font></td>
                    <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
                  </tr>
                  <tr bgcolor="#ccffcc">
                    <td valign="bottom" width="82%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proportional
      part for XTL&#8217;s shareholders</font></div>
                    </td>
                    <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td align="right" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">30.56</font></td>
                    <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
                  </tr>
              </table>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div id="FTR">
                <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
              </div>
              <div id="PN" style="PAGE-BREAK-AFTER: always">
                <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-8</font></div>
                <div style="WIDTH: 100%; TEXT-ALIGN: center">
                  <hr style="COLOR: black" noshade size="2">
                </div>
              </div>
              <div id="HDR">
                <div id="GLHDR" style="WIDTH: 100%" align="right">
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Furthermore,
to examine the reasonableness of the merger ratios, we estimated the value of
the IP assigned under the Share Swap Transaction.&#160;&#160;The estimated IP
value was obtained through comparison with transactions where IP was sold in
biotechnological companies and through the Discounted Cash Flow (DCF) method,
described at length under Item 4.5 below.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based on
the indications of IP value calculated by means of these two methodologies, we
reached the conclusion that a value of $2 m. for the assigned IP is reasonable
and fair.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Thus, in
our opinion, based on the above data and the analysis presented hereafter, the
proportion of new shares in XTL, after merging the Xtepo operation (70:30), is
reasonable and fair.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Below is
a detailed description of the analyses and the reasons leading to the said
conclusion.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Minority
Shareholders at XTL</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As of the
present writing, there are no interested parties at XTL, and the latter is being
managed like an &#8220;orphan&#8221; company. Additionally, the ownership structure is such
that no individual party or group of parties constitutes a controlling
shareholder(s) in the Company who, in other cases, might have different
interests than those of the minority shareholders. It appears that the interests
of all the shareholders are adequately represented by the
management.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In this
respect, it is worthwhile noting that, during the early months of 2009, the
shareholders took steps to replace the Company&#8217;s Board of Directors and
management &#8211; a move which, in itself, shows that from the Transaction date and
thereafter, the interests of all the Company&#8217;s shareholders are being adequately
represented under the new management&#8217;s administration.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accordingly,
it emerges from the above that the Transaction being formulated is one that has
been approved by both parties (while giving full consideration to the needs and
interests of the Company&#8217;s current shareholders), and constitutes a deal between
two unrelated parties and between a willing seller and willing
buyer.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div id="FTR">
                <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
              </div>
              <div id="PN" style="PAGE-BREAK-AFTER: always">
                <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-9</font></div>
                <div style="WIDTH: 100%; TEXT-ALIGN: center">
                  <hr style="COLOR: black" noshade size="2">
                </div>
              </div>
              <div id="HDR">
                <div id="GLHDR" style="WIDTH: 100%" align="right">
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Value
of Company&#8217;s Share on the Stock Exchange</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL is a
biotechnology company which, as of now, owns two IP assets but is not engaged in
any development activity for the said assets. Furthermore, the Company is
currently in the stage of acquiring technology in the framework of the Xtepo
deal outlined above.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Notwithstanding
the above, there were significant changes in the value of the Company&#8217;s shares
on the Tel Aviv Stock Exchange, although no clear factors leading to such change
have necessarily been identified. Accordingly, the value of the shares, as shown
hereafter, expresses certain expectations of investors for a possible future
occurrence following the Xtepo acquisition, and not necessarily the Company&#8217;s
present &#8220;na&#239;ve&#8221; value (without the operation due to merge with the Company
through the Xtepo acquisition).</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Below are
graphs showing, respectively, the value of the Company&#8217;s shares on the Tel Aviv
Stock Exchange and the trading volumes in these shares from the beginning of
November 2008 (prior to the failure in the Bicifadine trials) until the end of
August 2009 (NIS thousand).</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="right"><img src="graph3.jpg" alt=""></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="right">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="right">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div id="FTR">
                <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
              </div>
              <div id="PN" style="PAGE-BREAK-AFTER: always">
                <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-10</font></div>
                <div style="WIDTH: 100%; TEXT-ALIGN: center">
                  <hr style="COLOR: black" noshade size="2">
                </div>
              </div>
              <div id="HDR">
                <div id="GLHDR" style="WIDTH: 100%" align="right">
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="right">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="right"><img src="graph4.jpg" alt=""></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">It
emerges, from the above graphs, that on November 18, 2008, there was a
significant change for the worse in the Company&#8217;s business. The Company filed a
notice with the Stock Exchange that the targets contemplated for Phase II of the
clinical trial conducted on its flagship drug (Bicifadine) had not been attained
and thus the trial had failed. Consequently, the value of the shares on the
Stock Exchange plunged from NIS 310 m. to only NIS 20 million (a drop of
approximately 94% in XTL&#8217;s value).</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">From the
date of filing notice that it could not meet the Phase II target, through March
2009, there was no material change in the Company&#8217;s operations, and the latter
even announced that it was reassessing its continued activity including the
possibility of liquidation. All this prevailed until March 2009 as
aforementioned.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On March
19, 2009 the Company filed a notice stating that it had signed an agreement with
Bio-Gal for the acquisition of assets.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">From that
date onward, there has been a gradual increase in the Company&#8217;s value, both
after filing the said notice and also due to more changes taking place within
the organization &#8211; such as replacement of the entire management and appointment
of a new one. This was despite the Company&#8217;s delisting from trade on the NASDAQ,
causing a</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;drop
in share prices.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div id="FTR">
                <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
              </div>
              <div id="PN" style="PAGE-BREAK-AFTER: always">
                <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-11</font></div>
                <div style="WIDTH: 100%; TEXT-ALIGN: center">
                  <hr style="COLOR: black" noshade size="2">
                </div>
              </div>
              <div id="HDR">
                <div id="GLHDR" style="WIDTH: 100%" align="right">
                </div>
              </div>
              <div>&#160;</div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Thus, in
our opinion, the Company&#8217;s value after filing the notice of the Transaction
between XTL and Bio-Gal, was significantly influenced by the notice, and it
embodies certain expectations of investors that XTL conclude the deal and resume
development activity.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accordingly,
the value of the Company must be assessed before the official notice was filed
concerning the Transaction, so as to determine the value of the shares on the
Tel Aviv Stock Exchange as viewed by investors after the failure of Phase II
clinical trials in Bicifadine &#8211; namely, before certain expectations of investors
had an impact on the contemplated Transaction with Xtepo.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The value
of the Company&#8217;s shares on the Tel Aviv Stock Exchange between November 20, 2008
(two days after the clinical trial failure) and March 18, 2009 (eve of notice of
Transaction), was in the range of NIS 17 m. and NIS 4.7 m. (between $1.2 m. and
$4.2 m.).<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">1</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Thus, the
merger ratio determined under the acquisition deal as specified in the original
agreement (March 18, 2009) varies within the above range, reflecting a value of
$1.5 m. for XTL.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <hr style="COLOR: black" align="left" noshade size="1" width="15%">
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">1</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>The Company&#8217;s value in
dollars was calculated on the basis of NIS 4/$1 throughout the said
period</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div id="FTR">
                <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
              </div>
              <div id="PN" style="PAGE-BREAK-AFTER: always">
                <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-12</font></div>
                <div style="WIDTH: 100%; TEXT-ALIGN: center">
                  <hr style="COLOR: black" noshade size="2">
                </div>
              </div>
              <div id="HDR">
                <div id="GLHDR" style="WIDTH: 100%" align="right">
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
following graph shows the value of the Company during the said period (from the
time of filing the notice concerning the clinical trial failure until the notice
of the Transaction with Bio-Gal), in NIS thousand:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><img src="graph5.jpg" alt=""></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">It is
evident, from the above graph that volatility in the value of the Company&#8217;s
shares had existed during the said period as well. This derives, inter alia,
from investors&#8217; expectations, also during the said period, that the Company
would continue operating and resume its activities (regardless of the notices
filed by the Company during the said period), on the assumption that management
and the Board of Directors were using their best efforts to revive XTL and lead
it to a successful operation.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accordingly,
in our opinion, the value of the Company&#8217;s shares on the Stock Exchange, as of
the present date, is not a reliable measure for fair value prior to the notice
of Bio-Gal Transaction. Thus, one cannot rely on it for testing calculations of
the merger ratios in the subject Transaction. The current share value expresses,
in our view, certain expectations of investors for executing and finalizing the
Transaction with Xtepo, due to the fact that notice on this subject was filed by
the Company with the Tel Aviv Stock Exchange, and the new management&#8217;s
intentions are clear to the shareholders who had appointed it.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div id="FTR">
                <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
              </div>
              <div id="PN" style="PAGE-BREAK-AFTER: always">
                <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-13</font></div>
                <div style="WIDTH: 100%; TEXT-ALIGN: center">
                  <hr style="COLOR: black" noshade size="2">
                </div>
              </div>
              <div id="HDR">
                <div id="GLHDR" style="WIDTH: 100%" align="right">
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On the
other hand, in our opinion, the value of the Company&#8217;s shares on the Tel Aviv
Stock Exchange during the period between filing the notice of the clinical
failure in November 2008, and notice of the Transaction with Bio-Gal in March
2009, adequately reflects the Company&#8217;s value derived from the merger ratio
between XTL and Bio-Gal.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As of
April 2009, the Company&#8217;s share was delisted from the NASDAQ, and since then it
has traded under the Pink Sheet regulatory framework, through ADR.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There is
no significant change between the average share price value and, consequently,
the Company&#8217;s price on the NASDAQ, and the Company&#8217;s value in Tel
Aviv.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the
Company&#8217;s value based on NASDAQ share prices &#8211; see Appendix A.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Given
that the Company&#8217;s current value on the Stock Exchange expresses certain
expectations of investors to finalize the Transaction, other ways must be found
to estimate its value.&#160;&#160;Accordingly, we will review the Company&#8217;s
equity value, on the eve of filing the notice, and compare the XTL case with the
events occurring at Avigen Inc., after the latter&#8217;s failure with the clinical
trials in October 2008 and with those at Acadia Pharmaceuticals, Inc. after the
latter&#8217;s failure with the clinical trials in June 2008.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div id="FTR">
                <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
              </div>
              <div id="PN" style="PAGE-BREAK-AFTER: always">
                <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-14</font></div>
                <div style="WIDTH: 100%; TEXT-ALIGN: center">
                  <hr style="COLOR: black" noshade size="2">
                </div>
              </div>
              <div id="HDR">
                <div id="GLHDR" style="WIDTH: 100%" align="right">
                </div>
              </div>
            </div>
          </div>
        </div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Asset
Value</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On the
eve of signing the Transaction, XTL&#8217;s value stemmed primarily from its tangible
assets, net of financial liabilities. This implies that XTL&#8217;s accounting equity,
plus the public platform value in Tel Aviv and the U.S. of $1.5 m., adequately
reflects its fair value. The Company has a further commercial agreement, drawn
up in 2008 and connected with its IP, which is likely to generate further income
for XTL in future. At the present time, according to the Company and as
indicated to us, there are no indications of any significant future cash flows
to be generated for the Company as a result of this agreement, if at
all.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In our
opinion, since XTL was not involved in any development activity at the said
point in time, $1.5 m. reflecting equity + a premium in respect of public
platform value, adequately expresses the Company&#8217;s value prior to Xtepo&#8217;s IP
asset.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
estimate the Company&#8217;s asset value, we performed a review of the said value
based on the Company&#8217;s balance sheets as of the 4 following periods: 31/12/2008
(based on audited reports), 31/3/2009, based on management&#8217;s reports, and
30/6/2009 and 30/09/2009 based on reviewed financial statements filed by the
Company with the Tel Aviv Stock Exchange.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div id="FTR">
                <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
              </div>
              <div id="PN" style="PAGE-BREAK-AFTER: always">
                <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-15</font></div>
                <div style="WIDTH: 100%; TEXT-ALIGN: center">
                  <hr style="COLOR: black" noshade size="2">
                </div>
              </div>
              <div id="HDR">
                <div id="GLHDR" style="WIDTH: 100%" align="right">
                </div>
              </div>
            </div>
          </div>
        </div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Following
are the Companies&#8217; balance sheets as of the above dates - $
thousands:</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <div align="left">
          <table cellpadding="0" cellspacing="0" width="100%">
              <tr>
                <td align="left" valign="bottom" width="44%" style="PADDING-BOTTOM: 2px">
                  <div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$
      Thousand</font></div>
                  <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
                </td>
                <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September
      30, 2009</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Reviewed</font></font></div>
                </td>
                <td align="left" nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">June
      30,</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Reviewed</font></font></div>
                </td>
                <td align="left" nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">March
      31,</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Management
      </font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Data</font></font></div>
                </td>
                <td align="left" nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December
      31,</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2008</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Audited</font></font></div>
                </td>
                <td align="left" nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="bottom" width="44%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Current Assets</font></font></div>
                </td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td colspan="2" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td colspan="2" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td colspan="2" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td colspan="2" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="44%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash
      and cash equivalents</font></div>
                </td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">640</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">899</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,013</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,924</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="bottom" width="44%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Assets
      o/a of employee benefits</font></div>
                </td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="44%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounts
      receivable</font></div>
                </td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">20</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">134</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">195</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">305</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="bottom" width="44%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Income
      tax receivable</font></div>
                </td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">49</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">49</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">49</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">49</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="44%" style="PADDING-BOTTOM: 2px">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Restricted
      deposits</font></div>
                </td>
                <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">40</font></td>
                <td align="left" nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">71</font></td>
                <td align="left" nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">71</font></td>
                <td align="left" nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">71</font></td>
                <td align="left" nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="bottom" width="44%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font></div>
                </td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">749</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,153</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,340</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,361</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
              <tr bgcolor="white">
                <td valign="bottom" width="44%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="bottom" width="44%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Non-Current Assets</font></font></div>
                </td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="44%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fixed
      assets</font></div>
                </td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">29</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">36</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">41</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="bottom" width="44%" style="PADDING-BOTTOM: 2px">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other
      long term investments</font></div>
                </td>
                <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">95</font></td>
                <td align="left" nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
                <td align="left" nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
                <td align="left" nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
                <td align="left" nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="44%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font></div>
                </td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">124</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">36</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">41</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td valign="bottom" width="44%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="44%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total
      Assets</font></div>
                </td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">873</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,185</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,376</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,402</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td valign="bottom" width="44%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="44%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Current Liabilities</font></font></div>
                </td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="bottom" width="44%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Trade
      payable<font style="DISPLAY: inline; FONT-WEIGHT: bold">s</font></font></div>
                </td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">228</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">169</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">316</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">416</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="44%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other
      accounts payable</font></div>
                </td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">405</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">777</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">420</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,058</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="bottom" width="44%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Employee
      benefit liabilities</font></div>
                </td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">447</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="44%" style="PADDING-BOTTOM: 2px">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Liability
      for share appreciation rights</font></div>
                </td>
                <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
                <td align="left" nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">178</font></td>
                <td align="left" nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">54</font></td>
                <td align="left" nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7</font></td>
                <td align="left" nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="bottom" width="44%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font></div>
                </td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">633</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,124</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">790</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,928</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="44%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Shareholders
      equity</font></div>
                </td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">240</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">61</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">586</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,474</font></td>
                <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="bottom" width="44%" style="PADDING-BOTTOM: 2px">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total
      liabilities and equity</font></div>
                </td>
                <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">873</font></td>
                <td align="left" nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,185</font></td>
                <td align="left" nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,376</font></td>
                <td align="left" nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,402</font></td>
                <td align="left" nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
          </table>
        </div>
        <div align="left">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">One may
concluded, from the above, that the net equity value of the Company&#8217;s assets,
derives primarily from cash at hand.&#160;&#160;This value has substantially
dropped from $1.5 m. in December 2008 to $600 thousand close to the date of
filing notice of the Transaction, and to $240 thousand in September
2009.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">It should
be noted that as of September 30, 2009, the Company has accumulated losses to
the extent of $141 m.&#160;&#160;However, the Company believes that the ability
to utilize these losses in future is questionable.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div id="FTR">
                <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
              </div>
              <div id="PN" style="PAGE-BREAK-AFTER: always">
                <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-16</font></div>
                <div style="WIDTH: 100%; TEXT-ALIGN: center">
                  <hr style="COLOR: black" noshade size="2">
                </div>
              </div>
              <div id="HDR">
                <div id="GLHDR" style="WIDTH: 100%" align="right">
                </div>
              </div>
            </div>
          </div>
        </div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
mentioned earlier, the Company&#8217;s value fell dramatically due to failure to meet
Phase II EPO clinical trials &#8211; a drop of 94% in one day. This has actually led
to the decline in value of the Company&#8217;s IP.&#160;&#160;For comparison purposes,
we performed a test of the events occurring in a similar company, resulting
likewise in a decline in the value of that company&#8217;s IP.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Analysis of Avigen Inc.
Event</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Avigen
Inc. is a company traded on the NASDAQ. In 2008, the company had 3 drugs being
clinically developed. Two of these were in Phase II development phase while the
company&#8217;s flagship drug (AV650) for the treatment of patients with multiple
sclerosis was in Phase IIb.&#160;&#160;During this period, expectations for the
success of the trial both on the part of management as well as investors were
great, and accordingly, the company was traded at a value exceeding $100 m.
However, in October 2008, the company announced that the AV650 test had failed
and consequently, its share value plunged in one day by 83%. This downward trend
continued for a short time.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Similar
to XTL, Avigen&#8217;s IP also stemmed primarily from its flagship drug, AV650, which
failed in Phase IIb of the clinical trials. As of the end of Q2 2008 (about 20
days prior to filing notice of the failure of the clinical trial), the company&#8217;s
value on the Stock Exchange stood at $119 m. , whilst its equity amounted to
only $47 m. In the course of the 8 following months, significant changes
occurred in market value, when the picture regarding the Phase III experiment
failure and the company&#8217;s future abilities in this area became
clear.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">It is
evident that in the period following the notice, the company&#8217;s market value
stabilized in similar scopes to the book value (composed primarily of the
Company&#8217;s cash balances), as shown in the following table ($
thousand):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <div align="left">
          <div align="center">
            <div align="center">
              <div align="center">
                <table cellpadding="0" cellspacing="0" width="100%">
                    <tr>
                      <td valign="bottom" width="30%" style="BORDER-TOP: medium none; PADDING-BOTTOM: 2px; BORDER-LEFT: medium none"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td valign="bottom" width="1%" style="BORDER-TOP: medium none; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td colspan="2" valign="bottom" width="12%" style="BORDER-TOP: medium none; BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">June
      30, </font></div>
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2008</font></div>
                      </td>
                      <td align="left" nowrap valign="bottom" width="1%" style="BORDER-TOP: medium none; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td valign="bottom" width="1%" style="BORDER-TOP: medium none; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td colspan="2" valign="bottom" width="12%" style="BORDER-TOP: medium none; BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Sept
      30,</font></div>
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2008</font></div>
                      </td>
                      <td align="left" nowrap valign="bottom" width="1%" style="BORDER-TOP: medium none; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td valign="bottom" width="1%" style="BORDER-TOP: medium none; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td colspan="2" valign="bottom" width="12%" style="BORDER-TOP: medium none; BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Dec
      31,</font></div>
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2008</font></div>
                      </td>
                      <td align="left" nowrap valign="bottom" width="1%" style="BORDER-TOP: medium none; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td valign="bottom" width="1%" style="BORDER-TOP: medium none; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td colspan="2" valign="bottom" width="12%" style="BORDER-TOP: medium none; BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">March
      31,</font></div>
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></div>
                      </td>
                      <td align="left" nowrap valign="bottom" width="1%" style="BORDER-TOP: medium none; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td valign="bottom" width="1%" style="BORDER-TOP: medium none; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td colspan="2" valign="bottom" width="12%" style="BORDER-TOP: medium none; BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">June
      30,</font></div>
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></div>
                      </td>
                      <td align="left" nowrap valign="bottom" width="1%" style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    </tr>
                    <tr bgcolor="#ccffcc">
                      <td align="left" valign="bottom" width="30%" style="BORDER-LEFT: medium none">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash
      and cash equivalents</font></div>
                      </td>
                      <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">65,314</font></td>
                      <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">56,410</font></td>
                      <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">56,839</font></td>
                      <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">44,499</font></td>
                      <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">41,635</font></td>
                      <td align="left" nowrap valign="bottom" width="1%" style="BORDER-RIGHT: medium none"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    </tr>
                    <tr bgcolor="white">
                      <td align="left" valign="bottom" width="30%" style="BORDER-LEFT: medium none">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Equity</font></div>
                      </td>
                      <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">56,546</font></td>
                      <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">47,182</font></td>
                      <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">47,204</font></td>
                      <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">40,349</font></td>
                      <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">39,353</font></td>
                      <td align="left" nowrap valign="bottom" width="1%" style="BORDER-RIGHT: medium none"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    </tr>
                    <tr bgcolor="#ccffcc">
                      <td align="left" valign="bottom" width="30%" style="BORDER-LEFT: medium none">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Market
      value*</font></div>
                      </td>
                      <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">86,033</font></td>
                      <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">119,076</font></td>
                      <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">22,625</font></td>
                      <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">36,318</font></td>
                      <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">39,364</font></td>
                      <td align="left" nowrap valign="bottom" width="1%" style="BORDER-RIGHT: medium none"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    </tr>
                    <tr bgcolor="white">
                      <td align="left" valign="bottom" width="30%" style="BORDER-LEFT: medium none">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Period
      after (prior to) </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">clinical
      failure -months</font></div>
                      </td>
                      <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-3.5</font></td>
                      <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-0.5</font></td>
                      <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.5</font></td>
                      <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5.5</font></td>
                      <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8.5</font></td>
                      <td align="left" nowrap valign="bottom" width="1%" style="BORDER-RIGHT: medium none"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    </tr>
                    <tr bgcolor="#ccffcc">
                      <td align="left" valign="bottom" width="30%" style="BORDER-LEFT: medium none; BORDER-BOTTOM: 4px">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Market
      value / equity</font></div>
                      </td>
                      <td valign="bottom" width="1%" style="BORDER-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">152</font></td>
                      <td align="left" nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
                      <td valign="bottom" width="1%" style="BORDER-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">252</font></td>
                      <td align="left" nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
                      <td valign="bottom" width="1%" style="BORDER-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">48</font></td>
                      <td align="left" nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
                      <td valign="bottom" width="1%" style="BORDER-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">90</font></td>
                      <td align="left" nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
                      <td valign="bottom" width="1%" style="BORDER-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">100</font></td>
                      <td align="left" nowrap valign="bottom" width="1%" style="BORDER-RIGHT: medium none; BORDER-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
                    </tr>
                </table>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">*</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>Market value is based on
share price multiplied by the Company&#8217;s weighted share average used to calculate
the net share earnings in the Company&#8217;s financial statements for the 3 months
ended on the said date.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div id="FTR">
                <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
              </div>
              <div id="PN" style="PAGE-BREAK-AFTER: always">
                <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-17</font></div>
                <div style="WIDTH: 100%; TEXT-ALIGN: center">
                  <hr style="COLOR: black" noshade size="2">
                </div>
              </div>
              <div id="HDR">
                <div id="GLHDR" style="WIDTH: 100%" align="right">
                </div>
              </div>
            </div>
          </div>
        </div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">It
emerges, from the above table, that similar to XTL, failure of the clinical
experiment and interruption of development activity led to a sharp decline in IP
value to almost zero, such that the equity value (given that the company owns no
other IP apart from the aforementioned) adequately reflects the fair value of
the company and its assets.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Furthermore,
an agreement was signed in October 2009 to acquire the company at a price
reflecting a value of $37 m. This was below market value on the date of
signature and also below equity at the end of Q2 2009 (total equity amounted to
$39 m.).</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Analysis of Acadia
Pharmaceuticals, Inc. (&#8220;Acadia&#8221;) Event</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Acadia is
traded on the NASDAQ and is engaged in developing and commercializing innovative
technology for the treatment of illnesses and disorders connected with the
central nervous system (&#8220;CNS"). In 2008, Acadia had 6 drugs being clinically
tested for the treatment of nervous system disorders and pain.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based on
the company&#8217;s flagship technology &#8211; the Pimavanserin &#8211; three neuroleptic drugs
were experimentally tested:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
        <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td align="right" style="WIDTH: 27pt">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.&#160;</font></div>
              </td>
              <td align="left">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Drug
      for the treatment of Parkinson&#8217;s disease Phase
  III</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
        <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td align="right" style="WIDTH: 27pt">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.&#160;</font></div>
              </td>
              <td align="left">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Drug
      for the treatment of schizophrenia Phase
II</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td align="right" style="WIDTH: 27pt">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.</font></div>
                  </td>
                  <td align="left">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Proving
      clinical performance criteria of a drug treatment for sleep maintenance
      insomnia in healthy older
adults.</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At the
same time, the company conducted another Phase IIb clinical trial (based on a
different technology) for the stand-alone treatment of schizophrenia; a Phase II
trial for neuroleptic pain; and a Phase I trial for the treatment of
glaucoma.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Due to
the advanced phase of developing the Pimavanserin, coupled with investors&#8217;
expectations for the success of experiments based on this medication, Acadia was
traded at a value of hundreds of millions of dollars. However, on June 16, 2008,
Acadia&#8217;s management announced that the trial had failed, as a result of which
the value of the company&#8217;s shares dropped sharply in one day by 43%, and the
downward trend continued during the following period.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div id="FTR">
                <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
              </div>
              <div id="PN" style="PAGE-BREAK-AFTER: always">
                <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-18</font></div>
                <div style="WIDTH: 100%; TEXT-ALIGN: center">
                  <hr style="COLOR: black" noshade size="2">
                </div>
              </div>
              <div id="HDR">
                <div id="GLHDR" style="WIDTH: 100%" align="right">
                </div>
              </div>
            </div>
          </div>
        </div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In this
case, too, Acadia&#8217;s IP at the time stemmed primarily from flagship technology &#8211;
the Pimavanserin &#8211; which failed in Phase II of the experiments for use by
patients with schizophrenia.&#160;&#160;The company&#8217;s market value, as of the
end of Q1 2008 (two and a half months prior to filing the notice) stood at $336
m., while its equity amounted to only $98 m.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
compared Acadia&#8217;s equity value with its market value, to assess the value
attributed by investors to the company&#8217;s IP after the clinical trial had
failed.&#160;&#160;The following table shows that in the period after the said
notice, Acadia&#8217;s share price stabilized at values not materially different from
equity (sometimes, even below it), as detailed below (In $ m.):</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div>
          <div align="left">
            <div align="center">
              <div align="center">
                <div align="center">
                  <div align="center">
                    <div align="center">
                      <div align="center">
                        <div align="center">
                          <div align="center">
                            <div align="center">
                              <div align="center">
                                <div align="center">
                                  <div align="center">
                                    <div align="center">
                                      <table cellpadding="0" cellspacing="0" width="100%">
                                          <tr>
                                            <td valign="bottom" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                            <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td colspan="2" valign="bottom" width="12%">
                                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">March
      31,</font></div>
                                            </td>
                                            <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td colspan="2" valign="bottom" width="12%">
                                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">June
      30,</font></div>
                                            </td>
                                            <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td colspan="2" valign="bottom" width="12%">
                                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Sept
      30,</font></div>
                                            </td>
                                            <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td colspan="2" valign="bottom" width="12%">
                                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Dec
      31,</font></div>
                                            </td>
                                            <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td colspan="2" valign="bottom" width="12%">
                                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">March
      31,</font></div>
                                            </td>
                                            <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                          </tr>
                                          <tr>
                                            <td valign="bottom" width="30%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                            <td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;</font></td>
                                            <td align="right" colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
                                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2008</font></div>
                                            </td>
                                            <td align="left" nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
                                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2008</font></div>
                                            </td>
                                            <td align="left" nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
                                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2008</font></div>
                                            </td>
                                            <td align="left" nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
                                              <div>&#160;</div>
                                            </td>
                                            <td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
                                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2008</font></div>
                                            </td>
                                            <td align="left" nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                            <td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
                                              <div>&#160;</div>
                                            </td>
                                            <td align="right" colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
                                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></div>
                                            </td>
                                            <td align="left" nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                          </tr>
                                          <tr bgcolor="#ccffcc">
                                            <td align="left" valign="bottom" width="30%">
                                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash
      and cash equivalents</font></div>
                                            </td>
                                            <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">106,499</font></td>
                                            <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">89,621</font></td>
                                            <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">72,698</font></td>
                                            <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">60,083</font></td>
                                            <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">46,384</font></td>
                                            <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                          </tr>
                                          <tr bgcolor="white">
                                            <td align="left" valign="bottom" width="30%">
                                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Equity
      book value</font></div>
                                            </td>
                                            <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">98,667</font></td>
                                            <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">81,204</font></td>
                                            <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">66,242</font></td>
                                            <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">52,992</font></td>
                                            <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">38,386</font></td>
                                            <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                          </tr>
                                          <tr bgcolor="#ccffcc">
                                            <td align="left" valign="bottom" width="30%">
                                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Market
      value*</font></div>
                                            </td>
                                            <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">335,700</font></td>
                                            <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">136,906</font></td>
                                            <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99,527</font></td>
                                            <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">33,460</font></td>
                                            <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">35,320</font></td>
                                            <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                          </tr>
                                          <tr bgcolor="white">
                                            <td align="left" valign="bottom" width="30%">
                                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Period
      after (prior to) </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">clinical
      failure -months</font></div>
                                              </div>
                                            </td>
                                            <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5.5-</font></td>
                                            <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.5-</font></td>
                                            <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.5</font></td>
                                            <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.5</font></td>
                                            <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6.5</font></td>
                                            <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                          </tr>
                                          <tr bgcolor="#ccffcc">
                                            <td align="left" valign="bottom" width="30%">
                                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Market
      value / equity</font></div>
                                            </td>
                                            <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">340
      </font></td>
                                            <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
                                            <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">169
      </font></td>
                                            <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
                                            <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">150
      </font></td>
                                            <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
                                            <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">63
      </font></td>
                                            <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
                                            <td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                            <td align="right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">92
      </font></td>
                                            <td align="left" nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
                                          </tr>
                                      </table>
                                    </div>
                                  </div>
                                </div>
                              </div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">*</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>Market value is based on
share price multiplied by the Company&#8217;s weighted share average used to calculate
the net share earnings in the Company&#8217;s financial statements for the 3 months
ended on the said date.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">It
emerges, from the above table, that here too, the clinical failure and
interruption of development activity, coupled with weakening of the Pimavanserin
technology&#8217;s validity, led to a sharp decline in Acadia&#8217;s IP value, such that
the company&#8217;s equity adequately reflects its fair value and sometimes even above
it.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On the
other hand, in the said XTL case, there is a wide gap between the value of the
Company on the Tel Aviv Stock Exchange and its asset value. As XTL was not
involved in any business activity during the said periods, one may conclude that
the substantial gaps in market value stem primarily from certain expectations of
investors for resumption of the Company&#8217;s activity by concluding the Transaction
and/or other developments likely to influence the Company&#8217;s business in
future.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As the
Company was not engaged in any development activity prior to the Transaction, a
review of its equity value constitutes an adequate assessment in our opinion for
determinin</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">g its
fair value.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div id="FTR">
                  <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
                </div>
                <div id="PN" style="PAGE-BREAK-AFTER: always">
                  <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-19</font></div>
                  <div style="WIDTH: 100%; TEXT-ALIGN: center">
                    <hr style="COLOR: black" noshade size="2">
                  </div>
                </div>
                <div id="HDR">
                  <div id="GLHDR" style="WIDTH: 100%" align="right">
                  </div>
                </div>
              </div>
            </div>
          </div>
          <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Goodwill
and Synergy</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Bio-Gal Transaction embodies further potential goodwill and synergy. Apart from
Bio-Gal&#8217;s IP, assigned through Xtepo and merged into XTL, the new Xtepo
investors bring added value to the merged company.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under the
Transaction, Xtepo is bringing New Investors. XTL&#8217;s management considers it will
be benefit from the support of these entities, the business contacts they bring
with them and the ability to promote XTL&#8217;s business in the world of
biotechnology. The Share Swap Transaction with Xtepo is being executed after the
financial investment by these New Investors in Xtepo.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Thus,
Management believes that not only will the merged company benefit from the
acquired IP and cash at hand,&#160;&#160;but also from the contribution and
added value embodied in the contacts and know-how of the New
Investors.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 48px">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.5</font></div>
              </td>
              <td width="829">
                <div align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bio-Gal&#8217;s
      IP Value (transferred through
Xtepo)</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
derived value for Xtepo&#8217;s IP, based on the capital inflow from Bio-Gal&#8217;s New
Investors (Xtepo investors), under the merger Transaction and the issue of
warrants, amounts to approximately $2 m. This figure is calculated based on the
New Investors committing capital in the amount of $1.5 m., in exchange for 42%
warrants in Xtepo (as detailed at the beginning of chapter 4 of this
Opinion).</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
establish the IP&#8217;s estimated value, we performed the following tests and
analyses:</font></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 18pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Analysis
      of similar IP sale transactions</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 18pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Estimated
      cash flows for property</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.5.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<font style="DISPLAY: inline; TEXT-DECORATION: underline">Analysis of Similar
Transactions</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An
analysis of IP sale transactions of similar companies made in the past, gives an
indication of the Company&#8217;s IP value. Findings show a considerable dissimilarity
in values, fluctuating between $3 m. and $40 m. It further emerges that the
correlation between the sums invested in these companies and the value of IP
sold is not high.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div id="FTR">
                  <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
                </div>
                <div id="PN" style="PAGE-BREAK-AFTER: always">
                  <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-20</font></div>
                  <div style="WIDTH: 100%; TEXT-ALIGN: center">
                    <hr style="COLOR: black" noshade size="2">
                  </div>
                </div>
                <div id="HDR">
                  <div id="GLHDR" style="WIDTH: 100%" align="right">
                  </div>
                </div>
              </div>
            </div>
          </div>
          <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        </div>
      </div>
      <div>
        <div align="center">
          <div align="center">
            <div align="center">
              <div align="center">
                <div align="center">
                  <div align="center">
                    <div align="center">
                      <div align="center">
                        <div align="center">
                          <table cellpadding="0" cellspacing="0" width="100%">
                              <tr>
                                <td valign="top" width="20%" style="BORDER-TOP: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name
      of</font></div>
                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Company</font></div>
                                </td>
                                <td valign="top" width="2%" style="BORDER-TOP: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                <td valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-TOP: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date
      </font></div>
                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Established</font></div>
                                </td>
                                <td valign="top" width="2%" style="BORDER-TOP: #000000 1pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                <td valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-TOP: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date</font></div>
                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Sold</font></div>
                                </td>
                                <td valign="top" width="2%" style="BORDER-TOP: #000000 1pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                <td valign="top" width="25%" style="BORDER-RIGHT: black 1pt solid; BORDER-TOP: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proceeds
      </font></div>
                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">of
      Sale</font></div>
                                </td>
                                <td valign="top" width="2%" style="BORDER-TOP: #000000 1pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                <td valign="top" width="15%" style="BORDER-RIGHT: #000000 1pt solid; BORDER-TOP: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total
      </font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Investment
      </font></div>
                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">in
      Company</font></div>
                                </td>
                              </tr>
                              <tr bgcolor="#ccffcc">
                                <td align="left" valign="top" width="20%" style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Ester
      Neurosciences</font></div>
                                </td>
                                <td align="left" valign="top" width="2%" style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                <td align="right" valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: black 2px solid">
                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1997</font></div>
                                </td>
                                <td align="right" valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                <td align="right" valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: black 2px solid">
                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2007</font></div>
                                </td>
                                <td align="right" valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                <td align="left" valign="top" width="25%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: black 2px solid">
                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$15
      m. plus a further $17 m. based on meeting targets</font></div>
                                </td>
                                <td align="left" valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                <td valign="top" width="15%" style="BORDER-RIGHT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10</font></div>
                                </td>
                              </tr>
                              <tr bgcolor="white">
                                <td align="left" valign="top" width="20%" style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Hamilton
      Pharmaceuticals</font></div>
                                </td>
                                <td align="left" valign="top" width="2%" style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                <td align="right" valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: black 2px solid">
                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1932</font></div>
                                </td>
                                <td align="right" valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                <td align="right" valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: black 2px solid">
                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2007</font></div>
                                </td>
                                <td align="right" valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                <td align="left" valign="top" width="25%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: black 2px solid">
                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$4.4
      m. in shares plus a further $4 m. based on meeting targets</font></div>
                                </td>
                                <td align="left" valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                <td valign="top" width="15%" style="BORDER-RIGHT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11</font></div>
                                </td>
                              </tr>
                              <tr bgcolor="#ccffcc">
                                <td align="left" valign="top" width="20%" style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Miikana
      Therapeutics</font></div>
                                </td>
                                <td align="left" valign="top" width="2%" style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                <td align="right" valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: black 2px solid">
                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2002</font></div>
                                </td>
                                <td align="right" valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                <td align="right" valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: black 2px solid">
                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2005</font></div>
                                </td>
                                <td align="right" valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                <td align="left" valign="top" width="25%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: black 2px solid">
                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$21
      m. in shares plus a further $18 m. based on meeting
targets</font></div>
                                </td>
                                <td align="left" valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                <td valign="top" width="15%" style="BORDER-RIGHT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8</font></div>
                                </td>
                              </tr>
                              <tr bgcolor="white">
                                <td align="left" valign="top" width="20%" style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid">
                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">MacroChem
      Corporation</font></div>
                                </td>
                                <td align="left" valign="top" width="2%" style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                <td align="right" valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: #000000 1pt solid">
                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1981</font></div>
                                </td>
                                <td align="right" valign="top" width="2%" style="BORDER-BOTTOM: #000000 1pt solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                <td align="right" valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: #000000 1pt solid">
                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></div>
                                </td>
                                <td align="right" valign="top" width="2%" style="BORDER-BOTTOM: #000000 1pt solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                <td align="left" valign="top" width="25%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: #000000 1pt solid">
                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$3
      m.</font></div>
                                </td>
                                <td align="left" valign="top" width="2%" style="BORDER-BOTTOM: #000000 1pt solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                <td valign="top" width="15%" style="BORDER-RIGHT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid">
                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">100</font></div>
                                </td>
                              </tr>
                          </table>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">It is
worthwhile noting that the value of the said transactions is primarily
influenced by the assessments of the parties involved, of the prospects that the
product&#8217;s development portfolio will succeed close to the date of acquiring the
IP, and the development phase reached by the patent.&#160;&#160;In the
Transaction discussed herein, Bio-Gal is a private company with no resources or
ability to develop and commercialize the patent.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Furthermore,
as this involves considerable price ranges, the IP value in different
circumstances might have reached amounts exceeding $10 m. In the biotechnology
sector, IP transactions usually include patents and data from research and
studies made on the basis thereof, when the proceeds in such transactions are
composed of three factors:&#160;&#160;payment of an advance (between hundreds of
thousands of dollars and tens of millions of dollars, depending on development
progress and the likelihood of success in ongoing development), payment for
compliance with milestones (also between millions and hundreds of millions of
dollars). The third factor stems from payment of a percentage of sales once a
product has been approved for marketing based on the IP sold. This is
particularly viable in situations where large pharmaceutical companies fail in
the clinical trials conducted by them and a gap is created in the development
pipelines of future products.&#160;&#160;In such cases, pharmaceutical companies
might agree to pay higher prices for IP assets which would inherently constitute
a potential for developing future medications.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                  <div id="FTR">
                    <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
                  </div>
                  <div id="PN" style="PAGE-BREAK-AFTER: always">
                    <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-21</font></div>
                    <div style="WIDTH: 100%; TEXT-ALIGN: center">
                      <hr style="COLOR: black" noshade size="2">
                    </div>
                  </div>
                  <div id="HDR">
                    <div id="GLHDR" style="WIDTH: 100%" align="right">
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.5.2&#160;&#160;&#160;&#160;&#160;&#160;Estimated
IP Value Based on Future Discounted Cash Flow Method</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
discussed earlier, Bio-Gal was set up with a view to commercializing a patent
for&#160;&#160;&#160;Erythropoietin drug therapy (hereafter: &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">EPO</font>&#8221;), to treat patients with
blood cancer of the Multiple Myeloma type. The EPO was approved by the relevant
authorities for the treatment of anemia and is currently sold for billions of
dollars.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">EPO is a hormone produced by the kidney
that stimulates the formation of red blood cells in the bone
marrow.&#160;&#160;Today, EPO is also produced through a genetic engineering
method (&#8220;EPO Recombinant&#8221;) and is prescribed for patients suffering from several
types of anemia associated with chronic kidney malfunction, as well as cancer
patients where chemotherapy treatment has affected the production of healthy
blood cells in their body. A number of studies made over the past decade have in
fact substantiated the claim that EPO indications and usage has also shown a
potential for treating several diseases other than anemia, even beyond
stimulating the red blood cell production process</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super"><font size="1">2</font></font>.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bio-Gal
has a preliminary plan for commencing Phase II clinical trials with EPO therapy
in Multiple Myeloma cancer patients.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
establish the value of Bio-Gal&#8217;s IP, assigned through the Share Swap
Transaction, we estimated the future cash flows to be generated from the EPO
therapy among Multiple Myeloma patients in advanced stages of the disease. To
this end, we assumed a future cash flow that weights the probability of
completing drug development, production, and marketing.&#160;&#160;The cash flow
multiplied by the cumulative probability of success was discounted at the
relevant capital price estimated by us.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
        <div>
          <hr style="COLOR: black" align="left" noshade size="1" width="15%">
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">2</font> e.g.
Mittelman M, Zeidman A, Kanter P, Katz O, Oster H, Rund D, Neumann D.
Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical
observation supported by animal studies. Eur J Haematol. 2004
Mar;72(3):155-65</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                  <div id="FTR">
                    <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
                  </div>
                  <div id="PN" style="PAGE-BREAK-AFTER: always">
                    <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-22</font></div>
                    <div style="WIDTH: 100%; TEXT-ALIGN: center">
                      <hr style="COLOR: black" noshade size="2">
                    </div>
                  </div>
                  <div id="HDR">
                    <div id="GLHDR" style="WIDTH: 100%" align="right">
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
success of the Company (and its products) does not depend merely on development
risks likely to be reflected in the Company&#8217;s inability to succeed in its
attempt to prove and demonstrate the EPO&#8217;s efficacy and safety, or that the drug
will prove less effective than anticipated, but rather in further risks
envisaged by the Company, stemming primarily from the structure of market
competition, from regulation in a market where the Company operates,
etc.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
comprehend the probability of the trial&#8217;s success and the ability to generate
future cash flows, an assessment must be made of the current competitive market
structure and the parameters affecting the success or failure of the said patent
commercialization.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Xtepo
program for EPO drug therapy is intended for the treatment of patients with
advanced Multiple Myeloma. Further medications are currently available in the
market for treating patients in the advanced or early stages of the
disease.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Additionally,
the Velcade drug, currently available and even included in the &#8220;medications
basket&#8221; in Israel, is also used for treating patients with advanced Multiple
Myeloma. However, to date, therapeutic treatment with Velcade has resulted in
lengthening patients&#8217; life expectancy by 12 weeks on average.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
hypothesis based on a clinical observation made by Prof. Mittelman and his
colleagues <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">3</font>
corroborates the high rate of success of the EPO Recombinant in the treatment of
anemia among cancer patients with Multiple Myeloma. Six patients continued to
use the EPO Recombinant beyond the contemplated 12-week period. These patients
were in the terminal stage of the disease, when the life expectancy anticipated
at the time was about 6 months.&#160;&#160;Much to the researchers&#8217; surprise,
these patients lived for periods of 46 &#8211; 133 months after diagnosing the
Multiple Myeloma, and altogether 38-94 months from treatment with EPO
Recombinant, with a good quality of life.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <hr style="COLOR: black" align="left" noshade size="1" width="15%">
      </div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td>
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">3
      &#160;</font>Mittelman M, Zeidman A, Kanter P, Katz O, Oster H, Rund D,
      Neumann D. Erythropoietin has an anti-myeloma effect - a hypothesis based
      on a clinical observation supported by animal studies. Eur J Haematol.
      2004 Mar;72(3):155-65</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>&#160;</div>
      <div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                  <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                    <div id="FTR">
                      <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
                    </div>
                    <div id="PN" style="PAGE-BREAK-AFTER: always">
                      <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-23</font></div>
                      <div style="WIDTH: 100%; TEXT-ALIGN: center">
                        <hr style="COLOR: black" noshade size="2">
                      </div>
                    </div>
                    <div id="HDR">
                      <div id="GLHDR" style="WIDTH: 100%" align="right">
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div>&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Below are
details of the major potential risks (other than development), presently known
to the Company, in its efforts to commercialize the patent:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 18pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      a condition for conducting the trials, the Company must obtain prior
      approval from the competent authorities to perform medical tests on human
      beings in each and every country where such tests are envisaged.
      Furthermore, the product which the Company intends to develop and market
      is a medical one, hence its production, sale and marketing is contingent
      on obtaining a license in each country where marketing is contemplated. In
      order to obtain such approval, the Company must comply with licensing
      requirements, including safety conditions and quality control standards,
      as prescribed by the authorities.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 18pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company is exposed to the risk of competitors developing a similar drug to
      the above.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 18pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      patent for using the drug to treat patients suffering from anemia is
      expected to expire in 2012-2013, when the drug will become generic.
      Accordingly, there is the risk that certain countries will make off-label
      use of the EPO; however such risk is qualified since the EPO has a &#8220;black
      box&#8221; warning that deters people from taking the drug otherwise than
      according to label.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 18pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bio-Gal
      has a preliminary plan to conduct Phase II clinical trials on some 50
      patients.&#160;&#160;Should a situation arise whereby several drugs are
      being developed during the Company&#8217;s trials, this could create
      difficulties in recruiting patients for Phase II and Phase III. The need
      for a substantial number of patients in the advanced stages of clinical
      trials is a serious obstacle in developing a drug that could impact the
      prospects and time frame for completing the development of Xtepo&#8217;s EPO
      drug.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accordingly,
to estimate the Company&#8217;s cash flow, we have assessed probabilities for
compliance with the following milestones (compliance with each is conditional on
fulfilling the previous milestone):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.</font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Completion
      of Phase II drug development and obtaining approvals for proceeding to
      Phase III.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.</font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Completion
      of Phase III drug development</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.</font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Successful
      completion by the Company of all trial and registration stages, and
      launching the drug for worldwide
marketing.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.</font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Recognizing
      EPO as an &#8220;Orphan Drug&#8221;, enabling it to be exclusively marketed for 7 more
      years after completing the development process and obtaining the necessary
      approvals for producing and distributing the
  drug.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                  <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                    <div id="FTR">
                      <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
                    </div>
                    <div id="PN" style="PAGE-BREAK-AFTER: always">
                      <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-24</font></div>
                      <div style="WIDTH: 100%; TEXT-ALIGN: center">
                        <hr style="COLOR: black" noshade size="2">
                      </div>
                    </div>
                    <div id="HDR">
                      <div id="GLHDR" style="WIDTH: 100%" align="right">
                      </div>
                    </div>
                    <div>&#160;</div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Generally,
biotechnological companies list several milestones for determining the failure
of a clinical trial in terms of time/cost:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a.</font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Interim
      results of a clinical trial (if planned) - for instance, in the midst of a
      trial phase.&#160;&#160;If the trial is planned for two years, the results
      could be obtained within a year.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">b.</font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Final
      trial results &#8211; these could be obtained three months after
      completion.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The more
progress is achieved in the clinical phases, the lower the R&amp;D risks, when
the most significant one occurs in Phase II.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Below is
a graph published by UBS/Julius Baer, illustrating the costs involved in the
development, failure risk rate and drug value. The graph shows how the
probability of failure decreases as the Company makes progress in its
development stages.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><img src="graph6.jpg" alt=""></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                  <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                    <div id="FTR">
                      <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
                    </div>
                    <div id="PN" style="PAGE-BREAK-AFTER: always">
                      <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-25</font></div>
                      <div style="WIDTH: 100%; TEXT-ALIGN: center">
                        <hr style="COLOR: black" noshade size="2">
                      </div>
                    </div>
                    <div id="HDR">
                      <div id="GLHDR" style="WIDTH: 100%" align="right">
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accordingly,
we estimated cash flows in order to determine the IP value in each of the
situations discussed above. The Company&#8217;s success with the following R&amp;D
phases (Phase II, Phase III and registering the drug with the authorities) has
been assessed by us on the basis of studies conducted by Salim Kanji, Gilles
Lamarche and Jean Sassevill in August 2006<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">4</font>:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <div align="center">
          <div align="center">
            <div align="center">
              <div align="center">
                <table cellpadding="0" cellspacing="0" width="75%">
                    <tr>
                      <td valign="top" width="33%" style="BORDER-TOP: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td valign="top" width="33%" style="BORDER-TOP: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Success</font></div>
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Probability</font></div>
                      </td>
                      <td valign="top" width="33%" style="BORDER-RIGHT: #000000 1pt solid; BORDER-TOP: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cumulative</font></div>
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Probability</font></div>
                      </td>
                    </tr>
                    <tr bgcolor="#ccffcc">
                      <td align="left" valign="top" width="33%" style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Phase
      I</font></div>
                      </td>
                      <td valign="top" width="33%" style="BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">62.5%</font></div>
                      </td>
                      <td valign="top" width="33%" style="BORDER-RIGHT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">62.5%</font></div>
                      </td>
                    </tr>
                    <tr bgcolor="white">
                      <td align="left" valign="top" width="33%" style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Phase
      II</font></div>
                      </td>
                      <td valign="top" width="33%" style="BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">35%</font></div>
                      </td>
                      <td valign="top" width="33%" style="BORDER-RIGHT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">21.9%</font></div>
                      </td>
                    </tr>
                    <tr bgcolor="#ccffcc">
                      <td align="left" valign="top" width="33%" style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Phase
      III</font></div>
                      </td>
                      <td valign="top" width="33%" style="BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">68%</font></div>
                      </td>
                      <td valign="top" width="33%" style="BORDER-RIGHT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">14.9%</font></div>
                      </td>
                    </tr>
                    <tr bgcolor="white">
                      <td align="left" valign="top" width="33%" style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">File</font></div>
                      </td>
                      <td valign="top" width="33%" style="BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">90%</font></div>
                      </td>
                      <td valign="top" width="33%" style="BORDER-RIGHT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13.4%</font></div>
                      </td>
                    </tr>
                </table>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Likewise,
apart from probability of success in the said phases, we assessed the prospects
of the Company obtaining a 60% Orphan Drug Designation based on assessments made
by the Management and its professional consultants.<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#160;</font>Furthermore,
during the second half of 2009, Keryx Pharmaceuticals obtained an Orphan Drug
Designation from the FDA when this drug is in the Phase II process and intended
for an identical indication to the Company&#8217;s.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Assessing the Market
Potential</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Company&#8217;s revenue forecast is determined on the basis of product market
penetration rate. Multiple Myeloma is a type of blood cancer characterized by an
uncontrolled formation of white plasma cells in the bone marrow. These cause the
formation of malignant cells that damage and destroy part of the bones. The
disease is of a multiple-focus nature, reflected in the production of a large
number of malignant cells. The malignant cells and proteins secreted are
responsible for a series of clinical manifestations and complications, including
bone damage with pain and fractures, damage to bone marrow with anemia,
vulnerability to infection, weakening of the immunity system, damage to the
nervous system, renal failure, failure in coagulation mechanisms, etc. This is
an incurable disease, when the average patient&#8217;s life span is 3-5
years.</font></div>
    </div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
      <hr style="COLOR: black" align="left" noshade size="1" width="15%">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super; FONT-FAMILY: Times New Roman">4</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#160;</font>Probabilities
based on a combination of studies and analyses by Pharmaprojects, Tufts DiMasi
and Frenkel Group and Decision Resources.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                  <div id="FTR">
                    <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
                  </div>
                  <div id="PN" style="PAGE-BREAK-AFTER: always">
                    <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-26</font></div>
                    <div style="WIDTH: 100%; TEXT-ALIGN: center">
                      <hr style="COLOR: black" noshade size="2">
                    </div>
                  </div>
                  <div id="HDR">
                    <div id="GLHDR" style="WIDTH: 100%" align="right">
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In the
U.S. alone, close to 1.4 million new cases of cancer were diagnosed in 2005
(about 0.4% of the population), when the number of deaths from the disease stood
at about 0.6 million (close to 0.2% of the population).</font><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Multiple
Myeloma is a common blood cancer, comprising approximately 10% of all blood
cancers.&#160;&#160;In the U.S. alone there are currently some 600,000 Multiple
Myeloma patients, when 16,000 new cases are discovered each year, with this
figure increasing as the average life expectancy worldwide gradually
increases.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Multiple
Myeloma is in most cases associated with advance age, when the disease usually
appears between the ages of 65-70, although in rare cases it has been diagnosed
among 50 year olds as well.&#160;&#160;&#160;Also, Multiple Myeloma constitutes
1% of the various types of cancer and 2% of overall U.S. mortality originating
from cancerous diseases.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Size of Relevant
Market</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To assess
the size of the market targeted by the Company, we have assumed that the number
of U.S. patients constitutes nearly half the number of patients worldwide to
whom the Company plans to sell its products (Europe, United States, the Middle
East, North Africa, etc.).&#160;&#160;Accordingly, the total number of new
Multiple Myeloma patients across the world, constituting the basis for
calculating the overall number of patients treated with the drug, is estimated
by us at some 40,000 persons each year.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Assessment of Average
Duration of Drug Use</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Because
the proposed treatment must be administered to patients for the rest of their
lives after starting therapy, we have assessed the life expectancy anticipated
by the Company for Multiple Myeloma patients undergoing EPO therapy &#8211; based on
the latest survey conducted by the Company as well as Management&#8217;s forecasts and
expectations &#8211; as 48 months (approximately 4 years). This implies that the EPO
will increase patients&#8217; life expectancy by 4 years, during which the drug will
be sold to persons undergoing such therapy.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                  <div id="FTR">
                    <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
                  </div>
                  <div id="PN" style="PAGE-BREAK-AFTER: always">
                    <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-27</font></div>
                    <div style="WIDTH: 100%; TEXT-ALIGN: center">
                      <hr style="COLOR: black" noshade size="2">
                    </div>
                  </div>
                  <div id="HDR">
                    <div id="GLHDR" style="WIDTH: 100%" align="right">
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Assumptions
concerning the EPO&#8217;s selling prices are also dependent on market
competition.&#160;&#160;Widespread off-label use of the drug could lead to a
considerable reduction in drug prices.&#160;&#160;Also, competitive products
launched in the market could affect prices. To calculate the Company&#8217;s revenue,
we have assumed that sales income will remain fixed, amounting to $11,700<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">5 </font>per
treatment per person for a year, when the Company will be entitled to fixed
royalties from sales by a large pharmaceutical company.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Date for Launching the
Product</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The date
for launching the product is a reference point likely to change significantly,
and it fluctuates over a relatively wide range of years. Accordingly, the
Company&#8217;s revenue from the EPO&#8217;s production and marketing depends critically on
the success of clinical trials and obtaining all the necessary permits for this
purpose. We have therefore assumed that successful completion of R&amp;D in
Phase II and Phase III, regulatory registration of the clinical trials, the
start of serial production among subcontractors and marketing the products to
patients will commence in year 2016, as detailed below.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Company estimates that Phase II will cost approximately $1.5 m. (and last 2-2.5
years), while Phase III is estimated at approximately $10-20 m. (lasting 3-4
years).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On the
other hand, it is likely that the Company will be exempt from executing Phase
III. At the moment, the Company is unable to assess the likelihood of obtaining
such exemption, but it is known that obtaining such approval is relatively rare.
Hence, we consider that the Company will be obligated to conduct Phase III
clinical trials in order to obtain approval for producing and marketing the
drug.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="TEXT-ALIGN: justify">
      <hr style="COLOR: black" align="left" noshade size="1" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">5</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>The price of a single
injection of similar drugs currently amounts to $150.&#160;&#160;The Company
estimates that due to allowing the generic use of the drug for anemia patients
commencing 2012-2013, prices will drop by about 50%.&#160;&#160;Each patient
using the drug must take three injections weekly &#8211; which means that the cost of
the drug per patient will be: $150 x 50% x 3 x 52 = $11,700.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                  <div id="FTR">
                    <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
                  </div>
                  <div id="PN" style="PAGE-BREAK-AFTER: always">
                    <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-28</font></div>
                    <div style="WIDTH: 100%; TEXT-ALIGN: center">
                      <hr style="COLOR: black" noshade size="2">
                    </div>
                  </div>
                  <div id="HDR">
                    <div id="GLHDR" style="WIDTH: 100%" align="right">
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based on
the foregoing, it is estimated that the Company will require $17 m. over 6
yearsup to and including R&amp;D completion and success of clinical trials, as
shown in the following table:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">
      <div style="DISPLAY: block; TEXT-INDENT: 0pt" align="center">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt" align="center">
          <table cellpadding="0" cellspacing="0" width="75%">
              <tr>
                <td valign="top" width="33%" style="BORDER-TOP: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Trial
      Phase</font></div>
                </td>
                <td valign="top" width="33%" style="BORDER-TOP: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cost
      of Trial ($ m.)</font></div>
                </td>
                <td valign="top" width="33%" style="BORDER-RIGHT: #000000 1pt solid; BORDER-TOP: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Period
      up to Completion of </font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Trial
      Phase</font></div>
                </td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td valign="top" width="33%" style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Phase
      II</font></div>
                </td>
                <td valign="top" width="33%" style="BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.5</font></div>
                </td>
                <td valign="top" width="33%" style="BORDER-RIGHT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.5</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td valign="top" width="33%" style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Phase
      III</font></div>
                </td>
                <td valign="top" width="33%" style="BORDER-BOTTOM: #000000 1pt solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16</font></div>
                </td>
                <td valign="top" width="33%" style="BORDER-RIGHT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.5</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We wish
to emphasize that conducting clinical trials on human beings in Phase I, Phase
II and Phase III, necessitates the preliminary approval of IRB/Helsinki and the
regulatory authorities in the countries where such trials are being performed.
It should also be noted that only successful results in the preliminary phases
will guarantee the possibility of transferring from one phase to another. After
a successful transfer through all the said phases (including completion of Phase
III), the Company may file an application to approve registration of the drug by
the relevant regulatory authorities &#8211; e.g. the FDA in the United
States.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Projected Penetration
Rates</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">From the
revenue aspect, in order to estimate the number of new patients who will undergo
therapy with the new drug being developed by the Company, we have in each year
assumed that the penetration rate will gradually increase. The implication is
that the Company will have 4,000 new patients in 2016. additionally, the number
of new treated patients is expected to increase every year&#160;&#160;with each
patient treated over a four-year period on average, as the following table
shows:</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left"><img src="graph7.jpg" alt=""></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As we
have assumed that under a certain probability,&#160;&#160;the Company will gain
an Orphan Drug designation, the Company&#8217;s cash flow has been weighted over a
7-year term - from R&amp;D&#160;&#160;completion and obtaining approvals, in
which the Company will benefit from exclusive EPO marketing and distribution
(similar to the rights granted under the patent). Once the 7 year term expires,
the price of the drug and number of patients will substantially decline, such
that the Company&#8217;s cash flow from the drug will be insignificant.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                  <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                    <div id="FTR">
                      <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
                    </div>
                    <div id="PN" style="PAGE-BREAK-AFTER: always">
                      <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-29</font></div>
                      <div style="WIDTH: 100%; TEXT-ALIGN: center">
                        <hr style="COLOR: black" noshade size="2">
                      </div>
                    </div>
                    <div id="HDR">
                      <div id="GLHDR" style="WIDTH: 100%" align="right">
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Thus, we
have assumed that the Company&#8217;s cash flows from 2023 onward will be
insignificant for the above reasons, as shown in the following
graph:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><img src="graph8.jpg" alt=""></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Furthermore,
as the practice in the industry is that R&amp;D companies sell the production
and marketing rights for drugs to outside entities (in the majority of cases to
large pharma companies) that produce and market the drugs themselves, against
granting royalties and further payments to the R&amp;D companies, we have
estimated the Company&#8217;s future revenue according to a similar royalty model,
based on the execution of similar transactions.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Assumptions of Royalty
Rates</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
amount of royalties paid to a drug development company depends on a range of
factors, and principally: (a) the risk level of the projected development; (b)
the future R&amp;D costs and the Company&#8217;s financial position; (c) the market
potential at which the drug is targeted; (d) the competition level and
alternative products available in the m</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">arket.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Usually
in such transactions, a certain exchange ratio exists between the lump sum paid
to the Company upon signature of the agreement and the royalty rate payable from
future income.&#160;&#160;Companies in various R&amp;D phases are also likely to
demand payment for attaining development goals, or alternatively, to demand
funding for the drug&#8217;s ongoing development in the future.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                  <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                    <div id="FTR">
                      <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
                    </div>
                    <div id="PN" style="PAGE-BREAK-AFTER: always">
                      <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-30</font></div>
                      <div style="WIDTH: 100%; TEXT-ALIGN: center">
                        <hr style="COLOR: black" noshade size="2">
                      </div>
                    </div>
                    <div id="HDR">
                      <div id="GLHDR" style="WIDTH: 100%" align="right">
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
following table sets out a number of transactions executed with similar
companies over the past years:</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">
      <div style="DISPLAY: block; TEXT-INDENT: 0pt" align="center">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt" align="center">
          <div style="DISPLAY: block; TEXT-INDENT: 0pt" align="center">
            <div style="DISPLAY: block; TEXT-INDENT: 0pt" align="center">
              <div style="DISPLAY: block; TEXT-INDENT: 0pt" align="center">
                <div style="DISPLAY: block; TEXT-INDENT: 0pt" align="center">
                  <div style="DISPLAY: block; TEXT-INDENT: 0pt" align="center">
                    <div style="DISPLAY: block; TEXT-INDENT: 0pt" align="center">
                      <div style="DISPLAY: block; TEXT-INDENT: 0pt" align="center">
                        <div style="DISPLAY: block; TEXT-INDENT: 0pt" align="center">
                          <div style="DISPLAY: block; TEXT-INDENT: 0pt" align="center">
                            <div style="DISPLAY: block; TEXT-INDENT: 0pt" align="center">
                              <div style="DISPLAY: block; TEXT-INDENT: 0pt" align="center">
                                <table cellpadding="0" cellspacing="0" width="100%">
                                    <tr>
                                      <td valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-TOP: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Company
      name</font></div>
                                      </td>
                                      <td valign="top" width="2%" style="BORDER-TOP: #000000 1pt solid; BORDER-LEFT: #7ba0cd 1pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-TOP: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Development
      status</font></div>
                                      </td>
                                      <td valign="top" width="2%" style="BORDER-TOP: #000000 1pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-TOP: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Down
      payment</font></div>
                                      </td>
                                      <td valign="top" width="2%" style="BORDER-TOP: #000000 1pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-TOP: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Royalty
      rate</font></div>
                                      </td>
                                      <td valign="top" width="2%" style="BORDER-TOP: #000000 1pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-TOP: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Competition</font></div>
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(high/low
      level)</font></div>
                                      </td>
                                      <td valign="top" width="2%" style="BORDER-TOP: #000000 1pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td valign="top" width="15%" style="BORDER-RIGHT: #000000 1pt solid; BORDER-TOP: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Potential
      </font></div>
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">market
      size</font></div>
                                      </td>
                                    </tr>
                                    <tr bgcolor="#ccffcc">
                                      <td valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Montigen
      Inc.</font></div>
                                        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
                                      </td>
                                      <td valign="top" width="2%" style="BORDER-LEFT: #7ba0cd 1pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td align="left" valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Number
      of drugs in para-clinical trials</font></div>
                                      </td>
                                      <td align="left" valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td align="left" valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$18
      m. ($9 m. cash and $9 m. in Supergen shares).&#160;&#160;Further payment
      up to $22 m. upon attaining milestones</font></div>
                                      </td>
                                      <td align="left" valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td align="left" valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Apparently
      there isn&#8217;t any</font></div>
                                      </td>
                                      <td align="left" valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td align="left" valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">On
      all levels &#8211; but still far from commercialization</font></div>
                                      </td>
                                      <td align="left" valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td align="left" valign="top" width="15%" style="BORDER-RIGHT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$
      billions.</font></div>
                                      </td>
                                    </tr>
                                    <tr bgcolor="white">
                                      <td valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Hunter-Fleming</font></div>
                                      </td>
                                      <td valign="top" width="2%" style="BORDER-LEFT: #7ba0cd 1pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td align="left" valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2
      drugs in 2 phases.</font></div>
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2
      drugs in phase I.&#160;&#160;One in para-clinical</font></div>
                                      </td>
                                      <td align="left" valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;&#8364;&#160;&#160;8
      m. after deducting debt</font></div>
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(amount
      unknown) &#8211; in shares</font></div>
                                      </td>
                                      <td valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Additional
      &#8364; 17 m. in shares after completing milestones</font></div>
                                      </td>
                                      <td valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Great
      competition</font></div>
                                      </td>
                                      <td valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td valign="top" width="15%" style="BORDER-RIGHT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Vast
      markets &#8211; Alzheimers, arthritis and more</font></div>
                                      </td>
                                    </tr>
                                    <tr bgcolor="#ccffcc">
                                      <td valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Elbion</font></div>
                                      </td>
                                      <td valign="top" width="2%" style="BORDER-LEFT: #7ba0cd 1pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td align="left" valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">1
      drug ready for phase II.</font></div>
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2
      drugs in para-clinic</font></div>
                                      </td>
                                      <td align="left" valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td align="left" valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Approx.
      $30 m.</font></div>
                                      </td>
                                      <td align="left" valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;
      </font></div>
                                      </td>
                                      <td valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td align="left" valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Medium</font></div>
                                      </td>
                                      <td align="left" valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td valign="top" width="15%" style="BORDER-RIGHT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;
      </font></div>
                                      </td>
                                    </tr>
                                    <tr bgcolor="white">
                                      <td valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Innovive
      Pharmaceuticals, Inc.</font></div>
                                        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
                                      </td>
                                      <td valign="top" width="2%" style="BORDER-LEFT: #7ba0cd 1pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td align="left" valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">4
      drugs in clinical trials</font></div>
                                      </td>
                                      <td align="left" valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td align="left" valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$3
      m. in CytRX shares</font></div>
                                      </td>
                                      <td align="left" valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td align="left" valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Not
      known, but deal reaches $21.3 m. presumably accord. to
      milestones.</font></div>
                                      </td>
                                      <td align="left" valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td align="left" valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Variable
      (depends on drug)</font></div>
                                      </td>
                                      <td align="left" valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td align="left" valign="top" width="15%" style="BORDER-RIGHT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$
      billions.</font></div>
                                      </td>
                                    </tr>
                                    <tr bgcolor="#ccffcc">
                                      <td align="left" valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Targanta
      Therapeutics</font></div>
                                        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
                                      </td>
                                      <td align="left" valign="top" width="2%" style="BORDER-LEFT: #7ba0cd 1pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td align="left" valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Phase
      3 successfully completed,</font></div>
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">FDA
      demands more completions</font></div>
                                      </td>
                                      <td align="left" valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td align="left" valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$42
      m.</font></div>
                                      </td>
                                      <td align="left" valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td align="left" valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$95
      m. before milestones</font></div>
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(inc.
      attaining market targets not indicated)</font></div>
                                      </td>
                                      <td align="left" valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td align="left" valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Medium
      competition</font></div>
                                      </td>
                                      <td align="left" valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td align="left" valign="top" width="15%" style="BORDER-RIGHT: #000000 1pt solid; BORDER-BOTTOM: black 2px solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">aprx.
      $ 1 billion.</font></div>
                                      </td>
                                    </tr>
                                    <tr bgcolor="white">
                                      <td valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">IDM
      Pharma, Inc.</font></div>
                                      </td>
                                      <td valign="top" width="2%" style="BORDER-LEFT: #7ba0cd 1pt solid; BORDER-BOTTOM: #000000 1pt solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td align="left" valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: #000000 1pt solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Phase
      3 successfully completed; approval to market in Europe</font></div>
                                      </td>
                                      <td align="left" valign="top" width="2%" style="BORDER-BOTTOM: #000000 1pt solid"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td align="left" valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: #000000 1pt solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$75
      m.</font></div>
                                      </td>
                                      <td align="left" valign="top" width="2%" style="BORDER-BOTTOM: #000000 1pt solid"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td align="left" valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: #000000 1pt solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">No
      royalties</font></div>
                                      </td>
                                      <td align="left" valign="top" width="2%" style="BORDER-BOTTOM: #000000 1pt solid"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td align="left" valign="top" width="15%" style="BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: #000000 1pt solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Medium.
      Orphan drug in Europe up to 2014</font></div>
                                      </td>
                                      <td align="left" valign="top" width="2%" style="BORDER-BOTTOM: #000000 1pt solid"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                      <td align="left" valign="top" width="15%" style="BORDER-RIGHT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid">
                                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$
      100
ms.</font></div>
                                      </td>
                                    </tr>
                                </table>
                              </div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: left">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: left">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                  <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                    <div id="FTR">
                      <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
                    </div>
                    <div id="PN" style="PAGE-BREAK-AFTER: always">
                      <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-31</font></div>
                      <div style="WIDTH: 100%; TEXT-ALIGN: center">
                        <hr style="COLOR: black" noshade size="2">
                      </div>
                    </div>
                    <div id="HDR">
                      <div id="GLHDR" style="WIDTH: 100%" align="right">
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
      <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold">Figure 1:&#160;Frequency of Royalty Rates Paid by
the&#160;Top 15 Pharmaceutical companies<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 70%; VERTICAL-ALIGN: super">2</font></font></font></div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><img src="graph9.jpg" alt=""></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Royalty
Rates Actually Paid Per Product &#8211; Segmented According to R&amp;D Phase on
Signature of Agreement <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">7.</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><img src="graph10.jpg" alt=""></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <div>
        <hr style="COLOR: black" align="left" noshade size="1" width="15%">
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">6&#160;Source:&#160;&#160;PharmaDealsTM,
PharmaVentures Analysis</font></font></font></font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">7
Source:&#160;&#160;PharmaDealsTM, PharmaVentures
Analysis</font></font></font></font></font></font></font></font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
          <div style="DISPLAY: block; TEXT-INDENT: 0pt">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                      <div id="FTR">
                        <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
                      </div>
                      <div id="PN" style="PAGE-BREAK-AFTER: always">
                        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-32</font></div>
                        <div style="WIDTH: 100%; TEXT-ALIGN: center">
                          <hr style="COLOR: black" noshade size="2">
                        </div>
                      </div>
                      <div id="HDR">
                        <div id="GLHDR" style="WIDTH: 100%" align="right">
                        </div>
                      </div>
                      <div>&#160;</div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Below are
the effective royalty rates specified under the companies&#8217; licensing agreements,
according to the product&#8217;s clinical trial stage.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><img src="graph11.jpg" alt=""></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As the
Company contemplates signing a distribution agreement only upon R&amp;D
completion (Phase III), based on the transaction shown in the above table as
well as the graphs contained in this chapter, the Management expects that,
bearing in mind the commercial conditions prevailing in the market after R&amp;D
completion and obtaining all the necessary approvals, a lump sum of $25 m. will
be transferred to the Company along with a fixed royalty rate of 12.5% of sales
derived from the drug.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As to the
scope of expenses, apart from the costs incurred in completing development as
outlined in the above table, the Management believes that its current expenses
in connection with the patent will amount to $0.6 m. per annum.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Company&#8217;s expenses (both development and current) have been weighted at
identical probabilities to those taken into account when calculating the
Company&#8217;s revenue.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <hr style="COLOR: black" align="left" noshade size="1" width="15%">
    </div>
    <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">8
Source:&#160;&#160;Deloitte Recap LLC, 2009</font></font></div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
          <div style="DISPLAY: block; TEXT-INDENT: 0pt">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                      <div id="FTR">
                        <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
                      </div>
                      <div id="PN" style="PAGE-BREAK-AFTER: always">
                        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-33</font></div>
                        <div style="WIDTH: 100%; TEXT-ALIGN: center">
                          <hr style="COLOR: black" noshade size="2">
                        </div>
                      </div>
                      <div id="HDR">
                        <div id="GLHDR" style="WIDTH: 100%" align="right">
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cash
flows estimated for the Company, based on the foregoing
assumptions:</font><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><img src="graph12.jpg" alt=""></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <div>&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
            <div style="DISPLAY: block; TEXT-INDENT: 0pt">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                        <div id="FTR">
                          <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
                        </div>
                        <div id="PN" style="PAGE-BREAK-AFTER: always">
                          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-34</font></div>
                          <div style="WIDTH: 100%; TEXT-ALIGN: center">
                            <hr style="COLOR: black" noshade size="2">
                          </div>
                        </div>
                        <div id="HDR">
                          <div id="GLHDR" style="WIDTH: 100%" align="right">
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
statutory tax rate has been fixed at 18% (according to the tax rate currently
expected to apply from year 2016 onward). The losses shown in the above cash
flow derive from the Company&#8217;s investments in R&amp;D and its annual current
expenses.&#160;&#160;These expenses will be setoff against its future revenue as
shown above.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
annual price of capital for discounting the calculated cash flows is estimated
at 25%, based on the following parameters.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">
      <div style="DISPLAY: block; TEXT-INDENT: 0pt" align="center">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt" align="center">
          <div style="DISPLAY: block; TEXT-INDENT: 0pt" align="left">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
              <table cellpadding="0" cellspacing="0" width="75%" style="TEXT-ALIGN: left">
                  <tr style="TEXT-ALIGN: left;">
                    <td valign="top" width="60%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Parameter</font></font></div>
                    </td>
                    <td valign="top" width="20%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Value</font></font></div>
                    </td>
                    <td valign="top" width="20%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Source</font></font></div>
                    </td>
                  </tr>
                  <tr bgcolor="#ccffcc">
                    <td valign="top" width="60%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Non-risk
      interest rate</font></div>
                    </td>
                    <td valign="top" width="20%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.10%</font></div>
                    </td>
                    <td valign="top" width="20%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Bank
      of Israel</font></div>
                    </td>
                  </tr>
                  <tr bgcolor="white">
                    <td valign="top" width="60%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Market
      premium</font></div>
                    </td>
                    <td valign="top" width="20%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6.50%</font></div>
                    </td>
                    <td valign="top" width="20%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Damodaran</font></div>
                    </td>
                  </tr>
                  <tr bgcolor="#ccffcc">
                    <td valign="top" width="60%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Beta</font></div>
                    </td>
                    <td valign="top" width="20%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.12%</font></div>
                    </td>
                    <td valign="top" width="20%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Damodaran</font></div>
                    </td>
                  </tr>
                  <tr bgcolor="white">
                    <td valign="top" width="60%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Addition
      in respect of small company</font></div>
                    </td>
                    <td valign="top" width="20%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9.83%</font></div>
                    </td>
                    <td valign="top" width="20%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Ibbotson</font></div>
                    </td>
                  </tr>
                  <tr bgcolor="#ccffcc">
                    <td valign="top" width="60%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Addition
      in respect of specific risk for company</font></div>
                    </td>
                    <td valign="top" width="20%">
                      <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.00%</font></div>
                    </td>
                    <td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  </tr>
                  <tr bgcolor="white">
                    <td valign="top" width="60%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Price
      of equity capital</font></div>
                    </td>
                    <td valign="top" width="20%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">23.21%</font></div>
                    </td>
                    <td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  </tr>
                  <tr bgcolor="#ccffcc">
                    <td valign="top" width="60%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Rounded
      off price of capital</font></div>
                    </td>
                    <td valign="top" width="20%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">25%</font></div>
                    </td>
                    <td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  </tr>
              </table>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Below is
a sensitivity analysis of the discount rate, for the royalty rates shown in the
said model:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><img src="graph13.jpg" alt=""></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Also,
attached is a sensitivity analysis of the discount rate, for a royalty rate
below the rate shown in the said model:</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><img src="graph14.jpg" alt=""></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
            <div style="DISPLAY: block; TEXT-INDENT: 0pt">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                        <div id="FTR">
                          <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
                        </div>
                        <div id="PN" style="PAGE-BREAK-AFTER: always">
                          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-35</font></div>
                          <div style="WIDTH: 100%; TEXT-ALIGN: center">
                            <hr style="COLOR: black" noshade size="2">
                          </div>
                        </div>
                        <div id="HDR">
                          <div id="GLHDR" style="WIDTH: 100%" align="right">
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Also,
attached is a sensitivity analysis of the discount rate, for a royalty rate
above the rate shown in the said model:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><img src="graph15.jpg" alt=""></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based on
all the analyses shown above, a value of approximately $2 million for the IP
assigned to XTL is reasonable and fair.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.&#160;&#160;&#160;&#160;&#160;&#160;Conclusion
and Recommendations</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In light
of the foregoing considerations, the share allotment ratios of 70% to Xtepo
shareholders and 30% to XTL are, in our opinion, both reasonable and
fair.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">These
allotment ratios reflect a value of approximately $1.5 m. for XTL prior to the
Transaction, and a value of $3.5 m. for Xtepo, out of which $2 m. are attributed
to the&#160;&#160;IP assigned to XTL (through the holding in the subsidiary
after the Xtepo Transaction).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">
          <div style="DISPLAY: block; TEXT-INDENT: 0pt">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                          <div id="FTR">
                            <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
                          </div>
                          <div id="PN" style="PAGE-BREAK-AFTER: always">
                            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-36</font></div>
                            <div style="WIDTH: 100%; TEXT-ALIGN: center">
                              <hr style="COLOR: black" noshade size="2">
                            </div>
                          </div>
                          <div id="HDR">
                            <div id="GLHDR" style="WIDTH: 100%" align="right">
                            </div>
                          </div>
                          <div>&#160;</div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Appendix
A &#8211; Company&#8217;s Share Price on NASDAQ</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><img src="graph16.jpg" alt=""></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">
          <div style="DISPLAY: block; TEXT-INDENT: 0pt">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                          <div id="FTR">
                            <div id="GLFTR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Fairness
Opinion</font></div>
                          </div>
                          <div id="PN" style="PAGE-BREAK-AFTER: always">
                            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C-37</font></div>
                            <div style="WIDTH: 100%; TEXT-ALIGN: center">
                              <hr style="COLOR: black" noshade size="2">
                            </div>
                          </div>
                          <div id="HDR">
                            <div id="GLHDR" style="WIDTH: 100%" align="right">
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Contact:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor Relations, E-mail: ir@xtlbio.com; Tel: +972 3 612 7011</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cautionary
Statement</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Some of
the statements included in this Form 6-K may be forward-looking statements that
involve a number of risks and uncertainties. For those statements, we claim the
protection of the safe harbor for forward-looking statements contained in the
Private Securities Litigation Reform Act of 1995.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 4
- -</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="left">
          <div align="left">
            <table border="0" cellpadding="0" cellspacing="0" width="100%">
                <tr>
                  <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                  <td colspan="2" valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">XTL BIOPHARMACEUTICALS
      LTD.</font></font></td>
                  <td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                </tr>
                <tr>
                  <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                  <td colspan="2" valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                  <td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                </tr>
                <tr>
                  <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                  <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                  <td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                  <td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="50%" style="BORDER-BOTTOM: #ffffff solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date:
      January 15, 2010&#160;</font></div>
                  </td>
                  <td valign="top" width="3%" style="BORDER-BOTTOM: #ffffff solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:
      </font></div>
                  </td>
                  <td align="left" nowrap valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid">

                    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/
      David Grossman</font></div>
                  </td>
                  <td valign="top" width="12%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                </tr>
                <tr>
                  <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                  <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                  <td align="left" nowrap valign="bottom" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">David
      Grossman</font></td>
                  <td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                </tr>
                <tr>
                  <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                  <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                  <td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief
      Executive Officer</font></td>
                  <td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                </tr>
            </table>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 5
- -</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>graph1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 graph1.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`"A`C0#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#T[Q=XBOO!
M]]!JLS&[T>X7[*;0>6CQ7!R8V5CC*M]ULDXX/`S47B9/$&F>`[[53XBNH=2L
MK.:Y9;>&W,3/@L$P\3':OW1@@D=236Q=^%[?5=;FOM7=;ZW^SFWMK-X_W<*L
M,2$\G<S<#/&`,#J2:[>%;F7P+?>&+C5FG$UO+:PW3Q9>.)@0@;YOG900,Y&<
M=J`*MW/JFBW'AJ$ZW=WHU#4A%.US%`#Y?V>5]H\N-<#<BG/7CKBNPK`U_0+K
M5$TA[&_AM;G3+H7*//;&9'/E/'@J'0]'SU[5I:;%J<4+C5+RSNI2V5:UM6@4
M+CH0TCY/OD?2@#`T;QA-KES<K;VEK]GB:5"\=\KSP,A(_?0E04R1P`6ZC.*S
M_"'C'5;O3/#*ZW9)OUBUS!=),"\TBQ>8Q>,(JH"%8C#'WQTK1?PA=7>NVFI:
MCJ5O.;)Y&MY([$17#;D9-LD@;#*`W0*N2JYZ4EOX)$%AX6M3J+$:#$T>]8MI
MGS;M#D?-\GWMW?ICWH`@7QS/!K5IINHZ=:6\MZDS0Q1:BLTR&-&<K*@7"\*1
ME6<9XS58_$8PZ+I-[>VFFV$NKQB>R2\U011^5M5F:20Q_*1N`"J&SD>^$L?A
MU<VLFB[]8MO(TA9(XHK?3A%YJM"T6Z0[SEP&SD8'7Y><C33PA/::5X>CL-22
M'4M$M5M8KJ6V\R.5-BHX>,,#AMBGA@00.3R"`9J>-KW5Y="DT2WAG-U/=6\\
M(N5,):-<AO.56^3C(*C)R,CL+MMXUN+^WLH+'2D?5[B>Y@:UENMD41MWV2L9
M`A)7=M`PF3N'`YQJ1:)=M>:5>7VIBYN;(S%V%N(UD\P8PH!^4#MDL?4GK67#
MX*GL3%<Z?JD<6HPWMW<QS2VOF1F.XD+O$R!P2!\O(93E0>F10`T>+I9;W3WF
M1K&.-[R/4+=BK[6A3=PV.1_$",9!&1VJK)XRU2WO]*NM4T]=-TF>UN;QRLXF
M)B2,.!(-HV.`<X4L.OS&M.'P9$&@>YO&N6\RZDNBT8'GM.NU@,'Y0!@`<\`<
M]ZJCP1=W;6<.L:TM]8VEK/9K`MIY;2Q2($S(V\Y<`=0%')X%`%;3?B5:7\[Q
M;=-D=K26[@2RU1+E@(QNV2A5'EL0>VX<'GIE9/'FH06VE-=:/86<^JHTMJ+O
M4S%%MPA5'D\KB5M_"`'[I^:M:TT#6EL);"_U^.YM?LC6T02Q$;G(VAY&WG<P
M']T(#SQTQ)?:#J$FEV-E9:E:)';P"":*]L!<0S@``,5WJP(QQ\V.3D'@@`V;
M*>6YL8)YK=K:61`SPNRL8R1R"5)!QZ@XJ>L_0M)BT+1+33(7+QVZ;0Q&,\YX
M`Z#G@#H,"M"@`HHHH`****`//-9\07UGJ6IB]UZXT.6%B+%+BS7^SY5X"-),
M8R>21D!U(XX/4[]WXBU!;^:QTS2HKZ>TMX[B[9KHQ(`^["QG8V]OE)P=HQC)
M&:2X\/ZRQO+:VU]/[-O"Y>*[M#<31A\[ECD,@`7G@,K8Z=.*27PK<VMRTNB:
MH+$2VL5G.LT!GRD8(5D^==K@,1D[ATR#B@#)N/B.[V][>Z9I"W>GV>F0:I+-
M)=&)S#(')"IL.7`C/!(!YY&.;LGCA]/AU*;6=,6S2ULDOXO+NA)YL;,556)"
MA'R`",E?F^\>:8/A_;P:7K6G6EXT-MJ&D0Z5&&CW&%8TE4.3D;B?-SCCIUYX
MO:CX0BU1KGS[N14GTY+']VN&0JY<2`DGD$@@8[4`0^&O&]IK^K3:7YNF-=)#
M]H3^SM16\0QY"G<0J[6!8<8(YX)YQ-J?B/4(+^^MM+T=;]=/B26Z9[H0GY@3
MLC&T[GVC.&*CD<^FAI=GK$$KOJFK0W@VA42"S\A1_M-EG);Z$#VJAJ7AR_GU
M"]N=+UA;%=0B2*[5[42GY05WQG<-K[3C+!QP/E]0#-T/7=4U_P`<7!AN(TT&
M'3K:Z@2.129A.)"K.#%G^#HKC&!][<0KO%?B2^\'ZK!>S-]LTO4`+2&V)1&A
MN^2F&."4?D').T@'IG&MHOAF#0M3N+BUEQ;O96ME%!M_U:P>9@[L\Y$GH,;>
M^>&77A6WU75[R\UAUOH9;<VMO:M'A((F'S]SEV/5N.```.20#(FU'Q#I'B?P
MYI][>07<,UG>7%_*2(@60QGY55#P@?"C.6!.XY`)CT;XG:=J]_9P*VG%+]6:
MT2WU!9IP0A?$T04>5E5/=L'@X/%:$'A&[0Z,USJXO)=.CGM6DFMSNGMY=N5;
M#C#@(@W]#@_+S4VEZ#JNDV<-D=:$^FV<!BMX!:`2NH7:HDD+'=CC&U4/'.:`
M*&C>.KF\M-'OM5TA-/L=7BWVLB79F8,(S)M==B[<JK$$$YQS@G%6].\77-S<
M:2U[I0M+'6.+";[1OD)V&0+*FT;"54D89NF#@UD>#O"M_/X9\-'7KG?#862&
M"Q:U,,D,C0F,B1BQW%59E`VKC/.2,UKZ=X1N+:?24O=5%W9:/S81>1LD!V&,
M&5]Q\PA6(&%7KDY-`$GB#Q4VC:M::9#!9R7-S$\R?;+T6RN%(!2,E6WOS]W@
M8ZD5FW7B77K?Q;J-M;:<EQ:V^E6]X]O/<+$826FW@,J-N<A5`&=ORGD=]SQ!
MHU]JZ>3!>V2VSH8YK:^L!<QN#_$!N4AL$CDD>U4=*\%QZ2;A8K^22.32;?3%
M\U,L!%YGSEL\D^9TP.GOP`1:AXSF@TBVU>SL+1M.FLDO1/?:@MKN1EW;4&UB
M6`QG=M'S#GKB*W\?"[DDGAT]5TNWTR#5+FZEN"K1PRH[#"!#N8!#QD?7L:\7
MP\N+:""*VU>!=NE6^F2S2V`DE`B5E#PL7_=D[B2"''2KNC>!8-.L;JRN[O[9
M;W6D6NE2IY7EY2%)$+?>/WA)T[8ZF@#.M/B/#J:W%M"^FK<26,]S:M9:E'=L
MFQ<XE4`;&P<X&Y>",^MG3O'%S;6]D?$%@MI'/I+ZBEPD^]BL2H9/,3:H1OG!
M`!8=>E:5IH&M+82V%_K\=S:_9&MH@EB(W.1M#R-O.Y@/[H0'GCIAEWX,@OY=
M-%U<>9;VFF3Z;+%Y>/.658U+9S\N!'TYZ]>.0"M)XKU1+8K?Z2NG27=C-<64
MB7(GPR)NV2#:`KX.<#>O!YXYS=6\9:POA+5)])M8YY].TL2W5XTP1HIV@\P%
M(]A5]H*L02HP>,]*UT\)7]PD:ZKK2W?V:UEMK4I:"+'F*$\R3YCO<*,?+L')
MXYXJ7_@2[ETW4-/T[6H[2WU.R6UO0]GYA9EB\KS$.]=I*A00=V0!C!R:`(-4
M^)=GI,TELTFFR2V=O')=K<ZE';3,S('VPQD'S&P<\E1R!GKB]<^-+I+O4FM-
M&-UIVG6:7<UP)R)'5XRZK''L.YOEP06&,@\]*G/AC4;._GN=%UF*R%Y'&MVL
MMEYQ9T4()(SO4*Q4`?,''`XZYT$T26*[U>YBU&2*:_CC595C4M"R(5W<@JQY
MS@KCVH`@\,>(9_$$,D[6UD+;:K0W-C?K=129SE2=JE7&.1C'/!/.-^N=T/PU
M/IVL7.K7US937LT*P,UE9?9590<[G&]RS9[YX'0<FNBH`****`"BBB@`HHHH
M`****`"BBB@#GV\8:;%#J37"7%O/I\P@DMI%'FR,V/+V`$A@^1MP>>AP00);
M'Q5I=]K-_I0N8HKNPB26>*29-Z`C+9`)X7*@GH"?IGD-5TS5]4\0+XWM]-*G
M2'\JUT^2#$U["-PD<[AE7^9O+''?/W^$\16NH:JVO16-OJ,;78L+R,K:LIDA
MC9?,0%U*>9@']VW)[@C-`'=0Z_HUSIQU"#5["6Q5PAN4N4:,,2%`W`XR20,>
MI%26FL:9?VDEW9ZC:7%M&2))H9U=$(ZY8'`Q7EWB.RMI/#>M:B__``D&H"XD
MTV&;^T[*.W6=5NT^18Q'&2V&()9<$$`$XXT]:TZ[UNZU/4M,TV[2QV:>DEO+
M`\#W8AN"\JB-P"?W>%!(^;H.*`/0-/U33]7MOM.FW]K>P9V^;;3+(N?3*DBF
M/K6E1:HNER:G9IJ#C<MHTZB5AZA,Y_2L/0P;[QAJ.LVUE<VMA+90P;KF!X&F
ME5G)/EN`PVJP&XCGZ"L/5K:XL_$MP-*M;Z::ZU&"XFLKS2_/M)2-BF9)P,1%
M54$;FR"G"Y(R`=7IOBW1M3N9+2.]AAO$N9[86TTJ+*[1.48JN<E<J<'T]*MO
MKVCQZJNEOJUBNHO]VT-P@E;C/"9SV/:O/WT.ZC\,W?E:9.MU+XO^V,%@.]D%
M\")>F=OE@'=TV\]*K:X-7U`I;?V;>P/!X@AG:TM-*(B\M;A<3-,5(D++\Y*'
M()YP`<@'I">(-%ENI[6/5[![BW5GFB6Y0O&JMM8L,Y`#<$GH>*JW?BS1K?1D
MU:&\BO;)KB*V\ZSE210TDBQC)!Q@%AGG@5QDWAZ_E\&ZM'!:74,[^))[R58X
MP)981=EBRAU(?*`$`@A@`.<U'J.BG4=-O;B#_A(=2:[O]-68ZC9+")$CN%+%
M8EBC;A2=S,O0#D@4`>AVVN:3>:>^H6NJ64]E'G?<Q7"-&N.N6!P*JS^*-)CT
MVUU"VNH[ZTN;N*SCELY$E7?)((QR#C`+#/<>E<AK.F7I\8:Q=C3;FXT])=+N
M'B2$L)PAFWE1T=E_=L0,GY0/2HK^QO-3U.ZU6QTZ\CL;G5])98Y+5XGD:*<&
M6<QD!E&TJ"6`XCSTP:`.SU/Q7H^EW,5I+>12WCW,%L;:&5&E0RN$5F7((7+#
M)]/6KHUC3#JG]EC4K,Z@%W?9//7S=OKLSG'X5YO=V<Z:?I&CRZ%?3:E;>)8K
MN2X6U=XUC-V7,_FXQ@H0"`<KGD`#-/TO0[E+F/3M3N?$OVF/5WO/*M[6+[.W
M[XNLOV@Q9VE<97S-V,J!CB@#OO\`A)-"!N0=:T[-J"UQ_I2?N@&*DMS\H#`C
MGN,5=L[VUU"U2ZLKF&YMY!E)89`Z,/8C@UP%IHWE^"[D75KJEK.-;NKI9;*V
M#SQG[2[)+Y;*=ZX"\!6R,8'<=#X,DOY+/4&O;940WC-!<&R-I)=(54F22(\A
MLY7)`SMS@9H`Z6BBB@`HHHH`****`"BBB@`HHHH`****`"BLGQ)I<VJZ+)%:
M2"*^B9;BTD.<+,AW)G'\)(P1W!(J;1-6BUO1K;48E,?FK\\3'YHG!PZ-[JP*
MGW%`&A1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%8FCZG<ZSJ=
M[=1$+I$+&WMSM'^D2*?GD!_N@_*/7#'D8K;H`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`*NHZ;::M9FTO8O
M-@,D<FW<5^9'#J<@@\,H/X5:HHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`*YFV/]@^,IK,G;8ZUNN(,GA+I1^\
M0<_QJ`X`[K(>]=-61XDTJ75M&DBM7$=]"RW%G*>B3(<IG'8GY2.ZDCO0!KT5
MGZ'JT6N:-;:A$I3S5^>)B-T3@X=&QW5@5/N*T*`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"N>\27=Q<S6_A[3I6CO+X%IIE'-M;`X=\]F.=J^YSR%-:NJZG
M;:-I=QJ%XQ6"!-S;1EF/95'=B<`#N2*SO#>F7%O'/JFIH@U;4")+C;_RR09\
MN$'T0''NQ8]Z`-:SL[?3[*"SM(EAMX(UCBC48"J!@`?A4]%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!45S_QZR_[A_E4M17/_`!ZS?[A_E0!C>")'F\`^')979Y'TNV9G
M8Y+$Q+DD]S6]7/\`@3_DGGAK_L%6O_HI:Z"@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`YBW`\/^,I;?.VPUPF:($\1W:K\ZCG^
M-!OQZHY[UT]97B+2GU?1I8+>017D96>TE.?W<R'<A..V1@CN"1WJ30M636]&
MM[]$,;2`K+$2"8I%)5T..ZL"#]*`-&BBB@`HHHH`****`"BBB@`HHHH`***P
MO$FI7$26^DZ8X&JZB2D3?\\(Q_K)B/101CU8J.]`%0?\5/XF+<G2=&FP.N+B
M[`_58\^_SGU2NHJIIFG6^DZ9;Z?:*5@@0(F3DGW)/))/))ZDFK=`!13)3((7
M,*HTNT[`YPI/;)`.!^!KG=!UJ_NM=OM*OKC3KN2VB2226P1E6!R2#"^YFRPQ
MG/'!Y4<9`.EHKCM9\5WVG3:[>`6T.FZ$JFXCFB)ENLQA_P!V^\!/O;1E6RP(
MXJUJWBB6T\3Z'I-G`DL=Y<>7=3,#B(&&21%7G[Q\O/?`[?,#0!T]%<)9>-K^
MXEOX3%:2W`Q';P1*P:&=I&189N3DX4.2`N%R<8P3W2[@B[R"V.2!@$T`+111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`5%<_\`'K-_N'^52U%<_P#'K-_N'^5`&)X$_P"2>>&O^P5:_P#HI:Z"
MN?\``G_)//#7_8*M?_12UT%`!1110`4444`%%%%`!1110`4444`%%%%`!7/^
M+=2N=-L;1H;D65O-=+%=WYV?Z)$58F3YP5^\%7+`@;LD5T%5-1@O;BUVZ?>K
M:7`8,LCPB5#C^%ER"0?8@^XH`\\3QT;R\&BP:Q=%$N95&IVELMQ/<0QQ0N&1
M%C9229P,JA!520!G(Z^363IW@:[UE[Q=1-I:33F9(O+\S8&."N>&XP1QR#P.
M@K+X3GMW34;6_MTUSS9)I;N2T+Q2&145U\L."%Q''@!\C8,D\YM6OAI;?19-
M'>:.6QN4N?MBO"=TKS,68J=V%7+O\N#U'(QR`<QJGB35?"NV.[U5[XWM@)XI
M+B&-5MY3-#%TC5<IF=3@Y/RGGFKIU'4!H]Q]CUS4[TI/"LSOI82]MHB3O81>
M6-^<?+^[/`/WZM?\(7->@MK.IQ7<T5L+:TDAM/*,0#I('(+,&?='&<\#Y>@K
M4TK1;JTO[S4[^\@N=2NH8X&DAMS#$J1ERH"%V.<R-D[N?:@#(T/Q)<3W5C;Z
MO>V]G*L(BEBF*1O<W+88(H/.Y4P64=Y`.Q%=C7(7'@;S4M574<'9LO7:#<UP
M3*)F93N'EL7'7YN#C'`(Z^@`KF83_87C*2W)VV.MYEBR>$ND7YU'/\:`,`!U
M1SWKIJRO$6E/J^C2P6\@BO(RL]I*<_NYD.Y"<=LC!'<$CO0!JT5GZ'JJ:UI$
M%ZJ>6[`K-"2"895.UT..ZL"#]*T*`"BBB@`HHHH`****`"BBB@"O?7MMIMC/
M>WDRPVT$9DED<X"J!DFL?PW9W,TEQKVI1M'?7^!'"W6VMQ_JX_KSN;_:8CH!
M4%YGQ+XC&FKDZ5I;K+>'M/<<-'%[A>';WV#^\*Z>@`HHHH`CG$QMY!;LB3%3
MY;2*64-C@D`@D9[9%<[#IFM3:V-;O(+".[MK*6UMX(+IS'.79&W2,8P4&4P`
M`^-Q.37344`<AXF\+S^))W@N--T9[>>`P&^<'[7:JP(D$?R'=D$@'<F,]#4-
MWX&O/[:TR]L]?OO)@U1KZ:&808`,<B80B'<?O*F&8X3..0I':T4`<WXB\/7>
MNO<?OHDC2U:*U4D_ZQS\[/@<#:`@QSAG]:M^&-)FT;2#;3);PEII)5MK8DQ6
MZL<B-"57*C_='T%;-%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`5%<_P#'K-_N'^52U%<_\>LW^X?Y4`8G
M@3_DGGAK_L%6O_HI:H>+8I5\0>%)_M4WEMJRQ>0#A/\`CWG))QU)(7KTQQU-
M7_`G_)//#7_8*M?_`$4M:UYIMI?RV<EU%YCV<_VB`[B-DFUDSP>?E=A@\<T`
M>>ZM:VZV^H:^+>,:S#X@MH([G;F41_:(8_+!ZA2C'Y>AW9HTW3K)(]'UV)$7
M6+K7+B*>\7'FRJ7G4QLW\2J%&%/`\L>E=H_A;1Y-7;5&MI/M+2K,P%Q((FD4
M`*YB#;"X`&&*YX'/%)!X4T:VU?\`M.*U<7(E>90;B0Q)(X(=UB+;%8Y.6"@G
M<?4T`>=0Z3/X0273]1,4L-TEJEU%8DNUUMD*"1]X4>=<22(A!.-J,2YQQZ=H
MNKV^N:8E];))&I=XWCE`#QNC%'5L$C(92."1QP2*;>:#IFH1WB75MY@O-GG'
MS&#$IRA4@Y4J1D%<8/(YYJQIVG6FDV$=E91>5;QY(7<6)))))8DEB2222222
M2:`+5%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`<RA_L'QH
MT9.VPUSYTR>$NT7YAU_CC7.!WB8]6KIJR_$6DMK.BS6L4ODW2E9;6;_GE,AW
M(WT#`9'<9'>G:!JRZWHMO?>7Y4K`I/"3DPRJ2LB'W5@1^%`&E1110`4444`%
M%%%`!6/XBU6;3K.*"Q02:G>R>1:1GH&/5V_V4&6/TQU(K5EEC@A>:5U2.-2S
MNQP%`Y)-<[X=ADU:]E\47<;*;A/*T^)U(,-MG.2#R&D(#'IP$'\-`&KHNDP:
M)I,-A`S/LRTDKXW32,<O(V/XF8DGZUH444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`5%<_\`'K-_N'^52U%<_P#'K-_N'^5`&)X$_P"2>>&O^P5:_P#HI:Z"
MN?\``G_)//#7_8*M?_12UT%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`07=W#8VKW,Y<1(,L51G('KA037G%]X^\/^&;S
M5-7L=5LK[3;^!IU2"X5]M[&H&P@'CS%V]NJ$]6KTZO)OB1\%=/\`%'FZIH8C
ML=7(+,F,17!_VA_"WN/Q]:`.W\!WT^I^!-&O[I]]Q<VRS2MZLW)_4UT5<[X#
ML+K2_`>B6%["T-U;VB1RQMU5@,$<5T5`!1110`5FZSK,&BI927)"QW-W':@G
MLSG"_KBM*O'?VB;N6W\)Z,D#E9_[366,K]X,L;X(_%A0!W6L_P#%1ZR/#B8:
MP@"S:J2,AU/*09_VL;F']T`?QBNH`P,"O(OAH/B1?62RZE#I^EV,TC3S3SV[
MM>73L<EBI;"Y''(````7`%>N*"%`)+$#J>IH`6BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"N8U+Q?9:9XC;0-5Q:27</F6$[G]W<<89,]G![=P1]*Z>N!
M^+_@_P#X2[P-<""/=J%AFYML#EL#YD_%?U`H`B\#>+[*XTOPOX9TTBZOX]'M
MI;QDY2UC$2?>/]XD@!??)]_0Z\S^"7@T>&/!<=]<Q;=1U0+/+N'*1_\`+-/;
M@Y/NQ]*],H`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`\
M_P#BQ)>?V=X:L[/4K[3_`+?X@M;.::QG,4GEN'#`,/P/.1D#BC_A5G_4^^.?
M_!Q_]A1\4_\`F2O^QKL?_9Z]`H`\_P#^%6?]3[XY_P#!Q_\`84?\*L_ZGWQS
M_P"#C_["O0**`//_`/A5G_4^^.?_``<?_84?\*L_ZGWQS_X./_L*]`HH`\__
M`.%6?]3[XY_\''_V%'_"K/\`J??'/_@X_P#L*]`HH`\__P"%6?\`4^^.?_!Q
M_P#84?\`"K/^I]\<_P#@X_\`L*]`HH`\_P#^%6?]3[XY_P#!Q_\`857N/@Y9
MWDT$USXQ\8SRV[;X7EU,,T38QE24X..XKTBB@#S_`/X59_U/OCG_`,''_P!A
M1_PJS_J??'/_`(./_L*]`HH`\_\`^%6?]3[XY_\`!Q_]A1_PJS_J??'/_@X_
M^PKT"B@#S_\`X59_U/OCG_P<?_858^$%_>:G\+=&O+^[GN[J3S]\T\AD=L3R
M`98\G``'X5W%>?\`P2_Y)#H7_;Q_Z424`>@4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`5YO\`$.&\U/QWX*T.'6M5
MTNUO_MWVA]-NC`[>7$CKR.#@CN#U/K7I%>?^+?\`DKWPZ_[B?_I.M`!_PJS_
M`*GWQS_X./\`["C_`(59_P!3[XY_\''_`-A7H%%`'G__``JS_J??'/\`X./_
M`+"C_A5G_4^^.?\`P<?_`&%>@44`>?\`_"K/^I]\<_\`@X_^PH_X59_U/OCG
M_P`''_V%>@44`>?_`/"K/^I]\<_^#C_["C_A5G_4^^.?_!Q_]A7H%%`'GX^%
M8``'CSQP`/\`J+__`&%'_"K/^I]\<_\`@X_^PKT"B@#S_P#X59_U/OCG_P`'
M'_V%'_"K/^I]\<_^#C_["O0**`//_P#A5G_4^^.?_!Q_]A1_PJS_`*GWQS_X
M./\`["O0**`//_\`A5G_`%/OCG_P<?\`V%'_``JS_J??'/\`X./_`+"O0**`
M.'^$%_>:G\+=&O+^[GN[J3S]\T\AD=L3R`98\G``'X457^"7_)(="_[>/_2B
M2B@#T"BBB@`HHHH`****`"BBB@`HHHH`\_\`BG_S)7_8UV/_`+/7H%>?_%/_
M`)DK_L:['_V>O0*`"BBB@`HHHH`*RH/$ND7&KZAI27@6]TZ-9;J*2-DV(1D-
ME@`P]P2*U:\-^-B)>Z];0:+;74VKPV,K:JUFP!%AQE7SW/)'\CD4`=_=_%;P
M58V-I>W.LM';7F_[/(;2<B0(<,1A.F3UZ'M3;;XM>![RRO;R#6]]O8HKW#_9
M)AL5G"*<%,GYF`XSUINK7&EW7P4U.;1`HTQM"G^S*HQM00L`,=B.A]\UQGB7
M_DU>W_Z\;/\`]&QT`>T(ZR(KJ<JP!!]J=4-G_P`>5O\`]<U_E4U`!1110`44
M44`%>?\`P2_Y)#H7_;Q_Z425Z!7G_P`$O^20Z%_V\?\`I1)0!Z!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!7G_BW
M_DKWPZ_[B?\`Z3K7H%>?^+?^2O?#K_N)_P#I.M`'H%%%%`!1110`5F#Q#I1\
M1/X?^UA=46`7'V=D928R<;E)&&_`G%:=>0?&Y#>OHUCHL-S)XJS+);&T.UTM
M]A$NX]@1P.1ST]P#T"U\;>'+RV^TPZG'Y!O?L"R.CHLEQG&Q"P&\^ZY%;]>`
M>(K/1M7^'?PYDT*[O+*Q_M>"T\NWF"&.1\[W/'^M5E.&[;F/>G>*M5\97?BS
M7++2+G4A!X>BBCBECUF"T2/,8/FW"R#]]D\YR!VXS0![[17B_G:WXI^)%AI5
M]XBU+1DN?#4=U-%IEZH5I=_.PC<O/7<O.!UQFJ5AXI\0ZO9:!X;GUJ[@AO=6
MO;&7686"S210@%`KXP&;=C<.?E[\T`>ZT5P'@2[U&S\6>)/#$^K7.KV.F"![
M>[NF#S(74EHW<?>(QGU_IW]`!1110`4444`>?_!+_DD.A?\`;Q_Z4244?!+_
M`))#H7_;Q_Z4244`>@4444`%%%%`!1110`4444`%%%%`'G_Q3_YDK_L:['_V
M>O0*X?XFZ3K.IZ=H,VAZ;_:-UINMV]^UOYZ0[DC#D_,YP,D@=^O2J_\`PEOQ
M#_Z)A_Y7[?\`PH`]`HKS_P#X2WXA_P#1,/\`ROV_^%'_``EOQ#_Z)A_Y7[?_
M``H`]`HKS_\`X2WXA_\`1,/_`"OV_P#A1_PEOQ#_`.B8?^5^W_PH`]`K+L/#
MFDZ9J.HZA:V:K>:BP:[F9V=I,#`'S$X`'88'M7)_\);\0_\`HF'_`)7[?_"C
M_A+?B'_T3#_ROV_^%`'26/@_0M-T&\T.TL3%IEYY@FMA-(5Q(,.%RV4!'9<`
M=J6Y\):'>>%5\,SV._1UC2,6WFN/E0AE&X-NX('>N:_X2WXA_P#1,/\`ROV_
M^%'_``EOQ#_Z)A_Y7[?_``H`T-$^%O@SP[J\&JZ5HWV>]@W>7+]JF?;N4J>&
M<@\$CD5V%>?_`/"6_$/_`*)A_P"5^W_PH_X2WXA_]$P_\K]O_A0!Z!17G_\`
MPEOQ#_Z)A_Y7[?\`PH_X2WXA_P#1,/\`ROV_^%`'H%%>?_\`"6_$/_HF'_E?
MM_\`"C_A+?B'_P!$P_\`*_;_`.%`'H%>?_!+_DD.A?\`;Q_Z424?\);\0_\`
MHF'_`)7[?_"M#X6Z)J/ASX<:3I.K6_V>^@\[S(MZOMW3.PY4D'@@\&@#L***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`*\_\6_\E>^'7_<3_P#2=:]`KS_Q[I_B+_A+_"6OZ!H?]K_V5]L\Z#[7';_Z
MV-47YG/^\>`>G;-`'H%%>?\`_"6_$/\`Z)A_Y7[?_"C_`(2WXA_]$P_\K]O_
M`(4`>@45Y_\`\);\0_\`HF'_`)7[?_"C_A+?B'_T3#_ROV_^%`'H%9<'AS2;
M;Q#<Z_':_P#$TN8Q#)</(SG8,85020HX'"@9[UR?_"6_$/\`Z)A_Y7[?_"C_
M`(2WXA_]$P_\K]O_`(4`;%S\._"EW8:A8S:0C6M_<B[N(A-(%:8?QKAOD/KM
MQGO2:E\./"&L7-G<:AH=O/+9QK%$S,P^10`JL`?G``_BS61_PEOQ#_Z)A_Y7
M[?\`PH_X2WXA_P#1,/\`ROV_^%`":S\,[3Q%\0Y-7UBULKK1&TD62VY9ED24
M2;@PP!M&W(R&SSTKHKGP3X:O/#L>@3Z-:MI<1)CMPNT1DYRRD<AN3R#GDUSW
M_"6_$/\`Z)A_Y7[?_"C_`(2WXA_]$P_\K]O_`(4`=7H'AO1_"^G_`&'1;"*S
MMRVYE3)+'IEF)))]R:U:\_\`^$M^(?\`T3#_`,K]O_A1_P`);\0_^B8?^5^W
M_P`*`/0**\__`.$M^(?_`$3#_P`K]O\`X4?\);\0_P#HF'_E?M_\*`/0**\_
M_P"$M^(?_1,/_*_;_P"%'_"6_$/_`*)A_P"5^W_PH`/@E_R2'0O^WC_THDHK
M0^%NB:CX<^'&DZ3JUO\`9[Z#SO,BWJ^W=,[#E20>"#P:*`.PHHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#
"_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>graph10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 graph10.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`$%`<<#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#TZTT>'6_$
M'B62]O-5_P!'U".&)(-4N8$1/LEN^`D<BK]YV/3O6A_PANE_\_6N?^#V]_\`
MCU'A[_D.>+/^PK'_`.D5K704`<__`,(;I?\`S]:Y_P"#V]_^/4?\(;I?_/UK
MG_@]O?\`X]7044`<_P#\(;I?_/UKG_@]O?\`X]1_PANE_P#/UKG_`(/;W_X]
M7044`<__`,(;I?\`S]:Y_P"#V]_^/4?\(;I?_/UKG_@]O?\`X]7044`<_P#\
M(;I?_/UKG_@]O?\`X]1_PANE_P#/UKG_`(/;W_X]7044`<__`,(;I?\`S]:Y
M_P"#V]_^/4?\(;I?_/UKG_@]O?\`X]7044`<_P#\(;I?_/UKG_@]O?\`X]1_
MPANE_P#/UKG_`(/;W_X]6OJ.HV>DZ?/?W]PEO:P+NDED.`HK+\->,O#_`(PB
MGDT'4DO!;L%E`1T9,],JX!P>><8X/I0`S_A#=+_Y^M<_\'M[_P#'J/\`A#=+
M_P"?K7/_``>WO_QZN@HH`Y__`(0W2_\`GZUS_P`'M[_\>H_X0W2_^?K7/_![
M>_\`QZM+5-8L-&B@EOY_)2>XCMHSL9MTCG"KP#C)[]*DLM1M-0:Z6UE\PVL[
M6\WRD;9``2.1SP1R.*`,G_A#=+_Y^M<_\'M[_P#'J/\`A#=+_P"?K7/_``>W
MO_QZI-,\8:#K":HUA?B5=*9DO#Y3KY1&<]5&?NGIGI4GASQ3HWBW3I+_`$.\
M^UVL<IA9_*>/#@`D8<`]&'YT`5_^$-TO_GZUS_P>WO\`\>H_X0W2_P#GZUS_
M`,'M[_\`'JOZYKNF^&])EU75[G[-90E0\NQGQN(4<*">I':M!6#H&4Y!&0:`
M,#_A#=+_`.?K7/\`P>WO_P`>H_X0W2_^?K7/_![>_P#QZN@HH`Y__A#=+_Y^
MM<_\'M[_`/'J/^$-TO\`Y^M<_P#![>__`!ZK]WKNFV.M:?H]S<[+_41(;6+8
MQ\SRUW/R!@8'J1[5HT`<_P#\(;I?_/UKG_@]O?\`X]1_PANE_P#/UKG_`(/;
MW_X]3_$OC+0/!\5O+KU_]D2X8K$?)DDW$8S]Q3CJ.M8DOQ'L=8M+>+P>PU:^
MNRPB&QD6(`X+N&`(`_#-3*:BKLVH8>I7GR4U_DEW;Z(T+SPYH&G0&>]U35K:
M(?QR^(;Q1^9FK%^U>`_,V?\`"2:GGU_MZ^Q^?FXK4T_P+;/-]O\`$4QUC46Z
MF;F*/_91.F/K^0KI#IFGF'R38VQBQC9Y*[<?3%0G5>NB.IQP5/W6Y3?=62^5
MTV_P,*T\-:#?P">SU/5[B(]'B\07C#\Q-4__``ANE_\`/UKG_@]O?_CU4-0\
M#0PS'4/#4YTC45Y`B_U,OLR=,?YQ4?A_X@6%Z);'5YH++5;:X^R2QALK)+O\
MOY/7+<8[4*HT^6:L_P`!5,)&5-UL-+FBMTU9KU[KS7S2-/\`X0W2_P#GZUS_
M`,'M[_\`'J/^$-TO_GZUS_P>WO\`\>KH*H:SK-AX?TFXU35+C[/96X!EEV,^
MW)"CA02>2.@K4X#._P"$-TO_`)^M<_\`![>__'J/^$-TO_GZUS_P>WO_`,>J
MOX>^(OA/Q5?-9:-K,5Q=*N[RFC>)F'^R'4;L8YQG%=10!S__``ANE_\`/UKG
M_@]O?_CU'_"&Z7_S]:Y_X/;W_P"/5JVFJ6-_<75O:744\MH_EW"QMGRW_NGW
M]JMT`<__`,(;I?\`S]:Y_P"#V]_^/4?\(;I?_/UKG_@]O?\`X]705A:[XR\/
M>&KRSM-8U.*UN+Q@L",K,6YQDX!VC/<X'O0`S_A#=+_Y^M<_\'M[_P#'J/\`
MA#=+_P"?K7/_``>WO_QZM+5]8T_0=*GU/5+I+:S@7=)*^2!S@<#DDD@`#DU:
M@GCN;>*XA;=%*@=&QC((R#S0!A_\(;I?_/UKG_@]O?\`X]1_PANE_P#/UKG_
M`(/;W_X]7044`<__`,(;I?\`S]:Y_P"#V]_^/4?\(;I?_/UKG_@]O?\`X]70
M44`<_P#\(;I?_/UKG_@]O?\`X]1_PANE_P#/UKG_`(/;W_X]7044`<__`,(;
MI?\`S]:Y_P"#V]_^/4?\(;I?_/UKG_@]O?\`X]7044`<_P#\(;I?_/UKG_@]
MO?\`X]1_PANE_P#/UKG_`(/;W_X]7044`<__`,(;I?\`S]:Y_P"#V]_^/4?\
M(;I?_/UKG_@]O?\`X]7044`<_P#\(;I?_/UKG_@]O?\`X]1_PANE_P#/UKG_
M`(/;W_X]7044`<OH=H-,\9:Q807-]):KI]E,J75[-<[7:2Y#$&1F(R$7IZ"B
MK%G_`,E"UG_L%6'_`*-NZ*`#P]_R'/%G_85C_P#2*UKH*Y_P]_R'/%G_`&%8
M_P#TBM:Z"@`HHHH`****`"BBB@`HHHH`****`.5^(UOIMUX*O(M6O196N^)O
MM#P&:-'#J4WH`<IN`!SQ@]:\R\$:C%#XAUJ&TBT&Y<:1,T>J:!&]NJ*IR!+&
M`$#G@@@9&",G/'NDT,5Q"\,\:2Q."KHZAE8>A!ZU2L-"TC2[::VT_2K&S@F_
MUL5O;I&LG&/F``!XXYH`\IT236/(^'\DGB36)'UVWDBO"]P&&P1&0;01@-GC
M?]XCO5>;Q;?VO@@65UJ=\\W]OW&F0W37Z6O[J/./.N&4D`#DD88XZ^OL2:1I
ML8LQ'I]HHLLBU"PJ/L^1@[./EXXXQQ44OA_19[*6RFTBPDM993-)`]LA1Y"<
MERI&"Q/?K0!XQ8ZO?ZKX*MTO]02^^Q^,;6W@F2X-P/+#(P'FGF3!8_,>OTKT
M_P`&?Z_Q-_V&YO\`T".MH:%I`4J-*L0IF6<C[.F#(N`K]/O#`P>HP*M0VUO;
M&4P011&5S))L0+O<]6..IX'/M0!\U:-JUQH=WXD@AB9QXCU2\TE2J\B421!.
M>@^6>4_45>\,ZE<:)"VDQWKZ/X<NO$^H6]]>PD1F%5BB\I!(?]7GD9X/'!&*
M]Z7P[H:[=NC:>-ES]K7%JG$_'[T<??X'S=>.M/31-)CL[FS32[);6Z=I+B%;
M=`DS-]YG7&&)P,D]<4`>%^+=8O=0^'OCBQ34)=4T&QN+*/3=0E82-+EU,B^:
M/]9M.!GD\\DYIOB?QOXKMO%6JVUC,Z7=E<116*'5(8(PC*AP;9N9RP)^;/&[
MC&*]WET72IM*&ERZ99R:<H"BT>!3$`#D#9C'!`QQ3I=*TZ>]@O9;"UDN[<$0
MSO"I>,'^ZV,C\*`/.-;UFW;Q/JD?B#Q?=>'3906TME#%<+$&W*2[;,'SOFRN
MT[@,=*EN/%D&E>./$4>I:Z;>U?1[>:QCN;CR@[$/DQJQ`W$XX`SFO0KO2=-U
M"X@N+W3[2YFMSNADFA5VC/JI(R/PI+O1]+U"ZANKW3;.YN(`1%+-`KO&#UVD
MC(S[4`>0V%W=W7B#X1W<TLES=R:;>NSRN7:1OLW4D\DDU!\._%OB35/%VF1R
M"25;N.1M2$NM17.,+PRVXPUOA\#&.AP<GFO9(]&TN*2RDCTVS1[%2EHRP*#;
MJ1@B,X^4$<$#'%.MM(TVRO+B\M-/M(+JX_U\T4*J\O\`O,!D_C0!YM\9$G:]
M\,FWM;2Z<33CR;JW6=7R$7`1@03DC%9OA"%_#_A_QA<6,G_%4V4$BMIBVZK]
MG*@LA5%X8-PPQQC`QZ]AI*CQ5XTNM:D&_3M*8VMB".&D_CD'Z8_#TKK%TO3T
MU-M36PM1J#IY;70A7S63CY2^,XX'&>U807/+G>RV_P`SU,1/ZK16%C\4K.?Y
MJ/RW?GZ'E&C^(7?6O"T6A^*[O79M4!.KVS3"40IL&Z0`#]QAN,#'TS2:+?\`
MB:^\2:;X(N;Z^$FC7\T^HWGFL))[5`K6^YQ]X/OP1WVFO6;73+"QFGFM+&VM
MY9VW3/%$J-(?5B!R?K61X=\.7>EZA?ZGJFJ+J6I7JQQO,EL(%6./=M4*">[,
M2<\\>E;GEGC7_"?:E=^,])O]-U>ZBMKG6TL9+2\U%7E>(O@YM54+$O8,?GSC
MFJMY!`EKXJU$N(;F'QE+#'<&3RQ$';J6XV@,%.<\8S7OK^'-"EN9+F31=.>>
M619I)6M4+.Z_=8G&2PR<'J*5_#VBRVUU;2:/I[P7<OG7,36R%9I,YWN,89LC
M.3S4S@IQY6;X?$3P]55:>Z_JS\GU/(-&\;7FHP7OA?\`M"]2[U.YMET^<SLT
MT<;D"X`DZ@H%<C/9EKO_`(FV\DGPXO[6#RVD9K:./[1\ZD^?&!OSG(]>N:P;
M[PU;>&?B1I?B&Y2%[*>=H8!#%Y2V;NFQ<@$A@1D9P!WQD5Z7<6T%W"8;F".:
M(D$I(@92000<'T(!^HJ:4FU:6Z-L=1A"2J4O@FKKR[KY/\+/J>)>&O"\^E?%
M+2D\5?V-IE[;QR2Z8FD62P17S,-K@N`,E!_"0#\W!QG.9J7CW4YO&EG>:7K%
MU#"=<2P>UN=15I'CW8;_`$54"HG;<V6Z<^GO5YI>GZA);R7MC;7+VT@E@::%
M7,3CHRDCY3P.14$OAW1)[B>XFT;3Y)IV5YI'M4+2,OW2Q(R2.Q/2M#B/"9+^
M?PJ_Q!N]+U6[75H=3"BW:[RQ@9TW2[&R,C('F$';FM#0_%'BBZ\-^*8[?5!I
M]K:P1-:WMWJ<>I?9Y"PWJ9T!)#`G&0=OJ*]K_L?3/[0DU#^SK3[;+'Y4EQY"
M^8Z?W2V,D<#BG66EZ?IME]BL;&UM;7G]Q!"J)SU^4#'-`'F_PH\2/>ZCJ&C7
M-S?7%S#$)MYU--1MBN=NY9@-RL?[C-T&0!S4_BV_TZQUSQ=%K%S;0F\\/Q16
M*3N`9O\`CXW(@/WCN*<#GD5Z!IVD:9H\+0Z7IUI8Q,=S):P+$I/J0H'-%[I.
MG:C+;RWVGVMU);OYD#SPJYB;^\I(X/`Y%`'D/Q0.IW?AC^S]5T34Y[&RTI;C
M[3;X\O[9MQNERP(5.3@9R6Y'%=C%XFUNRTOPO%IWA2[OH+RWB%Q*9A&;0?*,
MLH#9X)/4=*[2YMK>]MI+:Z@BGMY5*R12H&5P>H(/!%/CC2*-8XT5$0!551@`
M#H`*`/'-*\07KC1-1BU^XN?%=YJ"6^HZ(UUN2&/>1*/LV?W>Q5SNX/&23DYM
M^*;G5(-.\<ZQ;ZYJ<$NCWT;6<,<^(E_<0D@KCYE)8Y4_+WQGFO38M&TN'5)=
M4BTVSCU"5=LEVL"B5QQP7QDC@=^PITVE:=<0W4,UA:R17;;KE'A4K,<`9<$?
M,<*HY]!Z4`6(6+P1N>K*"?RI](`%````'``I:`"BBB@`HHHH`****`"BBB@`
MHHHH`Y^S_P"2A:S_`-@JP_\`1MW119_\E"UG_L%6'_HV[HH`/#W_`"'/%G_8
M5C_](K6N@KG_``]_R'/%G_85C_\`2*UKH*`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`*YWQMJTND^&IOLO-[=,+6V4'!+
MOQQ]!D_A715QE[_Q//B99VGWK718#<R8/'G/PH(]0,$?C655M1LMWH=V7TXR
MK<\U>,$Y/Y;+YNR^9T.@:1%H6A6FFQ8Q#&`S`?>;JQ_$YK2HHK1))61R5*DJ
MDW.;NWJPHHHID!1110!D^)=&CU_P]>::^-TJ?NV/\+CE3^8%5O!NL/K/ANWE
MGXO(";>Y4]5D3@Y^O!_&M^N-TM3HGQ%U/3^EKJL0O80!@"0<./J>OY5C/W9J
M7?3_`"_KS/0H/VV&J47O'WE^4E]UG_VZ=E1116QYX4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`<_9_\`)0M9_P"P58?^C;NBBS_Y
M*%K/_8*L/_1MW10`>'O^0YXL_P"PK'_Z16M:VIZA!I.EW6H7._R+:)I7V+N8
M@#/`[GVK)\/?\ASQ9_V%8_\`TBM:OZ[;_:M&GA-O)<*VW='%)L9EW`G!]<9.
M._3O0`RYUR*RBMS=VMS#-<SBWMX#L9Y7*EL#:Q`X5CDD8P<U17QKI#P).AN&
MBW^7*WDD>0WFF'#@\C]X".`>F>G-8D^E7D6J:1?6B:A/IFGZCYHCN7EEG"-;
MR1NX\PF0@,Z\'GAL#&*CA\-7$NAWET]A<17M]J,DB6FX!=AN2\32@'HO^L8`
M@G)4Y)Q0!W%G?0W\<LD&XQQRO%N(P&93M;'J`01GV-6:Y7PLNLP7,EI?_:/)
MA:X0*\2+&$$H$!1E&6+1Y+<GGK@\5<\73WFF^&M6U:SOI89;*PFGCC"(R,Z(
MS#=E2>H`."*`-ZBJ_P!GE_Y_)_R3_P")H^SR_P#/Y/\`DG_Q-`%BBJ_V>7_G
M\G_)/_B:/L\O_/Y/^2?_`!-`%BBJ_P!GE_Y_)_R3_P")H^SR_P#/Y/\`DG_Q
M-`%BBJ_V>7_G\G_)/_B:/L\O_/Y/^2?_`!-`%BBJ_P!GE_Y_)_R3_P")H^SR
M_P#/Y/\`DG_Q-`%BBJ_V>7_G\G_)/_B:/L\O_/Y/^2?_`!-`%BBJ_P!GE_Y_
M)_R3_P")H^SR_P#/Y/\`DG_Q-`%BBJ_V>7_G\G_)/_B:/L\O_/Y/^2?_`!-`
M%BBJ_P!GE_Y_)_R3_P")H^SR_P#/Y/\`DG_Q-`$[,$4LQPH&2?2N/^'Z_;;3
M4]??E]4O'=&(P?*4E4'X<U9\;W4NE>#=3N1>7!8Q>4H`0'+G;V4'OG\*T-"T
MB32]!L+$7<JF&!%8*J8W8Y_A]<UD]:J79?G_`$ST(?N\#*76<DOE'5_BXFQ1
M5?[/+_S^3_DG_P`31]GE_P"?R?\`)/\`XFM3SRQ15?[/+_S^3_DG_P`31]GE
M_P"?R?\`)/\`XF@"Q15?[/+_`,_D_P"2?_$T?9Y?^?R?\D_^)H`L5QOCX?V>
M=&\1+P=-O%\UN?\`4O\`*_3KV_.NJ^SR_P#/Y/\`DG_Q-9?B31WU3PWJ%FUS
M+(9(&VJRI@L!E?X?4"LZL>:#2.O`552Q,)2VO9^CT?X-FX""`0<@T5SG@^ZD
MU;PEIEY]NG+-"$?Y4^\ORGJOJ#6W]GE_Y_)_R3_XFJC+FBFNIC6I.C4E3EO%
MM?<6**K_`&>7_G\G_)/_`(FC[/+_`,_D_P"2?_$U1D6**K_9Y?\`G\G_`"3_
M`.)H^SR_\_D_Y)_\30!8HJO]GE_Y_)_R3_XFC[/+_P`_D_Y)_P#$T`6**K_9
MY?\`G\G_`"3_`.)H^SR_\_D_Y)_\30!8HJO]GE_Y_)_R3_XFC[/+_P`_D_Y)
M_P#$T`6**HV\LHU6YM7E:1$@BD4L`""S2`]`/[HJ]0`4444`%%%%`!1110`4
M444`<_9_\E"UG_L%6'_HV[HHL_\`DH6L_P#8*L/_`$;=T4`'A[_D.>+/^PK'
M_P"D5K705S_A[_D.>+/^PK'_`.D5K6EK%C+J6DW-E#<FV:=/+,H!)53][&""
M"1D`@@C.>U`%>3Q-H\=K+<B]62..<VW[E&E9Y0,E$502[8[*#T/H:A/B_0O]
M%(OMRW+;4=89"J'?LQ(P7$9W_+\Y7D$=0:Y:32;W2[ZSOC:L]IIFM&5HK.T<
M'R6L_*#)&"Q8`L!@9Z'Z4R#PY-<Z0^HO:ZA!<7NI22C3U"JLB-<EXFG&-RA?
M]80&4G)4Y)Q0!Z#;7D%YYWV=]XAD,3L%(&X=0">#CH2,\@CJ#6-X[_Y)[XE_
M[!5U_P"BFK.\(R:S'J=W8WYO/*MS*@26U$<**LF(6BD"CS"\>6?YFPW]WI5G
MX@)>'P+XB:&>!(!I5SO1X2S']TV<,&`''L:`.HHK/\G6/^?ZQ_\``-__`([1
MY.L?\_UC_P"`;_\`QV@#0HK/\G6/^?ZQ_P#`-_\`X[1Y.L?\_P!8_P#@&_\`
M\=H`T**S_)UC_G^L?_`-_P#X[1Y.L?\`/]8_^`;_`/QV@#0HK/\`)UC_`)_K
M'_P#?_X[1Y.L?\_UC_X!O_\`':`-"BL_R=8_Y_K'_P``W_\`CM'DZQ_S_6/_
M`(!O_P#':`-"BL_R=8_Y_K'_`,`W_P#CM'DZQ_S_`%C_`.`;_P#QV@#0HK/\
MG6/^?ZQ_\`W_`/CM'DZQ_P`_UC_X!O\`_':`-"BL_P`G6/\`G^L?_`-__CM'
MDZQ_S_6/_@&__P`=H`T**S_)UC_G^L?_``#?_P".T>3K'_/]8_\`@&__`,=H
M`Y_QSF\NO#ND*PS=ZBDCJ?XHXQEOYBNPK@KM-0O?BAI]L]S:M+86$ERCBW;:
M"[;""N_KC'.>_2I?&?BO6/"-J)O]!N\VT]QCR'C_`-4%./OGKNZ]L=ZBA!U)
MRY?ZLO\`ASLS"I##X>BINR2N_64G^ECN**S_`"=8_P"?ZQ_\`W_^.T>3K'_/
M]8_^`;__`!VK.,T**S_)UC_G^L?_``#?_P".T>3K'_/]8_\`@&__`,=H`T**
MS_)UC_G^L?\`P#?_`..U@^,]>UCPCX4O-<WV-W]F,8\G[.\>[?(J?>\PXQNS
MT[548N<E&.[`ZZBN9\,ZKK'B/PW8ZOYUC;_:H]_E?9G?;R1C/F#/3TK6\G6/
M^?ZQ_P#`-_\`X[1*+A)QEN@.?\``VD6M:0RA!8ZC(L:CM&W*_P!:["N#TZ*_
MLOB5K%JEW;":^LXKIF-LQ4[3LP!OR.OJ>]=9Y.L?\_UC_P"`;_\`QVL*.D;=
MKH[\RUK^T_F49?-I7_&YH45G^3K'_/\`6/\`X!O_`/':/)UC_G^L?_`-_P#X
M[6IP&A16?Y.L?\_UC_X!O_\`':/)UC_G^L?_``#?_P".T`:%%9_DZQ_S_6/_
M`(!O_P#':/)UC_G^L?\`P#?_`..T`:%%9_DZQ_S_`%C_`.`;_P#QVCR=8_Y_
MK'_P#?\`^.T`:%%9_DZQ_P`_UC_X!O\`_':Y+4/&&L6'Q+TKP?ML7^WVQG^U
M^2X\O"RG&S?S_JNN1][VYN$)3OR]-?N"YUL/_(PWG_7I!_Z'-6A638+<KKMZ
M+J6*5_LT&#%$4&-TO8LW\ZUJ@`HHHH`****`"BBB@`HHHH`Y^S_Y*%K/_8*L
M/_1MW119_P#)0M9_[!5A_P"C;NB@`\/?\ASQ9_V%8_\`TBM:Z"N?\/?\ASQ9
M_P!A6/\`](K6M3539#39AJ!Q:/A).6`PQ`P<<XR1GMC.>,T`7**\PFLTM]3T
M_1+C3K2UTI]:*7-C;?-:;&M7,:$;5'+J&*E<;F'7.3132FN-/&IP2VLFGVNI
MRPV=S,Y,ULJWAVK;<<ES^Z'S*,!?O#B@#UVN?\=_\D]\2_\`8*NO_1351\'Z
MPUW/<V[V,<)>6X+3BXWR32Q2"*4NNT;1NP$Y;Y0/NX`J;X@7$L?@7Q%$ME/*
MC:5<YE0IM7]TW7+`\=>`:`.HHK/_`+1NO^@-??\`?<'_`,<H_M&Z_P"@-??]
M]P?_`!R@#0HK/_M&Z_Z`U]_WW!_\<H_M&Z_Z`U]_WW!_\<H`T**S_P"T;K_H
M#7W_`'W!_P#'*/[1NO\`H#7W_?<'_P`<H`T**S_[1NO^@-??]]P?_'*/[1NO
M^@-??]]P?_'*`-"BL_\`M&Z_Z`U]_P!]P?\`QRC^T;K_`*`U]_WW!_\`'*`-
M"BL_^T;K_H#7W_?<'_QRC^T;K_H#7W_?<'_QR@#0HK/_`+1NO^@-??\`?<'_
M`,<H_M&Z_P"@-??]]P?_`!R@#0HK/_M&Z_Z`U]_WW!_\<H_M&Z_Z`U]_WW!_
M\<H`T**S_P"T;K_H#7W_`'W!_P#'*S-;\7Q^'X()K_2-2"3R&)-AA;YA&\A_
MY:?W8VII7=D3*2A%RD[)%+0F:Z^(WB>X8?+;QV]NA_X"6(_.N?\`C+_R#%_[
M!E__`.@QUB:)\6=$T34M5DO;+4I)=2OO.B$,49VHQVH&RXY]<9^M4/&GC[2_
M&]A?IIUM>P-8:?>)+]J1%R6"CY=K-_</IVK7+82E+F2VNWY?U=%\3KV=Z<M&
ME!?=RK\TSWJBL_\`M&Z_Z`U]_P!]P?\`QRC^T;K_`*`U]_WW!_\`'*Q$:%%9
M_P#:-U_T!K[_`+[@_P#CE']HW7_0&OO^^X/_`(Y0!H5Y=\=-?MK#P2VBR0SO
M<:F5:)T"[$$4T);<20>=P`P#^%=?KWBU/#>C3ZKJ&CZBMK"45RAA8Y9P@X\S
MU85X/\5/'VE^.4T\Z;;7L'V2*7?]J1%SOEM\8VLW]T]<=JZ,+_'AZH4XR]FY
MI:*WXNQ[=\,O^2;:%_U[_P#LQKK*X;X;WUQ'\.]$1=+NY5%OPZ-%AOF/3+@_
MI74_VC=?]`:^_P"^X/\`XY2Q7\>?J_S".R.?U=A:?$[P].%_X^[:>V9O91O'
MZG]:["N$\87TT6K>&;Y]+N8VBU$1#>T66$@P0"'/IWP..M=7_:-U_P!`:^_[
M[@_^.5QT])27G^B/0Q?O4*$_[K7W2?Z-&A16?_:-U_T!K[_ON#_XY1_:-U_T
M!K[_`+[@_P#CE:G`:%%9_P#:-U_T!K[_`+[@_P#CE']HW7_0&OO^^X/_`(Y0
M!H45G_VC=?\`0&OO^^X/_CE']HW7_0&OO^^X/_CE`&A16?\`VC=?]`:^_P"^
MX/\`XY1_:-U_T!K[_ON#_P".4`9'CKQG;^!M%@U*XM);I9KD6X2-@I!*.^>?
M9#^=>7VGB5/%/[0/AF^2U:W$=I)#L+[LXBN3G.!_>J/XX>,;/4K*/PT+*]M[
M^SODFE,PCV8,#D`%7.3B1>WK7/\`@N1HOC)H#I#),PCEQ'&5#']S/TW$#]:[
M<'%WJ7_E?XIF=?FA*DOYN;\.6WYGT7#_`,C#>?\`7I!_Z'-6A638323Z[>M)
M;2VY%M`-DI4D_-+S\K$?K6M7$:!1110`4444`%%%%`!1110!S]G_`,E"UG_L
M%6'_`*-NZ*+/_DH6L_\`8*L/_1MW10`>'O\`D.>+/^PK'_Z16M;LL4<\3Q2H
MLD;@JR.,A@>H([UA>'O^0YXL_P"PK'_Z16M:^H0^?831?:GM0R_-,APR+W(/
M8XSSVZT`5TT#1H]*;2TTFP73F))M%MD$1R<GY,8_2K265I'!#!':PI#`08HU
MC`6,CIM';'M7!2RS"[TW2K/4+XZ+J.K-"DYNY6E:)+9G8+,S%]ID0X(;.,X.
M",40?$$D8E2^OIH=.OI8$OS>"..)([D[S<+N'FYB&P?*QRI^Z3NH`](@TVQM
M;VXO+>RMHKJYQY\\<2J\N.FY@,MCMFLGQW_R3WQ+_P!@JZ_]%-5?PIKR:G)=
M1-'?^:\LK^=<`")F1PDD<0#$@1MA.0N3EAG)-5_B+K-K9^#=?L98KYIIM*N-
MK0V$\L8S&X&Z1$*+R.=Q&!R<#F@#L**Y_P#X3+2_^?77/_!%>_\`QFC_`(3+
M2_\`GUUS_P`$5[_\9H`Z"BN?_P"$RTO_`)]=<_\`!%>__&:Y\?%K0]5N[.P\
M*R1ZM?W,QC\N<36L<:B-W+%S$W]S`&,G/L:F<E"#G+1)7?DD-)MV1Z!17,V?
MC>PGL;>:>QU>.:2-6=(=(O)D5B,D+((<.,]&'!ZU-_PF6E_\^NN?^"*]_P#C
M----70CH**Y__A,M+_Y]=<_\$5[_`/&:/^$RTO\`Y]=<_P#!%>__`!FF!T%%
M<_\`\)EI?_/KKG_@BO?_`(S7-Z[\8_#NFZ)=WNFBYU&ZM]G^C-:7%N#EU4[I
M&BPN-W?J>.IJHQ<MD)M(]$HKB/#'Q*L=?\/6NISZ9JMM)-OW16^G75TB[79>
M)4BVMTSQTSCJ*U_^$RTO_GUUS_P17O\`\9I--.S&=!17/_\`"9:7_P`^NN?^
M"*]_^,T?\)EI?_/KKG_@BO?_`(S2`Z"BN?\`^$RTO_GUUS_P17O_`,9H_P"$
MRTO_`)]=<_\`!%>__&:`.@KS?XHZE;3V]A8QM(9X+Z3S`8G"C-C<'&XC:3AE
MX![^QK9U/XG>%-%\K^U;N_L/-SY?VK2KN+?C&<;HAG&1GZBN-\4ZK9ZW#!J-
MA(\EK-J[[&>)XR<:?(I^5P".0>HK"M7G0G2:6DI)???_`",<53=3#5%_=?Y'
MBU__`,A>U'I)#_Z,J[HO^H\6?]>EU_-JH7I_XG,'_76'_P!#%7]%_P!1XL_Z
M]+K^;5[F2_PJW^!?G3.GC1WQ<OZ^VSZ]HKG_`/A,M+_Y]=<_\$5[_P#&:/\`
MA,M+_P"?77/_``17O_QFO*(-NZN8K*TFNKABL,$;22,%+851DG`Y/`[5REQ\
M4?!]IJC:9<:I+'>K@-"UE/N&5W?W/3FL'QO\1!"MOI6GV5R4U""=)GOK&XMB
MH&Q1L\Q5W?ZPYQG&!GK7D/BW_DMMY_OI_P"DJUW83"*M**EHFS3"QC6Q$*+>
M[2?S9ZM\3?&&AZQ\.KZUL;J:66=+*YC!M94#1O<(5;+*``0C8Y[5\[M_JI/^
MN(_]&Q5Z7KW_`")</_8O:'_Z.DKS1O\`52?]<1_Z-BKDRZHZJP]5[R;_`#:_
M05*JYX;$P?V917_I#_4^LOAE_P`DVT+_`*]__9C765YS\/?%&GV?@#1K>6WU
M=GC@P3#H]W*A^8]&2(J?J":Z;_A,M+_Y]=<_\$5[_P#&:TQ7\>?J_P`S..R*
M7Q#0#1;"Y.?]&U*WE!!QCYL?^S5UM><?$+Q%8:GX,O+>&WU59"T9#7&DW4"#
M#CJ[QA1^)K6U+QXL3Z?;Z7I=W<7EY.80M_;7-E$H$;R$^8\)!/R8`')SGH#7
M'#^*TO+]3T*RO@J4O[TU^$7^HNF?%+P=K-TMMIVJR7,S<!$LI\G@G^YZ*3^%
M=3:7<-];+<6[,T;$@%D*G()!!!`(Y!KY8^#7_(Z6_P#OC_T3/7T#I7BC3[.T
MDMY;?5V>.YN`3#H]W*A_?/T9(BI^H)JL3+V6/^JK;D4K];N4E^AS3I*-*$_Y
ME^K7Z'6T5S__``F6E_\`/KKG_@BO?_C-'_"9:7_SZZY_X(KW_P",U9B=!17/
M_P#"9:7_`,^NN?\`@BO?_C-'_"9:7_SZZY_X(KW_`.,T`=!17/\`_"9:7_SZ
MZY_X(KW_`.,U1U+Q_IMLBP6\>H+?3$"".ZTF[B4C>BLQ+1J,#>N3D#D<\B@F
M4E&+D]D>#?&3_DI&K_\`76+_`-)5K0\"?\EJ\/?]<Y?_`$1/6%\3;J:]\:ZC
M<7'E^:\L>[RU*KQ;J.`2?3UK5\)7D6G_`!>T*ZF2=XTCDR(('F<YAF'"("QZ
M]AQUZ5ZE*+C*:?\`)^C%BZL:OU6I!W33:]&H'T?#_P`C#>?]>D'_`*'-6A6'
MH^IP:KK-]/;QW:(MO`A%U:2V[9W2GA9%4D<]<8Z^AK<KRRPHHHH`****`"BB
MB@`HHHH`Y^S_`.2A:S_V"K#_`-&W=%%G_P`E"UG_`+!5A_Z-NZ*`#P]_R'/%
MG_85C_\`2*UK4U32[/6M-FTZ_C:2UF`$B+(R$X(/WE((Y`Z&LOP]_P`ASQ9_
MV%8__2*UK=E9TA=HX_,<#Y4SC)^IH`R/^$5THV#V<GVZ:)I%E!GU&XED1UZ%
M'9RR'_=(JQ#H&EV^FVVG16:+9V\JS1Q9)`<-O#'GYCN^;)SSSUK!?Q3J4B6=
MI%#:0W]]JEQ81NP:2*(1+(V\C*E^(^F5Y/M69)X\U2.Y@MY(["*Y2Z:U>U*L
MSWS+/Y3&`AOEVKB0Y#X#<X`)H`[&QT'3=-U"YOK2W,<]R2TG[URH+'<Q5"=J
M;CRVT#<>3DU1\=_\D]\2_P#8*NO_`$4U6=$UN'5FN4%Y923HP?[-!*&D@C89
M3S!DD,P^;H.N.<9-;QW_`,D]\2_]@JZ_]%-0!T%%%%`!7R5\'_\`D>--_P"N
MW_MM<U[KXQ\4ZC!XST;PMI\TMC]J'GRWT)C9]OESGRPDD;*.8U.[KVQWKPKX
M/_\`(\:;_P!=O_;:YHQD&LMQ+?6$O_26;822=;3S_)GU'X>_Y%K2O^O.'_T`
M5I5F^'O^1:TK_KSA_P#0!6E6=+X(^B,GN%%%%:""OEG6?^1<\3?]<X__`$JB
MKZFKY9UG_D7/$W_7./\`]*HJ]'`_!4^7YHY*_P#%I^K_`"9[3\%_^23:)];C
M_P!'R5WM<%\%_P#DDVB?6X_]'R5WM<=?^++U?YG4M@HHHK(857O[ZWTS3KF_
MO)/+M;6)IIGVD[44$L<#DX`/2K%>5?&0DQQ1DDH=%U-]O;</(P<>HR?S-)NR
MN73ASR44<#\=O%&D^)X]`DTF:>:.$70=I+66$9/E<`R*N>G.,XXSU%;/3PII
MO_86G_\`2*:O._&W_(MZ+_UVO/\`T&"O1/\`F4]._P"PM/\`^D,U;9Q3]E0I
M072M'\IFF'G[3+:LGUY/_29GEE[_`,AF'_KK#_Z&*T-%_P!1XL_Z]+K^;5GW
MG_(8A_Z[0_\`H8K0T7_4>+/^O2Z_FU>GE&D*W^!?G3,.,?\`>I?U]MGU[6-K
MWBO1_#/E?VK<31>:CR+Y=K+-A$*AF/EJVT`N@R<?>%;->3?$F\FO5F=X$CB3
M2M1BC(D+%MMU:*21M&/N^IZUY"LY)/J'4P?B+XKT;Q5JOAZ;1KB6XBBBN@SO
M;2Q*<O`."ZC=RI!QG&.:XKQ;_P`EMO/]]/\`TE6DL_\`D$>&O]V^_P#2A*7Q
M;_R6V\_WT_\`25:]K+MZ?K^ITX.FJ>9PBOYH?C9FSKW_`")</_8O:'_Z.DKS
M1O\`52?]<1_Z-BKTO7O^1+A_[%[0_P#T=)7FC?ZJ3_KB/_1L5>'E'\+"^K_]
M*9RX;^#C/\<?_2:1]9?#+_DFVA?]>_\`[,:ZRN3^&7_)-M"_Z]__`&8UUE=&
M*_CS]7^81V1RWQ'B:;P!JJIC(5&Y]%D4G]!7GE_KVK7GQ;L=(N+YWTVTND,-
MMY:`*QT\L6W!=Q.7?J<<].E>E>//^1&U?_KA_45Y+-_R7%/^OF/_`--HJ,)%
M.O*_;]3IQ,VL#32_GE^43C?@U_R.EO\`[X_]$SU]-^'_`/D%?]O%Q_Z.>OF3
MX-?\CI;_`.^/_1,]?3?A_P#Y!7_;Q<?^CGKFQ_\`R.?^X2_]+F75_P!WI>C_
M`/2I&G1116IR!1110!GZWK>G^'=(GU75;C[/90;?,EV,^W<P4<*"3RP'`KS3
M6?&&A^+=>TZ31+Q[F."RGWLUO+$.;JS`P749^Z>F<8YJ/XUZKJ3Z%K>D1/:)
MI\-G8W$H:%FE=I+IEPK[P%`\I3RISD]*\]^''2U_Z\YO_2VWJJV'4L+*JWLX
M_P#I<5^HY4E/#UG_`"P;_%+]3&^(G_(V7W_75/\`TG%='X$_Y+5X>_ZYR_\`
MHB>N<^(G_(V7W_75/_2<5T?@3_DM7A[_`*YR_P#HB>O57\6K_A?ZG!3_`-UP
M/^#_`-M@?0\/_(PWG_7I!_Z'-6A6?#_R,-Y_UZ0?^AS5H5Y!W!1110`4444`
M%%%%`!1110!S]G_R4+6?^P58?^C;NBBS_P"2A:S_`-@JP_\`1MW10`>'O^0Y
MXL_["L?_`*16M=!7/^'O^0YXL_["L?\`Z16M=!0!S-QX3=X8GM[Y8KZWU&;4
M+:=X-ZHTF\%63<-PVNPZCUXJ>T\-R6N@G3?[3E:2>Y:XO+D(%:;?(7=0!]P'
M.WC)"]#GFG^(M7NM/ETNQL!#]MU.Z-O%).I9(@(WD9BH(+8"'C(R2.:Y=O'F
MJK+:PO%I\5TERUM-:,'+WC+<>4WV<[AC:@$AR&X8`X'S4`=%H/A<Z'J5S,MX
MDEJSSO;PB#8\?G2>9(&?<=XW`;>%P.#GK5'XBZ%H]]X-U_4+S2K&XOH-*N/)
MN9K='DCVQNR[6(R,$DC'0UL:%KD.KO=H+JR::*4D6T,H:2*(_<,@!)!8#<.!
MP0.H)JOX[_Y)[XE_[!5U_P"BFH`/^$$\(?\`0J:'_P""Z'_XFC_A!/"'_0J:
M'_X+H?\`XFN@KS;XK^/]8\#OI*Z5#8R?:TN&D^U1N^/+\O&-KKC[Y]>U-)R=
MD.,7)V1@^(-)TW1OC/X>M]+T^TL8&M][1VL*Q*6\NZ&2%`&<`#/L*\Q^#_\`
MR/&F_P#7;_VVN:[ZXU#4M1^+F@S:I+:23K$54VL#1+M\JY/(9W.<D\Y].*X'
MX/\`_(\:;_UV_P#;:YK3'M/*JS7_`#[G_P"DLO"0E3Q,HRW5_P#TD^B-&\&>
M%KK0M/N+CPUHTT\MM&\DDEA$S.Q4$DDKDDGG-7?^$$\(?]"IH?\`X+H?_B:O
M>'O^1:TK_KSA_P#0!6E7-2^"/HB'N<__`,()X0_Z%30__!=#_P#$T?\`"">$
M/^A4T/\`\%T/_P`37045H(Y__A!/"'_0J:'_`."Z'_XFOG?58TB\,>(XXT5$
M2*)551@`"YBP`*^J*^6=9_Y%SQ-_USC_`/2J*O1P/P5/E^:.2O\`Q:?J_P`F
M>H_"7PGX;U/X9:1>7_A_2KNZD,^^:>SCD=L3R`98C)P`!^%=K_P@GA#_`*%3
M0_\`P70__$UA?!?_`))-HGUN/_1\E=[7'7_BR]7^9U+8Y_\`X03PA_T*FA_^
M"Z'_`.)H_P"$$\(?]"IH?_@NA_\`B:Z"N$^*%K;WEEX?M[J"*>%]5^:.5`RG
M%K<$9!XZBHA'GDH]QLS=?T'PBGC'0M&@\*Z9&XN5FN'6PA6-XWM[S:AXR?FA
M+8QCY0<YKQV2UM[/Q7XWAMH(H(DL]31$B0*JJ)0``!T`':NC^%\,4'B&R$42
M1AKNU8A%`R?LFH<U@WO_`"./CK_KUU3_`-&BG_R[G_75'9AH<F(E%]%^IE^-
MO^1;T7_KM>?^@P5Z)_S*>G?]A:?_`-(9J\[\;?\`(MZ+_P!=KS_T&"O11_R*
MFF_]A>;_`-(IJWSW6%/_`*_1_*9S85\N4U'_`(/_`$F9Y7>_\AF'_KK#_P"A
MBM#1?]1XL_Z]+K^;50O?^0S#_P!=8?\`T,5?T7_4>+/^O2Z_FU=F3N].L_[B
M_.F3QDK8N2_K^(SZ=_X03PA_T*FA_P#@NA_^)KSSQO!#:Z3]GMXHX8(M-U9(
MXXU"JBB]M@``.``.,5['7D'C[_CQE_[!^K_^EMM7D+^)#U!;KU7YGF-G_P`@
MCPU_NWW_`*4)2^+?^2VWG^^G_I*M)9_\@CPU_NWW_I0E+XM_Y+;>?[Z?^DJU
M[F7;P_Q/_P!*.RA_R-H>M/\`)&SKW_(EP_\`8O:'_P"CI*\T;_52?]<1_P"C
M8J]+U[_D2X?^Q>T/_P!'25YHW^JD_P"N(_\`1L5>'E'\+"^K_P#2F<.&_@XS
M_''_`-)I'TQ\/?!_AB_\`:-=7GAS2+BXE@W22S6,;NYW'DDKDUTW_"">$/\`
MH5-#_P#!=#_\35/X9?\`)-M"_P"O?_V8UUE=&*_CS]7^81V1Y_XW\+>&-(\&
MZE>VGAS2;>X1%$<L%E$CH68+D$#(ZUYY%9VUC\:8K>SMX;>!;I2(X4"*"=.!
M)P..223[DUZK\3FV_#_4AC[QB'_D53_2O*+>_&I_&A+M;::V#WN/*FV[EVZ?
MMYVLPYQGKT/;I4X-_P"T2_P_J=6*B_[/I/\`Z>2_])B<M\&O^1TM_P#?'_HF
M>OH'2O!_AB_M)+J\\.:1<7$MS<-)+-8QN[GSGY)*Y-?/WP:_Y'2W_P!\?^B9
MZ^F_#_\`R"O^WBX_]'/7+C_^1S_W"7_I<RJO^[TO1_\`I4BE_P`()X0_Z%30
M_P#P70__`!-'_"">$/\`H5-#_P#!=#_\3705#=W4-C93W=PY2""-I9&"EL*H
MR3@<G@=JU.0XWQ9X2\,:9X-UR_L_#&AQW5KI\\T+_P!FPG:ZQL5."N#@@=:\
M4O\`P]I]C\99-*:"&YMDF`VR6T*!@;0/RD:*@Y.>%'KUYKN?$_B*/Q?J/B_3
MY[2RN=,TK1+N:Q:6T82K+Y,+;SO/!!=@"%!'K7-Z_P#\G`7'_7=?_2$4_LS3
MW2.K!Q_VF"?7_-&+=6\%KX7\?16\,<,8DLP$C4*!B[D`X'L`/PJ?X<=+7_KS
MF_\`2VWINH_\BYX__P"NMI_Z62T[X<=+7_KSF_\`2VWKNQ7^XS_[<_\`2X&,
M/]VQ7^"7_I<3&^(G_(V7W_75/_2<5M^$K"SU/XO:%9W]I!=VLD<F^&>,2(V(
M9B,J>#@@'\*Q/B)_R-E]_P!=4_\`2<5T?@3_`)+5X>_ZYR_^B)ZZ%_%J_P"%
M_J>;3_W7`_X/_;8'O>CZ3INC:S?6^EZ?:6,#6\#M':PK$I;=*,D*`,X`&?85
MN5GP_P#(PWG_`%Z0?^AS5H5Y!W!1110`4444`%%%%`!1110!S]G_`,E"UG_L
M%6'_`*-NZ*+/_DH6L_\`8*L/_1MW10`>'O\`D.>+/^PK'_Z16M=!7/\`A[_D
M.>+/^PK'_P"D5K704`9.LZ*=4N=,NXK@07.G7)N(F:/>IS&\9##(.,.>A'(%
M5[;P[-;Z'=:?_:!,MY<RSW$Z1E21(Y9E0;OEX.T')(Z\FMZB@#G]"\,#0[IY
M$N8Y(?,N7C00[6'GRB5@S;CNP1@<#BH_%_A#3?$^C:BCZ9ILVJ2V4EO:W=U`
MK-$Q5MA#[2R@,V>.G)%=)10!S_\`P@GA#_H5-#_\%T/_`,31_P`()X0_Z%30
M_P#P70__`!-=!10!S_\`P@GA#_H5-#_\%T/_`,31_P`()X0_Z%30_P#P70__
M`!-=!10!S_\`P@GA#_H5-#_\%T/_`,31_P`()X0_Z%30_P#P70__`!-=!10!
MQ^H_#KPW<7VDRVWAS0XH;:[:6Z3[#&OFQF&5`N`OS?.Z-@\?+GJ!6A_P@GA#
M_H5-#_\`!=#_`/$UT%%`'/\`_"">$/\`H5-#_P#!=#_\31_P@GA#_H5-#_\`
M!=#_`/$UOD@$`D`GI[TM`'/_`/"">$/^A4T/_P`%T/\`\31_P@GA#_H5-#_\
M%T/_`,37044`<_\`\()X0_Z%30__``70_P#Q-5T^'_A8:C-,WAC0S`T4:HGV
M"+A@7+'&W'(9?R]JZBB@#G_^$$\(?]"IH?\`X+H?_B:/^$$\(?\`0J:'_P""
MZ'_XFN@J%[RV2\BLWGC6YE1I(XBPW,JD!B!W`W+^=`&+_P`()X0_Z%30_P#P
M70__`!-'_""^$`<CPKH@/J-/B'_LM=!10!YSX!\)^'K_`,*Q/J>@Z3>7<4TL
M4DTUG'(QPYZLRY/^%=-_P@GA#_H5-#_\%T/_`,36?X`9DCU^T8G]QK$ZJ#V4
MX_\`KG\:["LJ'\-'?FEWC*C?5W^_7]3E[/X?^%H8&6?PQH;N99&!^P1'Y2[%
M1RO92!^%6/\`A!/"'_0J:'_X+H?_`(FN@HK4X#G_`/A!/"'_`$*FA_\`@NA_
M^)H_X03PA_T*FA_^"Z'_`.)K<AN(;CS/)E23RW,;[6SM8=0?>I*`.?\`^$$\
M(?\`0J:'_P""Z'_XFC_A!/"'_0J:'_X+H?\`XFN@HH`Y>\^'_A::!5@\,:&C
MB6-B?L$0^4.I8<+W4$?C5C_A!/"'_0J:'_X+H?\`XFN@HH`\[\;^$_#EAH</
MV#0-+M)Y[R&`2V]K'$^&;D!E`/(%=)_P@GA#_H5-#_\`!=#_`/$UG>.U,]SX
M9M5&2^KPN1QT4')_(UV-91_B2?H=]?3"45YR?XI?H<__`,()X0_Z%30__!=#
M_P#$T?\`"">$/^A4T/\`\%T/_P`37045J<!S_P#P@GA#_H5-#_\`!=#_`/$U
MGZC\.O#=Q?:3+;>'-#BAMKMI;I/L,:^;&894"X"_-\[HV#Q\N>H%=A10!S__
M``@GA#_H5-#_`/!=#_\`$T?\()X0_P"A4T/_`,%T/_Q-=!2,ZJ5#,`6.!D]3
MZ4`8'_"">$/^A4T/_P`%T/\`\31_P@GA#_H5-#_\%T/_`,37044`<_\`\()X
M0_Z%30__``70_P#Q-'_"">$/^A4T/_P70_\`Q-=!10!S^C>%[/0O$.I7FFV-
MC96-W:6T0AM8A'^\C>8LQ50!R)$&>O!]!70444`%%%%`!1110`4444`%%%%`
M'/V?_)0M9_[!5A_Z-NZ*+/\`Y*%K/_8*L/\`T;=T4`'A[_D.>+/^PK'_`.D5
MK705S_A[_D.>+/\`L*Q_^D5K704`%%%%`!1110`5CZ_J]OI\'V:6V^TR7$4K
M"`D*K(BY<L3VP?<\].M4M2\7:=9:Q/8-J=L&AA)FB4$RPMP=Q[$!3N(Z@<XQ
M659:7JEWHVGZ9<13M,64ZCJ/G*Z7*;#\\;$DY9@C8``XP>.H!>\&:C)+]KTX
M3W%U;VKE4>Y(^T6W3]Q-DY9AG*OSN7J21ENLJM96,%A$4A!)8[I)'.6=NY8]
MS_D59H`****`"BBN5U[6[U]0MK#2`)HF)%S)#;M/G!`:(,K*L38.=SL.HP#S
M@`M7$^@>+DN-,BOXIKBW.[?;2XE@8<!T8="#QD?0]:T-'DU%K(1:I`$NH3Y;
M2JP*3X_C7'(SZ$#!R.>M<9X)TK5KE-.O+BZW6-H7%O<+)MEGB`:-8FB5?+1!
MPQ*,0Y13TQCT.@`HHHH`****`"N.UR*X\Z:SUNY,.GW%PITW58'$<MG,WW4;
MT^;A6Z,#L8<_-D^(?$\>M7MEIE@FZ2<,/*$REU#*KK(%#;2X4/A&8'G=@@&N
MRTBSE;0TM=2B,J@D*ER1(YC#?)YAR06P!GWH`FT;^U!ID::Q]G:]0E'DM\[)
M0#PX!^[D8)7G!R,GK5^BB@#C_#3-;^.?%EFPPID@N$XZ[DY/\J["N/.^T^+(
M/2*^TO';ET?^@_G785E1V:[-G?F&LX3_`)HQ_!6?XH*R/$EQ);:5(QMY9+(J
MRWCV\C+-%$5.7C"C)8'!X(.,D9.!5O4-2M].B4RNGG2Y6WA+A6G<`D(N>I.*
MY7PUXIU&]N;)K]H9;;5,BU$,!CDB=59I`RDY\M=NW<P4[B..16IP&?8F]AU#
M39;74_M-],N8+S'^C:O;``X<KPLZKT;`SC(R"0OHU5;'3K/38GALK=((GD:4
MQH,*&;EB!T&3D\=R3U)JU0`4444`%%,FFCMH))YG"11J7=CT4`9)K#U[Q%;6
M5K=00S3?:%M1,9;>(2F!7)5)"I/S98'"C).TX!H`P?&=S<_\)QX6M[,P>>IG
MD5;F0I&6*@#)&3G@XXZG'>I_`;WT5]KEI<Q%]EX?,F>0/)'+M5C&S<;UVNA1
MAS@D,`5YXW0K"?7?&&GPR7%M>)!8(+^=;@2+=`@GSD/4$DQL,8*G'3`SZKH.
ME-HVF"S>99V$CL91&$9\G(+X^\^,9;C/I65+5R?G_P``]#'>[&C3[07XMR_)
MFG1116IYX4444`%<-XLUS2=6LA8PZFGV5+@)J%Q;(LLEHF&`D&00N'V@O@[<
MYXZC0D\1:M<WRV.G:=;-=1!I;A9KCY)(P0N(G4$;LD9W`;>,CD&LWPEI.J2W
M-K=W<@-K:^8D,QE<32H,H(9(BH5%7O@MN9%.>,T`;/@_4)+W2WA^T-?VUJ_D
MV^I^8KK>(`,-D=6'W6.,$@X]!T5-1%C0*BA5'0`8`IU`!1110`4444`%%%%`
M!1110`4444`%%%%`'/V?_)0M9_[!5A_Z-NZ*+/\`Y*%K/_8*L/\`T;=T4`'A
M[_D.>+/^PK'_`.D5K705S_A[_D.>+/\`L*Q_^D5K704`%%%%`!7):_XHDT[4
MY;:UN]-?RH-YCDFVF*0=IL9VQL&7Y@!M.,Y!K4UW7?[*%O%#]E:XGD*`W-P(
MHXP%+$L<$]!P`,G/IDURNB6^K7]E/IEO]ECMY;QKB]D:9OM%J\CB=HBFW$@9
M7`R2N%;!!Q@@%S286U666U:)GLFF-R6:1/M6FW1^<QODD,#N^4C(*G'*D&NM
MT_3[72[-;2SC\J!"Q5`20N220,]!D\`<#M3K*RM].LX[2UC\N"(;43).!V'/
M8#CZ"K%`!1110`4V1BD3NJ,[*I(1<9;V&:=6/XEFO(-*\RU9TC$J?:9(L^;'
M#D;V0`')`_3..<4`96I>)/MUK>6\=I?6^GB)H;S45(CDLG9<\H?FX#`E@,#(
M(R,D96A^'I=0NYO-M8K326WJ\$"QFWNHE?\`T<H5Y/R99FX)+`=!@:?AFQ$]
M]/J-KK$]];;O*\]]K+=QE<@-@`%D+$!P!Q\ISC-=:B)%&L<:JB*`JJHP`!T`
M%``B)%&L<:JB*`JJHP`!T`%.HHH`****`*EUJ=E92".YN8XI&C:158X+*OWB
M!WQD=/6N2\2:X;A%:RU">VB$T4!D7=$;61MS,\ZLH(`4+M#8#%@".<TGB*YD
MUZUU6%[..--*G5A'<H4F;"AO.B;.!U('!#;2"1D@=-8Z?+]L_M&]6-+_`,LP
M.;=V\N5`V58J>_7`YQN(R:`,KPYH2_9+2[OK"WM)H9&GBM[=%6)78%?-P%!#
MLK-D$G!8UU%%%`!1110!QWC#;9>)?"NK'.$O&M&(])5P/RP?UKIM4NIK+2[J
MZM[9[J>*)GC@3K(P'`KEOB?<01>$FC,RI>M*LEJN1N+(=S$?10Q__76#X8>Y
M\1:D]X=4O(K^-(_L4[;MJHJ+NAEB)VMNR)-PQO#`@C;@91TJ27>S_3]#T*_O
MX.E4_E<H_P#MR_\`2G]Q.TFJZCK["XCEN[EX6BMI]/E%NDD:.HE!)#-%AS@,
M""P4=P,]=X;\-6>@VHE%K;C4ID'VJZ5=TDIZX9S\SXZ9;DXR>35S2M(MM.\V
MX6U@BO;G#W3Q9(9^IP3SMR2<>Y]:T:U//"BBB@`HHK%N->AFEMK*P?-U=B9(
MW9?EB9%;.[U(8`;>O?H*`#7]=_LSR;.VL)-1U&Y1WALHV53(B%?,.YB%``8=
M^216#I%A8:LDD>ERS6LMC-&B2O;Y98T+$029Z^6[/A>V$/(ZX.D:+J.H:E:(
M6U:SU*&0F^G?S"ELP1U,D4DJE)7D8KD*-FW^$$`UU>G:8?".C:OJ5Q-OF:-I
MY<,6#LNYBY)`R[%N>`.%`&!2;LKLJ$7.2C'=F3\.]$T^*^UN_AM$'E7S6UO(
MR@L%08+`XX+;B3CU->@US/P_LFLO!.G!V+23H;AV/4ER6'Z$5TU9T5:FOZW.
MS,IJ6*FELG9>D=%^04445J<(5R^K^(U>2^L+>WG>UB1H+W4(''^A2,I(W)G<
M0`021T!!Z9(BU7Q?IKW;Z5EVC<%)I`63?&<J[0L/O%#][!!`!(SBD\/6\UUJ
M\UY#J?VNTAC6V-SM!%\N"1OXP70G&]>#N8$9'`!6T+29+BXL4/AY="CL5\UI
M+-XO*GD(51Y90[F3:&!WJ,@C@D9';TBJJ*%50JJ,``8`%+0`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`<_9_P#)0M9_[!5A_P"C;NBBS_Y*%K/_`&"K
M#_T;=T4`'A[_`)#GBS_L*Q_^D5K705S_`(>_Y#GBS_L*Q_\`I%:UT%`!6'K^
MOOI%YI=E';EI=2G,"7$G$,)"EOG(YR<84=R:W*BN+>"[@>"YACFA<8:.10RL
M/<&@#@M!T4:A>>)-)UBQ$\<M_P"=-*)/GCEV1LA5QAL8*[3PRD$<\,>WTW3+
M72;);2S1EC!+$NY=W8]69B268]R3FJ^A:4=%T\V?F1R(LC&-EB"-L_A#8^\P
M'!;OWYYK3H`****`"BBB@`HHHH`KVME;V1G^SQB,32F9PO0N0`3CMG&3[Y/4
MU8HHH`****`"BBB@#&USPY::U<V-ZRQI?V$HDMIVC#[>1N4@]0<?4$`@@BMF
MBB@`HHHH`****`*.L:19:[IDMA?PB2&0=^JGLP]"*Y?X91);Z)>VSC_3+:\>
MVN'+$EB@"KUZ`+@`#T/J:[:N,M2=%^)UY;,2+;6K<3QY/'G1\,!^&2?PK*?N
MSC+Y??\`\$]#"_O,/5H]=)+_`+=W_P#)6W\CLZ***U//"BBL7Q)K4NCZ:TMI
M`+B8/&)!N&((F<!I6&<[5&3P#T^I`!)K>J36#6-K;+#]IOYF@A>=]J(PC9\G
M@EC\G3OZURMDT.O:_J>F2E[6^0K]M2%MI2=`"EU"V.01A3W^Z",9S7T?P]K9
M>RM=4TRU>2`117%RX26.[08,DK,3N9V*C:"OR\G//'5Z5X9ATW43>M*)71'B
MMD2%8D@C=@S`!>I)5<L>NT=.<@&XH*J`6+$#&X]3^5<C\199)=`@TB!F6?5+
MN*U4KV!;)/TXY^M=?7&28UOXH1H`&@T.V+,>>)I>@_[Y`/X5E6UCR]]/Z^1Z
M&6KEK>V>T$Y?-;??*R.PAB2"&.&,82-0JCT`&!3Z**U//;OJPK.U:PGNU@GL
MIDAO;9]\3R*2K`\,C`=B/R.#VK1HH`X[3_#S7=S,9[&VM++[4DDEHT19MT8R
MH1\X*;SY@(&<L00#FNQHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@#G[/_DH6L_]@JP_]&W=%%G_`,E"UG_L%6'_`*-NZ*`#P]_R'/%G_85C
M_P#2*UKH*Y_P]_R'/%G_`&%8_P#TBM:Z"@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"N2\?VDJZ3;ZW:)NO-(F%RF.,I_
M&N?3')^E=;39(TEC>.10R."K*>X/6HG'FBXG1A:[H5HU;7MT[KJOFM"*RNX;
M^Q@O+=MT,\:R(?4$9%3UQG@V5]%U*_\`"5RY/V5C/8LQY>!CG'X'^?M79T4Y
M<T;O<>+H*A5<$[QW3[IZI_=^)D:_K1TG3YI;:);BXCVEXPP_=(2-TC#.[:HR
M3@$\5RL7A"^BUJZN7@@NYI;AGMM38J&CAD?=(LG5G.WY%&"NU5Z<U'K-E]BU
MJ."\L#)<3W\<MGKCE(PFXA3%(PP<XR@4C#@J.N<=Y86%OIEE'9VB%+>($(A<
MMM&<X!))P.P[#@<59S#[6UALK6.VMTV0Q*%1,D[0.@YJ:BB@"MJ-]#IFG7-]
M<'$5O&TC?0#-<]X"L9HM$EU2[!%YJLS7<F?X0WW5^@'/XU4\7R?V_K-AX1@.
M5E876H$?PP*<A?J3CZ<>M=HBJB*B*%51@`=`*Q7OU+]%^9Z,U[#"*'VJFK_P
MK;[W=_)"T445L><%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`'/V?_)0M9_[!5A_Z-NZ*+/\`Y*%K/_8*L/\`T;=T4`'A[_D.>+/^
MPK'_`.D5K705S_A[_D.>+/\`L*Q_^D5K704`%%%%`!1110`4444`%%%!Z4`-
M21)%W(ZLN2,J<C(.#^M.KRB[\1:WI&C^&(+">WL[:;2%NOM%PC.MS<_)^Y(5
M'8DAG;:@#'&0<*0;&I^+M9A\7206]_\`-#J$5H-*\M`'C>$-O/R%\%VP'W*,
MC&W/4`]->1(]N]U7<0HW'&2>@H=TB1GD9411DLQP`*\GM]7O_$.CZ6+C7Y'O
MI+VR>XBCLE1M.F9FW1ABNW(QPCAF&,G(8"M1=9OM5^$_B234)O/N+1KVT\[R
MP#((V90Q50!G`&<`?2@#T:BO*K_QCJ%MJ%S:0^(0^D&\@B_MITA582R2M)&9
M-OEC:409*-C=M//(U/!&OZQK^O,+S46-O!I5I.8$BC"O+)YH9B=NX?<!P"!G
MMVH`]!HKSJ_U_P`217/CJXL)GNFT<QK8V`@0J2T".2<+O;!)(`/J.>,.@\17
MW_"+QW`\107,9U.WM_[2A,<G[M]F_)\I8\@D\A2!T/(-`'H=%>6Z!XC\0:SX
MFL--.L2?V<7O3%>QV\0:_BB:'RWY0@`[W4E0`P!(QD$6_"OB?Q#J<6IRWUU:
MK<I;3R261C=GT^56(1"B1Y(*\D%F9L97@\`'H]%>11>-/$BZ#=[;V.X2._MH
M9-841/#;PR`^8PD50K;2,$F,;-XW!L&NF&I:M=Z;H,46M@->2W*-?6JQR>:B
M)(48%HPI/RJ20H4\XX(H`[>BO$O#GBK6-62YUFXUT6=_<Z!"\"2A1"76:5'D
M"[&(V[0Q(!`W98%0`/0_!FL7>I>'KNXN+O[>T$\B1W"/%*)5"JPVO$JH^"2N
M0J\@C&1D@'54V21(8VDE=4C099F.`!ZDUXW#XZUV;38'@UU9IKF7369O)B/D
M&:9TEBVA!MP`H*DLRG^+FNB.NW]]\*?%5S=R1W%S8C4+99)8482"(NJETQL.
M0!D8P?2@#:\8:3<7=O:ZYHY!U33CYL.T\31G[R<=01T_^O6EI'B;3-8TF"_C
MNHHEE0L4DD`9"OW@?I7#^'/$>LRW$!EOLVJ:E;6*VJP1HGEO9HYZ+D88Y&".
MXY&`.%UJ40:DM];M;OJ]W;7S7UH\221V3_==2I&TX#*2K`Y"Y/WA6,[TY<ZV
MZ_YGIX?EQ=)8:;M)?"WU_NM^NJ?>ZZGT0[1B,NY78!N+-T&.<TUYX8T5Y)41
M&("LS``D]`/K7E,GC'4M;2\T[2KDM!;P37UQ/+:IM%N(<"W*E<9\TL#Q]U>O
M-1^)]6O+I[:SO+I;=(=2TG[+9+&N)XV>-C-D#(^?<O'RC9C&2#6J:DKH\^I3
MG2DX5%9KHSUZLOQ!KMKX=TB6_NCG;\L<8^](YZ**\YTOXB7]KH&GR:OJ`;4U
M6_CNX3"F\3)*!"K(H&/E(XXR.?>J'AC4;WQ3XHTJ]U:\DNTM[\0PPSQH!M>W
MFF5_E55)S&F"!V]16<ZFO)#?\CMPV$7+]8Q&E-??)]E^KZ(]"\':+<V5M<:K
MJG.KZDPFN./]6/X8QZ`#_/%=/7F\GBC4AXRUVP_M<H;/4;.&RL/*C47"R(AD
M3<5RV`S-\IRN,GY>*FL-<UA_"]]J=UJ[HK:O+:-.8XE6QMTN&C+CY,9"@9+Y
M`QD]#FX1459'+B*\J]1U);O\.R7DEHCT%F5%+,0J@9))P`*2.1)8UDC=71P&
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M2R#R[CD`*J1?.PZ#<3@@8(!Z@702+&64.P)"YY(&,G'XC\Z4D`$D@`=2:\0F
MUO6]>T?6=U_.VH6%GK%O;W%NJK-)&CVC(3A`,LIZJJY!R,&NIAU/Q(WBS3=#
MMM4\^PO%AU&*^\J)LV:1[98N%P2SF,[L=).,8H`]%CD26-9(W5T<!E93D$'H
M0:=6%X/`3PS;QJ,)%+/%&/1%E=5'_?(%;M`!1110`4444`%%%%`!1110`444
M4`%%%%`'/V?_`"4+6?\`L%6'_HV[HHL_^2A:S_V"K#_T;=T4`'A[_D.>+/\`
ML*Q_^D5K705S_A[_`)#GBS_L*Q_^D5K704`%%%%`!1110`4444`%%%%`$%G9
MP6%JMM;)LA4L57<3C)).,]LDX'0=!Q4]%%`!1110`4444`%5[NRM[Y8EN8]X
MBE29/F(PZG*GCT-6**`"BBB@`HHHH`****`"BBB@`HHHH`YS5O!6DZI=F]03
MV%^?^7JRD\IS]<<'\LU5_P"$3UDJ8SXQU/RL8P(T#_\`?76NMHK-TH-WL=L<
MPQ,8J/-=+:Z3MZ73L<[H_@K2-(N1>%9KV_Z_:[U_-DS[9X'X#-=%1151C&*M
M%'/6KU:\N:K)M^93M-*LK&^OKVVAV7%\ZR7+[F.]E4(#@G`^4`<8JY115&04
M444`%%%%`!5#2]%L-&6<643JUQ)YLTDLKRO(V`,L[DL>``,G@#`J_10`5031
MK*/5+C4@DIN[B,1.[3R-M3T0%L(#@$[0,D9/-7Z*`*]C8V^FV$%E:1^7;P((
MXU+%B%`P,DDDGW)R:L444`%%%%`!1110`4444`%%%%`!1110`4444`<_9_\`
M)0M9_P"P58?^C;NBBS_Y*%K/_8*L/_1MW10!<711%>WMU:W]W;->2B:98Q&5
M+B-(\C<A(^6-1U[5)_9UU_T&;[_OB#_XW110`?V==?\`09OO^^(/_C=']G77
M_09OO^^(/_C=%%`!_9UU_P!!F^_[X@_^-T?V==?]!F^_[X@_^-T44`']G77_
M`$&;[_OB#_XW1_9UU_T&;[_OB#_XW110`?V==?\`09OO^^(/_C=']G77_09O
MO^^(/_C=%%`!_9UU_P!!F^_[X@_^-T?V==?]!F^_[X@_^-T44`']G77_`$&;
M[_OB#_XW1_9UU_T&;[_OB#_XW110`?V==?\`09OO^^(/_C=']G77_09OO^^(
M/_C=%%`!_9UU_P!!F^_[X@_^-T?V==?]!F^_[X@_^-T44`']G77_`$&;[_OB
M#_XW1_9UU_T&;[_OB#_XW110`?V==?\`09OO^^(/_C=']G77_09OO^^(/_C=
M%%`!_9UU_P!!F^_[X@_^-T?V==?]!F^_[X@_^-T44`']G77_`$&;[_OB#_XW
M1_9UU_T&;[_OB#_XW110`?V==?\`09OO^^(/_C=']G77_09OO^^(/_C=%%`!
M_9UU_P!!F^_[X@_^-T?V==?]!F^_[X@_^-T44`']G77_`$&;[_OB#_XW1_9U
MU_T&;[_OB#_XW110`?V==?\`09OO^^(/_C=']G77_09OO^^(/_C=%%`!_9UU
M_P!!F^_[X@_^-T?V==?]!F^_[X@_^-T44`']G77_`$&;[_OB#_XW1_9UU_T&
M;[_OB#_XW110`?V==?\`09OO^^(/_C=']G77_09OO^^(/_C=%%`!_9UU_P!!
MF^_[X@_^-T?V==?]!F^_[X@_^-T44`']G77_`$&;[_OB#_XW1_9UU_T&;[_O
MB#_XW110`?V==?\`09OO^^(/_C=']G77_09OO^^(/_C=%%`!_9UU_P!!F^_[
MX@_^-T?V==?]!F^_[X@_^-T44`']G77_`$&;[_OB#_XW1_9UU_T&;[_OB#_X
MW110`?V==?\`09OO^^(/_C=']G77_09OO^^(/_C=%%`!_9UU_P!!F^_[X@_^
M-T?V==?]!F^_[X@_^-T44`']G77_`$&;[_OB#_XW1_9UU_T&;[_OB#_XW110
D`66DI::C<W[7,]Q=7$4<+O+M'R1ERH`50.LC_G[4444`?__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>graph11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 graph11.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`%7`;(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#UZQEO=3U?
M78FU&>WBL;U+>)(4CQM-O#(2=R$D[I&_#%:']G77_09OO^^(/_C=9_A[_D.>
M+/\`L*Q_^D5K704`9_\`9UU_T&;[_OB#_P"-T?V==?\`09OO^^(/_C=:%%`&
M?_9UU_T&;[_OB#_XW1_9UU_T&;[_`+X@_P#C=:%%`&?_`&==?]!F^_[X@_\`
MC=']G77_`$&;[_OB#_XW6A10!G_V==?]!F^_[X@_^-T?V==?]!F^_P"^(/\`
MXW6A10!G_P!G77_09OO^^(/_`(W1_9UU_P!!F^_[X@_^-UH44`9_]G77_09O
MO^^(/_C=']G77_09OO\`OB#_`.-UH44`9_\`9UU_T&;[_OB#_P"-T?V==?\`
M09OO^^(/_C=:%%`&?_9UU_T&;[_OB#_XW1_9UU_T&;[_`+X@_P#C=6+V_L]-
MM6NK^[@M;=/O2SR!$7ZD\54D\2:%#:FZEUK3DMP54RM=($!;[HSG'.#CUH`?
M_9UU_P!!F^_[X@_^-T?V==?]!F^_[X@_^-TV3Q#HD(C,NL:>@E?RXRUR@WMC
M.T<\G':I6U?3%MEN6U&T$#L464SKM9AU`.<9X-`#/[.NO^@S??\`?$'_`,;H
M_LZZ_P"@S??]\0?_`!NFW7B+1+%&>\UG3[=%.&::Z1`/KD^XI?\`A(-%WHG]
MKZ?N=69!]I3+!>&(YY`[^E`"_P!G77_09OO^^(/_`(W1_9UU_P!!F^_[X@_^
M-T]-9TN2SAO$U*S:UFSY4RSJ4DP"3M;.#P#T]*2SUG2]18+9:E9W+')`@G5\
MXZ]#0`W^SKK_`*#-]_WQ!_\`&Z/[.NO^@S??]\0?_&Z2?7]&M;F6VN-6L(9X
MMIDBDN45DSTR"<C/:M$$$9!R#0!G_P!G77_09OO^^(/_`(W1_9UU_P!!F^_[
MX@_^-UH57^WV?VR2T^UP?:8XQ*\/F#>J'@,5Z@<'GVH`K_V==?\`09OO^^(/
M_C=']G77_09OO^^(/_C=:%9D_B+0[6YEMKC6=.BGBQYD4ETBLF>F03D9H`?_
M`&==?]!F^_[X@_\`C=']G77_`$&;[_OB#_XW4]W=BUMTF"B0-+%&,''WW5<_
MANS5@$,,@@CIQ0!0_LZZ_P"@S??]\0?_`!NC^SKK_H,WW_?$'_QNK=Q=6]G&
M)+F>*",NJ!I7"@LQ`49/<D@`=R:EH`S_`.SKK_H,WW_?$'_QNC^SKK_H,WW_
M`'Q!_P#&ZMW-S!9VTES=3QP01*7DEE<*J*.I)/`%/CD26-9(W5XW`964Y#`]
M"#0!1_LZZ_Z#-]_WQ!_\;H_LZZ_Z#-]_WQ!_\;JXT\*31PO*BRR`E$+`,P'7
M`[XR/SJ2@#/_`+.NO^@S??\`?$'_`,;H_LZZ_P"@S??]\0?_`!NM"B@#/_LZ
MZ_Z#-]_WQ!_\;H_LZZ_Z#-]_WQ!_\;K0HH`S_P"SKK_H,WW_`'Q!_P#&Z/[.
MNO\`H,WW_?$'_P`;K0HH`S_[.NO^@S??]\0?_&Z/[.NO^@S??]\0?_&ZT**`
M,_\`LZZ_Z#-]_P!\0?\`QNC^SKK_`*#-]_WQ!_\`&ZT**`,_^SKK_H,WW_?$
M'_QNC^SKK_H,WW_?$'_QNM"B@#/_`+.NO^@S??\`?$'_`,;H_LZZ_P"@S??]
M\0?_`!NM"B@#/_LZZ_Z#-]_WQ!_\;K-UM[_1[*WNXM4N92;^S@9)4BVE);B.
M-ONH#]USCGKBNBKG_&7_`"`[;_L*Z;_Z6PT`=!1110!S_A[_`)#GBS_L*Q_^
MD5K705S_`(>_Y#GBS_L*Q_\`I%:UT%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110!R7Q.2:?X<ZU;6UK<W5Q<0>5%#;0/*[,3Z*"<>_2N)\6SW>I_"==
M$M+'Q#>7L1M=TDNDS(Y/F;B`/+`.T*>0,<*,DD9]CHH`\N\:07DFF^%(8;OQ
M!=R+J?VR34(]+=YX8BLGS,BQ85AO4;2@/'3BKM]+<7/BS0/$ZZ7J=QIEA%<6
MDF^SD6=&8)B80L/,*G:5X&>^*]$HH`\U^+B7.K_#*^MM/TG4);J\GB\N&&T=
MY'VNI+,%!*_*O\6#P!UXK<O[OS?'_AQTM+]HELKD/*+&;RT,GE%`S[<*?D;(
M)&,<XR*ZZB@#A_!D.IZ'!J^FZC;3KI^DW<SV<RQO(T\+_O%"*`2VT,RX7.3P
M.14'PYNI+:R6RN%USSII)6$%YIDL,5LOF2-PYC53N#+U);)ZXX'?T4`>2>)[
M+4+GQKXCFBL]4GL1:6GGV:6+F+4HXRYEB60I]X!A@*PW$E>><:DDNLZGXGM/
ML$>L6UO<3XD5XIX(8K#[/CHP"I*)<XQA^G\.#7H]-DC26-HY$5XW!5E89#`]
M010!Y5-;>);?P;;VLZZW<ZDD[6#W%E?2GS1%YNV=^K`,2,[2"2JAFVC%87B>
MQ\1Z[8SW2Z;J_P!ME\-Z>L^R"6-FE$Y::/@#<VUB2H_+BO<HXXX8UCB1411A
M548`'L*=0!Q/A[0;_3O%NH1SWVI7.F@1WED;C4)Y&CWJR-"X9CN`*EAG/4=Q
M7(^*++4KOQWXCN8-,U.[T\6ELL]G]CD6+48XRWF1K)L^\-P*[6&[!'/;UZWL
M[:T$@MK>&$2.9'\M`NYB<ECCJ223FIJ`/&M;NM:U#6M-N-+L/$5E8/J,=K+%
M.)HHQ$8T*$1G"Q@/P&QN#`Y89`J3P7!XDL;CP[875MK,-N+1&,DK7!1;@3-Y
MXD'(P4P%WX3G<N3BO6[FV2ZB6-RP`D23Y?5&##]0*FH`XOQ[:SZUI=_I]O:2
M2R6MH;N-FBEP)@<QF,JA#N"I^4'/S#UKEO%6LZWJMC<ZAI=IXILKM]'B>"UC
MM+I-ET)SE2H7:6QG/9EZY&*]=HH`\CUF;6[]/$BIIWB#R;G3]2M?*G2619'V
MQ^28T`VJ#N<+@9X.YB>!J:7HVJV&KP#[3JK6-YI:72H;N;=:7$04%!&6QAC(
MIV$8RI!XXKTBH(;.UMYIIH+:&*6=M\KH@5I&QC+$=3@#KZ4`>826_B-;[1[.
MVN-=BD-G?0W-UMN)8C)\HCD*N<#YO,(!;('0XVFN\\*"5=!C2:.Z1E=Q_I,L
MTC-SU!F_>8/8-R!ZC!K:HH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"N?\9?\`(#MO^PKIO_I;#705S_C+_D!VW_85TW_TMAH`Z"BBB@#G_#W_`"'/
M%G_85C_](K6N@KG_``]_R'/%G_85C_\`2*UKH*`"BBB@`HHHH`****`"BBB@
M`HHHH`*\WO->U/3Y?':P3SRK97=G%;*7W&%94BWD$^A=F]L5Z16);>$]&M9=
M4DC@G9M5_P"/PRW<LGF\8'WF.W`X&,8``'04`>;_`/"6ZZVG^)@;N=#HL6HO
M:3$_ZPQ3[8RW]_:HV\YSU.3S71^%/$>IZIKS&[+A9KZ_MC"?NQI"8PA`]>3D
M]]WL,=(?"&A-;6UN;']U;[MH\Y_GW'<XD.[,@8@$A]V3R<FKT&CV%KJD^HPP
M;+J<8D8.VT],G;G:"=JY(&3M&2<"@#E=:2>'X@>'=-CU"_6UU"*^DN%6Z<99
M0A3&#\H7<<`?CFJ5GXTFT.363JBS75C;ZA>*LYDS(BPPK)M"XP01OYR,''&#
MD=A=>'-,O=>M-;GCG:_LU*0.+J550'[PV!MO/?(YP,]!58>#="&H/>_996E>
M:6=U:ZE:-GE78Y,9;8<KQC&!VQ0!@Q?$&^NK?1Y+;P^2VIW$EO$MQ-+!R(?-
MC8;X065AD%@,`@XWCFI;OXA"UUC4=-6PAFEM+.>X!CN\@R0JK/&^%^0X=<$;
MO<"MF#P9H5LNEK#:S*NER-+9K]KF*Q,PP>-V",<`'(`)`P#52_\``.BSMJ5U
M96RVFIWT=PK76Z1@&F0*[%-X!SM4XXY'J30!EWWQ'ETP+;WFC?\`$PFEB6VA
MMYI)T=9$9U+%(BX.$8$*C=L9'2.Y^)<UKXGM-'DT(HMS<64*R/<E9$%RCMEH
MS'PR^605S^(K:@\":.VDQV>H0FZGWQS/<)+-&XEC7:K1MYA>(`9PJM@9/J:L
M:AX+T#5-3MM2N[%FO+9HWCE2XDC(:/.PG:PW$;FQG/4T`<Q:^.KZ/1M/UO6+
M58[1I+^1OLER6)CB#E0R&,9X5APPY53DY('9Z+JDNI:)%J5W;1VBRIYRA9O,
M'ED;E;=@<X/(QP<\GJ:L?@[0HC;[+)@ENTSQQ_:)#'F7(DRF[:P(8C!!`SQB
MIAX9TE-`;0XX)8M/*A?+BN9$8*#P`ZL&`X`P#C''3B@#A;KQU<3V'C>T$UW;
M7MO82:CIHGM9+:1(?*V\*Z@G:ZDDX(RW4T-XFU&U@MGFFN9DFU'2X&9+D1LG
MFQ1D]48,I8G<ORY!."*ZW4_`?AW6;M+K4+6YGG2U-F'-]."82""IPXSD$Y)Y
M/>FGP!X<8QEK6Z81R02JK:A<%0\*A8VQOQD`#ZXYS0!DR?$9UL=1NHM+@F6U
M$$D1CO"5FCDF:$G=Y?!#(W`R"/XJFT[QW=ZM!;QV6C1-J+7-U!-;O>;47[.P
M5RC[/F)W+@%5SSDC%:$?P^\,16+V46G/';.BQE$NIE^59#*J\/G`=F(';..G
M%/M_`GAVT$?D6EPC1W37B.+Z?>)6&'.[?G#=US@]P:`,FV^(-U?QZO+8>'+R
MXCL7=(F`D`E*2>6^3Y>.#D@1F1B`>`>*MZOK=Y-HGAS4+)D22\O[=72.5MC!
M@V4+%0<?50>.@/%:MOX5T:TDNWMK:2'[5*9I%CN)%42'.610V$8YR2H!)P>H
M%6)]!TVYTR'3I8&-O"08L2N'1@"`P<'<&Y)W9SGG.:`.6;QWJ:WNF6_]@VP&
MHM/;PRM?L$^U1,RM$<1$@'8Q5NX'0'BKOBN[UBPO[>_@$\ND6UK*U[#92*)X
MVX*2A6'SJH5_ESSGHV,5J0>'X[:XLTC=/[.LP&M[9HRSI+\P,AD+$G(<YSR3
MSGDYLZAHFGZH2UW`78J$9ED9"R`YVDJ1E3GE>AZ$$4`<P/&UQ$+^5(+6>S@M
MK-K662Y,37#SYVY!0[<Y'`W'V.>,^\^*;_V5H][IFB+<OJ<"2Q6T]WY4CLTF
MPK&!&_F%?O-TPN#SGCK[[PKH>I,S76GQN6,).UF3F)MT>-I&,'TZC`.0*Y^^
M^'1#:;#H.MWFBV%G%Y7V>":=BPW%A@^:!P6/W@P_#B@#0\+>,/\`A)[N\2/3
M+B"WA=UCN&239)L<HP+,BKG(/"LW'7!XKEO$GQ6NM+M=9CM=,MS/;V3W5G.+
MDO'(JSB!BPV#!#'.`2#@_,*[_2]"T[1I;F2QA>(W,AEE7S7*%SRS!"=JDGD[
M0,GK65)\//"DRRK)I",)8)+9\S2<Q/)YC+][@;_F']T],4`2ZO<ZNNFZ9-%9
M&XEWB2]M+.Z"R,FPY\MFV;L.4.#MR/R/*67Q!47][+"+NZA@TY9@UW,(5!-T
M\3>:OE_NRA!W."PVID+7>WFBV5]:16\RSJL0Q&\-S)%(O3I(C!LG')SD\YZF
ML34O`.EW$-Q)IC2Z;J,ELEM'=0SS8C17#@;%D4?>R<@@Y).<DT`8,/Q0OW2"
M27P[`L<]E=WD;IJ!8,ENQ!(S$,JPP58=<CIUJ2Y^(-S8>)I[!=+-P)=6MM.0
MM>X5/-A$BN%\O@8^\,GGH36G9_#G36MH#K=W?:K?1P26_P!I>]N$_=R9WH!Y
MI.#D]23TYP!BV_P^\-27*W+V=RTZW$=T)#?W&[S8UV(^=_4+Q0!D:G\1[FVM
M]%-CH/VJXU2-'2*2Z,8+,P4JA",7*\LW`PO/L.^&<<]:XG4/AZ7ETY-&UW4-
M)M+.,QF**XG=F!8L/F,O8GHX<8XQBNV'3KF@`HHHH`****`"BBB@`HHHH`**
M**`"N?\`&7_(#MO^PKIO_I;#705S_C+_`)`=M_V%=-_]+8:`.@HHHH`Y_P`/
M?\ASQ9_V%8__`$BM:Z"N?\/?\ASQ9_V%8_\`TBM:Z"@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`S]8U%].M(VAC66YGF2W@1C@%V.,GV`RQ]@:S;G7
M[JU\9:5HS0(UK=03"2YVD?Z0H5E0<\?)O;!SVYX-7==L)[VWM9;78;FSN4N8
MT<X5\`@J3VRK-@]CBLC4/!-KJ4]MJ:+:V6LQ7:W?V^.S3SB!G$;-G)&"%//0
M4`:4WBO1X/MNZ>8_8I%BE\NUE?+L2`J;5/F'(((3.,<XJ&7QMH$&KKI4EW,M
MZTHA$9M)L%RF\+NV8Y7D<\X..AJ.\\(Q7LNIR37;'^T8TCF01C80I8JV/[XW
M`!N#A$ZXYHWGP_AN?$-OK":E.LD-Q#<%)$#[WCB,7)X/*G\^?:@":+XE^$YK
M!+Z/4I7M73S!*+*?:$WLA<_)\JAE().`.,]1G2E\6:%#]M,NI1)'9*6GE8,(
MUP0"`^-K,"0"H)(+`$<BN3M/A-!9^''T2/5Y#;O8/8%V@&_8\QE+?>QG+$=*
ML'X3Z*UGK%N7VOJ4WG_:D@03POO60[9,9*;U!VG/^`!H>`?%-[XIM=;DO4@4
MV&K3V,1BA>+=&@7#,KDD,=QR./I3M-\9I-K?BC3]0C,`T=EECV1.S26YC!W@
M#)?Y@X^4>@QGK8\/^%'\.VFM1VVHEY]4OIK\RO"/W4DF,X&>0,#']:H?\*[L
MH=:75+!K:QG:PEL[@6UH$%QYG5WYR3D`^O7)-`&G:^-O#U[IYOK:_:2V#0*6
M%O)D&8@1\;<X8D#.,9X.,&H!\0?#)4'[?*`;>:YYLYP1'$Q63(V<,I!ROWAZ
M<BLS2?AM%I-I)!'J;R!TL8\M".!:R;T_B[]#^F*9)\,;>2-O^)I,LKI?1,PB
M&-MT27P">H)X.>G4'K0!O:QXLT[3I9K!;I%U0VLL]M'+$^R0JF[&[`4G&"5#
M9Q65<>,+R#P!H6NO%$DVI1VQGG$+R0VGF)N,C(#N*`\8W#J,GJ:;JOP[CU;7
MX=7GUBZ\V$.$B**44-#Y1`[@=6`SU8]<UO:=H<FF:'I&F6VH2H--B2(,$&)U
M2,H`X/;H>"#D#D=*`*K>+M.TW2[*ZUF^MHUNG98[BV#R0,-^U6+J"$!!7[QQ
MDXR:HZ?XW@C;7&UR:"VBLM6DL8&CC<YC6-'W/C=C`8EFX4`9.*J:Q\+[#5]!
METDZA<V\,WG-)Y:K@O).LS,`>GS(`!Z<>]6'^'.G3WDUQ>&"\\S49+\PW5JL
ML>7C6-EVGKPBD'J"._2@#I+'6;+4;NYMK5Y7>V.V1C`ZH3R/E<@*^""#M)QW
MK"U?Q]I%KH>JWFFW4=Y<6*C,:([9)?RPP`&70-D%ER,JPSD&M33O#UOINL7F
MHQ,JM<HL;QQQA%;;T9@."P'RYP.`!7*P_"32;6SO+>VNYD$MH;*`L@/D0FX:
M<J.F3N8C/H![D@%W6_$VL:)I&DF\:RAN;R0K-??993;0\@KO4D-'N!'WCA3G
M.<5:\7^);[0O#=K<6WV&#4KITC7[8DLMO&2,MN,0+8&"-W`R03Q6QJVES:I:
M>1]K$8:,QRHT0>.0'&<J3GL<<]SG--CTB>QT_3+'3-0>W@L42+;)&)?.C5=H
M#$X.>`<@B@#EF^($MKK&GV,_V*X0K8QWD]MN*-+=;PC1')^0%!UR2''(QS1;
MQWX@N+6>&PCTV349M.MM5L%:"38T4TA01.-^2P.WYP0#G[HQ71S>`]*EU:UO
M@740_9B8@!M=K??Y1/IC>2?7"],<QVO@>.SF%Q!>_P"D1VUM9P,\(*QP02>8
MBX!&23C)R,@#`%`&7'XUU;5K7P>-+%A;SZVC&ZDN(7F6!A"[E50.A/S1N.6X
MQ78Z1J#ZA:R^>BQW-O,T$ZH<J'7N/8@AAGL:PH_!,=E>65U97106=_<Z@(3%
MNWR3!PRYW#`PY`'K@Y[5LZ'8SVD-U/=*J7-[<-<R1JVX1Y"J%SWPJKD^N:`-
M2BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`KG_&7_`"`[;_L*Z;_Z6PUT
M%<_XR_Y`=M_V%=-_]+8:`.@HHHH`Y_P]_P`ASQ9_V%8__2*UKH*Y_P`/?\AS
MQ9_V%8__`$BM:Z"@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`*Y_P`9?\@.V_["NF_^EL-=!7/^,O\`
MD!VW_85TW_TMAH`Z"BBB@#G_``]_R'/%G_85C_\`2*UKH*Y_P]_R'/%G_85C
M_P#2*UKH*`"BBB@`HHHH`****`"BBB@`HHHH`**Y?5M8URTU:_MK&WAN8$T]
MYXG2!V:"88"HX#?O-V20%VD!>^0:1/$L]I;VQGEM-1'F;;N:VC>W,(+A!B%B
MY)#,-V6&!S[4`=3163;^(M.;1SJ=W=0V5O&J&:2X?RTCW8Q\[@`@[@`>ASQ5
M7_A._"'_`$->A_\`@QA_^*H`Z"BN?_X3OPA_T->A_P#@QA_^*H_X3OPA_P!#
M7H?_`(,8?_BJ`.@HKG_^$[\(?]#7H?\`X,8?_BJ/^$[\(?\`0UZ'_P"#&'_X
MJ@#H**Y__A._"'_0UZ'_`.#&'_XJC_A._"'_`$->A_\`@QA_^*H`Z"BN?_X3
MOPA_T->A_P#@QA_^*H_X3OPA_P!#7H?_`(,8?_BJ`.@HKG_^$[\(?]#7H?\`
MX,8?_BJ/^$[\(?\`0UZ'_P"#&'_XJ@#H**Y__A._"'_0UZ'_`.#&'_XJC_A.
M_"'_`$->A_\`@QA_^*H`Z"BN?_X3OPA_T->A_P#@QA_^*H_X3OPA_P!#7H?_
M`(,8?_BJ`.@HKG_^$[\(?]#7H?\`X,8?_BJ/^$[\(?\`0UZ'_P"#&'_XJ@#H
M**Y__A._"'_0UZ'_`.#&'_XJC_A._"'_`$->A_\`@QA_^*H`Z"BN?_X3OPA_
MT->A_P#@QA_^*H_X3OPA_P!#7H?_`(,8?_BJ`.@HKG_^$[\(?]#7H?\`X,8?
M_BJ/^$[\(?\`0UZ'_P"#&'_XJ@#H**Y__A._"'_0UZ'_`.#&'_XJC_A._"'_
M`$->A_\`@QA_^*H`Z"BN?_X3OPA_T->A_P#@QA_^*H_X3OPA_P!#7H?_`(,8
M?_BJ`.@HKG_^$[\(?]#7H?\`X,8?_BJ/^$[\(?\`0UZ'_P"#&'_XJ@#H**Y_
M_A._"'_0UZ'_`.#&'_XJC_A._"'_`$->A_\`@QA_^*H`Z"BN?_X3OPA_T->A
M_P#@QA_^*H_X3OPA_P!#7H?_`(,8?_BJ`.@HKG_^$[\(?]#7H?\`X,8?_BJ/
M^$[\(?\`0UZ'_P"#&'_XJ@#H**Q;3Q?X:U"]ALK'7],N[J<D1PVUVDKMA2QX
M4D]%)S6U0`5S_C+_`)`=M_V%=-_]+8:Z"N?\9?\`(#MO^PKIO_I;#0!T%%%%
M`'/^'O\`D.>+/^PK'_Z16M=!7/\`A[_D.>+/^PK'_P"D5K704`%%%%`!17+W
MWCC1-,U!K&]UC3(;CS2C(]U$A@`S@R*T@;D8/`[BMS2;T:CI-M>"2*031AQ)
M"<HX]5Y/!ZCF@"Y1110`4444`%%%%`&0VBS_`&Z^N8=<U&%;L9\E%@*1/M5=
MZ[HBV<*.&)')XIH\,::T5OYT?VBX@F,XNIE5I2Y(+'=CY=V,$+@8XZ<5LT4`
M<;XAT:+1/ACXGM8KFXG3^R[G89RI,:"%@J`@#*J!@9R?4FNRKG_'?_)/?$O_
M`&"KK_T4U=!0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'/^(?^0YX3_["LG_I
M%=5T%<_XA_Y#GA/_`+"LG_I%=5T%`!7/^,O^0';?]A73?_2V&N@KG_&7_(#M
MO^PKIO\`Z6PT`=!1110!S_A[_D.>+/\`L*Q_^D5K705S_A[_`)#GBS_L*Q_^
MD5K704`%%%%`'`:C>-#K%\'\`W>L`S';=)!;%6'L6(8^G/<>E=EI$@ETBUD6
MQ-B&C'^BL`##_LD#C(Z<<5SGB?5]?TYS9>'M%B6:=U`O[Z8+;*SG'"J2Q;)'
M!`]>:Z/2$O(](M4U&XCN+U8PL\T0PKN.I`[#/:@"[1110`4444`%%%%`!167
M=:_966JC3;@2I<O"9H05XF`95(4YZ[G08./O<5%!XHTR9XXF>:*9[AK8QO"W
M[N5<?*[`%5SD8).&R,$YH`@\=_\`)/?$O_8*NO\`T4U=!7-^-)X[GX:^(IXB
M6CDTBY9201D&%L<&NDH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBD+!02Q``ZDT`
M8'B'_D.>$_\`L*R?^D5U705S_B'_`)#GA/\`["LG_I%=5T%`!7/^,O\`D!VW
M_85TW_TMAKH*Y_QE_P`@.V_["NF_^EL-`'04444`<_X>_P"0YXL_["L?_I%:
MUT%<_P"'O^0YXL_["L?_`*16M=!0`4444`>5>+?'FJ:5K.I6=OK/A;RR?LT5
MG>RE)("0"9923@C[WR@<AE]Z[_PNJIX6TQ5O8KT"V3_2H4"),<<LJC@`]0!Q
M1.^D1R2/?VUM;MO(\RY10']PQX/TSGVK0M?LYM8S:&,VY&4,9!7'MCC%`$U%
M%%`!1110`4444`<OJ6D:O>ZE?RI;:>/E0V-V]TYD0H8W$;1^7A5+H22&)(QP
M<#%?_A#IKH2W5U*L-U>WJ75Y;0R"2!MOEA1EDW$J(E92-GS=>.*["B@#@=0T
M:YT7X6>*H+J*SCE;3KHDVA.V4B`@RL"HP[D$L.>>YKKO[&M?^>M]_P"!\_\`
M\76?X[_Y)[XE_P"P5=?^BFKH*`,_^QK7_GK??^!\_P#\71_8UK_SUOO_``/G
M_P#BZT**`,_^QK7_`)ZWW_@?/_\`%T?V-:_\];[_`,#Y_P#XNM"B@#/_`+&M
M?^>M]_X'S_\`Q=']C6O_`#UOO_`^?_XNM"JM[J>GZ:(S?WUM:B0[4\^94W'T
M&3S0!#_8UK_SUOO_``/G_P#BZ/[&M?\`GK??^!\__P`75\$,H92"#R".]+0!
MG_V-:_\`/6^_\#Y__BZ/[&M?^>M]_P"!\_\`\75X2(9&C#J74`LH/(!Z9'X&
MG4`9_P#8UK_SUOO_``/G_P#BZ/[&M?\`GK??^!\__P`76A37D2,`R.J`D`%C
MCD]!0!1_L:U_YZWW_@?/_P#%T?V-:_\`/6^_\#Y__BZMRW,$#HLTT<;2'"!W
M`+'VSUI[R)'&9'=50#)8G``^M`%'^QK7_GK??^!\_P#\71_8UK_SUOO_``/G
M_P#BZT`<C(Z44`9_]C6O_/6^_P#`^?\`^+H_L:U_YZWW_@?/_P#%U?)"@DD`
M#DDU%;7=M>P">UN(IXCP)(G#*?Q%`%7^QK7_`)ZWW_@?/_\`%T?V-:_\];[_
M`,#Y_P#XNIQJ-D8I91>6YCB.V1_-7"'T)SQ4IN(1+'$9HQ)("40L,L!U('>@
M"G_8UK_SUOO_``/G_P#BZ/[&M?\`GK??^!\__P`75L75NUTUL)XC<*NYH@XW
M@>I'7'(I5GA>9X5E1I8P"Z!@67/3([9H`I_V-:_\];[_`,#Y_P#XNC^QK7_G
MK??^!\__`,76A10!G_V-:_\`/6^_\#Y__BZ/[&M?^>M]_P"!\_\`\76A10!G
M_P!C6O\`SUOO_`^?_P"+H_L:U_YZWW_@?/\`_%U=FFBMX6FGE2*)1EG=@H'U
M)K#W7?B*258I6MM%*M&70.D]R>A*-P43J-P^9NH*@`D`\T^+M]XCM?L%OX(G
MU:?8T@OWL)YKAHV&`JM@MM_BXZ\5U6C0>+;C0-.DN-'C^UO:QM.UUK]U"WF8
MYRBQMCUQGCD=J[BRL+33;9;:RMHK>%<82)0HZ8[>P%6*`.5_LC777K;0G`_Y
MB=W+@]^ZU&?#GB-Y\_V[:Q0[@=JQ7;/CN-QN@/QVUUU%`',?\(M?O]_Q%?+S
MG]S)(O'I\SM7%_$'X6:]KOA_R-,\4ZI?2B8.UIJ%PHA=?;:HY'&-Q->MT4`>
M;:%X9O/#%AX$L=3OIKR_BU&59'-Q(Z`&TNB%4,<8484'`Z=J])KG_$/_`"'/
M"?\`V%9/_2*ZKH*`"N?\9?\`(#MO^PKIO_I;#705S_C+_D!VW_85TW_TMAH`
MZ"BBB@#G_#W_`"'/%G_85C_](K6N@KG_``]_R'/%G_85C_\`2*UKH*`"BBB@
M#AI_"/AK5?$E[J>NR27\@<I#;:A,K00C`!\N//'.>6&?2NPT^WM+2P@M[!(T
MM(UVQ)%C:JCH!CL*P+WP'X<U*[NK[4-`TV\O)7+&62/YG]`QYZ#C\*V=%CMX
MM%M(K2V-M;I&%C@./W0'&WCCCI0!?HHHH`****`"BBB@`HJM<:A9VB7#W%W!
M$MM'YLY>0#RTY^9O0<'D^AHL-1L=5M%NM.O;>\MF)`FMY5D0D=>5)%`&1X[_
M`.2>^)?^P5=?^BFKH*Y_QW_R3WQ+_P!@JZ_]%-704`%%%%`!1110!ASZ%J,U
MQ+*GBS68$=RRQ1Q695`3]T;H"<#IR2?4FO,/B9\'O$'BO4K&^L=?>_>./R)!
MJ7EQF-<D@KY4:@CDY^7/3D]![710!RNE^$M3T[2;*R'C+60+>!(<)#9[?E4#
MC=`3CCN2?4FMRQMI-,LI/MFK7-\%)D,]X(E*+@<?NT1<#!/(SR>>F+U%`'FC
M7^H6GBT>(D2Q@TW6(9+,7"W!D8&,,T$CQE5"XPRD;FY<`XQ5>U\6ZY+H=BTF
MK*MY/_9;RDP)N02L$N%48P-N"QR"5R<X&,>IT4`><6_B/5FT);B34[E[E6M@
M!%:H[2`73QR':J$_,FPG`XR"-H-8^KZA>:G;)-?7$US9F_L+NS%W%$LENPNO
MWF%2-2F(\Y#,S`9R1SGU^B@#E?%>87>[BEMC*MG)']EO(BT5TK$'RP5.0Y*]
M@V0?NG''&^+KW4-2T36X)Q.=/FTR=/[/N4B/DW"HAC"@1[]V[."SG)Y5>A'K
ME%`'`)>:W>3W<MKXFCM-JM%%I[V:$;=OR3))@MSD-N(=!R"O%;5C?Z]?>$HK
MBQAM'U7>R$7TQ\I@KD%@\:?,"!D$*`?05TM%`&#:QZY>:+J$'B--.MFEC9%;
M3I'E`0J02=ZCD>F#4'A"X:;39Q((2T956NH4*+-\HYP2>1T)R1P/3`Z6B@#B
M1*\5[I?VV<WNEV-T!%?M&`"3`X#.5`4@$XW@`98#@BLO3;2^BO8X9DVZE)+I
MCV[M"01;(@\Q-V.HQ.#Z>8,_>&?2J*`.*\1W"6/BN'5K>V>[O+*"-&@M\&5X
MI'*L`/8F-S_NUK^&U6*XU>.2:.2\:[$MQM/\1BC'Y#&T?[OKFMZB@`HHHH`*
MI:GJD&EVXDE6661B%C@A0O)*QXPJC]3T`Y)`!-07>KD:@=-T^)+F^">9(K2;
M4@7L7(!()[#&3@]@31I6B1:=)+=2R-<ZC<8,]U)RS?[*C^!!V4<=^222`10:
M=<W]S;7^K-M:+YXK%,&.)CT9C_&X'&>%&3@9P:V:**`"BBB@`HHHH`****`.
M?\0_\ASPG_V%9/\`TBNJZ"N?\0_\ASPG_P!A63_TBNJZ"@`KG_&7_(#MO^PK
MIO\`Z6PUT%<_XR_Y`=M_V%=-_P#2V&@#H****`.?\/?\ASQ9_P!A6/\`](K6
MN@KG_#W_`"'/%G_85C_](K6N@H`****`/+/'%OX#T_59IM3DU.\UFZ8%=/TV
M\F:9SC`Q&C@*..^*[[PU&D7AO3XX[:>U1855;>X;=)$!_"Q[L.AJGJJ^'=.G
M?4]52TTR:1E3^T)62+>5.Y07SSR,@-^5:VF31W&FV\T-X+V-TW)<C&)1V88X
M(/J./2@"W1110`4444`%%%%`'&:AIM[+XG\1/_9-\UE?:5!;I<VLEN&>1#*6
M"AW^]B50"PQE3GC&5FT36[^PM/MK^=.LR%99"B7$*K(KJQ,?R;L`JX3`(X&>
MA[*B@#@+ZSO;+X5^*HKV"X@<:;<_NYK@2C(@(9HSN;;&6R57C`_A7I6__P`(
M]JG_`$.6N?\`?FR_^1Z/'?\`R3WQ+_V"KK_T4U=!0!S_`/PCVJ?]#EKG_?FR
M_P#D>C_A'M4_Z'+7/^_-E_\`(]=!10!S_P#PCVJ?]#EKG_?FR_\`D>C_`(1[
M5/\`H<M<_P"_-E_\CUT%%`'/_P#"/:I_T.6N?]^;+_Y'H_X1[5/^ARUS_OS9
M?_(]=!10!S__``CVJ?\`0Y:Y_P!^;+_Y'H_X1[5/^ARUS_OS9?\`R/7044`<
M_P#\(]JG_0Y:Y_WYLO\`Y'H_X1[5/^ARUS_OS9?_`"/7044`<_\`\(]JG_0Y
M:Y_WYLO_`)'H_P"$>U3_`*'+7/\`OS9?_(]=!10!S_\`PCVJ?]#EKG_?FR_^
M1Z/^$>U3_H<M<_[\V7_R/7044`<__P`(]JG_`$.6N?\`?FR_^1Z/^$>U3_H<
MM<_[\V7_`,CUT%%`'/\`_"/:I_T.6N?]^;+_`.1Z/^$>U3_H<M<_[\V7_P`C
MUT%%`'/_`/"/:I_T.6N?]^;+_P"1Z/\`A'M4_P"ARUS_`+\V7_R/7055U#4K
M+2K4W-_=0VT`(7?*X4$G@`9ZD]AWH`R?^$>U3_H<M<_[\V7_`,CT?\(]JG_0
MY:Y_WYLO_D>K+:O>7=H9=)TN69F_U3WC?9HS[G(+@?\``.:;;Z5J,\C3:KJL
MC[NEK9_N8D_X$/WC'U)8#C[HH`Q=1!TN=;:X\>:VUXZ[DM(8+.29QTR$6V+8
MSWQCWKS3QS:_%63Q#I?]B7'B,VTL?R!WA4QN2<B;[.JQ@8QC=GZ]J]TLM-LM
M.5Q:6T4/F-ND95^9SC&6/4G`')JU0!R]CX2OK&TC@A\6:Q$`!N5(;+!/<Y^S
MY)]SR:L?\(]JG_0Y:Y_WYLO_`)'KH**`.?\`^$>U3_H<M<_[\V7_`,CT?\(]
MJG_0Y:Y_WYLO_D>N@HH`Y_\`X1[5/^ARUS_OS9?_`"/1_P`(]JG_`$.6N?\`
M?FR_^1ZZ"B@#G_\`A'M4_P"ARUS_`+\V7_R/1_PCVJ?]#EKG_?FR_P#D>N@H
MH`Y__A'M4_Z'+7/^_-E_\CT?\(]JG_0Y:Y_WYLO_`)'KH**`.+U#2KRQ\2>%
M9;C7]2U!#J<BB*ZCMU4'['<_,/+B0YXQUQR>.E=I7/\`B'_D.>$_^PK)_P"D
M5U704`%<_P",O^0';?\`85TW_P!+8:Z"N?\`&7_(#MO^PKIO_I;#0!T%%%%`
M'/\`A[_D.>+/^PK'_P"D5K705S_A[_D.>+/^PK'_`.D5K704`%%%%`'E?B;2
M'N?&+7A\#7_B:U5BKRW5_&(8>F1#"YP<<Y)QSG!KT?2%LTTFU2P@^SVJH%CA
MV;/+`XV[>V.F.V*XC7]:T^PUN]B/BG7=-BA_>3PPV:O"['!V1.T3?.<YVJ3W
MZ8..R\/R1R^'K"6*VN;9'@5EANL^<@(SA\\[O7WS0!I4444`%%%%`!1110`4
M444`<_X[_P"2>^)?^P5=?^BFKH*Y_P`=_P#)/?$O_8*NO_135T%`!1110`44
M44`%%%%`!114<T\-M'YD\L<29`W.P49/09-`$E%`.1D=**`"BF22QQ#,DB(/
M5F`JHNM:4P)74[(@=2)UX_6@"]161<>)=,MXO,#W%PO;[':2W!/_`'[5JB?Q
M#<.J&S\/:O<AB.3''`%![D2NI_3/M0!N45A&\\3S3((=&TZ"$C+/<7[%UZ\;
M$C(/;^.N6^(FB>/-8\(W=OI6I67FLR'[+:0-%)(F?F7S6DQZ'H.!C//(!Z*[
MK&C.[!549+$X`'K63_PD=E/:F?3$FU4$93["H=9/82$B/\V%<E\/O!NIQ>%+
M1/&TDM_?1NQBMIYS(D$?&U64':[`@G<<D9P#Q7H@````P!0!C6T>O7KF2]F@
MTZ'^""UQ+)[;I'&WIC@+U_B(J2T\.Z;:7YO_`"GGON<7-S(TLBYQD*6)V`X'
M"X'M6K10`4444`%%%%`!1110`4444`%%%%`!1110`4444`<_XA_Y#GA/_L*R
M?^D5U705S_B'_D.>$_\`L*R?^D5U704`%<_XR_Y`=M_V%=-_]+8:Z"N?\9?\
M@.V_["NF_P#I;#0!T%%%%`'/^'O^0YXL_P"PK'_Z16M=!7/^'O\`D.>+/^PK
M'_Z16M=!0`4444`<?JO@JXO]1GO5\8:[8QL^]8+>6-8XCC'RY0D=^_<UTNEV
MAL=,M[4W4ET8T"F>4@O+_M,1P2>IKF[I/$]OJDKZ1I&G-;&=G>0ZAY37/7[X
M\AB,'CAN@KH-$MY;71;2">".WE2,!HHFW(A]%.!D#L<#Z"@"_1110`4444`%
M%%%`'!ZI((/%OB+[\L4EAIYEB)+AD$THF"J?^F9&0/4'O52UL]2L967289UT
MM-2)TUK:;;!'&1%N5X]PWHS&95P&"\'``R/1Z*`.#U&^N+_X3>(FN&W%='G&
M2K!U;[.2R/N))8$D$\?05N?;/%__`$`M#_\`!S-_\BT>._\`DGOB7_L%77_H
MIJZ"@#G_`+9XO_Z`6A_^#F;_`.1:/MGB_P#Z`6A_^#F;_P"1:Z"B@#G_`+9X
MO_Z`6A_^#F;_`.1:/MGB_P#Z`6A_^#F;_P"1:Z"B@#G_`+9XO_Z`6A_^#F;_
M`.1:/MGB_P#Z`6A_^#F;_P"1:MWFOV]O>_8;:">_O<9:&U4-Y8]78D*GL&()
MP<`XJ.YTW4=6.R]O&L[/'S06,K+(Y_VIN"![*%/^U0!D7OB;Q'9[D71-%N;D
M'`MK;6)9)2?]T6W'U.`.Y%<9\0_!'COXD6FFK)!HVE0VY:3[,U_)*VY@!\Y$
M07(P>GJ>M>N6EG;6%LEM:01P0(,+'&H4#\*GH`\ST'PSX^T7P]I^D&]M'CLX
M_+W0ZF$WKG@?-9,P`'`PV<`<UHG0?$,DPFN=+M;EP,8E\4WFP_\`;,0!/TKN
MZ*`.*M=$U*RF>>V\%>%(IGP6E747WM@8&6^R9/%:HNO%R@`:%H0`Z`:S+_\`
M(M=!10!S_P!L\7_]`+0__!S-_P#(M'VSQ?\`]`+0_P#P<S?_`"+7044`<_\`
M;/%__0"T/_P<S?\`R+1]L\7_`/0"T/\`\',W_P`BUT%%`'/_`&SQ?_T`M#_\
M',W_`,BT?;/%_P#T`M#_`/!S-_\`(M=!10!S_P!L\7_]`+0__!S-_P#(M'VS
MQ?\`]`+0_P#P<S?_`"+7044`<_\`;/%__0"T/_P<S?\`R+1]L\7_`/0"T/\`
M\',W_P`BUT%%`'/_`&SQ?_T`M#_\',W_`,BT?;/%_P#T`M#_`/!S-_\`(M=!
M10!S_P!L\7_]`+0__!S-_P#(M'VSQ?\`]`+0_P#P<S?_`"+7044`<_\`;/%_
M_0"T/_P<S?\`R+1]L\7_`/0"T/\`\',W_P`BUT%%`'/_`&SQ?_T`M#_\',W_
M`,BT?;/%_P#T`M#_`/!S-_\`(M=!10!S_P!L\7_]`+0__!S-_P#(M'VSQ?\`
M]`+0_P#P<S?_`"+7044`<_\`;/%__0"T/_P<S?\`R+1]L\7_`/0"T/\`\',W
M_P`BUT%%`'%ZA/KTOB3PJNJ:;IMM!_:<A5[74'G8M]CN>"K0H`,9YSV''/':
M5S_B'_D.>$_^PK)_Z175=!0`5S_C+_D!VW_85TW_`-+8:Z"N?\9?\@.V_P"P
MKIO_`*6PT`=!1110!S_A[_D.>+/^PK'_`.D5K705S_A[_D.>+/\`L*Q_^D5K
M704`%%%%`'&:W%XNU+47M-"MK#2+99,MJTSB61\$YVQ+U_X$?7CH:ZZV#BVC
M6699I%&'D5=H8C@G';GM7FNLW'@U/$&H#6=*U.>[\XY>VM+MEQC^\AVG\,>G
M6N_T)K-]"LFT^.6.S,0,*2@AU7L"&Y!^O/K0!H4444`%%%%`!1110`4444`<
M_P"._P#DGOB7_L%77_HIJZ"O-OC=XDU#P_X#ECL;-9H]1WV=Q,P)6&-T()X[
MGH">*T_"6M>*O%GA;3M1E@LM*\^(,\KJTLDAR02L?RA`<`@EFX/2@#MJR[KQ
M%I5K>FQ-T)KT8S:VRF:50>A9$!*CW.!2QZ+$8@MY=WEXQ`#-+,5#?5$VK^E6
M[.QM-/MQ;V5M#;0CD1PH%7/T%`&1JNHZW+8M%I.BS?:)5*K+<3QQK%GC<<,2
M<=<8S7F/PV^&OC'2/%%U<^)[Z233FC8-&M^[BYDW#!8`\CK][UQCDU[;10!'
M!;PVT?EP0QQ)UVQJ%'Y"I***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`Y_Q#_P`ASPG_`-A63_TB
MNJZ"N?\`$/\`R'/"?_85D_\`2*ZKH*`"N?\`&7_(#MO^PKIO_I;#705S_C+_
M`)`=M_V%=-_]+8:`.@HHHH`Y_P`/?\ASQ9_V%8__`$BM:Z"N?\/?\ASQ9_V%
M8_\`TBM:Z"@`HHHH`S+*XC1[_-_"RI,V8R1F#U#<]^O;@CZU8TN\CU#38+N)
MHWCE7<KQ'*./[RGN#U!]#7G'BVP^'.J>)DG\1OI/]IQR^6^Z]2$H%^[YRF12
MPP!CCH0.E>AZ+<QWFBV=Q$8#$\0*&W_U97L5_P!G'3VH`OT444`%%%%`!111
M0!1UHW@T2]_L\.;SR6\@(5#%\<8W?+G/KQ7.CQ%=&VBFA%]E)!&\=U"AW/O*
M,C/&"@93MQ@\DXY.<=7=6MO>VLEM=P13V\J[9(I4#HX]"#P138[.UA@A@CMH
M4AAQY4:H`J8Z;1V_"@#C];U275_A9XGDN(8U9-,N-K1RB19%-OO5P<#!(89&
M.#T)&">F&L6B@`0WP`X`%A/_`/$5D^+[&TT_X;^)X;*U@MHFTR[<I#&$!8Q,
M2<#N3U-=/0!G_P!LVO\`SROO_`"?_P"(H_MFU_YY7W_@!/\`_$5H44`9_P#;
M-K_SROO_```G_P#B*/[9M?\`GE??^`$__P`16A10!G_VS:_\\K[_`,`)_P#X
MBC^V;7_GE??^`$__`,16A10!G_VS:_\`/*^_\`)__B*/[9M?^>5]_P"`$_\`
M\16A10!G_P!LVO\`SROO_`"?_P"(H_MFU_YY7W_@!/\`_$5H44`9_P#;-K_S
MROO_```G_P#B*/[9M?\`GE??^`$__P`16A10!G_VS:_\\K[_`,`)_P#XBC^V
M;7_GE??^`$__`,16A10!G_VS:_\`/*^_\`)__B*/[9M?^>5]_P"`$_\`\16A
M10!G_P!LVO\`SROO_`"?_P"(H_MFU_YY7W_@!/\`_$5H44`9_P#;-K_SROO_
M```G_P#B*/[9M?\`GE??^`$__P`16A10!G_VS:_\\K[_`,`)_P#XBC^V;7_G
ME??^`$__`,16A10!G_VS:_\`/*^_\`)__B*/[9M?^>5]_P"`$_\`\16A10!G
M_P!LVO\`SROO_`"?_P"(H_MFU_YY7W_@!/\`_$5H44`9_P#;-K_SROO_```G
M_P#B*/[9M?\`GE??^`$__P`16A10!G_VS:_\\K[_`,`)_P#XBC^V;7_GE??^
M`$__`,16A10!G_VS:_\`/*^_\`)__B*/[9M?^>5]_P"`$_\`\16A10!G_P!L
MVO\`SROO_`"?_P"(H_MFU_YY7W_@!/\`_$5H44`<KK&H0W7B#PHD:7*D:I(<
MRVTD8_X\[GNR@?A755S_`(A_Y#GA/_L*R?\`I%=5T%`!7/\`C+_D!VW_`&%=
M-_\`2V&N@KG_`!E_R`[;_L*Z;_Z6PT`=!1110!S_`(>_Y#GBS_L*Q_\`I%:U
MT%<_X>_Y#GBS_L*Q_P#I%:UT%`!1110!YYJ_Q+\(:#KMQIVJZG`EU%,5GB:Q
ME8QC!(PRH0Q/R]^_MBNVTB^L]3TFUOM/.;.XC$L)"E<H>0<'D9ZXKA=:\?#1
MM:O=.F\,^)M142D-/:60,:KC(\ME(+=LY/7-=EX:N&NO#6G7#K.K20*Q6X0+
M*,]G`Z-Z^^:`-6BBB@`HHHH`****`"BBB@#G_'?_`"3WQ+_V"KK_`-%-705S
M_CO_`))[XE_[!5U_Z*:N@H`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#G_`!#_
M`,ASPG_V%9/_`$BNJZ"N?\0_\ASPG_V%9/\`TBNJZ"@`KG_&7_(#MO\`L*Z;
M_P"EL-=!7/\`C+_D!VW_`&%=-_\`2V&@#H****`.?\/?\ASQ9_V%8_\`TBM:
MZ"N?\/?\ASQ9_P!A6/\`](K6N@H`****`"BBB@`HHHH`****`"BBB@#)U\N]
MK;6@>6-+NY2"22*1HW5#DG#*05)QMR#GYN*Y#2+G79[O3M3>[D:U@EN+%@\K
M8N1')/&I*9P7.V)R^.`K\@<'T"YMH;R!H9TW1D@X!(((.001R""`<BF0V-K;
MQPQPV\<:0(4B55P$!Z@#\*`./U?5K35OA3XAEM99Y5_L>>3S)QAI%D@9U?'8
M,&R!VZ8&,5L?\)WX0_Z&O0__``8P_P#Q5:NGZ79:5`8;&W2"+CY5S@````>@
M```'0`8%6Z`.?_X3OPA_T->A_P#@QA_^*H_X3OPA_P!#7H?_`(,8?_BJZ"B@
M#G_^$[\(?]#7H?\`X,8?_BJ/^$[\(?\`0UZ'_P"#&'_XJN@HH`Y__A._"'_0
MUZ'_`.#&'_XJC_A._"'_`$->A_\`@QA_^*KH**`.?_X3OPA_T->A_P#@QA_^
M*H_X3OPA_P!#7H?_`(,8?_BJZ"B@#G_^$[\(?]#7H?\`X,8?_BJ/^$[\(?\`
M0UZ'_P"#&'_XJN@HH`Y__A._"'_0UZ'_`.#&'_XJC_A._"'_`$->A_\`@QA_
M^*KH**`.?_X3OPA_T->A_P#@QA_^*H_X3OPA_P!#7H?_`(,8?_BJZ"B@#G_^
M$[\(?]#7H?\`X,8?_BJ/^$[\(?\`0UZ'_P"#&'_XJN@HH`Y__A._"'_0UZ'_
M`.#&'_XJC_A._"'_`$->A_\`@QA_^*KH**`.?_X3OPA_T->A_P#@QA_^*H_X
M3OPA_P!#7H?_`(,8?_BJZ"B@#G_^$[\(?]#7H?\`X,8?_BJ/^$[\(?\`0UZ'
M_P"#&'_XJN@HH`Y__A._"'_0UZ'_`.#&'_XJC_A._"'_`$->A_\`@QA_^*KH
M**`.?_X3OPA_T->A_P#@QA_^*H_X3OPA_P!#7H?_`(,8?_BJZ"B@#G_^$[\(
M?]#7H?\`X,8?_BJ/^$[\(?\`0UZ'_P"#&'_XJN@HH`Y__A._"'_0UZ'_`.#&
M'_XJC_A._"'_`$->A_\`@QA_^*KH**`.?_X3OPA_T->A_P#@QA_^*H_X3OPA
M_P!#7H?_`(,8?_BJZ"B@#G_^$[\(?]#7H?\`X,8?_BJ/^$[\(?\`0UZ'_P"#
M&'_XJN@HH`XO4/$N@ZSXD\*V^EZWIM].NIR.T=K=)*P7['<C)"DG&2!GW%=I
M110`5S_C+_D!VW_85TW_`-+8:Z"N?\9?\@.V_P"PKIO_`*6PT`=!1110!S_A
M[_D.>+/^PK'_`.D5K705S_A[_D.>+/\`L*Q_^D5K704`%%%%`!1110`4444`
M9^N231:#?S6UP\$T5N\B2(%)4JI(X8$=NXKG=8UR^\-6_P!LDFNM2A_LRXO)
M8L1*Z>4(SN4A5&,,V<Y[8]#N>)CIO_"/W2ZN+PV#+B<6BSE]O?\`U/S[?7'&
M,YXK'C\/^%9X6TQ8KZY35K7)F:XNI?,@&/E^T%CM4\?)N&0>AS0`YO%]REP;
M7^S4^T2A19I)<E#,3M&6S&`%RQY3?P.@)"TZ3Q;>17;6DFD1K-:)"^H#[7D0
MB5V13'A<R#Y2QR$^4]VRM&J^'?#6GZ8TM_:WLMO'$L("R75RZ`$,&15+,K95
M274;OE!)XID<7A.75M.:)IIKM(XUBN4DN)%93\\:S2@E6)+!E$A))((Y-`#5
M\6ZLMN[7&B6T4\1>.>%;YY#'(91'"/EA)*R;@P(&0O8GBG1>)]?NTD2U\,(M
MU!`)I8KN],0;+2*!&1$S-GRP1N5>&&<$$5K_`&+1]8AU.(*)EFE$=V4=E/F(
M%QA@05(PN"I&#SUHM?#UEI]TUY9FX%V;<6_F3W<TP90<@LK/\Q!/WC\V.,XH
M`DTG51JR//"(6M=J&.:*4L'+*&(P5&,9'/.?8C%1:I+=)K6C0PW<D,4TL@F1
M%0B0!"P!+*2.1V(ZU;TO3H=*L$M(%4*&=VVJ%!=V+,<#IEF)K*\0VVA7NJZ3
M;:K/>0W<C2"R-O=7%N"VT;AOB91NQT#')YQWH`+GQ2L?B8:-:V<ETT:QO=21
MY_<K(SJIX4@X*'=DK@=,GBJ&G>,;S5K6:.'2HXK[[4MO%&UZ&1@T7F[O,5&&
M0N>`&&X8#$?-5A-/\+Q^(+72DCE;4[:W+A5>9SY18G]\^2&RQ)`D)))R.>:=
M%X9\,Z?+#I<,4D$LNV:*)+J8-B(!000V5`4A>HROR\CB@"YX2OKK4O"NGWEZ
MS-<RQYD+!0<Y(Y"\9^G%;54M*TFPT/3H]/TRUCM;2+.R*,8`R23^I-3W=U!8
MVLMU<R".")=SN>@%`$U<[X[O[W2_`^L:CI]T]M=VML\T4BHK<@<9#`C'X5T5
M8_B:TT2_T62U\03I%ITAQ)ONVMU?@_*65ER.O&<&@#"T_7?$=MJ$]O>:>\]G
M-=.;6ZO'2!EMT1"Q944DMDOM&T9V\D9!J2Q\:7NJZ;%<6&ADS7>U[%;B=HH[
MB-HS)G>8SA@JX(P1DC#$<C<:VTF36+#?<[K^UA8V\1O'W%"-I8IN^?C^)@?K
M567PUH%K:+:OYMM%+<`P[;^:)DDP0%B8."@P6&Q"!@GCDT`4Y_$6H6<]SNL+
MBX)O8(%@1XE,&^%&*DGALL2.IY;J!R*6G?$%M4TPW2:1/&3!9W*JLZ$^5<.R
M!B2,`@HV0,\8[D@:=WX;\-W%^\$TLR74[1S>3'JD\3$HA5&55D&,*.PYQD\C
M-5K#P+X25'BL5N&2)$MG2+5;A@JQOO1"/,XVMG`[9(Z&@"1O%MX='N-4BTF$
MVC/&ED\M\L?G[I-GSY7Y#G!`&\D$`#=\M3>']>DUVZMKN,R)9WFE07B6[A<Q
MLY;/(&3QCOVJPW@_0V2>,6DBI-.+@JES*H20-NW(`W[LEN3MQN/7-2Z3X9TK
M1)(GT^&:,Q6RVD:M=2R*L2G*J%9B./7&?>@"IXNOKO3[?3)+6ZN(!+?Q0R^1
M$LC,C9R`&5O3MS6#)XEUO1M2MFO4FN;5XI&>.41Q,L?VI(XY"`N2^R0?+P/7
M!Z]+XBT_1-16RBUJY,.V<-;;;^2V)E[;2CJ6;TZU7U/P[X<\1:K/]K=Y[V.%
M898X=1EC*)N#@%$<;?F53G&3@4`5W\77::GJ=F=*B;[*@DADCN6<2*)?+;?M
MC.PK]XA=_'7!&*EL?%5QJ.J6T-KIHFL9`HEN8IF?RG:/?V385P5&=^<G[N.:
M+S1O"VG3227=R+.62-]SOJ<D3;6?>2#O&/G&01T.<8R:LVNA:#8ZS']D_<7L
M=NH%O'=R*&C7Y59H@VU\9QN92>G/%`%N`W'_``D5Y&UW*]NMM"Z0%4VJS-("
M00N[^`=2>]7Y4:2)D61HV(P'7&5]QD$?F*IP:-9V^L7&JQFY^UW$8CDWW<K1
M[1R`(RQ1<<]`.I]3F>_6W>PG2[F,-NR%7D68PE0>.'4@J?<$&@#SB'Q'XH6_
M\-2Q2W-Q8Z@;>.7[7!'"))F@FD95(0$*-B$G!]L]*Z.+QF\NI:7;+IT9CO;6
M.=BMVK2HSH[!1&!DC]V1N8J"2,9P<6FT7PW<66A6OGEH;5A-I>W49`S;5P&5
M@^9`%;')(P?0U"WA+POHT4=Y-YMM%;(J>;/J4P15!;;N+28.-[*"V2`=O3B@
M"I-XZF2&WCAT=[C4I#(S6,4C%U2/R]__`"SX<>:N%8*#_>`P3>\0WE]#K_AJ
MWM;^:V@O[J6&=%CC.5%O+(#\RD@[E7\JD?0/#<1AM3MAE><W$6R]>.5W("G#
M!PS+M"KMR5VJHQ@`"34M"T/6]4A^TR2M>V$>Z..WOY86@5PRAMD;C!(W@-C/
M!`/%`!X.N[N_\)Z?>7UR]S<S(6>1U52>3V4`?I47CN_O=+\#ZQJ.GW3VUW:V
MSS12*BMR!QD,",?A6GH^C66@Z;'I^G))':QYV)).\I7/8%R3CVSBJWB:TT2_
MT:2T\03I%I\IQ)ONVMU?V+*RY'MG%`',QZ[XGTZ34[FXM9+NS@6XFM8[LI;O
M)#&L)+-M0D$$R!1M&>,XX(N3>-+]-0N+>#1([F,*_D&&[,DC.I08D18SL'SD
M\%F`4_+GBM>^T?1=6G2SN9I9)DM'B$27\J.T+X#;@K@L#A?F.3[U4?PSX7TB
M,/,!:QM*SJ9K^15#MRQ7<^`21N..I&[KS0`RS\8-?ZS!86VG^<H53=RQ.["`
MMN"X^3!&5.=Q0CT)R!F^,=7U?3I]?>QU2:W6ST)KV&-8HF42@N,_,A)'RCC-
M;%KI/AA=7MI+:6)M1MXO+7;?.TCKG>/,&_,O)W@ONP3D<G-2:MX+T/6[R>[O
MX;MY;B#[-,([^>)'BY^0HCA2.3QCO0`JR7J>*[&T.H3O;-I\DKQLD>'=7C4$
MD)D<.>A`Z5O5D1>&=-AU.TU%/MINK6'[/$[W\[#9W#*7(?/!)8$D@'J!6O0!
MB^([F]M4L6L1>R.]P4>&S\CS)%\MSP9L*,%0>H[]:R]+U6_O6TAI+NXC9KVY
MM[FWD2+=A%D*JY4$;AM7)0X/O6OKVGZ5>002ZM=36T<#EHY(]0EM,,01]Y'7
M/&1SZGUK,30?"M\;&TMKR0R11O<VZVNL3I(RL<-*2D@9\EL%SG[V,\T`2>+/
M$$ND0HUHTA-N1<WACMVEVP*1N4[0=I89P3V5L>HL:O/?7=O,VEWYMECMPZ3H
MB.KN_P!W[P/``R0,9W#FB#PUHFCVEVJO<Q0W:>3.\VHSL6#,?XG<D,6<_,"#
MD]:E@\+:3:Z#'HEO'<Q6$9&U$O9@P`Z#>'WX&`,9Q@`=*`,$Z[J=[IFJO)/<
M:7JFGV:&>S58V5)"7^=2R'<C!>#G&,]""!L->3Z5KP@N=1EN;1[&6Y<2QIOB
M,;1@8V*,A@YX.>5XJ]J>A:?J\,\5Y%*5N$2.4PSR0LRJ6*@LC`XRS<9[UG-X
M(T)X9(VAO"TCH\D_]HW'G.4R4#2^9O*@DD*6P#@XR!0!#X.UN\U'^T[#4VD-
M_8W!.9(#"SP2?-&VT@<#YDSCDQFK'C+_`)`=M_V%=-_]+8:TDT>RCUN76%27
M[;+`+=V,\A4H#D#86VCG/.,\GGDUF^,O^0';?]A73?\`TMAH`Z"BBB@#G_#W
M_(<\6?\`85C_`/2*UKH*Y_P]_P`ASQ9_V%8__2*UKH*`"BBB@`HHHH`****`
M,SQ"+AO#U_':6<MY<20-&D,3(K,6&WJ[*N!G)R>@XR>*YX>%=35;RUL[TVMA
M=J9X4E:3S+*5G1Y$!AE1BA()`5QM.1RI`KM**`.%;PE>VND7UEJ$]]K,-\%A
M,=E=7$3Q#DERUQ=N-O3(7D]"&'%)HOAW7[2_:*XG'DRFTGOYI(D(GN(DC!:$
MJ^5!\M00R#D9''![NB@#,THW+7FJM<6,]JC7>8FE:,^:HC1=PVL<`E3PV#C'
M`K3HHH`*YKQ;I5QK4<5A#;S`RQ2>7?)Y96SF5D>)V5F#'YD'W0>G.!72UA>(
M-5U+2)(;JUMH[NRCC>2ZMT1O/*KC+1D'!(!^YC)[$'@@'*ZCI&O7&IR[=%N)
M$DAA:YE^TPI'.1,LLD0._=C;F,;E`.W!P#FC4?#^NR:7;6.D:?+8HR7)0>9"
MHM(W=&\GAB`2H=1M#*NX=A706?B9H(YI]2E>[@EF86C:9I-S+B,`$%RGF<D,
M.?ESS@>E]=8DFU#3Q#%ML;J*1RT\4D4RLN."C@%1SW&?:@#D-'\*264VGF;0
M[ZXL5<O%;7$EK&]A/O!\T)"5C"D`<IEA\W!WM6=!X0UG2I+U+/04,*6VJVL(
M@EB3>EQ,LD(0%AA5&00VW'.,\9W].\<W&L>:]M$MJ+A(&TY;FV9O,CED*+.2
M'&Y>_EX5AQS\P-=-HFH3:A;3BZ2-;FUN'MY3%D([+CYE!Y`((.,G'3)ZT`<Y
MX:\.ZC9>+M1U74GOFGF,NV3?`+=XF?=&A"CS"Z`!?F)`^;:?F(K=\4SQP:!/
MYEO<W"R,J>7;VLD[-\P)^5%)Q@'MBMFB@#AH=(\00WD6FP7$D4%K;2+9W\)5
M&,1D3;$XDBD`954#./F`SP<BK5Y#J6F:3;G4[B_U*3^T;=@4B%PZ(&!/$,"8
M`P3DJ?KT%=?10!QWB*VU*XO;Z+P[<W\&HR6TB2^:CBUR86$;JSC:'#[/]7GO
MN%3^![8VFG2P007]MI\8BC@@OE=7C94`<*&_@R!C'RYW8XQ7544`%%%%`'.>
M+H;.\BTZPU"RN+NTN;HQS)%:R3*%,;KEMBG:,L.3C'7M6=9:5XB$%Y8K?74$
M]M+%%'?!X@UW$J'#$O%(,\@-\H.Y2<X//:44`<^T%]#I=CI]])<WUQ/=JKS,
M%<*BGS#O,<:*%PFW[HR6`YS5.VM-5C^(8NI[6(V[V,JM<([;1^\7:OW<;MH'
M&?4^U=910`5%<W"6EM+<2+*R1J6811-(Q`]%4$L?8`FI:*`.$T71-3T^*&#3
MYKB+3KNU:XMPZ^7+8S,%+)\Z-A6)+`,IVD,,8(`B\1:9K]OX-\1+>7^H:GY^
MFS6\-LBQSLTKC:N%AMD;OC.2`"21W'H%%`'GVHZ;=7VH220V,[_VK%II@EDB
M=/)$$QD<2`C,9`)89`R>.M:.@66JV_CS6+B^MEV3V%J&N%=BCN))R0N4`X#`
M8SD#;US7844`%8WBF>.#0)_,M[FX61E3R[>UDG9OF!/RHI.,`]L5LT4`<5%I
M'B*$)IEM>2006J'[+>PLB,T!/RQ.)(I`&4!1G&6P#D<BJOB#3]<M]'M_.O;^
M[NQ=$I.L2W!13&RF,K##&0KY*[L?*2&SQ7?T4`>?>'K:\M_%L:_8;RQMG59'
MTYH':"W<6ZJ)(YP-G_3,QY_VL#G/H-%%`!1110!SOBB&&6[T$SIJ+(E_DM8B
M?Y,Q2`%S%T7<5!+<8)SQFN`O)?$4US83Z=%K,EVFF7$3W=UI\RN4-[$3GA/G
M,4;D*"IZ8QE:])\0ZW)H%HEZUB]S:*W^D&)LR1)@DN$Q\P`!)&0<#@$\56_X
M3#2;:6<ZIJ6EV%OY@6UEFOE7[0NQ'+`,%[.O0GK0!PTB:R+:**Y.NZI;*D<N
MG^3:7,!>43DR),LKEN$"[3,VT\G.<&O60<J"002.A[5RZ^-K*YUZ#3K!K2[A
MGBCDAN8[H$3YD9'$6`0YCVY;D8!%6?#WB637;N[A.GO;K;EE9BY)5P[+L8%1
MAL*&P">&!S@C(!T%%%%`!7/^,O\`D!VW_85TW_TMAKH*Y_QE_P`@.V_["NF_
M^EL-`'04444`<_X>_P"0YXL_["L?_I%:UT%<_P"'O^0YXL_["L?_`*16M=!0
M`4444`%%%%`!1110`4444`%%%%`!1110`53N;%Y]1M+M;VXA%N'#0QA-DP;'
M#[E+<8XVE??-7**`,%?!?ATVJ6USI%G>PQR/)"MY"L_D[R"53<#M7@``=``.
M@%6$\/VL%[82VCM:6ME&\<=C;QQI`0_7(V9'X$"M:B@#G;;P9I]G;O#;W%VF
M$6*U;<K&S16#*L65(P&`/S!CT!R``-?3M.@TRU,,)=B[M+))(<M(['+,?<GT
MP!T``JW10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`4[RVNI[JS>&X@CABD+31R0ES("I4!2&`7J>2&JCI_
MABRTZ"6WA:>.W:8R110S/$(E*J-@VL,@;>/0<"MJB@#F;SPF]QKMI?1ZA_HT
M'EMY-S&T\B,C,VZ*4OF,L&*MD-E>.*DT'PQ)HVJ7E[)J+W)N!M`\O86&XL&D
M.3O<9VAL#Y0!CO7144`%%%%`!7/^,O\`D!VW_85TW_TMAKH*Y_QE_P`@.V_[
M"NF_^EL-`'04444`<_X>_P"0YXL_["L?_I%:UT%<_P"'O^0YXL_["L?_`*16
MM=!0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%<_P",O^0';?\`85TW_P!+8:Z"N?\`&7_(#MO^PKIO
M_I;#0!T%%%%`'-G1=>M=6U2[TO6--A@U"X6X:*ZTUYF1A#'%@,LZ`C$0/3N:
MD^Q^+_\`H.Z'_P"":;_Y*HHH`/L?B_\`Z#NA_P#@FF_^2J/L?B__`*#NA_\`
M@FF_^2J**`#['XO_`.@[H?\`X)IO_DJC['XO_P"@[H?_`()IO_DJBB@`^Q^+
M_P#H.Z'_`.":;_Y*H^Q^+_\`H.Z'_P"":;_Y*HHH`/L?B_\`Z#NA_P#@FF_^
M2J/L?B__`*#NA_\`@FF_^2J**`#['XO_`.@[H?\`X)IO_DJC['XO_P"@[H?_
M`()IO_DJBB@`^Q^+_P#H.Z'_`.":;_Y*H^Q^+_\`H.Z'_P"":;_Y*HHH`/L?
MB_\`Z#NA_P#@FF_^2J/L?B__`*#NA_\`@FF_^2J**`#['XO_`.@[H?\`X)IO
M_DJC['XO_P"@[H?_`()IO_DJBB@`^Q^+_P#H.Z'_`.":;_Y*H^Q^+_\`H.Z'
M_P"":;_Y*HHH`/L?B_\`Z#NA_P#@FF_^2J/L?B__`*#NA_\`@FF_^2J**`#[
M'XO_`.@[H?\`X)IO_DJC['XO_P"@[H?_`()IO_DJBB@`^Q^+_P#H.Z'_`.":
M;_Y*H^Q^+_\`H.Z'_P"":;_Y*HHH`/L?B_\`Z#NA_P#@FF_^2J/L?B__`*#N
MA_\`@FF_^2J**`#['XO_`.@[H?\`X)IO_DJC['XO_P"@[H?_`()IO_DJBB@`
M^Q^+_P#H.Z'_`.":;_Y*H^Q^+_\`H.Z'_P"":;_Y*HHH`/L?B_\`Z#NA_P#@
MFF_^2J/L?B__`*#NA_\`@FF_^2J**`#['XO_`.@[H?\`X)IO_DJC['XO_P"@
M[H?_`()IO_DJBB@`^Q^+_P#H.Z'_`.":;_Y*H^Q^+_\`H.Z'_P"":;_Y*HHH
M`/L?B_\`Z#NA_P#@FF_^2J/L?B__`*#NA_\`@FF_^2J**`#['XO_`.@[H?\`
MX)IO_DJC['XO_P"@[H?_`()IO_DJBB@`^Q^+_P#H.Z'_`.":;_Y*H^Q^+_\`
MH.Z'_P"":;_Y*HHH`/L?B_\`Z#NA_P#@FF_^2J/L?B__`*#NA_\`@FF_^2J*
M*`#['XO_`.@[H?\`X)IO_DJC['XO_P"@[H?_`()IO_DJBB@`^Q^+_P#H.Z'_
M`.":;_Y*H^Q^+_\`H.Z'_P"":;_Y*HHH`/L?B_\`Z#NA_P#@FF_^2J/L?B__
M`*#NA_\`@FF_^2J**`#['XO_`.@[H?\`X)IO_DJJ]WH?B34UMX+_`%O2FM8[
?NWN76#2I(W;RI4E"AC<,!DH!G!ZT44`=11110!__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>graph12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 graph12.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`'!`SL#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W:XO4MY`C
M#DC-0_VI%Z?S_P`*K:M_Q]+_`+@_F:H4`;']J1>G\_\`"C^U(O3^?^%8]%`&
MQ_:D7I_/_"C^U(O3^?\`A6/10!L?VI%Z?S_PH_M2+T_G_A6/10!L?VI%Z?S_
M`,*/[4B]/Y_X5CT4`;']J1>G\_\`"C^U(O3^?^%8]%`&Q_:D7I_/_"C^U(O3
M^?\`A6/10!L?VI%Z?S_PH_M2+T_G_A6/10!L?VI%Z?S_`,*/[4B]/Y_X5CT4
M`;']J1>G\_\`"C^U(O3^?^%8]%`&Q_:D7I_/_"C^U(O3^?\`A6/10!L?VI%Z
M?S_PH_M2+T_G_A6/10!L?VI%Z?S_`,*/[4B]/Y_X5CT4`;']J1>G\_\`"C^U
M(O3^?^%>,>);VPOO%UR+0RVFI:?&S1W31N?M$HB?;$DA^2-`3\W(W-@8.,U3
MM(;&/PYK,UM?W4<,\4,,$`E>&:>8(5::0##_`#/)ENF1'DY6CI<'O8]S_M2+
MT_G_`(4?VI%Z?S_PKQB\6TN?&,44=ZJ?9KBU-K.7_=06L:;I-K_=#.WR%<Y(
MP<8%>FHZ21K)&RLC`%64Y!![BF!M?VI%Z?S_`,*/[4B]/Y_X5CT4@-C^U(O3
M^?\`A1_:D7I_/_"O$M6O-.U#7=8O+"1K&\M(9E29$<27C&,(2)"-I10?D122
M6&0!W=<1:9-X:O(;"9H+2^U&-+:SCE:'9$1'&TDBC#`?*\A#8!SE@2:`/:_[
M4B]/Y_X4?VI%Z?S_`,*\VW:=)X_743JD9@MK(A0]R/+#N0H"#.T$!&)QS^\Y
M.,"NP5@RAE(((R".]`&S_:D7I_/_``H_M2+T_G_A6/2,P52S$``9)/:@#9_M
M2+T_G_A1_:D7I_/_``KPC4M0L;V[U2_TYI+(M*L$ZI!*LUQ`TZ&64N1\_P`J
MD*BY*J3TS@:)M]/OM&T^WBN5L[6?5C*MFDHB2&WW;_G0$8RL>-IX!EZ9Q@6H
M/0]F_M2+T_G_`(4?VI%Z?S_PKR/1[_0[[Q[=ZE'*]@]OYL>9T=?MF=H+F5OE
MV#&$0'U.!7HE'1`][&Q_:D7I_/\`PH_M2+T_G_A6/3)94@A>61@L:*69CV`Y
M)H`V_P"U(O3^?^%']J1>G\_\*\"2YTBZ:;4HC>65G/=1)>V'D2^:\"M(Y:0D
M$S,[;0VW.U"`36WI]A9K9^&8+[5`_DSM<26PNAY,`&^1%(!P2K-&HSD83@#F
MFEI=@]#V+^U(O3^?^%']J1>G\_\`"O+/#-WI-UXNO]2M!]D2:WCCV2CR7DF9
MV+A@3^\887##*@-@$\UW=(#8_M2+T_G_`(4?VI%Z?S_PK'JO?W$5II]Q<3[O
M*BC9GV9W$`=L<Y],4`=!_:D7I_/_``H_M2+T_G_A7@EE-HJV"7Q@E33[BY!N
M-',4AQLB?RPZL,R%F92SG*Y"@DX).[;B&TU3PZLM\+R73]->21FO`(O-5%14
M'.S<2SG)R?E'.*8'KW]J1>G\_P#"C^U(O3^?^%>5>!+ZYN=3U>[U@B*_N)(X
MU$EQ$^X`,VV,(Q^5=^!Z^I.ZN]I`;']J1>G\_P#"C^U(O3^?^%8]9NOWUKIV
MA7MS>+*\"Q,&CA)WR9&-JXYR>@QTZ\4GH"5SJO[4B]/Y_P"%']J1>G\_\*\&
M\[2_[#AQ;1M:W1N)1I:0L(X;@QQI$A5E'RCYV,A`7=D^E;EXT%KK+WZ:M)<2
M6.CE(V682!IF`4&-"ZJ6`C9B,Y/F<GI3>@+4]=_M2+T_G_A1_:D7I_/_``KR
M_P"'/V"SL+FTM[B"13,!!*UJEK-<*(UR6C`!.#N&6&3@GGJ>XH`V/[4B]/Y_
MX4?VI%Z?S_PK'K#\8:A9Z;X9NY;ZVGNH6`C^SP%@\I)^[E><>OL#UZ4,:U9V
MG]J1>G\_\*/[4B]/Y_X5X#.EJ-,@L(9$O+>Y@N#:KY)BBM;J64#=L<`Q+$N2
MA;&><<D5M^($AW^(KZRU:22]-@L$$QN-S+O<M((E!`X4)C;R2.230)GL?]J1
M>G\_\*/[4B]/Y_X5YWX">U@\/QVD<\!?S961541/(FX[7:(?<)&"1@=<D`DU
MUE-B1L?VI%Z?S_PH_M2+T_G_`(5CUS7CJ_L;#PZWVZRDODEE1%MDWX<YSEPG
M)08R1@Y'&#G%(9WO]J1>G\_\*/[4B]/Y_P"%>'6T&GQ76FV2WS7#1BU>SNI%
M*);J)6EF(R,1$@",*?FV[1TS6O=3:7:0^)KIO*U>1Q'%%;WDHF%PP&\8!X"!
MI`/E``V$]0338(]:_M2+T_G_`(4?VI%Z?S_PKC?"]IIFEZ+;Z;I\]K(84!E^
MSE?F<_>;"],G/TZ5M4@-C^U(O3^?^%']J1>G\_\`"L>N3\?W]A9Z/;17UB+W
MS[A5CB='>-2`<R2(@)=5S]W!R<?4`'HG]J1>G\_\*/[4B]/Y_P"%>,6AL$\0
M:?;?:_.DM&MQ!?S<!+:.'YOG/"L\A*E,Y]1@5%<_8[31M29[Q;@7VK+YAN`U
MVPABX!>('=(K-&?E&!B4$844,#VS^U(O3^?^%']J1>G\_P#"N*\(/$/"^G0)
M)&9HK:/S8E=6,3$9*X!.,'(`[8QVK=H!&Q_:D7I_/_"C^U(O3^?^%8]</\0]
M0TQ%LM.O;4S2S[RLKPR316PQCS&C0'<W]T$=<G(H!'J']J1>G\_\*/[4B]/Y
M_P"%>,6;PS^*PDMT(I[>XD_XF;2+E;80>7$B.PPQ9F,A'(#*<CI6=JRV-IH=
ML8#]MDEO;JZ>UN0UREPQ!2)9N2P.W806^4%3DCBB^EQVUL>\?VI%Z?S_`,*/
M[4B]/Y_X5R?APA?#]A;&[BNI[>VBBFDCD#Y<*`22#ZBM2F]Q(V/[4B]/Y_X4
M?VI%Z?S_`,*QZX#QW-I5YK.G:1>)-%/(N?MZK(RV@+#[H4%5D.,!SC:,G/8I
M;V`]7_M2+T_G_A1_:D7I_/\`PKP1+N(W]]J6HQS3O`MZ+P1.1+=*\@6"&-E(
M+*$4-E3A<^I-(T6FMI44$<@>.]BN'MK81.D-G=2%$7Y64;!&`S!FQD[F')%"
MU!Z'OG]J1>G\_P#"C^U(O3^?^%8%K<07$`:WN([A5^4NCAN<=R.]3T`;']J1
M>G\_\*/[4B]/Y_X5CUP?B6[TFX\<:=8W$1AN(1'*=0='81;7W")"`50MCYF)
M'RG'.>#J'0]4_M2+T_G_`(4?VI%Z?S_PKP6*[L(K6\U.YM9+G%D(+ZU7<CW]
MT\H8DX&YT3&-V""K$#(X.PB:;]C\,6\.H;XOMIGD57:"&W4,\V#$<8`8*BAQ
MP,8&:.@,]B_M2+T_G_A1_:D7I_/_``K$AFBN(EEAE26-NCHP8'\13Z`-C^U(
MO3^?^%']J1>G\_\`"L>O/-?U#3[CQIL@2.+4+*/>EW*CGS)`CE85DP4C7)^8
MDC)(7!/1-V&E<];_`+4B]/Y_X4?VI%Z?S_PKP6#4=+M=(FFGTY[E+@6D!AD1
M_P!_<(&:6XG1`69=SX.5.[8.",$:*S:$^I>'].$_S6D4,O\`:4EK+@8;>(H\
MC;#GHQ.,+A3G^%B9[3_:D7I_/_"C^U(O3^?^%8D<L<T:R1.KHPRK*<@_0T^@
M#<AOXYI5C4<G_/I5NL+3_P#C^C_'^1K=H`I:E]F@M)KVXC+K!$7."<D`$X'O
M6?!=:<UA'<W,#02,[QM""TC*Z$AA\N20,'G'3GBK^J:>=3@BMS,8X/-5YE`.
MYU7D*&!!7Y@ISSP".^1E-X=O+:]EN=+U*.!F?<HNH'N-NX`29)D!.=D9'/!!
MZ@X`@++W>AQR,C3("KB,G+;=Q8)M#="=S*"`>,C-1MJ.@+(R>>I96*-MWMM;
M>R8..A+JR@=R,#)JO+X7N&MKNRBU)$LY)_M<"&WR\=QYHFW,V[YTWC.T!3@D
M;NF':9X7DL89UFOQ/+-<+<.X@V#(N7G(`W'CY]O7MGFEK<NT+;ZW_`O1OI$L
M>]'4CY<@E@068H`0>0=P(P>X-065[I%[%"R*?,EA$OEC<QY`)`(X)&X9`Z9Y
MJ,^'9Q>&2/4%6!Y%EEC,&68K<-,H#;N!\[`\'/!R,$&KIGA.\T_6+2]?54N(
M[6(PQH]NQ<1L@#+N,A"_,B$;5`P""&.&`KN]Q.R6A>LKW1[V*U=%=&N8UD5)
M%=2NX9`8]`3V!Z]LTZSN-+O[Z6VMD+^7$LN_Y@&5BP!&>H^4X8<'L:HVGA.Y
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M'!!Z52_X1>::*:TN]1$E@PE,<<4)CD1Y`RDE]Q!`#'`VCDYR>E3Z/H%QI\ZW
M-Y>QW-S\^]XXG4-N"`??D=N`G=CU[4Q:":MJ&C:/:W<UPKL;6%Y62,,2VU"Y
M4'INVC.W.<<].:<]WI-M#:->[;>6YB,JQDN3@`%CT!PNX9)`QWQ5?6?"\VK?
M;X!?QPV=W'(3']G+.LS1&+=OW@%`I!V[<Y'WL<4_5]'U*[UK3+BQNHK>."UG
M@FD>+S"0[1<*N1@X1L'D`@9!'%1J6E%VU[_\`DNK_1;6"XDR93!"TQ6+<VY5
M&2%(X)&1P.F1FI7N-(BB624A0Q8#&\D!3ABPQE0.,D\#/)K(?P5<F\>2/54\
MA;>6U@22W:1XHI$"E=QDQPRH1M5>%(.XD,+%_P"%KF\@AV:DD=P&F$S^3)LD
M25@SJ%652#D#!)8=<@]J>Y&EB34=7T/3D8NLLKB9(2D2.QW-(L?'8X+KG'(S
M[C.C:C3+TN+<%]G4X<`CGD$\,.#R,BL_4/"WVRS2&*\$+13--&QBW`-YR2KD
M;AD`H`>1D'M5K1=%FTJYO7:ZB>"=RT4$,+1)'EF8D@NP+DMDE0H/7&:2W&^6
MVFY?_L^U_P">7_CQ_P`:/[/M?^>7_CQ_QJS13)*W]GVO_/+_`,>/^-']GVO_
M`#R_\>/^-6:*`*W]GVO_`#R_\>/^-']GVO\`SR_\>/\`C5FB@"M_9]K_`,\O
M_'C_`(T?V?:_\\O_`!X_XU9HH`K?V?:_\\O_`!X_XT?V?:_\\O\`QX_XU9HH
M`K?V?:_\\O\`QX_XT?V?:_\`/+_QX_XU9HH`K?V?:_\`/+_QX_XT?V?:_P#/
M+_QX_P"-6:*`*W]GVO\`SR_\>/\`C1_9]K_SR_\`'C_C5FB@"M_9]K_SR_\`
M'C_C1_9]K_SR_P#'C_C5FB@"M_9]K_SR_P#'C_C1_9]K_P`\O_'C_C5FB@"M
M_9]K_P`\O_'C_C1_9]K_`,\O_'C_`(U9HH`K?V?:_P#/+_QX_P"-']GVO_/+
M_P`>/^-6:*`*W]GVO_/+_P`>/^-']GVO_/+_`,>/^-6:*`*W]GVO_/+_`,>/
M^-']GVO_`#R_\>/^-6:*`*W]GVO_`#R_\>/^-']GVO\`SR_\>/\`C5FB@"M_
M9]K_`,\O_'C_`(T?V?:_\\O_`!X_XU9HH`K?V?:_\\O_`!X_XT?V?:_\\O\`
MQX_XU9HH`K?V?:_\\O\`QX_XT?V?:_\`/+_QX_XU9HH`K?V?:_\`/+_QX_XT
M?V?:_P#/+_QX_P"-6:*`*W]GVO\`SR_\>/\`C1_9]K_SR_\`'C_C5FB@"M_9
M]K_SR_\`'C_C1_9]K_SR_P#'C_C5FB@"M_9]K_SR_P#'C_C45Q;6%K;R3S)M
MC098[C5ZJU]I]MJ4*172NR)(LBA)&0AE.0<J0>#S]0/2@#)%U:/HMA?Q:?(T
MM\(O)MR^&#.,X8YP`HR3UX4X!.`:]OJ]A="-X;,F)66.X)E(,3M*T.T#^+#H
MP/(X&1FK*Z%<PZ99V%M>*ALHT:WN)4:0B901E@7Y4@D;<@@'AAQB&#PH;5X4
M@NXQ;NXEO4:`EIY!*TP9&W80&1V)!#<$`8QFJBU;46I+8W=C=WR6KVOE&>%K
MBU/F%O.B5@I;V^\AQZ..^0-;^S[7_GE_X\?\:S=-T!K/44NY[B.86T+VUDB1
M%##"Q4E6.X[S\B#.!PO3DD[=)VTL/J5O[/M?^>7_`(\?\:HZN]CH^E7-_+:3
MS+!&S^7`K.S8!...G3J<`=R*UZKZA:_;M-NK/?L\^%XM^,[=P(SCOUH6^H&7
M=216M]%$VG,;:21(O/\`-P=[9QA>I`P,GMGH0"03S6D%^83:9MT=(I9_-(V.
MXRHV]^J\_P"V.O."?2-2E\20ZB-0LVLX0`EM+:.SQ\$,4<2A0QR1DH2`2.A-
M*VC7-Q>1RSW,`MI#'-=6ZP',DR``,K[_`)5^5?EP?NCGKE`45U:T;R(_L&+F
MZ\HVD1G.)%D#L,G^$A8W)'.,<$YK6TY++4=/ANTMI(A(.8Y&^9&!P5."1D$$
M'!(XZUEKX5N%2*7[?`;ZS9!83&U.R%$5T4.GF?.VV5P2"H.1@#%;VGV2:?8Q
MVR.[A<DN^,LQ)+$XXY))XINW0`_L^U_YY?\`CQ_QJCJ2)90A[?3C<$!F?,WE
MJJJ,G)/<]!]>2!DUKUC>(=)O]7MX8+.^M;>(,3/%<VKS),,<*0LB''J"2#T(
MQ28%6UU+3;W48K:WAC<.0K#S\2H3'YF3'UVX(&<YR<8QS3;G5=/LVN)KFS:+
M3X7DC:Z,F<M'&7<A1SM`5AGKN4\8P39_L6\COS<QW=N8\FX\K[,VXW/E^7NW
M>9]S'\&,Y_CQQ4%QX6:_\ZVOKJ.32YQ([VJPD.)9$9'(DW?<(=SMVYR<[L#%
M/0$0_P!J1>:;7^Q9OMX^;[/YPQY>S?OW9Z?P8QG?Q]WYJV+&/3M1L+>^M1YE
MO<1++$^6&Y6&0?R-9O\`PC=]N^V_VM'_`&MCRS<?9?W?E=-GE[LYQSG=][G&
MWY*VM.L+?2],M=/M5*V]K"D,2DY(50`.>_`INUA:A_9]K_SR_P#'C_C69K=S
MI^B6:W$MK),SR)&L41.X[F`)Z]`#DGT'K@5N5CZWX=M=;0M(\L5QL$:RI*XV
MKN#$8#`<D#\AZ"H=[:#&"XT]O$7]C+;.91;&X:3<=@PRC;U^]\P/T(]:JRZG
M90><TFGR,@$OD".7+S-&XC*X)`!+,`O.#WVU,WAM;35WU;3I76Y\F5!'/+)(
MC/(RMN.7X'RXP/;'0"D;PT\TUQYUXI@^<V:QP[7@9W$C,S%B'^=01\JX'!W=
M:I6LKDZW96;5[-1<)]@S<6?FF\B$Q_=+&J,<'^(E9$('&<\D$5OBPM"`1'P?
M]H_XUA-X4N"DLGV^`7EZSC4)?LK;9D=41A&OF?NSMB0`DL!@Y#9KI@`H``P!
MP!3=N@]2O_9]K_SR_P#'C_C65>75A:ZG'8B*)Y3Y9=#<;7P[%054_>Q@D],`
M<9/%;U9%]H\MWJ23QW,<=N_E_:HVA+/)Y;;X]CAALY)SD-D=-IYJ4,JV5Y!<
M:O\`V=<Z7-:RO"\\.^3=NC5PA+`'Y2<J0#U!]00&#4+7;DV&/."FT_?']\&<
M("?[O+*3UX8=3D!^E:3KEA>W-Q=ZI87IG9=S"P>*7:'X4MYK#:JE@`%')SU)
MR@\-W'E.IOH"8`%TX_9CBW575P'&_P#><H@.-G`[$YIZ:!W&'4;3R]XL"1"&
M-W^^/[D+(4)'][E7/;A3WP#N?V?:_P#/+_QX_P"-8Q\-S^4B+?0CSU9=1/V8
M_P"D!G9R$^?]WR[@9W\'')&:Z*AVZ`5O[/M?^>7_`(\?\:S+UH[/4;6W-G`T
M=PQ`;[2P<`*2S;=N,#USW'K6Y5&32XIM7-_,0Y%L;9$*_<#-E^?]K"?]\"D!
MGZ1=V&KK))%%$8E1)5DCN/,!5LX#8^ZP`Y'(Y&"><5%U:T;R(_L&+FZ\HVD1
MG.)%D#L,G^$A8W)'.,<$YJ_INCW6G[O,N8)QM2WC"P&/;;IG:K?.=S_,<L,`
M]E%4E\*W"I%+]O@-]9L@L)C:G9"B*Z*'3S/G;;*X)!4'(P!BGH"$MM6L[O9)
M%IDRP*T4<[R2`-%)(VWR\`G)4XW<X`(P6YQO_P!GVO\`SR_\>/\`C6-#X8>U
MFC2WOQ]C>1)[N*6'=)-*K!@ZN"`F6`W#:P(&!MZUT5#L!6_L^U_YY?\`CQ_Q
MK*^U67]N_P!F?95SNV9\[Y\[-^[9UV8XW?WN,=ZWJP;CPXUUJLTLMVOV"5FF
M:!$9)O-,7DDB97&%V=@N<\[L<4@([75-(N-/U2_>%X;73I9$DD<GYE10Q<8_
MA(.1ZCGO4']J1>:;7^Q9OMX^;[/YPQY>S?OW9Z?P8QG?Q]WYJFB\*Q06NHZ>
M',NGZG(_VF.1G++&T0CVJ2QYXZ^A]A1_PC=]N^V_VM'_`&MCRS<?9?W?E=-G
ME[LYQSG=][G&WY*>GX(4=M>[_P"`%EJ6FZC+;/:V^^RN2J17'F$%F:+S1\O]
MW9WSG/&.];7]GVO_`#R_\>/^-9&G^&%TNYM8K:=%TNU5&BMC$3()%B$0)DW8
M*[!]W;G/.[M704Y<M_=!7ZD$=G;Q2!TCPPZ')JQ24M2,RO$31+I&9R@A^T6X
MD,A&W:9DSG/&,9S6):W$H\0R6NE3QQZ-++"JO`%91+Y<S2*G50,)"3@=6;N2
M:Z74;W^S[*6Z^SS3K$I9EAV[@`"2?F8#MZU`=;M(4@-Z6LGF^XDY7.,@`DJ2
M`"64<GJ0.IH74+&#%XD>Z6S4ZA#!%)#;FXN%V?NG9)689;(4DHHY'&<=2*M0
MZS--X>T6ZGO8X!>$">[4*H4;&8$;L@9*@<YZXZXJ6YU'1=;T^V6YGNX(IW4Q
MLLDUJZL6*KET*E=QR!DC=T&:O6^HV$&C6URBO#:E`L2!"S``=`JY)P`3QV!-
M'0;=V<_<>(=16[CAMKRR>:2>6$QR+E(HU@=TG?:<A2RKDYQAP!SR9-%UEK_6
M;<2ZA+B*.>-T<Q[)'`@;AEX<#><$8]",@YV)/$^B1221OJ4"F-=[G=P!Y?F=
M>A^3+8ZD`GL:GM=4T[508[:Z24\Y520PQM//<<.A]PP/0T:C]497B#6);'6-
M/MEU&"R@GM;F8R2*IW.ABV`9[?.<@<D=,=:R-2\4ZK;6NH2[4M[JWM7D$$C1
M[>+;S=P4MYC$/QTVX![@FMR^U;0[/_B:N3)+964LD1C!YB*+(RKG"EBJ(<$Y
MQSP":LZSXCTW0;"2[OIBNV![@1*,NR*!D@?4J,D@98#/(I)-MI%IKW7;_@ZE
M35-1FL6TV&35(K5)DD:2>5%RQ500!G`')]#P".O(YB[\8ZK,+*W<?9+BXB\F
M[AVA#`[69F!3)+$A\#<<*/NX+<CM?[0TNXG^TF4%[59?G(8!0I`DP>AP<`XS
M@\5-'J]A-?\`V%+A3<_/A,$;MI`?:<8;:2`<="<&J>MT9Q=K,YG^W9K>VC5+
MK-N7"_;$,(+$01,,LY5#DLWOA>/4)JNI:F^F7KM>^02&AVP!<1_Z)YQ96())
MW`C/3!Z9YKI&UO3D>1&N,,AVXV-\Q#;2$X^<AN,+GGCK4/\`PDFF_:S`)';]
MQ%<(Z(6$BR%PH4#+$_NV)&.G/KB7K\QQTZ;(U5(**0VX8^]Z^]+5--6L9+B*
M&.X5VE`*%02K97<!N'&2HSC.<<TV_P!8L=+=5OKB.!3$\QDD8*JHA4,23VRZ
M\TQ)/8O452.K6*V'VXS@6^\1[BISO+;`NW&=V[Y<8SGBH8/$&EW2.T-V'"C/
M"-D_-M(`Q\Q#?*0,D-P>>*!&G16+=>*=*MHT83-,SF+$<2Y8"27RE)SC`W9!
MSSP>,\58_M_2\1'[8FV4@(^#MY;:I)Q@!FX4GACTS0-IHTJ*JZ=J$.J6,=Y;
MB4129V^9&4/Y&K5`@HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"J]]`US8S0I<2V[,I'FPD!U^F01^E6*CGGCMK>2>9ML4:EW;T`&32>PUN
M<]$)9+7PG,;F<#*[XPPVR$VS\MQDX^N,\\D#$NJK8WVOZ3:>3#)/(7N3,%!8
M1PE>`W4?O'3CN-PI?^$NTWS+&%?,-Q>0Q3);ED60+)DK\K,-QPKG"[C\IXJ]
M=:Q#:7ZVCQ2LQ\O<ZE=J>8Y1,Y8$Y8$<`U<G=W)6F_8T:*Q3XFM!(D9M[D23
M)YELN%_TA=ZIE?FXYD3[VW[P]\:5E=I>VPF1'3YF1D?&596*D'!(Z@]#2L[7
M&6*R?$\4DOAC4UBNI[9A;2-YD!`;A3QD@X^HP?0BM:J>J:E#I.G3WT\<[QPH
M6*P1&1C@9Z#^9P/4BA;@BCJ$+CQ%HUP+JX"EI(S`'Q&<QL=Q&.3P.I..V,G,
M5U;PWWBNQ$=O;E8(3=37`4;V)^6)0W]T_.3_`+J^IK1N=6MK74;.Q?S&GNBV
MW8F0@"LV6/0`[2!W)Z=#A-.U6+42P2&:(B-)E$NWYT?.UA@GKM/!P?:@+Z6+
M]%8G_"46374]M%%<231W(M415`\Z3:6(0D@8`5\DX^Z<9XS)'XAMI3%L@N"K
M[!(V%`A9W*`-\V<[@1P#T]*2U"QKUB^*X7E\.79CNKBW,2^;F!]I;;SM)QG!
M.,XQGIT)!VJJ:A?C3K9IVMYID4%G\O:-B@9))8@8_&@:W,:Y+P_$2P=KJ7R)
M-*NRT3,!&A66W^8#U^8\G-3"RMKGQ<)HXH$^R0B9FCC`>623>HW,.2`JGCN6
M!["KJ:Q"]\ML(9\-)Y0F(`7?L\S;C.[.WGICMFDL-;M=2M[V>V2=DM)FA;Y.
M9"JALH.X(88/>J;T7DOU_P""*_XFE16(/$D9N'M?[.O1>(`S6W[HN%QG=D/M
MQVQG/M3[;Q)9W@@EMXYY+.<QJEV`OEYD4,@P3NY#+_#C)I6`V*YOQFDPL-/G
MBNYX1'JED&CC8!9`US$I#<9Q@G@$#US725CZMXDL=&U"RLKK(EO,B(F6.-2P
M*@+EV7+'=PHR3@^E.#M),.@0Y@\4:E)+=2&(V=NP21@$B^:4<#`Z]R<GWP`!
M!IL5G<>*=3GM[>*,V6+9V1`I>5PLKEL?>^5H\$]/F]:U(M1AFU.YL%2426T:
M2.[QE4(?=C:3U^Z<XX]\YQ4'B&Q/AZ?7/W@LH5E9B5P2J,03R>AVY&<<=<4N
MH=[FM16*?$MN(&D^R71,?FF5!L)C$>-Y)W8(&X?=)/48R"!;BU:*6]%N(9@C
M.T<<YV['=1\RCG=D8;J`/E/MDL%R_61JD4AU?195NIT073*T*D!'_<R\MQDX
M],X[XR!6O5"^U,V-Q;0FRN9OM$BQ(\1CQN.<\%@>`"QP.@/6A;@5K)&M_$&I
MB6[FE5XX'42L,)DR#:H```X'N?4U#H=K&VK:K?1VT$$7F_981$H7<J??9L=R
MY8?1!ZFDO/%MGITDB7UM<VI6%IU,QC4/&KJC-G?A0"Z'Y]O!]CC3@U.VGTE=
M3#@6K1><'#JXV8SD%"01CG@FCS#R+E%8L/B:VGL8;M+6[\IXA-)N508$R1EP
M6]FX&3P:MVNK175Z;989DR)"DC;=LFQ@KXP2>"1U`]J2UU`OUBZC"X\2:-<"
MZN`A:2(P!\1G,;'<1CD\#J3CMC)SM5GRZQ##JB6!BE+L5!D&W:"P8@8)W'A#
MT!'Y'`%[&7X9WQ:CXFAGNI9PNJA4:=@2`UM`VT=`!EC@`58\/64,<E_?11Q1
M">=HDCAC"*J1,R#@=23N)/N!V%.@\2VUPB&.UN3)((S#%F/=*KABI'S8`PC'
MYB#Q5O\`M17L8[FWM+BX+N8_*C"[E8$A@26"C!4@G...,Y%5*5]?1`7Z*Q+;
MQ/:W:))%;7)AWI')+A-L3LVT*?FR3DCE01R.:L:9KEMJC)Y,4R)+")X'D``F
MC)^\N"2!R.#@\CBI`TZYRX65/B-I_P#I4YBETJZ_<EAL4K+;X(&.OS'DYKHZ
MRYM>MH+J6%XI]D;F(S!05+B/S"H`.XG;[8[4XR47=^?Y6#5D.A1J-)EM;J=K
MDO=72$W!#-(/.?((P!C'8#`';%)X9L8(+.:^A14%_*9PB`*BQ](PJC@?(`3[
MDGO1:>)([^-VL]/O)WC<(\:-$2F8Q("3OV\JR\9SR.,<TZZ\2V5KIUA>E)72
M^7="H**<>69#DLP'"J3U[4-ZMB-FBLG_`(2&T#C=%.L'3SV4!0WE^;M(SN!V
M<_=]NM3:?J\.H7$UMY,UO<Q1QRO#,%W;'W;6^4D8)1AUS\IXHY6%T:%+24M(
M97O;?[98W-KOV&:)H]V,XW`C.*R[_P`/M=S32172Q"YM5M+@-&7W(I8C;\P"
MGYVYP>WI5G7H_,T:^/F31M';LZM#*T;`A6QRI!KF;K4;[1=>E^S3M+:K;:<'
M@N9))23-<R1LRDM\IP1V.=H%1&5U=]W^II&+>W]:K_@%NY\&W%U#;0MJBA('
M@=!Y#8_=3>8O'F8R>%)QGKC&:TIM`DDTFRL4NP!;-EB\9*RC:PPRAAQ\W3)!
MQR#5/PGXCO\`7O/^V6(M@D:.!YD1(9LY4JDLA&,#E@IZ\<5!!J5M;Z7#>1WM
MS>:S';/-)8)<L[32",EHVCY"?-Z`8.!WP;>BU)3;=D07/@#[1I,MB=3`,C!O
M,^S]/]"-KTW>^_\`3WK6A\/7%IK-UJ-K?1*]PQ)22W+``QPICAQS^Y!S_M8[
M9JI;:[J-[J<5C:WFFS*\1D-U'`S)G'W,"3J."?FZ,.!W@C\2ZB+NQ@NKS2[9
M;JU2Y,LL+`+N!^09DY.1UR..U3RJY?/.26NB"Z\#RW5FULVJ+M-NT"LUN690
MUN83CY\`<[L`#.`"3P:TM>\.S:O9W<%O?);?:[%K*5G@\WY3G#*-PP1N/KGC
MTK)C\97QO+&"2V@42RA)'.`KH9VB5TRX;Y@H<`*PP>6Z$V$\37]O;"[NXX)8
M?)CG9((F#A6=DVCYCDYV?KQTJTG%W6Y+E)KT_P"!_P``OW/AZ:6V,,-ZD>Z.
MZB<M!NRL[ASCYA@C&.^?2HK'3;^/Q!'(ZE;&W^TE"Z*&8RN&ZAV)'7JJ\8SS
M3+K5+W1[O3+:5DD%W(/..5=T=W'`5I%;8-V`5#D8Y&!5O4]4NK2[N5C:W2"*
M*`[Y4)VF21E+L=P&U0N<<?44M$3JU8@N?#=S-=O-%J7V>,R%Q!$LJH223D@2
MC!Y/*[<DG.>E4H/!,D+VTHU("2V@BA39$\8Q'YPYVR`\B;&`1ROH<5/%XAO_
M`#8]XM9;>1962:)&P5B9P[8R>"/+QC/)/7BL:3Q3J.IZ/=.DL5G<V\K[=C*2
M$^S2."X21EZJ2,.1P.X(H^S?L-7O;O\`\.=+'H<UK-:S6T\<2V\84Q0HZ^<0
MA4!LR8(R01D$C`Y[TNJ:"VK7EG=R7`A:"!XF0)N!+/$YYSV\K'_`O;F32M0O
M;J\O;>Y6#%JVTR1*0)-Q+(1DG'R%<]>3V'7%/BN^BN-(@D2V9KN*WDG8*$4>
M:^T!<R;B1[*PX.2O%'4$VM4;PTC%K)#YWW[P7>=G3$HDV]?;&:J7/AUYHT$5
M\8F5I6W!",[YUEQ\K`_P[>".N>.E8L'BG5(+C2K$VZW0FCA,MSNB0,S2,KCY
MYE;*@=%5R3Q@<5W%*R>H7:;1R!\"J]M<027L9280*52VVJ!'=//@#=T._;[8
MSSTJU_PBTY9-^H+(HA2W9'CD"O$C,5!"R@$[6P2002,X'2NEHH2ML#FY;_U_
M5BGI=D^G:=%:/*LOE9"L$V_+GC(R><=_Y5<HHIDA1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%5KZPM]1@6&Y5VC5UD`21D^8<@Y4@\'GZ@
M>E6:K:A#-<:?/#;W36LKH0)D4,R>I7/&<=,@C/8]*3!&##X-BMTVPW9S+8PV
M,[2H9&9(RY!0ELJ<NW7<!A<#BK4^BS7]_'?3R0QNI08\K<ZA)&8;'W?+N!`;
M@UBW-Y'+!I,`UF2/5)[.!@CWIC2%>IF91]\L?E"MG<1Q@;C6MJ5P(]:@N$OA
M(N(D2S29PTA,A#,H#!3C/.0WW>W6JM9V$(?"Q::WF:ZC+V47DV7[DXC3S(Y/
MF&[YS^Z0<;>A]:V-/LS8VIB9P[M(\KLJ[06=BQP,G`R?4US%QJ-QX<,L]W/)
M=PQS#>J2L[%O+8X`/\1`SY8XR4`ZYKL:+NP:7"J^H6OV[3;JSW[//A>+?C.W
M<",X[]:L5D>*([F3PSJ/V2^FLI5@=Q/`%WC"DX4L"!G&,XR.<8."!;C'W6A6
MUSJ5O?%YEEBD#N!,^UP$9`-N[`^_GIZ^IIFGZ3-IV"98YB(8K5=L9CVQ)NQ_
M$<M\QY&.@XJC>W<#>*;:S@OI1=Y227==;8XD'2,1Y`=GR>QP,DD80&6ZFV>(
M$G6^$FX11QV:2N&().9`H8*0-V2=IX7J,4A$2^#[>VNQ=6=PZ2Q31S6XF9YE
MC*QM&0=SY.5=NX[=<5/#X;,'EJMTA1C$UQF$[I&24RY!W?+EF/&#Q6?9WUQH
MU[!:7ES)=^9+Y:N\K8W$QH0I;[Y!8-CMEP/NUUU"5MAWN%4M1LI;V)8TD@$?
M\<<\`E1QQCC(.01QS^'3%VL7Q5'<MX?N)+:^GLWA'FEX,!G"\[<D'`)QG'..
M,C-%KZ`B-?#2Y6)[IFM`V]E&Y9F?R?))\Q6!''/`!SSFEL=!ET>"_CTRXVM=
MS&1&F#2B#]T%7@O\V"H[C(..V:K/=V[^+Q#!J+;X&+W2R7A"`&(@1+%G!/1R
M<<>O.!!)'.^L7\<&M,9[V1XX8TE=FLAY.`X0MMVY7/*\E\[N@HW^X+*ZN7+?
MP[<VT<3Q7ML+Q-^^X^R',V]0&+_/RQ*J<YXVXQCHMEX733H;6RMKA5TZW>%Q
M"8R9"8D5%^?=C'R*?N]JK66JS:?J%K8W0>3S':*-C.6)RQR5W<R!3A23R`N>
MAKJ:=W;^N@D%9NI:;/?&017,<22P-!(&@#MM/4JV00?KD<#CUTJYSQBUY%9Z
M=/:W\ULB:G9K*D6`9E>XC0JQ_NX8Y`Z\<XR"1CS22[C-*XT>"\GNC<%G@N;>
M.!X@Q4X5G/W@<\[\8]O>J@T`Q:5/ID,[^5.\LIDD9I-K-)N"D,W*X)!&1GGI
MFJ%E=VTOB>7[+K!EBMVE^U&:]W!G)/[I(_N@)QE@`1C')W$.1)Y;Z]LX=0,T
M\YE;*3R#[.!(,(PW?+D'`*JI&#C/6EOJ%E<D3PH\<=RJ7L:_:1*DB"`B...1
M44K$N_Y/]6&ZGYF8XYK1@T<PWJ2><AMHI9)HHA&0RNX.26W8(^9^,#K[5F:;
MJ[VVK6NF7/F2O<)B)E<N`H\PACGDCY"-_O'GEJZ>FVQ+4*HSZ>\^LV5\;@B&
MVCE7R-O#.^T!\YX*J''3^,_C>K'U2.Y_MO198[Z:*W%PZ26R!0LV89""YQDX
MP,`$#/)SQ@2N,AM=$U"'[1)/J5O<7,SA_/>S^8`/N5,;R-BC@`8/?.XDFTFD
MAK0V=T[2Q/(T[O&[1'S#)OXVMD#/;/;O61H=U;W.O2RV.LO/9Q1O%(D]R9&G
ME+K\ZJ3\BKRHV@!B_3"KE(EFE2\MHM3\Z23=.\RW,@$`$@)C8[CLR"0,!<!3
MQQ2Z("U;^%OLM@EE%>9B>'R+@R(SM(F]FP"7^4_.PYSU]JO66D-:7PG,R-%&
M)A#&L94KYKAVR=QSR..!6?H.JR/J3Z9<O<2W"0*_F3+L)`5!G9_M;MV?7<O\
M-=)0E960D[K4*Q[C0C<:M]M\^-071\^5F5-H^ZDF?E4XY&#U;UXV*Q-22XC\
M1Z5.+^=+9O,B:V7`C8^6S;VXR2,#'.!SQZ!2*]MX8:UM9(EN+<NRQ*K"W9!E
M,_.=L@)D.>6!'2II=$O!I<>F6=Y%;0JP>5_)+>;EF9T`#@J"2.<DXR,Y.17\
M,74%S+=3VNH-<616..(379FD<C=F0@D[-W&`.NW.!G%4(H;JXT]X;?66<P*D
MTUS'/(0V5=2A)8D,IP^!MS@`@`T,1KIX>=#Y:36T=J[0O+!%;%1NB(V[/GPH
MPB#&#T]ZDT;0/[(,"?:%DAM+86EJ@CVE(@1]XY.XX51GCITYIFC:PUYJ%S93
M0M'.@\Q@9`Q3)QM8?PXXQV;!(K<HN]Q+:P5@:IX9&JW,TC77V=)%?:UNK+(K
MM$8]X;=MW`,<-M!P`,X'._7*:O+-;^,H_/UB>TT^71;MG"NJ)`4>'][R"-P#
MMRV0`!QURTKZ>OY%)V)&\+7>P1Q:C;00.X,]M#9E(IE"D!2HDR,DY;!^;:H/
M&0;=[HLU^+>-C9K';+M1)+7?$V5`)";Q@@C@YX!(]ZIZ'>*UCJ%U;7P>!P3:
MQRW3SNNU3\S9RP+8!V#)`'J2!6ABN39+';ZB]RMHJ,UREU*1.QX&"6;+`K]S
M.TEQD#I2ZV%TN7X?"JQVT=G+>O<6B`;O.4M-(X@\DLSYP<KS]WKWJ[I>D/97
ML]]<W"W%W-#%;LZ1F-=D>XKP6/.9&).>X]*BT+5_M\][9.C>?:/^\?)*$EW&
M`3T(*'Y?[I0_Q5M53E+KU$DF%+24M2,P_$&K3:3&9XXY9N$411!-SLS;0!N(
M'4CJ169;^*FDMWEO&;3G23RWBO#$I5L;@,JQ4Y!!X)_0U?\`$FG2ZDJPHLFW
M,3%DR/NR!B`1R#@5E3:)=0&.73X")07W^?O;?N4#)/))&U>O88X[+;8.I:_X
M2B#]]NU*W00R>4[.R`!MH;&3[&FW?BNVLO,$^IVZO'C='O3<,XQQ_P`"'YUA
MGP==Q7$,\0D=K=3'&IDDBW(T<2G)3G.8@?3!(]ZEN/"EXUFL,*A6CN$F3,;!
M?EA$8'<CE?4\>M!5D;@\0@!/,O88S(Y2,.Z9<AMO'KSVZ\\X/%0OK<!,-]<W
M,<#1R2P1/,RI\P)#`=CG83]!6/?>%]4GCVQ`!C)YG)D4*?.,N"%^^"#MY^[U
M`.2*MS^';N9;$;3_`*/>RW39C/S!Q*`/J/,'Y4^P::FJ/$*&8PC4;?S1C*;T
MW<XQQ[Y'YBF3:S%++'!+?0^89`4C\Q02RGICO@CI[5A77A:^DCFA*RO:B2>>
M/8I\[?(#T8D`;2S$?\!Z;>1?"NHJ;3:H&PPR3'YUW2+(9)#M'!W,Q//3L.:$
M)I&I8^,8=0E>."Z&Z,?O0VP>7\JOR,YZ,.1D=:L?\)/;^3YO]JVGE;MN_P`U
M,9QG&?7'-<[#X+O4^V([GR[B)DRL;94M"D1_]%YZ]_;-3/X9U1FDG2$17##:
MKBXN&=.#AMY/(R<[-N#QDT(<E&^AMS:U%!J2^=>(EQ]G9QN8`+&"-QQT')'/
MM[47'BB&UL1>R7\1MC(L8D7:REF8*!D>Y_"J6K:!>:BT13>ACC."5/+AXW7.
M.JYCP1QP:AG\.ZA<Z;<1N`+F:\CNSMC;8NQT8)GJ>(P"WJ2<=J6H)+2Y=L/$
MEI):RW,-_$BLV^;S95)0DX&[).WI@#VP*M3Z]+#9BY24SJX'E+"%8RD]`O;G
MU)`[D@<UA-X3O!';%0Q>WC0`#?'N(9B?F7D9#'\?7I5T:)>QZ7!%%$$N8)?.
M3(=EW$DD$DECD,PS[YQVIB>Y9A\4,UL9KQGTYE?8T=X$0AL9P&!*MQSE21VZ
M@@22>*+:&0QRZM:(XZJTJ`],]/H0?I6;)H^NRSI=L\1F21MD!B;RTC9<8W=2
MV<-NQC&5P,[JK6/@Z>P@TRW0L\=C<)*"T1!95MO)_`YYH!)=3>B\1Q3RB*+4
MK:20@-L1T)P1N!QZ8(/T--/B6`0^<=4M1%OV;_,3;NQG&?7'./2N:TKPEJMI
M8K82HBQ0%3',L9)8BV6+[IXQG)Y],8[U?L/#M_!<^=,AQ]I$X3=)(5_<F/&Y
MN3SSVZXQQDG0;23M<W(]::4@1WD3DYP%*G.,9_F/SJ;^T+K_`)Z_^.C_``K`
MTGP[<6-X9I('8QV\<*-L[[5#D>QV1]?[IK:^S3_\\9/^^302R7^T+K_GK_XZ
M/\*/[0NO^>O_`(Z/\*B^S3_\\9/^^31]FG_YXR?]\F@"7^T+K_GK_P".C_"C
M^T+K_GK_`..C_"HOLT__`#QD_P"^31]FG_YXR?\`?)H`E_M"Z_YZ_P#CH_PH
M_M"Z_P">O_CH_P`*B^S3_P#/&3_ODT?9I_\`GC)_WR:`)?[0NO\`GK_XZ/\`
M"C^T+K_GK_XZ/\*B^S3_`//&3_ODT?9I_P#GC)_WR:`)?[0NO^>O_CH_PH_M
M"Z_YZ_\`CH_PJ+[-/_SQD_[Y-'V:?_GC)_WR:`)?[0NO^>O_`(Z/\*/[0NO^
M>O\`XZ/\*B^S3_\`/&3_`+Y-'V:?_GC)_P!\F@"7^T+K_GK_`..C_"C^T+K_
M`)Z_^.C_``J+[-/_`,\9/^^31]FG_P">,G_?)H`E_M"Z_P">O_CH_P`*/[0N
MO^>O_CH_PJ+[-/\`\\9/^^31]FG_`.>,G_?)H`E_M"Z_YZ_^.C_"C^T+K_GK
M_P".C_"HOLT__/&3_ODT?9I_^>,G_?)H`E_M"Z_YZ_\`CH_PH_M"Z_YZ_P#C
MH_PJ+[-/_P`\9/\`ODT?9I_^>,G_`'R:`)?[0NO^>O\`XZ/\*/[0NO\`GK_X
MZ/\`"HOLT_\`SQD_[Y-'V:?_`)XR?]\F@"7^T+K_`)Z_^.C_``H_M"Z_YZ_^
M.C_"HOLT_P#SQD_[Y-'V:?\`YXR?]\F@"7^T+K_GK_XZ/\*/[0NO^>O_`(Z/
M\*B^S3_\\9/^^31]FG_YXR?]\F@"7^T+K_GK_P".C_"C^T+K_GK_`..C_"HO
MLT__`#QD_P"^31]FG_YXR?\`?)H`E_M"Z_YZ_P#CH_PH_M"Z_P">O_CH_P`*
MB^S3_P#/&3_ODT?9I_\`GC)_WR:`)?[0NO\`GK_XZ/\`"C^T+K_GK_XZ/\*B
M^S3_`//&3_ODT?9I_P#GC)_WR:`)?[0NO^>O_CH_PH_M"Z_YZ_\`CH_PJ+[-
M/_SQD_[Y-'V:?_GC)_WR:`)?[0NO^>O_`(Z/\*/[0NO^>O\`XZ/\*B^S3_\`
M/&3_`+Y-'V:?_GC)_P!\F@"7^T+K_GK_`..C_"C^T+K_`)Z_^.C_``J+[-/_
M`,\9/^^31]FG_P">,G_?)H`E_M"Z_P">O_CH_P`*/[0NO^>O_CH_PJ+[-/\`
M\\9/^^31]FG_`.>,G_?)H`E_M"Z_YZ_^.C_"J.K>(YM'TY[R7S9E5E01Q*FY
MBS!1]X@#KR20`,FK/V:?_GC)_P!\FJM]IUU<0IY=LKO'(LBK-$2I(/KCY3Z$
M=*`&3>)Y[?2([^:*=&D*JEOB-I&=CA5R&*9)(YW8YY-5T\9R2W=E;P07,IND
M#[AY*B(9(.X,P)Q@YV!NGTJM+X=OWTL:?Y1EC,K3R"<,T<H:1F:$CKLPV!U'
M`R",@NM?#E_;6\5N1O4E#)+M*N@60R!%XY09V@$C`'?-/06IH6?BB2\O&MAY
ML3%3)"9%3$\8(!=,$G:"1UP>1Q@BM'^T+K_GK_XZ/\*PK#P]=6]_!<31DBSM
MWM;8(IY1F4DMD=<(@X]">^!L?9I_^>,G_?)H=N@R7^T+K_GK_P".C_"JNH^(
M'TNQEO+F5_+B4L0D>YC@9P`!DFI?LT__`#QD_P"^35>_TZXO-.NK98G5IHGC
M#%#@9!']:2`@N?%%[;:K;61L+QTN&")<IY'EYP2<@N'X`.?EITOBBXCUR/2U
MAGD=XQ(TRF$(@.>H9@Y^[_"IZB@Z/.^L)?O$Y\JW,,2[#\NY@7/X[4_*HGTN
M^FG5VM1$KM'+(R@^8K+_``Y`^8<8R3T)%`$,'C>6XM7G2TN\F0101YMR]PQ!
M.%`<X.`20^T@5KVNLRWELEQ#,3&XR,H`1Z@@C((/&*P7\-WSR6ER($2>Q,?V
M>-%(B(570Y`7Y<K(PP,XP.M:FFZ7<V.GQ6[J\L@RTCK$5#.Q+,0.<#)/&3BC
MH!H?VA=?\]?_`!T?X52U+Q!=:=;B;R;BY&?F$")\J@9+$L0,`>^3V!JQ]FG_
M`.>,G_?)JCJFE7-_;"`V45Q$Q^>&YC)0]P>AY!`(_IUH`<OBB5]4%DJSE3\H
MN-J>7OV[]G7=G;\V=NWMG/%-;Q7(M\]N4N3$NY?M"Q*R-(H+&-0/G+8!/"XX
M(SGBL^/PW>6^JK?B'SYHUP+AU/GN@CV^23C[A;Y^N,]L\TKZ'K"ES`L*A9I+
MJ#?&QVR.C#:P'4!G9LC'&!CO1H`L_CV2W@4R65^+EIA%]D985D7*LP8EG"!2
M%/\`%UP,9XK?34KMXU9F9"0"595ROL<9'Y5S]OX?OH5$O]GVQNC(7EDDS(TK
M,FTMNV`J<`#`&,#'`QC4T_2Y[#3;6SQ<3>1$L7F2*2S[0!D^YQ3T$7O[0NO^
M>O\`XZ/\*S=3\4R:8T:,)IW<C*0JF54Y^;YB,]#A5RQ[`X-7?LT__/&3_ODU
MD:EX?N+J\EN8K93)/:&S=I$(9$))RIP?7E>^%Y&.4AE__A(V.L#2Q*YN/(,Y
M(0;0H(&"?7GIZ?49K7'BZ6U^W&>"[1+6%YE8QI_I"I][RQG/!('S!<Y&,CFJ
M@\.WMIK+:G`US/\`N95\B4`;F9E/WMN0`%QWZ"GW'A^\NKFXFEMH=[1-$&:'
M<)EW;D$BD<A>0.3]XGC-'1"N[L>/&=Q]BAN7L[Q!)N9DS`QCB7&Z4E7*E1D<
M*2WHIK:_M&Z_YZ_^.C_"N;E\,ZC(]U,!B2]65)4;<5A5UC7Y..<>7G&!DL>1
M6^+695`$$F`,#Y33TL!-_:%U_P`]?_'1_A6?=>)Y;2_CM669E(4RSJJ;(=QV
MINR0?F8$#:#CO@<U;^S3_P#/&3_ODUD:CX?N;^^20VY$7[K>VZ16^1R^"H^5
M@>@SC')YZ4EN,MV?BEKV\:V1I4;:7A:1%`G0$!F3O@$@<@=01D$$UT\87$XN
M_LMG=W)M]I41>1^^![J2X`QUPY4D<@&J]CX=OK.\@N)(_-^R1/:VP12O[IW4
MDMG/(5$''7!/&<!(_#5W'826D<0B1+5[6%D4\AOXF&!R,=L\DGO3=N@#H?'4
MUQ%ISQV-[F_+;%+6X*J&`W$^9A@<Y&PL2.<5T']H77_/7_QT?X5DWFCW4O[N
M"V5(WB\EGV%7C7/!4@<_3CG!K1^S3_\`/&3_`+Y-("7^T+K_`)Z_^.C_``JI
M+XA:'4;>Q:60SS@E<194``GEL8'0X'4_@:F^S3_\\9/^^356YTRYGN[.81N!
M!(SD%#SE"O\`6@"*'Q?'-#J$RRS>78S>3*?(R6;:K?(H!+`AQC`Y[9&"9I_$
MIM]&.J2RN+<0B;`C!8@C(``ZGVJM9:)=6MQJ\C*S"^N/.4!#\H\F./!_%"?Q
MH.CWAT-]+,3#_0Q`)=IP6VE3QZ=#^-5I?[O^"`7'BZ:'7(M*2"XFE=%D:5?)
M5$#%ASN8,V-I)"AL#'K4VG>*6U)V6)I4!7S(F=%VSQ]I$(SE<^N#T.,$$P3Z
M+>273E;=!%*8FDD"%9!Y9R!D#Y@<8Y(QD]>E0Z-X=O-,:!'!:"TMA:6RK&=V
MP'JQ]<!!@#^$G/.`M`6QO?VA=?\`/7_QT?X5GS>*?)U4::TDS3_9GN3LAW`*
MA4$<#EOG'RC)_,9M_9I_^>,G_?)K*O\`1=1EU6+4;0!)8;*XMXQ+&Q&]VC*D
MX[#R^?K0K=?/\@$'C.Z:%O+TS4WNU8!K,11"1002&)+;`"!_>SVQGBIKSQ?]
MET^UNU,TZW8!A2*-0S#:7)^;`&%!)R<\8&3Q6<-`U=(/+CMD0S2&2\99W$ER
M=H&2XCRO0#``P``"`,5)J.@7M_;V]N+"!;>W`'V:4,T3C;P<`#!1@",CMV."
M$!;3Q@TFI-:(DQC2+S7N28@BKMW<J6W]".0N.>O6K&G>)9-1:5%\Z"6/#&*9
M%#%&SL?`S@-@XS@\$$`C%9H\-7C6Z6<_F2PA1YEQM(FF;RO*._`P21SNSZ#'
M%3Z7H=];7<U[>+YEW+#%;L8HV"%8]Q!P>A)=CC)QP,G&37NZBUT.AL[RXENT
M1Y,J<Y&!Z5K5BV,$J7D;-$Z@9Y*D=C6U4C$-%0WMU'8V4]W-N\N&,R-M&3@#
M/`]:I'7+:!I1J"MIPCB,S/=O&J[`0"VX,0`"1G)'44`:=%0?;K3RO-^U0>7A
M3O\`,&,-]TY]^WK4"ZWI3VUS<IJ=DUO:R&*XE%PI6)QU5CG"D9'!H#<O457C
MU"RE@2>.[MWA=$D619`59&^ZP.>0>Q[U''J^FRFY$>H6CFU?R[C;,I\EO[K\
M_*?8T`7**@M+RUU"TCNK*YAN;:092:%PZ,/8C@U/0`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!113)4:2)D65XF(X=`,K],@C]*`'T5G_`-G7
M7_09OO\`OB#_`.-T?V==?]!F^_[X@_\`C=`&A16?_9UU_P!!F^_[X@_^-T?V
M==?]!F^_[X@_^-T`:%%9_P#9UU_T&;[_`+X@_P#C=']G77_09OO^^(/_`(W0
M!H45G_V==?\`09OO^^(/_C=']G77_09OO^^(/_C=`&A16?\`V==?]!F^_P"^
M(/\`XW1_9UU_T&;[_OB#_P"-T`:%%9_]G77_`$&;[_OB#_XW1_9UU_T&;[_O
MB#_XW0!H45G_`-G77_09OO\`OB#_`.-T?V==?]!F^_[X@_\`C=`&A16?_9UU
M_P!!F^_[X@_^-T?V==?]!F^_[X@_^-T`:%%9_P#9UU_T&;[_`+X@_P#C=']G
M77_09OO^^(/_`(W0!H45G_V==?\`09OO^^(/_C=']G77_09OO^^(/_C=`&A1
M6?\`V==?]!F^_P"^(/\`XW1_9UU_T&;[_OB#_P"-T`:%%9_]G77_`$&;[_OB
M#_XW1_9UU_T&;[_OB#_XW0!H45G_`-G77_09OO\`OB#_`.-T?V==?]!F^_[X
M@_\`C=`&A16?_9UU_P!!F^_[X@_^-T?V==?]!F^_[X@_^-T`:%%9_P#9UU_T
M&;[_`+X@_P#C=']G77_09OO^^(/_`(W0!H45G_V==?\`09OO^^(/_C=']G77
M_09OO^^(/_C=`&A16?\`V==?]!F^_P"^(/\`XW1_9UU_T&;[_OB#_P"-T`:%
M%9_]G77_`$&;[_OB#_XW1_9UU_T&;[_OB#_XW0!H45G_`-G77_09OO\`OB#_
M`.-T?V==?]!F^_[X@_\`C=`&A16?_9UU_P!!F^_[X@_^-T?V==?]!F^_[X@_
M^-T`:%%9_P#9UU_T&;[_`+X@_P#C=']G77_09OO^^(/_`(W0!H45G_V==?\`
M09OO^^(/_C=']G77_09OO^^(/_C=`&A16?\`V==?]!F^_P"^(/\`XW1_9UU_
MT&;[_OB#_P"-T`:%%9_]G77_`$&;[_OB#_XW1_9UU_T&;[_OB#_XW0!H45G_
M`-G77_09OO\`OB#_`.-T?V==?]!F^_[X@_\`C=`&A16?_9UU_P!!F^_[X@_^
M-T?V==?]!F^_[X@_^-T`:%%9_P#9UU_T&;[_`+X@_P#C=']G77_09OO^^(/_
M`(W0!H45G_V==?\`09OO^^(/_C=']G77_09OO^^(/_C=`&A16?\`V==?]!F^
M_P"^(/\`XW1_9UU_T&;[_OB#_P"-T`:%%9_]G77_`$&;[_OB#_XW1_9UU_T&
M;[_OB#_XW0!H45G_`-G77_09OO\`OB#_`.-T?V==?]!F^_[X@_\`C=`&A16?
M_9UU_P!!F^_[X@_^-T?V==?]!F^_[X@_^-T`:%%9_P#9UU_T&;[_`+X@_P#C
M=']G77_09OO^^(/_`(W0!H45G_V==?\`09OO^^(/_C=']G77_09OO^^(/_C=
M`&A16?\`V==?]!F^_P"^(/\`XW1_9UU_T&;[_OB#_P"-T`:%%9_]G77_`$&;
M[_OB#_XW1_9UU_T&;[_OB#_XW0!H45G_`-G77_09OO\`OB#_`.-T?V==?]!F
M^_[X@_\`C=`&A16?_9UU_P!!F^_[X@_^-T?V==?]!F^_[X@_^-T`:%+5*"SG
MBF5WU.[F4=8Y%B"GZ[4!_6KM`&7X@C$VF>2WF[))H@_E)(S;`X9A\@)&5!&>
M.O45RE_8DW,\MM:SW06>*XMQ="]20X1E*-*(V8*I/F+C/S%A@<&NK\1W,]KX
M?O9+19&NFC\N`18W>8YVIC<0,[F'4@5A0RZM%?0R".ZT^VD.?LVH7*S.H1)"
M\A*N_P`N6B&T/V_A[FP6(OL$'FQP@W2626RKA;"Y9C.I<JPW`X52^X#).0O(
MV\MTNW6!;7[18O$L4J;HDCO)U\N-'$>#)&.0S!L8`&.I(!K17Q0?M-@DBQQB
M?:LL;(X\LF$RL3(0%&T=N?J.E5?^$PF2.&.X1+>XD5WE+VTK"V"(K,K!<[L;
MU&X-M()/;!&P4>A3AAOX[JWB96:S(MC<RFUN?-_=;G*JOE8.9"&W$]&(P,#-
M8:=.FBS6GV!96_=PB*47Y$\2$G<9-F8F+$-M56`P1D[LKL^(=<N[33].U"$-
M&([:;4+B`')D5(2!%T[R21_E72V4<T5A;QW$ADF2)5D<_P`3`#)_.A1L.ZT:
M,GPN9(=-2UNGFDO"7ED=K:1!RW"[V1=Y4$+N(!;;D@<UNT44,04444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!2TE+0!%<>0(2]SY?E1XD)DQM7:<AN>F,9S[556ZTR^6.3S+:82[X8RV#O&<
M.JYZ@[><<'%+JMI+>60CAV&1)HI0LAPK;'5L$@'&=O7!KFSX6OF2ZW1V/^EK
M(I3S&*VQ:=Y?,C^3YF)92?N_-&O/<`U:VYT7V;28[LW_`)%DMRRIFXV('*X(
M7YNN,%@/J:@M=+\/)81PVEAI8LX+@2HD,,8CCF!X8`#`<'OUK"7PIJ?GRJ\U
MHUNRRQC+-NV*&6V7I_")')Z\@$9SQ=U;16_L#5+5+6&>.Y:$+;A2590(T*L`
M.F%]^*`L;,TNF31PS3R6<B2'9$[LI#$D'"D]>5!P.X'I5EIX44L\J*HSR6`'
M!P?UXKB]7\(ZMJ&GZM!!/;1?VDEPK1>:=D)DCC0`'9DKF,N0-N2W>G7WAJXU
MFRUJR)1H96C$,=RC*B/N1Y@,K\RED#!L'DF@$KM7.MAU"RN&"P7=O*S*7`20
M,2H.">#TSQ0NHV+1QR+>VY24XC82KASG'!SSR0/QKG=9\)MJ,-ZD`MHC<WAN
M&)7[ZFW$15OE(.2,'.1M]>E4M2\&WVIK=/*;8S36-[!F67?^\FCB1&^6)0`!
M&0<#/3KGA7TN5&*<DF['8VMY;7L326LZ3(KM&60Y`93@C\"*GJCI-K/9630S
M^66\^5U*,3E6=F&<@8/S?_7J]3("BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHI",@CUH`IV6K66H2%+68N
M0N\$HRAUSC<I(PR^XR.GK5VL#0-#N=+%G%.\1AL+(64#(Y9I%!'S-D#!PB\#
M/4\UOT`]]`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*6DI:
M`*U]<FTMO-5`[%T15+;02S!1SSW-9$WB1H&*-:(SH=LFR;(#-*(D`.WG+9Z@
M8VGK6M>V,5\L23[C''()"G&U\9P&!'(SS]0*%T^R5'1;.W"N@C8")<,HR0IX
MY`R>/<T#T,6YUZ\34/L\=O#NMDFEN0)_D*HJ$#=MSSYGH/NFH[_QA%;27$4-
MM)(8XY"KA7`9T3)4,5V$AOE(#$@]1UK<_LK3OE_T"U^3[O[E?EYSQQZG-#Z5
MITDC2/86K.V2S-"I)SR<G'L/RIZ!<PI/$=S;6UU'-;LUS81NTK1,&$A6)&X^
M4<DR*,#'/?M4B:OJ,7(A%SY*.)%,@4NRNL>X`+P"1(<?_JK<6QM%146U@"+]
MU1&,#D'C\0#]0*@^SVM[&[6CF!@[1M+#&H;(8[ERRGC=D_6A^0*W4J7>JSW6
MB7<^F;%D9Q;VTSG*EV8)NQCH&)^NVJZ^(9XXK4&T$K7*GR-TX#OAU3<P"@*"
M7!R/4<#.*V;>&T2W6SA1/*M=D83&0FT`J.?0;33#:Z?:R`BVMXWGD'*Q#+OR
MV3@=>"<T:"*^H:O)I\UI&]L&\\[7<,Q6-B0%!(4XSDX+;1D8SS49UX%83'`K
M><SB,^9P<2K&IZ=&+`^P]:TI;2VGE26:WBDDC^X[H"5YSP3TYJ(:;I\22XLK
M95D'[S$2@,`<\\<\\TAE(ZU,AFW6D6VV.+AA/G'4_)\OS$*,D<>G)K.C\8.\
M,SC2;H-$L;%6AF4@,2#PT08XQGY0W&?2MNRATVY@MKZUMH=CQ*89!#M(0C@#
M(!`P>GO3$MM)>>73UL[8M$%F>+R!M&[<JGIC/RL/7\ZK3L)6((-<\[58+(P*
MOG1"59!(65OER0K!=I(XXW`X.<8YK8J@O]F174DJP0QSQH&>3R=K*I!`R<=,
M*?R'M5V-UEC61#E6`8'U!I.P#J***0!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`8%S=:@MY)%:W'FF>WD>W+>6(]VY0NTC
M)^4-SNZ]@>@DEO[N'2R(V+W;7*VV^0J0I9@"P(4`@`DXQR1BI&DT-?M4;6\`
M4*TDV;;Y7"'YCG;AB">V>:G*:6-.DD>UBCM%7YUDM]@P#G[I`[G/3J::\QOR
M,635-1MY9;G[29;&"9HD9O+'FE?O[SC@`@C*XP%8GI6WI%TUW8AI'D:53^\W
MJ%P2`V`!VPPQGG'7G-0I?:0\\5N$7S`IB5#;,/+!P-IROR`\8!QGMFKEA]D^
MR+]AB2.W).T)'L4\]0,#@]<]^M'03M<LT444@"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`*6DI:`*.L6\]UIDL%N6#N5!*A2VW<-V-P*YQG&1CUKG]/T'4
M;8QI=1PW49X43%<0'SG8N`JJ-Q0H!M`Y7MUK:\0S30:.[07,UM(TL,?G01AW
M0-(JDJK*P)P3_"?I6+'J.L:<IS)-J$,:SR(]\JV\LJ*D9R0L8P0Q=1\JY'7/
M4EQJ[]U%J/2IEMK7?IZ;HI(FG"LNZ=D#'>><?ZPJV3SP3[5';^'&-N@N8(6D
M9X6DSAAD.99"/J[,/I1'XP\_5)+*'3VD;R+F:(I(6\PPNJ%>%VY)8?=+$="`
M>*9/XQEA#K'I<EU-%$TLL-L)7<`'`0+Y0.\X/#!1TYYS33=[`T/?1+HP26GD
M(T%P#&WS`+'&\S-(H'NA4`#T_.AKGAS5[^Q$5JY279N`S%M#M(SN"61F[C&W
M'?/:KNJZQ?6WC/1K"&?9:W,J++&47Y@8;ICR1D<Q(?\`@/N<])'<P3/(D4T<
MCQ';(JL"4/H?2F[Q2;$GKH<7=^%-1O)96+M`99)A^Y,17YG`61@Z-D^6!R,,
M"".AR-6RTB]BU:W>XCCE6&>:4WC/F1P05C3&.@5L'W48ZTD/BBYD>U4Z4Y,T
M,$[^29)=BRL0.1'CC!)R1QTS2#Q<)$A^SV1E=V6%PK.PCFQ(9(VV(QRGEX/'
M\0Z4KZ#=[L8-&GNR[FT6'S7F\V0G#RI(^`#WP(\Y![A<>S+W0;Z0W*VMM;))
MYDLD5P7P64QD)&,#*#<>>HP,\ECB-_'$T1D:32&2))!"=\Q60/\`9/M.&0IQ
MQE>N<\XJS=^+9+?5+ZPATR6XDM78?N][%PL43G`1&P3YP`!XXZCI2YBG3DNG
MF176@73VKI9PFTB=PR6\0A.TK&%7<'5DP3G)`)P%QW%/AT6\CF#_`&9//B,;
M1W.\%F5(0H3/49?=GM@GG/%:UIJLEQJDEG);"`!69#(7#N`1R`4"D?,.C$C(
MR`>F9#XLFFMY+E=*E^SK$\P<^8,HK`$9,87<5)(`)R1C(ZTVV1Y%>_\`#][/
M:O9",26Q0J<N,E1$D0`S[&4_7'K6AH]C+_:-U++`T5G!*PL4.5^\`7;;VY)4
M>V<<-1#X@N)&61[&-;;="CNMQN8&0*1A0N"!N&3GU(S4-CXHGOHHBFENC7`C
M-N93(B,'#-@LT8P0%Z*&ZCGO3NP:T.DHKD)/%E_93ZPMU8P.;.4*D<,KM\H@
MCD;.$)/+]=H'KCC-F_\`%DFGR%WT]7MO-,*N)_G+"V,_*[<`8!7K[U)7([V.
MFHK&N=8N[*:V@N+"-IKEML:P3EQG>@/)5>@8M]$-;-!(4444`%%%%`!1110`
M5#=7=M86LEU>7$5O;Q#=)+,X1$'J2>!4U%`'/_\`"=^$/^AKT/\`\&,/_P`5
M1_PG?A#_`*&O0_\`P8P__%5T%%`'/_\`"=^$/^AKT/\`\&,/_P`51_PG?A#_
M`*&O0_\`P8P__%5T%%`'/_\`"=^$/^AKT/\`\&,/_P`51_PG?A#_`*&O0_\`
MP8P__%5T%%`'/_\`"=^$/^AKT/\`\&,/_P`51_PG?A#_`*&O0_\`P8P__%5T
M%%`'/_\`"=^$/^AKT/\`\&,/_P`51_PG?A#_`*&O0_\`P8P__%5T%%`'/_\`
M"=^$/^AKT/\`\&,/_P`51_PG?A#_`*&O0_\`P8Q?_%5T%(3A2<9P*`.`N/%O
MAZ[N&GN-<\.R@1"&2)M8C*S`NI8H-V%&%Z'&XG#8`!ITOBKPQ+IHA'B#00$N
MTN5M_P"U(`H19`P08;[P"AL?=W'&<<UL>&-5OK\6<UU,9%U&Q%^(F10;4G;^
M[!`&5^;^+)R&Y.0!TU-:6_KK_F-]F>=W&O\`AB>!W/B?P]]MN"\LLAU.+8#C
MY(R`_P`PZ`G'3=C&ZM31O&GAFWL2ESXJT4'=\B/J<+%5``Y(;')!.!P,X[5V
M%%(&[G/_`/"=^$/^AKT/_P`&,/\`\51_PG?A#_H:]#_\&,/_`,57044".?\`
M^$[\(?\`0UZ'_P"#&'_XJC_A._"'_0UZ'_X,8?\`XJN@HH`Y_P#X3OPA_P!#
M7H?_`(,8?_BJ/^$[\(?]#7H?_@QA_P#BJZ"B@#G_`/A._"'_`$->A_\`@QA_
M^*H_X3OPA_T->A_^#&'_`.*KH**`.?\`^$[\(?\`0UZ'_P"#&'_XJC_A._"'
M_0UZ'_X,8?\`XJN@HH`Y_P#X3OPA_P!#7H?_`(,8?_BJ/^$[\(?]#7H?_@QA
M_P#BJZ"B@#G_`/A._"'_`$->A_\`@QA_^*H_X3OPA_T->A_^#&'_`.*KH**`
M.?\`^$[\(?\`0UZ'_P"#&'_XJC_A._"'_0UZ'_X,8?\`XJN@HH`Y_P#X3OPA
M_P!#7H?_`(,8?_BJ/^$[\(?]#7H?_@QA_P#BJZ"B@#G_`/A._"'_`$->A_\`
M@QA_^*H_X3OPA_T->A_^#&'_`.*KH**`.?\`^$[\(?\`0UZ'_P"#&'_XJC_A
M._"'_0UZ'_X,8?\`XJN@HH`Y_P#X3OPA_P!#7H?_`(,8?_BJ/^$[\(?]#7H?
M_@QA_P#BJZ"B@#G_`/A._"'_`$->A_\`@QA_^*H_X3OPA_T->A_^#&'_`.*K
MH**`.?\`^$[\(?\`0UZ'_P"#&'_XJC_A._"'_0UZ'_X,8?\`XJN@HH`Y_P#X
M3OPA_P!#7H?_`(,8?_BJ/^$[\(?]#7H?_@QA_P#BJZ"B@#G_`/A._"'_`$->
MA_\`@QA_^*H_X3OPA_T->A_^#&'_`.*KH**`.?\`^$[\(?\`0UZ'_P"#&'_X
MJC_A._"'_0UZ'_X,8?\`XJN@HH`Y_P#X3OPA_P!#7H?_`(,8?_BJ/^$[\(?]
M#7H?_@QA_P#BJZ"B@#G_`/A._"'_`$->A_\`@QA_^*H_X3OPA_T->A_^#&'_
M`.*KH**`.?\`^$[\(?\`0UZ'_P"#&'_XJC_A._"'_0UZ'_X,8?\`XJN@HH`Y
M_P#X3OPA_P!#7H?_`(,8?_BJ/^$[\(?]#7H?_@QA_P#BJZ"B@#G_`/A._"'_
M`$->A_\`@QA_^*H_X3OPA_T->A_^#&'_`.*KH**`.?\`^$[\(?\`0UZ'_P"#
M&'_XJC_A._"'_0UZ'_X,8?\`XJN@HH`Y_P#X3OPA_P!#7H?_`(,8?_BJ/^$[
M\(?]#7H?_@QA_P#BJZ"B@#G_`/A._"'_`$->A_\`@QA_^*H_X3OPA_T->A_^
M#&'_`.*KH**`.?\`^$[\(?\`0UZ'_P"#&'_XJC_A._"'_0UZ'_X,8?\`XJN@
MHH`Y_P#X3OPA_P!#7H?_`(,8?_BJ/^$[\(?]#7H?_@QA_P#BJZ"B@#G_`/A.
M_"'_`$->A_\`@QA_^*H_X3OPA_T->A_^#&'_`.*KH**`.?\`^$[\(?\`0UZ'
M_P"#&'_XJC_A._"'_0UZ'_X,8?\`XJN@HH`Y_P#X3OPA_P!#7H?_`(,8?_BJ
M/^$[\(?]#7H?_@QA_P#BJZ"B@#'L?%GAO4[R.SL/$&E7=U)G9#!>1R.V`2<*
M#DX`)_"MFDI:`(YH8YT"2H&4,K`'U4@@_@0#4+16M\"Q5)0`\)/L3AU_,8_"
MH-;LVO\`2Y+81+,C,AE@;&)HPP+H<\'<H(P>#G!X)KED\*W2(!'8PQHJN-/B
M#@?V<YE=MZD=,HR#"YQLV_=)-`TM+W.E'AS1UG><:?")'61"V/X7.7`]`QY(
M'4\]>:)?#NDW"!)[))N&#-(Q9G5L;E=B<NIVKE6R#M&1P*YO_A&M5D:6">*!
M[8H\:'S.B1!A;#&.N9"3Z%15R\T-=-\/:I:V=I''%/-$\<,+&,$GRPQRO*DD
M$EASWZT+R#5[G12Z;9SWL-Y+;HUQ`08Y".5(#J,?A(X_X$:M5YYJW@V^N]*N
MK2TM8H8F::73;<>6!I\ACC5""0P3YED?=&-RE^".:N:AH5_JMGK-G'(LB,4-
MLOF;3&S,CS(6'^TF[K_%BA@DK[G4OHVGR-`6ME_<*BH`2!A#E00#A@IY&<X/
M(I6TFQ990+<(99O/9HR4;S,;=P92"#@8R.W'>N7N_!,</G-HMI;6$QG*QR6Y
M$3);F(;HU(!VJ9,M@#&26QFJ%WX%::T,5E8^3%%:7@M893$GD7#B'RV18@%3
M#1LV1R&^;J>%?2Y48J4K-G7QZ'HLD&R*RMVA$A.%'&Y8S"?R0%*/^$;TC;*/
ML8S,Q:5O,;=(2H4[FSE@550020=HSTH\/:8FDZ?+;I:16Q:YFE(B50'W.6#<
M=\$#GGBM6G:Q+;95ATZTM[IKF*+;*P(X8[1D@G"YP,D`G`Y(YJO_`&!I7FF3
M[%'G?Y@7)VJV\2$A<X!+J&.!R1DY-:5%`C,M=!L+2^>ZCB^?*E!N.U`%V@`9
MQP,X],D"G+H6FHDB+;8#[1P[94*<J%.<J%))`7`':M&B@#*?PUH\BNK6*8D&
M)`&($@V[2&Y^8%0`<YW`#.<"IFT73GA2)[2-XT;<JOEN?+\O)SU^0E>>U7Z*
M!W90BTFVAE@:->(7:0;R7<N5V;MS$G[N1],>E7Z**!!1110`4444`%%%%`!3
M)1(8F$+HDF/E9U+`'W`(S^=/HH`S_)UC_G^L?_`-_P#X[1Y.L?\`/]8_^`;_
M`/QVM"B@#/\`)UC_`)_K'_P#?_X[1Y.L?\_UC_X!O_\`':T**`,_R=8_Y_K'
M_P``W_\`CM'DZQ_S_6/_`(!O_P#':T**`,_R=8_Y_K'_`,`W_P#CM'DZQ_S_
M`%C_`.`;_P#QVM"B@#/\G6/^?ZQ_\`W_`/CM'DZQ_P`_UC_X!O\`_':T**`,
M_P`G6/\`G^L?_`-__CM'DZQ_S_6/_@&__P`=K0HH`Q;71[NRGFGMIM.CEF/[
MQQ9/D\DXSYO`RS''3+$]S5KR=8_Y_K'_`,`W_P#CM:%%`&?Y.L?\_P!8_P#@
M&_\`\=H\G6/^?ZQ_\`W_`/CM:%%`&?Y.L?\`/]8_^`;_`/QVCR=8_P"?ZQ_\
M`W_^.UH44`9_DZQ_S_6/_@&__P`=H\G6/^?ZQ_\``-__`([6A10!G^3K'_/]
M8_\`@&__`,=H\G6/^?ZQ_P#`-_\`X[6A10!G^3K'_/\`6/\`X!O_`/':/)UC
M_G^L?_`-_P#X[6A10!G^3K'_`#_6/_@&_P#\=H\G6/\`G^L?_`-__CM:%%`&
M?Y.L?\_UC_X!O_\`':/)UC_G^L?_``#?_P".UH44`9_DZQ_S_6/_`(!O_P#'
M:ANI-1LK=KBYU/3XHEQEFLW[G`'^MZDD`#N36M534I;R'3YGT^W6>ZQB-&8`
M9)QDY(Z=<9&<8R*&",O^T[HHA74K5RY90B:9,S@KC.5$F5QD9R!U'K4US=WE
MG)''<:KIT;R<J#9OTR!D_O>!D@9/&2!W%4SI=Q]B5DM[W[>XDS<M<K&XD8+A
MV5&VE/E7CG`4#:<FH]?TJ[UJWU.WMXQMO[%].:5R!Y1RW[S&>5^<].<J..<A
MQLY),72Y<?49XYI8I-:TQ&B4L^^T=0`,;N3+@XR,XZ9&<9J>VDU&\B\V#4;%
MER5.;&0%2.H(,N0?8UA2>&=1,"VD:PE;:^N+Y)7;`E,DK2*F!DC[Q!)]!@'/
M&YHFGS6D^K7<XV-J%Y]I$1P3&!%'&`2"03^[SQZT)*VXWOH3^3K'_/\`6/\`
MX!O_`/':BN9-1LX3-/J5@B9`_P"/)R22<``"7))/``Y-:M9^K6T\RVDUN@D>
MVN%F,9."XPRD`GC.&R,\9'4=:0$<!U.YA2:'4M/>-QE66S?!_P#(M2>3K'_/
M]8_^`;__`!VHO#VFRZ5I/V>9E,CW%Q<,%Z+YLSR;??&_&?:M6FTD]`1G^3K'
M_/\`6/\`X!O_`/':/)UC_G^L?_`-_P#X[6A12`S_`"=8_P"?ZQ_\`W_^.T>3
MK'_/]8_^`;__`!VM"B@#/\G6/^?ZQ_\``-__`([1Y.L?\_UC_P"`;_\`QVM"
MB@#/\G6/^?ZQ_P#`-_\`X[1Y.L?\_P!8_P#@&_\`\=K0HH`S_)UC_G^L?_`-
M_P#X[1Y.L?\`/]8_^`;_`/QVM"B@#/\`)UC_`)_K'_P#?_X[1Y.L?\_UC_X!
MO_\`':T**`,_R=8_Y_K'_P``W_\`CM'DZQ_S_6/_`(!O_P#':T**`,_R=8_Y
M_K'_`,`W_P#CM'DZQ_S_`%C_`.`;_P#QVM"B@#/\G6/^?ZQ_\`W_`/CM'DZQ
M_P`_UC_X!O\`_':T**`,_P`G6/\`G^L?_`-__CM'DZQ_S_6/_@&__P`=K0HH
M`S_)UC_G^L?_``#?_P".T>3K'_/]8_\`@&__`,=K0HH`S_)UC_G^L?\`P#?_
M`..T>3K'_/\`6/\`X!O_`/':T**`,_R=8_Y_K'_P#?\`^.T>3K'_`#_6/_@&
M_P#\=K0HH`S_`"=8_P"?ZQ_\`W_^.T>3K'_/]8_^`;__`!VM"B@#/\G6/^?Z
MQ_\``-__`([1Y.L?\_UC_P"`;_\`QVM"B@#/\G6/^?ZQ_P#`-_\`X[1Y.L?\
M_P!8_P#@&_\`\=K0HH`S_)UC_G^L?_`-_P#X[1Y.L?\`/]8_^`;_`/QVM"B@
M#/\`)UC_`)_K'_P#?_X[1Y.L?\_UC_X!O_\`':T**`,_R=8_Y_K'_P``W_\`
MCM'DZQ_S_6/_`(!O_P#':T**`*<$>I+,IN+NTDB_B6.V9&/T)D./RJ[24M`%
M>]N?LEL9?+:0[E144X)+,%'7W(K,E\0I`WER6Y\Q<B0*X(!WA%`/<LS8'3H<
MXQ5_4;!-1A2&21UB$@=PA*EL<@`CD<X.1SQ4*:%IJ1RH+<D2Q+"Y:1F)52S`
MY)SNW,QW?>).<YH'H4;G7KF._2U2U'FQ++)<@/E-B*AX8@<GS%QQV(Z<TNH>
M*+>Q6=@$D$<<C!8Y5:0E4+GY!T'&.3G/;'-63X<TH^6?LS!D`&X3.&<9R0YS
MEP2<L&SNXSG`HD\-Z3-/)-)9AV=BS*SL4R2"V%SM&2`2`.3R<T]`N4'\2-;6
MDXNH9%NK&)Y+@(5*MMB5_P!=Z\<'/J.KAK=Y"`[0>>L:-YP!`8NK(GRC'3=O
MZGM^%:::+8)"L0A8JH/+RNS-EE8EB3ECE5Y.>F.E1BQMY=\MA*(Y-S1N_P`S
MC[Y9A@G&=Q//.,D"AVZ`O,CO=5EDTF\FTU8WF1Q!`\A^1I"0H/&>`S8/N"*@
M'B$P0V_F6LTIG!$)5E+2D,JDXX`!+`@^G7;TK2M[*SCLHK")08;78H0'[I7#
M+G'?H:@72-+M9_,$(6264%<R,<,#OPH)PHR-Q`P"1DBC070=>:H;*:TADA7?
M/GK)M7(*C:&(P6.[@'&<'TIC:W&!'LB+&5I%3YA@E9%C'/H2P_"K%UI=I>74
M-S,CF2+&W;*ZAL'(#*"`X!Y`8'':JT?A[3(8IT2*4+,/FS<2$H`=P"'=F,`\
M@+C':D/04ZM*K2*]DW^CX-R1*N$!SR,XW<?,>AP1P3Q5,^*H5A:0PC'[L[UE
M#H@<X'F,H.PCOP0,CG&2+=GIFD3I;7]I$KQM$/*8.Q1U(X8KG#'!/S$$\GGF
MHAHVC.TFGKYWGQ[)V*W4HF4'<JGS-V\#AP!G&,BJT$3PZPLNI1V1B5'>,2;6
ME&[!&<J.C*.A()P3TQS6G67#8:5!J#7,2-',B*2F]PB#&T-Y>=JG"D;L`X&,
MXK21UD170AE8`@CN*3L`ZBBBD`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%5=2O!I^FW%WL+F)"RH/XF[#\3@5:J*Z6![29;G;Y!0B3<<#;CG)[
M<4`CGVU/4(X##+),UPDC>;Y4";U58E8D#)7&YE[DX(')YJW=:C<@6T`D2%C:
M-=7%PH!1`H'`SZDY^BGN0:B>WT%M.BWO/Y,<AY,TWFL2NXASG>X*@$AL@@`G
M@"K%_:Z0D4$]YN95=FC;S'<MG+%>"2R<9VG*@*..!AL:,N;7-3A?=<*MO'<0
MJ8E6,RLA(3Y@BY8X)88(Y.P#C)KJ(94F@CEC?>CJ&5O4$<&LB];0[Q+N.XN!
MRBS2LD[HP4`8*LI!`PPX4_Q_[7.Q&JI&JHH5``%4#&!Z8IO8D=5'6+J>RTR2
M>WCW2!E7.,A%+`,Y'<*"6Q[5>JIJ<%G<:?*M\=MNH#LPD9"FTY#!E(((QU!S
M4E(Y^V\07%[9W)@GW?9%N)&G\K'F+&[*@P?4JV2/[O&,\7M<U.]LX;J2U50+
M.T-RRE=QE<YV1CV)4Y[\C%2M#HDUM;7;>6(+9O*3YRBAMVT(RY&2&Q\K`X;'
M&:FN[/3H##?73.HML`.\[X.3\NX9P^">-V<$\8--6ZB9E7.NW6G2S#42]NA;
M>'$8D\N,.V2`F3R@'49X=CPIQTX((!!R#6-/;Z)=I/',H<)<"249?+.24`/]
MX$Y3;R."N,<5LT/8`HHHI`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4M)2T`4
MM52XDTZ1+9-\C%05SU7<-W<=L]Q6!;Z=JFY4NK(/#D^2J2+&(&,S$MP3C"!"
MH&?XAP#6YK5Y+8::T\.WS/-B0%HVD`#2*I.U2">">!60VOZG;LQ>S6>-1*^[
MRGMRR(B,2%<D]69?<XZ#)HN-:Z(6/3[L6]MNLKA7\V%[K;.NZ5EW.6^]C&_;
MWR1QC`%11:#=S6P^T_:%ED:(OMN2"A,AEE(*GC[Q0$<@#C@U./%]LVISV,=M
M),Z6\\Z>4P=F\DJK*0.C$N,#G(SG'&89_&UK;#]Y'#)L1I96@NDD78I`^3^)
MVY/R[0?D;_9W-2;T7J%F.DTW4'MYK3R)%BF1HE:*15$*23,7[YR(]N,`]*JZ
MMIFLR:<T=I:*\I7>FXK\CO*6<9WC!`(&0#GUJ+QOXQU#PVQ^Q0VL@^SO*/.5
MCR(+F0=&'&8$_`M[8[$7$7FI"TL8F9-XCW#<1Z@=<53BTDV*]F<=<:+K$[73
M+;;#*\^U5D"@N2%25F5@0=BJ0<$@EN,XK2M;#46UBVFO('+17$TCW(D78R;2
MD:[<Y^Z0>G!#?WJLWOB)+.>:)XHDVW*VT;SSB-7?RO-))P=HV\#J2>P'-5I_
M&=E;V*W3P2Y8!EARH=E,8<-R0,;B$R3C<>M3?0;N5UTZ[O1--`MP@N6G#S"?
M[T;N%79S\H"#=T&".,DFDOM*U(M,;.VD$RR2,DOGA5,?E,%C49[L03N&,Y;.
M0*L+XN619/*L_-,"S/<-',"BK&(R=C8^?(D!'09!!((JU=^);>SA622/;O:1
M%+N%4,DRP\GL"7!SV`/!HN-)[HSQI-Y:VGD6EDQM0PV6T[+)]V,*"P,@!R<G
MJ>0#C)X+?2M0BO!<M;SFZ3RAY[3*0Z)#C;C=U9V;.1[YX%68_%:236T:VGRS
M,$\PSHJ.QD,9$3'`DQMW$<':00"3MJ6\\46UGK/]G-'DJ\4;MY@W!I#A0J?>
M8#C<<8`8'G#;7=O4FUM#-U'2-3GLY;-(7D1XS&T@=`2!$D8ZGKEY6&>Z^XS?
MT5'N+R9D9AIUI,ZVNPC9(6'S'CJ%RRCMG/H*@_X2_P`Z:&*RTR:Y>1)W($@7
M:80F]?F[[I-H[9'4#FD'CG3?WLYP+*(.3)Y@,F%C,C-Y8YVX!7)P=PZ8P2N;
M1E<KLCJ**Y]M>OH9U%WIL=M"8))2TERO./+QSC`&9,'.,$'&1@EO_"4[K6.>
M.R,B^7<2RLLHVJD+A6*DC+9SE>`"!R12%9G145BMX@$16:>V\JP:X:W%T91\
MK!RGS+V#.,#&>HSCI6M;R^?;13%&3S$#;6ZKD9P:/,1)1110`4444`%%%%`!
M113)88YXFBFC22-AAD=001[@T`/HK/\`["T?_H%6/_@.G^%']A:/_P!`JQ_\
M!T_PH`T**S_["T?_`*!5C_X#I_A1_86C_P#0*L?_``'3_"@#0HK/_L+1_P#H
M%6/_`(#I_A1_86C_`/0*L?\`P'3_``H`T**S_P"PM'_Z!5C_`.`Z?X4?V%H_
M_0*L?_`=/\*`-"BL_P#L+1_^@58_^`Z?X4?V%H__`$"K'_P'3_"@#0HK/_L+
M1_\`H%6/_@.G^%']A:/_`-`JQ_\``=/\*`-"BL_^PM'_`.@58_\`@.G^%']A
M:/\`]`JQ_P#`=/\`"@#0HK/_`+"T?_H%6/\`X#I_A1_86C_]`JQ_\!T_PH`T
M**S_`.PM'_Z!5C_X#I_A1_86C_\`0*L?_`=/\*`-"BL_^PM'_P"@58_^`Z?X
M4?V%H_\`T"K'_P`!T_PH`T**S_["T?\`Z!5C_P"`Z?X4?V%H_P#T"K'_`,!T
M_P`*`-"BL_\`L+1_^@58_P#@.G^%']A:/_T"K'_P'3_"@#0HK/\`["T?_H%6
M/_@.G^%']A:/_P!`JQ_\!T_PH`T**S_["T?_`*!5C_X#I_A1_86C_P#0*L?_
M``'3_"@#0JMJ+S1Z=<-;VGVN;80D!8*)#Z$G@#U]O6H/["T?_H%6/_@.G^%4
M]5TJQM-+N)K+0K*XNE3]U$+5&W,>!QQQSSR/J*&-;C'MK_\`L^<+;SF[N@[2
M3(T:%)-JJ,`L0%P,<$D8]3FF:O9:A,ENEE!*BPV\J1^2Z(5D("KDDG"$9Z9(
MX[BJ,D=O'X=>['AZR-]',D4T+V<8,`9U#,RHS@A4;><,<@=1VSY;J*.4R#0]
M.?3K5I!>7R:<I15`1ED`9U.S:S9QO)P"`13W=@U2N;%QH<]O="XLX&VIY>5C
M*Y8@#.P,<`#:IYZD`_PC/1V_G?98OM&WS]@\S;TW8YQ^-<GIQL+Z[A<Z1I8M
M)[NYM$06@WJ86==Q;H0?+;C`QD<GOT/]A:/_`-`JQ_\``=/\*'V$U9FA5'5W
MNDTYS9V*WLY90L3LH7J/F.2.!UQU.*;_`&%H_P#T"K'_`,!T_P`*HZGIFG6R
MVT=OI6FK-<SB%7DM%95X+$D#&>%(ZCDT@VU$?0DN(;'SH99'6\^TS-.RE@P^
M8-@';U5`,9(!QW-2:QIMYJ4UFR2HL$<L;M!)$&PRMDL3NYX&`/<GTQ!H-KI6
MK:7]IDT;3TD2>>W?;;K@M%*T98<<`E,XYQG&36E_86C_`/0*L?\`P'3_``JG
M=.W8-S&OM+U.*6:XTV-MXD/DH[H1G#L'.?X0[XQR<%CUV[>H&<#.,]\50_L+
M1_\`H%6/_@.G^%']A:/_`-`JQ_\``=/\*D#0HK/_`+"T?_H%6/\`X#I_A1_8
M6C_]`JQ_\!T_PH`T**S_`.PM'_Z!5C_X#I_A1_86C_\`0*L?_`=/\*`-"BL_
M^PM'_P"@58_^`Z?X4?V%H_\`T"K'_P`!T_PH`T**S_["T?\`Z!5C_P"`Z?X4
M?V%H_P#T"K'_`,!T_P`*`-"BL_\`L+1_^@58_P#@.G^%']A:/_T"K'_P'3_"
M@#0HK/\`["T?_H%6/_@.G^%']A:/_P!`JQ_\!T_PH`T**S_["T?_`*!5C_X#
MI_A1_86C_P#0*L?_``'3_"@#0HK/_L+1_P#H%6/_`(#I_A1_86C_`/0*L?\`
MP'3_``H`T**S_P"PM'_Z!5C_`.`Z?X4?V%H__0*L?_`=/\*`-"BL_P#L+1_^
M@58_^`Z?X4?V%H__`$"K'_P'3_"@#0HK/_L+1_\`H%6/_@.G^%']A:/_`-`J
MQ_\``=/\*`-"BL_^PM'_`.@58_\`@.G^%']A:/\`]`JQ_P#`=/\`"@#0HK/_
M`+"T?_H%6/\`X#I_A1_86C_]`JQ_\!T_PH`T**S_`.PM'_Z!5C_X#I_A1_86
MC_\`0*L?_`=/\*`-"BL_^PM'_P"@58_^`Z?X4?V%H_\`T"K'_P`!T_PH`T**
MS_["T?\`Z!5C_P"`Z?X4?V%H_P#T"K'_`,!T_P`*`-"BL_\`L+1_^@58_P#@
M.G^%']A:/_T"K'_P'3_"@#0HK/\`["T?_H%6/_@.G^%']A:/_P!`JQ_\!T_P
MH`T*6J4&DZ;;3+-;Z?:12K]UXX55AVX(%7:`(+Q+=K9FNBJPQE969FVA=A#`
MD^@(!_"J<DVD:C$\QNK::-(WC9UG&%5AE@2#QPN?PI^MVTU[I,UI!NS<;8G*
MD`K&S`.1GCA2QK-UFQU.2V-M;RSW:2PR12-(8UP7:-<D#:"%4R-C';UP*0UH
M[HLV_AS1X;HW-O"R3*)5#)<2#9YI#R8&["[CACC'.#4H\/Z<K^8J7"2DDM*E
MU*KOG'WF#9;H.I.*PSI.N2VUS+//>-<F.3[.L=T8U1Y9F(W!7`/EH(QSZ-C.
M2*-#GO+[Q#$?M4TD5O;RM=LMRKQ2RLX$>T*Q``59./EZJ2,\U745S9U;PUI&
MN$G4K3SR4,?^L=?E*2(1\I'\,L@_X%Z@8U@```.@HHHNWH!3FTNTG+%XW#-+
MYQ9)61@^S9D$$$?*,<5#+H&F3SF>:U\R<VWV3S7D9G\K=NQN)SG(!SUR!SP*
MTJ*2TV`H#1[+RWC=9I0\;Q$RW$DAV/C<,LQ/.T?3M3&T#36D=S#)N<L?]?)A
M2SAR5&[Y3N4-D8Y%:5%`[LSI-$L9UA687$JQ.KJLEU*Z[E;>I(+88AL$9ST'
MH*EDTNUDO3=XF28[=QBG=`V.FX*0&_$&KE%`C"G\*V4VIVETK2Q16\$L)ACE
M==^\1`'<&!X6(#'?/M5S^PM.S*/(;RI01)!YK^4X*[2#'G:<CVK1HH'=Z>1F
M'0-/94#K</L!"%[N5BH)4\$MGJBD>A&13H]#T^.%XA"Y1TE1M\SL2)""_).>
M2`:T:*!+38RKO0+2YM;FW`*QW)/FH[NZ'+;F*KNPK$\Y`ZUJT44`%%%%`!11
M10`4444`%,E,@B8PHCR8^578J"?<@''Y4^B@#/\`.UC_`)\;'_P,?_XU1YVL
M?\^-C_X&/_\`&JT**`,_SM8_Y\;'_P`#'_\`C5'G:Q_SXV/_`(&/_P#&JT**
M`,_SM8_Y\;'_`,#'_P#C5'G:Q_SXV/\`X&/_`/&JT**`,_SM8_Y\;'_P,?\`
M^-4>=K'_`#XV/_@8_P#\:K0HH`S_`#M8_P"?&Q_\#'_^-4>=K'_/C8_^!C__
M`!JM"B@#/\[6/^?&Q_\``Q__`(U1YVL?\^-C_P"!C_\`QJM"B@#/\[6/^?&Q
M_P#`Q_\`XU1YVL?\^-C_`.!C_P#QJM"B@#/\[6/^?&Q_\#'_`/C5'G:Q_P`^
M-C_X&/\`_&JT**`,_P`[6/\`GQL?_`Q__C5'G:Q_SXV/_@8__P`:K0HH`S_.
MUC_GQL?_``,?_P"-4>=K'_/C8_\`@8__`,:K0HH`S_.UC_GQL?\`P,?_`.-4
M>=K'_/C8_P#@8_\`\:K0HH`S_.UC_GQL?_`Q_P#XU1YVL?\`/C8_^!C_`/QJ
MM"B@#/\`.UC_`)\;'_P,?_XU1YVL?\^-C_X&/_\`&JT**`,_SM8_Y\;'_P`#
M'_\`C5'G:Q_SXV/_`(&/_P#&JT**`,_SM8_Y\;'_`,#'_P#C507<.H7UN;>Y
MTRPDB)5L&]<8*D%2"(L@@@$$="*UZ*`,(6.HK&8DL[=(V!W[=3F#N3M^8OLW
M9`7&<].*@?0Y)(VCDTBS=75DD#ZE,WFJ>HDS'\XY/#9KI**`,.*PNX;UKR/3
M+(3'<?\`D(2E06QN(7R]H)QR0.?QJYYVL?\`/C8_^!C_`/QJM"B@#/\`.UC_
M`)\;'_P,?_XU4%W#J-]!Y,^GV97<&!2_D1@0<@AEC!'X&M>B@#*MDU*SMT@@
MTZP2-.@^VN?<DDQ9))Y)/)-2^=K'_/C8_P#@8_\`\:K0HH`S_.UC_GQL?_`Q
M_P#XU1YVL?\`/C8_^!C_`/QJM"B@#/\`.UC_`)\;'_P,?_XU1YVL?\^-C_X&
M/_\`&JT**`,_SM8_Y\;'_P`#'_\`C5'G:Q_SXV/_`(&/_P#&JT**`,_SM8_Y
M\;'_`,#'_P#C5'G:Q_SXV/\`X&/_`/&JT**`,_SM8_Y\;'_P,?\`^-4>=K'_
M`#XV/_@8_P#\:K0HH`S_`#M8_P"?&Q_\#'_^-4>=K'_/C8_^!C__`!JM"B@#
M/\[6/^?&Q_\``Q__`(U1YVL?\^-C_P"!C_\`QJM"B@#/\[6/^?&Q_P#`Q_\`
MXU1YVL?\^-C_`.!C_P#QJM"B@#/\[6/^?&Q_\#'_`/C5'G:Q_P`^-C_X&/\`
M_&JT**`,_P`[6/\`GQL?_`Q__C5'G:Q_SXV/_@8__P`:K0HH`S_.UC_GQL?_
M``,?_P"-4>=K'_/C8_\`@8__`,:K0HH`S_.UC_GQL?\`P,?_`.-4>=K'_/C8
M_P#@8_\`\:K0HH`S_.UC_GQL?_`Q_P#XU1YVL?\`/C8_^!C_`/QJM"B@#/\`
M.UC_`)\;'_P,?_XU1YVL?\^-C_X&/_\`&JT**`,_SM8_Y\;'_P`#'_\`C5'G
M:Q_SXV/_`(&/_P#&JT**`,_SM8_Y\;'_`,#'_P#C5'G:Q_SXV/\`X&/_`/&J
MT**`,_SM8_Y\;'_P,?\`^-4>=K'_`#XV/_@8_P#\:K0HH`S_`#M8_P"?&Q_\
M#'_^-4>=K'_/C8_^!C__`!JM"B@#/\[6/^?&Q_\``Q__`(U1YVL?\^-C_P"!
MC_\`QJM"B@"G!)J33*+BTM(XOXFCN6=A]`8QG\ZNTE+0!6OKQ+&V\YT>3+JB
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M;>6&C*HKGDMAB5=2`I).?4$5/>^*["QL[FY:*XE^S%EECB52ZD,B]R`,AU89
M/*\U%=^'='O+,Q7%U(4OUDCED$P5KL2*"P+`<Y6,?=Q\JXZ4Y=%TK4/[01KF
M*?[8(4E\EP"0@#)G!.6P0<\9&WB@:2TN%QXLMK)96O+&]MDBD,+/)Y>-^P.%
MX<]01@]/4BJ\WCK384D86UU+Y44TTHA,3^6D2QLY)#X/$JD`$GK6IJ&C:==P
M3F\W")I#/(WFE-I\OR]P8$%<+SD$8(S58Z!IVK6S3RWD]\ES:S0"?S@0T4RH
M&V[0%`Q&N,#U/4FEK;S''DYES;&AI5^VHV;3M`T.)I8PK$'(1RH/!/7%7:KV
M=G'8PM#$SE#(\@#$'!9BQ`]LD_G5BF0%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!114%W>6MA;-<WES#;0+C=+,X11D
MX&2>.M`$]%0->VJW:VC7,(N60R+"9!O*C^(+UQ[TD-_9W"0/#=P2I/DPLD@8
M28Z[<=?PH`L4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%+24M`&;K<QBL51'D1YIHXP8OOX+#=CWVAC^%8;6^K;"EO\`;UAMP&AW
MSL7=7E()))RS+&I(#9^^`02*Z:]GAM;9[F9-RPC>,`$YZ<9Z'G&>.M9L/B2"
MYAA>"TNIG<_O8XO+=H%#%2S8?!&0?NEB<'`.#0AF)/I][).(U355LX4E:T)G
M<R&1@@3<Y8N!D2'YC@!@&P/EI=2CUZ:XN9(([L3/'-`$5B4"XVQL`6"$L2'S
MMR.5+=JWEUV-E#_8[P(\L<<+%%Q,'.`RX/0<DYP0!G'2HO\`A)K4Y*VMXRB0
M(66($`&1HPW7)!9>,9)#`XZX=M-@N9/V#5H[.Z@M)+L6Y2468E8EE)2-!NSS
MC<TC!3T`&,``!TVE2AGDDN;JT\F-UAE$[HBJ90H&`=OW47K_`'LUL?\`"06Z
MV,MT]O<H88I))(<*74HQ7;PQ!8L"!@X..M4M0\1V5M:J^H6GFH99,`>7A`KE
M`3O89)Q_#G&?3FF[]`2U'2VEUK/AV5+Z.53?R1AX%D93'"64%<@C!V9+>Y(Y
M%4TM-6,D2Q2:A&SCR[IWE)"?O%"B,'(X3<=PZC[V2>+4_C&SM)IX[JWGC\N5
ME7E"6C4#=)][H">GWCV4G(%X:Y%+?06]O%))'+*8A<`#RR0K,P!SG(VX.0!S
MC)((!<6Q6U:UN!/I\5J][MA9>%DDP^64$LX;DJN3AP5;..O2ONU*>%=R7D87
M>;@`L"`\H^52.3MCW8*^V.:OR>(;:*6=9(+I8XA)B7RQMD9/O*O.2>O;'!&<
MC%-;Q'!&S"6TNHHU+*TKJNQ7`)V$AB<D#.0".Q(;BD,II:W@E"QMJJF$;K,2
M39!&"3YI).[)PN&RP&",')%/[!J2V%Q']NU%DE9"S-'*#O&2Q!$GF(#@#"84
M'&!C=6E%XF":2MQ=V4\=VNQ9+8%$)9EW9!=@H&,_>(/&,9XJ2+Q"DFJ"$0R&
MSD2+9<A<*'=2VUL_[.WH#UYQQ3U$GU*]I%J!UVSED%X$6`)*LDK;5(3.>#Y<
MF6)!.`X([KQ71US]UXF2UL9+PPM-&D0=4C`#L?+,A&"<#Y=O<\FK]GJ\=T+>
M-HI([J4N'A."8BOWBV"1C.!D9^\*3NP-&BBBD`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%17+RQV[M`BO*!\H=MH^I/Z
MT`2T5@2:]<I96\D5B;EY[Q;9)(SM0H6`\WYN=N.<#.<<''S5=U;5&L%BB@B$
MUS+(B*A.`H9@NYCV'/XGCU(=@-*BL`^('AN)8KH1VWSX1YP8U10S`LQ;`(PH
M((X)8#L36_UI6`***KWLLT-L7@$6X$9:5MJHO=CZX&3CC/J.M`%BBL6#6KJ4
MZ:ATZ13=RNC2E@$15WD-@G<=P3(`'`/..]F_U0VMU;6L,1FFFE16'01H3RQ/
MK@'`ZG![`T[:V`T:*Y^T\032W:VUS#';.[J1YY,>U2!\N&Y9LG`(X.">V#T%
M(`HHJK?S26]OYB/!$H/[R68_+&N#SC(SV'4=?:@"U16/'K,[W^F6AL)$-W`9
MI79@!%A?NX/).2`>,#/J<5)>:N8=2MK*VMS.7<K,X8`180L%]V..G8<G&1D`
MU**P--U^6[GCM[E(;64M\RR,58C"X4*<'=EL?0`X^85OTVK`%8.MPWKZG:2P
MFX$$4$VWR$5R9CM"9#`X&-XST&3DBMZL[6]3DTK3_M$-H]S(76-4#!0"QP"2
M>V2.G)["D-&.VD2W\$VGWD,D2R2N9I(!M58O*,:!#ZX(X`.,'/49?80:G::M
M;A8-]O+DNTJ<Q1L9&/((`;=Y>1CG=Z+FM:2]FCU:*U(B*2$@("2X7:3YA]!N
M&W&.IZ]JS+OQ++;W,\4-LES*GG*EI$^9B8T+`D=@V,`8[J><X%*[$SHZ*QM/
MUL75S';2O#'-\P96RC.P)P%4\YVKN/ID>^-FIL`4451U"_DLY;2**U>9KB98
MRP("QKGEB3[=`,G\`30!>HK-6_N?[8%F\495@QPA):-1T9CT^8Y`'!X[\XIG
M7I6GFBB6*60>9MBC!9XPDBQDL!R<[MV``<#'/6BP&]161I.L_P!HR")PD4JQ
M;G0G#,V><*><#O[G&<J:UZ`"BBJ%Y?RV^HV-I':22+<N5>;("1`*S=SDD[2,
M`<=\<9`+]%9EKJ%Q+JSV;QQ.JHSN\1SY)R`J-ZLP.[MC'3H:H?\`"0SO%(8(
MXYY=JOY<*L[0`MM(=1R2.N!CH1VS18#HJ*R](U<:IN),"$(I\I90[9P"QX_A
MR<`XYQGH16I3:L"U"BBLZXU.2+7+/3DM&9)T>1YRP"J%'0#.2<D=L#/O2`T:
M*SK"_FN)KF.81,854L8<D*QSF,GNRX&3Q]X<"LAO$]T8%:WMXKEF5)&,.YA`
MK+(VU\9YS&%SP,L"0,<NP'4450T[4HM1:<QRQ$(V!&K9<+R`S#L"0<>WY"_2
M`*6DI:`*>IP17%BZ37+6R@JPF4J"C!@5(W`CJ!U!%9]KHU@MQ'/;WT[.<M)L
MG'[\;VD&X@9P&<D8QD-@Y'%6-=M3=V,*!96*W=N^(V8'`E4DG:>@&3^&>U<I
MI)UX:3)+,E\EY+IFYV:(AS.((\<$?>W;N/7-*^Y<8W5[G3C0=MM'"FIWRF&0
M/%)F,M&H4J$`*;<88C)!;WX%30:+;6\,42O*5C,1&X@Y\L`*#QZC=]:Y;6;R
M[TMM3CEEU?[+'&WV%K97E82;%;+D`MM!)PS_`"#Y@QX%=FC7&^(>7&8BF7<N
M0P/LN,'\Q33):L4&T"`S*XN;D("K/$"NV0K(9`6^7/WF;@$#GITJ&\\+VM[;
MF![N\6)HDBD5&4>9M8LK$[<YR3T('/3IC(U6YU&PCCN&CU*6*2:Z#>3Y[.KB
M3$)"QHYV[`W50AXW9)&6W+>+A97D%LKF]MHU,4IVA;@R.K'&<@%`LBXYX(/>
MA,+:V-R+PW!`[M#>WL>^:260)(J[P[%RA(7(4,2000W.,XXJ6WT*WMM1%VDU
MQM5Y)$MRP\M'?EV`QG)))Y)QN.,`XKC[BZUZZM9IK!=5AB2RO9;=/+GW^<JP
M^4#YJ*[9;S"`PYY'(I\^H>(X[DP>1J+^0;N2X(A<(T1N(FC".JG<WDEP`F6&
M"`-PQ2YM;&GLVX\U]SJ8=!0$O/<S2,7+JF5VQEI/,;;QGYC@')/`XQDT7/AR
MTNY9C--<F*3>RPAP$C=E*LZ\9#$,>I(&20`:Q8;[40^DO)#J$BW$C+'$(KA3
M&OFC!D;9V0])@N0.#G-6]:N]1@\16T4<5R;>01>3)"LK*I#GS=X1"O*;<;R/
M]GG-5=F9H-H"M$N=1O1<;RTER/+$D@(`*GY-H&`HRH!XZY))1/#T*2.1>7?E
MLO$)9-J-L$8<?+G(48QG;WQGFN>&H74/D1Z@=:"OYC1I#!(TA0A/*W;`3D9^
M;T;[W!J;[3XA&L?97CE^UF,,LH60P,OD\@X3R@?-R>6W].-IH#S-F[\.6MT[
M$W5S&6#!0A3"DB,9`*GD",8SD<G(.:LZ;IAL[J^NY)-\UW(&('1%50`!^I/3
MEC7(74L@U&PU2SM==E6"UNH7,L,ZNLA\DGY60G!".<A2"1A<G:*A>[\17.FR
M-"-4CD@M-1EB`@E4EP8WMA\XW.=K$`'DD,"`0RA<UKE1AS-)=?\`@GHU%<F+
MV\2WOY`NI'4;5S+(KQNL+QB3*JA(V,3'Q\AZ_>P:Z2QBG@L+>*YG\^X2-1++
MC&]L<G';)[4$%BBBB@`HHHH`****`"BBB@`IDID$3&%$>3'RJ[%03[D`X_*G
MT4`9_G:Q_P`^-C_X&/\`_&J/.UC_`)\;'_P,?_XU6A10!G^=K'_/C8_^!C__
M`!JCSM8_Y\;'_P`#'_\`C5:%%`&?YVL?\^-C_P"!C_\`QJCSM8_Y\;'_`,#'
M_P#C5:%%`&?YVL?\^-C_`.!C_P#QJCSM8_Y\;'_P,?\`^-5H44`9_G:Q_P`^
M-C_X&/\`_&J/.UC_`)\;'_P,?_XU6A10!G^=K'_/C8_^!C__`!JCSM8_Y\;'
M_P`#'_\`C5:%%`&?YVL?\^-C_P"!C_\`QJCSM8_Y\;'_`,#'_P#C5:%%`&?Y
MVL?\^-C_`.!C_P#QJCSM8_Y\;'_P,?\`^-5H44`9_G:Q_P`^-C_X&/\`_&J/
M.UC_`)\;'_P,?_XU6A10!G^=K'_/C8_^!C__`!JCSM8_Y\;'_P`#'_\`C5:%
M%`&?YVL?\^-C_P"!C_\`QJCSM8_Y\;'_`,#'_P#C5:%%`&?YVL?\^-C_`.!C
M_P#QJCSM8_Y\;'_P,?\`^-5H44`9_G:Q_P`^-C_X&/\`_&J/.UC_`)\;'_P,
M?_XU6A10!G^=K'_/C8_^!C__`!JCSM8_Y\;'_P`#'_\`C5:%%`&?YVL?\^-C
M_P"!C_\`QJCSM8_Y\;'_`,#'_P#C5:%%`&?YVL?\^-C_`.!C_P#QJCSM8_Y\
M;'_P,?\`^-5H44`9_G:Q_P`^-C_X&/\`_&J/.UC_`)\;'_P,?_XU6A10!G^=
MK'_/C8_^!C__`!JJ.L6.JZQILEC)%#;QR$;V@O2&(!Y4[H2"IZ$$<CBMZJ]]
M:QWME-;3!S'(N&".R$CTRI!H;MJ-;F.%U."SMI;LVDRVK&7[1/?!=V58?-M@
M5<8;L!T'XU+ZR@OKFQ?4M/T.YNQM,$L]TIDD`)(`/D\C)S@4MW?6^G>&--CN
M]*NKVXABMW6W2SDEV.,;68*K$;6&3@$C`.,XJGI$2:=#IR::VJF:<`8ETYXH
M7'G.\@8-'NA`WOM#%1C8%W8JNKUZDEVYTZXU87$+):R/YN9]FHDMC:R^4?W/
MRKM9A@8/).<G-;(EU<``6%B`/^GQ_P#XU65I89_%$LEK:W45HEN\4XN(&B$<
M@<%0AP!*&W2,6!;!Z$;B#TM+HAF?YVL?\^-C_P"!C_\`QJLKQ!:WVHZ:([PV
MEE!'*DC2+?``D'@-YD#*1G!P1U`KI:SM:F@MK-;BXANW$;_*]K;-/)$Q4KN"
M*K$]2.%/7D8R0KVU&C/N'OK1K.YOGLE-NK(KSZ@$$C$`;C^Y`W8!Z8')X]*L
MMM;W>IV%U-8Z%/J*;9()FNU,LH"D`Y\G)')(QQD<=*M[;I?"UMIT8E@O%BM[
M>3R0<Q*Q5693[+N.><8ILD8L=8AM+!;Z-VCBC6,6^;80H<']X%PI`+8!8$G'
M!%&PD[H@73KF[N1<0+:,\<[-.8[_`'>8V5.Q_P!R<8V(,#!PH%;/G:Q_SXV/
M_@8__P`:K&\(I<^;,7A>*WM[6"R026TD)=H]^6PX!(PR],KUPS=NIIL&9_G:
MQ_SXV/\`X&/_`/&JR=>M;^^AMC<O:V*P3B1'6]7!?^'(D@8$CJ..N#VKIJYS
MQ:C-#;$K<^5^\5GMK0W+!F0J`4"M\IR<MCC&,C.:5[:C1+-:ZHUPMTT5LEPM
MNULDWVSE=Q&6`,.-Q*KVQP.*KOHO_$\@U0Z+I"WZ!\2"?#2,0,L3Y.20!Z]S
M5C4K?^T-'MHGAE,]M=6C/$C.0KJ\;'G^,`'.>1QGJ.,[4-.U27Q9!?2VXDC6
M*YBADMI3OBC*#`PR[`[,`<DXZ#MR3;BKB6I+;6D]Y-!<VK6<RP,3*(M0#+,^
M=P+D0YR&^;"E>W!``K:\[6/^?&Q_\#'_`/C55O#SR-;%$^U&QC1$@-Y`89<C
M(8%2JG`PN#CGDY(P:V:`,_SM8_Y\;'_P,?\`^-52U(WDR6\=Y!I\:_:(WC5K
M\KO=6#*.8N>0#@<\5NUQWBZVF?4HY5@N6$EC-:Q&"T,_F2.RG8Y`/EH=HRQ`
M'^TNWD6X="=++5;#5)KIKV-'O9,B&2]CPQXPJDV^[`'`&3U/<YJ2UDNFU2X9
M+BQN+D!PL3:D&-N"1O"@0YQD#[V<8`&!Q5#Q9<Z;>R_89M.OV:>-H)KZ#3)Y
MS#&'!9$*(Q#DJ"#P!@-DX`-S4K6XU9]:+V4CQP+':112)_Q\1'9)-MS@$."$
M],QX]::U28:W'6VFW,ES::A%#:3K$G[O%^61V^;]X2(>6_>2=\?,>,XQK^=K
M'_/C8_\`@8__`,:JGX:2<_VI=LDL=I=WAFM(I8VC=(S&@.48`KEUD;!&?FSW
MK<HDK`G<S_.UC_GQL?\`P,?_`.-5#.-4EEMG>SL@T4A=!]M;YCM9<?ZKT8G\
M*UJR=3L5GU?1KO9*[V]RQR';:@,,HW%<[>^,D9YQWH0&=IVE:SIUW<R)<^=Y
M\GG21RWB'YB1SD6X;&%VC)X7@=!@1;R(W[O<6KN`5>1]2^:U4\[0?)^4>[9/
M`YX&+UK;1Z=KFI7&R81W"V^78N^YRSK@$YP!E>!P!Z"L.UAE%JZW7]J.]I"H
MNY4LOG659%?]U^[_`'RY#L<!SZ<G!&.]R]86$MO=#4;*VT_R6C6*-$OR8AC"
MY7$6<X55ZXXZ9)SK^=K'_/C8_P#@8_\`\:K`OH-6U2QTZ9H?/@CNHID$K/#*
MV)U*.\83C"#)!Q@DD@%1CKZ0KZF?YVL?\^-C_P"!C_\`QJJTR:I)>VUP]K9A
MH=X1/MS;6+#K_JLY`!Q]36S6-J6GK)XATC4$A=YHFDC+[F*HAC;MT7)"\XR<
M#T%`T4](T[6-+1X$G2Y4/O*37:9!.2<E;=22Q.23DDCKUS'"EPMG>,\]G.A(
MBGGDU/)1%/\`JR1"``,D<_-\QR<\TGA^WN]+U+69M1MEC>ZDA=Y86>42R%,'
M&4'`P`/3`%84<@NXFOK;3[^UACFME:%=)GCDM;>,2;"$=/W[[C@A0P4$<';N
M9<S?]>8'0PB?3]6=V.GB:X'[FVDU'`0'&=@$()W$#J3TP,#BM;SM8_Y\;'_P
M,?\`^-5R^CVLVD'38DAOX+^2WM[<QK:9MFAC8]6"L(L*SG:6')`&[`%=Q3$9
M_G:Q_P`^-C_X&/\`_&JHW%OJ,]\)S!:1W1MI(8RE\=R*Q4LR@PGG(7U'`XK>
MKF-2TZ0^-[>^A@NCOT>[A>6(YPV^`HJEOD5C\Y&<9P<]*:5_Q_)C1%HT=Y9:
M:R0W]M>6<*E69M00!!CG+1P*0>^2<\Y)I+8M]@EQ<V%RKN@N+A]4W&3L$8B+
M`!'&`!GGN23?T.[\M(K?=>?9&"Q6AN[9HI-RAMRD;5P`%&"0,\X)XK!U72W:
MQL[^2VN%DN;B:YN9([,W$J,\31QH8\'`"LJ$X.`IZ;BP&^HEJ;-C;W5AJ=T4
MAL7O+C]X4?4#N2/<S8"B(?+N=SDY.6Z]`-/SM8_Y\;'_`,#'_P#C5<SIT&HC
M6K&U>U>WE$D5[=$Q2.J8MA$8Q,1L?YL<[MW7Y<?-7;425A)M[E."34FF47%I
M:1Q?Q-'<L[#Z`QC/YU=I*6D,0T4&B@"E?:1IFIRV\M_IUI=R6S;X'G@60Q-P
M<J2/E/`Z>@J[110`4444`%%%%`!1110`TQH9%D**74$*Q'(!ZX/X#\J=110`
M4444`,EABG4+-$DBAE<!U!`92"#SW!`(/J*?110`4444`%%%%`!1110`4444
M`%,EB6:)HV+A6&"4<J?P(((I],E=HXF=8GE8#A$(RWTR0/UH`I?V-:_\];[_
M`,#Y_P#XNC^QK7_GK??^!\__`,71_:-U_P!`:^_[[@_^.4?VC=?]`:^_[[@_
M^.4`']C6O_/6^_\``^?_`.+H_L:U_P">M]_X'S__`!=']HW7_0&OO^^X/_CE
M']HW7_0&OO\`ON#_`..4`']C6O\`SUOO_`^?_P"+H_L:U_YZWW_@?/\`_%T?
MVC=?]`:^_P"^X/\`XY1_:-U_T!K[_ON#_P".4`']C6O_`#UOO_`^?_XNC^QK
M7_GK??\`@?/_`/%T?VC=?]`:^_[[@_\`CE']HW7_`$!K[_ON#_XY0`?V-:_\
M];[_`,#Y_P#XNC^QK7_GK??^!\__`,71_:-U_P!`:^_[[@_^.4?VC=?]`:^_
M[[@_^.4`']C6O_/6^_\``^?_`.+H_L:U_P">M]_X'S__`!=']HW7_0&OO^^X
M/_CE']HW7_0&OO\`ON#_`..4`']C6O\`SUOO_`^?_P"+H_L:U_YZWW_@?/\`
M_%T?VC=?]`:^_P"^X/\`XY1_:-U_T!K[_ON#_P".4`']C6O_`#UOO_`^?_XN
MC^QK7_GK??\`@?/_`/%T?VC=?]`:^_[[@_\`CE']HW7_`$!K[_ON#_XY0`?V
M-:_\];[_`,#Y_P#XNC^QK7_GK??^!\__`,71_:-U_P!`:^_[[@_^.4?VC=?]
M`:^_[[@_^.4`']C6O_/6^_\``^?_`.+H_L:U_P">M]_X'S__`!=']HW7_0&O
MO^^X/_CE']HW7_0&OO\`ON#_`..4`']C6O\`SUOO_`^?_P"+H_L:U_YZWW_@
M?/\`_%T?VC=?]`:^_P"^X/\`XY1_:-U_T!K[_ON#_P".4`']C6O_`#UOO_`^
M?_XNC^QK7_GK??\`@?/_`/%T?VC=?]`:^_[[@_\`CE']HW7_`$!K[_ON#_XY
M0`?V-:_\];[_`,#Y_P#XNC^QK7_GK??^!\__`,71_:-U_P!`:^_[[@_^.4?V
MC=?]`:^_[[@_^.4`']C6O_/6^_\``^?_`.+H_L:U_P">M]_X'S__`!=']HW7
M_0&OO^^X/_CE']HW7_0&OO\`ON#_`..4`']C6O\`SUOO_`^?_P"+H_L:U_YZ
MWW_@?/\`_%T?VC=?]`:^_P"^X/\`XY1_:-U_T!K[_ON#_P".4`']C6O_`#UO
MO_`^?_XNC^QK7_GK??\`@?/_`/%T?VC=?]`:^_[[@_\`CE']HW7_`$!K[_ON
M#_XY0`?V-:_\];[_`,#Y_P#XNC^QK7_GK??^!\__`,71_:-U_P!`:^_[[@_^
M.4?VC=?]`:^_[[@_^.4`']C6O_/6^_\``^?_`.+H_L:U_P">M]_X'S__`!='
M]HW7_0&OO^^X/_CE']HW7_0&OO\`ON#_`..4`)_8=F'+[[W>0`6^W39(';[_
M`+FE_L:U_P">M]_X'S__`!=']HW7_0&OO^^X/_CE']HW7_0&OO\`ON#_`..4
M`']C6O\`SUOO_`^?_P"+H_L:U_YZWW_@?/\`_%T?VC=?]`:^_P"^X/\`XY1_
M:-U_T!K[_ON#_P".4`']C6O_`#UOO_`^?_XNC^QK7_GK??\`@?/_`/%T?VC=
M?]`:^_[[@_\`CE']HW7_`$!K[_ON#_XY0`@T2T!)$EZ">I^W3<_^/TO]C6O_
M`#UOO_`^?_XNC^T;K_H#7W_?<'_QRC^T;K_H#7W_`'W!_P#'*`#^QK7_`)ZW
MW_@?/_\`%T?V-:_\];[_`,#Y_P#XNC^T;K_H#7W_`'W!_P#'*/[1NO\`H#7W
M_?<'_P`<H`/[&M?^>M]_X'S_`/Q=']C6O_/6^_\``^?_`.+H_M&Z_P"@-??]
M]P?_`!RC^T;K_H#7W_?<'_QR@!!HEH"2)+T$G)Q?3<_^/TO]C6O_`#UOO_`^
M?_XNC^T;K_H#7W_?<'_QRC^T;K_H#7W_`'W!_P#'*`#^QK7_`)ZWW_@?/_\`
M%T?V-:_\];[_`,#Y_P#XNC^T;K_H#7W_`'W!_P#'*/[1NO\`H#7W_?<'_P`<
MH`/[&M?^>M]_X'S_`/Q=']C6O_/6^_\``^?_`.+H_M&Z_P"@-??]]P?_`!RC
M^T;K_H#7W_?<'_QR@!%T.S0$(]ZH))(%],.3R3]^E_L:U_YZWW_@?/\`_%T?
MVC=?]`:^_P"^X/\`XY1_:-U_T!K[_ON#_P".4`']C6O_`#UOO_`^?_XNC^QK
M7_GK??\`@?/_`/%T?VC=?]`:^_[[@_\`CE']HW7_`$!K[_ON#_XY0`?V-:_\
M];[_`,#Y_P#XNC^QK7_GK??^!\__`,71_:-U_P!`:^_[[@_^.4?VC=?]`:^_
M[[@_^.4`(=$M&&&DO2,@\WTW_P`72_V-:_\`/6^_\#Y__BZ/[1NO^@-??]]P
M?_'*/[1NO^@-??\`?<'_`,<H`/[&M?\`GK??^!\__P`71_8UK_SUOO\`P/G_
M`/BZ/[1NO^@-??\`?<'_`,<H_M&Z_P"@-??]]P?_`!R@`_L:U_YZWW_@?/\`
M_%T?V-:_\];[_P`#Y_\`XNC^T;K_`*`U]_WW!_\`'*/[1NO^@-??]]P?_'*`
M$.B6C8S)>G!R,WTW'_C]+_8UK_SUOO\`P/G_`/BZ/[1NO^@-??\`?<'_`,<H
M_M&Z_P"@-??]]P?_`!R@`_L:U_YZWW_@?/\`_%T?V-:_\];[_P`#Y_\`XNC^
MT;K_`*`U]_WW!_\`'*/[1NO^@-??]]P?_'*`#^QK7_GK??\`@?/_`/%T?V-:
M_P#/6^_\#Y__`(NC^T;K_H#7W_?<'_QRC^T;K_H#7W_?<'_QR@!#HEF6#%[T
ML.A^W3<?^/TO]C6O_/6^_P#`^?\`^+H_M&Z_Z`U]_P!]P?\`QRC^T;K_`*`U
M]_WW!_\`'*`#^QK7_GK??^!\_P#\71_8UK_SUOO_``/G_P#BZ/[1NO\`H#7W
M_?<'_P`<H_M&Z_Z`U]_WW!_\<H`D@TR"WF65)+LLO027<KK^(9B#5VJ4%Y/+
M,J/IEW"IZR2-$5'UVN3^E7:`$-%8FO7%[`&-B%>81@K'),8D8Y/5@K$?D:X_
M2_'K3Z#:ZKJP:R2[#/!%;R2W3;%^\S!8P5`[G!`XR>:`L>ET5P`\;V@FO4DF
MO0MM,D*LD$TGG%H_,&P*I+<9/&>!GH0:MZ;XB;5+RYBMY7:&**&6.82'$BR*
M6!QVX'ZT`=I17':GXCM](>V2\N[A7NG,<*1QR2L[`9(`0$]`:IR^.=*@@N9Y
M=2GCAML>9(\4H7!;;E3M^==W&5R,]Z`.]HKA[_QAIVFO(EUJ,JM&Q5E1)'(P
MH<G"@_*%926Z#/)%.'BVQ;5$TY;^9KERJKMCD*99-ZC?C;DKR.><4`=M17$G
MQ98BU%Q_:$IC,23+M20LRNVU<*!DDMP%`SGM49\9Z<!:G[?<G[22$Q#*=I#[
M#O\`E_=_-\OSXYR.U`'=45Q>H>*;+2[N.UO-0DCFD"D`!V"@MM!8@$("W`+$
M`GBJQ\<Z0JW;'5G'V-'>X7;)NB5'V,6&,CYL@>N"1D47'9G>T5P+^.M)BMS-
M)J-R@#O&R-!,)$*@,Q9-NY0`RDL1@`@YYI+KQSIMNUPB7UQ/)"C,1#'*ZLP0
MR;`X!7=M&=N<XYQ2;LKA9G?T5Y]9^.].NC9Q->W$5Q=1JPB>.7Y69"X0MMP&
MV@D`X)`R!BEL_'NCW]I-<VVJ3/%"D<C9BE4E7.$*J5R^3P-H//'6F(]`HK@U
M\;Z4T<C_`-IS+Y:JSJ\<J,-TAC`VD`YW@J1C(/4"MO[3/_SVD_[Z-`'0T5SW
MVF?_`)[2?]]&C[3/_P`]I/\`OHT`=#17/?:9_P#GM)_WT:/M,_\`SVD_[Z-`
M'0T5SWVF?_GM)_WT:/M,_P#SVD_[Z-`'0T5SWVF?_GM)_P!]&C[3/_SVD_[Z
M-`'0T5YQ;^.))_$[:48I%@-S)9QW/GDEIDC$C`ICA=IX.>HZ=ZZ;[3/_`,]I
M/^^C18#H:*Y[[3/_`,]I/^^C1]IG_P">TG_?1H`Z&BN>^TS_`//:3_OHT?:9
M_P#GM)_WT:`.AHKS_3?%ES?ZRUFT;1P2?:/LTPN"QD\B01R;EP-OS'C!.1Z=
M*W_M,_\`SVD_[Z-`'0T5SWVF?_GM)_WT:/M,_P#SVD_[Z-`'0T5SWVF?_GM)
M_P!]&D-S.!DSR?\`?1H`Z*BO.?#GC:7Q!>O`(I(4>W%W;2"<OYL)=D!(P-IR
MN<<\$<UTOVF?_GM)_P!]&@&K:,Z&BN>^TS_\]I/^^C1]IG_Y[2?]]&@#H:*Y
M[[3/_P`]I/\`OHU%<:A):VTMQ)/*(XD+M\QZ`9-`'345Y[X8\8S^(1*LD,EI
M,D,-RJ"<R`Q2J60DX&#P<CG&.IKH?M,__/:3_OHTVFG9@=#17/?:9_\`GM)_
MWT:/M,__`#VD_P"^C2`Z&BN>^TS_`//:3_OHU4U/5WTO2KS4)996CM87F8!S
MDA5)/\J`.LHKBM%UZ]U)+J.[C-K=VLHBFBCN#*H)17!#87/#CL.<]>M:GVF?
M_GM)_P!]&@#H:*Y[[3/_`,]I/^^C1]IG_P">TG_?1H`Z&BN>^TS_`//:3_OH
MU0UO77T31+W4Y979+:%I-ID*[B!P,\XR<#I2;MJP.PHKS<^.)$\('7MT-P#(
ML2)9WK21LS.$&79%QR>?EX]ZS)OB>\4ME:E;:&[GN+BWD%UJ+1Q1O$P4@2"-
MMV2W&0/?%.VM@Z7/6Z*\YL/&\E]XC.F"*18'DGAAN1.27DAVB0%<<#+<')SM
M/2NE^TS_`//:3_OHT`U8Z&BN>^TS_P#/:3_OHU3U36+C3--FNPEW<M&N5A@R
M6<^GM]3P*3=E<#K:*X>37]1;0+/4+*TFN;BZ6(K`)RH3?CEFP<*N>3@].E8-
MI\2GO+_1[,)%;R:@K,1=7S)C$ACQ'A#YA.TE<[<C'3-585U:YZM17`Z3XIO=
M0UW4-*N(#;RVBJYV77F$!B=H<8&UB`&P"PP>N>*W?M,__/:3_OHTA^1T-%<]
M]IG_`.>TG_?1K,UW6M0TK3'O+:/[1Y>6D\VZ,*1H%)+LV&.!C&`"<D=LD#=@
MW.THK@=4\3WMCX777(4C,8@%Q*ES=M%L0KG`*H^6S@8QSZU17QU=+KEEI-RE
MO:W4UI'<2PRW["12P8E$41X<C;W*]:'IN!Z917G_`(<\676N[UEC-LYMH;N,
M)=&7=%*&V;N!M;Y3D<CI@FM_[3/_`,]I/^^C0!T-%<]]IG_Y[2?]]&L'Q3XL
MG\-V<-P=CB1V7=<7?D1C"%L;L-\QVX`QR>XH`[^BN$UGQ1<:1IEM=_9KR9IY
M(D\O)7R@[*"7;D+C=TZD\>XAO/&BVGBF#1<RON@DFGN!*=L.Q0VTCN2#GM@$
M>M#=MP2OL>@T5Y_X3\6R^*-,-\DUNJY`V6UXTQ3(SA\HNUAGIS]:W_M,_P#S
MVD_[Z-`'0T5SWVF?_GM)_P!]&N7\4^.)_#5W;0>29O.B>7=+=^3NVE1Y<?!W
MR'=PO&?6@+'I-%>?>)?%>HZ!'Y\=A/=6T<?FSR^>4VC<JA5&#N<[N%XZ=:JZ
MEXUU+1Y]2-[9QFVLK0W1>"^9W(+;8U93&H4MANA.-IHL!Z717$:#XBN=8ANA
M,KV]U9W#6UQ$LYD4.`&^5L#((8'H*UOM,_\`SVD_[Z-`'0T5SWVF?_GM)_WT
M:R=0\1W-CK.F:>(+N47LA1K@-B.+"LPR>[';T'U..,@';T5Q.F^(KC4=4U&S
M\F[@6S*!9)F*F4-NY"]0,J<$]?Y\_'\2UEL]8ND:!H=/`(*W^3RY0"0;<Q]C
MP&&/<8I7`]6HKS:3QU)%I6DW8"W4FHW"1*+*Z,L:(T@0R%RJG`+*#\H^9@/>
MNH^TS_\`/:3_`+Z-,#H:*Y[[3/\`\]I/^^C6/=>);FV\2V&CB"Z9;I'8W1<J
MBE5)VC^\>.>PX^E)NP'<T5P6A^+)-;U#5[:)9HX]/F6)93*3YP*YW`=AZ<G(
MYK)N?B!J-E!<&[T[R)HOLYP]^1'$LQ8`SOL_=$;.1AN67!.:&[#LSU.BO*+7
MXF->:KI%BJ16SZA;0W.+R]:-P)&("H`C!VPN1DKG(]:[;[3/_P`]I/\`OHT[
M".AHKGOM,_\`SVD_[Z-85QXMEMO%(T:2*Y6(64EVUV[D+\A7*J._#`D]!TYY
MPFTMP.^HKSOPSXON_$VB2W]JUFT@'[N**_=P&VY"R'RP4/(S@-^-9%Y\1]4T
MZREN+S38HT6\>T2;^TF$#E$9G.]HP1RI0#;RP(S3!:['K=%>;V7C:ZN]5AMW
MM9;>WEF6V#37!$RS&`3[6CQP`IQG=G(Z8YKI_M,__/:3_OHTVFMQ)W.AI:Q;
M&>5[R-6E=@<\%B>QK:I#,O4[>6:<%$+#9C(^IKB&^'MPFC:=86>HWEI)9PR6
M_P!HCC1FDBD(+J0P(&2J\CD8KTHT4#3:/--2^'<M_P";'%?W5M;2/$_V=8HY
M$^6+RB"'4A@5V]<X*@BM/2O"!TRWD@(EFCDM8;9@PQE8T*YX]0:[BB@1Q4_A
M3S;O1YHXY(ETMW>*,<AMR%,$GGHV:S=&^'-MI$^H,85N(KLX$;6T2;%W%L%E
M4,_..6)/`KT>BAZ[A<\JO?A1!?:796LT]Q)<6SRL;J:*.5I!(?F!#J5S@*`<
M9&T8K=3P@8KL31B10MQ%.J!1@;(O+"_3'-=Q10#5SRX_#)Y+"[L[F_NKB*6.
M.*`2PQ%8%CD+H-NW#C)YW9R*27X7))#HT:7$L)TUB^Z&VB0R$MN.,*/+R<_=
MQQ]*]2HH6FP6/.==^'<&O:]::M.KI+"JI(IACD$BJVY1EU)3DGE<$@XJK??#
MJ[DL]8>UN96U#5(72XEEX60[LQGC.W8N5&!T/->H44FDU8+GE.H?"H:K"K7]
M[<W%]Y[RR7<MO"Y<,JH5V%2@^6-,$#((SWK1@\!36M_=-;7U[#IUUEIK!5CV
M,YC$>=VW<!@`XSC(_"O1:*+:6'=GE-O\+98]4LK^?5;ZYDM-FQ98H\#;&8\`
M@94$8.`<9&3GM9M_AM]FLO(CNKE72RMK6*4(N4:!S(DF#P3N(X/'%>FT4R;'
MF[>"]1GU?2)KYS>QV"N\ES,P$D\A;<JF-5"A5(5@<\%1QWKJ?L5S_P`\6K?H
MH&8'V*Y_YXM1]BN?^>+5OT4`8'V*Y_YXM1]BN?\`GBU;]%`&!]BN?^>+4?8K
MG_GBU;]%`&!]BN?^>+4V2VGBC:1H9"%&2%0L?P`Y-=#10!YC!X9MH/$\FLC^
MU65I6N$M&L9/+CG9!&T@.S=RHQ@G')-=%]I_Z=;[_P``I?\`XFNLHHN!R?VG
M_IUOO_`*7_XFC[3_`-.M]_X!2_\`Q-=910!R?VG_`*=;[_P"E_\`B:/M/_3K
M??\`@%+_`/$UUE%`'FVFZ&FG:U-J&_5)8SYOV>V>P<+;^:X>3!"9.Y@#STZ5
MN_:?^G6^_P#`*7_XFNLHH`Y/[3_TZWW_`(!2_P#Q-'VG_IUOO_`*7_XFNLHH
M`Y/[3_TZWW_@%+_\32&XR,?9;[_P"E_^)KK:*`/,M`\-V_A^]GN8O[5F#1B"
MWCDL9`MO"&9PBX3)Y8\G)X'I70_:?^G6^_\``*7_`.)KK**`>NIR?VG_`*=;
M[_P"E_\`B:/M/_3K??\`@%+_`/$UUE%`')_:?^G6^_\``*7_`.)J.9TN()(9
M;.^:.12C#[%-R",'^&NPHH`\T\,^'X?#<<H5M5NY'2.$2SV+AEBC&V-/E0#@
M$\]3FM_[3_TZWW_@%+_\37644VV]P.3^T_\`3K??^`4O_P`31]I_Z=;[_P``
MI?\`XFNLHI`<G]I_Z=;[_P``I?\`XFJU_'%J6G7-C/:W_DW,31/BSESM8$''
MR^]=K10!Y]H=@^D6TPG?4[ZZN)?-FN9;!U9R%5!PJ`#"JH_7O6K]I_Z=;[_P
M"E_^)KK**`.3^T_].M]_X!2__$T?:?\`IUOO_`*7_P")KK**`.3^T_\`3K??
M^`4O_P`35+5K9=6TN>R>/4X/-`Q+#:3!D8$$$?+V('!X/0UW-%`'EH\/7!TV
M:PEO=4E2Z65KJ9M-.Z25BFUMOE[<`*1MZ$'D&L]O`%F=.@LDNM;BBVR)=B.Q
M95N4=@S`J(]J<J`-H&!Q7L5%"T#I8\QL?#-K8>(GU:/^U2@,KPVAL9/+A>7;
MYC`[-Q+;1U.!D^M=%]I_Z=;[_P``I?\`XFNLHH`Y/[3_`-.M]_X!2_\`Q-,F
ME\Z"2(VU^`ZE<_8I>X_W:Z^BAJX'EFHZ%J%YIJ:5;ZCJMG8I:1P9BT]]Y93R
M<[.A``(SCV]6#PM,YL1<ZEJ\L4`C6>(:842=8Y#)$-JQX3:>/EQD`9KU:B@'
MKH>:Z9H?V#6YM4GN-9O93&T-N)[.3]Q$S[R@(3+<@<L2<`5O?:?^G6^_\`I?
M_B:ZRBBX')_:?^G6^_\``*7_`.)K.UFVN-3M$CM+G5M.GCD#I-!92'L00RLA
M#`@G@]\'M7>T4`>;1:,$L(=-(U`Z?;&V\B(V,A($)!PQV<Y*K^5+>:*;S7H=
M0:?5UMT9)'LQ8N4>1,[6R4W+C/0$`X%>D44`>:>&_#\'AQ[R1%OYY;EAECIC
M1X5<D`A(P"<LQ+'DYYK?^T_].M]_X!2__$UUE%`')_:?^G6^_P#`*7_XFL+Q
M-HB^([6"+=J5J\3,0ZZ<T@(92I!5T(Z'KU':O2:*`/.IM,DNM-GT^<ZB;<RP
MM;_Z#*6C2/RSM)V<Y9"<G/WOPJE=>#]*N=:&IB#6HG;SS,B+=!9#*H4G'13@
M=@.WH*]2HH>H+38\X\/:,-"6Y>275KZYN2GF3SV+J=J+M085`.`.O4UM_:?^
MG6^_\`I?_B:ZRB@#D_M/_3K??^`4O_Q-<SXF\+0^)+N"X:35;9HX7MW":>SA
MXW(+`;HSM;Y1\RX(KU*B@#R?4O#^KZI=0SR:UJMO]FG>2"--+,B@$_)D-'@E
M1T)!(]<\U=G\.VMW;:[!=)JDBZP1YK"RE#1@(J`+\G;&1[FO2Z*!WUN>?:%I
MRZ)9RQD:E=7%Q,T]Q<R6,BM*YP,X5`!P`,#TK5^T_P#3K??^`4O_`,37644"
M.3^T_P#3K??^`4O_`,352]A6\FLI&@U!3:S^>H%E+\QV,N#\O^W^E=O10!P$
MUK.+RYN[3[?%/<&W5LV$A`2-R6'*'[RLP_PZUDQ^%!$MX$O=94R8%H5L&'V0
M"3S0%Q'\XW8^]G@8]:]5HH`\I/@S3Y+*".;^VWNHY1+)=)%<1&5O.\YLH@5>
M6SVXXQR!75?:?^G6^_\``*7_`.)KK**`.3^T_P#3K??^`4O_`,36?>V4=]J%
MC=O#J*FT\S"K9S#=O7:>=N1^%=Y12:35F"=CRW3/#$6A7EQ/I!U>(7#P[HY8
M+B55C1=NT;P<Y`Z]1T!QQ6>G@B4Z=/:W&JZO,\ERMTDQTG#"49R7_=_O,@XP
M^<8&,8KV*BF.YY);>"H;-K&."]UQ;.W2!9;9K)V6<PMO0Y*93YNNW&0`*Z_[
M3_TZWW_@%+_\37644".3^T_].M]_X!2__$UD7^DP:CJR7TT6IC;9S691+.9<
MK(5).X+D$;>WK7H=%*UPN>6Z1H%YHMW'-%?ZK<F60&\>?3FS,BQE(T&V,8QP
M<]3@YSFH]5\(V^IZ)I^G^9JD+V19EF&GN^\LI5RRLA!)#,<]03FO5J*;U`\L
MM/"5G9^(+75%&I2"UA6.&.33F+`JGE@F7R]Y&W/RDXR<UT_VG_IUOO\`P"E_
M^)KK**+W"QSVF3[]0B7R+M<YYDM9$4<'J2H`KHJ2EH`KW]VEA83W<BNZ0QER
MJ8W-@=!D@9/05%%?@AC=6\ED!]TW#Q_-@$G&UCT`)-5_$-M+>:4;>&$RL\L9
M*A%<$*X8@JSJ"#MQU[UA7ND7-]80VC:6]O'%.+DK;6T"*\BD%<@S'Y>#N'5A
MQD#.0#IUU*P>X^SI>VS3XSY8E4MC`;IG/0@_0TP:QIAM_M`U&T,&_9YGGKMW
M8SC.<9QSBN573-6OK*[AU&RO%6YEN9"L/DAAY@=$R_G?PQL!P`<CK3K'1;_3
MV5XH-2=U,D@,THGQ(4"(<R7+-M4%_ESR6[8Y6H]#JUU.P>7REOK9I-GF;!*I
M.W&=V,],<YJ,:UI1@$XU.S\DML$GGKM+8SC.>N.:XZ;PK+<1SPR65[Y$ML+8
MH@B0N``JLY$_+!05W*%8JV">!37\)SFU$:0:L)3,9FG:Z9I`VT*-DGVOS%&T
M$$;B#GIP,4)'?HZ21K)&RNC`%64Y!![@TZJ>FM-]CCBFMYHFB54S+Y8+X'7"
M,0/IQ5RD`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!2TE+0!4U&Y>TLVEB4-(65$!Z%F8*/U/J/J.M85KX
MCN+OY`]K$Z_QRH2LI,S1JJ[6.#E#D@MC(KH;V2UALYI;YX4M40M*\Y`15')+
M$\`?6JL-_H\TEB(+NQ=[A&DL]DB$RKC+-'@\C!&2/6@?0HQZM>R1VK*]FQN3
M"P&U@8D8,[!N>3L4X/'/;%00ZUJES")8EM`CO$(\HQR))#C/S=1%L8^Y/2I_
M[=\+22PV::AI4K7-TT*1)+&VZ=1EA@'[PXSWR1ZBMB4VUK;O-*8H88EWN[X5
M4`'4GH``.OI3NK"L[V,-]=O%M)\"W^T*#'#N4A9)6E:.+C=T.S)&>_451O\`
MQ'=:3ILURI210QE+2_-\KRL$`RZX&U<C&?P[ZD^O^'8%ANY;W3Q;_.HO#+'Y
M491@"I?.`=Q`QZU>$NE3WYL@]E)>11!C!E3(D9/!V]0I/X47&<W)XDU))KLV
MZ0RQAIF5F&,>6RQ!`"ZYR^X%AGMQ\PJ_#K4]]JEG"&CA5KF9&M\GS=L2L&8\
MXQOV]NA'/-6_[8\."SGU#^T=*^RVLY6:X\^/9#*2`0S9PK<@<\\BI-2U.QTF
M2UGE@+/>3+`LD2*3D]"3D<4;[`S/GU^]2\GBCAA9?+G,.1U:-@@_BR<N0,;1
M[$TR76]36ZNH$-H5M6D:69H6P42)68!=_7<Z#.>F>.*Z(6MNLC2""(.YRS!!
MDGW/X"G>3&<_NTY!!^4<YZ_G1<1A-KEU%;[YXX8Y0S%H^3A4A#.<^SG;G'<<
M4VSU*\O]02VFPC0795_*(7(6+)!`9N`SIW_"MW[+;B5Y?(B\R08=]@RP]">]
M+';PP@"*&-`!@!5`QT_P'Y47#H<W>^)+F,7+69M9G$LT-O`5;>[1KC).[IYI
M"GC^(<U*VOSVJSS7DUF(K>=H9$16WD+'O9OO?+@9.,'*@'/S<;5O86EJA2"W
MC0$Y/&23N+9)ZGDD_4U(UK;O(\CP1,[KL9B@)9?0GT]J-!W.6M]>O;>SB@,M
MM<2)#&\LO/R#RR[YRV&(&P_>7A\]N6:?KMW,PU2>>&,2K:PM9$L=K%/-<J-W
M!"29/!X3\:ZLVELT:QFWB**V]5*#`;UQZT"TME;<+>(-MV9"#.WT^GM1=!<Y
M*+4;\037\I>*8P*QMVE9DB986E)QNY^:5%(Y&`/08W+*]NWU)].81R"UQY\W
M()!12O&?O$EC]%]Q6FT$+!@T2$,"&RHY!X(/Y#\J;!:PVWF>4I!D;<Q+%B3@
M#J?8`4-H1RUIJNHQB_O&>-V=UDCA<.=Z-(T<2H-V$W!`<XY+\CBM=M1O%T:2
M]Q`TDCXMHP,;@7P@)+`$D%>ZC)QD5I_9X"\;F&/?$,1MM&4'MZ4YH8GA\EHT
M:(C&PJ"N/3%%T'6YA+KL_P!G);R1)M"+E2-TKRM&BXSVVG(!/L<<TRUUZYO/
MLK1S6:+=*'"/&VZW4J[#?\V"2$(_AP1WK=%K;AD86\0,:A4.P?*!V'H*&M+9
MXVC:WB9';>RE`0S>I]Z`.?A\07QG1G2W>T\Q4,L8P'4Q^87&7R`%(.W:>AY-
M13>)KJVM&-RUM%,@,DH,9;RXU0,[8#_.!N3E6)PWW>*Z?R(O/,_E)YI7;YFT
M;L>F?2F+96BQK&MK"$1MZJ(Q@-Z@>OO1=#ZDD3,T*,X4.5!8*<C/MFGT44A&
M+JT]U!?>='./*MK.:X$(!`9P`%WG/(Y;C';/88S`MPFJ364NHSG365#/<-.5
M8R!'>0*P(*#'E'"X`&<8YK:UC51I0MBFG75_<74ODQPVHCWG"LY)+LJ@`*>I
MZX]:JG4]/CN%T^;36@MD&3*Z1>3'+M\PQX#$[PN6R!M_VL\4^FH=0=YGTG3(
M+VXD@$R9N9!(8WVB,L1N&"IZ$D$'@]*R=^KP7=K/+/,7DMHT*1NS%-Q5?F1O
MW8;=G#'DD\_*ISNZ?J%IK!F@EL7MYXBLCVUTJ%]K9V284L,':<<Y^4@@$8K2
MD@BE5UDB1U<88,H(8>_K3>FX+R(M/DCFTZVDB\SRVB4KYK;GQCC)R<GWR:LT
M@`50J@``8`':EJ0.?OKR]CU74?+N0(K:R5D79A4=R<,QR<D;"?8&JK#9+<V<
MU[=#3HS++YHNG$K%!'D;P=V-[-P".5QTXK7U/4#8RQ10Z3=:A+<AMR6WE`A5
MP"6,CJ,?,!U)YZ56?5=-BGDMIK%H[2UW/'<LB>270994`);<HS_".AP3@TPZ
MD%]/,[6=GJ%PT$8L7N;DPRM%([IL&%92#@%B3C_9'0D&C(VJV][*;VYF*3PQ
MK*()<>6"O.,D*C95^5/0DD@A16_IT]OJEL6DTY[66&8[[:X6,O%)PV3L9ER0
MP;()^]ZY%7I+>&9'26&-T<@LK*"&(Z9]>@IWL`EK*L]I#*@<(Z*RA_O`$9Y]
MZEHHJ0.9O[K4HKZ^=;Q5A,]M9Q97:L1=AO/4Y;:Z@$\9QQUJG/,R)<VBW=RE
MK;J[VCF[??+)N"*N\MN?$FX;22#N4<C%;VHZ@+>\AL8])N;XW0+2^1Y6V-05
M7<^]UR.>@W'`/%5'U_38)95ELI(X[7*VLI6/;.P81LL6&R"'94^8+DD8R.::
M8R/Q!)>,MREO<O'/;VR26T<;[/,N'9E3=ZJ"H^4_*=QR#Q6?<75_I4M^^I33
M3V[2EY&M9FRJJ&=44$@(VP`$*>BYR6?CI-/GM-2@CN%M?*EA8QF*5%$D#_Q*
M<9`/NI(/4$@@U;:"%_O1(?F#\J/O#H?K[T[B'@Y`/KZT.RHC.QPJC)/M2T5(
M''R?:;K4+VSL]4D2.Y\AEF>X9U=7)8[""-C;%8;5P,;6W9/%ZVD:70M-ABEF
M@CNI2C2M</(Y3#ME9');#;1@YR`W&"!6V;.U,+0FVA,3'<R;!M)]2*=);02Q
MM')#&Z-C<K*"#CID55U:P'%"YU6T^RWKW#-&(Y#`AG=V,(=PK-']U_D:([F;
M.X`?Q$UU^FR++I\3)YV!E29F#.2"022"0>0>G%6'ABD#!XT8,NU@5!R/0^W-
M*B+&BHBA44855&`!Z"DW<!U,FD2&"261]B(I9F_N@=33Z"`1@\BD!R+6MU))
M>V+ZK+'%]I7<\MR^X@1EV*NI4J3E"44JJ@''!YORS"33]*MGDFMK:XA+S/\`
M:'WJJQ[MOFD[L]]V<X4\UL?8K7R%@^S0^2IR(_+&T'UQ3Y+>"52LD,;@L&(9
M0>?7ZTV[@<AOU>"[M9Y9YB\EM&A2-V8IN*K\R-^[#;LX8\DGGY5.>JT^2.;3
MK:2+S/+:)2OFMN?&.,G)R??)J62"*5762)'5QA@R@AA[^M/`"J%4``#``[4-
M@+4-U-'!;.\LQA7A?,`^Z2<`\@CJ1UXJ:D95=2K`,I&"",@BD!R,D,OV"XM6
MOWBBMYYI3YE],6:-$'`E#!R,MEN?E.5P0*N:M=8DMK266:WM19O<.L<SK.[J
M455#`[CRW/<DJ.<D'=^R6WEQQ_9XMD9W(NP84^H':G&W@.W,,?RL77Y1PQ[C
MWY/-.X[G)2-JMO>RF]N9BD\,:RB"7'E@KSC)"HV5?E3T))((45UEK*L]I#*@
M<(Z*RA_O`$9Y]Z62WAF1TEAC='(+*R@AB.F?7H*DHN(*I:M/#;Z;*T]R]NC8
MC#Q\OEB``N.=Q)P,<\U=J.:"&XC\N>))4/.UU##\C2`Y6]%S;:)Y4UU/'<PO
MYL<1O7#I&S;8\L.9G']PMAB<$G@U/XFEO'N8XK2XDB6&,2.8Y2C*[OMC8`?Z
MP@AOW;85LC.>!70I:6T8C"6\2B(DQ@(!LSUQZ4IMH"\;&",M%GRSL&4SUQZ4
MT]09R%Q>W.F3ZBUY+/+;><6E:VN79@%#2!5#;1&Q3&54X`4<DOQV8.0#Z^M,
M:"%@`T2$!MX!4<-G.?KGO4E%P"L_69(DL-DL]S%YKB-1;9\V0G^!2.1D`\C&
M!DY&,C0J*>W@N4"7$,<J`Y"R*&&?7FD!C0KJ-N='M+B]!=G9I4`RY558@%\\
MA<H"<9;&3U(I^JWMR-5L;*+S88GF0M(L;'S",L5W`8`PAS]?3-;"PQ($VQ(-
MB[4PH^4>@]!P/RI0B`*`J@)]T8Z=N*=];@<C937EG>M#>3W,L;W.]FAE9E+A
MD7`9R"%W,"43@$[1G#9["HS;PL4+0QDH2R$J/E)ZD>E24`%9FMF)K6."5[O,
MLFU(K21HY)2`3MW*05'&2<CIR<'!TZBGM;>Z4+<013*#D"1`V/SI`9"/?IJ^
MD6<UUNVVKRW"HGWV4*N2WH2^0,#H:9>ZA<R^(;.QC::WC\QB?W+?OL(Q)W=-
M@)3W)/8#G;,$3*5,2%2NP@J,;?3Z>U.V)O5MJ[E!`..0#U_D*;`Y+2I[JUFM
M[;4)[J4+-\K1S%E9R=G+,0S(#DXQUSQM52>OJ/[/#OC?R8]T0(C.T90'KCTJ
M2ANX!63XBFN8M+`M)_)EEECA#!-S?.P7CGCKG//`-:U(RJV-R@X.1D=#2`QE
M!N?$7G6LURZPL8[@F8^2HV?ZL)G!;<0Q;&1TSVK-E?5;G5IH[&XE2XD6X03/
M(&@15^5,(#PP<C)(R<,.1C'2"PLQ,TPM(!*QR7$8W'\:D6"%'D=8D5I/OD*`
M6^OK33`YC2+^6&\L+.\^TL6RL#+.TJMN#MN=F(9P`A521VR<;ACJZ8(8E=7$
M2!U78&"C(7T^E/H;N`5G:F;GSK&."X$2R7"AP%^9@,N0#G@84YX.:T:0JI()
M`)4Y&1TI`8=B9+K79+NTNIY;,&2.=WD)C9P0`D:=/E(;+#'/'S<[<YFO)I]0
M$,TRM)#*\LDEV1$%$@"!=I)BRBR`L%!R"3DBNFCL;.*0R1VL".W5EC`)YSU^
MO-2+;P*)`L,8$AR^%'S'U/K3N,YWP_?3-=I97;W+S0P[$+;@,80DON.XL=R\
MD'`."=Q85TU,$48E,H1?,(VE\<D>F:?0Q!6;?R3_`-IZ=#'<A(Y)&:2,+\SJ
MJL?O9X&=G;\>:TJ:40N'*@LH(#8Y`/7^0I`8ND1RR:A->07%R]A*I.9Y"PF<
MMD-&"?D0#(&``V<XX!./OO+FSOQ!<S(Y@CFGDDO'V$EB3Y90DQ@H.`H!P5X!
M.:ZV&RM+<DP6L,1)R=D87)_#ZG\Z>L$*(42*-5+;B`H`)SG/US3N,Q=$NY);
MMXKIKIKH1;3YC*$VH<9VJ<!B3DG'7(!(45O4Q88DD>1(T623&]@H!;'3)[T^
MANX@K(O+B=?$5E"+D);+#+/*FW`PN%RS9Z9?(&.Q-:],:*-]V^-6W+M.1G(]
M/I2`Q]'WQQ75XLMRUI(BR1O=2,[.W):0`YV*<KA1@#'"C-8`.I7=C.+2[N$5
M'A:Y:2Z9B\K*Q81,I;'+0L$&%/W?E!-=G#9VMM_J+:&+_KF@7^5/6"%(UC2)
M%13E5"@`'KP*=]1W,G1-1-Y>7D<R3I=+M:16;,:#<Z!4Y[%&R<#/7IC&U3$B
MCC+%$52[;FVC&X^I]Z?28@I:2EH`I:I:/>68CB91(DL<JA_NL4</@^F=N,\X
MZX/2L:[\.7-[.SN]M$)Y[>XE**2T9AD#A5/&0V.O&"S'!W8&OK%U/::>7MC&
M)WDCAC:52R(SN$#,`02!NSC(SC&1UK"N/$&I6-RB3-83+;S6]O<K&C*\[S2!
M`\8W'8JY)(.[)##(VY(MQZENRT.ZM;BWD!B6*"92L/G/(`HC="0S#(^^,)R!
MMX/-/\0Z?=S^&_$,45Q<74EW9RI!;LJ8C8QD!4PH)R?[Q//I6;::GXAGU+3X
M+FYL8"USF:%;,Y:%HG90KB9@>8V^;OQ\JXPVOJ^M?8]%UNYM8Y#<:;;22_O[
M>18V8(6&&(`<<<[2?3(-2[69<.;GC;^M2K9^'G&K0ZG<K:JRQ>7Y,2?*N%V@
M@GOC(/H,#G&37T?PS>:9?V<SS0R+;QO&Q#N-X95`(3[JD;`.Y;.21C!K_P!J
M>(+G4X=/@NM-6Z$;2&=87>##`,H*;P2P''WQD,&X^[5C1_$UYJ>KVJ/#"EC=
MV[O%@?,'39N^8MEAEB,;!C'WCFKZLA_"AW_"-7&V(@JJV\JM%;K=R@8".AQ)
M]Y1A^%Y`VX_B)$]_X<:YT_1[6"1(5T^:.3!+,"%'0$DG\S6?_;OB'[-]E,5K
M_:D\ZB+;;92*-D=P2//Q)_JV`(=>N=HQ@S:[JU\EAH,Z%K66ZNHEFC1U88(Y
M7(R"/<41O?04O,ZNBL_0II+G0-/GF<O+);QL['J25&36A28!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`8]UI$TTKR221:BK2;T@OXH]L`QC$;*
MF1_P+<3ZBL^'PK.EG'I\]Z9X%`9[AR3*[_9_(.0<]?O9R3GC'>NHHH3:`R=-
MTN:#5;O5+IT^T7$$-N4B)*!8BY!Y`.29&^G'UK6HHIMM[@E8****0&)?:)-<
MP&-Y8[YF,FV:\1!);!\8\LH@^[C@'D\9;BH;GP]-=0R6CSJML&FDCDR2^^16
M!W#&,#>QZ\\=,<]#10M`*6G6LT#7<]QY8EN9A*R1L65,(J``D#/W<]!UJ[11
M0`4$9!&<>]%%`&!-H$\B*DMQ'>2^68_[0N846ZCY)!5HU53C.``%QUR<U7N_
M"\UXJQM.B);RM-;L"278W"3@,,<`&,+P3D$GCI73T4+38=V4=,LY;1+AYW5I
MKF8S.$'RJ2``H]<!0,\9Y.!TJ]110(***;+(L43R,&*HI8A5+'`]`.2?84`.
MHKD;OQ6)/$.CV\,.K0VLDV'+Z5<*)BT;[028_E"D`G)![G@$U;U&XEL]<-Y+
M(T]H&MK9;>"Z96B=Y"NYHP`&!WKG)Z)D"FE<5SHZ*YFR26[M-7FT[4;F",3-
M;PR.[3%/*.V1E$A(#%MZY.1\JG!YSLZ1+)/HMA-*Q:22WC9F/<E02:2U_KN4
MU8NT45'<3I:VTL\@D*1J781QM(Q`]%4$L?8`DT")**Y0>)&N_%MA:11ZC#:N
MK#;+IL\:RDQ[P2[1@+MZ8R#DL"!@5H.TB:XQE)EAFF\B,Q7C@Q'RMQ#1@!1T
M8YR3\P/T`-NBN&U*?48O`&OZM87MQ:$1SSVI>0S.L4:';@N3@L5W=\!L<'D=
MP.@JN72X"T457OKV+3K1[J=)WC3&1;V\D[\G'"("Q_`5(%BBN7M==EN_'`L_
M]/BMA;2JL,FGRQQLRM&?,\QD"G@D``X'U;`GB=FU.;[5+YD=U-)%$]M?R$1A
M!R"HP%(V')!)!.*5[`M3H:*Y*#^TD\.6MZE_)']IOH9RI+2D0/(H6,,Y)'RD
M;CSR6QC(QUM5;0`HHJM?7T.GP":9+AU+A`(+>29LG_912<>^,"D!9HK!TII)
MM7EDM;JZN+)%DCFFFD!267<N/+`X`4;U)``S@?,0<9=Q-?&>:;3]0N)K#>MM
M(\LF/.G>>,#RV`^154NA9>YX!930M09V5%<-<:O?QV5VSO,(M/MY9F\JYVRD
MI+(I"%D(E*A%`W<'<-PR>.X!R`?7UIM-*XKBT444AA1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%+24M`%34S:#39Q?Q+-:NFR2)X]XD#<;=O\`%G.,=\UDB?1+
M&&&=M)CMI]/9+2WA%L@DA,I552,KP%;*C(.W@Y(VG&IJEF][9[(F42I(DT>_
M.W<C!@#CL2,5R5[X4U?4K>^EO/*D^URQ.^E-JUPUO\F_)$I7*9+JVU8PO[M1
M@Y)H7F!L./#FE:3;WD>F6L=K/.MV@AM%'[TKN\W`'W@H)+=<`ULW]E#J6G75
MC<`F"YB>&0*<':P(.#]#7-V7AG593&NM:Q]H%M$\,+V\2()%?[V^,J5!"@*"
M.VX\;L#?TF&[MM+MX+YT>XB7RVD1BV\`X5B2!R0`2.Q)&3UHMH";3NMQ]IIE
MA811Q6EE;P)&6*+%$JA2QRQ&!U)Y/K4,6A:1!>?:X=*L8[DE3YR6Z!\JI1?F
M`SPI*CT!(Z5H44`9O_".Z)]@N+#^Q]/^QW$GFSV_V5/+E?(.YEQACD#D\\"K
M;V-I)'#'):P,D)!B5HP1&1TVCMCVJ>B@!L<<<,2Q1(J1H`JHHP%`[`4ZBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`*E]J$=BJ;HY99'SLBB
M7<S8&2?P`[^PZD`UX]>LI94"F3R7`Q.R[4W&/S-O/(.SYNF.V<\55U?19KJX
MCO(U@OI8@ZI;7V%B57*Y(94)!&W(R#GID9R,^#PK>1PQ:9/<+-8)&&:[:5O/
M>3[/Y!!3;C!'S[M^<\8[TU:P'0:?JD&H&1$22*6,*S12C:X5AE6QGH>?Q!'4
M$5=K%T?3;R+4KO5-2$"7=Q#%;>7;R%XPD1<JV653DF1LC''`R>IVJ)6OH)7Z
MA1112&4[[48K!<O'+(=C2,L2@E47&YL9YQD<#).>`:ADUNTBFG242)'"KDS%
M<HQ0`L%QR2`>F.QQG!QG:WH%Q>S1SPB"[E9)+=FO'">0CD'?'M0Y9=HP#C.?
MO#'++CP_>79GLI6A6Q!FEAF$C&5I)58$,FT``%V.0QSQP,<BVU`W;*]2]20B
M.2*2)_+DCD`W(V`<'!(/!!X)ZU9K.TBWO(DN;C4(X(KJZE\QXK>4R(F$5``Q
M52>$!^Z.N.V3HTV`4444@*%[J]O8S")UED8!6D$2;S$K-M#,!SC.>0#T)Z`D
M0R>(+*(S>8)46,-L<KQ*5<(P3N3O(7!QDD8S67?>%IY=7DO8Y(KF2ZMX[:6X
MNB%EMPC2,'B"I@M^\(Q\N,`Y/0QW7AF]O"\3FW2&UE,]DZS,6E<SI/B0;?D`
M:,+P6R"3QTICT.DL;Z+4+<RQ!UVNT;I(NUD=3@@CZ]QP1@@D$&K-9^D6=Q:P
M3279C^U7,IGE6(DHA(`VJ2`2`%`R0,]<#.!H4A!112,"R$!BI(P&&,CWYH`S
M[K4[.*^B@EB=V21!Y@CW+"[Y5<GL3DCCIGG`(SEQZCH2R6T_]G-]JMX8TLF:
MU!E>*0[5\INP..1D;1RP4<TV[\,SRZB)$DB=9;B*XFO7.VXC,93Y%"K@JX3!
MY7`)X;.!"F@:OBTN&^Q"YTM!%8QB9RDZ@8+2-M!0L.,`-M/.7Z4[1ZBU.ATU
M[&?3UDL8XTMY&=BB(%`<L2^1V;=NW=\YSS5J.-(HUCC141`%55&``.@`K/T+
M3#I.EBV9P\CS2W$A'0/+(TC`>P+D#V`K2HEN[`@HHILBEXV59&C)&`ZXRON,
M@C\Q2&4+F^LS=>1/"Q52R&<H"D;;"Q4GJ/DYSC';.>*H0W.DK<)?Q:21J6Q;
M6/-N@N&C*[PNXG[F`3@D#*D=1BJ\WAF:;4YPP@-M<;I)+W?BY9C%Y1C*A`NW
M&&W;NO&WO3CIFM,ZZHT%@=4B=`EN+IQ"Z*KKDOY>03YC-C:>@&>].R`VX8[&
M^TF.)((9-/G@`6)HQL:-A]TJ1C&#TQ5NJNFV8T_3+6S#[_(B6/=C&[`QFK5#
M$@HHJ.>-YH2B3R0,>DD84D?]]`C]*0S-O;_3V:XCNX',*PRHUP8PRX`!D0$9
M/0=,<[>Y%59-4T>TEN;Q].:.^E!2Z5+96G9(T#$MMR7558="?O`#DXJM+X8F
MEGNX!':Q02^<XO$<^?*TF[*.NT#:"V0=QSM'`IAT+6'O5UC;8Q:G+YL4D/GN
M\,4<BQ*65M@+L/)5L$*#DC(^]18:L=,D5M+:Q(D<36X"F-0H*@#!4@=.,`CZ
M"IJ@LK9;*QM[1&++!$L8)ZD*,?TJ>F]R4%%%13Q/*@5)Y(3D'=&%)/M\P(I#
M.7CM/"5DUQ<P:#:6GF(Q^U0V,:&X`D4%00,DE]F`<;C@KGK4<:>#+3SWCT"Q
M@>=)8[W&G(FR,.%D$QQC;N(ZDAA\PRH)"'PA<&$6R0V4$=HL9MIXG(>Z=)(Y
M5\Y=GRX:,#(+9W$_+TI;SPMJ5[;7ZR26H;68F@U%5D;$",,9B.WYR`2/F"Y)
MW<8VFHJ-]=@>WF=+_9.F^1:0_P!GVGE6;*UJGDKM@*C`*#'RD#@8Q5RD`P`!
MVI:D`HHJ&X@:=%59Y(0#EO+"_,/0Y!X^F#[T`4AKD#(S+!<$GRS$H49F#DA2
MO..<$\D$`9(`IL?B"RF,)B\UTDV[G"\1%G**K\Y!W@K@9P0<XK'LO#VH6$`>
MWMM/CGM#&MM"D[+'<!%==\A$>49E<\`/C`Y;L6GAB]LC'"C6[P7,HN+V1I6#
M1.+A[C$:[<."TA7DJ0`#\QXJK1$[G6T445(PIKNL<;.[!44$LQZ`4ZJ>I6!U
M*REM3<2PI+&\;A`IW!E(YR#TSGC%`$']MQ;/^/2[\XN$2`H`\F5+`CG&-H8\
MD=".O%$.O65Q<11PEY$D"?O@OR*77<BMGD$C!QCNN<9&<F/1M4@"WMO9:9#>
M0R@Q6<=RZP.-KJ6+B/*L0^<;#]P#/<)8>&;K39Q;1/#)82RP7,\S2$2B6)(T
M"JFT@J?*0DE@1SP<\/2X=#JJ***0!4<\T=O!)/*VV.-2[-Z`#)J2L_5]+_M:
MQN+5KF1(IH6C:,*I4Y'4\9_`$4`03^(K6UC8SP722H6WP"/?(JJH=FPI.Y0K
M+]W/)`^]Q4L&NV-S?BTB=R68HDI7$<CA0Q56_B(4YXXX;G*L!A1^'M4CGCU*
M"#3K6](FA:U29FMX8Y!&&93Y:EF!A5MNU0=Q&1]ZI['PQ/:7NG0M+&VG:;,U
MU;N&/FO(T;QE77&-H$C'(.3P,#&34;=0>VAU%%%%2`5%<W"6L!E<$C(4*O5F
M)``'U)`J6LK6M+DU&U8(ZRE2DB6LVT0R.CAP&.TL,XQGG'7::`(W\3V,0'G1
MW,3+O\X21$>0JL%+.>@7)&""<C)&0"1;MM4@N;Q[9$D!&_8[+A9-C!7V]^&(
M'(&>V1S7-W/A6_N;&[MP+."/58&M;R&.1MMK&01^Y.WYB,MP54$MGC&#K:=I
M5Y;ZJTDX@%K;^=]F9)69Y/.<.V]2H"[2,#!;.<_+TJM++N)WOH;E%%%2,*AN
MKE;6(.49V9@J1IC<['L,D#]>U35D:UI<M]&DL8BNGAD$L=I=$+"QVLN"P1F'
M#$YPW('%`$@URU+PKY<X\P(7)3'E%V**&[Y+`CC.,<X'-36>J07L[Q1I(I4;
MD9UP)5R5W+SR,C]0>A!.*F@7\<L$:BV^SS>4UT?.8&`QRF55B7;AU^;9R4P`
M#@]*N:1IEY:W*?:A`L-I";:U,4K.TD9*G<X*C:WR*,`GN<\X#T`VZ***0!5>
MZNEM43]V\LDC;8XX\;G.">,D#H">3VJQ6)K>D37OE7$4<%]+;R^9':7KA(3E
M2A&X1L1PV>0W(QQG(`)H_$-A+<P0J9<3;`)#&=J.ZEU1_P"ZQ49P<=0.K*#8
ML-4@U$L(DE0A%D7S%QOC;.UQ['!X.#QR!6#:>%KJUG-OY\3V,TL-U<2LS>;Y
ML4:1A57&-I\M3N)R.1@YR-'0=-O;)G:]$"F.&*TA\F1GWQQ[L.V57:QW<J,@
M8^\<T]`?D;5%%%(`I:2EH`R_$,]W;:.\EB^RY\V%$.`<[I%4CGCD$C\>U8<'
MB*XNO$D#6]P9-,NTC$,>Q0!][<W3=G((()XVC@<YZ>_GMK:U\V[&8@Z8`C,A
MW%@%PH!).[&,"JUC'I=R#):VD2M`Y7YK;RVC8_,>&`(SOS[[L]ZFSYDPZ,QM
M+\1:A=B%%M6N&$:))B)EW.8%EW^9C8`2P7;[YSVJI<>*-4@U.*,?9Y`MO<,\
M!@DA+2+Y&P,6R4&9CE@&&.?8=4-+TX2I*+"U\Q%V*_DKE5QC`..!CC'I51K7
M0H+I+(V5FDK`E(Q;CHX(..,<A"#Z@<TR[J][&'>>+-1M5U5%MK5Y=)BN);AM
MS!9O+CAD"J/X=RS8).<%>AS6A::_?WDTWV?3VF0-*J+L>,*8Y`G,C#:VX;FX
MZ;<<]:UH]-T[[*84L+98'C9#%Y`"E6QN4KCH<#([XYI1I>GK,\RV-L)9!AW$
M*[FZ'DXYZ#\J;%=66A5TW4Y)[2YDNN7@<*ZQ6TBL,JIP4()S\W;((Y]AGZ[K
ME[INK62VJQR02V5Q,89%*%Y%:%4RW)09DY^4X&>#6W%#9::B0P0PVRRR85(D
M"AFQZ`=<#]*6[M;29?-NK6.;RT<`M%YC!2,,`,$\CC`ZTF$='J94.HW]_9ZQ
M;1&./4=.F\H.G^KE;RTE7@YP"'"D=1S@]#6;9:KJ6J1:9?0S7_D:G!+>1P0)
M;AHH_P!UY8)<8^ZV3R?F8X.`,:\.K:)8VD*VP6."9(Y(X[>V8AA)G80JKWVG
MMVYIDKZ#Y%G;R::&1$9;:`Z:Y\M%V@A4V?*O*CH!T]*=U9V)952:_FU;4(9-
M4NK:*ULX)0K)"2&;S-Q<[2/X1T...*IR>*;U-1MII()8[")84NPD#.!)*N6)
M;;A1'F,GD<,V>@K2N#X7AAM+JXM+%5N94M(7>T&=^XA4/RY7#9&#C!ST-;7V
M2V\B6#[/%Y,I8R1[!M<M][([YR<^M,25EJ34444AA1110`4444`%%%%`!111
M0`4444`%%%%`!15--5LWOS9+*?/!*X,;!2P&2H;&TD#G`.>OH:N4`%%%%`!1
M110`455@U&UN+I[:-W,J;LYC90=IPV&(PV"<'!.*M4`%%%%`!1THHH`YS6=4
MN%A%SI]VRF`QR3V[QA&2(N=\CJXWXVJP4*!DCKW%34K[5[6\U":"\E>TBFMK
M149(R5>65-[C"@X1'7&2<DMD'`K;AN-)U>Z#)'%//`-R/)`<A22-R,PY&1U7
M(J\UM`\<T;01LDV?-4H"'R,'<._``Y]*$.^I2T>>>5+R*>9IOL]RT2RLH!<`
M`\X`&021P!TK2J."WAM85AMX8X8ESA(U"J._05)0(***1F5%+,0%49)/0"@!
M:*J6.I6FHJQMI&)0`LKQLC`$9!PP!P>QZ'!]*MT`G<****`"BBF2RI!"\TK;
M8XU+,WH!R30`^BH+2\AO8V>$OA&VLLD;(RG`."K`$<$'\:GH`****`"BBB@`
MHJC)J]C#.\,DK*R!B6,;;?E&6`;&"0,G`.>#Z5/:7D-[&SPE_D;8RR1LC*<`
MX*L`1P0?QH`GHHHH`****`"BLQ_$6D)=7]L;Z(SV`B^U(,DQF3(C4XZLV.%'
M/(XY&;EG>P7\'G6[ED#,AW*5*L#@@@@$'/K0!/1110`4444`%%9J:]ITD!F2
M61E&S`$$FY@^=I5=N6!P<$`C@U<M;J&]MDN+=]\3]#@CH<$$'D$'((/(H#R)
MJ***`"BBD9E1&=B`JC))["@!:*R;CQ-I%II-SJEU=_9[.V`,LD\3QX!QM^5@
M"<Y`&!R>!S6M18`HHHH`***CGFCMH))YF"11J7=CV`&2:`)**RI?$6EPQ[I9
MY$/S9C:WD#@*`6)3;N``923C'S#U%:BLKH&4AE89!'0B@!:***`"BBH[BXAM
M+:6YN9HX8(E+R2R,%5%`R22>``.]`$E%9XUS3&L]/NQ>1^3J)1;1CQYQ<;E"
MCKR.?H*DCU2UEU#["//%QM9\/;R*I52`2&*[3RP[\]J+`7****`"BBJ]]?6N
MF6,U[?7$=O:PJ7DED;"J/<T`6**IOJEE'#9RO<*J7KJEN2#^\9E+``?0$_A2
MVFIVE]*\=O(S,HSS&RAADC*D@!AD=1D?G0!;HHHH`***IZKJMAH>F3ZCJ=RE
MM9P#,DK]!DX'3DDD@`#DDT)7T`N455.HVPO_`+"#(T^T.0L+E5!SC+`;1]T]
M3266IVNH[OLSNVU5;YHF3*MG##<!D'!Y''%`%NBBB@`I:2EH`SM8MTO;,6QF
M6,F:&0YD*':LBL<$<@X4X]ZQ3HYCW*QL;^(7$DBI>7!.\,HPS$JWS)C8/]GN
M#FKGB&*2?='%<RVSM&,31!2R\GIN#+^8->=:)XEU6+PQIUS,S:M?7EO->2?:
M9([=(XXL!@I2/D_,N`1Z\@"E9#2>Z.MFT*XDANX;?4(3*L,4:2RG"EB(Q,<$
M,"2L:D$AAEF!!&08]&\,3Z>;3[3<6$PMKAY$!FW;5,LK#'RC!42`#``^7MVP
M&\7W\/VZ;[#!+&;B..TC,[!]IMQ*VY5C9LX[*&.3C@#-:.B:^^HRWMW,QCLU
MM+:Y2,@$QAT+-R!D]ORH\PN[<O<N6?A6[MM;MKV761)%'Y'[M9HE$>R)4*J3
M"SE25)P'0'>>.N=GPUIS:+'=Q27%KY4D@:%59&9!C&TLJ)N`XP6!;KECVYC7
M_%J:3!ISV=H]Z^H,PA`$F,*NXDA(W?IZ*??`YJ&#QA-<ZQING1Z6%>_M$NT:
M6X"%$*,2&4KG<&`&!G()/\)II=`<F]6=Q>0&[CL3-/932V]R)BV-BXPPRH);
M!&[/7MVJMH.G_P!F2L\KV40\B.(B"3/FLI;,C<#YCGW[\FO/)OB4;19YKK1\
M6ZF[6%HKG>[M`X0@KM&T'((.3W]LVT\;7\UO"(=#S>27$L/E3320I\D/F[@9
M(@Q!''*#GVYI745S!J]#K)-!5+`QVTEKYIU(W;?Z4T>Y-S%5WJ"5PI``'`QB
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MZ;3BK:AYGI7VF#_GM'_WT*/M,'_/:/\`[Z%>0Q_$A_LJRSZ/L::#SK98[@R[
M_P!^L.&"H2OS,#P&.,\9XJXOC>YF%I';Z*S7,D$UQ-%-/Y&Q(I!&VTR("22<
M@,$XZX/%%F!ZE]I@_P">T?\`WT*/M,'_`#VC_P"^A7D<OC;4=-M+F:ZT^WN`
MES=;?+N&W"&*0+]U8B<_,.3\O=F7(K0N_&,MEJS6\NF#[$+QK/[0MQERX@\[
M.S;C&,C[W44KBN>F?:8/^>T?_?0H^TP?\]H_^^A7F%GXW9K*TO\`4M/BLK&Z
M\MUG^V+($CD1F0L,`J<J%(Z988)YQTNGW$MWIUM<SP&WEFB5VA+;C&2,[2<#
MI3::'<ZK[3!_SVC_`.^A1]I@_P">T?\`WT*YZBD!T/VF#_GM'_WT*/M,'_/:
M/_OH5SU%`'0_:8/^>T?_`'T*/M,'_/:/_OH5SU%`'0_:8/\`GM'_`-]"C[3!
M_P`]H_\`OH5SU%``-*9]6LY7N;5;6SOIKZ-EE)>0R1R)M*XP`/-8YR?NCCGC
MH?M,'_/:/_OH5YWXDUBZCT>_;1KB!;FSP9VE0DH.OR@C!)QCT'OTI_C*]U/3
M_#LMWI<T,,D3*TDDB;B%R`0HZ9.<9/09HE/37H%M3T'[3!_SVC_[Z%'VF#_G
MM'_WT*\IOM>U*UUZZD2=WMX;PV:V6Q,,!:&?S,XW9W#'7&,\9YK2\*WM[<"Y
M@O;Q[PI'!,LSHBD>9'N*_(`,`].,X/)-%M+@>B?:8/\`GM'_`-]"C[3!_P`]
MH_\`OH5SU%`%BPLVMM1226>U\F`7`C*S$L_FR!^00,8QCJ<^U;/VF#_GM'_W
MT*\\U[5;T6<,VCW$"QQ7T4%VTB$M@RHI5`1C)W<GL.G/(3QCJ&J:;::?-ITT
M42-J%O%<,R[F9'D52J@C`SDY/;''7(5^@>9Z)]I@_P">T?\`WT*/M,'_`#VC
M_P"^A7BMUXPUBVOM0G63?$HU%([1HUQ$;8+L<$#<=V23DD<C&._7>';B[=M3
MM+N\>\:SNA$EPZ(K.IBC?G8`N07(X`X`IK4;BT=Y]I@_Y[1_]]"@W$!!'GQ\
M_P"V*YZB@0OA_2VTI;&*>YM3'86(LH6CE):4`K\S`@;3A!QD]3S70?:8/^>T
M?_?0KSG4=9NY;W0Y=,N(?[.N+SR)V*'?(=CG:`1P/ESGJ>.G?/\`&GC`:+JN
MDZ;:W]O;3R74#W7FE<_9VD"D#=Z\G(Z!3TR*:]ZR\[?K^H-ZNYZM]I@_Y[1_
M]]"C[3!_SVC_`.^A7DM[=:S:W>J/;Z]=RVL,UM9`S0P'RYI94#,I6,<(CK@-
MD9)STK;\*7]W?Z?=K>3&XDM;Z>U$Y55,BHY`)"@#..#@`9'2D!W_`-I@_P">
MT?\`WT*@OOL][87-J;F-1-$T>X,.,@C/7WK%IKNL:,['"J"2?:@$6=)LW@U:
M[U.\GM$FGMH+;RH9=Z@1&0[LD#DF4\8XP.3FMK[3!_SVC_[Z%>>RZK>3Z]HS
M6<\']D71D5L*?,D8(Q[CY0"O;D_SQ-:\2:G:?$&WTV&["6.ZV5P8E,2^87!$
MC8W!VV@)M.,_>IW<Y"2LM#UW[3!_SVC_`.^A1]I@_P">T?\`WT*\K.IZY_IU
MI=7D<4[:K#:QRVL:X@B=$;`W@ACR1EAU/0<"M_P[>3W^@VEQ<MOF92KO@#>5
M8KNP..<9X]:2U5QG:_:8/^>T?_?0JKJ0AOM+N[1;B)6FA>,$OP"01613)IH[
M>"2:5ML<:EF.,X`Y-`&KIH,,EY<7,MLDMU,)"D4V]5`14ZD#/W<].]7_`+3!
M_P`]H_\`OH5YZFI7\_BNR6.>`Z/<V<LD2*A\QV4Q_,Q/0?,0`/<GL!F/KNI#
MX@?V>MQ(;+S_`"-AC009^S^9LWXW^;NY_N[/>B]V"1ZK]I@_Y[1_]]"C[3!_
MSVC_`.^A7DEMJNNW$`LKK4A#=2ZQ-:-=6T*`0HL+2`*'!'50,L"<$_AU.@7L
MNI>'=,OIP!-<6L4KX&!N903C\Z47=70VK'9?:8/^>T?_`'T*CGG#0D6]U;QR
M]FD&\#\`P_G6%4-W=P6-L]S<OLB3&YL$XYQT%,0LVB&2.ZA2XM$\YIV:X$IW
MR^9O(1EQPH+`_>/W>G-;&FYA>\GN9;9);F82;(IMX4!$3J0,_=ST[UQ5KJ&H
MR^-GMI)X3ILEAY]O$B<_?4;F8\Y.3QT`QU-<S_PE.J2>+=1L'UJ"RL@+I8[J
M>!/L\9C\L+L)P2Z[FWACMSTH4K[>?X#M_7J>T_:8/^>T?_?0H^TP?\]H_P#O
MH5Y#_;/B&'0+LFY'VBSU1+>:6X6-I1$S1X`$:A"6$@.>,`XQGD=[0+K8Z'[3
M!_SVC_[Z%1SS[D`M[JWC?(R9!O&/H&%855[R]M]/@\^ZD\N/(7=M)Y/3I0!=
M2Q:T\0:GJ5I+8A+FUMXHXR^W+I),SEL#C/FC!YYR2/6WHT$>FVLL330*))FE
M6-)=X3=C(W'!8EMS9//S5XW%XN\27%O>W"-<1M*)3`C0PL@2.Y2-VC`._<JM
M]U]VYCQC&#%+XWUT03^7=2`:?%=3AI;=%>\$4Z(JNI7Y258Y"A3GTZ52O*7G
M;\@:/>OM,'_/:/\`[Z%'VF#_`)[1_P#?0KG5.5!QC(Z4M2!T/VF#_GM'_P!]
M"HYI]VSR+NW3#`OO&[*]P,,,'WY^E855[N]M[%8VN9-@D<1I\I.6/0<4`37&
MGW5U<2W,DUF&=H2T*W;@/LW<A\;H^6!`4'[O7YB:TM#A_LW28K6XNX)'5Y&&
MQAA59V94SQNV@A=QY.,GDUP*7FN2V^M076HPP7D5XJ6PME0$J8T<1(9>"[9(
MW,#R3P!@"E8ZOJ.JP>&VBUNY2]O"1<P1PP^7MA)\XME"V<@1Y5@,D$#%">@/
MN>N?:8/^>T?_`'T*/M,'_/:/_OH5SU%`'0_:8/\`GM'_`-]"JU\[3V[QVU[;
MPED92SKOZC`(^8#@\\@YK'JO<WL-JT4<C@23-LB4@_,WID`XHW`9=:"]UX7U
MK35DLH9+VS:"!&N6F5',;)N+LNX#D#`!P%XZXKK!<0`#]]'_`-]BO&K_`,6Z
MGI/A'6);[4;-=66]FMK60JJ1H50/@`]<#.,Y).!WQ2:;XMU34/$EI'YDW]G+
M]FB>:-86AE:6'?EOX\EC@%.!MY!S34^=*W]7'RV/9OM,'_/:/_OH4?:8/^>T
M?_?0KGJ*0CH?M,'_`#VC_P"^A5#55>]LKFV@O;1$F@>/;(NX[B"`<YP!^!K-
MK(U_6(M,TV[VW$<-X+26:$R*2H*J3DX'08I/8:W-9=.F-A=VLGV*2"[D)DA>
M]D)"[$7_`%A&YONG((Z$#.!BMRTDC@LX(9;N.62.-5:3(&X@8)QVS7A>I>,-
M?M-$=H[R\6YBGN/W4MK#]K"I`D@,B@>6$!;+%>=K+CG->IV<IGLK>5G1R\:L
M6C^ZV1G(SVI^8/H=/]I@_P">T?\`WT*/M,'_`#VC_P"^A7/44".A^TP?\]H_
M^^A4+R))-A[BU:VV\QLN6W9SG=NQCVQ^-8E8'B?5VLK)K>TGDCO28F/E0^8Z
MQ&55=E4@AF"EL#!.>QZ$`Z=-/C71=,M6FM3<VGD`R;NR,A8*<9YV_P`JLV:-
M'JVHWES<6Q$S1QVX1^5B5<X;/?>TAX[8KR1-?\17NF![/5,7:74]K:P26R+-
M>LL@"F12ORJ$SOP%(([=*])&<#/7OBF]5<-M#HOM,'_/:/\`[Z%'VF#_`)[1
M_P#?0KGJ*0'0_:8/^>T?_?0JO,R3><CW%LT3*-B$<JWJ3GGG'88K&KGO$FKO
M;1I:VES/%/YT?GM;6_FRQQ,>2BE6#'.!C#'!)Q2:OH%[:F^=(FQI;+J%CNLT
M@1E="VW9]\HVX8W8'4=A6A:QNNKRWL\ULFZ,QD).7\SD;3A@-F`#P,YW'TKR
MR+Q1JTMYHLDLMVMCY,1O&@$`8N\QC0R(X+;6V\[,=3Z5Z+5/OZBZV]#H?M,'
M_/:/_OH4?:8/^>T?_?0KGJ*0SH?M,'_/:/\`[Z%8WB.R;6O#FL::MU9F2ZM9
M(;8O\HC9D*Y8Y/<]0!QZU7KF?$NKS1-!;6-U<P;;@)=R6MMYTL:F-V7:I5@<
ML%R0#@9Z=0*7*[@==/9B34VN87LHF9XV^U+(?-VKC*$="#@CJ!STR,TSP]8-
MI>_[1/;#,$,("7!DR4W9;Y@-H.X84<#''6N&TV[UG5+_`,/SQZK<1I<V27U]
M;&*$Q*NQ0$7Y-X+.2<[C@*WM7:46L%^AT/VF#_GM'_WT*/M,'_/:/_OH5SU%
M`'1+/$[!5E1B>P8&I:PM/_X_H_Q_D:W:`*-[8M=2APX`"XP17/W/@#1;W3K;
M3[G3[2:TM3NAB>/(0^U=::*`.3O_``!HNIS22WVGV=P\A1G,D>=Q0$+GZ`D?
M0U=L_#%O8#%JD40V)'\H/W4&%'X"M^B@#F]6\'V&NVJVVJ6]O=PJV]5E3.&]
M1Z=:C?P1IDC!FM8-P96!`(VE4*+C'3"DC`]37444`<5IWPTT33FO9%M8)YKT
MR_:)9XPS.LC%F0G`^7)QCT`SG%7++P-I6G6\$%G9VT,4#.\:HI&UF&UC]2#B
MNIHI66P'*#P%HXO[>^%A9_:K:(112F/YD0#`'X#BH$^&_A^/3[BP32K%;2X<
M22Q"+AF'0^V.V*[*BG8#E[KP1I=[I$>DW-G:R6$6W9;F/Y5V],#M3CX+TYIA
M-]F@$B^5M8*1M\O.S'H!DXQZFNFHH#R.*T[X9Z'INFW%C'9V\L=RNVY>6,%I
MADD;B`,\FIY_A[H=S:65I/IEC+;V7_'O&\((C]0/8]QW[UUU%`6.-NOAKX>O
M;F2YN=*LI9I)&D9WCR2Q&"?KP/RK0;PG9O,LS10F19_M`8@Y$FS9N^NWBNBH
MH`X:X^&&B2:=+86UO#8VT\Z37"6L2KY^QMP5B5/RY[#&.Q&372?V2_\`SU7\
MJU:*`,K^R9/^>J_E1_9,G_/5?RK5HH`RO[)D_P">J_E1_9,G_/5?RK5HH`RO
M[)D_YZK^5']DR?\`/5?RK5HH`RO[)D_YZK^5,DTJ<1L8GC9\?*K$J#]3@X_*
MMBB@#E[C1M2N[>2WN+33Y(I!M=&NGP1_W[JL_A>ZD6]66QL)$O9!).K73X8A
M54?\L_1!78T4`<:?"DIUC^USI6E?VAY?E?://;?M],^72Z5X5FT.V>WTO2]+
MM(7<R,D5PP!8\9_U?L/RKL:*`.<_L[6/^>%C_P"!3_\`QNC^SM8_YX6/_@4_
M_P`;KHZ*`.7N-&U*ZB\J>TT^1-RMM-T_52&!_P!7V(!JJ?"MR\<D<ECI\B27
M(NB&NGQY@((;_5]BH/X5V5%`'&+X1==2N=1&CZ1]LNH_*GF,S;I$QC:3Y?3`
M'UP/2I-+\,7&BV0L]-TW3+6W!+"..X<#)ZG_`%==?10!SG]G:Q_SPL?_``*?
M_P"-T?V=K'_/"Q_\"G_^-UT=%`'+SZ)J-RT+36>GN89/,C)NG^5L$9'[OT)_
M.JJ^%;D6RV[6&GO$MR;I0UT_$I<R;O\`5]F.:[*B@#CY?"\\]G=VDNF:8]O=
MLS3QM<.1(3C)/[OKP/RJ33_#UYI5C'96&GZ9;6T0PD4=PP4<Y/\`RS]>:ZRB
M@#G/[.UC_GA8_P#@4_\`\;H_L[6/^>%C_P"!3_\`QNNCHH`Y>31=2FEBEDM-
M/9X23&QNG^4D$''[OT)%9D'@2.">QN!HVDO<V,2PV\[SL715&!SY?;].U=W1
M0!QUYX4FU"VNK:[TO3)H;ME:='N'(D(``)_=]MJ_E5FVT74;.UBMK:STZ*")
M`D<:7+@*H&``/+KJ**`.<_L[6/\`GA8_^!3_`/QNC^SM8_YX6/\`X%/_`/&Z
MZ.B@#E+C0-0NFWRV=@SB-X@WVE\A7QN'^K[X'Y53M_!7V;4HM1BTC2A?10B%
M;C[0^_8!M`SY?IQGTKMZ*`.*O/!QU"RGL[O2-+FMYY?/EC>X<AI./F_U?7BM
M"/2M5AB2*.UT](T`556Y8``=`!Y==+11L!SG]G:Q_P`\+'_P*?\`^-T?V=K'
M_/"Q_P#`I_\`XW71T4`<?>^&+O4%G%Q96!:>W:V=Q=/GRVZC_5U7_P"$(C^W
M75Z="T8W-W&8IY#*Q,BG@@_N^<]_6NXHHL!Q5IX.-CI?]FVND:5#9;Q)Y*7#
M@%@0P/\`J^N0/RK2_L[6/^>%C_X%/_\`&ZZ.B@#G/[.UC_GA8_\`@4__`,;H
M_L[6/^>%C_X%/_\`&ZZ.B@#A1X%A$M_*-!T8/?@K='S6_>@G)S^[[GGZ\]:7
M_A!8?)L(?[!T7R]/;?:KYK?N3G)*_N^YY/J>>M=S10!SG]G:Q_SPL?\`P*?_
M`.-T?V=K'_/"Q_\``I__`(W71T4`<Y_9VL?\\+'_`,"G_P#C=']G:Q_SPL?_
M``*?_P"-UT=%`'&WGA2;4+:ZMKS2],FANV5IT>X<B0J``3^[[;5_*G6_A>XM
M)+9[?3-,B:VA,$.RX<>7&<$J/W?3Y1^5=A10!SG]G:Q_SPL?_`I__C=']G:Q
M_P`\+'_P*?\`^-UT=%`'.?V=K'_/"Q_\"G_^-T?V=K'_`#PL?_`I_P#XW71T
M4`<E_P`(Y=_9[JW^P:=Y5V6:=/M+XD+##9_=]Q4'_"'L=1M=1.D:3]LM8_*@
MG\]MR)@C`/E^A/YFNTHHV"YSG]G:Q_SPL?\`P*?_`.-T?V=K'_/"Q_\``I__
M`(W71T4`<Y_9VL?\\+'_`,"G_P#C=,ETG5)X7AFM-/DBD4JZ-<L0P/!!'E]*
MZ:B@#S\_#NR.FQZ<?#NBFTCD,J1&9B`YZG_5]_Z5N+IFK*H5;:P"@8`%R^!_
MY#KI**`.<_L[6/\`GA8_^!3_`/QNC^SM8_YX6/\`X%/_`/&ZZ.B@#G/[.UC_
M`)X6/_@4_P#\;JO?:!?:G92V=[8:;/;2C:\<ERY##_OW75T4`>>W/PVL+NWM
MH)_#NC-#;(4A3SW`0$Y.`(^YY/K6^--U<``6]C@?]/3_`/QNNCHH`YS^SM8_
MYX6/_@4__P`;H_L[6/\`GA8_^!3_`/QNNCHH`YS^SM8_YX6/_@4__P`;JKJ7
MANZU>Q>RU#3M-N;:3&Z.2Y<@X.1_RS]:ZVB@#B'\%K)<V%PVBZ09=/4):-YS
M?N5'0+^[[=O2M3^SM8_YX6/_`(%/_P#&ZZ.B@#G/[.UC_GA8_P#@4_\`\;H_
ML[6/^>%C_P"!3_\`QNNCHH`YS^SM8_YX6/\`X%/_`/&ZI:IX7GUNS^R:GIFF
M75ON#^7)<.1D=#_JZ["B@#EHM"OX9O-BL=.1_+6+*W+CY%SM7_5]!D_G4W]G
M:Q_SPL?_``*?_P"-UT=%`'.?V=K'_/"Q_P#`I_\`XW1_9VL?\\+'_P`"G_\`
MC=='10!BV%EJ4-[&]Q#:+$,[C'.S-T/0%!_.MNDI:`(+JZALX#-.Q5`0O"EB
M22```.222!@55_MJQ%Q;P,\L<EPVR,202)EL$[22H`.%)P><58O;-;ZV\EG>
M/#JZO'C<K*P8$9!'4#J*R'\)VDNM0ZO)<W#WT17$Q2'>57/R[MF0ISRH(&>>
MO-"`EE\16Q2QFMQ/);W$VPL+64DKY;N"@VY/W1R`1BJ.N^)I[*_TF#3UBEBO
M8VG9Y(W(\L-&HP1P#^\'7_`&_I_ABQTVX:>`N':X-R^U(XP\A1E+%45020YR
M<9.!D\4LWAJSG%@&DG'V*W-O'AARI:-LGCKF)?3J?P6I:Y>I.NN:>\JQB9PS
ML%0M"ZA\MMRI(PPR0,CCD<\BIK+4K/45#6DPD!19/ND?*Q('4>JGCKQ5"3PW
M#);/!]MO$`C,4#(R`VZ[E;Y/EYP57[V[[OUS;TS1[;2EN1;F0_:)3*V]LXSV
M&.@']31J0[!J>H?V>+5RI9)9Q&^V-G;!5CP%YSD#L:C3Q!IDACV7)8.0,K$Y
M"$N4PYQ\AW*5PV#D$=JEGTM);>")+BYB,$GF)()/,<'!')?=D?,>M8__``@>
MAF_@OFMHY+J%M_FS00RNS>8TI.YT)4EW8_+MZ\8P,->8W:Q9TOQ#'<65O)?-
MLFG(90D$@559RJ;B1\I.,<G!/3BIX/$NE7-M%<Q3RM#*@D5_LT@`0]'.5^5>
M?O'`X//!P#P];KY(2XN%1$B1D!7$HC;<FX[<]2>A%4)/`FBRPZ9'-`DYTZ!+
M>&2X@AF;:N,<NAP?=<=?88%YC?+9V+LFO10^(+K394DVP6L4^Y('8DN[K@8!
MS]SH!Z^AQ8M]<TZZ>U6&X+FZC$L&(VQ(I!.0<=L<^F1G&1FGJ_A2PUNZEGNV
MD82Q1Q21%8WC<1LS+N5U8'!=NO'0]0");+P]%9&S*7MV_P!D39%O*<*2<@X4
M9S\N?]Q<8.21;:BE:^AKT444""BBB@`HHHH`****`"BBB@`HHHH`*9+#'/$T
M4T:21L,,CJ""/<&GU#=326]K)-%:RW3H,B&$H'?V&]E7\R*`,+7[33=)TB:Z
MM]!M+B5?NJMJA`]6;IA0,D\]L#)(!9XCM;'2-'DNK/P_9W,P8#`MH]J+_$S9
M(X`!Z'/3`-17&H7UQ:W<#>#_`!%MNE*N?M=FV,C'RAKDA?P&*6ZU35+ZTN[6
MX\(:]Y4X*C9-8@JI`!_Y>.N<^M,"&Z_L^TU29I=*T@:7$[0L1:CS1((3*?;&
M!]<U;T;3;>8SV^J:1I`NXPDF+:V&W8P./O#.<JWZ52FEN[BZDFE\(^(FCD8N
MT'GV&PL8_++?Z_=]TXZX]JGLM1U.S:21O"GB*XED"JTDTUAG:N<#Y9P,<D].
MYHZ`_(V_["T?_H%6/_@.G^%']A:/_P!`JQ_\!T_PJA_PD.J?]";KG_?ZR_\`
MDBC_`(2'5/\`H3=<_P"_UE_\D4@(M;M=/TR*T-OX>M;AI[N&%F6VCVQ(TBJS
MMDCL<#&3DC@C-0^)(K#1K>P>VT&QF-Q?V]M(QM4*QI)*J%CT_O`#&>2.,`X)
M=1OI;?R3X/\`$6WSDFR;JS8[E<.!EKDX&5''ITQ45_?:CJEL(+KPCKX1+J&Y
M3RY[$$&*19%!S/TW(,^QZ]ZJ-KJ_?4"HUU8+-=7)TG2#I@-S#;L+4>898<A@
MW;&4DQCT'2MG1],M+B.YBU#2=)^UV\WEO]GMALY56&-PST85D&.=C*I\(^)/
M(<S.(/M%AL1Y<[V'[_.268\D@;C@5?LM4U.S$Q_X1/Q#/)-)YDDDLUAECM"C
M[LX'10.E2ANU]#9_L+1_^@58_P#@.G^%']A:/_T"K'_P'3_"J'_"0ZI_T)NN
M?]_K+_Y(I/\`A(-4/_,FZY_W^LO_`)(H$-U&STZTU/2K6+0K-TNYV267[*FV
M-1&[#GCDD#'!XS]:@U^/3-*?38[?1=/DDNKR*%P;9#LC9@K-V[D`=>2.,9PT
MZA?8M1_PA_B+%M*94WW5FY)*LO):Y)(PQ[^E4KY;C4YTN;KP=XB6Y66-_,@O
M+1-RQR%XU(%S@@9/;/)Y[TU:Z%*[3MV&26U[#J-Y#)I'ALP1I&D3+;-GSI)`
MJ*WL%Y..?F7UK:T;3K"[M95O=(TP7D$S0S"&V79D<C&1G&TJ:I27E_)'=+_P
MB7B)6N)UN"XGL,HZA-NW,^,#8O4'O4MCJ>HV,4BKX1\02O)(9))))K'<['N<
M7`'0`<`=*2_K^OO&;/\`86C_`/0*L?\`P'3_``H_L+1_^@58_P#@.G^%4/\`
MA(=4_P"A-US_`+_67_R136U_4W0J?!NNX(P<3V0/YBYXH`;=VFFP:YI]@F@V
MC17&_P`V<VJ;5PI*J#_>.T]`<`<XR,Y]Z;*W\60Z:FCZ3]F(BWJUJ/.<OO&4
M[%5VC.>GXBK)U*_W6A_X0_Q#_HKETW7-FQ)*LO):Y)/#'O5&;[==S++=>%/$
M3;I(9Y85GL`CRQ$%6SY^X8*J<`@?+TY.6K75Q.[6A*H@NDOHX/#VG6URM^+2
MT6[M4`=?+5R[;22`1O(Z'&,@'-;&F:9I5YIT4TNDZ<)N4E"6R[0ZDJV,CIN!
MQ67+=W\C3.OA/Q%%+).MP)$FL,HP0)QF<C!48Y!ZGVQ9M-7U&SM4@C\':\P7
M)+--8Y9B223BXZDDG\:-!FM_86C_`/0*L?\`P'3_``H_L+1_^@58_P#@.G^%
M4/\`A(=4_P"A-US_`+_67_R13)-=U.6-HV\&Z\`PP2MQ9J?P(N<C\*0#6M=/
M_P"$GBTM?#UJ+8VDDS7+6T>TN&0!%YSP&)/RXY&#G(JKY5E_PE1T_P#LO1OL
MH;R]GV8>?GRM^_'39VSZ\5(=3U`3PSIX/\0>9!"\*;KFR;(8J223<$D_(.?K
MUJM'/J`OEO'\*>(F<2^>8A-8;/-\ORRW^OW?=[9Q[4`1P;;VT=8?#^E6M\]^
M]O#%>6RX"!-X+[">2O/![C('-;VG:9H]]IMK=_V38#SX4DP+9!U`/I6/)<7[
M.\D?A7Q'#*UP;@2)-IY*L4V$`-.1C'J#5RUUC4+.TAM8O!FN^7#&L:9FLB<`
M8'_+Q3Z#>YJ_V%H__0*L?_`=/\*9-H^B00O-+IE@L:`LS&W3@?E5/_A(=4_Z
M$W7/^_UE_P#)%5[W5+S4+8V]UX)UUXMRO@7%FI#*P92"+D$$$`_A2$+I%OI]
M]H+:C<^';:*4/-_HPM8_,PDC*JXR1NPHSSC/I51#9G1M"NF\.V9GU`P>?MM4
MV0!]NXDY]6``!8Y/<`D26&H:EIJ"&W\(^(6@+2R,);JS=BSONZFXS@9;_P"O
MUH2\O4TVUL!X/\0>5;&(H?/L=Q\L@C/^D?[(S35NOD+4@TZ2PN]:\F72=(2S
MFN+BVMT^S`3EX20Q8=-ORL0?0KTS72?V%H__`$"K'_P'3_"N<BENXM9EU0^#
M]>:XD()^;3EZ`JN668,V`6`W$X#&M3_A(=4_Z$W7/^_UE_\`)%(I[E_^PM'_
M`.@58_\`@.G^%9/B.QM--T@SZ?HNFRW;311HLEH&7#2*&)"C)PI8\<\=#TJ?
M_A(=4_Z$W7/^_P!9?_)%0W.M:M/%L7PIXA@8'(>*:PR/SG(/XB@1C3W=F)H+
M6UTW09;J*..:\_T;Y`C.RX4G`5OW;CY\`'`/I6GI=K!-K-S8ZAHNDH0GG1+#
M;J61-Q`$G4;B,'CCK[5FQ6;P&X,/@_Q'']J4K=8N+`_:`7>0[LS\?-+(?EQ]
M['0#%V&YOH]334)/"?B.>XBCDAB,L]A^[1RI91B<9R47ELGCKUIW5P:['0?V
M%H__`$"K'_P'3_"C^PM'_P"@58_^`Z?X50_X2'5/^A-US_O]9?\`R11_PD.J
M?]";KG_?ZR_^2*0%_P#L+1_^@58_^`Z?X5GZQI-M;V0DL-)T<2!LO)=0*(XT
M`)+''/8#C/7TY"_\)#JG_0FZY_W^LO\`Y(J"ZUG5[B-53PMXBMV5L[XIK#/3
MH0TY!'/I0!!?+IT6CZ=/;Z1IBWE\%\N.6SW#.PN?E0%N`#TS_6H%@/VC39I-
M$T-;&Y$2,H@5I7=E)8QX)4J.#]%8\C!I1/J"PVT,7A+Q!"EH`+9XYK`NGRE3
M]Z<@Y![BHK=;RUU""\B\*^)`8(1!$C2Z<51.,@$S;AN(!)!YP/08.HNA?T.S
MMKRXN[?4-(T<2PA&VV\"G9NW?(QY&\;><<<CK6S_`&%H_P#T"K'_`,!T_P`*
MP[/4-2M)Y)V\*^([B5T6/?-/89"J20.)Q_>/)R>>M7?^$AU3_H3=<_[_`%E_
M\D4#+_\`86C_`/0*L?\`P'3_``K&\36,&F:4]WI^EZ)N3@K=6WWV.`BJ%'+%
MB`!W)%6O^$AU3_H3=<_[_67_`,D56N]3O[TV_G>#=>*P3+,%$UCAF7.,_P"D
M=B0?J!0!6UF*&P>QM(-(T47DMO+<3//;`0A8PN\`\'.7!&>P.<8K-;5M/2VF
MU9M(TAM)_>"%$M`;EF2%I<%>G(4X[X(]<UHZE<ZEJP5+GPEKH2*830A3IK[6
M`&&^>9L,#D@C!&>M5X[>6+55U*/P;KJW,<7E1./[,W1H%VA0_F[R!UPQ(S^%
M'>XU;0T="M;*\:YMK_3-%:[@$;M]DMP4"N,KU[\'\,>M;/\`86C_`/0*L?\`
MP'3_``KGM(FNM%A>*V\&:YAO1M.C`&2<!4F51RS'IR6-:7_"0ZI_T)NN?]_K
M+_Y(H$7_`.PM'_Z!5C_X#I_A7-^)/LFE7MO!:Z5HJJT,DSFZMA\^TJ-B8ZN=
MQP#U_.M7_A(=4_Z$W7/^_P!9?_)%9FHSW^HRR2-X5\20^;`;>98IM/Q)&<\'
M=.<=3R,=?I@6X%_5[33=/>Q2'0;27[1<I%(_V5-L2%@"Q/'<@`#)R>F`2,R%
M4N+[4;:#1M$E>-9A;1+;C>K(X0>;G``.<C'4`X]*MR:KJMS%Y=QX0UTA9UE3
M;-8Y`5@R@_O_`%'_`-?O5:.2_CG>5/#'B8-B7RP)]/'E>8X=BO[_`"?F`^]F
MA;`S1T*RT[4;&1[G2=+,\4SQ.T%NOEL0>JYYQ@CKW![5I_V%H_\`T"K'_P`!
MT_PK#T^^OM.:ZDC\'^())KJ433RR3V.7<(J`X%P`/E11P!TJ[_PD.J?]";KG
M_?ZR_P#DBFQ(O_V%H_\`T"K'_P`!T_PK+U"UT^UUC2K*+P]:R1W<KK-/]FCV
M1`1NP&<@[B5&,`\`YQQ4O_"0ZI_T)NN?]_K+_P"2*@GU?4;B6VD?P=KP-O(9
M4Q-8\G:R\_Z1TPQH7F,?86FFWFKZC:OH-I%%;>7Y3/:H#+G=EA_LY4@9`Z$\
M@@G(62WCM[Z6YTK18_W_`)5DGV)@SYE**2"/FR"OW,]?H*T6U;5%NI;J+PAK
MHEE$:-F:QQM1B>/](ZD,WZ=*J32WUPXDG\+>)9)$_P!2[3Z?F'YE;Y?W_/*K
M][/3ZTGN`F84LM)=_#NG22W-WY%S)':IY<2;RF>2&!)V@#!(.<@8..E_L+1_
M^@58_P#@.G^%8"W5Z+1+<^$/$+;;@7)<SV&YW#[\G$^.3Z`5H?\`"0ZI_P!"
M;KG_`'^LO_DBGT`O_P!A:/\`]`JQ_P#`=/\`"LF\M;&#Q%IVGQ^'[,VUPKF6
MX:VCVA@I*J.<Y^4D\$8[C-3_`/"0ZI_T)NN?]_K+_P"2*K7&J7]S/;2R>#M?
MS;LS*!/8@'*E3G_2/1C2&A-&AT[4]2U:%]#L$M[69$MW^S)F5"@);OQNSCIQ
MCZUCK>PSR7MM%X>TR"Y&L?V=:BXM%"[/(6;?)@G&1G'?E00#FKMC)>:5/-+8
M^$/$:^<8PZ2WEHZJJ#`"AKDXXJ.XCN+F'4X9/"&OM'J5PMQ<)(VFR*2(T3;M
M>8C;B-3R"<]Z<=GS?UJOT`CLY[:_:&Y@TK0VL(Y(K>[;[-\QE9]A\O'!7)4Y
M/8]ZZS^PM'_Z!5C_`.`Z?X5S$8O(G!3PMXF$9=)98_/T_;+(K;@[?OL@D@$[
M2!QTK8_X2'5/^A-US_O]9?\`R10Q%_\`L+1_^@58_P#@.G^%8-T=.MO%J:6^
MA6*V7]FS7C7#6J<NCQC:OL`^3QW&#P0+_P#PD.J?]";KG_?ZR_\`DBJ%S=WM
MUJD.H-X1\1+-%;36J[+BQ4;9"A8_\?&<@QK@@^OX"MU\_P`M/Q&B+3VL(?#-
MWJVMZ7I$;6L!N)8[>TVE%";CE7&<\''8]C5!99'<6PTCPZMR[LZ,]OMC\H)D
M@@_-OSR.,$<C.":MW+ZA=PSV]SX2\07,-Y$8+PS36(:2+:P"C;.,8+GD8-,N
MXKN^C9;KPKXBG9F0LTITQ\[,E!AI2HVEB00`<]Z3$BUI<^D:Q?Z:+7P_;"PO
M=--Z+F2UC`))CVH.<Y`<D\8Y&#G(KH/["T?_`*!5C_X#I_A6%;7EU9_8A;^"
M]>CCL[<VT*">R("'9US<9)&P=_6KW_"0ZI_T)NN?]_K+_P"2*J5KZ`C3@TG3
M;:99K?3[2*5?NO'"JL.W!`J[6-8ZS?W=Y'!-X9U6RC;.9YY+4HF`3R$F9N>G
M`/7TYK9J0"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
EHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>graph13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 graph13.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``\`1\#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#WZBBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"J>K:BFD:-?:E*C/':0/
M.R+U8*I8@?E5RF311SPR0RJ'CD4JZGH0>"*3O;0:M?4XGPK_`,)EJ$FG>(;O
M7;&;2=1A$[Z6;0)]E1TW)Y<H.78<`[N,$^U3V/Q"M[J_A272KRWT^[\[^S[X
MLC)=F($MA5)9<A6*[@,@5:T_P/::?/INW5-3EL],8M964LJ>5#E2G4('8!68
M#<S<&BR\"Z?97%NRWM_);VGF_8K5W0):&3(8QE5#YP2!N8X!XQ5.U]-A>IS"
M_%B;5?#.IWVDZ)*+FWABFBW7$4L;*[!>65L*ZYR4;##(R*[+5_$,^DZ/8W!T
MBYGU&]D2&+3HI$W^:REBI;.W"A6).<<5C1_#'2%FOKF>_P!1NKR\M!9O=3-%
MYH0%2#N6,;V!5?F?<>`"2*W]3T!=4L+.";4;V.YLY5FAOHC&LPD`*[L;-G(9
M@1MQR>*6E_N_7]`_K^OF<'JGC[6-;N?#]CX>@N=.FGU=['4O-2)Y(&B&Z2/#
M':<KEMP[#CGBNNUSQ9-I.K"QM-"O]4,4"W%TUIM)@C9BJD*2"Y.U_E7)XIEC
MX#TJQGL;A)KM[BUOI=0::1U+7$\B%&:3"XZ'HH4#`^E6]5\,1ZGJ+WT6JZEI
M\LL"VT_V*1$\Z-69E!)4LI!9OF0J>>O3!'?7^M%^H.W3^M?\C'NOB/:VGC&#
M0)M,NE6>Z%I'<M)&NZ0J&R(RV\IR!OQC/%11?$,W4BPR:/?6$-T+J.SO9&C=
M))80^X!0V1PA(+`9Q^-6V^'>FMJR7XU#40$U%=36`-%L\\+MR24WL"..6/MB
MJ^A^`Q':6S:O>7<DMO)=M!;"1/*@,SR9=<+N)V/T8D#)P*3W2]?TM^H1OS:_
MUO\`\`P="^(^K*KRZA8W6H6-OH=K>O/!%&)9))-W)C!_B(Q@<+M)/&#6W8^-
MY==CT::TB^Q^9K36%W%YL4X8"WDDP'0LI&0G(.<@CUI+CX4Z+<Z?]@:_U-;8
MV,%C)&'B(D2%MT;-F,_,">V`>XK:M/"%I:R12M>WMQ-'J']HF25DRTODF'D*
MH&W:<X`'/3CBGU_KO_D+I_7;_,Z&BBB@84444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`45BZ;X@?5M*L]2M='U`V]W`D\19H02CJ&&1YG'!
MJU_:-U_T!K[_`+[@_P#CE`%3Q7)J<.AO+IE]:V'ENKW5W<#/DVXYD9!M8%P!
MP",>M<<VL^(/^$`CU2;4M6COIKIX=-CCM[:.:\61\0>:KQ,J<<DJ%XR<=JVO
M&'A\>---@L+VUU^TABF$P-E<6\99@.,DL>!G/UJ6PT=[*VTF&6#Q#?G3)9)H
MY;VZ@EDE=@PR[%^=H<@8QCBE;>XV]K?U_7]6#Q#)XFTWP+;PZ?+<7OB!S!"]
MQ!!&S%BR^8X4@(!MW8W8`XS6$FN:W<Z2+_2]6O7L[1[E=0FU-+5'MI8V0;)-
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MKBM/`>L:Z;S4;]]/,XECU!(4ECEC&#$?)4)C<.HSUZFL>P\*VNG^&YM#CF\8
M/"SH\,[ZA#YMJ5Z>4P<!!UXQWJ_%HNEQ::VFC2=;:P>SDM);9KF+9+O.7E?]
MYDRD_P`?7GC%4\XP%FO;1^]$JG--.W]?U_PQGV.K^,WU!]-%Y]LOGT^SO;B-
M8H5^R&28B1(S@`XC!QO+'(SGM6MHWB>[$^E6NNW@MY63[.SA`1=W(.QLE5(1
M`P*@DKO<X7@#=#HVD66AZ-=V%M9>())KP8N=0GN8)+J48P`7+\87Y1@#`Z<\
MU-/INF3ZS9:D-#U.(VBHJ6\3VZPMY>[R]R[_`.`NQ`!`R<D'`P?VQ@+_`,:-
MO4?)/EVU.XHK+BUB>;.S1K_CKEH/_CE2?VC=?]`:^_[[@_\`CE=M&M3K052D
M[Q?5$M-.S-"O/CJ'BX^/)=/LM1MKV)%N);JV:-1!9H5/V52X4/YC$98?-P>!
MC!/8_P!HW7_0&OO^^X/_`(Y7#V'@)=/?5VCNO&+_`-JQRK.KW]MM#2$;I%4$
M`/@8!(.`:TZ_)AH7_!.H^(+S6]1M]1U$ZC:VD*13SB!$B6]!/FQPLJJ611@9
M8$@]ZCCUK6)_$]]"\FKVAD>X32K::WMTMKGRHP#DE3-R^Y@254C&"14&@^"/
M^$>MX;:TNO&3V\-Q%,D,NI0;`$W?N\!@`C%LLHZ[16AI'AJ#1=8NM2M['7Y9
M)E988KF\AECLPQRXA4R?+N(!.<]!VXHZBZ:$$GB*_L/-M-1N+^$13JTMT+5)
MI8XO+!"!8E8-(S*[8"G;'DMCBNYBD2:))8W#QNH96!R"#T-<=<>'8Y]#BTO[
M%KL>R1I'NDN+?SYF=65RSESRP=AD`8&-NW`QT]E,Y"P?V;<6L4:84R-&5P,`
M`;7)_P#U4`>)>+WNF^(_BV5O#UYK=G9P6KN8M6DM!9@Q<OM3EP<9.`<;?>NQ
MT_6=>TW2=/TB#5=.O+BTT/\`M&?4KI'G2Z`.`J,'0XQU<YZJ<<UW2:/IT=]>
MWJV<0N;Y52ZDQDRJH(4-Z@`D5F7'@3PM=V%E8W.AVDUK9;OLT<B;A%DY(&>Q
M/;I25TK?UU_S*DTY7\O\O\CEY?B)JTGD6EOIL$6IZI:V=SI4,RN0WFG$P?&-
MWEC+'&WY2..]6K+QQJ%WXXBTI?L<VG2W=Q:;X+>4;&BC+',KE07R,%51E']\
MGBMR3PO)<>.;7Q#<:@)+:RMGAL[$6RKY+O@,_F`Y.0,;2.*LV_A'P]::R^L6
MVCV<6HR2&5KE(@'+$$,<^^XY]<Y/-5*SV\_^!^!&MK>G_!//-%U;Q)9:-!?V
M%S!=K:^&K6Z-E-#([S8,FX*PD&&.WKM.?E&.*[CPIXCG\3S:C?0+`=#5TCT^
M9%;?/\@,C$DXP&.T8'56S3M1\':?/;0/ID<&GZG9VYM["^$`E-JI!&`K'!&"
M1@^M7?#&A0^&?#6GZ-`_F):1!#)MV[VZLV.V22<=LT*UOZ[L;WNC6HHHI`%%
M%%`!1110`4444`<_X$_Y)[X:_P"P5:_^BEKH*Y_P)_R3WPU_V"K7_P!%+704
M`%%%%`!1110`5D77_'S)]:UZR+K_`(^9/K7R/&'^ZT_\7Z,Z,/\`$R&BBBOS
MPZPHHHH`****`+^F_P#+7\/ZU>JCIO\`RU_#^M7J_5>&_P#D5TO^WO\`TIG#
M6^-A1117N&04444`%%%%`!63XHO+C3O"6LWUI)Y=S;V,TL3X!VNJ$@X/!Y`Z
MUK5'/!%<P203Q)+#*I22.10RNI&""#P01VH8T[.YXOXX\8>,/#,<.GP>((Y=
M2BM&U2YD6PA1/++X6+YWP%&"!MW.<4_7/$'BK2-5UV\L]?CDENELXK:TDAB"
MVWG<B12[`?+\R_,0I+@GISZ[=:3IM]+'+=Z?:7$D:/&CRPJY5&&&4$C@$<$=
MQ4<VA:1<,S3Z58RLUO\`96+VZ,3#G/E\C[F?X>E3;6_]?UMZ"6W]?UW,+X=:
MQK6L>&F?7OLSWMO</`9[>:&03!<?,PB9E1N2"N>"/>NMJ*VM;>RMH[:T@B@M
MXE"QQ1(%5!Z`#@"I:MNXD%%%%(85Q'Q.AFF\/0I'JMY9K/.EHL%HZH;B25U1
M0S$$[0"Y*C!/J,5V]07%E:WC0M<VT,Y@D$L)EC#>6X!`9<]#R>1SS1:X'F7B
MVPTS5/'%KIMCJ1.LQ&"0--=;(M)B1E)$2K@^;*.-N22.3@8S?^))MM9LK&%-
M3\-FV@\R]EAU2<E90JE`0B,"P!9N<\$#@UU\GA?P_+J7]I2:%ICW^\2?:FM(
MS+O'1M^,Y&!SFI3H&C&VM+8Z18&"S<26T1MDVP,.0R#&%/N*35XV'=)W.(AL
M/(N=$O\`3+.PM[^>U1K."3.^UB%N5,;8&1"K,6.#RY4<$YKH?!=U:36,T5M;
ME)/W4\\Q8,T[R1AM\A_YZ$8R.<<`'&*Z);6W2ZDND@B6XD54DE"`.ZKG`)ZD
M#)QZ9-1V6GV6FP&"PL[>UB+%S'!$$4L>IP!U/K3>KN+HD9'@3_DGOAK_`+!5
MK_Z*6N@KG_`G_)/?#7_8*M?_`$4M=!0`5AZK:,=>T:[-W<[1<%%MPX$0/E2Y
M;`&23P.20,#`!R3N4UXTD9&=%8HVY"1G:<$9'H<$C\::=F#V.6\<ZB(-+-@\
M>IK%<PRM)<6-K-+M50/D+1*2A8D<G'RAN0<5CZNL5WX<O-22VWWUCHD4^F22
M0'S8)2LF"@9=RL65`1U.`#7<P:?;6ZW*I&I6YD:652HPQ8`'C'H*;-I.FW-Q
M:W$^GVDL]G_Q[2/"K-!T^X2,KT'3TI0]V7-Z?K_F#U_$X^\UA[CQ_HT<\5_$
ML-S)!'']AN`C$Q/ND,FS8P)VXP3@`DGD@=+=?\?,GUK4>&*22.1XD9XB6C9E
M!*$@@D'MP2/QK+NO^/F3ZU\EQB_]DI_XOT9MAE:3(:***_.SM//OB7;Z3<+:
M0W<[2:G<QO;Z;:O-LACE;'^D-CD;!SNSTR`,FM[73IL?@R>/6M19K2WMXVO)
M(W&Z91@D'KD28*X[AB`:T]0T'1]6D234M)L;V1!M5KFW20J/0%@<4V70-*G\
M];BPMIH9HXXWAD@1HRL9)0;2.V3C/3M7HQQ,'3IP;?N._3NMNVGX_A%M;GDL
M\+G1-&MXY;:'1M4U*9TT^ZF806J&$M%%+M.?O#>4R/F..V:FU*[MM6T30[M[
M?23#8:0UW_9^HO/(9!N`_=.2`3^[P"68C<,CU]3C\.:'%I\NGQZ-IR64S!Y+
M=;5!&[#&"5Q@G@?D*L7.EZ=>?9_M5A:S_9F#P>;"K>4PZ%<CY3P.GI7:\WI\
MR?*]&^O>_P"+O:^^E[ZD*GW_`*U-?2'\R$N4*;E4[3U'M6C5'3?^6OX?UJ]7
MV_#?_(LI?]O?^E,YJOQL*K:A;VEW926U\L;VTN$>.4X63)`"GU!.!CH<XP<X
MJS45S;07EM);74,<\$JE)(I5#*ZGJ"#P17N&9@^&/+MK75=/,*VL5E=-'LB.
MV&-&17"QD`84!L'I@[N@Q7.:S;/HLLT6B16T-IJ#6?RPY9'4W"+++,>Y=9`"
MW4A22QXQW,.DV%LEG';6L-O%9DF"*&,(B9!!P`.!@GI1;:1IEE#<0VFG6D$5
MRS/.D4"JLK-P2P`^8GN33OJG_3".A@Z9HZP:+?Z1^ZLUMYB7.DQM:1290-A4
M#,8^HSM89(SGYB*W-#.?#^FD_P#/K%_Z`*FLM.L=-LUL["SM[6U7.V"")409
>.3A0,<DFIXXTBC6.-%1$`5548``Z`"B^_P`@/__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>graph14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 graph14.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!!`24#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#WZBBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#@YM0\7^(=8UR/0
M+[3=.L]*F^RQ"XMFF>ZF"*[;CN`1/F`!`)ZFM74?%_\`8B+#?:;=W5W!8K>7
MYL%5H[9.06)=E)&5?``+$*>*K:GX%FGU34+[2/$FI:/_`&D!]MBMPCI(P7;O
M7<I,;XX+*0>!Z4:UX"_M,1I;:]J5A&U@NG78CV.US`,XW,ZG#?,WS#GYC1TT
M_K_@7_`>E_Z_J]AD?Q,T6YUN'2["WOKV62."7?!&GRI,`RML9A(P"D%BJD*#
MSBM+PQKUYK4NL+>:?+:+9WKP1LY3#*`./E=CD=3G`Y&.^,+4OA5IU]J=K<1Z
MC=0VD"VZBT,<<JH(<;1$SJ6AR`,[",]ZZ?2=#;2M1U6=;Z6:VOY_/%LZ+MA<
MC#$,!DYP.#TQQ2?Q76VOZ6_4.GW?\$PF^(UF\<8BTS4HY+VWFFTQIHXPEZ(U
M+';A\J,#(W[,@\4W0/%TMI\,+;Q5XIG(WPBXD,<`7"L0$555FSG(P20>>0O(
M":?\.(;2\@ENM:OKZ"Q@FM]-MYEC"VB2#:<$*"Q"X49/`_33E\%Z?=>`8_"%
MW)-+9):);>:IVO\`(!M8=@00#Z4:W?R_-_I8:M=7%?Q=Y&F7%Y<Z#K-NT#JK
M0RQ1@D%=V_S`_E!`,Y8N`,8.#Q5>+Q[8W-EI-Q9:=J%XVJ^?]GAMQ$S9BSOR
MWF;.QP0Q!]>15*[^'UUJ5C''J/BK4KJ[BNDN(YY(82B;5*A?**;,88G.,YP>
MU5KGP)?VK^'++2-6O;:'3S>,]^GE>8IEY4,A&U@22.%[`\<4:ZD-[6,C7?BN
M19RZCH#S3(=%>^BMI[-0JLL_E%G<R!LJ<C8%.<9!/2NON?'%K8:EIVGWVG7\
M$MZT42O)Y2J)'Q\H!DS)C<-QC#J,\FL7_A4&CK:?9(;V[2#^R)-+YPS'?+YI
MD)_O;L\=*L+\-$.MIJD^O7DTPFMKB17@A_>2PA0"6V;@I"_=4@`DGVHL^=]O
M^"_T+FXV]W^M%^IT7AK4KC5+&[EN2I>+4+JW7:,?)',Z+^.%%;-9^D:4FD6T
M\,<K2":ZGN26&,&61G(^@+8K0I]$2]V%%%%`!1110`HHH%%`"4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%9-MKGVU)9+/3;R>*.>6`R*8E!>.1HWP&
M<'AE8=.U3?VC=?\`0&OO^^X/_CE`%V8RB"0P*C3!3L5V*J6QP"0#@9]C7FFC
MWWC&_N_$>E77B>T62VACE.IV^GJ8+"8L2\";B!*%4=6Y&>>:[74);N_TZXLQ
MI^JVWGQM'YUO+`LD>1C*DN<'T.*P=,\-/IGA:X\.*GB";3I8#;HLCV0:%#G=
MM9-I).XY+;C2[C36A)\-+GQ!?>&6U/7]4EOOM<ADM#-:1V[K`.%+*G`+?>ZG
M@CFN3\,>)/%>J'6;F[U?58Y4A\R#3;C0TC9(WDP)H2,M,$4'C;R<<'OZ'.;J
M95B6PU:"W$31&&"6W0,"``=V_>I7L58=>_&,[3M*N-/EN+ADU^[O9H%MEN[F
M2T:2*-<D!<$+U8DE@23C).!57UN39V\RII_B6>=+6SN=0EM%@DWW6H7B1PF1
M=[&.'#*!YI0(7`4;02/E8C'<5Q-]X5L]0M;.WFTK6?+MHI(3^_@)F21E>3S"
MSG)9D!)&#R>>:Z;^T+K_`*`U]_WW!_\`'*0WN:%%9_\`:-U_T!K[_ON#_P".
M4?VC=?\`0&OO^^X/_CE`'+>)]1\06'B_21::Q:16<]Q##'I*0"26\4M^^D9C
M@QJBG(*Y''/4"LO1->U_4OBC>6=UJ^HV>F1S3"VLIM(C6"[2/Y3Y=R3N8@_,
M1CH.M;D.B7,'BJYU]#XA,]R%22!FLFC\M<XC7/SJN23A6&3R231;:'/;W?VI
MO^$CN)HHI8K1KB>TD-H)""Q0DY9N``9-_`QT)R1T_$):[>1F^./$FNV=UJ$V
MB7L-M;:#!%<WD3P"0WKR,=L`)^X-JY)'/S#%6'\3ZGI^M7CW2WCHY:.&RDM?
M+B1BRB,I)M&]=OF/(VY@@QT/!LW/A]+K5_M\EEK0\QX)+FW62U$=S)#S&[_-
MNR"`<*0#M&15R\T\W\M])=:;J\AN[8VN#+;@0QG[P0!^,G!).2<#L`*%>VOF
M-VO<U=#=GTF'S-5CU249$MU&$"LV>0`G``Z`<G`&23DG1K#TP3:9!)&FEZG,
MTLKS22RO;[G9CDD[7`]!P.@%7/[1NO\`H#7W_?<'_P`<H]1&A6-XI;45T"<Z
M9J5II<H(,E_=`,MM'G+.%/#$#H"0.>35G^T;K_H#7W_?<'_QRL3Q+I<OB>TM
M[:>VUNTBAF6?;;/:8D93E0X<L&`(SC&,XSG`I,:.<N]9\4S?#G3]5C\16NG2
M)YSRWTUDIEO55F$(2$\`R@`X!R,C`YQ6SXLUWQ!I_P`-4U"ULYH=?GC@7R+6
M#SWBD<KO"H<[BHW8!]*;JGAVYU:ZTJ[N)?$0NM,#&&5?[/.YVZNRLI7=C@$`
M8[8R:U+^'4+Z':HU^UD$PFCEMY+0%,+MVX)*LIY.'#<G(Q@8IZH6S.(TSQ#X
MHET33;F+7KG4$DN)FN;J?2DMS;/&8U^S3JH81*/WK,YP?E`##C/=:'K#:OJ=
MU,+^W%OMQ;6*D>;M!YF?/S#=E2HZ!2"<EL"C::%!9:1%I<6DZJ;43FXG#R6[
M&ZD+;R9"7YRW)`QG&.G%6;*Q-CJDU_'I>J,\K2-Y;O;;4,A4N1A\\[%ZDXQQ
M0W?^OZ_KSU)U_K^OZ_`Z845'!(TL*N\,D+'K'(5+#Z[21^M%(H\$\2:E>1^)
M/$UQ-JGC:,P:B+6R;3;Q$L8G9$V++O;Y06//;!%=_K?C+Q%IMS=VEAI-C>OH
M^G1WNJ22W)BW%@Q*1`*><(QR>/Z]2WAG1WMM5MWL4>'57,EZCLQ$K%0I/)XX
M4=,=,]:IW_@?P]J<B27EG+(X@%LS?:YE,L0.0DA#CS!GL^:.EOZV'IS7_K?_
M`"^XSHO&L[7$EJ]K$MQ/<VBV"%B#-!.-V\CU55FS_P!<_>H-0\;ZC8^,H-+%
MC:RV#7<5E)*CR&19'C#YR$,:@;A\K,&."0,8-:2^$S-X]C\179M3%8VGV;3X
MHHB'C#?>9R3@GJ!@#AC5V?PEHMSJ9U&6WF-P;A+K`NY1'YJ@!7\L-LW8`&<<
MCK35KJ^Q,KM.VYYEX?\`$/C"74M-@L+B&\1EU.5X[Z=R7\NYVCD`DE5*A1D#
MD],"NZ\,>-&\5ZE"+"U4Z;_9L=S/<%\F.=V(\G'J`K9_"K@\%:+;M;3V-J\%
MU9M-);.MU,H5Y&WN&VN-ZE@"5.1VQ3?!?AJ3PSI-U%</;/>7EY+>7#6T92/>
MYZ*"20``!R:(V2LU_7]?D.6K;7?^OZ\SI****0!1110`4444`%%%%`'/^#?^
M0'<_]A74O_2V:N@KG_!O_(#N?^PKJ7_I;-704`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`"BB@44`)7-^/O$%WX6\$:EK5C'#+<
MVJH42924.75>0"#T)[UTE4=8T>PU_2I]+U.#S[.<`21[V7=@@CE2".0.]!46
ME)-['GGB+QYXK\.7&FP36>DW,JHD^IQV\-R^R.25E78X&U,!<;I",GH.*J:I
M\0=>TG6]4U@PV]QHT.D6=Q'8[F\T23DJ@!`QG?G<2/NA<<YKO]7\&:!KMW]J
MU*P\Z;R1"6$TB90$D9"L`2"20>H[$5')X%\-RS1RS:8LK)9BQ`EE=U:`9PK*
M6PV,\%LGWINSCYW?Y,S2ES7OI;_(I>`/$6O>(-+N3XBTAM/O;>7:&%M-#',I
M&0564!N.0?I[UUU9FB>'M+\.6CVVE6OD1N^]R7:1W;IEG8EFX`')X`Q6G0R@
MHHHI`%<I\0M8UW1/"MU>Z##:M/&A9YKECB,#&-J`'>Y)P!P,]?2NKJIJ6G1:
MI:+;3M(L8FBF.P@;C&ZN`<@\$J`?;-`'G>O>(O$5DESIPU7[/)HN@C4-0OTA
MB+3W)!"1[64J%)5B<#/0`BM_6?$-\EIX9TZWE^S:IKDB(9552845/,E958$9
M`&!D$`L,YQ@V=:\!:-KWB"#5[TW9=$5)K:.8K!=A"603)_'M8DC]<CBHM4\`
M6&KV;PW6J:QY_P!LDO(+Q+LK/:EQ@QQ-CY8]OR[<=#Z\T.[U_K?_`"_(:LM'
M_6G^?YF0-8\2R:!#?6]T\EO;7%PLUXR0CS(HKK;N=<#.8D?_`%:C)(QCBNAT
M#7QJ.J7MG=3F&_7]XNGE0?)B&!]\##MR"P5F"E@/<VX_#.F16^EVL<++9Z8/
M]'M=V8]P&%9@>6*\D9/4YY(!$>E>%=.T?5KS4K<S--<EL+(X*PAG,CA!C@,[
M%CG)Z#.``!;^0-Z:$7@W_D!W/_85U+_TMFKH*P_"=O-;:/<)/#)$YU._<*ZE
M25:[F93SV*D$'N"#6Y0(****`,_7#J`T.\_LD$Z@8BMN0%.USP&PQ`..N#Z5
MGMJDUM:36JS3'5GPEM%?"/[[!MI_=8!7Y&8X.<*:V;VSCO[22VF+A'`^9&*L
MI!R"".A!`-4K?0K9("E^[:I,Q!>>]CC9VQG'"JJC`)'"CJ>Y)I:C,32]4U.]
M_L/3KB]<3W%E/<7%W#$BEVC>-,!2I4`^83^`]ZZ+1[J2^T6QNI?]9-`CO]2`
M35`^%K:+3K6TL+JYT][4MY5Q:K'Y@#?>7YD9<'C/'4`]16Q;V\=I;16\*[8H
MD"(,YP`,"B-^77<3Z6)****8"'.#@`GMFN>\*WVK7<VN0ZQ+;M/:WXB1+<?)
M&A@BD"`D`M@N?F(!/7`Z#HJRSI#6RZI)I]S)%=:A.L[2-M(1@B1_*"IXVQC@
MYY)Y':HM*]^WZH3,^YGU"UURTM%U.XNKFXG,IMH[9!#%;9P2[8+#`X!+99LX
M&,@5[6]U]_$'B:QFN()##9PSV$,$8`B+F=0"S?>8^6I.<`$XZ<FY8>%Y-.U2
M>]AU_5&2XN&GEMY%MV1R23M+>5YFT9P!NX``J^=%MFU&_OBTOF7UM';2KNP`
MJ&0@KQD']XW.>PZ4E91?]=A]61:3?;[RXT^>:\:\BC29H[I8@P1BP4@QC:02
MC=\C'N*UJS],TD:>TLTMW<7UW*%5[JY6,2,BY*K^[15P"S8X[FM"A@%%%%(#
MF]=GU"QN`T&IW#7%U*J6-C!;(5.`-QD)!.WJ6;*@#`'.-UK4;RY?Q'8:1#-)
M;I/;3W+S1JI;]VT:A?F4CGS"?7@5#)X7D.O7.K0:_JEM)<%-\*+;N@50!M4O
M$S*IQD@-U)/>K-[HLM^JNVHW-K=1RN8;FV$?F)&W5/F0@J1CJ"<@<Y&:78?4
MR[G4+RYTW0C#J-U;7NI^4@6&.(J/EWR/\R''RJV.V2O'-7;Q-0?Q%86UKJ]Q
M'%\US<Q^7$P,:X4(,ID;F8'.<X5@.N1<30[2/4-/O$\Q6L+62U@CW94(Y3).
M>2?W8`.>YJ6+2X8=:NM5#RM/<P10,K$;56,N1M&,Y)D.>>PJNN@NA>%%`HI`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
B444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>graph15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 graph15.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!#`3$#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#WZBBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@!"<`GTKS'PW;^(/
M'&A_\)0GBF\T^XGN7-I:1(AMX8DD*A'7&7)"G)R.H]*]/KB[SX9:/=:J;N*^
MU:SM))1-<:9:W9CM)WSDL\?OQG!&<?6A;CZ$FM^,[S27UBYBTB.?2]&*+>3F
MZV2DE5=A&FPAMJNIY9<YJ!_B'"OC]?"P@M@Y9`&DN3'(ZL@8.BE-C#+8P'W<
M'"\5<U?P!INL:_\`VK-?:G$DA0W5C#<E;:[*?=,J8^;@`=>0!1?^`-+U+Q;;
M^(;FZOV>!ED6R\__`$8R*`%<IC[PPO0X^44U;2Y,KV=BQX3U#5KZ#4Y-4CMP
MD5]<1PO%,78JLK+@C8H````.3GOBLJ'QQJ$L>F23Z1#;P:U%*VFR"[WME8S(
MGFKL`0,HS\I?'<5O:/X;AT74]4O(;Z^E74)?.:VGFW0PL22WEKCY<DY/7-9>
MC_#S3-&U22]COM3N$"NEK:W5SYD-F'Z^2I'R\<=^.*FWNV\OQL5U^9F>!-3U
M'3_A:_B/7+F>]D:V:_.Z<2,4$><#Y%"9P?E^;']X]MN3Q!K%CHU[>ZMI%E9F
M!8VC=M37[.P<@'=(RJ4VYR?E.?X=QXJ_IWARQT_PK#X<`>>PCMOLI$Q!9X\8
M.2`.H/8"L*'X;:?'H-YI<VLZ[=27+1M]NN+XO<1>6P9/+;&%P1G@=^>V*=KN
MQ*V5RKI?Q(DUK0(-0T[38+J6;51IJK%<L(SE=WF!GC5L`=05'0XSQF=/%MQ?
MSVMO):&WO[?6FT^:&&[S$SBW>0$L4RR$8XVJ<_3!;?\`P[A;2K?3K.]O6C;5
M(K^YFN+QS-E8]C,L@^;<2`W)ZYQ@8%:NF>"M.TRST^!+B\FDL[UKYKFXE#RW
M$Q1T+2L1\WROCM]T>E)6MK_6W_!%=W_KS_X!S/\`PG^H:!X&TG5-:CTH2W,)
MD\R?4&3S``N,*L)<N2Q^55*@#)8<5T&@ZW-K'B0R@NEK/HEG>)`3D(TCS9_'
M`4?A6?'\+-,1;93K6OE+>24HHOV3]U)MW094`B+Y!\H(^M=#I'ANTT:>*6":
M>1H["#3QYA4YCB+%3P!\WSG/;IQ0OZ^YE=+?UNO^";-%%%`!1110`4444`+1
M110`E%%%`!1110`4444`%%%%`!1110`4444`%%%%`!15#6-5AT736O9XII5$
MD42QPJ&=WDD6-0`2!RS#O6=_PD\__0LZ[_WYB_\`CE`'05B>*KF\L]%:YM;Z
M&PBB=7NKN0`F&`<NR@@@M@8`([U%_P`)//\`]"SKO_?F+_XY7.^+EG\66,%F
M^G>*+*".02.EO#`1*005#;G.0",XI,:MU&W>MZROP^M=7.I7\=]-*\5HD5O"
M)+S?(5@WJZ$*2NTG`&,GZ5LZA>Z_H7PVDN;@M?\`B&.TQF"$-ON&X&%4`;0Q
M';H,FJ*W$S1Z0MUH_B2Z;39#*&DAAS*^UE!;#]@QQBDO[J^OEOA]C\6V_P!H
M9&A,"Q)]G*C'RX?D$\D'.:;V8DW=%&SUKQ!?6D\&FW^I7.H6MRL.H0W=O;))
M;#RG8%0HVD,WE\DGC-:VE^+HKV_L!<W_`),4L21Q[83LNYCD%@V#M3(PA)7<
M<XR,5FV5JEAIMS;0:-XG\^]E66^NVCA:6Y.,$$E^`1QQC';%2W44-UJMI=GP
M[X@2WMA#MM$@A$9:(L8C]_/REB0`<=/2G?;Y7_7_`(!.OY_\`[^BN?\`^$GG
M_P"A9UW_`+\Q?_'*/^$GG_Z%G7?^_,7_`,<I%'05P/BW5?$^G^(((K&\B1+F
M6&/3[**)9&N?F!G:4LN455/!4^E;W_"3S_\`0LZ[_P!^8O\`XY7('3;P^,G\
M2>7XO\YB%\CR;?RUB#;O*'S9"G'/<T+XD/HRS'XHU"3QK);W]WJNFZ?+J0L]
M/46D(AN"B`L&9U,GS,'P1@8Q@U)XS\3ZS!J^HV.D7265OI.D/J5W<F-9&9L-
MY<0#`@`E"2<9QP,=:KC3O,U07UWIWBZ\:!VDLH[CRG6T=@1N7,G)&>-V<=J9
MJ.D0ZG?K=3Z1XI_>6\=M?1B.';>HA)42?/[G.,9S22]U7_K3_,5[2?;_`(/^
M1H6'B37C9:1JNH6\P@NHH&:WAB0B0O!G:H/S;S*1U(`523CFNA\-:RNK6]PL
MEW'+>PR'SX$'$&2<(#@;@,8W<@D'GL,IM0:34XKN3P_XA9((]D%OY40CB.""
MP`DY8@XR>@SCJ:I^&TA\,I.+;P[XBE>4(GF2Q1$B-`0B<2=`">>I))/)JI.\
MFU_7]?UYI:)([VBN?_X2>?\`Z%G7?^_,7_QRC_A)Y_\`H6==_P"_,7_QRD,V
MKLW`LYS:+&UR(V\H2'"E\<9([9Q7G6C:EXYN;_5;%+^ROY+>PP\[1JD$%^3G
MRE90"RJI!.03G\JZ'4M<NK_3+FTCT3Q%:/-&4$\,40>//=<R=:Y'2_#\FE>$
M]1\/0P>+S;7B[?,,-N'BR27*D-U;."30NOH/30Z7P)J>N:C<ZM]OO5U#3(9$
MCL[[REC,SA<38V@`H'R`<<^_6H=,UG59O%<\%]=:E;I+/<BPMI+:%;>=(OEQ
MNP9,_P`63C/;BJ_AP7/AS2[33HM/\47$%K)N0200#*;-HCX<?*#\WKFETX2V
M>M-J=QIGBJ_=`XM8[I8F%L'/S!?GR<X`R<G`IR=W\B+.Q"/$OB#3OM-OJUS%
M`[-;N))44O;Q$!9#M0'<S/N$:\DX)/`P?0K>>*YMXIX)%EAE0.DBG(92,@@U
MYW>Z?!>V@4Z%XD2]^TK=/>^5"TCR*"H)R^,`,0!C`[8P*ZG1=25%M-+@\/ZK
M96T48BC>>-!'&JKP"0Y/8#I1TUW*>^AT%%%%(#P[QKX@EMO&NN6\WB;Q)8>5
M+#%:P:?$#!EH8R`6/"DLQ_.NQC\7Z_;VVBZ,NE)>^))=,%]>QO((UC484_\`
M`BQQ@5T=YX4TW4+?6K>[1I8=7=7G4G[I$:H"I[$!`<^M9=U\/K6>VTT1:I?V
MUY86ILUO(9,220G'RMZ]!S4ZV_KL_P!;%:7O_706R\=P3W]FES!]GM+[3X[Z
MVF9OX2CNZGW4*/SK$UKXH76E>'=/U@:3'Y5S:"[=9I]I"L3M51U+$#/84[Q;
MX%O=>U#0-&MK2"/P_8PB.2Y\[$JJ,90+W!5%7/\`M&MCQ%\.M*\1WDD\UQ=6
MZRV@LY(H'"JT:DE1C'&"3TZTW>UU_6__``%\K]1:7L_+^OU.'USQGXDM?&&L
MQZ7*9(#=Z1'%!,^%C69264>FXX!-=?!X_FDG@T]M._XFK:RVF/`&X"*N]IA_
ML["#^-37OPWTR]GOYS=7,<]V;1_,C;!C>V&$9?>ET/PY>'QWJOB35;*W@D\M
M;2R,4F_?&"296]'(V#Z+2@FGK_6W_#?.XYM-)KLOOMK_`)_([*BBBJ)"BBB@
M`HHHH`****`.?\9?\@.V_P"PKIO_`*6PUT%<_P",O^0';?\`85TW_P!+8:Z"
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M%HHHH`2JFJWZ:5I%[J,J,\=K`\[*O5@JEB!^56ZI:OIXU;1;[3FD,8N[>2`N
M!G;N4KG'?K2E>SL5"W,N;8P)O&KVVC6NHS:+<QI<QM,@>:,*L856W.^=JY!Z
M'GC%5K/QM/J][X?GTZP>33M0AN7E/FI\GENJ%LYY`R3QG.1BF^)?AU'XAM]$
M1=5DM9-)B,2,($E60$*#E&XZ+[XS[4^'P"UE:Z+;V&M36Z:9/,Q(@4F>&63>
MT3=`.@&0.W04WOH3V'>%/B/I/BW5#860`D,!N$Q,CDH"H.X*24/S#@X/7TKL
MJXOP?\/8O"6J7%VNH"Z0QF&VC^R1Q&",G."RC+GA1D^GO7:4=`"BBB@`HHHH
M`XZ'Q7J#2^)+BZL19VFE623QI(P:1F*NY+8/R\*OR]>:H?"_Q/J_BBUO[G5-
M1LKGRC&BQ06KP/$Q!)W!^H/&"/0UK)X5O%L?$B_VBBWFKW33I-Y0<1H%540J
MW##"X/U-+HN@:Y87EQJ%[JEK<7M[/&;HI;E46!%8*B#/!R<Y/J?:DKC:70R;
M3Q?JU]XEM[JW%NWAVXO)M-BBV'SWECC=C(#TVYC9<?C4>A>,M;U#2[EIX+=+
MRYD`L!(/+5/W8:0/GJL3$J6[D8ZU;\->`KG0M6A>;5!<:98O<26%J(L,CS,2
MS.V?F(#,H]F-:%]X3^W+)<SM%<7LEP)'\[)C,0;*PX[)]TGCYBO/L1ORZ]OZ
M_KL$K7=B7Q9N_P"$=L][B1O[3TS+J,!C]L@Y%='7*Z_9_P!G>#M+LM^_[/?Z
M5%NQC=MNX!G]*ZJF)!1110!R?BG5-=T9+G5('M!8VWEK%:,A:2[=B`5!_A.2
M`HP<GK@5M:K'JL\<$>EW$%J6?,TTT?F%5P>`N1DDX[],U2FTK4I->EOY&MKJ
M!2GV2&5V40$#EL!3EB2>>PQC'.9-4LM0U0QQH5BMXIF\R+S63SUVX&6`R!DG
M@=<#GM1T![F#)XKOY](L!&S07\R32%HK1IQ(D<FP.%!R$;(;=V!'K4VL>);J
MW>R>/4+2U,MI'<1PF/S1>.QYC1L\=`,\_?'I6XVG7*M;7%O%:13Q0/;>6&/E
MJA*D8X[;1Q@=:H)X7DLM-.FV4L;6SZ=%I[--G<JH&`88')PYXXZ>]/3^OG_P
M!6V.FHI`,`#TI:0PI&+!&*C+`<#U-+3)4:2%T5RC,I`=>JGU%`&#H>H7\FKW
M>GW]W;W4T4222""/8+=VS^[Z_-Q@YX]P,BFZIJ5[8:_9HU_;I#<S+%#8F++S
M+QO??GC;N)QC^'WJPFFW@OH]4NVCENK2TD@C6(D"7<5)9AC@YC&!SC)J>[L;
MNZE>%Y(VLWGCF!)(>/85;:!C!!*YSG^(^E-]!*^I5;5K]?'4&D-;HEA)837"
MR%LL[H\2_@`)/Q-4O#>LWNJ:E+)/>2?9G+M!!)8&)67<=I60GY\+C.!WK8FT
MII?$UIJPE`6"SFMBF.29'B;/X>7^M-MM/O/-L_MMPLPL\E)1]^4E2NYQ@`'!
M/3O2>RM_6K_0IFK1110(*K7UU]BLWF$9D<85(P<%V)PH_$D59JK>Z=:ZBL2W
M4;.(G\Q,2,N&P1G@CU-`&1;^(9+7P(VOZJBB2"U>>=(NF5SD#\L57T#7KFYE
MO);^ZC:U6$3HQ@,.Q><E2?\`61XQA^_/%6!X>C_X1G_A&Y0TEK<03132!CE0
MV>F>_P`WZ5*^@_VCA=8\N>-81`$C+*'&Y6+-C&,E5^7D=>N:F+=M=_\`@?YA
MT_KR_P"#_5BIH?B.ZNM,U:\U&%8FMKUX885^\5PI13_M'<!]35SPEJ=YJ_AJ
MUO=06-;MVD618_N@J[+@?E5>Q\'V%N;T7`:99[[[9&/-<;#M`'?DCD_EZ"KO
MAO15T#1TL1(9"))'+9)SN<MW]B*:O97[+[[(G6_W_GH:]%%%,H****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
>BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>graph16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 graph16.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`.7`5X#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#VS5+]=/CN
M;F>Z^SVEK;-<S2>7OVJN2QP!D\#M5/3=<M]6N/L]OJ%Q'/L,BQ76GR6SN@(!
M95E52P!(!(R!D>M,\66-QJ>A:Y86<?F75UI%Q#"FX#<[*P49/`R2.M5"FM:K
M+!,-%ET_[':3J@O9X]\LK*%4#R7?"=<G(/`P.].XC=N'DM5C:?4`@DD6)<Q#
MEF.`/SJ;R+O_`)_/_(0KR[3/!>H17DEU<>'";<R6,XM)$M%(ECDD$KA48KG:
MRG<S%FYYZ*-SPMX7O]-\53WUW#>B4F;SKIWM1%<[FRN-B><^!VD(VXP,T7"Q
MVOD7?_/Y_P"0A1Y%W_S^?^0A5JBBX6*OD7?_`#^?^0A1Y%W_`,_G_D(5:HHN
M%C!N]82PM89KN^E5YB1'#!:-/(^#SM1`6..,X'&>:?9ZO;:A-;0VNKK+)<Q2
MS1!8.JQNJ29]"K.H*G!SGC@XI2Q7UI>V.KVFGR:@B6TMM)!"Z+*-SJP9?,95
M(^7D%AVQG&*R=?T37=8O+"]CTZ.W"6TXN+>.=3O4W5K)Y1/`W21Q2`_P@G!8
MCDMO4$=IY%W_`,_G_D(4>1=_\_G_`)"%>:WO@Z_N+65H]`DBLS>O-9Z8C6SB
MT4PQIS&S>6,NKMF.0,F>,[F`MW?A76;OQ/9ZA>074DH%LT<UI);"*UVJOFJ7
ME1IP"P;[A^8-@XY-*X6._P#(N_\`G\_\A"CR+O\`Y_/_`"$*M447"Q3ECNXX
MG?[9G:I./+'-5X+AYS*HU#:\*JTJF'&T,N0<GJ,=QZ'TJ_<_\>LW^XW\JP=3
MTNYNC;-:1@QWD"V=ZVX*5A^]N]3@&10!SF3/8T[Z`:-O,]SI\=_%?M]GDB$R
MLUOM.TC()4@$<=B,U);^==6T5Q#?[HI4#HWD@94C(/-<?=^';V37II(M&_TL
MW1E36!)&`+?;CR/O;_\`9V[=G\6<U7ET7742"P32))(WO=+NWN1-$$C6$P"1
M2"^XL/*)X!!'0YXI7"QWGD7?_/Y_Y"%'D7?_`#^?^0A7G3^`)#;!!I$6Z;1K
MM+@[T!>\WQF`L<\LH\S:W\'8CBI[GPEJ]QXQ34;A;Z8_:+:6">&6V1+>-%CW
MHS,C3#+*Y*H=KAL$KDFBX6.^\B[_`.?S_P`A"CR+O_G\_P#(0JU11<+%7R+O
M_G\_\A"CR+O_`)_/_(0JU11<+%7R+O\`Y_/_`"$*J27,D%QY4U[LS(D2-Y.0
MS,"0..G3O_6M6LF^LO[1CU&V!"R$1M$Y&=DB_,C?@P!_"FF!*DLDE]-9I?DS
MPHDD@\C@!BP7YNA/RGC.1QGJ,K&\DMU-:IJ&9H0K2+Y/0-G'/3L:Y34M"O;P
M6FH:EH0U..5II+W2-\3_`#L$6(YD8(WEJA'7JY8<U4AT#7]-ET6^:PDOI=/>
M!I88KE&=P+>XB8*TC*&*F5>6(R`3R>*5PL=YY%W_`,_G_D(4>1=_\_G_`)"%
M>=KX+U"[>[NKW2T%T-.B2T;S4+13BYN)#L8'*L%D3YN/O$9ZBI=3\':B;74K
M.SM9(M*.LBZ6RM?LY\ZW-JJLJ)*#%_KMS%7`!()ZD&BX6.\E2>&)Y9;\)&BE
MF9HP``.I-8__``DVGC58=-.KR+=2JA56LG"@L`55G*[58[E^5B#\R\<BJ<6C
M75C\-IM.>"YDE5)'^SS2I+(R&0OY>454Y7@*HVKG:"0`:HW]KJLWC>TU#0]+
MEB2XV/)J45TK6T\.8=QDC)!#[%91M4DXC.["D*7"QUD,\ES9-=6]^)8QNZ1`
M<J2"#GD$$$$'H156UUFWN]2N]-CU8?;;.&.:YB,&/+5QE3N(P>G8\=Z31E8V
M&K7`/[BXNYI(.,?)@+D>H+*S`]PV:Y75O#&LW.J7=]I]MS?%+*247`C9;22&
M-99%_P!I6C!`Z]<>[OH!T^@>(;'Q1:?:M&UC[3#M#[OLK)P691PP!ZHP_#Z5
M:COXI='75EU>/^SVB\\7!C`4IC.[GMBN%\/^#-7TW5C/<V0?3A=2`V#-$T;Q
MO<7++)C/55DC.">C-QN`QM:3X9O(/A9I^A"T6SOK-(2T0=5662*17/S)D;9"
MAR>N'.0#D4KA8V],U>+5I98;74)A+$`S1SV3P,5/1@)%4LO^T,CWK2\B[_Y_
M/_(0K"OI=7UC2-2C'A^2TD-LT4:W-Q'YDK'J%\MR`N/5ER<9`'-<7!X=GL+J
MW@O/#+7%C-?M-#IA-L@*_92&`C0B(?,#\I8@YW;B:+A8],N#+:6TEQ/?A(HE
M+NQB'`%9G_"0V7]L_P!D?VL_VS(!7[&^U6(#!2^-H;#*=I.>1QS5&_TV^MOA
M_:6T@(DM)K:>>-7+8ACG21X\_P`6(U*^^/>J]S8ZH/'4=UI>FRVL<K*]Q?)<
M*]M<1?NPVY"01(5!4$+V0EB%P"X6.HM7DO;9+BWU#?$XR#Y('L00>00>"#R*
MF\B[_P"?S_R$*S_#*G^S[F=5VPW%Y/-"/5&<D,/9N6_X%6U1<+%7R+O_`)_/
M_(0I;-Y'242/O9)"N<8Z59JK9?\`+Q_UW;^E'0".:&.?4@LB[E$.<9QWK#MM
M1%_K.M:7::,RSZ=##)$]W.T2W!D,@XP&*J#$?F().>F,$[DTT<&I!I&VJ8<9
MQGO6=%!;PZ_J6JI?8:]M8+<)Y)_=F(RG=GOGS>G'W??AZ]`T,JPUB:XMR]UH
MMK$[ZDMA;^1J#2I/S^\=6,:G"`2<8Y*'H,&KNFZI9ZC_`&P1I-W&=-N!!Y9R
M9)<QI("%SQD2#@GZX[+8Z=:6*:'$+_S(=*MVC"M$Q:60J$$A8G@X\S(YSOZ\
M<VM-BM-/U/6+S[9YG]HW*3[/*(\O;#'%C/?_`%><\=<=LT>\&AGQZO%-I6DW
M4.B32W.HJ["T6=0T86-G(+$A2<JJ]<9<<XYJE)KMU!>C2KCP_;)J\LD201KJ
M#M;OO65^9?+R"JPN2-AZKSS5ZVTQ+**`V^JH+BVL9+6VD>U+"-W8,7*[N?NI
MQD=#SS5&/1K_`,B!IM=TY[^VNA=P7(TN49D*/&YE4SG?E'(&"NW`QP``>\&A
M$_B@OISW5IH44\EI!-/J$)OF0Q"*1XW6,[/WAW1R8SL!P.1FKB>(+*3Q8FBK
M90%7<(/],/V@@Q^9YODX_P!3_#OW?>XQ5-_#+)8M;V>NP0/=P30ZA*U@SF7S
M9'D9HQY@$9W228SO`R.#CG333(X]35EU.(::MR+L6_V5O.\T+@?O=V-G'39G
MMG'%'O!H;5E96\MHCO'ECG)W'UJ?^SK3_GE_X\?\:@LKVWBM$1Y,,,Y&T^M3
M_P!HVG_/7_QT_P"%#YKB5@_LZT_YY?\`CQ_QH_LZT_YY?^/'_&C^T;3_`)Z_
M^.G_``H_M&T_YZ_^.G_"CWAZ&%-<S6NN6MK<:(B6-W.UO#<+>;I=P1GW&/&`
MA"'D,3TRHYP[6)Y]+N!(FBQRZ<K1K+.UX4DR[;0(X]IW8)&<LO7C-1P0ZA'X
MCEU&?6[&>V8LL<+:;()(8C_`L@EV]0"3LR<>@&&7$.K3ZG:W3:]IK0PHFZ!]
M*D*^8/O.I$PP3G`W;MOOSD]X-!D&JB7Q%=:-<:7%!(MM)<QM'>>:Z(K!094`
MQ&6W94;FR`W3&*Z&"PMGMXV:++,@).X^E8WV:634?M5[JT5TD"2BT1+0Q2#>
M,$.^XAN,`85?4Y-;,%_;);QJTN&5`"-I]*/>L+0D_LZT_P">7_CQ_P`:/[.M
M/^>7_CQ_QH_M&T_YZ_\`CI_PH_M&T_YZ_P#CI_PH]X>@?V=:?\\O_'C_`(TV
M2QM(XV<PL0H)(4L2?H!UIW]HVG_/7_QT_P"%']HVG_/7_P`=/^%'O!H<C>>)
M[.UT5+Y].@M)9;][)(]1OO(1=NXEG<!@HVH3C!["DU'Q$+&*26/2[*YCL[!-
M0U!X]0<K%$Q8`Q'R_P![Q'(>=G0>M:IAFMK69=,UF*WGDNY+G=-9F6,AR3L9
M0RDXSP0R\@=L@XMSX4B>&X@MM8BCAU"U-KJ0EM'D:9&DDD/EGS!Y?,TH&0V`
M1Z4>\&AN^(6DTG3&OK+3[.XBB5GF^TWLD.`!QMVQN6)Z8X[=:R6UNXA>-I_#
M\*0Q/;17Y%^Q>WDF*@!5V8<+O4DY7@G`.*U[K9JL`@O)DCBAO4F15C)\R.-@
MR@\_W@#^'2J.HZ5]MU6:6+5H8=/N9K>>ZMS9LTKO$01MDW`*"$0$;"<`X()X
M/>#0?IFH_;M3BAGTB*&RNO-^R7"7;.[^6V#O3:-N1DC#-TYQ6U%96[7=PACR
MJ;=HW'C(K%TS3C8ZC%+/JT,]G:^;]D@2S9'3S&R=[[B&P.!A5]\UM17MNMW<
M.9,*^W:=IYP*%S"T)_[.M/\`GE_X\?\`&L#Q-J$?AZ**X_LZ&6W+!6:6]\IG
M8G`CB7!,DA[+\H/K6_\`VC:?\]?_`!T_X5CZ['+JL$EM;:O#;VMQ$8;B*:S,
MV4.02AW+M;!QEMPX'R^I[P]"G>ZQ%IWB6WTVZTR)+>XW^7*MYNFPD9=I#$!Q
M%\I7=NSN(&WG-.\+ZK!XB$[&RLXT14<?9M1%PR;AG9*H`,<@&,CYAZ,:==:?
M]NN(X;K5HY-*B82);FT(F5@NT#S0V-O)XV9Y^]BH[&UN-)C,J7]M=3Q116EL
MJ69B580XSO\`G.YL9Y&T>B]B>\&A4D\306JS7E[HZQ:9FY6WF2[+RRF#=D&/
M:`N[8Q7YCTYQ5NTUB"?1;[4#IL-T;9BJII=\+I9".V[Y=K#ON``]35.7PQ;W
MD4]C?:M'-I1-RUO`MF5EC,^[.YRQ5@H=@!L';.:U[&W6);^2]U&&:ZO(UA+P
M6K11JJA@N$+-S\QR<\\<"CW@T+MO%;7>C17RV_EM-;B8+O)VY7.,]ZL06%L]
MO&S199D!)W'TJO;RVUIHT5BMQYC0VXA#;"-V%QG':K$%_;);QJTN&5`"-I]*
M/>L+0D_LZT_YY?\`CQ_QK.UR?3="TF2_N(EV*\<:AI"H+NX103V&YAD]AS6C
M_:-I_P`]?_'3_A6?K4=AK6F-9RS[?WD<R,4)"O&ZNA([C<HR.XXH]X>AS$WB
MZVBTNSNF@T%'N9I46:370+0H@&76<(<\LJX*@YS[$]3=V\B:?')9:;#=73[?
MW9NBD2Y')+X)V^X4D\<>F3;V5]:--<V_B"W6\NIS-=AM/9H)"4C0;4W[D(6,
M8^<C+,2#QAALKNVT2+0M'U:*PM+2"WA@N);9IG=%!#J<.I&0$^8$$9..Q![P
M:$":^TUNK1Z'"LT*SO>K-?E$C6&0QN8W"GS,D$C(08ZE3Q4MIX@L=1\3?V5:
M1:88E"%C-J12X;=&LGR0A#N`#KD[AU/IRR_T/^T]-L;6YO\`2#]F5D(&C91%
M/`:$,Y,3A>`VYA_LU=FL3-<P0MJZ'28)89H[;[*PE1HRI4"4,!LRH)!0DY(W
M8.`>\&A%JNL6MCXGMM$AATSS9(TD<WNI&W;#LR@1KL;S&^1CC(Z#UJ)->M[C
MQ'=:):V-E)=1B14B;4")@RKD-+&%)CC;*X?YOO#Y:FO(;[6K!8+O5H;>VNK?
MRKVV%HQ89SDQ2*X*$@\YW]!C'<M](AAU2"9]4#V5M>37T$/D.)1++YFX-)N(
M9/WK87:.B\G%'O!H3^'YKC5+C4([[2;2V2UE$*RVU]).LC@?./FC3[O`SSSD
M=C6W8*$2=5&%69@!^54=%6ST?28;+[2LCIN:218BGF.S%G;'.,L2>O>KU@P=
M)V4Y5IF(/Y4:VU#07_F*_P#;#_V:N5N-:URVU;Q;#+<VBK:6%O/IZ+&2L;.T
MZC<>K,2B>PX`'4GIIGD34@8XO,;R>F['>JLNFQ37-Y<2Z4'EO84@N"9_OHA<
MJ,=!@R-R,'GV%#0&!IVK:R7CTRXGO4NWU*-5^V)`;A+<1^:_F>4/*PVQU!7D
M!AT;IHZ)J.MWESXDMKA[1KJRO$AMP%(C16@BDP>[8+GTS[=I['0[;3KF.Y@T
MZ=KB,.!-/?R3.=^W.6=B6^XH&<X&0,`G-RVMC:75Y<P:=LFO)!+.WGYWL$5`
M<'I\J*.,=*5@N85MJFM7NC^'[>"\@74KU)'N+AH05"HC981Y&1YC1#&1P3SW
MJL;G7(;EM/37+BXM)[J&UBU)H(1,DF)&F"@1B,@!$`.TX)8')%;9T6V^S^0-
M*94^S/:`K=,K+$QRRA@<C)`Y!SP.:JQ>%;*'3WL4L]1-NQC*J^LW#&,H<KY;
M&0F/'^R1GH<T6"YS[ZOX@GLM3B36I8KC1K:YE\X6\1%VR2R*GF`IP-L8W;-N
M2Q(QP*T8=:UB7Q3%)YLZZ6]TMN?DA^S`&+.W/^N\[S#C/^KQ[U=F\(Z7/:P6
MSZ1/Y,*NFQ=1E42J[;G$N&_>AFR3OW9).>IJ[_8\']JC4O[-E^T!MVW[8_E;
ML8W^5G9NQQNVY]Z+!<T]._X\(OQ_F:M5G64MPMH@2VWKSAO,`SS4_GW?_/G_
M`.113:U!,M455\^[_P"?/_R**//N_P#GS_\`(HI6"YR\6I:J=;MKS^T939S:
MM-I[6#11^6J*DF'5@N_=NC!Y8C!(QT-:.O:CJ=CKWAZ&W>!+&\O3;S@KF1_W
M,S@#L`#&/<Y[8Y5=!M5UDZL--F-WO,@W7SF-7*["ZQEMBL5R-P4'D\\FK#:>
MKIIZR:?)+_9\@EMFENV=E<(R;BQ)+':[#YB>N>O-%@N94MSJVG^)Q;7U_+-9
MWT<PB#PQ)$'`+)'%MS)N"*Q8N<'&5QT'46W_`!ZP_P"XO\JPX]%MK.XN+R'3
MI(Y'#MAKQWCC+9W,D9)1"<G)4#.3GK6G!-<BWC"VFY0@P?,`SQ3MH%R]39`Y
MC81L%<@[689`/8D<9JOY]W_SY_\`D44R5IYX7AEL%>.12KHT@(8'@@TK!<YR
MQDUI[O5M*N]8NK9H1'+%=SV\'F&/+;W3:/+"';A=X+#G<#Q6KI']J7&@2K+>
M$W+-(MM=SP+N9,D)(Z+M&<<X&W/'`Z52D\*:?+:36TFFW;I,R,[-JDQD&PY0
M*^_<J@Y(4$`$]*>V@;H1:M'?O8FWF@EAEU.:1I!(5.2[.6R`I`YR-QP1SDL%
MS.N)=4M]'U2=O$.I2VMF0;>Y@AM1/<O@AHOFB\LC>5`(4<Y&>*SM0UG7M*D_
MLZZU+47?3=/AOKW4(+>U9?G>7<948+^[41?\L\.1GN*Z2#PY:6]C]B%A>36X
MEBF"7.IS3[6B8.F-[G`#*#@<''(-6-1TF'5I4DO-,=V4;2%NV02+_=<*0'7K
M\K9'/2BP7'^(4U-],:72KBZ26,;O+M(X3+*>R@S?(!W.><="#7+1Z]K%Y:C5
M8M49$M)+&*6U2!/*N/-\OS2=R^8I_>$#!&"HR#R*Z&YT8WR.M[;W+GS6DCDA
MOGA>(-C*JZ,&"\#(!P?2HF\,Z>UW;W/]D.IMQ$(XDO76']V<QDQ!MC%3R"5)
M&!Z"BP7*VC7NJ/JEA<W.I2SVVH_:/]%>*-5@V-\NPJH;H"#N+9)[5TD'_'_=
M_P#`/Y5E66B6VGZC)?VVFRK.^_[]Z[HF\[FV(S%4R>3M`S5Z*6X%W<$6V6.W
M<OF#Y>*:07.6U?QS!#X[TC1+;5+*&,7WV:^BDE3S9&:"1D4*>0N[RQGNS*H/
M4'7\7W^JZ=#I<NG300POJ5I!<ETW.R23QH57L,ACECDCL,G(T+JV-Y<6<]QI
MV^2SE,T#>?C8Y1D)XZ_*[#GUJM_9KS6$=I?6LEVL=R+I6>X.0ZR^:G.<X4A<
M`GHH'2E8+F1=:QJEEXEV227[B2[6"*S%F!;&)EX?SBO+Y!XW\?W>]6?"%QJX
MS;>(9]0_M1H$E>&Y6V\H'HYA,(SMW''SG/`]S5PZ):MJCZBVE,9WR64W;&(L
M5VEO*SLW;>-VW..,U%%H0L[:6*PM[F!Y&3]X]])*R*K`[$+,2B\8VC"\]#TH
ML%S*LM<U>+Q)%97;7TEQ=W-Q$;:6T\JUMT59'B9)=F7W*J9PS\L>%Z4]]2UY
MM$+2W,N]=3F@N[G3[3S)(8%WX,<6URQW!%Y5C@DX]-BRT:WT^_FO;72W2:5F
M8@W;-&K,<L40G:A8\DJ!D\G-%UHUO>6CVTNF2!&N#<[HKQHW64DDLKJ0RGDC
M@C@D=#18+D?AS5YM;\+RW<ZN'6:ZM\NFUF$<KQAF'9B%!(['-;EM_P`>L/\`
MN+_*J"1O9Z<;6&Q$4"(0/WH./4GN3U.>IJ:":Y%O&%M-RA!@^8!GBG;0+EZB
MJOGW?_/G_P"111Y]W_SY_P#D44K!<I>(H]3;36DTN>Z2:/+>7:1PF64]E!F^
M0#N<\XZ$&LZ\U>^E\$V-Y:3$WUT($+6\:AV9B-XC$GRAL;MN_@'KQ6AJ>G+J
MR(MU8S!H\[)+>]>"1<]0'C*L`<#(SSBJYT57BEMFLY!9&**.*WBN3&(/+SAD
M*D%&Y'*X/RBBP7.>BU+7[ZTDM_[7N;*ZL;>XFD)@@:1V5\1I-\I3.W!;R\`Y
MX(%3V/B/4;_7/-D>]MK&.ZBM2%@A:W8O%&P#DD2[RTF`5^4<`C-:<_A;3[BW
MA@DTRXVQ!UW+J4JO('(+"1@^Z0$@9#DYJVVCV[:DM_\`V6PG!#;5NV$98``,
M8P=A8``!B"1@<\46"YC>*_&L&E:Y8:5#JMA:2BYMS>"XE0.T3OC:BL?3)+=@
M/4Y&>OB;7;F]NKBU%XA>:^LK&VFB@-I<30^:$4,")5<^46).4P&'7!KJX[&5
MM.M+2\MGNC;LD@D><Y+H=RMG))Y'<GWS44FA6<MY+=2Z09'E#!HY+IFB^8$,
M1&3L#$$@L!D@G)YHL%REX6UNXO-9U#2Y9[^Z2VMH+@3W]I]GEW2-*K+LV)\H
M\L8.WGGD]:Z*R_Y>/^N[?TJAI>FIHT+16=A-AL;GGO&F<@=`7D+-@=AG`[5>
ML"2DY9=K&9LC.<=*+:`+_P`Q7_MA_P"S5Q%S8K%XB\;J;VX`FTNSE>25G?:"
M]SE0%&53`QA1TR>223V<R2/J0$<OEMY/7;GO6/'XHTV22=!K++Y,33EI+-T6
M2->&:-F4"0#(R4)ZCU%-@<QH,D&H:A;:;9PZ3#IDMZEW'!IDGFVVV!`SF-@J
MAL3-#DA0`<]Q6[X;L3_:?C"Q-Y=D?VC&/.,O[P9M8&.&[<D],8SQBK]MK]I=
MVAN8]3F51<);,DMC)'(LCE0JF-E##.Y3DC&#GIS5FWU*"[%Z8-:A=;&0Q7+A
M%VQ,%#$$].`1GTI6`Y2R6RET70[2^G>+3K#3Y[RZD-PR%5VF)26!W?=>4YSD
M%,]<&L3/A&:6WN[&YT5/#,E]`E]8I-";>*-8;CRY9D^ZA>4Q\'GY$SSD#T!M
M<LDTB#5GUR);"X&Z*=HP%8;2V?IM5CGT!-5H_%.GR6LUP-3N1Y)0/"^FRK/\
MY(3$13>=V#@A3G!]#18#SZ;^Q_[`E35VLA#]@O/^$?WE=W_'Q+Y1M\<[MGV?
M;M^;&,5OPQQ_\)]%<2SV?]J?;%#6NP?;C'Y.TMOW9^SYRVS;C/.[/%;\OB_2
MH+."[?6)?(F5WWK82-Y:HVUS)A?W05L@E]N"#GI5W^V;?^U_[+_M1_M6[9G[
M(WE[]N[9YF-F_;SMW;L<XHL!IZ=_QX1?C_,U:K.LHKAK1"ESL7G"^6#CFI_(
MN_\`G\_\A"FUJ"+5%5?(N_\`G\_\A"CR+O\`Y_/_`"$*5@'7_F_V?<^1GSO*
M;9C^]@X_6N(\'7'ARTO3-I%QI\5JUC;I>-"ZJIN6<A0Y_P">I)(.?F)(![5O
MKKMJVM#2!JD@NRYC7-DXC9PNXH)"NPL%R=H;.`>.*6^URVT[48["ZU.19Y-G
MW;)W1-YVKO=5*ID\#<1FBP$`M1!XQU*7SIY&FTU6(DD)"_.^`HZ*/H.>^:Z&
MV_X]8?\`<7^5<Z?$5K+J)THW5^MTZR;4FTJ>)'"#+8D9`N/?.#D8ZBMF"&Y-
MO&5N]JE!@>6#CBG;0"]157R+O_G\_P#(0H\B[_Y_/_(0I6`R?&BP'PZ[736P
MMDFC>5+LE8)5##Y)6"MM0]R00.XQ6%8W0_X0'5;>,P(9H;M["VTZ?;^X`"Y@
M.,[`6&&5<<J0.0*ZG4+HZ79M=7>H,D0(7Y+<NS,3@*JJ"S$GH`":K6]S:W]H
MFN1ZFI@ACE4S21%/*4$>8&5L%2"F"&`(VD<<T6`\_BMM)?29K635O#B:,EY#
M,MU'IX.ERMY;KY3()=JL&"NQ+@$E1UJUJUQX1N],M+/46TG2M6DM6AM9))D@
M6S@$CJMQ`&;$9;&Y=OS'Y03A<CK3XGL5MVF.I761*(O)_LV7SF8@D8BV;V&`
M3D*1@$]*;/XMTJV6)I-;)22+SR\=F[K%'DC?(RJ1$N589?;RK>AHL!5\6SZ!
M-?:4-?GTU]&5IXY?MKH8O/"KL!W<;L>9@?UKC[+[";6P747A_P"$C']EG2_.
M/^E^3F/.T'Y\?ZS?[;MW%>C7=Q#H:AI;R4-<RE@D-H\[NW<A4#-@#'.,`>E5
MY/$NGQW=M;'6&9KD1F.1+-VB_>'$8,@4HI8\`,03D8ZT6`P?#(TD^)+1K$VO
M]L_Z6-6\HCS?O\>=CGKC;N[=.*[B#_C_`+O_`(!_*LJRURVU#4Y-/MM3D:X3
M?]ZR=$?8=K;'90KX)`.TG%7HHK@W=P!<X8;=S>6/FXII`:-<!\01$D[.?[/G
MNWL9%LH;QF5XY@&(>WPIWRDE1M#*V`"#7:^1=_\`/Y_Y"%96K:Y:Z(X6_P!4
MDC^7S&*6;R"-,XWN4!"+U^9L#@\\4K`<B$1?&RW,ES:#55N1NMA%NOO+\C:6
M#!LFWSEMFW&[G=GBKW@--'T:.6VLKO1;N%((DGU*SMU@D:0$*$N&WL6E))/.
M#DGCFM\:[;-JTFFIJ,\D\6!*\=A(T,9*!\/*%\M3M(."PZCU%-L=1LO$J36]
MMJ+RB+9(\<EJ\)*DY1P&"ED)4X894X(R>:+`<=K,WAF[DUIO#]Y9QZE!;7?V
MHV]P#=W;[6#J0#YC!.2#V(4+P*BN/^$;%U']B.D'P9_:$'VO88_L>[R)L[OX
M?]9]GS_M8SWKMI/$-C#<7,,NL&/[.DCR2/:LL0$>=^)"-C%<'(!)&.13$\36
M+V+78U*Y"K((O*?395F+D;@HB*>821R,+T!/2BP#/!PQX)`3;]F\RZ^R;,;?
ML_G2>3MQQM\O9CVQ71VW_'K#_N+_`"JA'*U[IGVN"_$UO)&6!$0&1Z>H]*F@
MAN3;QE;O:I08'E@XXIVT`O455\B[_P"?S_R$*/(N_P#G\_\`(0I6`P/&UYX9
MMK2U3Q&MA*9F9;6#4)%6%WQR6W?*`!_$02.W)`-'4!IT?@"TM6U:QU"WM([9
MII+F<M!<)D8\UP'VQM@_,P8<<Y&:WM4U)-'CC:\OYLR9V1P63SR-CJ0D89L#
MN<8%0O>V=MIYUX:F'M[F./;/#`93*I/R!57);)8X`&>:+`<1)<>&&T..#6FT
M.":=YQI`EG`MK>'(`DB+8&%/*LH!(QMP.E@I!'X\2X2YLY[Q;NW1(74/?2P&
M)$,L<F_Y8,DNRA2"5<YRV!UXUVS.CKJK:P([,R"+?+;F-@^[9L*,`P;=Q@C.
M:=_;-O\`VN^EC4W-RC!'(M&,:.0"$,F-@<@@[2<X(XY%%@.1\4SZ/=:Y?333
M64FHO8VS:'([J69_,DSY![MNV[MO.-N>,4X'2[/Q7>7`.FW\MS-<I?\`D6#Q
MZE9Q".0[RX8R%,1J@VJ-VX%3T!ZF>_L]":"PDU%X\*N%6U:01J20&=@#L!((
MW.0"0>:3^W[4W=Q:KJ4SRVX<L([&1PQ3[ZH0N)&'=5RP/&*+`9O@DV<6IZQ;
MZ4UC-I?[J6&?3E"P*Q+J8MH+#S%"J6;/)<9"UU-E_P`O'_7=OZ5EZ3K46M3W
M,-G>7@EMMOFI<Z;+;E=V<?ZQ5ST[5IV`(2<,VYA,V3C&>E'0!?\`F*_]L/\`
MV:N0NHM9U[[=)>>';ZTNHX'2S$D]N8@-RMC*R%M[[%Y*@*!CU+=7-#'/J061
M=RB'.,X[UAPWLJ:P++4="^SQRV\MQ`T-T9Y"L94,'0*-K'>N-I<'ID'&6[`0
MVECJ>H^)8K^ZTJXL;0S_`&AHYIHBP:.+RT#!'8<F1F&"?]6,XR!5_1-$-GJG
MB/SK*)+*[O8I;=,*59%MX4SM'3#HW4#IGTJE9:W:WVE6]VFE/%-/J;Z>MO-/
MA@4E9'8D9Y"H[8&>F,]ZGTW5+/4?[8(TF[C.FW`@\LY,DN8TD!"YXR)!P3]<
M=EH&I7M-+U*UMM&:73?/.EVD\RPK*FY[DC:BJ2<#Y&D&2<?,.:J"#5KMUUF?
MPWJ$>IPW4$LD+2VN98E$BB.,B8C">8S9<KDDXZX%T:Q`^C:3>1:--)=:D6$=
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MM/\`GE_X\?\`&F[7!%JBJO\`9UI_SR_\>/\`C1_9UI_SR_\`'C_C2T#4Y:+3
MM4_MJ"S.F3"UM]6FU`W[2Q>6R.DF%50Q?=ND"\J!@$YZ`KJ-MJUW<W4<>BW7
ME:HMLQE::$"T*GYQ(-^20!D;-P)[]ZD350VMQ6YTB/\`LV:\DL4NUNV,GFHK
M,=T>W`7*,N0Q.<<8.:?JFH_8-1EB@TB*>RM?)^USM=LCIYC8&Q-I#8')RR\=
M,T:!J78+*Y.LZYJ-W"4&Q+:S)D#!H50,S``_*3([@]SL7MBMFV_X]8?]Q?Y5
MQ]EX@M+_`,07VD"SMHY(!/M1;W?<((SMWRPX^1&R"IW'(*],XKIX+"V>WC9H
MLLR`D[CZ4]+`7J*J_P!G6G_/+_QX_P"-']G6G_/+_P`>/^-+0-1-3EN(;&1[
M:SDO'Z-#%,(W93UVL2!N],E?J*Y)=*N&\)WGAA+:>TEU&WNY;999$=H`67Y9
M7#,6<M)DM\_?))Z])J%H8+0O8:<MW<E@JQO<&)>3U9N2`/8$^QJEI\PO='N+
MDZ3_`*9`\D36T5QN5Y$)!".VT$$CJ0/<#%&@:F9%)X@TNTN'L-$U29)Y%6."
MYO8IIH.&WRY>;:5)VX0.._`Z4EZ+\Z9;Z/%X2U232YH2;L":T,C98[HF!F`^
M;DLP)X;`P3D#ZQ=QW*Z8^@6PU9YEB1!J#FV(,;R9,OE[@0J'@(3DCL<AEWK=
MP=.M;_2M&T^\@N)/LRJ^IR1R-.)&1D4+$P(!4G=D<`D@8HT#4TM9\^_>"YT^
MSU`SVD[P&2TD@615.W=@2Y1D.`#R&&..:YZR\.:UIFGIH9L)KH7#V,LE^)X_
M*A,1C\P'<WF,?W>1A3DL,D<D=-XAG31-,-ZEE:M'&-TTEU??9XHE]W()R3P!
MCD]2*RGU\;XIXM#!L%-JET\ETR30-/MP!'M(;;O4M\PZG`.*-`U+.BV.IIJ5
MA;W.F36\&G?:/]*>6-DGWM\NP*Q;IR=P7&.]='!_Q_W?_`/Y5SVF:C]NU.*&
M?2(H;*Z\W[)<)=L[OY;8.]-HVY&2,,W3G%;45E;M=W"&/*IMVC<>,BFK`:-<
MWXGGU.5ETVWT*^O=.N(B+J:TF@5L'@Q`22(1N&<L.@Z<G*[7]G6G_/+_`,>/
M^-8OB&_M=!_L\#2Y[K[7>06I9&*I"))%CWLQ]"XP!DGV&2%H&I5&EW,'B)I]
M/T>\LW>832W/V_-K,NQ5*M%OX?"JN?+(`48;M2V'VBRU;4-;N=)O+);A(89H
MYKB.9Y9-^%,9#G;&-Y^7*YR2$!/,;Z]:KXN.AC3X6/F>6%%Y_I)_=^9Y@AQ_
MJOX=^[[W&*GT#44U?4M1T^ZTR&WN+(1L_D7AN%7?NPCL`NV0;<LHR`&4Y.:-
M`U,*7PMK2V.I:?:Q7F^07;--->@VUP)&D>-$CW'8P9ERQ0=#RU;"C5I9-3U)
M_#]\JWJQ6[V8O8HKD1JKY=&23;G<X`_>*<`G.0`8;K5;ZQU>ZM9O#]G-#;6L
MMY(;/4GDF$:AO+_=M$HW.5(`W=FY..7Z1XBTW4-&N[^2&SD^SR"(?V;?&ZCE
MD8`JB/A<O\P!&.,_C1H&IJZ#8W6F^%OLMWPZ&8QH2"T<1=C&C$<,RH5!/.2"
M<GJ=BV_X]8?]Q?Y5BZ/-;:SX5L=96T\AKRS2Y$?F%MFY`V,\9QGKBM&"PMGM
MXV:++,@).X^E/2P%ZBJO]G6G_/+_`,>/^-']G6G_`#R_\>/^-+0-3/\`$5[J
MUK!#'I6E7-X9F*RRV\D(:W7'W@LKJ&8]!S@=3G&#G3JXTJSLM-T>[632S:SB
MS:2+>4R1L#;RI<`$G+8/'/.:T=5M[BWC3^R])ANY6R6\^\,$:`>K!6.3VPN/
M4BJT=U'=^%K;6+'2]TEQ"DRP7%R(E0,`27?D!0.20&X'`-&@:G.ZEX6\1ZI:
M37D+VMJTDSS1Z==VPF>)V?[^])E0-L`'\6,L`?F-7KS0-3NO$H0)?061O8+Z
M22*>'[+,T>PDE2/.5R4"[02F`#G)(H7Q3IQ\,VFJ_P!FM)-<RM$EO!.75@LF
MQI5?C,7&X/@9!7C+`5I7D\]GJL4<FB)_9TDZ6ZW`NR969OXA$!C8.Y+`\$[<
M<T:!J9-[8:AJ6JMK6G0:CF_M8%MGCNUB2V=#(=TRAQYBD..!O!YX'4Z4EIJE
M[XNLKPZ?/:"TED66=KI98)[<JX4(F[*R%C&Q.Q<8*[F'6;6M0L-'N]/M19/<
M37EQ'$0CD"%&8+YC'TR0`.I/L"1!-J]D/%!T.VTV2YD6SFN&D27`+QF,>4,G
M!8B4$DD`9'J<&@:FGX;L9[+2B]XC+?74KW-R&96(=VSMRO!VKM4>RBKME_R\
M?]=V_I6+X?O(-9^VQS6=M'-:2^5)]EO#<1[NZ[\+\R]&&.#W-;-@H1)U4859
MF`'Y4=`&331P:D&D;:IAQG&>]8FBPW]AJ-Q<ZEK=C?";.YDTZ2*7&?E7=YK+
MM4$C`4=<YR23O_\`,5_[8?\`LU<O=:O=^'-0NKS4M;-YIL%NSW@EBBBCMY2R
M")(V`&"VXY#LV/E)*Y&6[`3Z;I-M87<$K:D)8H;N]O!']G(/F7$C,.<G&U7=
M>G.[/'2K^FQ6FGZGK%Y]L\S^T;E)]GE$>7MACBQGO_J\YXZX[9K`T/Q3=ZU9
M6\<.J65S=S:N87>P9)4BA4>:5SSD%5V;CR=V1@XQJZ)J.MWESXDMKA[1KJRO
M$AMP%(C16@BDP>[8+GTS[=EH&I%!IJVD%J+?5PLUI92V\#O;%E61RI\PKGG&
MT#&>YYYJI%I5^MCLFUW3I+V.Y2ZAN5TN49D`*L95,QWY4X&"NWMP`!-;:IK5
M[H_A^W@O(%U*]21[BX:$%0J(V6$>1D>8T0QD<$\]ZK&YUR&Y;3TURXN+2>ZA
MM8M2:"$3))B1I@H$8C(`1`#M."6!R11H&I')X;E^RS1P>(((YKZ&:'4)FT]F
M,@DD9R8AO`C(WN!NW\8SG'.DFF1QZFK+J<0TU;D78M_LK>=YH7`_>[L;..FS
M/;..*PGU?Q!/9:G$FM2Q7&C6US+YPMXB+MDED5/,!3@;8QNV;<EB1C@5HPZU
MK$OBF*3S9UTM[I;<_)#]F`,6=N?]=YWF'&?]7CWHT#4Z:RO;>*T1'DPPSD;3
MZU/_`&C:?\]?_'3_`(4:=_QX1?C_`#-6J;M<$5?[1M/^>O\`XZ?\*/[1M/\`
MGK_XZ?\`"K5%+0-3D8]*VZTDYU>'^S8KU[Z*U6S82>:Z,IW2;R"N79L!0<XY
MP.6W6FW%W<EWUJU6&Y6$7\:V#YE:,YS&3)^[!Z$$/QT.>:;%J6JG6[:\_M&4
MV<VK3:>U@T4?EJBI)AU8+OW;HP>6(P2,=#4FM7NJ)J5]<6NI2V\&G?9_]%6*
M-DN-[?/N+*6Z'`VD8//-&@:B0:2D%VKMJ:2VEM+//:0I;ND@>4/N\R3<0X_>
M-@;5[$Y(S70P7]LEO&K2X94`(VGTKDM/UO5)=>F2\N+AK"[ENX;=G2%;=S&6
MVK%M_>[]J,6+_*2C%>,5VUM_QZP_[B_RIZ6`B_M&T_YZ_P#CI_PH_M&T_P">
MO_CI_P`*M44M`U,769YKW37@TS58["Y9A^_>V:4!<\C:&4\CC((([<U0BDU2
MWLHM/AU'3X_]&F7[5#I[JL4F5\LB-I6)X+D@DY('(Z'=U.*>:Q=+?4#8'@M<
MJBLR*.6QORH..Y!`]#5#2#JMQX?E62\S=,9%M;NX@&YDR1'(\:[03T.!MR/2
MC0-3#DT6YNM$;3[[5M(NB9Q,PFT9I(ICSGSD>5BQS@@JR8*CJ.*T++2M.LCI
M"QW*F'3?.=8_(/S2R=7']W&Z08]']N:$6I:]!I7B"T%Z6U&P7S89-1CB,JQ%
M&Q(5APC`LC[1QP/FY&*B\0^(=4M'B>TGN-EKI\=[=F!(2D0)/SS[_F\O"N<1
M?-\C>U&@:FW<W>HW*2&UU*VLY$E8()K-IHY(^,%E#J<]<88=>1V&+%X:CMA%
M:6NLQIIA-L]S"UD6EE:$J1MD#!4#;$!&P\`X(SQMZY+>7.I:;IMCJ,]@+E)I
M6N;>.-VP@7"CS%9<$N#TSQ7+V7B#7;_3(M7.I-$;5K"*:T2"/RK@R^7YC$E2
MXSYAV[6`&!G-&@:FYIFG&QU&*6?5H9[.U\W[)`EFR.GF-D[WW$-@<#"K[YK:
MBO;=;NX<R85]NT[3S@5A:->ZH^J6%S<ZE+/;:C]H_P!%>*-5@V-\NPJH;H"#
MN+9)[5TD'_'_`'?_``#^5-6`/[1M/^>O_CI_PK-UR*TUFSM[?[9Y/DWEM=;O
M*+9\J59-O;KMQGMG/-;E<YXOO]5TZ'2Y=.F@AA?4K2"Y+IN=DDGC0JO89#'+
M')'89.0M`U*\FG!]3:0:M&M@;G[9Y0M6\X3;<9$I;&WVV9[9QQ2PI>VL\NH3
M:E;7U_L2WB*6;0KY6\%BXWG<V"3D$`=E[&I+J^LIXM8K)<-IHO/LN`L/V8CR
MLA<_ZWSO,P,_ZO'O5OPA<:N,VWB&?4/[4:!)7AN5MO*!Z.83",[=QQ\YSP/<
MT:!J23:=9W4>O)<Z@SC5L("L14PQB)4"#^]SO;_@9%4SX>L=0E>[US4'N;YB
MA66P-Q9+'L5U!4)(3G$C`G=SQZ503XD:<?$]X7UG3QI-M93,($E0S&2-U!9N
M<KG+`+QP"QZ\0:=XMOM=CBLX=;M?/N];:U^T::\4OV:'[.TP52P96.8RNXCG
MYB,8`!H&ITN@V=GX>\)66B17DEP;2U$/FN'RY`P3\Q.T9Z+G`&`.`*U8+^V2
MWC5I<,J`$;3Z5F^';^YU'PO+)=R&6>&:ZM7E(`,GE2R1;R%``)"9(``R:V[;
M_CUA_P!Q?Y4]+`1?VC:?\]?_`!T_X4?VC:?\]?\`QT_X5:HI:!J<WXB2YU:"
M"&PU>VM(0Q-Q%<63SK<+CA3M="!ZC//0\9!>;K4I(9(!J5I!(D<1BN$LV*/)
M\V\&,N3L^[@!@>3\W>K>OI/]B\V/6)M+BCR9)+>%))&/157>K#KQC:220!CN
MR*/6KKPK;"XN/L>K-"AN'MXD9@V`6"!R4#'D#.X`^M&@:G.W7@_2-0M9GN]1
MN1J5P<RW%I-<6\1)?<0(DDQC/J2>Y)K1$%\OB%;W^V[.2QC(6*VFT^1I(DP`
MP63S0-QQ]XJ3SCI7-7GC^XTS0XK&]U6RM-<25S<&^DB21(5F*J"H(5I63&=G
MR#YB.``>LNSJ:ZY:2VFLF:.XE4K8+#'Y0M\#>Y;!?=Z-N"G(&WO1H&IFWGA_
M3]<^RZA?W-S:ZGYD$MQ]FN;A(V\MMP78LFT'J,\D9R":3_A%-(@U^/5M.U.^
MLY4@ND"B>:4+).RL9%5V*#!#'9M*DD$CY12^*_&L&E:Y8:5#JMA:2BYMS>"X
ME0.T3OC:BL?3)+=@/4Y%>#QNNK?$!='T[6-/2W:TNXDB+(\AN8VC`9ER&P,R
M87(+!&/3!!H&IMZ5;K::G=ZI?ZA#<WUS#'`S06S0IY<9<K\I9LM^\;)SZ<"M
M>P8.D[*<JTS$'\JQO#=]?'4]4TK4;FYEGM?+EC-U'$LCQ.6`?]T-FPLC;1]X
M`?-S6U9?\O'_`%W;^E'0".9Y$U(&.+S&\GINQWK*TGP];:'.TMA9WR;MQ,<F
MJS2QY8Y8['<KDGG.,\GUK9_YBO\`VP_]FKSC'A+69M7_`+!UBQL=VGW%M<RV
MLGF7,Y8@-*Z`[V$>#AFR<L2"%Y9L#N(]-CAOUODTPBX4RD-]I)&9-N\XSC)V
M+VXYQC)S-;6QM+J\N8-.V37D@EG;S\[V"*@.#T^5%'&.E<7HPTV>XL-$TU=#
MDLVO1>M/I%LL4$ZPJ&R%5F!99/(!;/IT(Q6OX;L3_:?C"Q-Y=D?VC&/.,O[P
M9M8&.&[<D],8SQBE<#2.BVWV?R!I3*GV9[0%;IE98F.64,#D9('(.>!S56+P
MK90Z>]BEGJ)MV,957UFX8QE#E?+8R$QX_P!DC/0YK$MA9R>'_#]C>W,L.G6M
MG/>WDGFLO[I$,8W2`[AS)N!!SE,YXK*C;PC+!)=V%UHT?AV2[M4N[&.:(V\4
M0$FV25`=J%W9`0>H1<\Y`+@==-X1TN>U@MGTB?R85=-BZC*HE5VW.)<-^]#-
MDG?NR2<]35W^QX/[5&I?V;+]H#;MOVQ_*W8QO\K.S=CC=MS[UYI<#0/[(O$O
MGL_L9M+P^'O,(W;_`#Y-OV;OG_5;-G.-NWBM^&./_A/HKB6>S_M3[8H:UV#[
M<8_)VEM^[/V?.6V;<9YW9XHN!W%E+<+:($MMZ\X;S`,\U/Y]W_SY_P#D44:=
M_P`>$7X_S-6J;>H(J^?=_P#/G_Y%%'GW?_/G_P"115JBE<#GUT&U763JPTV8
MW>\R#=?.8U<KL+K&6V*Q7(W!0>3SR:9)X<M)KFWN)=.N7D@6-`6U*4B0(<IY
M@W8E(/.7W'-<U`=+/C2W*-:?\)(NLS_:/+(^T"U\J3;YF.?+V^7C/RYV]Z77
M[C0KW6YKB2>PFU.1;.319-ZM(ZE\Y@/4@G.[;VZ\47`Z==&M[6YN+Z/3Y4E<
M.QW7CO'&6!W,D9)5"<G)4`G)SUK2@FN1;QA;3<H08/F`9XKEK+0=$F\9:QJ=
MKI6GP2:8IMQ)#:JDAN)(_,E=F`^;Y)$`^K^M=E;?\>L/^XO\J=]`(O/N_P#G
MS_\`(HH\^[_Y\_\`R**M44K@8^K:>NMV)LK^PE:`NKXBO&B;<IR#N0@\'GK5
M5=#VA(#!=360@FADM[J_DG$OF%3EC(Q)QM(&<XW'!'.=N\MA>6DEN9I8A(,%
MX6VL!WP>V>F1SZ8KDO"NI3V_PPT(6B+>:J^D1RP6IF57F(103\Q&0"RY.>XY
MYHN!L6FD16=E<6D>GS21W"E)FN+YYI'4@C!=V+8P3CGC/%,O-#M;]HFN-+<^
M7&(L)>,@D09PD@4@2+R?E;(Y/'-<KI-M/=>$?%UK=QZK:LMS-)(\\\8DE8P*
M2"T;M@9YP"``0!QD!GC6ZU5;'1E32KV73H+C395EMY80)9?M$?R,&D5NF`.,
M%G!)`7-%P.JN]#_M&,I?07<F)VFB:&_D@:/(V[0R,&VX[9Q[=*C/AC3OM-K,
MNCNGV58DBA2]=80(N8\Q!MC%>,$@D8'H*9XP?0KS23'J5]ID&&98IM17S+:*
M48SO&Y5WC/`+`@\CH:XP/I\K6OV\1)XB#Z9_9BSONN_*S&&*Y`<J2)=YP.,[
MN*+@=[9:);:?J,E_;:;*L[[_`+]Z[HF\[FV(S%4R>3M`S5Z*6X%W<$6V6.W<
MOF#Y>*X[PR-)/B2T:Q-K_;/^EC5O*(\W[_'G8YZXV[NW3BNX@_X_[O\`X!_*
MFF`>?=_\^?\`Y%%5KZV.I0QQ7>G>8D<T<ZCS\8>-PZ'CT90<=..:TZ*5P,%]
M%MI-2-^^F2-,Q)*&\;R2V,;C%G9NQQNVY]ZBBT(6=M+%86]S`\C)^\>^DE9%
M5@=B%F)1>,;1A>>AZ5S-^D8\:S06;Z>=4DN@TERK.;^.`Q_,OE[<^4.,,&*D
MD#&[FI_`]Q9P7L[6IT>#3X[:..>6PF)22X+X#2EE7$Q'52"PR`2<BBX'8F)V
MOTOCI_\`I*1-"K^=T0D$C'3JH_*J5UHMO>0312Z;*HFN!=.\-Z\3B4`+N5T8
M,IP`."._J:\\O/L7V2_.G-%_PD&=3_M40'_2O*S)MWX^?'^KV>V-O%='IEIH
MUY9>(H/#T\$6AM#&4.E2A(_,"-Y@5DZ9&S.W!]\YHN!U%O;G3M)%E;6)BMXX
MRHW3[R.I)).2QY)))))JQ!-<BWC"VFY0@P?,`SQ5?2?^12L?^O&/_P!%BM&V
M_P"/6'_<7^5.^@$7GW?_`#Y_^111Y]W_`,^?_D45:HI7`P=7T:'7&M7OK&YW
MVK%X7M]0DMV1B,$YC93TXY]3ZTQM%,L4MO/#=2VS1Q)&C7\A>,INPZR;MX<Y
M'S`@\#FJ_C:\\,VUI:IXC6PE,S,MK!J$BK"[XY+;OE``_B()';D@&C?G2HO!
M.EV=SJEKJ&G0&U%[/),'CDA)P'<DGY&('))!`.2>:+@;T>F11Z6=-&FLUL3E
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MCLKPW4D]MJ=HT1^T`%9,O-O)+PY4(JE0OS@J2"!1<#I]-TU-)\PVMA*7DP'D
MGO&F<@9P-SDG`R<#.!DXJ]8$E)RR[6,S9&<XZ5S_`(%T?3;2PN=6L=/LK,ZG
M*9%6TA6-1`I(B&%`_A^8^['MBNALO^7C_KNW]*.@$<R2/J0$<OEMY/7;GO61
M'XHTV22X3^VO+$$+SM)-:M%&T:?>='8!749&2I(&1ZUM_P#,5_[8?^S5R%U:
MZQXD%^+[0;ZPN/L\D5F\D]N8D4LI(RDC-O?:O)7"@8]2S;`V;?7K6YMC.FI3
M(!<);-'-8212+(Y`4&-E##.X')&,<]`35BWU*"[%Z8-:A=;&0Q7+A%VQ,%#$
M$].`1GTK$TO3-3EU.R\^RU&VTR*X>Z$=_>K<2HZQ[`K-YCDAB[,`&(&SMD"M
M+1-$-GJGB/SK*)+*[O8I;=,*59%MX4SM'3#HW4#IGTI7"P]M<LDTB#5GUR);
M"X&Z*=HP%8;2V?IM5CGT!-5H_%.GR6LUP-3N1Y)0/"^FRK/\Y(3$13>=V#@A
M3G!]#5>TTO4K6VT9I=-\\Z7:3S+"LJ;GN2-J*I)P/D:09)Q\PYJH(-6NW769
M_#>H1ZG#=02R0M+:YEB42*(XR)B,)YC-ERN23CK@%PL:$OB_2H+."[?6)?(F
M5WWK82-Y:HVUS)A?W05L@E]N"#GI5W^V;?\`M?\`LO\`M1_M6[9G[(WE[]N[
M9YF-F_;SMW;L<XKE'T?78+34W30YYI=9MKJ+R5N(0+1GFD9/-)<9!64$[-^"
MIQGC.E%H%[%XGBF^PW)=+I9OMOVA?LOEB/9CR=^?-QQOV9Q_'CBBX6.ELHKA
MK1"ESL7G"^6#CFI_(N_^?S_R$*-._P"/"+\?YFK5-O4$BKY%W_S^?^0A1Y%W
M_P`_G_D(5:HI7"QSZZ[:MK0T@:I(+LN8US9.(V<+N*"0KL+!<G:&S@'CBEOM
M<MM.U&.PNM3D6>39]VR=T3>=J[W52J9/`W$9K+BT[5/[:@LSIDPM;?5IM0-^
MTL7ELCI)A54,7W;I`O*@8!.>@*ZC;:M=W-U''HMUY6J+;,96FA`M"I^<2#?D
MD`9&S<">_>BX6+9\16LNHG2C=7ZW3K)M2;2IXD<(,MB1D"X]\X.1CJ*V8(;D
MV\96[VJ4&!Y8..*SX+*Y.LZYJ-W"4&Q+:S)D#!H50,S``_*3([@]SL7MBMFV
M_P"/6'_<7^5.^@6(O(N_^?S_`,A"CR+O_G\_\A"K5%*X6*,_FVT#SSZBD44:
MEG=T4!0.Y-44N+6XT^'Q"-40VBVS21W)CPHB;#$X/KM7MFMF6&*>,QS1I(A(
M)5U!&0<C@^X!KE?#TE]X=\':)H\FES3ZI!I.XV\<L8!>)44QEBV`27&#R.#S
MTR7"Q,/%-@;8S?VE=!A((_LYTR87!8@D8AV>8>`3G;C`)Z5:DUJTATZUOWUJ
M,6UW-'!`_D_?D=MBJ!USNX/'&#G&#65'>Z]!9W%Y%X6U$ZG=2JDQ>6T_=H`<
M%!Y^&"],%@26)]JR]<\)ZYJ%EI\^EF.V6&:U9;"^MEDEA9;E9))2Z3A"3C<P
M&20N`06HN%CJ;ZZ@T"/S+B^D3[1(6VQ6KS.[8Y.U`S8``R<8`]*@D\26$5W;
M6S:NQ:Y$1CD2S=HOWG$>9`I12W8$C.1CK4NKW4E_IMQ;1Z3?7T'F-;SK9W2V
M\V1CE&WI\O7/S@\8P>17.0Z)KMO;?V5)IKS_`&I[&62\CEB6&W$1C#J1D,2!
M%QM3!)'3G!<+'1V6N6VH:G)I]MJ<C7";_O63HC[#M;8[*%?!(!VDXJ]%%<&[
MN`+G##;N;RQ\W%8>BV.IIJ5A;W.F36\&G?:/]*>6-DGWM\NP*Q;IR=P7&.]=
M'!_Q_P!W_P``_E33"P>1=_\`/Y_Y"%'D7?\`S^?^0A5JBE<+&$=9MQJ_]E_V
MH_VK=LS]D;R]^W=L\S&S?MYV[MV.<5%IVHVOBBU?[)>74UM\D@DDL)88Y!G*
ME'=5#CC/RDC'L><R?0[V3Q0]P-.N&<W1G%W]J"VIC\O9M,0?(EQ\N_R\@?Q8
MXJ70X9-!BD==*U#3].BCBMULY[P7&7W*BF+,K!4`.,?*3_=SU+A8GE\5Z?;W
MKVESJ%[;2(DLC/<:5/%'LC!+MYC($V@#KG!R,=15FWU^SN=.NK_^UF@MK49G
M:[M&MS$,9RRR!2`000<<U2U71=0U1/%$A@VSSVXL]/#S#:\8C#9XSLW2,RGC
M.$4],5-:6-UJ4FL7U[I,MHUU%''#;731.P9%;Y\HS*.7P.<\=J+A8U09;G3O
MM,=[YD$D7F+^Z`W*1D>XXJ2"&Y-O&5N]JE!@>6#CBF6,$EKX:MK>9=LL5FJ.
MN0<,$`(XJY;?\>L/^XO\J=]`L1>1=_\`/Y_Y"%'D7?\`S^?^0A5JBE<+&-JF
MI)H\<;7E_-F3.R."R>>1L=2$C#-@=SC`J%[VSMM/.O#4P]O<QQ[9X8#*95)^
M0*JY+9+'``SS4OB*]U:U@ACTK2KF\,S%99;>2$-;KC[P65U#,>@YP.ISC!SI
MU<:59V6FZ/=K)I9M9Q9M)%O*9(V!MY4N`"3EL'CGG-%PL7!KMF='756U@1V9
MD$6^6W,;!]VS848!@V[C!&<T[^V;?^UWTL:FYN48(Y%HQC1R`0ADQL#D$':3
MG!''(KE]2\+>(]4M)KR%[6U:29YH].N[83/$[/\`?WI,J!M@`_BQE@#\QJ]>
M:!J=UXE"!+Z"R-[!?2213P_99FCV$DJ1YRN2@7:"4P`<Y)%%PL:\]_9Z$T%A
M)J+QX5<*MJT@C4D@,[`'8"01N<@$@\TG]OVIN[BU74IGEMPY81V,CABGWU0A
M<2,.ZKE@>,5BWMAJ&I:JVM:=!J.;^U@6V>.[6)+9T,AW3*''F*0XX&\'G@=3
MI26FJ7OBZRO#I\]H+26199VNEE@GMRKA0B;LK(6,;$[%Q@KN8=2X6+>DZU%K
M4]S#9WEX);;;YJ7.FRVY7=G'^L5<].U:=@"$G#-N83-DXQGI5/PW8SV6E%[Q
M&6^NI7N;D,RL0[MG;E>#M7:H]E%7;+_EX_Z[M_2B^@$<T,<^I!9%W*(<XSCO
M7-W&KS:?<3IJ'ATHGV2:[MQ!>>;(RQ;=RNN`$)WKC:7'7D<9Z2::.#4@TC;5
M,.,XSWKF8=*O95U"/5-?LKM;Q"IEBTUXI5P<H-QE9=B\C:%&<DDY))>O0-`T
MWQ!:ZA8I*EE9S2OJ$=DC6=^9[>7<`S,DNT;MJ;B1M'*$9[U=TW5+/4?[8(TF
M[C.FW`@\LY,DN8TD!"YXR)!P3]<=HK+3636XM5U'5K>XG4LSI!9-$A?8$1E!
M=B"%+@\G._L!BM#38K33]3UB\^V>9_:-RD^SRB/+VPQQ8SW_`-7G/'7';-'O
M!H9\>KQ3:5I-U#HDTMSJ*NPM%G4-&%C9R"Q(4G*JO7&7'..:I2:[=07HTJX\
M/VR:O+)$D$:Z@[6[[UE?F7R\@JL+DC8>J\\U>MM,2RB@-OJJ"XMK&2UMI'M2
MPC=V#%RN[G[J<9'0\\U1CT:_\B!IM=TY[^VNA=P7(TN49D*/&YE4SG?E'(&"
MNW`QP``>\&A$_B@OISW5IH44\EI!-/J$)OF0Q"*1XW6,[/WAW1R8SL!P.1FK
MB>(+*3Q8FBK90%7<(/\`3#]H(,?F>;Y./]3_``[]WWN,53?PRR6+6]GKL$#W
M<$T.H2M8,YE\V1Y&:,>8!&=TDF,[P,C@XYTTTR./4U9=3B&FK<B[%O\`96\[
MS0N!^]W8V<=-F>V<<4>\&AM65E;RVB.\>6.<G<?6I_[.M/\`GE_X\?\`&H+*
M]MXK1$>3##.1M/K4_P#:-I_SU_\`'3_A0^:XE8/[.M/^>7_CQ_QH_LZT_P">
M7_CQ_P`:/[1M/^>O_CI_PH_M&T_YZ_\`CI_PH]X>AS::J&UN*W.D1_V;->26
M*7:W;&3S45F.Z/;@+E&7(8G..,'-/U34?L&HRQ0:1%/96OD_:YVNV1T\QL#8
MFTAL#DY9>.F:9'I6W6DG.KP_V;%>O?16JV;"3S71E.Z3>05R[-@*#G'.!RVZ
MTVXN[DN^M6JPW*PB_C6P?,K1G.8R9/W8/0@A^.ASS1[P:$>G:_:ZEK=[IBV4
M"-"DQ'EWADFB\M@O[Z/:/+W9RG+;ASQ7306%L]O&S199D!)W'TK`M=-%M<AI
M-3BFM;99OLD*VK)(#)RWF2;B'Z\85?4Y(K?@O[9+>-6EPRH`1M/I1[UA:$G]
MG6G_`#R_\>/^-']G6G_/+_QX_P"-']HVG_/7_P`=/^%']HVG_/7_`,=/^%'O
M#T#^SK3_`)Y?^/'_`!JGJO\`9^D:3=ZC/"QBMH6E958Y(`S@<]35S^T;3_GK
M_P".G_"J>K#3M9TB\TVYE/DW4+1.0IR`PQW&/SH]X-#`76S+H]Q?0Z=I4H@F
M*/.FM*;6)`"6:27;N4C&"-AY([985[CQ=8(;"."RM!=7-O#<-;WFHBV<K*S*
MJQ%@1(Y*-A25Z#D9K12UOXC-=1:]:)J,I168:<WV=HT#`*8_,W9^8G(<<@<8
MX-"7PI9BUG@MM46/[;;-:7[O;,[21L\DA\H[AY1W3/C[P`VC'`H]X-#H=5M[
MBWC3^R])ANY6R6\^\,$:`>K!6.3VPN/4BN>A\3I<Q6][;Z&#IQ-JMS))=E9H
M6GV[<(%(<+O4D[QP>,U?U==2U:`00ZK9V4"SN'BFLGG6YBP-JMMD4@9SG!YX
M!&,@P3Z1/<W9:36K1;:X>WFO8HM/<-+)"5/R,9"$5MB`@AC@'!R<@]X-"QIF
MH_;M3BAGTB*&RNO-^R7"7;.[^6V#O3:-N1DC#-TYQ6U%96[7=PACRJ;=HW'C
M(K%TS3C8ZC%+/JT,]G:^;]D@2S9'3S&R=[[B&P.!A5]\UM17MNMW<.9,*^W:
M=IYP*%S"T)_[.M/^>7_CQ_QH_LZT_P">7_CQ_P`:/[1M/^>O_CI_PH_M&T_Y
MZ_\`CI_PH]X>ARJ^(+1_$]_I2V^G+#8L5D,NHE;F3$2R,T<&P[E&X*3N'(;T
MYN:'>/J-T;?4-(BLG>W2Z@\J[:8/&Q(^;Y5VL.,@9'/!-.OK5]2O"EWJ\;Z7
MO\Q;<6C+*K8P!YH;&WVV9_VJK6%M>Z8IN)-4MK^Z2&*U@"V30JL0<;BV7.YB
M#U!`XX7L3W@T*#^,+"&_U6"73H3]@CN)#!%?;KK$1P6DBP!&K9!5MQR&4G&:
MEO/$]II:26VIVNG6NJ*\:>4=2;[.N])'4O,4!0;89"<IV'7-3C1!YI0ZT$MH
MI+B:T$5H1+%),'W%V8LL@!D8@%`.F<XJK9^%+"R@CF@N--M]2AG6>&2UTPPV
MR,J.@_<A^>)9"?G')SQBCW@T.@TTP:CH$6H&VBB>6(N!#<B=.^"KKPRGJ#@<
M$9`/%7H+"V>WC9HLLR`D[CZ50TR.UTO17LQ=&:1VFE=]A4,\CL[8'.U=S'`R
M<#`S5^"_MDMXU:7#*@!&T^E'O6%H2?V=:?\`/+_QX_XT?V=:?\\O_'C_`(T?
MVC:?\]?_`!T_X4?VC:?\]?\`QT_X4>\/0S]5M[BWC3^R])ANY6R6\^\,$:`>
MK!6.3VPN/4BJT=U'=^%K;6+'2]TEQ"DRP7%R(E0,`27?D!0.20&X'`-)XB2Y
MU:""&PU>VM(0Q-Q%<63SK<+CA3M="!ZC//0\9!>;K4I(9(!J5I!(D<1BN$LV
M*/)\V\&,N3L^[@!@>3\W>CW@T,E?%.G'PS::K_9K237,K1);P3EU8+)L:57X
MS%QN#X&05XRP%:5Y//9ZK%')HB?V=).ENMP+LF5F;^(1`8V#N2P/!.W'-9-U
MX/TC4+69[O4;D:E<',MQ:37%O$27W$")),8SZDGN2:T1!?+XA6]_MNSDL8R%
MBMIM/D:2),`,%D\T#<<?>*D\XZ4>\&A/K6H6&CW>GVHLGN)KRXCB(1R!"C,%
M\QCZ9(`'4GV!(@FU>R'B@Z';:;)<R+9S7#2)+@%XS&/*&3@L1*"22`,CU.*E
MYX?T_7/LNH7]S<VNI^9!+<?9KFX2-O+;<%V+)M!ZC/)&<@FD_P"$4TB#7X]6
MT[4[ZSE2"Z0*)YI0LD[*QD578H,$,=FTJ202/E%'O!H:7A^\@UG[;'-9VT<U
MI+Y4GV6\-Q'N[KOPOS+T88X/<ULV"A$G51A5F8`?E61I5NMIJ=WJE_J$-S?7
M,,<#-!;-"GEQEROREFRW[QLG/IP*U[!@Z3LIRK3,0?RHUMJ&@O\`S%?^V'_L
MU<IHFI:S+>Z=/)J#74>JV5Q<+:SQHB6[JR%`K(H;;AR#NW'@$8Z5T\SR)J0,
M<7F-Y/3=CO6;I^A6NEZA)?6NFS"X<.H,M\\HC5V#,J*[$1@D`D*`.!Z"AH#+
MTK6]7O=,LX9[E3?S:W<6CRPQ`*(H)I-V`<X!2+;GD_-USS5C3;O6]3D\265S
MJ,-G-9WT<4<\$(80Q&"*0@;^"WSM\S`C/.W'%:-KI,%E<I<6^EE)4>>13]I)
M`:9]\IP3C)89]N0,`D5%>Z!::A#?PW&ER;;^9)[DQWKQEW1553E6!&!&G`P.
M*5@N9T-]KLD5C86^H(\MU<3M#>W$"EFM4C.V1D4*"?,:,<;<J<C&:KFYUR&Y
M;3TURXN+2>ZAM8M2:"$3))B1I@H$8C(`1`#M."6!R16O'X?MHX)(OL-W)YD+
MV[23ZG++((WQN42,Y89P.A&,<5#%X5LH=/>Q2SU$V[&,JKZS<,8RAROEL9"8
M\?[)&>AS18+G/OJ_B">RU.)-:EBN-&MKF7SA;Q$7;)+(J>8"G`VQC=LVY+$C
M'`K1AUK6)?%,4GFSKI;W2VY^2'[,`8L[<_Z[SO,.,_ZO'O5V;PCI<]K!;/I$
M_DPJZ;%U&51*KMN<2X;]Z&;)._=DDYZFKO\`8\']JC4O[-E^T!MVW[8_E;L8
MW^5G9NQQNVY]Z+!<T]._X\(OQ_F:M5G64MPMH@2VWKSAO,`SS4_GW?\`SY_^
M113:U!,M455\^[_Y\_\`R**//N_^?/\`\BBE8+G+Q:EJIUNVO/[1E-G-JTVG
MM8-%'Y:HJ28=6"[]VZ,'EB,$C'0UHZ]J.IV.O>'H;=X$L;R]-O."N9'_`',S
M@#L`#&/<Y[8Y5=!M5UDZL--F-WO,@W7SF-7*["ZQEMBL5R-P4'D\\FK#:>KI
MIZR:?)+_`&?();9I;MG97",FXL22QVNP^8GKGKS18+E?[5J1\2:C:7,L'V,6
M(E@BC3E3N8$LQZDX'```]^M;=M_QZP_[B_RJA-$WG379L=LS0>2TGG9P@R>G
M3J34T$UR+>,+:;E"#!\P#/%.V@7+U%5?/N_^?/\`\BBCS[O_`)\__(HI6"X^
M\^U&TD%D8A<$80S9V@^I`Y./3OZCK6-X:OM0UOP#I=^US&FHWFGQRF=HMRK(
MR`[M@(R,GID5K>?=_P#/G_Y%%8\>A)#;6EC%8LNEVUF]F+(W!9&0[`-V3R0$
M(!.3\QY'.2P7,(WWB8QW>EP3:G/=6]W&SNHLA=K:LCD/@XA(9T*KQD#K@@XM
M7UUJMSHD-_H_B&X\\1M;VUK+;0EKF[5F5A,0I&`5P?+V!=KG)&,:'_",V1M?
M(.GW9(<2"<ZG,;@$`@8FW^8."1@-C!(Z&F7'A6QN+B*<V%]#+%#Y*-;:M/!\
MF2Q!\MQDDG))Y)ZFBP7+'BG^VS#9#2?MX7S2UT=/^S><4VD!5^T?)]X@GOA3
M6"VM:E.C:C8ZQ=-:V,UE`8)8(<72R&/S&D(0$/B0_<*@%>A'%;UQHQOD=;R"
MZD;S6DCDBOI(9(@V/E5T8,!P,C.#Z5&_AJP>\M[HZ1(K6XC"1)>NL/[LYC+1
M!MC%3R"02,#T%%@N5=&O=4?5+"YN=2EGMM1^T?Z*\4:K!L;Y=A50W0$'<6R3
MVKI(/^/^[_X!_*LJRT2VT_49+^VTV59WW_?O7=$WG<VQ&8JF3R=H&:O12W`N
M[@BVRQV[E\P?+Q32"YHUSGB^_P!5TZ'2Y=.F@AA?4K2"Y+IN=DDGC0JO89#'
M+')'89.1L^?=_P#/G_Y%%5KZV.I0QQ7>G>8D<T<ZCS\8>-PZ'CT90<=..:5@
MN<U-XZM9?&T>F6^KZ;';0>?#-$TR&9YD7)^7.552".F6.>PYL^#M2UBYNI(M
M7DN29;6*XC6Y6$$L20YB\K_EE]S`?]YSS6[/"US/#--IP=X0P0F88`88;CH<
MCUK.BT%;."5+"VN8))63,K7TDK(BL&V(68[%ZC:N%YZ$<46"Y52UU>Y\5W=K
M!XEU46=O"6F!AM"JR29V(A\G/R`;OFSU3.>:H6Q\33:'<7=IJFKWR7%X$MR(
M[)9X[="P9URBQDN1QN!P"O3DUU%O:_9)KR:#3MDE[*)KAO/SO<(J`\]/E11Q
MCI51]"M'T>RTH:4Z6EBJK:B*[9'AVJ4!612'!VDC(.2"<]318+DVCWR:AX;\
MU9[J9T$L,K7:QB42(S(ZN(P$R&4CY>#C(R.:U+;_`(]8?]Q?Y5GQ0M9:<UM!
M8>5"%8_ZW<<G)9B3R22223R2:G@FN1;QA;3<H08/F`9XIVT"Y>HJKY]W_P`^
M?_D44>?=_P#/G_Y%%*P7*7B*/4VTUI-+GNDFCRWEVD<)EE/909OD`[G/..A!
MJ.WGNM6\)V=RFIK9S2P1R37<40^7@%]HD&%[_>!QW!I^IZ<NK(BW5C,&CSLD
MM[UX)%SU`>,JP!P,C/.*I7/AV*\MI+*>SF&GE(5BM8;QX5B\LD@J48$'D=,?
M=%%@N49#KK:`+DZ[=1/&TBVNVTA\V].?W6\%<#<!T4(<'.5Y`:NIZT-3DO)M
M0=88=3@T]K!(H_*(=(]S;BN_=N<D'<!@`8[U<E\*64QMVDMM5,ENK+%*-<N1
M(`Q!8%Q)N/0=2>E6!H%JNK#4QILWVK<KG_3Y-C.JA`[1[MC.%`&X@G@<\46"
MYE>*-;U2PUYS:W%PNGV5O#-<F%(?*B#.P=K@R?/LV+D"+YAAL]5IE[J>OV&J
MWID_M(2W)GBTFWD%K]CEE6-FC0E<S!B(V;YB!VX.!6H/#T<JVKWMI<7-Q#&(
MWD^VR*)@#D"10V)`"3@/NQD^IJ0>'K$7$TQT<MYQ=GB>Z9H=S[M["(G8K-N;
M)`!.XYZFBP7*GA;6[B\UG4-+EGO[I+:V@N!/?VGV>7=(TJLNS8GRCRQ@[>>>
M3UKHK+_EX_Z[M_2J&EZ:FC0M%9V$V&QN>>\:9R!T!>0LV!V&<#M5ZP)*3EEV
ML9FR,YQTHMH`O_,5_P"V'_LU>9:5+X:BGCFFGLTE73KO_A(F@?#!O,C_`->4
MYW;MX&><;@.,UZ3,DCZD!'+Y;>3UVY[UD1>)].EFN8AK#H;:-Y7:6S>-61&V
MLR,R@2`$@$H3R1ZBFP.=T?\`L._O+.RT*?3#8W5^+TV5C(CQP1P*I!VH=JL9
M3"Q`Z9'4\F6$Z-IJ>,T\17;2Z9'J<`D:\E)#EK:W8*W0%2Q^[]W!P1BNBMM>
MM+JS-S'JD@07"6K))9/'(DKE0JM&RAUSN4\@<'=TYI7UZR2WO9QK22)93"WG
M\J`R%92!A`%!+,=R\+DY..M*P'*V']A7,4,<5_:C1+=+K4;@6-X/)LU*>4L8
M:,_+A7D;Y3PPR.QK*SX1FEM[NQN=%3PS)?0)?6*30FWBC6&X\N69/NH7E,?!
MY^1,\Y`[S_A(M/6Q2]DUI88'=X\SVYC961&=PRL`RD*K,=P&`*@7Q9ISVTDP
MU.Z!C9%,#:9,)\OG9B$IYA!VM@A<?*?0T6`X";^Q_P"P)4U=K(0_8+S_`(1_
M>5W?\?$OE&WQSNV?9]NWYL8Q6_#''_PGT5Q+/9_VI]L4-:[!]N,?D[2V_=G[
M/G+;-N,\[L\5T-QXKTRUL[>[EU>403QF4.MA(WEH#AFDPO[L`\$OMQSGI5O^
MV;?^U_[+_M1_M6[9G[(WE[]N[9YF-F_;SMW;L<XHL!IZ=_QX1?C_`#-6JSK*
M*X:T0I<[%YPOE@XYJ?R+O_G\_P#(0IM:@BU157R+O_G\_P#(0H\B[_Y_/_(0
MI6`X&`Z6?&EN4:T_X21=9G^T>61]H%KY4FWS,<^7M\O&?ESM[TNOW&A7NMS7
M$D]A-J<BV<FBR;U:1U+YS`>I!.=VWMUXKIUUVU;6AI`U2079<QKFR<1LX7<4
M$A786"Y.T-G`/'%+?:Y;:=J,=A=:G(L\FS[MD[HF\[5WNJE4R>!N(S18#E=$
M$2>)YH;$::\J"Z.H7%N[&ZE&3L^TJ54H03A0Q;(!*X%>B6W_`!ZP_P"XO\JP
MXM:MKZYN+&#4GDFC20D-:,B2!#A]CD!7P3@[2<'K6G!#<FWC*W>U2@P/+!QQ
M3MH!>HJKY%W_`,_G_D(4>1=_\_G_`)"%*P%JLOQ)$9O#.J1"XEM]UK(/.B1V
M=/E/("?,3_N\^G-6O(N_^?S_`,A"HKEI+*TFNKG4DAMX4,DDCQJ%10,DD]@!
M18#S:&.PNM`U:4:1X:DTTM;0:9!:(MW9I=R,T98$HH)S)'NPHQR">II/$6CV
MV@W*:>EOI?\`9ECIT+:;:74.7N+@22M(MNRNI2=OW?S#)!(P.M=G_P`)/8_8
MQ<_VC=C,@B$)TR83EB-V!#L\P\`G(7&`3TIS^)=/3[-_Q.2PN%#HT=HSJJDE
M07(!$8W`C+XY!'446`J>,)=.E_L^:\DTJ>VCF>)[;4I=MNTA`QN;:P$BX.U2
M!DG@@UQMM]G,-F-9-N/%0;3#IZR<70CS'NV`DOMSYN_VW;N*]$OKJ#0(_,N+
MZ1/M$A;;%:O,[MCD[4#-@`#)Q@#TJ"3Q)817=M;-J[%KD1&.1+-VB_><1YD"
ME%+=@2,Y&.M%@,'PR-)/B2T:Q-K_`&S_`*6-6\HCS?O\>=CGKC;N[=.*[B#_
M`(_[O_@'\JRK+7+;4-3DT^VU.1KA-_WK)T1]AVML=E"O@D`[2<5>BBN#=W`%
MSAAMW-Y8^;BFD!HT55\B[_Y_/_(0H\B[_P"?S_R$*5@."E@M9/B&97ELFO6O
M=ILVC!O6A,.PG?NS]G_BV;<9YW9XK5\(Z5HFG2:GKUM86.F1W5PUK&(HD@41
M1R&->!QEGW-GJ=RCL*U&UNU76/[*.J/]JW>6<6C&,/MW;#)C8'VX;:3NP0<<
MU'IVHVOBBU?[)>74UM\D@DDL)88Y!G*E'=5#CC/RDC'L>2P'%Q-8VVOW2R3:
M8+:*:\?6;U)I$O&@*R$"==JM&JL4"'<P95!7`Q6SHUMH.I:#KAT"]MH+"9!_
MHNDW*`0A5/)\L_NV?J0,'`'?-;D?B"RENKFW&KE3;"0R2/:LL7[O_6;9"`C%
M<$,%)Q@YQBIK/5H;ZWN9XM3>..VSYWVBT:`QC&<D.`<8Y!Q@]J+`2Z3_`,BE
M8_\`7C'_`.BQ6C;?\>L/^XO\JSK:X_M/1HM1M+_SK2Y@$T3>3MWHRY!P>1D'
MOS5B"&Y-O&5N]JE!@>6#CBG;0"]157R+O_G\_P#(0H\B[_Y_/_(0I6`P/&UY
MX9MK2U3Q&MA*9F9;6#4)%6%WQR6W?*`!_$02.W)`.=JJVP\`V%A#J]G?6T`M
M?M=U-)YL309'SR8;)B.WG+8*@@G&370ZIJ2:/'&UY?S9DSLC@LGGD;'4A(PS
M8'<XP*A>]L[:P_MX:FKV]S''MFAA,IF4YV!%7)8G<<!1DYHL!Q&H6WA^Z\&)
M;2W6D6DX\]=-N0CBW?YOO6@9RJ2$XV%2Q7^$$<5I9LX_&R7[_P!EW>KS2VZB
MPN+,?;[6-D12T<C/DHN7=B%P?F&<@UTPURS_`+'35CK*)9,XB#R0;2'W[-A4
MC<&W?*5(R#P12/KEK'JW]F-JCBYWB,G[&WE!R,A#+C8'((.W=GD<46`P?%%[
MX.O=4MX;C4=+CU::*-H+R:Z16MHMQP\3,>&)R/DY/&>!65J=]K*^.9;F\T35
M`_\`8^II;QPSPX,:M"5,>V0MN8@9)4',BC!"DCN)I(-#@L[>;4TMTFE2UMU:
M/)>1NBCJ2>IS]2:+G5+>SU#[!<:Q''<_9GNRC1CY84(#.3T`!8=>O..AP6`P
M?`"Q076I6]K/IUW;".%_M.EPB*V\P[PZ;0[_`+T;0S'/.Y<@8YZZR_Y>/^N[
M?TJAIFHIK$<CV>H2GRR`ZRVC0N,\@[7`.".0<8/:KU@"$G#-N83-DXQGI1T`
M7_F*_P#;#_V:N1TBQUJUN-/5M%E4:/9W$"R37$0%VS,FW9M9B`50D[PN"0,=
M2.JFACGU(+(NY1#G&<=ZYS3=;AN;R+[=ID-II]S;375K=B\+[HXV4'S%*KL)
M#!A@L,`Y(Q3=@(M)T6^.N13-IEW9:?)=O?NEW<)+*)EB$8WLKN6#;LJ-Q"B(
M#CA:LV]IJ7A^7Q-=:?HIN?M-["]G;0R11[T%O#&Q&Y@``5?@X)Q[YI+36[2]
MT^*YCTJ2-Y]1%E%#/*49AG)<CG'R!GV]>,''.'6FJ#4X]76PT*5KFPNDMEAN
M)_)\S<B.'8\E%Q(#T+8'3/%+0-2*PM=1%RFHOHMXDEM#/.89W@$EU=/M`(V2
M,J_*I49;@,,GBJ#6FKWE]9Z]/X;U!-2M+Q)I86DM<RQ>3-&(XB)B,(9BQ+E<
M[CCK@:*:N3'%$=!>34#<36[V\%SN7,<9<LCMM#`G:@)"\MSC!JK)KMU!>C2K
MCP_;)J\LD201KJ#M;OO65^9?+R"JPN2-AZKSS1H&IG+H6N6.EWT<6C3W,NKV
MEW&T8FA5;1Y9Y95$A+\@";!*;_N'`.16I%H%[%XGBF^PW)=+I9OMOVA?LOEB
M/9CR=^?-QQOV9Q_'CBJ[^*"^G/=6FA13R6D$T^H0F^9#$(I'C=8SL_>'=')C
M.P'`Y&:N)X@LI/%B:*ME`5=P@_TP_:"#'YGF^3C_`%/\._=][C%&@:G4:=_Q
MX1?C_,U:K.LK*WEM$=X\L<Y.X^M3_P!G6G_/+_QX_P"--VN"+5%5?[.M/^>7
M_CQ_QH_LZT_YY?\`CQ_QI:!J<M%IVJ?VU!9G3)A:V^K3:@;]I8O+9'23"JH8
MONW2!>5`P"<]`5U&VU:[N;J./1;KRM46V8RM-"!:%3\XD&_)(`R-FX$]^]2)
MJH;6XK<Z1'_9LUY)8I=K=L9/-168[H]N`N49<AB<XXP<T_5-1^P:C+%!I$4]
ME:^3]KG:[9'3S&P-B;2&P.3EEXZ9HT#4IZ9HMY::Q+<26%S"T:7/GW,MPKP3
M>8VX>1&'/EY."WRIG'.X\UV5M_QZP_[B_P`JY#3M?M=2UN]TQ;*!&A28CR[P
MR31>6P7]]'M'E[LY3EMPYXKIH+"V>WC9HLLR`D[CZ4]+`7J*J_V=:?\`/+_Q
MX_XT?V=:?\\O_'C_`(TM`U+59^N6MQ?:!J%I:^7Y\]N\:>8`5)*D<@\?G4W]
MG6G_`#R_\>/^-17-@BVTC6MK'+<!28TEF9%9NP+`,0/?!^E&@:G)V46N:);W
MDNF:!J;1W;QJMO=7L5Q<P$*P>0O).0RX$85-_&">,U)JVG:C>>'8]*L=#OK<
MM$7MYFO(@;>YR_S7"*^UUW%7P/,#$G*C`JI+XI>TLYIK[2M(M\7WV&"5M9<6
M\CJKM*6D,(*A-A'W3E@1QC-:&IW^HV5E975IHNDWBW0C10FKR@O*Y^[&1`0R
MXYW';P"2`!1H&II:M=2WVF7%LFE7U]#O:WG6SNEMYLC'*,73Y3SGYP>,8/(K
MG8=$UVWMO[*DTUY_M3V,LEY'+$L-N(C&'4C(8D"+C:F"2.G.-KQ+JECX>@M]
MT=@L\^XJ;Z_-K"H7&29"&QR0!\O)(Z51DUYDDCD&A)]CC:VCO':^S+`\VW`5
M5!5PN]22''!XS1H&I9T6QU--2L+>YTR:W@T[[1_I3RQLD^]OEV!6+=.3N"XQ
MWKHX/^/^[_X!_*N>TS4?MVIQ0SZ1%#977F_9+A+MG=_+;!WIM&W(R1AFZ<XK
M:BLK=KNX0QY5-NT;CQD4U8#1HJK_`&=:?\\O_'C_`(T?V=:?\\O_`!X_XTM`
MU.6_L;4H/$EP\-O?E9KEIS<_;MMJ8F3!C:(/G?D?>V''!W=J?H<,F@Q2.NE:
MAI^G11Q6ZV<]X+C+[E13%F5@J`'&/E)_NYZL?Q!9#Q%/IJV=F88&99"VHA;D
M[4W,ZP$?-&,[<[LY!^7')MZ'>/J-T;?4-(BLG>W2Z@\J[:8/&Q(^;Y5VL.,@
M9'/!-&@:G/7OA'5;]]1@BM[BVGF%XLMW+<AK:9)=Q011!SY;;O+W-Y8)PV=V
MXDZ(T'7-0MI8X)YM-M1.DHM=6)OFD*AMP)6;A"Q1@-^/E^Z`<4T^*]/WZE)'
M96TUO913OLCU`&Y)C9E^:$XVJS*0K;CVR!3[G7QIMG=_VGI=C:7EM)$K[]28
M6RK(#M=YB@*C*E?N'G'7.:-`U-3PGI]_I/P^TO3]3$:WEM8)%(J#`0JF-O#,
M"0."0<$@D``XK>MO^/6'_<7^59&F26FJ^'XM2CMQ&)8F==LA=3C."K?Q*<9!
MQR"#5Z"PMGMXV:++,@).X^E/2P%ZBJO]G6G_`#R_\>/^-']G6G_/+_QX_P"-
M+0-3/\17NK6L$,>E:5<WAF8K++;R0AK=<?>"RNH9CT'.!U.<8,-O=&TTC^S[
M#1+P&TMX0;0SQI($;(VJX<J9`%.<L.H.[G-3:K;W%O&G]EZ3#=RMDMY]X8(T
M`]6"L<GMA<>I%5H[J.[\+6VL6.E[I+B%)E@N+D1*@8`DN_("@<D@-P.`:-`U
M.8N?!NO3:.HLI;:VAC=Y+;3KZW^T2Q,\FYG:59@IDP3DG>>6^8EB:Z2XFU2\
MU^"TO-!O'T^WE1TNHG@\J1P`1(RF7>JJ<X4*3D`]L5G+XITX^&;35?[-:2:Y
ME:)+>"<NK!9-C2J_&8N-P?`R"O&6`K2O)Y[/58HY-$3^SI)TMUN!=DRLS?Q"
M(#&P=R6!X)VXYHT#4RM8TC6?$%UIVMZ;=6P@,ML\=M=6>Z2!%D#.P<3!3G`)
M`!)"@`TU/#GB6P\;IK*7%CJ$?V6]R6@,+%G:(Q0L_F-C[@`8)@!&RI+9K9UK
M4+#1[O3[463W$UY<1Q$(Y`A1F"^8Q],D`#J3[`D03:O9#Q0=#MM-DN9%LYKA
MI$EP"\9C'E#)P6(E!))`&1ZG!H&I-X=LKV+5]4OI;2ZLK6[$9%O>3K-+YP+[
MW#!WPA!C"KNP-IP%K:LO^7C_`*[M_2L7P_>0:S]MCFL[:.:TE\J3[+>&XCW=
MUWX7YEZ,,<'N:V;!0B3JHPJS,`/RHZ`,FFC@U(-(VU3#C.,]ZY2'PQ:S>7;:
MKJJW.FVT3PVEO;0RVSHK2(XWRK(68CRU`*[`><@YXZ__`)BO_;#_`-FKB(M4
M\3/:17%E?/>7.JZ9=3VUI-%$JV\ZE/*"L%4E?GP=Y;.`<CI3=@-'2M`L-)U*
M.XBU.XE@2>:X$5PTTS>8ZA5(>1V(VKO'OO[8YEFL98SKDVF:W':76J74<ZRO
M9M((0L4<97&X;LB/KD8W>V:@L]2U%!:Z8UYJIU&6_C$OV^.U,D<(4R-CR1LV
M,L97/+#?V.,3:;=ZWJ<GB2RN=1ALYK.^CBCG@A#"&(P12$#?P6^=OF8$9YVX
MXI:!J-L]/GMU$KZM9?:X;26VM'@T^1(XBY!+E6E8N<JN?F&<'GDU4CT:_P#(
M@:;7=.>_MKH7<%R-+E&9"CQN95,YWY1R!@KMP,<``6(;[79(K&PM]01Y;JXG
M:&]N(%+-:I&=LC(H4$^8T8XVY4Y&,U7-SKD-RVGIKEQ<6D]U#:Q:DT$(F23$
MC3!0(Q&0`B`':<$L#DBC0-2)_#+)8M;V>NP0/=P30ZA*U@SF7S9'D9HQY@$9
MW228SO`R.#CG333(X]35EU.(::MR+L6_V5O.\T+@?O=V-G'39GMG'%83ZOX@
MGLM3B36I8KC1K:YE\X6\1%VR2R*GF`IP-L8W;-N2Q(QP*T8=:UB7Q3%)YLZZ
M6]TMN?DA^S`&+.W/^N\[S#C/^KQ[T:!J=-97MO%:(CR889R-I]:G_M&T_P">
MO_CI_P`*-._X\(OQ_F:M4W:X(J_VC:?\]?\`QT_X4?VC:?\`/7_QT_X5:HI:
M!J<C'I6W6DG.KP_V;%>O?16JV;"3S71E.Z3>05R[-@*#G'.!RVZTVXN[DN^M
M6JPW*PB_C6P?,K1G.8R9/W8/0@A^.ASS38M2U4ZW;7G]HRFSFU:;3VL&BC\M
M45),.K!=^[=&#RQ&"1CH:DUJ]U1-2OKBUU*6W@T[[/\`Z*L4;)<;V^?<64MT
M.!M(P>>:-`U%M=-%M<AI-3BFM;99OLD*VK)(#)RWF2;B'Z\85?4Y(K?@O[9+
M>-6EPRH`1M/I6`D6J-XJO(EU[4)["TMS)/!-%;>67D#;(U*QAQM`W')SRG)Y
MKJ+;_CUA_P!Q?Y4]+`1?VC:?\]?_`!T_X4?VC:?\]?\`QT_X5:HI:!J5?[1M
M/^>O_CI_PI#J-K@XFP>QVFI+S[4;2061B%P1A#-G:#ZD#DX]._J.M97A/4KS
M5_!.D:E<,DE[=6,<SDC:K.R`]AP,GTHT#4J6UM/IWAW3]/T_6XTN[50)+B>R
M,B7#8.]F0,I&6);AQ@^HR"6FF65K+I;->^:MB]Q-AXB=TTI)+J23M`WR`#GA
ML9XYCM9M6O=#NGO==6P>VO9EGN;6W3(C5B`J>8&`[<D,3@]">*U\?$ZZ'!=K
MK!@U$Q%+:R6UCQ<SEFV^;N!8`KMR$V;<.22.AH&I=OEFOYX[R*[M;6^M)9%M
M9)K5ID,3``[D#J<G'4,.G3DBLR/PTEL(K2VUF--,)MGN(6LBTLK0E<;9`P5`
MP1`1L/`.",\=%XACU1M,:33)[J.:,;C'9I"TLI[*#-\@&>3GDCH0:Y:/7M8O
M+4:K%JC(EI)8Q2VJ0)Y5QYOE^:3N7S%/[P@8(P5&0>11H&IK:9IQL=1BEGU:
M&>SM?-^R0)9LCIYC9.]]Q#8'`PJ^^:VHKVW6[N',F%?;M.T\X%86C7NJ/JEA
M<W.I2SVVH_:/]%>*-5@V-\NPJH;H"#N+9)[5TD'_`!_W?_`/Y4U8`_M&T_YZ
M_P#CI_PH_M&T_P">O_CI_P`*M44M`U.2GT>"?4)B=1B&FS3FZDMQ:'S3*5VG
M$N[&W';;GK\V.*;86U[IBFXDU2VO[I(8K6`+9-"JQ!QN+9<[F(/4$#CA>Q??
M-J*>,$CMO$-VEM#"U[>VTD5NT218*H@Q&)!N8,<[CPC#N,,\':EK%S=21:O)
M<DRVL5Q&MRL()8DAS%Y7_++[F`_[SGFC0-2M/X9M+BVN+$ZHD>GL;E[=(K0K
M+%)-OW,SY(<`N2!M'09)J4Z1/++_`&A<:W;/JZ3I+'-'8R)`-D;H%:+S"6&)
M7/WQSCIBJ6I:_K.@_P!K7VI-J,3%;G^SK:1;5K638&9-OEYF+;$+D,<<D=>!
MI6E]K/\`9>K0I=3_`-HP*)$&JP1!HD8'#8@.UU.TX!VGC#&C0-30TR*UTO1I
M+-;HS2.TTKOL*@R2.SMM'.U=S'`R<#')K0@O[9+>-6EPRH`1M/I3+&>2Z\-6
MUQ,VZ66S5W;`&6*`D\5<MO\`CUA_W%_E3TL!%_:-I_SU_P#'3_A1_:-I_P`]
M?_'3_A5JBEH&IS?B)+G5H((;#5[:TA#$W$5Q9/.MPN.%.UT('J,\]#QD%YNM
M2DAD@&I6D$B1Q&*X2S8H\GS;P8RY.S[N`&!Y/S=ZMZ^D_P!B\V/6)M+BCR9)
M+>%))&/157>K#KQC:220!CO1N;G61X8TJ.YG^QZK=O!#<30QJ3$S??*JVY<\
M$<Y`)[T:!J9%UX/TC4+69[O4;D:E<',MQ:37%O$27W$")),8SZDGN2:T1!?+
MXA6]_MNSDL8R%BMIM/D:2),`,%D\T#<<?>*D\XZ5S^K>.9-#LGTJ;7+)=4AN
M&WW-Z\4;-;K)@$)P&<C*\#`VL<#`!T[S7M2LO$@,DM\\$U[;P6MM%9@VKV\F
MQ3*9]GWPS.<!QPH^0]2:!J.O/#^GZY]EU"_N;FUU/S();C[-<W"1MY;;@NQ9
M-H/49Y(SD$TG_"*:1!K\>K:=J=]9RI!=(%$\TH62=E8R*KL4&"&.S:5)()'R
MBGZ[KFH0^([BWAEO;>RL(()YIH((7C`=I-QE\PABH"#B/YAR3Q4]Y<:K:>*(
M+.XU.[CM-2\R&&58(1'%)L9D2/AG\P*C,3("AQP,_+1H&I:TJW6TU.[U2_U"
M&YOKF&.!F@MFA3RXRY7Y2S9;]XV3GTX%:]@P=)V4Y5IF(/Y5C>$O[0F%_=76
MKWM]:-.T-H+N*%&"QDJS_NXTX9@<9SP`>];5E_R\?]=V_I1T`CF>1-2!CB\Q
MO)Z;L=ZR(?#&GP37$HTF1VG1XV$U])(J*[!F6-68B,%@#A`.@]!6W_S%?^V'
M_LU>5VW]FO"W]FM$=6;2[Q-:-BX$JREXQF8KG#!MY&[G`;'&:;`[^QT2WT^Y
MBN8=/G>XB5U66>_DF?#[<Y9V);[J@9S@9`P"<I>Z!::A#?PW&ER;;^9)[DQW
MKQEW1553E6!&!&G`P.*Y+0$LIKRWT:QN-+NK.74!?;],B$=H4AC4D11AF"E9
M?)+?,?F;/!X%N$Z-IJ>,T\17;2Z9'J<`D:\E)#EK:W8*W0%2Q^[]W!P1BE<#
MH(_#]M'!)%]ANY/,A>W:2?4Y99!&^-RB1G+#.!T(QCBH8O"ME#I[V*6>HFW8
MQE5?6;AC&4.5\MC(3'C_`&2,]#FN>L/["N8H8XK^U&B6Z76HW`L;P>39J4\I
M8PT9^7"O(WRGAAD=C65GPC-+;W=C<Z*GAF2^@2^L4FA-O%&L-QY<LR?=0O*8
M^#S\B9YR`7`[2;PCI<]K!;/I$_DPJZ;%U&51*KMN<2X;]Z&;)._=DDYZFKO]
MCP?VJ-2_LV7[0&W;?MC^5NQC?Y6=F['&[;GWKS2;^Q_[`E35VLA#]@O/^$?W
ME=W_`!\2^4;?'.[9]GV[?FQC%;\,<?\`PGT5Q+/9_P!J?;%#6NP?;C'Y.TMO
MW9^SYRVS;C/.[/%%P.XLI;A;1`EMO7G#>8!GFI_/N_\`GS_\BBC3O^/"+\?Y
MFK5-O4$5?/N_^?/_`,BBCS[O_GS_`/(HJU12N!SZZ#:KK)U8:;,;O>9!NOG,
M:N5V%UC+;%8KD;@H/)YY-,D\.6DUS;W$NG7+R0+&@+:E*1($.4\P;L2D'G+[
MCFN:@.EGQI;E&M/^$D769_M'ED?:!:^5)M\S'/E[?+QGY<[>]+K]QH5[K<UQ
M)/83:G(MG)HLF]6D=2^<P'J03G=M[=>*+@=@EJ+3^T)H=/\`+>]?SKA_.W;F
M"*F<'I\J*,#'2K,$UR+>,+:;E"#!\P#/%<QIF@:0?%.MZO::39VCV2M9QR06
MZQF1V19)7)7[Q.Y5R>1M;'WCGL+;_CUA_P!Q?Y4[Z`1>?=_\^?\`Y%%'GW?_
M`#Y_^115JBE<"KY]W_SY_P#D45F66F/IIT^*QM9(+*QM6MHK47)*E3LVDY/)
M4)@$Y/S'GKG=K.UY3)X>U)!<-;%[:1?/6)I3%E2-P1>6QUP*+@9U]X?M-1A6
M*?3KA56Y:Z4P:A)"PE.<MN1@>YXSBH)O"EG/-#.]MJ@FAA\A)4URY1]F2V"P
MD!;D]3D]/05R'D:$^BFQ2\\+V^C0W44QOXM-4Z?=.4D`CE`EV[E*H2S,,DJ!
M@FJ^K2--Y<MU8Z1#96]@G]F6,MOC[1*DLP(L]KJ8Y'582I!8@,O!YHN!Z!<:
M,;Y'6]@N9&\UI(Y(KZ2&2(-C*JZ,&`X&1G!]*B;PSI[7=O<_V0ZFW$0CB2]=
M8?W9S&3$&V,5/()4D8'H*C\8/H5YI!CU*]TR`AF6*;45\RVBE&,[QN5=XSP"
M00>1T-<8'T^5K7[>(D\1!],_LQ9WW7?E9C#%<@.5)$N\X'&=W%%P.]LM$MM/
MU&2_MM-E6=]_W[UW1-YW-L1F*ID\G:!FKT4MP+NX(MLL=NY?,'R\5QWAD:2?
M$EHUB;7^V?\`2QJWE$>;]_CSL<]<;=W;IQ7<0?\`'_=_\`_E33`//N_^?/\`
M\BBCS[O_`)\__(HJU12N!F+;E;NXNAIH,URBQS,90=ZKG:,'C'S-^=9\6@K9
MP2I86US!)*R9E:^DE9$5@VQ"S'8O4;5PO/0CBL+64TI/&UI=Z?+`^KQ2O]JM
M(@5O95,3+G<3GR1D':%V[@"#D8,?@(V&G7-RT5_ILL36L"W$EFHB6.;<1MG^
M8[KABW+':3@?*.,EP.C3P_91W%Q+_9+.)]^^&2[9X1OSOVQ,2B;LG.T#.3GK
M4]EIB:?;S0P:?*RSC$C37C3.PYX+N2V!DX&<#/%<+;2WEGXDG_L"TTW4-1AN
M;I[QHI2M[.I$FQ)UD5=BJQ0+ER&505P,5I>';:XO/#OBBSNX]5M&^V2/))-/
M&)9&,2%ANC=MO/92``0`>,`N!V`$MMIWV:.R\N".+RU_>@[5`P/<\5)!-<BW
MC"VFY0@P?,`SQ5?2?^12L?\`KQC_`/18K1MO^/6'_<7^5.^@$7GW?_/G_P"1
M11Y]W_SY_P#D45:HI7`P=7T:'7&M7OK&YWVK%X7M]0DMV1B,$YC93TXY]3ZU
M')HGGP2VMQ!=S6CQPHD;7\F^,QDD.)-V\.21\P(/RCFH/&UYX9MK2U3Q&MA*
M9F9;6#4)%6%WQR6W?*`!_$02.W)`-&_.E1>"=+L[G5+74-.@-J+V>28/')"3
M@.Y)/R,0.22"`<D\T7`W(=*A@TDZ8FF.;0DLRO=,[,2VXEG)+$D\Y)S31HUN
M-8;51I;BZ<AFQ=L(V<#:',>=A?``W$;L`#/%<%J$UT/#DD&CZ;=S>'([EYX)
MM.F@6)QYWRQC=(I\L$$_*"#E1G`(.A>9'CMEM%TY]5EOK>5Y)W87T%OB/S(D
M3;@P[0QWJ^W<S#!;)HN!TPT".:.U-[9S7,\,8C:4WCKYP&2!(`W[Q02<!]V,
MFIK?1+:UU%KZ'2V68NTH4W;&-';.YUC)V*QW-E@`3N.3S7*^))XKCQ.UW++I
MES;BVMY--CG!>2Y<-(7%LZNNV3[N67<<8R,58DBT:X\<Q)91V5X;J2>VU.T:
M(_:`"LF7FWDEX<J$52H7YP5)!`HN!U]E"^G64-G:Z?Y<$*A$7S]V`/<\G\:F
ML"2DY9=K&9LC.<=*Y_P+H^FVEA<ZM8Z?969U.4R*MI"L:B!21$,*!_#\Q]V/
M;%=#9?\`+Q_UW;^E'0".9)'U(".7RV\GKMSWK(B\3Z=+-<Q#6'0VT;RNTMF\
M:LB-M9D9E`D`)`)0GDCU%;?_`#%?^V'_`+-7$0:)JMQ;VUE<:+,L>F6%S;K+
M)<Q+]J=F388RI8J,)NRX&#M&#SAM@='#K=O/:"Y&HS(AG2WV36+QR"1V"J#&
MRAQDD<D8QSTYI'UZR2WO9QK22)93"WG\J`R%92!A`%!+,=R\+DY..M8NCZ+J
M\NN6]YJ$>H>0TWVAVOIH#(#''Y:!UA.SDR.P"<?("<$XJY;VFI>'Y?$UUI^B
MFY^TWL+V=M#)%'O06\,;$;F``!5^#@G'OFE<+%S_`(2"Q&F_VA)K2PVV]HV:
M>W,;(RJ6965@&4A5)((&`,U#'XIT^2UFN!J=R/)*!X7TV59_G)"8B*;SNP<$
M*<X/H:J6MG?M/;:@^A70DM%N+MH[B2`2W%VRA%V[)&104,BC+<#`-5Q!JUVZ
MZS/X;U"/4X;J"62%I;7,L2B11'&1,1A/,9LN5R2<=<`N%C0E\7Z5!9P7;ZQ+
MY$RN^];"1O+5&VN9,+^Z"MD$OMP0<]*N_P!LV_\`:_\`9?\`:C_:MVS/V1O+
MW[=VSS,;-^WG;NW8YQ7*/H^NP6FINFASS2ZS;747DK<0@6C/-(R>:2XR"LH)
MV;\%3C/&=*+0+V+Q/%-]AN2Z72S?;?M"_9?+$>S'D[\^;CC?LSC^/'%%PL=+
M917#6B%+G8O.%\L''-3^1=_\_G_D(4:=_P`>$7X_S-6J;>H)%7R+O_G\_P#(
M0H\B[_Y_/_(0JU12N%CGUUVU;6AI`U2079<QKFR<1LX7<4$A786"Y.T-G`/'
M%+?:Y;:=J,=A=:G(L\FS[MD[HF\[5WNJE4R>!N(S67%IVJ?VU!9G3)A:V^K3
M:@;]I8O+9'23"JH8ONW2!>5`P"<]`5U&VU:[N;J./1;KRM46V8RM-"!:%3\X
MD&_)(`R-FX$]^]%PL:2:O%>7=W80W=U+)`'61O[/D6'*]5$I783SC`;/7TK2
M@AN3;QE;O:I08'E@XXKF[73+RUUB9[73KS3[<27$EV\M^9[>Y5P[#RT,A*,7
M96)*+C!4$C%=;;?\>L/^XO\`*G?0+$7D7?\`S^?^0A1Y%W_S^?\`D(5:HI7"
MQ4:*Y12S7P55&23&``*KZ?<_VK80WUCJ:SVLR[HY5B&&'J/:F>(M+O-8TP6E
MG>6]MND4S?:+=IDEC&<H55T."<9YY`((P:QM,M=7MO#<'AV:Y2VU6>WG=+N&
MW'EPA74<KYA).)!C!QUY!QDN%BY+XCL(H))AK!F6.Z:S*V]HTSM,HRR*B`LQ
M`R3M!Q@YZ'"7?B6QLC;B;592)T#JT=A)(J*6VYD*J1&,\9?'0^AKGK?PWKNF
M6-QF'S9(M2\VU;1UBMY8XS"(RR+.\D;`_=VN00-S`DX%59O"6LV6F:GI\5G<
MWS:UI9LWG$T1%K(TMPY:3>ZE@!<?P`_</'(HN%CL=0O(/#R(]Q>3@W<Y"I;V
M4EQ)))M+'"QAF^ZI[8`%12>([*&[MK674KB.6X$6S?I\BJADX178KB-F/`5R
M#GC&:CUN./5(8V&D:E??8YGBS97WV696P!N1A(@(()!RX(Y&#DUCG2=?"R:?
M<6$UT]]-93RWXFB\J'RC'O#98.6`CR,*02PY')!<+'066N6VH:G)I]MJ<C7"
M;_O63HC[#M;8[*%?!(!VDXJ]%%<&[N`+G##;N;RQ\W%8>BV.IIJ5A;W.F36\
M&G?:/]*>6-DGWM\NP*Q;IR=P7&.]='!_Q_W?_`/Y4TPL'D7?_/Y_Y"%96K:Y
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MH1PODM%-@[=V,,Z?>+=0!1<+'11O+=Z;]J2YE\IXRP2:U,3X]"K`,OX@5-!#
M<FWC*W>U2@P/+!QQ5/1K:^M/#;0ZA)(\H,Q02R>8Z1%V,:.V3N94*J6R<D9R
M>IU;;_CUA_W%_E3OH%B+R+O_`)_/_(0H\B[_`.?S_P`A"K5%*X6,?5]1AT'2
MYM2U75X[6SA&7EDC&![`#DD]@.3VJQ]BDAFFNC=A7=`))#&/NKDCOP!D_F:H
M>-M)EUKP9J]C;6R7%Y+9S);*VT'S&0J,%N`><9R.M&O6]UKL<VD65Q':M$8I
M)VN;8S13QMN_=X61#U49YZ<8(:BX6()O%&FPV-K>G66DM[I&EA:"S>7,:X#2
M$(I(09&7.%&1SR*T);^.&^LK*35HQ<WH9K:,1@F0*-S$8[`8YZ<CUKCT\-ZY
M:Z?8-<P75U<I;RP!=+N1:>2YDW([9E^9/4!F[?(>V@WAOQ"OB[3-5DO[&YB6
M<M,39D211^2R[0WFX(R3C"<%LG-%PL:4^JV&A7,&DR:E)'($0A4M'D$:LQ53
M(X!"!F!`+D9(/6F_\)/8?;);1=5F>6-I$^2PD99'C!+I&P7$CC:V50EOE(QD
M&LO4H=1U9[Z2RTJYEM-;LK>)9Q+$/LQ5GW%P7!(PP(*;L\]."=.*74=1\41'
M4/#M]#:V<LGV2<R6[1`[67SFQ)O!*DJ`%X#'/7Y2X6+.DZU%K4]S#9WEX);;
M;YJ7.FRVY7=G'^L5<].U:=@"$G#-N83-DXQGI5/PW8SV6E%[Q&6^NI7N;D,R
ML0[MG;E>#M7:H]E%7;+_`)>/^N[?THOH`UT#ZI@EA^Y_A8C^+VK`?Q.BW^OV
MQTV\3^RH(94:6<I]I,C2*`HS\JYCQN/7.<8P3ONZ1ZIEW51Y.,L<?Q5CWVAV
M]Y?:S=?VE&AU&S@ME&T'R6B:5@_7YN91QQ]WKSPW<"*+7;E";:^TY8=1%[#:
M^3%J#R1LK@,75RJDX0.<;1RF,X.:=::[-J<>KK8:3=-<V%TELL-Q<F'S-R(X
M=CR47$@/0M@=,\4ECHLR:S%JFI:S9W4ZL[LL-OY2;M@1"H,C$87S,\G._L!@
MNFTFXC.N3:9KEO:76J74<ZRO`)!"%BCC*XWC=D1]<C&[VS2U#0C3Q!<&.*(Z
M1/)J!N)K=[>"\++F.,N61VVA@3M0$A>6YQ@U5D\3:C!>C2KC1HTU>62)((UU
M.1K=]ZROS+Y>056%R1L/5>>:MV>CW5NHE?6--^UPVDMM:/!:,D<1<@ERK2L7
M.57/S#.#SR:J1^'M2\B!IM?TE[^VNA=P7(T]QF0H\;F53.=^4<@8*[<#'``!
MJ&A$_C&X?3GNK321/):033ZA"=1=#$(I'C=8SL_>'=')C.P'`Y&:N)XIBD\6
M)HJP(5=P@_TYOM!!C\SS?)Q_J?X=^[[W&*IOX1E2Q:WL]>LX'NX)H=0E:UWF
M7S9'D9HQY@$9W228SO`R.#CG331!'J:LNJ6PTU;D78M_*_?>:%P/WN_&SCIL
MSVSCBC4-#8L(5>RC8E\G/1V'<^AJS]G3^])_W];_`!JM83PI91JTJ*PSP6`[
MFK/VF#_GO'_WV*;O<$'V=/[TG_?UO\:/LZ?WI/\`OZW^-'VF#_GO'_WV*/M,
M'_/>/_OL4M0T.;37YFUN*W.G_P#$MFO)+%+M;YS)YJ*S'='MP%RC+D,3G'&#
MFGZIK=Q8:C+%!I_GV5KY/VN=KYD=/,;`V)M(;`Y.67CIFF1Z'(NM).=8M/[-
MBO7OHK5;?$GFNC*=TF\@KEV;`4'..<#EMUHMW=W)=]<L5AN5A%_&MH<RM&<Y
MC)E_=@]""'XZ'/-&H:%F/6;>]UF_TN"*=EMK<NUR93L9P2&11GG;W/3/'4'&
MS;P(;:(DR<H.DC#M]:YRQ\*Z1HVH/?6%Y=;1:-`MO+J$TRC)SD!Y"/PQ[UT=
MO<0+;1`S1@A`""P]*>M@)/LZ?WI/^_K?XT?9T_O2?]_6_P`:/M,'_/>/_OL4
M?:8/^>\?_?8I:AH'V=/[TG_?UO\`&JVHR)I^F7=Z(KF?[/"\ODQ2,7DV@G:N
M3U.,"K/VF#_GO'_WV*J:K!::KI-WI\MRJ1W,31,RN,@$8HU#0Y`>/;<Z,+P'
M2FD:[6T61-;8V>XQF0YGV<;5!R-G!QZYK4U#Q!-IMOI]Q+:6KPW(0-(FJDAW
M<\)!\N9FP,\A!CD9Y`='I>IQ//?)XBL5U2;RU=Q9G[,R(&P#$92V?G)W!P20
MO88J&Y\-O-H\NCKKT/\`9UW%+%>0RP!RWF,[.T3;P4),A`W;P`JX`P234-"[
MXGUJ/P[9PS'[./-D*"2^U!K6!2`3AI,-@G'`QS6=_P`)7._DW,>D2BQ!M5NV
MEO62>W:?;@>7M(;;O7=\P[XSBM&[MKV[DCN;?4+*TNK621+=IHS-&T3!1ED$
MBDMQP=P^G.*S(_"7V816EMK=LFF$VSW$+VX:65H2I&V0.%0-L0$;#@`X(SP:
MAH7],UNXOM3BAGT_R;*Z\W[)<)?,[OY;8.]-HVY&2,,W3G%;$,*F]NER^!L_
MC;T^M8^F:/)8ZC%+/K%K/9VOF_9($@V.GF-D[WWD-@<#"K[YK8AGA%[=,94"
MMLP=PYXIJX%G[.G]Z3_OZW^-'V=/[TG_`'];_&C[3!_SWC_[[%'VF#_GO'_W
MV*6H:'/7&N2VOBNTT>>Q"Q7;,L,@ORTQ"H7,AB`XBXV[MV=Q`V\YJSHNL6^N
M7>H1V\-PL%JZK',TK8G!&=ZC/W<Y`/?J.",P:GH[:S<F&_U>WETDOY@MUC\N
M93M*X$RN,+R>B[N?O5#8Z%;^'I;ZYTB\DEDN?)18KN]EG5%4@'F20]B?ICOT
MHU#0EO/$,%C=:LD]I=QP:;9&\:>28J)0-V0HSG`V]3USQFH-/UK4M4T<75C8
M:;>7#3B+9::VTD,0QEC))Y8*D$8VJK')'09(U;BT274;B]AU-8)9;06R,H5C
M&0Q8.,Y!Z]".U9$^C:K-'<3IXEL(M1NC&D\J6;B)H4WX14\_<I)<Y</G@8QQ
M@U#0U-+O1J^@M>O;S6TF9HWB:9F`:-V0D'^)25)!QR".*T;>!#;1$F3E!TD8
M=OK5.S!M=$6UN+JQDFCB*#[)%Y,>.=H5"[$8&!]X_ATJY;W$"VT0,T8(0`@L
M/2GK8"3[.G]Z3_OZW^-'V=/[TG_?UO\`&C[3!_SWC_[[%'VF#_GO'_WV*6H:
M&+XKUA?#'AR\U865W?&WC9_)BE89P"268G"J`.3S[`G`.G>%+2TDG$5U.4'$
M4+LS,>@`&?Y\#O53Q#90:]X<U+2/ML<'VVVD@\WAMFY2,XR,XSTR*M1W;F_N
M%DDMQ:!$\E@PW%OFWYYZ?=QP.]&H:',7'B:_?PEIWB'3=)@N(KRWCE%O/JDD
M,I>3&R-,1L&))`R2HS[<UL'4BFNV>E26-TK3PO(\_G-Y:,H4[%)(+?>ZX`X]
M>*J:;X?M[#2/#>GMJB2QZ*%R0`HG98FC!(W<8W;L<\@>F:U;B&"?5;*^^UQK
M]F61=F0=V\+WSQC;1J&A1UO4;[2G::+2FN-/A16FF-\R2')QB.,`[R.,Y*]1
MC-1-JU_;ZW;VM[H\D-G=3R06\T=ZTLOR(S[WC`PJ,$.,,QY4$`G`AFM-<O[F
MRO)-:TJ!8D5FLYK)I564$Y<%9UYP<`'<`1D9/-3V=CJ</B&74+K7-,N;=F94
MB^Q,LL41Y"*_G%1SM).S+8Y[8-0T+>AZ@-9@N96M+JT,-PT'ES2G>0`"&(!X
MSGIU]>>!>L1@7`&>)FZG/I4&GPP6#WK?:XW^TW+3]0-N0HQUY^[U]ZGL2&%P
M0009F((_"CH`O_,5_P"V'_LU9&GZYJ5SXFUW3;C3XXX;&W@FM520-)-O,P)8
M_=7/E#`[9R3S@:KL5U3(1G_<]%Q_>]Z@AL(X-;O-56*Y,]W!#`ZEDVA8S(5(
M&<Y_>MGGL.G<8&-I_B?4+[2[1WM[:&_GU>6P\H;G55BE<.<\$GRXGYX&<'':
MIM/UG6]6.NVT-K9V=Y8WB6\7GLTBJC11R;GVD;F`D/R@@<8W=ZL6.@6^GW44
M\0O6\N:ZG$;O&5+W$GF,>.>"6"\\!CG)YIEUX>6>/5A!<ZG9R:I/'/-+;R1!
ME*QI'A=P(VE8QD$'.3ZTK#*D.O:W(+:TCAL)[Z2>X02Y:*&:.*/_`%BC+%09
M&1#RV,D\\54E\0>([?4TT6233)+N>YBMXM0CM7\E',4LKHT7F[BRK$O\8SYJ
M\#%:MMX?>"-]VH:I+/\`96M8KAA;(\"-@_($15!X7JI^Z*JQ>$I([**W;6-:
MD>"99[:=EM/,@<!@S*1$`Q8.P8N&SD]R318#,_X2_7;G3+F:S&G+<Z;;7$UX
MLT#E9VAFDB*QXD_=AC"YR=^,C@\U?C\4W\OBR.R6.(6+SB$*;:3.#%OW_:,^
M7NW?+Y6-_?.*=-X+MY+-+6.\U:W1H9(;HPM`&O%D<N_F$J<$LSG*;#\YQCC%
M\:!$NIBZ5[X6XE$_V$&'R?-`P'Z;\]\;MN><46`U=._X\(OQ_F:M51L)&6RC
M`A=ASR"OJ?4U9\U_^?>3\U_QIO<2V):*B\U_^?>3\U_QH\U_^?>3\U_QI6&<
MS'K^JMK<#'[$VE3ZC+IPB$3B=&17.\OOVD%HR-NT<$'/&*?J^M:M:ZC=-9FR
M%C8>1]HCFB=I9?,;G:P8!<+@\JV3Z5,GAQ%UH:@;C4FB2X:ZCLBT(@CF9"I<
M8&\G#,<%B,L3CIAL_ALW-S'-+?ZLP*Q+<Q@VX6[,9RK287(.>NPJ#TQBBP%7
M2M<U/4-0OX=1*6L8-PL%H^F3Q.R*Y5'\]FV/E0&*JN1N'ISU-M_QZP_[B_RK
M%71S!<2W<UUJ-TJ*Y@BN7B9+?<#N*D`.>./F9L#I6M;RN+:(""0_(.05YX^M
M/H+J6:*B\U_^?>3\U_QH\U_^?>3\U_QI6&2U2UB]DT[1;Z^BCCDDM[>25$DD
M"*Q520"QZ`XZ]JL>:_\`S[R?FO\`C5>^MX]1L)[*YM96AG0QN`R@X(^M%@.7
MLO$.NW^D7CPO:BXM95\V:72;J-A&4W96T+>:YSA1\P!Y(SMVDNM=\0SZ5H]Y
MI]WI,%QJ!2!;.:S>8F;YB_SK,N%558D;21M(Y/%:"^&Y%624:IK(U&0INU`-
M;B5E7=M0J$\ME&]N"AY.>N#5NTT2VLGL6AAN1]C$Q52R8=Y3N=V_VB=QXP/F
M;BBP%;Q1KUQI'V*VMG5+FZWD2&QFNP`@&<11$.V=PZ'@9)SBLO\`X2G6)$6^
M@;2WLK=[..ZCC21S*9MFYHI-R@*HD!`*$G!!Q6U=Z7=W^9)+J\M;F.9VMKBU
M\G?'&P`*?.K*0<=U/;GC-4O^$0MEFA\F;4XK./R#)9))$8YVB(*,Y(+DY"YP
MP!VC(/.2P#M)UK5KG4[5KLV36%_Y_P!G2*)UEB\MN-S%B'R,GA5P?6MZ#_C_
M`+O_`(!_*LG3]`73]1^UBXU&>-/,\BVF:'R[?>VYMNT!C[;F;`X&*TH9&%[=
M'R7).SC*\<?6FA%ZBHO-?_GWD_-?\:/-?_GWD_-?\:5AF*^OS/XKMM+MK=6L
MR)%GN6/_`"U50=B#O@?>/;('7.'^']9O-5OM:M[RT2U:PNU@1%?<2K0QR`L>
MF?WG;@>_6HCX4T(:Y#K,>@6T5_%(\IFBMX59W?JS-U)Y)SGJ34W]F2VLFIW.
MG_:([K4;F*>5G,95=JQQD*.>"D??N3R.,%@.?_X3/4X[[5%:&U:.W2[:")H)
M(4S"2%S=,?+D+8R54`IR#G::+7Q9J]U%;V226RZA<WRVL=Q/ID]NJCR7F+-;
MR.),8C90=V"?H16G)X1LIWD2Y^W3VA:5X;1S%Y=NT@8.R$`/D[W^\QQN.,4C
M^%$E4327NJ/J8D21=2(MO/78'50`$V8Q)(/N?QFBP%[1-4FU?PW)<W(C%S&]
MQ;3>6I5"\4CQL5!)(!*$@$G@UK6W_'K#_N+_`"K.L;%-(T0V,,=PZJLC-+*4
MW.[$L[MMP,EF).`.O2KMO*XMH@()#\@Y!7GCZT^@NI9HJ+S7_P"?>3\U_P`:
M/-?_`)]Y/S7_`!I6&8OC36M0\/\`A/4-4TVSBN;BVA>7$S[40*I)9L<GIT'4
MD<CJ-/4]033;)IVC>5R0D4*?>E<_=4>Y/X#DG@&H-9L(]<T2^TJYBN4@O('@
MD:)D#!6&"022,\^E0WNE1:O/-'K&FP:AI_[MH+:ZABE6.0;@SX;N0P'?H?6B
MP'-W'C/518::0+*UNIK:2YN";6>Z0%7"A`(_F5>I,AR%P/E.>-J3Q),WB73-
M-M889+69G2ZN0Y(601&0(GJ<#))Z`CC).((_!UC9V%O9Z8+W3(XE>-C9B!3*
MCG+*P*D<GN`&'8CFIF\(:`=6L]430+>*\M)/,69((@[G:5&YOO'&<CG.0#18
M"#7-?U6QU&_-G]B%CIEO#<7*S1.\DV]GR$(8!,*F<D-DG&!C)DN;WQ+!K<-I
MOTHQ7CS+"B0R.]K&J,5FD)<>8"P0%0%P9``QQDMD\-2WSQW%[>:@L\D$<-['
M`T/E701F8!@5R/O,,ILR#SVQ8LM"N;+6I]1&K:Q,)I"[VTPM3&1SA`PC#A5S
MP`WYY.2P!X8OM7U!]0DO[JPN;6&<V]O+:VKP;V0E9"0TKY`8%1TY4^U:]E_R
M\?\`7=OZ5#IEJ-+TV"RABN'2%=H>1D+-W)."!DGGI4MB<BX)!'[YN#VZ4^@A
M?^8K_P!L/_9JYBW-W_PEOBJUU#6[A;3[!:2HZLL2VBLUP#L[*<(,L<DD=0``
M.E<.=4^1E!\G^(9_B^HJK=6^FW#W\5Y_9<K-;I]M2:%6)A^<IY@)^Y_K,9X^
M]CO0P,"WANH+BTL;:ZOQ97FH++`+B[D>98(DWN2[DOM9PHVDGAN<`XI=/:>9
M_%=GK&MW*PV^H1()XY/(*(UO`Y1".4!+D?*=W/!SS5S0X_"4$!OM`?PY'"LG
MD&XL(H@H=R@V;D/5CY8QU)V^U7-1M=$FL]1_M-=&>U#K)??:84*;@JX:7<<9
M"A<%NP'M2&8L,%]YMGIIU34+2W;[3>"1Y=TT-N$$:*[R;B3NDWC=G[F#G!%4
M)+.Y34+"VMM0U5O#^HWT4`,E],93MAGD:19M_F*CLL2CD`[3CAAGHK#3_#4>
ME?\`$NAT!=-O5,7^CV\8AG4@DK\IPP(!..>]9\%KX!70[NXMQX1&D.Z+<R1P
MP>0S`_*'(.TD$\9]:`.=^T7MUH>HFZU/4+8:58WDMG<)>R1EC%<3(CN=W[W"
M1Q_?R#N).<UL0SZF_BJ+47GF%H;];5A]KDXS#_JOLV/+QO.[S<[^V,<UIW:>
M#_L^D->OX:\@`#2S-'#MQQCR,G']W[OM5XIHG_"4#,FC?\)!Y/'[M/M7E?\`
M?6_;^E`&EIW_`!X1?C_,U:JC8"8V4>UT"\\%">Y]ZL[9_P#GI'_W[/\`\53>
MXEL2T5%MG_YZ1_\`?L__`!5&V?\`YZ1_]^S_`/%4AG%1R7"^(+._-]>+<3:U
M/9/;-=.8FA6.0@"(G:"`BON`SUYP:EUXRMJFHW8OKR&;3_LGV:**Z=(VWOSN
MC!VON.5^8'IQ@UJQ1^'1XIF\E]"_X2%DS+LBC^UE,#[V#OQC'7MBH[FT\,6>
MJZ;;W2^'X-1B4)I\<L$:RHHZ"($Y`'HM`&/H_B*YU;Q5?+/_`&E!#)8,T-G<
M6$\"1!6(W$N@!=AR3G'0#H2>WMO^/6'_`'%_E52X">;+F2U-UY!R`G[SR_SS
MC/X9J>W6?[-%B2,#8,90^GUI]!=2S146V?\`YZ1_]^S_`/%4;9_^>D?_`'[/
M_P`52&2U5U$QC3;GS;UK*/RF#72LJF$8^\"P*@CKR"*EVS_\](_^_9_^*J&[
ME6VLYIKVYM8K5$)E>9=J*O<L2V`/K0!P$JW]K=2Z-)-J$L4=ZD@L[?5G\^>)
MXI-J1W$KHQ;=&9&3>,`8!*\%;F_OIO"BZRUW<+>Z?')/+:)J!5H[999-LFQ1
M^^=D0*!(=I()!R#G36_^'W]BR62:CX/_`+*$B^9`#;^1O.2N5W;<G:2._P`I
M]*T)KKPM=QZ7>SWOAV9&?R].G<1,"P.W;"Q;KD8POIB@!_B4332Z<J?:I;=R
MYDMK2\^S32'`*L&WH=J\E@#Z<'I7(6.H:CJ&D0ZU=WU[!?P2::D,:W;K'(LI
MCW;HP0CE][#)7/I@BNQU2ST2QL)9-=ETI;.2Y\\MJ,:",2GH1O.`>..])<KX
M;/B&R>[DT$ZV4'V-I8X_M)7G'EY;=CENGO0!F:$95U;3;S[=>2RW_P!K^TPR
MW3R1C8_&V,DJFT_+\H'7G)KJX/\`C_N_^`?RK*TU?#XUV^_LN30_[7_Y?/LL
M<?VCK_RTVMNZ^M:,(F^VW6'3=\F3L//'UIH1>HJ+;/\`\](_^_9_^*HVS_\`
M/2/_`+]G_P"*I#.;U"XO[;Q_IZ?;S]BFTV\D%LWR1JT;089CW/SMSV';J3#X
M,M[O32++4I7N;V2UCF:[75)[N.?'!<+(`L66)(5.,=^*VFNM.DUQ+1KW3&U>
M*)BL)VF=(VP6PN[<%.U<]C@>E5XM!TKR+NSL8-.MU>=)+E+2V1"9`0XW@'KT
M.3S@Y'K0!@7>GG^V]<NM.U.ZMO[.M77?=:O<&W^U2H6^=&9E145D88'\?3Y1
M5&XEU.P6V\/6]M<-=37L:W3/K5U*KQO#,RXN6&^(EH1D*.,C&=PKK?[4T.&X
MU*#^U-&CFCS-J$>Y`R_*%+2C=D?*%&6[`5FVUYX(_L&[M[2_\*_V-&5^TQQ>
M3]G4N?EW@-M&2.,]<4`:'ARX-QX2&YK@O#Y\#^?,9F#1NZ$>80"X!4@,1DC!
M/)-;5M_QZP_[B_RJG"(O[(4V,EH;+R?W7V=!LV8XVX.,?2K%NL_V:+$D8&P8
MRA]/K3Z"ZEFBHML__/2/_OV?_BJ-L_\`STC_`._9_P#BJ0SG/B(]]#X!UFXT
M_4);&:"TEF\V$#>0J$X5OX<G'(YQG&#R.AO(II[22*WN/L\K#`E"!BGJ0#QG
M'3/Y'I4&HK#_`&;<_P!IR67V'RV^T?:8QY7EX^;?N;&W'7/%$=B8;ZXO5DC$
MLZ(CGR^,)NQW_P!HT`<)&DNN>`/"1FU#4TU;4[>&%+FWU">$J6C\R20A&"LP
M56(W`C.!WQ743QW=MXMTF,7\YLVMYD%L3P2H3YF8\LW7DG\,\TD^K>&]&@T]
M;C5M!L85CS8B1XXE"8QF/+`8P<?+VK4W12S6TGGV;RNC-;ML!9E(&2AW=,8S
MCVH`Q_$-D;N_06>I7Z:J546\,-RRQ0C)S))&I`93R/GSG`"X)J./3Y3XHCGT
MW5K^8I-*^H&:X:2`*58)"L>0BLK%#\H#83YB2V2RYT/PC:W6GV>J0^'WOR@C
MM?MUO$9Y`IXV;CDX)Z+P*FL]/\*+XEF-E#X=&O1,TDODV\7VI"P^9FP=X)#<
MD]<^]`%KPO\`:UBU.*\OI;R6*_=/-D`'&U3@`<`#/`_F<FM.R_Y>/^N[?TI+
M=5W3?9I+7/F'SO+C_CP,[L-][&.O/2BQSBXR03YS9Q^%/H(7_F*_]L/_`&:N
M.N/#L']M^,XVL+P66IZ9;+,]LN7G8FY$@5FX9@K*,=@5'I77N@?5,$L/W/\`
M"Q'\7M60/%&CFZUJ`/>'^QX4EN9`'*G=O&U.<N08V!P,9X!)R`,#,L6OM3U+
M3[5WU.YTZ.Y-TMS?6)@<B-,;&7RTVX=T*Y4$[&ZXS3+.WM_#DGBJ>71;NXM/
M[3@FMX8K5YVE;[/!^\48);#AB6&<$'N*VH]93[,LEUI>JV<S74=L+>=AO)<C
M#`K(4*@$DD,<!3QGBF0>(]/O;?49=/@U&]-C<+;M'`&W2NRJPV98#;AU^8D+
MWSCFD,P[:WM+V7[7<Z;=7%G''=7UY%+ILR^9.ZB/8D4B`M^[,@QCYL^YJH\T
M=YJ]GXE2PU2(PWD/VNW_`+*ND9+=8;A(@$,>9&#RY;8#MX_N@GI1XEL!;(\E
MKJ:3F>2W>U"M)+&Z1F1@0C,#\HXVDY+*!DFJQ\76JR&UETC6(M4W1!-.>2/S
MI!('*E3YOEXQ%(3EP1L.1TR`<L;6YM=%U&.[TS4;A=5L+V*R@2QED*>9<3.B
M/\O[K*R1??V@;3DC;6Q#872>*X@ZWYF6_6Y,'V8_9"OD^69_.V?ZS;D;=^/]
MC^*M";QEI\6GI>1Z?JL\:PR3W2PNI:T2-RC^8/,Y(97&$W'Y3C-7AK]DVM#3
MEM[XH9OLPNQ(/*\[R_-\O[^_.SG.W;[YH`UM._X\(OQ_F:M51L(5>RC8E\G/
M1V'<^AJS]G3^])_W];_&F]Q+8EHJ+[.G]Z3_`+^M_C1]G3^])_W];_&D,XF.
M.5O$%K8FQO3=6^MSWKW)M)!$L+128(E(VMD.J8!)[8P#A=6E^U7E[&EAJ$CZ
MFMF]I)]@EVJ%?/SL5_=%3\V'VGGCFMA?$%HVMIIQL]16.2=K6.]+CR'F52Q0
M8?>#A6Y*@9!&<T[4=>MM.U'[(UEJ4T:>7Y]S"X,5OYC;5W9<,>?[JM@<G%`&
M'H^G:_;>*KZ]U;3[)7N;!O.NK>[DE!(;Y$`:)0`!P%SZGDDUV]M_QZP_[B_R
MK"LM935VO5MM-U%;2%IHA>R2IY4CQN48*!(7^\K#E`#@^V=FW@0VT1)DY0=)
M&';ZT^@NI9HJ+[.G]Z3_`+^M_C1]G3^])_W];_&D,EI"<`GGCTJ/[.G]Z3_O
MZW^-5[^6UTW3KF_N7F$%M$TTA5W8A5!)P`<G@=*`.:A74HO`\E['!>1ZQK#H
M[GR?WUL9G5%W+CCR489R.!&<]ZS/$6C7MAJ,XTX77V5M+AM;&SALQ<0SRHTI
M,<VZ-A&C;H\ME<_WN*Z!?$#/9RS)H.L--"P$UM]H@#QJ5W!RQG"8QZ,3ZBJ;
M>-;)+*&Z?2=82,VPO+D-)&#9P%F59)1YO0A68;=QPIX'2@"3Q--]J>TEBFU&
MWBM994GN=/M#//$^T`*(S&^5(8Y;:<8'(S7.VUE<VVGQZ/-I-VMW,^F/;+%:
M2-%`D1CSF7!1"GENV"V>>,D\]EX@U;2O">B7.J7HN!!&&<I;[F>1L$G`!Y.`
M22<`8))`&:BO_$%II^I_8WL]1DB62**:[C<&*!Y2`@;+AN25Y"D#<"<"@#,T
M%';5M-MOL-W%/I_VL7,TMH\<9WOQMD("ON.&^4GISBNK@_X_[O\`X!_*LG3]
M>MM0U,68LM2A1_,^SW,KCRKCRVVMMPY8=?X@N1R,UI0PJ;VZ7+X&S^-O3ZTT
M(O45%]G3^])_W];_`!H^SI_>D_[^M_C2&<KJ$$=SXMTW[-9WT=Q:7AG=#9E;
M:3=&R-,9@N"X5BH!?/JO0A_A^UB\/ZCXI=[>6WLGU*)HF,;MYFZW@4L#R6^?
M=EN>0<G@UJ7&K:=;:W!H[/<->31/-M1G8(B]VP>,\X'4X/I4&EZK::Y<W-C-
MI]_:7%ND4Y@O2,LC%O+<!7;',;<-A@5Y`XH`P]$BE75;"T^PWD,]A>W\US(]
MHZ1NDCR%2LF-K[BR-@$GCG!%36]RNE^&;76M0T>]N]3OKC[7Y?V%Y9;:1U;:
M&"(S($C/ED@9`R.2>=$^([91J4[Z?J:Z?IXE\V^\Q#&[1\,JJ)#(3D$?<&2/
MI3/^$EB%K*SZ1J\=['-'#]@:6/SF,G*D'S=F,`G[W\)[C%`%K0+>VMO"NVT$
MX1_.E;SK:2W8R.[.Y\N0!E!9FP".F.O6MBV_X]8?]Q?Y550&?3#/);W-K(T9
M)@FE#,AQT.UF4_@2*FMX$-M$29.4'21AV^M/H+J6:*B^SI_>D_[^M_C1]G3^
M])_W];_&D,YSXB:2NL^`=9MOLCW<PM)7@A12Q:4(=N%'WCGH.><$<@5MW`LM
M2:YTN<&3:B--$0P!5B<<]"#M((SVP>M4?$>M:;X7T6?5=0:Z,,*D[(2[NY`)
MPHSZ`G)P``22`,U?G2SLH9[R=_)C1-\LK2,,*HZDY[<T`<?I&G7LOP^\(Z%<
M64R1SP01:BDD9!CB2(LR.".-S*J$''#&MVZTN-?&6F:C%:DR>1/').%)VKA-
MJY_A'!XXR:K?\)39RV5E<66G:O>F[A>X$,`Q)'$I`+,'=>Y'RC+'LIP<7Y]7
MTZWUK3])9KDW=\K/&H9_D55+9?GY<X(`ZD@^AP`8NMZKI>H2BQ_LZ_:&_BC-
MQ>Q:5<2!HPQPFY(R0P.?O8VY)Z\4L4VFZGXIM[4:7?V26%S/)"?[,GB26=E=
M7D\T($"D._);+,V>PW7K_6[#1;S^SUL+]X;>*-YY;=@(;5'8JF[+@_PGA0V`
M,G`Q22^(X8=0%H^D:RIEED@M9&*HMU*BLQ1-T@(R$;#.%4XR&P02`6/"^FII
M46IVT-J;:#[>[1+M(!4JOS#/7)SSW.:T[+_EX_Z[M_2LS1=7&L7-[;OI>IV#
MV;*DGVF:-@6(SM!CE<9`()!Q]X5I6(P+@#/$S=3GTI]!".Z1ZIEW51Y.,L<?
MQ5S^HZ$-0U+7YFO+58=1L+:VB^<DJ\33,2PXX_>+T.>#TXKHO^8K_P!L/_9J
MQ;36-8O_`!%KVD^1:V7V.WMY+.60&8MYC3`LZAEX_=#"@YQU.3@#`SM'T&2U
MU.UGE@T>PLXIGN?L5C.62.79Y:LN40'(:0MP,';UY-6S::II\WB*[TN;3)+K
M4;R*:W6XG9%5%@BC;<0IPW[MB,`CD9[BH--UW79+6%KJ73IVO-36ULI(;62(
M20KDRN4,C$$A)-ISC&TG.<5;T_6=;U8Z[;0VMG9WEC>);Q>>S2*J-%')N?:1
MN8"0_*"!QC=WI#*UC9:E$Z7DB:7'=6UK,L$0OWF66>0J3)(YB4_P@<*<;C@=
M*I#3=<F:VU"YAT;^U;2\6[4C5'9+@F*2)E)\@&-563*@!N>O)).A#KVMR"VM
M(X;">^DGN$$N6BAFCBC_`-8HRQ4&1D0\MC)//%5)?$'B.WU--%DDTR2[GN8K
M>+4([5_)1S%+*Z-%YNXLJQ+_`!C/FKP,4`4_^$;U6UT^XBLY=):?4K:XAO&F
MNW"V[2S22YC`C_>`&9Q@[,[1R,G&A'X?,7B2.\4:9M242#4C+_I8C"X\C&S&
MS_@>.?NYYJG_`,)?KMSIES-9C3EN=-MKB:\6:!RL[0S21%8\2?NPQA<Y._&1
MP>:OQ^*;^7Q9'9+'$+%YQ"%-M)G!BW[_`+1GR]V[Y?*QO[YQ0!T5A/"EE&K2
MHK#/!8#N:L_:8/\`GO'_`-]BHM._X\(OQ_F:M4WN);$7VF#_`)[Q_P#?8H^T
MP?\`/>/_`+[%2T4AG'1:5?+K42&335TJ#49=0647+&=V='^0IL"J`TA.[<>`
M..>"^L-4O+F8#^R4M]06W-X3>.6@9#\PC'EXD!&`"2GKCM75W4XM;.:X89$4
M;.1ZX&:P]`U/5[B]%OJS6,GG6D=W"UK$\>P,2"C;F;=CCYAC//`H`I6FD?9]
M7GO?L>B605)`9]/;$EX&S@2+L&W&<_>?)]*Z:WN(%MH@9HP0@!!8>E9?]IWL
MNNZAITUK'%:QV8EA??N>0EF4D@<*..!R?7'2MBV_X]8?]Q?Y4^@NH?:8/^>\
M?_?8H^TP?\]X_P#OL5+12&1?:8/^>\?_`'V*I:NB:AH]Y9P7R02SPM&LH?E2
M1C/%1>)=0O\`3=%>XTVW,]T98HU'D/,$5G4,Y1,,P52S8!&<8HTS5E;P^=0O
M[V&3RPQFE6TDM0N#T,4C,ZD#'!.3Z<XH`YJ#PS(NBZC90PZ+ID.H/`DVGV<N
M;98P^)F!$:$N\9*_=Q\J\]34_B70KK4;O4QI\FGFVU?34TVZ::Z,;0(ID^>-
M0C!CB9N"5Y4<]:CF\7:P=-EE^R0V<_\`:ILU5K>2Z>*+RO,#&&,AY'Z`JI&W
M)/(4DRW?C6XCT?2)K:WAEO+J:T%TI#!8(I9UB)(SD,22`IY!#9^Z00#0U^&3
MQ#X1US2(6@MYKB":T@::7Y6RN`QXR!D^AZ<9JGJFE7USJMVEM)IO]G7UQ;7%
MQ-+<L)8S$5W*L83#9$:@$N,$DX.,'5\47FHZ=I+WNGW=I`8OO)<6C3F5B0$1
M0LL>"6(')/4=*QI=?\0VKEYSIC)8RVEO?Q)!(&D>4IO:-M^%"B0$`ALX/(H`
ML:1IU];:C:K=R:<MC8>?]GDAN6:27>W&Y2H"8&<X9LGTK>AGA%[=,94"MLP=
MPYXK%TG6M6N=3M6NS9-87_G_`&=(HG66+RVXW,6(?(R>%7!]:WH/^/\`N_\`
M@'\J:$2_:8/^>\?_`'V*/M,'_/>/_OL5+7+^)]:U33M1M8;22.UM&B=Y[N;2
MI[Q%;*A0?*90@QO)9C@8'2D,K_\`"-R0^)HM6MO$<[(9IIY8)_(*Y==JJ"(P
MY48`P7R`!@T^RBN].O;W5IK32XKB<1QO!87#$7+;P#,^4&&`/3#<#EL<BW+X
MCE;Q)!86L$<EELE\ZZ9\`R*H8(O;@?>/09`ZYQ7\(^(M0UJ:>._2-<013KMM
M9+<H6+90"0GS0N!^]7"MGB@#*U'PK)J$MZL46A::TBSXO+/A[K>K[5F38,`,
MX<X=MS+GC.*M3Z5?7XN[S4+#PY<W$[Q*UC<3M-`T:(XXD:,%6)D/.QAC([Y&
M@FOWNH^(Y],T]+>*U^QR/!>2H9`\R.JGY0RY0;L=020>@&3E0>(/$;K%$UWI
M4C7VI&PL;D:=*B#RTD>5VC,Q+`F)E7##IGD&@#<T6RCT?PZU@UQ"2#,Z1QN"
MD2N[,L2=/E0,%'`X4<#I6K;W$"VT0,T8(0`@L/2LW1-4FU?PW)<W(C%S&]Q;
M3>6I5"\4CQL5!)(!*$@$G@UK6W_'K#_N+_*GT%U#[3!_SWC_`.^Q1]I@_P">
M\?\`WV*EHI#,/Q5:#7/">KZ5;7-LD]Y:2P1M+)A0S*0"2,G'/I4>KVZZ\[V#
M7T]A#;O#<)<VSQ,96^;Y"LB,N%(5NAYQTQ5W6GU..U\S3[K3[14#/-<7L;2*
MB@9^ZK)[Y)88QT-9UWKU]!X/L]4FBM]/NIUB\]KK<8K3=C<SC*G:OH2O;)%`
M'/OX.E73K.*:33-8N(X9(&.HRA1%N?<LB;(\%E[#:IYX8=]$>%GB\1:?J<7B
M2YD2*X,UQ%*T)#?NC&`I\O=CH,%N`3CFE7Q!K%YH<NH:?>:0T=DTB33M!(ZW
M3+C:(E#C:&SP=S\D`!NM"^*M2_X2M-/EABBMC+'`8_LLKD%H@Y+7`/EHP)VB
M,C<>"#\P%`$-[8ZEJ[W,T:Z?%;:O:0PW:3W3++;[&?)4;#ORK]#LP1SUP-&V
M.LR>)#<ZC#I#64;.MO)%J+EXHSG#>48L%SP"=_`)`[[H]<U_5;'4;\V?V(6.
MF6\-Q<K-$[R3;V?(0A@$PJ9R0V2<8&,E(-?U.3Q%=64DD$"EY8[*VN--N(O/
M95)'^DD^6<[6;:JD[02,@9H`U/#]LFEZ1'!<7$#73N\UPR2[@TKL78@GG&2<
M>V*NV)#"X(((,S$$?A67X<UB\O[K4;&_>![FS=06BMY+?<&SSY<A+;<JP#YV
MM@D=*U;+_EX_Z[M_2GT$-=BNJ9",_P"YZ+C^][U6738TU:^U)4NA/>V\5N^&
M3"K&9"I7T/[ULYST'XV_^8K_`-L/_9JXV[NM3M-9\9I)J]PVW3;62UPH"VK.
MUPHV+T_A7+$Y..N``!@=%9Z+;V(TE((KI8M+MC;P1;H]I!"J&;_:`7`Q@?,W
M'3$%UX>6>/5A!<ZG9R:I/'/-+;R1!E*QI'A=P(VE8QD$'.3ZUA::VHPWL>@S
M3313-J,<S1IJ$MSY4"1B0@3R`2.&=0"I`P),?=ZVM/:>9_%=GK&MW*PV^H1(
M)XY/(*(UO`Y1".4!+D?*=W/!SS2&:5MX?>"-]VH:I+/]E:UBN&%LCP(V#\@1
M%4'A>JG[HJK%X2DCLHK=M8UJ1X)EGMIV6T\R!P&#,I$0#%@[!BX;.3W)-5%B
MOU^PZ5_:M[:0S27%WOEE+7$-HL>U0SOGD22(WSYZ8.<&JYLIXY(XK;4=4.A7
MUW;VZ&6^F:4X61GD28MY@1SY:CD?=)'#`D`T9O!=O)9I:QWFK6Z-#)#=&%H`
MUXLCEW\PE3@EF<Y38?G.,<8OC0(EU,72O?"W$HG^P@P^3YH&`_3?GOC=MSSB
MN*DEN9M,UA)-9U&./2+2\DLKE;Z126CGE4&0AOWNP(B_/N!YSDFM>&?4W\51
M:B\\PM#?K:L/M<G&8?\`5?9L>7C>=WFYW]L8YH`Z^PD9;*,"%V'/(*^I]35G
MS7_Y]Y/S7_&HM._X\(OQ_F:M4WN);$7FO_S[R?FO^-'FO_S[R?FO^-2T4AD$
MA,L3QO;2%'4JPRO(/XUB:;X??3<LNHZM/+LCBCDF-N6CB1L^6,(!@\@D@MC^
M($`C'CDN%\06=^;Z\6XFUJ>R>V:Z<Q-"L<A`$1.T$!%?<!GKS@U+KQE;5-1N
MQ?7D,VG_`&3[-%%=.D;;WYW1@[7W'*_,#TXP:`.BGM5^USZAY4XE:V\@@LNT
M*"6SUSGFK5O*XMH@()#\@Y!7GCZURUOID4GB[4I[:[U'R-/B*RQOJEQ+')<2
MJ6(,;.4`5&4@`=7Z#:*ZVV_X]8?]Q?Y4^@NH>:__`#[R?FO^-'FO_P`^\GYK
M_C4M%(90U""6^M#"CWMH^0RS6[H'0CZY4_1@0?2LZ/1"H6UN$DOM/ECE^VQW
M:0O]JE8IM=P%`X"L,#`Y'!XQH:U';2Z:ZWE[/:6^Y=\D$QB=N?NAE^89/'RD
M,<X!K'\G4;#P-J0^WO:S"*=[:>]GW-;Q\E/,D?/(')+9QW)Q0`R'P5I5BDO]
MD6LVDS/<_:4FL8[=&B;9LVJ"I7;MW<$'[Q(IE[X!\-ZA9PP76A12R1RI*;EX
M(6F<B7S6#,0>'8MN'0AV'&:Q&FD&G:S#<6FL6T%FMN;*&YUJ43/<RED"--%*
MQVDF+`WMC=G`Z5N76G7VC:=H%M%K%X\<%W#'.9)#))<EGYWR.2VWD\9]!G`Q
M0!K26,MXH6^65TBO%N(538``I!13ZX(SZ].>*J7WAU+_`%4WCW&I1PN\,LUG
M$T(BF>(@HS$@OU"Y`8`A0"",Y;XKLK[43I]O93H&65Y7MO[3FL6G`4K@/$"^
M`6#$=,@9KFC>-=VYU:WO-1MFM)].ALX6OI"KQR-&&#J6Q*6WLNYLDX!!S0!U
M.GZ`NGZC]K%QJ,\:>9Y%M,T/EV^]MS;=H#'VW,V!P,5I0R,+VZ/DN2=G&5XX
M^M<QH1E75M-O/MUY++?_`&O[3#+=/)&-C\;8R2J;3\OR@=><FNK@_P"/^[_X
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MM9-:=W9W4<]YH=AJ,K0F>V:(7FL3QR2DI([Q).-TF3Y:M@=BQZ<4`=38V*:1
MHAL88[AU59&:64IN=V)9W;;@9+,2<`=>E7;>5Q;1`02'Y!R"O/'UK,T*[6[\
M,$B&:%H3/;.DMP\Y#QNT;8D?YG4E20QY(QP.E:]M_P`>L/\`N+_*GT%U#S7_
M`.?>3\U_QH\U_P#GWD_-?\:EHI#,/7-(EUL6H%[J=B+>3S,6I@(D/;>LBN#C
MJ..#SU`P/IVHSPRV\NHZB$\N(0W$;0I,LBDEG.%"G=\N5*E>#QSBG>(X;2:V
MB2ZN[^/+$16UC=-!)</C@`H58D8)^\!C);@<4;Z&_@\+:38:C?3&YEEM[>\N
M8)3&[9(#8==I&3QD8//&*`$E\*R-]E,&KZU;20,\C/&;5O.D8Y,CJ\;+N]-H
M``X`%6&\.12:A]IDDOWA::.YDM&\GRI)TV[93\NX,"BG`8+E0<5Q^K:_>Z7I
M<VF6]QJXAMKIS]N2VN+IFC67`B\U5;GJ"6.[``ZMD:5W>ZC#XH:>`7ETSZE;
MP)(EZ!;V\#B/?$\&_(EP7?+1YPP^8#``!K2>&I;YX[B]O-06>2".&]C@:'RK
MH(S,`P*Y'WF&4V9!Y[8GF\-QW-RTES<ZM-$'DEAA:X0"WD=74O&XQ(#B1P/G
M(7/R@8&,?Q%>7X\2WA(N!8Z;:V]QF"_:W9=S2[F"*I$Q.T#:^%XXYJ:Y&SQ1
M:[+^[N=/U26>SDDAU%V*RA9"4"+A80@C8;T._=@-SS0!N:9I7]G7,]W))?7M
MY,B1/<7)BW^6I8JGR!1@%V[9YY)J[8G(N"01^^;@]NE87@RR"07NHK/?M!=S
M,+:*ZOIKD)$A*JP,CM@O@MQV*CM6]9?\O'_7=OZ4^@B.;SO[2'D[-WD\[\XQ
MGVJLYB%U>E_[*^T>0GVO=C?Y/S[?,[[?]9C/'WO>KO\`S%?^V'_LU<?/H"1:
M]XP:.PN1!>Z?:.7BCWF>4/<%L;B`Y`*`KGIM'`Q3;`U-)71+>P@O=&'AV.S5
MS##/9A!&&D=5**R\99@@P.I"]\5+J-OIDUGJ/]IPZ$]J'62^^TJI3<%7#2[N
M,A0N"W8#VK!TJ+4]4UZ&:\$[V\UR+II3ILEHA\F/:`4DRR$NZD;CD^62.!4U
MG;V_AR3Q5/+HMW<6G]IP36\,5J\[2M]G@_>*,$MAPQ+#."#W%*X6-*QL=#31
M\Z?:^'%TRZ5H_P#1XT$,RMU7CY6!QR.^*H6MMX,&AWD]I!X/_LARHNY(DA\A
MBIRHD(^4X)XST)JO';VM_P"5<7&FWMQ9*;K4;V-]/F19)C&(A$L,B!G!1WXQ
M\Q&>IJ'SX+RZ_P"$A73]4CD2ZM?M-N=*N598$$HC`4Q@R,&D+,4!V\=@"2X6
M-2Y7PK]FTAKH>%/LXXTLR^5MZC_49XZ[?N^U7R-+_P"$H&1H/_"0>3Q]W[5Y
M7_H>W]*XN2WEAT[5Q+H^HR0ZO9WL=E;)82,0TD\K`.`N(M^]&^?;[X(.->&P
MND\5Q!UOS,M^MR8/LQ^R%?)\LS^=L_UFW(V[\?['\5%PL=;9?:_LB>5Y&SG&
M[.>M3_Z?_P!.W_CU&G?\>$7X_P`S5JFWJ"*O^G_].W_CU'^G_P#3M_X]5JBE
M<+'-1+HH\4S>2OA[_A(63,NP)]K*8'WL?/C&.O;%1W-MH%GJNFV]U!X;@U&)
M0FGQRI&LJ*.@B!Y`'HM9L<<K>(+6Q-C>FZM];GO7N3:2")86BDP1*1M;(=4P
M"3VQ@'"ZM+]JO+V-+#4)'U-;-[23[!+M4*^?G8K^Z*GYL/M//'-%PL;JW=LM
MY?64%QI0OF7SKJ"%QYQ^4+O91SG"J,GL`.U7X/MOV>/9]GV[!C.[.,5QVC6F
MH6>HO;S_`&J5TGO))EFL@L,*2/(RO%-LRS-E`0'/!.57%=U;?\>L/^XO\J=]
M`(O]/_Z=O_'J/]/_`.G;_P`>JU12N%C+U#3?[5M#:ZE9:;>6Q(8Q7,7F)D=#
MA@15"RT6PM4M[W3[;2+>TBMY5C%M&J0^7(49S\HQ@[![>M;MW:07UK);7*>9
M#(,.F2`P]#CM[=ZX6S@G7X06.@/:W`U.70"!:-"P9MD:JZ'(P&RP&TD$Y]C@
MN%C3M;OPU;>'O.M+CPO%HD,RMOA>-;9)0P*G(^4,&`([YQ6G=ZC;*;-+R]T@
M&X<-:B:4?O6'(*9/)[C%<^;BVGN]1U;^S]6BM93#';SQZ4YGMI5C=6E6)XR_
M1@FX(WO\N36)=:9JJ:9';_9;V!AI_D6<-M;F1;QA+(4CN248PKM$1)RF#(XW
M<#!<+'7ZM8Z5:Z9<-KZZ*;"6X\V0ZD%\KS#T^_\`+GCZTVX&@G7[![@>'/[9
M,8^Q&39]H*<X\O/S8Y.,>]5_$S2W-U87D-WJ%O!9O-#<O861N)4D95QA#&^1
MU&[:>&[9R,*.VNX[0:7<:1<)>W4NFRP+;V#""!8S'N^=1Y<>S8[;=W&>,Y&2
MX6.ITT:.-=OO[+_X1_\`M?\`Y?/LNS[1U_Y:;?FZ^M:<7VO[7<;?(W_+NSG'
M3C%<WH*.VK:;;?8;N*?3_M8N9I;1XXSO?C;(0%?<<-\I/3G%=7!_Q_W?_`/Y
M4TP#_3_^G;_QZLS4O#EEK,R3:IHNBWTJ+L5[JU65E7.<`L#@9)K=HI7"QS?E
M:/%XF4;/#Z:^8LKP@NC'C''\>W`QZ<5!IUIHFHVM[!HG]@F-IU>[_L[9S(K!
MOGV_Q9'?GZ5G?9;BV\472RQWDXEOVNFMSIPDMWB,07S/-V']X`NT*'!XQM(.
M:O:)JEA<75QJSV=_8!((K9()],G@\J/=A02R`,<MT4D*!]22X6+-K!HTFNWZ
MVD7A]M7*[;T1*AN"I[28^;!X^]37TW0K#0KF![+PY;Z.CDW$;1(EN&'!WC&W
M(]ZJ10)<>+K?['8WL$</VB*ZAEM3!#$K[F:6*15`=W<(3AVX).%.:S[K1;JS
MTNU6R6[T^TL]<GN)/L=OOD$)250R1[6W_,ZG[K>N#BBX6.LMW,FD(]BU@U@T
M.8FMCE"F.-F.,8Z8XJQ!]M^SQ[/L^W8,9W9QBL_P^ES'X4VW4/ER`S[<PB)G
M3>Y1W0`!79<,PP/F8\"MFV_X]8?]Q?Y4[Z`1?Z?_`-.W_CU'^G_].W_CU6J*
M5PL8.MZ98W]IY^OV.BW%M:JTGF7\2ND(Q\S9<848')]JJWVG:1I-A</J4>B6
MNF2Q16\D=T%2W"(3L7#87JQX^E'Q$TE=9\`ZS;?9'NYA:2O!"BEBTH0[<*/O
M'/0<\X(Y`K3U?5)+;3]473XGN-2M;7S8X`C?,S!MG..<E3TSC%%PL9":WX;L
M]#@5-4\,0:0Q,<(6XC6`E>2J\[<CK@=*N/\`V:OB*&1_[#&N20XB9MOVEH_1
M3]XK].*Q]1T>#1#ICVTVLQ7MO;2Q17%C9K.LLDC(\GFCRWVEW0$L0HZ_,*@M
M;75H?$DS72W+7%S?PW/V<68>U\ORHE9S,4.UTVN%&]3Q]TYS1<+&O):Z1ITN
MDV-\=#%W%QIZW>SSLCJ8P<'/3[HJ>#^S$UZ[>W_L)=95`;HQ[1<!.V_'S8^M
M<[XB2;4=6DO=/6_S=6<`M4@M&,5ZT<COY=PYC8PJ"1SE#\S<G``L:F(Y==CD
M32+Y[6W-RM_82Z;F%XF23=+&57$KR,$&W<V0QRJG-%PL=#H]_;7UBO\`8EWI
M%Q9Q?NU^Q2!XTQ_"-IP/I5^PW;)]^-WG-G'3/%8?A>:VU'4=1U9;2\M;J>.&
M)HKBQFMPD2;]BYD50[99R2N0,@=`"=VR_P"7C_KNW]*.@$<T7FZD%\QT_<YR
MAP>M8:Z]&+M[>:RUZ%S"\UOOC4FY5"`VQ5)8'YEX<*>?8XWG=(]4R[JH\G&6
M./XJYJV/B47%[>7-OX?:_,+I:2C49&2,9!5-GD@J#@%B&))`[`!7J!:AUJ)X
MR)X-7M;I;F*V:TE:,R!I"-K95BA7!+$ACPIXSQ1!KUE>V^HRZ>=5O38W"V[1
MP+\TKLJL-F<#;AU^8D+WSCFJ^FV%_)J%E<:K'I<7D327,KPWS3O-,4$:,<Q(
M``K.,=L+CVE-IJFGS>(KO2YM,DNM1O(IK=;B=D546"*-MQ"G#?NV(P".1GN*
M5V&@H\068MD>1=82<SR6[VH3S)8W2,R,"$+`_*.-I.2R@9)JL?%,*R&UEL-<
MBU3=$$TYWA\Z02!RI4^9Y>,12$Y<$;#D=,OL;+4HG2\D32X[JVM9E@B%^\RR
MSR%29)',2G^$#A3C<<#I5(:;KDS6VH7,.C?VK:7BW:D:H[)<$Q21,I/D`QJJ
MR94`-SUY))+L-"S-XMLHM/2\CM]:GC6&2>Z6%HRUHD;E'\P;^2&5QA-Q^4XS
M5X:U:MK0TY?[3*&;[,+L.GE>=Y?F^7][?G9SG;M]\U@_\(WJMKI]Q%9RZ2T^
MI6UQ#>--=N%MVEFDES&!'^\`,SC!V9VCD9.-"/P^8O$D=XHTS:DHD&I&7_2Q
M&%QY&-F-G_`\<_=SS1=AH=%96OF6B/Y\ZYSPKX`YJ?[%_P!/5S_W\J.PGA2R
MC5I45AG@L!W-6?M,'_/>/_OL4W>X*Q%]B_Z>KG_OY1]B_P"GJY_[^5+]I@_Y
M[Q_]]BC[3!_SWC_[[%*[#0YU=;MVUM-.,>K+').UK'>ED\AYE4L4&&W@X5N2
MH&01G-.U'6(=.U'[(T6K31IY?GW,+(8K?S&VKNRP8\_W5;`Y.*IQ:5?+K42&
M335TJ#49=0647+&=V='^0IL"J`TA.[<>`..>"^L-4O+F8#^R4M]06W-X3>.6
M@9#\PC'EXD!&`"2GKCM1=AH3IJ\DNL2:3-I>M6\GD23"::2!HBBG&3LD8C<3
MP"`3@^AQN06FZWC;[1<#*`X#\#BJ%K:BWNM;O9[F"26]<>5L892)8PJI_P!]
M;V[_`'ZU+>X@6VB!FC!"`$%AZ4];!H)]B_Z>KG_OY1]B_P"GJY_[^5+]I@_Y
M[Q_]]BC[3!_SWC_[[%*[#0B^Q?\`3U<_]_*J:A':Z=9W&J74]P$M('D>1?F9
M8P-S`8&?X1P.N!6A]I@_Y[Q_]]BJ6KHFH:/>6<%\D$L\+1K*'Y4D8SQ1=AH8
MA\0HMNNZPUM;UYUMTL-\)E9F0R#YA)Y8&Q6/+CICJ0#'=>*[&VB298]6GA%L
MMW<R1O$!:1%BH>3<X.,J_P!T-PAK,'A)A:N4TWP]%`TZ2OH23?Z#(51U+LWD
M_>.Y#S&1F)>_(;/X2OX["[L;6YTZ2#4M-&FW)DNC']EC#RE1"HC(<*DY4`[>
M$7WHNPT.D\0:CIOA/1+G5+V>\$$89REN-SR-@DX`ZG`)).`,$D@#-17^MV^G
MZG]C>/5I(EDBBFNXV0Q0/*0$#98-R2O(4@;@3@4_7X9/$/A'7-(A:"WFN()K
M2!II?E;*X#'C(&3Z'IQFJ>J:5?7.JW:6TFF_V=?7%M<7$TMRPEC,17<JQA,-
MD1J`2XP23@XP2[#0MZ?K$.H:F+,1:M"C^9]GN963RKCRVVMMPQ8=?X@N1R,U
MJ16NZ[N$\^<;=O(?D\=ZQ-(TZ^MM1M5NY-.6QL//^SR0W+-)+O;C<I4!,#.<
M,V3Z5O0SPB]NF,J!6V8.X<\4U<-"3[%_T]7/_?RC[%_T]7/_`'\J7[3!_P`]
MX_\`OL4?:8/^>\?_`'V*5V&AAIJ22ZR^GQ0:Q)''+Y$EZFTPI)M#;3SOZ$?-
MMVY.-V<BETR]TWQ"U]%:W%U,EE<+%(9.%9]JR`KD<C#*0?Q'K6:OA]8O%1U"
M./2PC7)N?M_FG[4H*X,(7;C83SG>.OW<\U>MHY='OM?U!6M[G^T+Z&6&))3N
M"^5#"=W!P048]QC&2.<%V&A%)K]I$EY.Z:O]AM4F9KU0K1.8B0ZJ`2V05(&5
M`)Z$TB:U++;S,FD:\;J!U$UF9K99$5E+!R3*$*\8X8G/;@XQ9?!68[ZWMWTN
MW\T7)6_60M-/YI=E25=H^1&<'ASG;P%K3ETS4-2L=9:^DTZVN]32*V>.WO'=
M%A4D.=^Q6W%7?&!Z<]Z+L-#4TNY76=`CU-%U"W2:-G2*Y=-Q7G!.PL"".1@]
M"*OP6FZWC;[1<#*`X#\#BGS36ZV<D<<D0`C*JJL/3@"G6]Q`MM$#-&"$`(+#
MTIZV#03[%_T]7/\`W\H^Q?\`3U<_]_*E^TP?\]X_^^Q1]I@_Y[Q_]]BE=AH9
M>J2R:='&8;75]0E?.(K1DR`.I+.RJ/H3D]@:JMJ-BNB0:W:_VA<+>"/R8XL+
M-*6X5<-M`//\1`'-2>(I=6G@AAT9].9'8BZ\^]:W?9C@(RH^">YQD#I@G(J7
M(N[BQAM+:TTZVFT_[-/!']J/V=F!(:(,(P0`HX8*>HXXQ1=AH+)XBT^WT9-1
MNI-2MRUQ]E^RR$&82[MI7"D@XP3D$C`SG%2_VQ;_`-K2V074_)BF6VDO=Z"%
M9F"D1\MO).]>0I7)QG.16'>>$+K4K6>ZDUXV.HSERT%K)%);IND#'#20E\X"
M@D;<[1Q5N[\-_;O$J74\EF;-+B&Z$R7DJNSQ[2-\`_=,^Y1^]&#C"[>,T78:
M&G<WD&FWB:;;0:G<&)$:5;/:5MXV)5202"1E6X0,1CIBFMJH74);,6>M%P)/
M(8E$6Y9!EE3<P/T9@JGL2.:Q[_0VUN^&K?9].2XO+>)&>YF/FV#(7(DB^3EB
M'[[#QR>PT6TZZNO%-KJ5RVE0_9)7(O+60B>YA*R!8)%(^Z-X;.\@LN0JYX+L
M-"SHNHMK%S>V[V>KV#V;*DGVF:%@6(SM!CD<9`()!Q]X5KV"[4G7).)F&3U/
M2J7A^V32](C@N+B!KIW>:X9)=P:5V+L03SC)./;%7;$AA<$$$&9B"/PIZV`1
MT235,.BL/)SAAG^*L!9M=CUE[![?1IVEM9)XUCB=!:L&`02.2=X;+8(5#\AP
M#R1NS2^5J0;RW?\`<XP@R>M85AH4EC]J!UCQ#<)<[BXE6`,&/1@Z1J^1C`RQ
M`'&,`4:@5-.UV]G4VD]M9-??VJEDDGV-X!+%L$COY+,73Y1(`22"5#<@XJWI
M^H:GJQUVVAT[3K.\L;Q+>+SP9%5&BCDW/MQN8"0_*"!QC=WJ:QT>*TU*+49I
M]6O;M%<-)<)&-^0`"0B*/E`(&`/OMG).:2ZT:*>/5A!<:Q9R:I/'/-+;A`RE
M8TCPNY2-I6,9!!SD^M*S#0J0ZKJ<@MK2.RTN>^DGN$$NUHH9HXH_]8H^8J#(
MR(>6QDGGBJDNKZW;ZFFBR)H\EW/<Q6\6H1V3>2CF*65T:+S=Q95B7^,9\U>!
MBM6VT?R(WW7VLRS_`&5K6*X:&!'@1L'Y`D:J#PO53]T55B\-&.RBMVU;7I'@
MF6>VG:"V\R!P&#,I$(#%@[!BX;.3W)-%F&AF?\)+JMSIES-9P:4MSIMM<37B
MS6K%9VAFDB*QX?\`=AC"YR=^,C@\U?C\07$OBR.R6TM18O.(0ILWS@Q;]_VC
M/E[MWR^5C?WSBG3>$[22S2UCNM:MT:&2&Z,*Q!KQ9'+OYA*'!+,YRFP_.<8X
MQ?&D6ZZF+I6U,6XE$_V$1IY/F@8#_=WY[XW;<\XHLPT-:P@A>RC9HD9CGDJ#
MW-6?LT'_`#PC_P"^!5.RNO+M$3R)VQGE4R#S4_VW_IUN?^_=-WN"L2_9H/\`
MGA'_`-\"C[-!_P`\(_\`O@5%]M_Z=;G_`+]T?;?^G6Y_[]TK,-#F8]6OFUN!
MC#IS:5/J,NG"(6["=&17.\ONVD%HR-NT<$'/&*?J^HWUKJ-TUG%IHL;#R/M$
M<UNS2R^8W.U@P"X7!Y5LGTJ9-$A76AJ!FU9HDN&NH[(I&((YF0J7&%WDX9C@
ML1EB<=,-GT-;FYCFEO=:8%8EN8PD06[,9RK283(.>NPJ#TQBBS#0C@?63XCO
M+*6729["WMFDE:&P>&2-V_U:!C*P8X!+'`Q\O'S<=);V\#6T1,,9)0$DJ/2L
MZ&""R&I2Q6]UYE]*9YFD0?>V*@_`*BU<@N]MO&OV>X.$`R$X/%/6P:%G[-!_
MSPC_`.^!1]F@_P">$?\`WP*B^V_].MS_`-^Z/MO_`$ZW/_?NE9AH2_9H/^>$
M?_?`J*ZMR+64VEM;-<[#Y0E&U"W;<0"<?04?;?\`IUN?^_=5[Z1KVQGM5&H6
MQE0H)[=0)(\CJI.0#^%%F&AB0MK\PO+0-H?FVTBA]0-HXAP5)9?*\S)9?E!_
M>`8;/;%5KO4?$":"FKP66CHJ0;OLTD3M)>2[B%2,Y`C#`)M)WDE\$#&3(WAN
M5M+33VUSQ#Y22"0$06HSP<JP$.U@2<G<#D\U-<Z'=7-S:W)U[Q$DUO'L5E@M
M2&.3ERK0E0^#C(`XX[G)9AH7/$[W6GZ0U[I\FGV[1#YDN+$SF5C@(B[9(\$L
M0.2>HK&EU;6K5R\\6CLEC+:6]_$EJX:1Y2F]HVWX4*)`0"&S@\BMV2%[U0M^
MEU(L5XMS"%C'`4@H#QS@C/KTYXJI?:+#?ZJ;QYM6CA=X99K.)(Q%,\1!1F)4
MOU"Y`8`A0"",Y+,-"'2=1OKG4[5KN+36L+_S_LZ16[++%Y;<;F+$/D9/"K@^
MM;\,$)O;I3$A5=F!M''%9&GZ1%I^H_:Q-JT\:>9Y%M,D?EV^]MS;=JAC[;F;
M`X&*U(KK;=W#^1.=VW@)R..]-7#0N?9H/^>$?_?`H^S0?\\(_P#O@5%]M_Z=
M;G_OW1]M_P"G6Y_[]TK,-#&N=3EM_&-KI+:9`+.:SN+@38#.[1F(8"CH/WO?
MDD=/6MX0U"\U:!FU>.VANS$DC60TN:U>`D992TC$2@'`W*`,@^O&G<VMO=:O
M:ZF\-\)K:WFMT"#`*RF,L3WR/+7!!'4_A2BTZYM%DEAO-4N;P[(XY[N.,F*(
M."R#:@R"`>6RQ_O#J"S#0S#X@O(I]8EG@M(DMDN3:6=SILUN9O+W;3]I=O+(
M;86P%R%(/09-9/%-T-,9I_[/@<7:P27]WILMI%;HT3/ODAE<.%R`@;<`2W!X
M(K8N/#]I?2R_;WU:\MR9##;3A&6W9U96*-MWYP[`;F(`.!@8H70\12O_`&CK
MO]H2-&6U$+"LQ5-VU"!&(V4;WX*'[V>N""S#0M:%J5OKWAR2_2&'*R7$.^-,
M*YBD:/>O<`[<CTS6O;V\#6T1,,9)0$DJ/2J%I%!INDM96]M<JF'8NZ#+.Y+,
MS8[EF)/UJU!=[;>-?L]P<(!D)P>*>M@T+/V:#_GA'_WP*/LT'_/"/_O@5%]M
M_P"G6Y_[]T?;?^G6Y_[]TK,-"CK4-W':^9I[Z7:*@9YKB]@,BHH&?NJR>^26
M&,=#5&6_O'\,:;=+86EIJ=^88_+GB+I"[]<K\K'`SQE3ZXJ77-/;6Q:@7FL6
M(MY/,Q:QQ$2'MO61'!QU''!YZ@8CN+&ZO('MKF\U,HJPM!<)%$)DE0DF3[FS
M)^7C:1P>!FBS#0S+CQ'=6>E/&UC976K0W+13>5&4A6-7"F4@DD9!&%R26.,X
M!(6Z\3I9>*'L;EM,BC%Y#:16!A)NIA)L`G!W8$89R/N$?*?F!X$UQX-\/W]D
M8=2TA]0N6)+7]W:1/<,2Q8_-MP!DG@`#G@5?.EPMJ:W1?53;*ZR+8$*8%D4`
M*R@C<N,#Y0P7/.W))HLPT*&LZ_\`9/$3:9;+91+;QPRS-/9RRAQ(SC!>/B$`
M)]]P02<=JEGOM0A\2C2Y%TR(7:2?9";.0A"`2A,A95E8A23&N&4`\D<TY]&-
MZD;WTVHB>6%8;Y840)=JN2%?*9`&YN4V$Y_`3II40U2.]FEU>Y2&9KBWMI]K
MQP2,&!93C?T=@`6(`.`!@8+,-!GAB74-0?4)+^32[FUAG-O;RVMDT&]D)60D
M-(^0&!4=.5/M6W8@*+@```3,`!^%5=,6+2]-@LH8+UTA7:'D0%F[DG&!DGGI
M5JP;<D[8(S,QP>HZ4];`+_S%?^V'_LU<F\DFD7EUJ^FW.JZG:P0.ERAEDN5N
M+@NH01HH;;L^;<8U``.,$@[>HF\[^TAY.S=Y/._.,9]JP=(L_#EKJEVVBVWA
MB'4+=2MR;)(UEB!/(?;R!QW]*&@,G0=6O-3@M[![Z_EN7UAVFEE@EM6$48\P
MA5<`A-P1-OHV#G)S>T]IYG\5V>L:W<K#;ZA$@GCD\@HC6\#E$(Y0$N1\IW<\
M'/-:=G>Z9=1KJUE<Z%,GF&%;R&16&^1E!4..[,$&,\D+[4:C;Z9-9ZC_`&G#
MH3VH=9+[[2JE-P5<-+NXR%"X+=@/:E8+F5#!?>;9Z:=4U"TMV^TW@D>7=-#;
MA!&BN\FXD[I-XW9^Y@YP15"2SN4U"PMK;4-5;P_J-]%`#)?3&4[89Y&D6;?Y
MBH[+$HY`.TXX89W;"QT*/2O^)=:^'%TV]4Q?Z/&@AG4@DK\O#`@$XY[UGP6_
M@E=#N[BWA\&C2'=%N9(UA\AF!^4.1\I()XSZT6"YA?:+VZT/43=:GJ%L-*L;
MR6SN$O9(RQBN)D1W.[][A(X_OY!W$G.:V(9]3?Q5%J+SS"T-^MJP^UR<9A_U
M7V;'EXWG=YN=_;&.:O7:^%_L^D->CPKY``&EF;RMN.,>1GC^[]WVJ\1I?_"4
M#(T'_A(/)X^[]J\K_P!#V_I18+FOIW_'A%^/\S5JLZR^U_9$\KR-G.-V<]:G
M_P!/_P"G;_QZFUJ"+5%5?]/_`.G;_P`>H_T__IV_\>I6"YQ\<EPOB"SOS?7B
MW$VM3V3VS73F)H5CD(`B)V@@(K[@,]><&I=>,K:IJ-V+Z\AFT_[)]FBBNG2-
MM[\[HP=K[CE?F!Z<8-:$2Z*/%,WDKX>_X2%DS+L"?:RF!]['SXQCKVQ4=S;:
M!9ZKIMO=0>&X-1B4)I\<J1K*BCH(@>0!Z+18+F5H,U\^H-=7SW.;U;L*?[1:
M5&*.?E,!7;%M`"@H<G'S<FNYMO\`CUA_W%_E7+VFH>'IM6OO[.N_#DFKS(PN
M?LDD9N7"CD-M.XXQWZ5OP?;?L\>S[/MV#&=V<8IVT`O455_T_P#Z=O\`QZC_
M`$__`*=O_'J5@N6JKWZJ^GW"O=/:(8VW7",%,0QRP)!`QZFF_P"G_P#3M_X]
M4-W!+=6<T%[%836KH1+',I9&7N&!X(^M%@N<@UE)]NTZR74M5CT6_O=D0>_F
M$S[()6.)2WF!6900-PX3^Z<58AFU.30]`N#J<ZHFH+#(HP6N4\XHI=SR05`/
M&,D\G'%+';>#(_#TT\</@]=$ED7S9%6$6SN.!N/W2PSQGFMAKW3[>+3[5KG1
M(HY=IL8C(JA]OW?*'?'&-M%@N9WQ!UN[TO0Y8+-;Z*2>WF8WEK:2S>0%7/5%
M8*Q)`!;``W'/&#DW-Y/=>9JRWVH036MQIT=M&T\L2NDACW!X20&+%W7YESQQ
M@BNFO)+71+&Y?5+O2[:TNI6,K7L@2-RPP5^;`.0.G>J]P-".OV+W(\.?VT8Q
M]C,NS[04YQY>?FQR>GO18+E'0C*NK:;>?;KR66_^U_:89;IY(QL?C;&253:?
ME^4#KSDUU<'_`!_W?_`/Y5BZ:-'&NWW]E_\`"/\`]K_\OGV79]HZ_P#+3;\W
M7UK3B^U_:[C;Y&_Y=V<XZ<8II`:-%5?]/_Z=O_'J/]/_`.G;_P`>I6"Y@WTM
M]'\0M-@.HR+97.G7;>0H"JC(T`#GKN;YVZ\#TZYE\.V9@OKB:SOKVYTQXD"R
M7=T\_G2Y.YT+$X7&!\N%)Z``9,TMY8W&LBPFN-%EU5(646[NK3B-L%AM/S;3
MM7/8X'I56V\,Z3$ES;Z;IFB6C%XQ<?8K=(VRI#JK;1]#SSSD8ZT6"YS-Q>W=
MIITFK1:IJ'VJZ?4XI\3M*L/E^:$*1,=BE"B#@#K\Q.<U/#JVIZ#:WVF3PWWV
MDR1;7MGN=56VC=&S)YC)O)RC?*1@$IS@UT%L-#&MZ@UJ/#HU8(?MQBV>>%[^
M;CYL=/O5-H!TW^S#_P`(Y_87]G[CG^SMOE;N_P!SC-%@N0>"[Z34OAKHUW-+
M/+-)IL?FR7`8.[A`&8[N3D@G=WZ@D'-=%;?\>L/^XO\`*LZV_P"0-%]@^P?V
M?Y`\C[+_`*ORMOR[,<8QC&.*L0?;?L\>S[/MV#&=V<8IVT`O455_T_\`Z=O_
M`!ZC_3_^G;_QZE8+F#\1'OH?`.LW&GZA+8S06DLWFP@;R%0G"M_#DXY'.,XP
M>1I^)#9Q^'[VXOWNEMK:)IW-K<20R$(,X#1D-VZ`\U%K-Y;6FG2?VY<Z1#8S
M#RG^W.%B<'^$[^#GTJ.[BM[:.\U2_ETU;6>&-9Y+A@(=BYVY)XQ\YY/M18+G
M,S:#JMI8Z;%)J,]RMO;3W-Y:RZ[<P3%W9""LBY=DC`=`&.#N&3GFI;74KV[\
M127\JW2645_#:P[;]T*K)%$55K?!5P2Y)9B&';@5OW,>FZY8V^H72:'J%G&P
MD@N90LL:G.`RL<@'/<42-IK>)(UD.AG7EAS&&*_:A'[?Q[>OM18+F%XLN=0B
MU^XN[::?[+IMK!-,JWDD/E`R/N9(D!%PS*N-KX`VC!RQQ->L]OXC@DAU>Z-C
MJ3W%H]U%?>;Y,P21L"(CRXQ'Y;#<,G=@..IJ_+8:/ILFDP7ZZ&+J#]W8-=A!
M+GN(\@'/LM).N@?;]3^T#PW]L^SG^T?,$?F>3CGS<\[,?WN,46"Y-X9LI+>Z
MO9;>\O9M(D2);5;RX>=F<;M\BNY+;&R@`SCY"1P03LV7_+Q_UW;^E<]X9/AW
M=<CPI_PC.["_:/[*\O/?;O\`+_X%C/O706&[9/OQN\YLXZ9XHZ`+_P`Q7_MA
M_P"S5P5\EOXFAO8[32;ZSDM[*>UM+:;2I85:-F7S,LR!#NV`*@;D$D\G"]S-
M%YNI!?,=/W.<H<'K6"_B.VMYI8[RWUNT40O/`\RKBX5"`=@#%@<LO#A2<_7#
M8%#34NM0U>UC*ZA-:-=F\:\O-.^S22>7&`%<>6G1W3:2H)"'&0,TZSM[?PY)
MXJGET6[N+3^TX)K>&*U>=I6^SP?O%&"6PX8EAG!![BM6/5XC`#<0ZM;77VF*
MW:TD>,R*9"`K95BA7&6)#'A3W&*9!KUE>V^HRZ>=5O38W"V[1P+\TKLJL-F<
M#;AU^8D+WSCFEH!D6UO:7LOVNYTVZN+...ZOKR*739E\R=U$>Q(I$!;]V9!C
M'S9]S51YH[S5[/Q*EAJD1AO(?M=O_95TC);K#<)$`ACS(P>7+;`=O']T$]`/
M$%F+9'D76$G,\EN]J$\R6-TC,C`A"P/RCC:3DLH&2:K'Q3"LAM9;#7(M4W1!
M-.=X?.D$@<J5/F>7C$4A.7!&PY'3)H!S9M;FUT748[O3-1N%U6PO8K*!+&60
MIYEQ,Z(_R_NLK)%]_:!M.2-M;$-A=)XKB#K?F9;];DP?9C]D*^3Y9G\[9_K-
MN1MWX_V/XJMS>+;*+3TO([?6IXUADGNEA:,M:)&Y1_,&_DAE<83<?E.,U>&M
M6K:T-.7^TRAF^S"[#IY7G>7YOE_>WYV<YV[??-&@&WIW_'A%^/\`,U:K.LK7
MS+1'\^=<YX5\`<U/]B_Z>KG_`+^4W:X(M455^Q?]/5S_`-_*/L7_`$]7/_?R
MEH!QT<<K>(+6Q-C>FZM];GO7N3:2")86BDP1*1M;(=4P"3VQ@'"ZM+]JO+V-
M+#4)'U-;-[23[!+M4*^?G8K^Z*GYL/M//'-::ZW;MK::<8]66.2=K6.]+)Y#
MS*I8H,-O!PK<E0,@C.:=J.L0Z=J/V1HM6FC3R_/N860Q6_F-M7=E@QY_NJV!
MR<4:`26]M+<ZUK.I7<#)Y"_8[(NO_++8KNZ\?Q.<'U\M:W+;_CUA_P!Q?Y5S
M]KJB:A-/%%;ZN+=1*([R4+Y$Q0[6`P2PY!QN50V,KD<UKP6FZWC;[1<#*`X#
M\#BGI8"]157[%_T]7/\`W\H^Q?\`3U<_]_*6@%JJNI+$^F72SV1O83$P>U"*
M_G+CE=K$`YZ8-'V+_IZN?^_E17-N\%M)+&U[<.BDK#%*H9SZ#<0N?J0/>C0#
MAD\R#78=9-GJEUI:WXG,TNG2BX5S!+'_`*@1JVQ/W:A@F?G.<X+4EW:SKX52
MRAT[4(M2EA:2V*V.Z.<>9(\5M,VTM$HRI.3'C/#?>%:R>*-[21'1_$*W2W*V
ML=N9+<M+)L9V"LLI0!57)+,.H')XI]YXE%MI]O?Q:7KMW:S!0)(9;<%9&?9Y
M95Y58ONXP`1SUZT:`6]=UZWM$B>/3[FZO/,>W$L6G37*VQV@L6V*6VXQP/O<
M#(&2.82PBL[;^QK*PU*59YM-DL9'T^50D<31Y+N4"QE=CL5;:1G@<@5UFKS_
M`-A6+74=EJ=U$`TL_P!FF@3R@!DLWF.@]>F>E4/^$F@#VWF6>N1Q2>0LTKF/
M;:O,0$20;]P.67.T,!N&2*-`(=!1VU;3;;[#=Q3Z?]K%S-+:/'&=[\;9"`K[
MCAOE)Z<XKJX/^/\`N_\`@'\JQ-/UB'4-3%F(M6A1_,^SW,K)Y5QY;;6VX8L.
MO\07(Y&:U(K7==W">?.-NWD/R>.]-6`T:*J_8O\`IZN?^_E'V+_IZN?^_E+0
M#G9KNRO?%$6G_P!G7ULMM=^>9AIDVRXFV8#>:$V!0#RQ8$D`=.IX?M8O#^H^
M*7>WEM[)]2B:)C&[>9NMX%+`\EOGW9;GD')X-7[G4;&VUN#2&N[U[R:%YMD9
M+;47NV.A/.!U.#Z5#IUY%K%Q)9W-IJMG*J+.D5[L_>)GY7&UFQ@@<-A@<<"C
M0#)EOM)O-0E$^@ZBMMIPN#';#1I\7#,")"#Y>Q@PS@9RQ;)[5$T=_KUK>76E
M66V6[EC6^MM0BN+$-`JMMC5FA)8G/S$#&"5ST-;5UKFEV>IW=A-?7@DL[-KR
MX<'*1HN,C/=L$':.<$>HRUM5F6U,G]D>(C<><(DM@(RSY!.X/O\`+"X!Y9Q@
MX'4@$T`3P7#>6WPUT:WU"V^S7,6FQQO"2<KA`!N!`(;`&1C@Y&3C)Z*V_P"/
M6'_<7^59&GW5OJ^C-?VTUX$S+&T<QPR/&S(ZL.G#*1P2..":O06FZWC;[1<#
M*`X#\#BGI8"]157[%_T]7/\`W\H^Q?\`3U<_]_*6@&7XFU2/2UMG&FW%U<RE
MXXIH;"6Y6W!`W,XC4L`>.!]XX'`R1ERBQLO#>EV5A#>S6^EM:2O";.3SO)R0
MK>7M#$Y4DJ!D;>@X%:7B/5;'POHL^JZA=7QAA4G9#EW<@$X4?0$Y.``"20!F
MK5]`]C!)<VUM?WLS%08K:2-9&'UD91@>YHT`X75M+U[4M+FFL=*AETQKI[N&
MVN99;:;S#+D.8O*8D`#<`2""Q)&0*T;NRU)_%#VEIY]NDVHV]_<!K!F5]@CW
ME;H'9LVILV,H?.?X<5;M_%27<5G]FTKQ!+<W8G>.U$ENK^7$RHTF6E"%=SK@
MACG.1QS6H-11]6:QBBU:98Y!#-<QE6CAD*A@K<[NC#D*5&>2*-`.?U<7=UKE
MQJ-FUY+!>VENEG"MAYD4[HTI*3%D/EKEE.3LZ]3C`O[9)O&-@]C8WL"P3S+=
M03V8C@5&63,Z2*N'=V$?&]OE8Y53DU;O=3M-'OX]-2'4G2**-Y7@*"*VC=BB
M$Y()R5880,1CD#(RLFL10WTUM-;ZVBHLACE\O<)S&,L(T!+D^GR@-_"31H!:
M\,6\PT^74+Q'6]OY6GD$B%&122(T(/(VIM&/7)[FM&R_Y>/^N[?TK(TC4DU6
MZN+.2+5;"]MXXY9+>[=-VQRP5@49E()1AC.1CD"M:P7:DZY)Q,PR>IZ4=`$=
MTCU3+NJCR<98X_BKF(K76[Y[]M7M]!:6:"2*&5+Z2144G*IY?EJ5!P"S!\D@
M'H`!T[HDFJ8=%8>3G##/\5<I=:[?Z=J.H6EU:Z<[I:M/;A;62-5;<JJN]CB8
M?,"Q0#;T(R13=@$T7P[+:ZO;WUV]FBB1IY(QJ$MTRR+'Y<?[R0!G^5Y22V,?
M*`#C-7C::II\WB*[TN;3)+K4;R*:W6XG9%5%@BC;<0IPW[MB,`CD9[BH8]3U
M"WN?[+O(],FU`W\,"2PVK)&\3)YCG878A@B2#.XC.#[5+I^H:GJQUVVAT[3K
M.\L;Q+>+SP9%5&BCDW/MQN8"0_*"!QC=WI:!J1V-EJ43I>2)I<=U;6LRP1"_
M>999Y"I,DCF)3_"!PIQN.!TJD--UR9K;4+F'1O[5M+Q;M2-4=DN"8I(F4GR`
M8U59,J`&YZ\DDW(]5U-H+>VCL-.N;^:[F@28*8X)$CC9O,QEF4%PJ?Q8)SS5
M=M3UJ"[ETN5-'ENFG@@BOH[-A"KNKNZ-%YA8E50'[XSYB]*-`U*G_"-ZK:Z?
M<16<NDM/J5M<0WC37;A;=I9I)<Q@1_O`#,XP=F=HY&3C0C\/F+Q)'>*-,VI*
M)!J1E_TL1A<>1C9C9_P/'/W<\UGOXBUF2RO?(M]'6[TJ">:\5[9REQY<KH!'
MAP8]PC)R=^,@8.,U>C\07$OBR.R6TM18O.(0ILWS@Q;]_P!HSY>[=\OE8W]\
MXHT#4Z>PGA2RC5I45AG@L!W-6?M,'_/>/_OL56L((7LHV:)&8YY*@]S5G[-!
M_P`\(_\`O@4W:X(/M,'_`#WC_P"^Q1]I@_Y[Q_\`?8H^S0?\\(_^^!1]F@_Y
MX1_]\"EH&IR<6E7RZU$ADTU=*@U&74%E%RQG=G1_D*;`J@-(3NW'@#CG@OK#
M5+RYF`_LE+?4%MS>$WCEH&0_,(QY>)`1@`DIZX[4L>K7S:W`QATYM*GU&73A
M$+=A.C(KG>7W;2"T9&W:."#GC%/U?4;ZUU&Z:SBTT6-AY'VB.:W9I9?,;G:P
M8!<+@\JV3Z4:!J5M*\.C2M2EF2+2XHT28"Z@E)N+L.<JLHVC`7M\S=.`O2NM
MM[B!;:(&:,$(`06'I7+V&J7-WK%]!=K!:P*TT=M;R:3-%(X0D!Q.S;'R%+85
M<X(/N>HM[>!K:(F&,DH"25'I3TL!)]I@_P">\?\`WV*/M,'_`#WC_P"^Q1]F
M@_YX1_\`?`H^S0?\\(_^^!2T#4/M,'_/>/\`[[%(;F#!Q-%GMEQ4-Y%Y5I(]
MK8Q7$X'R1G:@8^Y/0=S_`"-9WAN^&M>$=,UB6RA$]W9QW#11*,;F4':,_7')
MHT#4R8M(OK#1M":UDTN;5;&9KBZ1YVCAGDE1Q*0X5B,O(6!*G.,8&<BS8Z.8
M1HB7%S:F.RDGNIE28X\]]V-O`W*/,DZX_A.,]*JZOJEW!:V\5GI=GJ%SJ,]K
MNDC:>.*.-7;.`4+L0H'51R3VP<N_\;O86!O+F/2[5;:S>XD2:(YOI$:57B@^
M<8(\K.2&X=<CO1H&IU.H@ZY9FT=HH(4O4\P-+_KH48,<<?Q$8QTQGFL[5-*O
MKG5;M+:33?[.OKBVN+B:6Y82QF(KN58PF&R(U`)<8))P<8-KQ/>W5A;V+:9;
M1J)I3YTYTN:]\J/82/W<)#9+;1UX&:S)==OMWVJU.DW-A:26D-UBT96G,VS<
M\9WD(`)`0I#'@@D=:-`U+ND:=?6VHVJW<FG+8V'G_9Y(;EFDEWMQN4J`F!G.
M&;)]*WH9X1>W3&5`K;,'<.>*P-)U&^N=3M6NXM-:PO\`S_LZ16[++%Y;<;F+
M$/D9/"K@^M;\,$)O;I3$A5=F!M''%-6`L_:8/^>\?_?8H^TP?\]X_P#OL4?9
MH/\`GA'_`-\"C[-!_P`\(_\`O@4M`U.4;PY+;^)(]7M?$$\B^=-/);3M`$+,
MN%4,(M^T8`Y8D`#%2Z9<:Q9K<WNJV>ER7TGEIOL[]Y-XW8VA3$NQ5#$CD]\D
M<FHEU6\_X2RZM+B""UT^*7RX$?29F:Z'E*Q9;@,(U.\LH7:2=AQUXD\(:A>:
MM`S:O';0W9B21K(:7-:O`2,LI:1B)0#@;E`&0?7@T#4R[KP/Y]U>`>);B2TN
MK&Y@9)VA)#RL&SE(U8J",\MNX`SBK,.GZQIEG=-HUOH-E-<RH&M8KQEBC4;M
MTBL(?]8V5ZICC)+=[J:M-J/B.?3-/MK.*U^QR/!>2Q>8'F1U4_*"N4&['4$D
M'H!DY::KKRZ3=W9&G7*F]%M;3VVB3OA4+"61HED9F&5*K@C.`>=P%&@:G3:<
M?L^@+;S1VEM,L;*8;>Z,ZCK@[V52Q/4DC.2>O4W[>X@6VB!FC!"`$%AZ5GZ;
M+!?^'UNQ);7#F-PTL5LT`WJ2&'EL2R$$$%2<@@@UH6]O`UM$3#&24!)*CTIZ
M6`D^TP?\]X_^^Q1]I@_Y[Q_]]BC[-!_SPC_[X%'V:#_GA'_WP*6@:F1XJM!K
MGA/5]*MKFV2>\M)8(VEDPH9E(!)&3CGTHU:>YU"RU;3;.6*VE>UV6]VTG&]P
MP/&.JX![]15?QIJ%QX?\)ZAJFFZ;:W-Q;0O+B8A40*I)9L<GIT'4D<CJ-/4Y
M[33;)IVM5E<D)%"B#=*Y^ZH]R?P')/`-&@:F+KFBV]U;V=K::9H%W!#%Y*?;
MCM>V`QM:,A'SC'W?EY`^852@\+"VU[[6DFGREKB.Y;4I)3]J3:B*T8&TC:_E
M\G</O'Y3UJK<>*;T6&FD6^G6MU-;27-P39372`JX4(!'\RKU)D.0N!\ISQM2
M:V&\2Z9IMK96LEK,SI=7(Y"R"(R!$]3@9)/0$<9)P:!J9>JZ-/XBN8=0>WTU
M)9K>-8YKF;]_I<BL6\R`&,Y8DJ>=ARBYST%N]T_4[C74U./^Q8[JT,A@NHYF
M1[I"D@C@F&TX0%U8D,V67(5<\+KFK7MCJ-^;.#3A8Z9;PW%RLUNSR3;V?(0A
M@$PJ9R0V2<8&,F2YDUZ#6X;3R]&,5X\RPHEN[O:QJC%9I"7'F`L$!4!<&0`,
M<9)H&I;\._VA!]JDUF/38[J8JS36U\TWF'D8PT:;%'&`,]3GG).M8D,+@@@@
MS,01^%8GAB74-0?4)+^32[FUAG-O;RVMDT&]D)60D-(^0&!4=.5/M6W8@*+@
M```3,`!^%'0!DTOE:D&\MW_<XP@R>M8<F@07!G^UW.M7*-"\,*R[#]F#8R48
M*&+<+RY8C''?/0?\Q7_MA_[-7,V*W-MXK*0:C+/::A9RR6\SWC7*O(I3+E#A
M8PN[`$?#9YP<9;`M:?HT=EJ*:A-<:O?72[RTERD8WE@J@D(B@;57`P!]YLY)
MR"ZT:*>/5A!<:Q9R:I/'/-+;A`RE8TCPNY2-I6,9!!SD^M9.BWFH76GV.GS:
MA<3W#Z[>)).9-CF&WGD/\..#LC0@<8;'2K&GM/,_BNSUC6[E8;?4(D$\<GD%
M$:W@<HA'*`ER/E.[G@YYI:`78-&$48WWVLRW"6TEK#<&*%&@1]N=@2-4!&Q<
M':>E5X?#K0Z;]C.KZ](4D2:"=H;820.I)+*1$`Q;)#%PV<GN2:KK%?K]ATK^
MU;VTAFDN+O?+*6N(;18]JAG?/(DD1OGSTP<X-5S93QR1Q6VHZH="OKNWMT,M
M],TIPLC/(DQ;S`CGRU'(^Z2.&!)H!<E\)VLEJ+=;W78A)'+%=N@BWWBR.7?S
M"4..6;&S9@,0,<8OC2+==3%TK:F+<2B?["(T\GS0,!_N[\]\;MN><5Q\DMS-
MIFL))K.HQQZ1:7DEE<K?2*2T<\J@R$-^]V!$7Y]P/.<DUKPSZF_BJ+47GF%H
M;];5A]KDXS#_`*K[-CR\;SN\W._MC'-&@'665UY=HB>1.V,\JF0>:G^V_P#3
MK<_]^Z-._P"/"+\?YFK5-VN"*OVW_IUN?^_='VW_`*=;G_OW5JBEH!S":)"N
MM#4#-JS1)<-=1V12,01S,A4N,+O)PS'!8C+$XZ8;/H:W-S'-+>ZTP*Q+<QA(
M@MV8SE6DPF0<]=A4'IC%9T<EPOB"SOS?7BW$VM3V3VS73F)H5CD(`B)V@@(K
M[@,]><&I=>,K:IJ-V+Z\AFT_[)]FBBNG2-M[\[HP=K[CE?F!Z<8-&@&@=*C%
MXUW-/JMRL3226T-R$9+9V5E9E;;OZ,P^9F`!P,#%:\%WMMXU^SW!P@&0G!XK
ME;(W-IK<UQ?2?:AJ,UU%;36VJSS1(%WL$:`@1IM6/!89.[([Y/9VW_'K#_N+
M_*GI8"+[;_TZW/\`W[H^V_\`3K<_]^ZM44M`*OVW_IUN?^_=9&DV;Z);Z5I]
MG]M.FV-F;8QRHI>0C8$8D`<@*_0@?-T/&-J\BFGM)(K>X^SRL,"4(&*>I`/&
M<=,_D>E<_P"%;F74?AII-S?:A-%+/ID;S7F\!U)0%GW,"`>IR:-`%NM&@GB4
M0RZK:3QWCWD=Q`J;T=PP8`,K*5(8C!!]>H!J*7P[;2VD-F9]9%F(3#<VV$,=
MVI))\P%3@DELE-I.<'C`%:/3H$L[@SZKK":0\J?9(?M\WGSL%;(60MYI5C@A
M0PSMS]TXJ#4=$N9X-$L+F^U0:G<N8Y)H-3GB\J!-SDE4D56?!6/=@DE@3D"C
M0#;N(+V\1\WVJ6<BRL89+1(\K&<?*5=&1NG4J2,\&J/_``C%DL\/DRZO#:(8
M6DLD5/*F:(@HSDJ7SD+G#`':,@\YT_$4%I+:PQW5W?IDE8K>RNFAEN'QP`R$
M,2,$_>`ZEN!D<E(FJ6L33ZAJUX=4TV?3K=3'=.L4V]HP^Z,$(^\NZY*YX&,$
M4:`='I^D1:?J/VL3:M/&GF>1;3)'Y=OO;<VW:H8^VYFP.!BM2*ZVW=P_D3G=
MMX"<CCO7-Z$95U;3;S[=>2RW_P!K^TPRW3R1C8_&V,DJFT_+\H'7G)KJX/\`
MC_N_^`?RIJP!]M_Z=;G_`+]T?;?^G6Y_[]U:HI:`<]-IJW&HFYFN-8>WW^8+
M)@OE+(!PX.WS`1U`#[0><5%%IUS:+)+#>:I<WAV1QSW<<9,40<%D&U!D$`\M
MEC_>'49D,U\WC"6\N'N?LZZB;--FHL`H\L;4-MMV,IY8N3OR>/E`K3\+37QU
M?Q-;7U\]V;;4(TC9EVA%:VA?:JCH,N?ZDFC0!+;PWH%CKHUBRT%;2\$3Q[[>
MSC3.\@EB0,[N,9ST)]:D32DM]!L-*M+C6;7["BK%<Q%?-;:I7+Y!1\Y)(92,
M\XR!CF_$5Y?:#+>:EIVHW5W'=6UV(Y/MAG'GJK/CR\".)8PC*".IP'YY+G^U
MK>V>ASR7\$=SJ*"Y,6K33;8F@F==L_RR)N>)<KG`S@<&C0#K+2&#3-+DM+>W
MNL,9)'DD09=W8L[MC`R68DX`'/`JW!=[;>-?L]P<(!D)P>*RO"\]Q-X2D%Q)
M)(89KN".25BS/''-(B,6))8E57D]>O>MZV_X]8?]Q?Y4]+`1?;?^G6Y_[]T?
M;?\`IUN?^_=6J*6@&/K-O!KFB7VE7,%ZD%Y`\$C1(`P5A@D$Y&>?2H;VRMM7
MGFCUC3$U#3_W;06UU:)*L<@W!GPPZD,!WZ'UJK\1'OH?`.LW&GZA+8S06DLW
MFP@;R%0G"M_#DXY'.,XP>1H>)-5FTG2O-MX+B6>600HT-I)<>43GYV2-2Q4`
M$].3@9&<T:`9$?A;3K.PM[/3%U'3(XE>-C9Q1*94<Y96!0CD]P`P[$<U,WA?
MPZ=6L]43P^D5Y:2>8LR6:!W.TJ-S8W'&<CG.0#7*0W^I:KI&F+'<:C-'!83S
MRR2WLNGRNZ2`&0G9ERHZ*1Y9W<]!C6?Q-<7/C?1+<'5;>S\QH1$UA,$N282W
MF-($V$`X``.!AF/;!H!H2:"U\\=Q>W>JK/)!'#>QP)'Y5T$9F`8%,C[S#*;,
M@\]L6++2IK+6I]1&J:Y,)I"[VTT4!C(YP@81APJYX`;\\G.7XDDN&U?6)TOK
MR.;3+*VFM((;IXT9F>3)9%(#[BH7Y@1QQ@YJXVDFZ\1?Z'JVJ2H9)O[28WK^
M6$9&"PH%(6-U+*04`8!/F.6R30#9TQ8M+TV"RA@O72%=H>1`6;N2<8&2>>E6
MK!MR3M@C,S'!ZCI6%X,L@D%[J*SW[07<S"VBNKZ:Y"1(2JL#([8+X+<=BH[5
MO67_`"\?]=V_I1T`CF\[^TAY.S=Y/._.,9]JQ]/GT6+4M2ETV7P\E\GS:@]L
MR"5<9YE*\C'/WJW/^8K_`-L/_9JX&P*Q&P^U:+J-Q_9.G745\#ILA\YFDCPB
M;E`EW%"PVY'&21D9;8'36-UI<T":GI\^@O#YKQI=6[J5\R5QN4./XG?;D9RS
M8ZFF1+HWB2&^AA'A[5(GE4WB)LG#2```R`9^8!0!GG"CTK$$;Z]<AK>VOHI;
MJ9[JX\[3YK=$,46R),R(N3N=&SW*MC@<7=`MX-5N-K:==V]M'I<-G<)<VLEO
MN<,3L&X#<!SR,K\W4Y-*X6+]OI>D6FF^5;6'A^&QNE:+9%"BQ3!AEEP!A@0#
MD=\>U9=O!X*30KN>VB\'+I$K(MU)&L(MW8'Y`Y'RD@GC/<\5'9:<JZ7H]O?Z
M3+)I^F:=/-);&T+[F8&-8U3'S'RS*-N,X8<<U2>:.\U>S\2I8:I$8;R'[7;_
M`-E72,ENL-PD0"&/,C!Y<ML!V\?W027"QLW2>%A;:0;M?"OD#']EF81;>2,>
M1GC^[]WVJ_C2SXH.!H)\0"'G[OVH1_\`H>W]*XHVMS:Z+J,=WIFHW"ZK87L5
ME`EC+(4\RXF=$?Y?W65DB^_M`VG)&VMH6FH+XDAL(3<");Y+R;?I[8.(\,XN
M=Q0J>%"8#_A1<+'5V7VO[(GE>1LYQNSGK4_^G_\`3M_X]1IW_'A%^/\`,U:I
MMZ@BK_I__3M_X]1_I_\`T[?^/5:HI7"QS42Z*/%,WDKX>_X2%DS+L"?:RF!]
M['SXQCKVQ4=S;:!9ZKIMO=0>&X-1B4)I\<J1K*BCH(@>0!Z+6;''*WB"UL38
MWINK?6Y[U[DVD@B6%HI,$2D;6R'5,`D]L8!PNK2_:KR]C2PU"1]36S>TD^P2
M[5"OGYV*_NBI^;#[3SQS1<+&K"-)_MC4OL?]A?VQY?\`IOV?9]IVXXWX^;TZ
M^U:\'VW[/'L^S[=@QG=G&*X_0;2[M+]K:47;M`MT9UGL%CAA+N7#13;!O+DY
M;#M[A2,5W-M_QZP_[B_RIWT`B_T__IV_\>H_T_\`Z=O_`!ZK5%*X6*O^G_\`
M3M_X]67-H%NXA\VRTW[-;VLEJMN8AY(A;867;C&W]VO'3VZ5O5E^)+>2\\,:
MK:PVZW,DUI+&(6Z2;E(QP1USZBBX6.96P\#G0WNUM/!AT@2@O,(X/(\SH,M]
MW=SCUYJ_)JWAWP^;2WDU#PSIICA+6L;31P[8G/)09&%8KVX./:N=$-W$_P#:
MD4FKW*PW44MO?7VCO)*KF&2)P]LBQ.4"E0K(N=TASE0:V+#3-2?2]"TJ^\UX
MY+B>\O&,1`*!V>.)L<+\SQ_*>H0CUHN%B_J&@Z7+9S7.LV6BW-LCO=-+?Q*Z
M19`W,"PPHPHR?;FHY+3P]9:WI\$EOX:@U:.,)8QLD:SJ@S@1#[P`^;A?>F>/
MK*#Q#X"UZUBMI+R>&"81PK&Q)G"';A?XCD@C@\X(Y`JCKD4K:OJ%A]AO)KB]
MO;">VECM)&B1(WC+$R@;$VE';!(//`)-%PL:^FC1QKM]_9?_``C_`/:__+Y]
MEV?:.O\`RTV_-U]:TXOM?VNXV^1O^7=G..G&*YO04=M6TVV^PW<4^G_:Q<S2
MVCQQG>_&V0@*^XX;Y2>G.*ZN#_C_`+O_`(!_*FF`?Z?_`-.W_CU'^G_].W_C
MU6J*5PL<W)/HZ^*8UDE\/CQ$8]B!F3[64P3@?QXQDX^M.A^PZ]!>+87.DW(:
MX0W;VCJY,J;<!R,_,`BCGD`#&,"L_P`I[/Q1>?81K#R7ER)KRUFM%-K*GEJA
M=9=F`=J*`OF`Y'*\YHT62VM==U'54AOX;)[:"W87=BT!MRCL$BC4(NY!YC'<
M`P&?O$="X6+UL='36]0:U/A]=6"9OC%L$X7'_+7'S8QC[U58D\,3^&IS$OA:
M300^^;8(C:[LYRW\&<]S6)!;26FJ3R7-CJ-W;Q2WTEWIQL"T"1R%G#0-Y>9G
M<[<KO8?.W"X`#KQ)=7,.M6G]JV#I?I+>B/39DECA6"9$V1R1?O6#.I.%8#T.
MT47"QU]IM_L6/^SO[._L[R/W/V3_`%?EXXV;>,8Z8XJU!]M^SQ[/L^W8,9W9
MQBL_P^ES'X4VW4/ER`S[<PB)G3>Y1W0`!79<,PP/F8\"MFV_X]8?]Q?Y4[Z`
M1?Z?_P!.W_CU'^G_`/3M_P"/5:HI7"QF:CG^S;G^T_[.^P^6WVC[3_JO+Q\V
M_=QMQUSQ5:[EBT66YU>_O-/LTF6.*2:YE\M!M+;1DX&<L>IJG\1-)76?`.LV
MWV1[N86DKP0HI8M*$.W"C[QST'/.".0*T]7U22VT_5%T^)[C4K6U\V.`(WS,
MP;9SCG)4],XQ1<+&'>:EX4N=+M)[Z]\*2Z>LQ-K)/+$T0D'782<;AGMSS6Q+
M?0'5+:TFNM).H8,EO"\@\W&,%D4\]"1D=C6!J.CP:(=,>VFUF*]M[:6**XL;
M-9UEDD9'D\T>6^TNZ`EB%'7YA4%K:ZM#XDF:Z6Y:XN;^&Y^SBS#VOE^5$K.9
MBAVNFUPHWJ>/NG.:+A8U)M/T.PN=)M-030?MT0V:?]L"><<'_EGD9SG'W:6V
MT[P]#XAGEM;/PRFMP[IIGBBC%S'N!R[$#<,@G)/7)K&\1)-J.K27NGK?YNK.
M`6J06C&*]:.1W\NX<QL85!(YRA^9N3@`6-3$<NNQR)I%\]K;FY6_L)=-S"\3
M))NEC*KB5Y&"#;N;(8Y53FBX6.AT>_MKZQ7^Q+O2+BSB_=K]BD#QIC^$;3@?
M2K]ANV3[\;O.;..F>*P_"\UMJ.HZCJRVEY:W4\<,317%C-;A(DW[%S(JAVRS
MDE<@9`Z`$[ME_P`O'_7=OZ4=`(YHO-U(+YCI^YSE#@]:YL^+-/CCNIKE-7MK
M:&TFO(KB0H4N8HB-YCVL3W&`P4D'([UTSND>J9=U4>3C+''\5<C9Z%J`$%O=
M?V(UII]I/;6JO,TPN-[)M,JE5"C:F"`6Y;KQR]0-8ZKY.G+>7]GK%CON$@6&
M>6%G;<1\_P`CL-H!).3G"G@\9CT_7K:\2=[B/5M/$4*W"_:BG[V)B0K*$9NX
MQM.&Y''-9UGX;9KF/SH=(TZRS+*;*QFW)'*8S&K+^[0$D/(6)`P0O7DC2T"V
MOX+M;C5GTV-H;1+2(6ERTF\*<EVW*NW/'RC..>32NPT%_MVQ.EZ?J"OJSI?A
MC#$D9:7"QM(<H.<X0C'7)`QDU3/BF%9#:RV&N1:INB":<[P^=()`Y4J?,\O&
M(I"<N"-AR.F9K+3+RPALW2XL)9[&PEBMT><A&G=@<L=N0H"@9`)^9N*SQINN
M3-;:A<PZ-_:MI>+=J1JCLEP3%)$RD^0#&JK)E0`W/7DDDNPT+,WBVRBT]+R.
MWUJ>-89)[I86C+6B1N4?S!OY(97&$W'Y3C-:$>K02ZH;15U,VXE\C[=O3R3+
M@'8/FWYYZ[=N>,YKG_\`A&]5M=/N(K.726GU*VN(;QIKMPMNTLTDN8P(_P!X
M`9G&#LSM'(R<:#>'C)XDAN&:R6Q@F2X61+V7<S*N`#`?W8;/60')`QCO1=AH
M=%96OF6B/Y\ZYSPKX`YJ?[%_T]7/_?RH[">%+*-6E16&>"P'<U9^TP?\]X_^
M^Q3=[@K$7V+_`*>KG_OY1]B_Z>KG_OY4OVF#_GO'_P!]BC[3!_SWC_[[%*[#
M0YU=;MVUM-.,>K+').UK'>ED\AYE4L4&&W@X5N2H&01G-.U'6(=.U'[(T6K3
M1IY?GW,+(8K?S&VKNRP8\_W5;`Y.*IQ:5?+K42&335TJ#49=0647+&=V='^0
MIL"J`TA.[<>`..>"^L-4O+F8#^R4M]06W-X3>.6@9#\PC'EXD!&`"2GKCM1=
MAH7+75$U":>**WU<6ZB41WDH7R)BAVL!@EAR#C<JAL97(YK7@M-UO&WVBX&4
M!P'X'%<OI7AT:5J4LR1:7%&B3`74$I-Q=ASE5E&T8"]OF;IP%Z5UMO<0+;1`
MS1@A`""P]*>M@T$^Q?\`3U<_]_*/L7_3U<_]_*E^TP?\]X_^^Q1]I@_Y[Q_]
M]BE=AH1?8O\`IZN?^_E'V+_IZN?^_E2_:8/^>\?_`'V*J:I#;:II=S8M?M;K
M.A0RP2*'4'KC((_,&B[#0Q8?$%M>V<UQI<.LZCY=VUH$MPH+LJABP9V50F#P
MS$`]LY&4;Q#:BVM[I(=9DM9!F68*H6W^<IA]Q&3N!!";B.N,$&J-OI&O:+9W
M\6F:K:7SW=[YA:]N$@*0^6J_*8H,!\J/X2``,<YJ35M)OM6T:+33;Z'!$8=J
M.MT[2Z?-AAYT+E/G8`@CB,@@_,<\%V&AK:I<1Z-Y,<%MJ5[<7+.RV]F\8=L#
M+,=[*/3OG)%9R^*["4VLL":O-93BWW7B%!'`9L>6K@L'!.Y<X4XR,XJQJ#:A
M<7MKJ&GPV+W-E)-;A+R[:%98V"_.&6-CG<HXQCKSTK&M?#.HV-K%I<5QI<EE
M,;.2[N6N&617AV;PD>T@AA&,$N,9/!QR78:&YI^L0ZAJ8LQ%JT*/YGV>YE9/
M*N/+;:VW#%AU_B"Y'(S6I%:[KNX3SYQMV\A^3QWK$TC3KZVU&U6[DTY;&P\_
M[/)#<LTDN]N-RE0$P,YPS9/I6]#/"+VZ8RH%;9@[ASQ35PT)/L7_`$]7/_?R
MC[%_T]7/_?RI?M,'_/>/_OL4?:8/^>\?_?8I78:&#+JB6^K+9S6^L1P/+Y*W
MS[!"TF,[1\V__@6W;GC-)H=ZGB:P2[%EJD%E*D<]O+=O"5G4_,K*JNQ'0'Y@
MIY'?I',-7NM?+W,&BRZ;&Q^S,UZ^^,%<%VB\O#-R1]\``GWS6TJSDT1[B]33
M='M&8)%]ETN7"3DN`96_=KM8#.!\V!U;'(+L-">7Q#:6UQ=I>1:S:PV\4TRS
MS*`LR0_ZPHH)?CME1NZKD$&F'Q#&ML"]EK2WS3K;IIYE@\YV9"XP?,\O&Q6;
M[_`!JOJ6BW^K:A/,]QI=A)Y4L2W]G*1-<QLC*B2*5^55+!N';E<C;G%4[?PQ
M<V;P7]A:Z'83VUVES%I=K=;+7<(I8G<N(00S+*,_)_RS4>IHNPT.FT^XAU;1
M?M\$MVJL'5HIG&Y'0E61L$C(92#@GIUJ[!:;K>-OM%P,H#@/P.*SM#LQI7AU
M[6>>W-S+)<7$HBDW*'ED>0JI(!(!?`)`)Q6M;W$"VT0,T8(0`@L/2GK8-!/L
M7_3U<_\`?RC[%_T]7/\`W\J7[3!_SWC_`.^Q1]I@_P">\?\`WV*5V&AB>(]5
ML?"^BSZKJ%U?&&%2=D.7=R`3A1]`3DX``))`&:M7T#V,$ES;6U_>S,5!BMI(
MUD8?61E&![FH?%5H-<\)ZOI5M<VR3WEI+!&TLF%#,I`)(R<<^E&K3W.H66K:
M;9RQ6TKVNRWNVDXWN&!XQU7`/?J*+L-#'M_%27<5G]FTKQ!+<W8G>.U$ENK^
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M`&A!]JDUF/38[J8JS36U\TWF'D8PT:;%'&`,]3GG).M8D,+@@@@S,01^%/6P
M".B2:IAT5AY.<,,_Q5Q+>*+^SLUU&YM=+FM+RQGNK.-(6B:)D9`JR,6;<"'&
M2%&,'@YKM)I?*U(-Y;O^YQA!D]:Y^#PS9QO)Y\NL74/DRP002A%2V21@S"/8
MJGJJX+%B`.#UR:@58_$-Q%IFZ46%S=&]6$%=/FM3Y80R2;H9#N4[$?:VX@\'
MVJWI-]JKR/%?6FFW4TMDEY;):PF'&XD%&+LV<<?,,9Y^7UEM=#AAO%O+J?5[
M^XV2([W*1CS-P5>0B*/E4$#`'WVSDG(FT;3$T>1I#/JU\_E+!&UVD9\J-<X5
M=BKGKU.2>,FE9AH4[?5[Z[TS1#;Z?IIU&_CEEEC<D1H$0]#@G'F&-<XX#$XS
M@51EU?6[?4TT61-'DNY[F*WBU".R;R4<Q2RNC1>;N+*L2_QC/FKP,5L1:/;V
M\`2!M4B=+-K.*953?$K')9<KC=D+U!'RCBJ47AHQV45NVK:](\$RSVT[06WF
M0.`P9E(A`8L'8,7#9R>Y)HLPT,S_`(275;G3+F:S@TI;G3;:XFO%FM6*SM#-
M)$5CP_[L,87.3OQD<'FKR>)4_P"$B6UD?3$BDN$MTT_R3]JVLH*S%MV-A.1C
M9C_:SQ3YO"=I)9I:QW6M6Z-#)#=&%8@UXLCEW\PE#@EF<Y38?G.,<8TCIL;:
MLEZ\NK/"CB6.R<*84D"[0PXWCC/R[MN3G&>:+,-#3L((7LHV:)&8YY*@]S5G
M[-!_SPC_`.^!5.RNO+M$3R)VQGE4R#S4_P!M_P"G6Y_[]TW>X*Q+]F@_YX1_
M]\"C[-!_SPC_`.^!47VW_IUN?^_='VW_`*=;G_OW2LPT.9CU:^;6X&,.G-I4
M^HRZ<(A;L)T9%<[R^[:06C(V[1P0<\8I^KZC?6NHW36<6FBQL/(^T1S6[-++
MYC<[6#`+A<'E6R?2IDT2%=:&H&;5FB2X:ZCLBD8@CF9"I<87>3AF."Q&6)QT
MPV?0UN;F.:6]UI@5B6YC"1!;LQG*M)A,@YZ["H/3&*+,-"EHVO2ZMJ%PCK8I
M;,DYAB%E-&ZA&*@B9OW<I(&6"X*9QSUKK;>W@:VB)AC)*`DE1Z5APZ5#:7,E
MPLFIO$JR?9[:54\JW+\L5PH8YY^\S8SQ@5KP7>VWC7[/<'"`9"<'BGK8-"S]
MF@_YX1_]\"C[-!_SPC_[X%1?;?\`IUN?^_='VW_IUN?^_=*S#0E^S0?\\(_^
M^!5352EAI%[=P6(N)H('D2&.+>TC!20H`&22>,"IOMO_`$ZW/_?NHKJ9;JUE
MMVAOHQ(I4O%E'7/<,#D'WHLPT.>T^YU;4-,<1W6CK>QR`SO<:1/;BWCP?^6+
MR;GR00&W*N,D9Q@R?VM?C3]%G;2+0?;+A(KB0G"JI?:"B]26&&&<8![GBHKC
MPT+J)O,U37OM4C)YUV(K??,B;MD;KY6PH-['&WJ><UKM;B:RM+>Z?4KE[>9)
MO/DC17=E;(W;5"_D!19AH-\1-=6.FM<Z?#:CRLM(7LI+EB.P6*/#,2>^>.N#
M7/CQ%?W$::A;V^E"Q@:SCNH/*,CL9]FXQRA@H"B08^4[L'D5N7,%[>(^Z^U6
MSE$K&&2T2/*QG'RE71E;IU*DC/![U0'A>R2:'R9=8ALT\AI+)`GESM$049R5
M+DY"YPP!VC(/.2S#0=I.HWUSJ=JUW%IK6%_Y_P!G2*W998O+;C<Q8A\C)X5<
M'UK?A@A-[=*8D*KLP-HXXK(T_2(M/U'[6)M6GC3S/(MIDC\NWWMN;;M4,?;<
MS8'`Q6I%=;;NX?R)SNV\!.1QWIJX:%S[-!_SPC_[X%'V:#_GA'_WP*B^V_\`
M3K<_]^Z/MO\`TZW/_?NE9AH<_>7U_8^++"SEMK!M.O96C4+;.&C`C+!VF)V;
MBR[1$!NP<@G!JSX?U"75;[6K>\TVWM6L+M8$1<,2K0QR`L>F?WG;@>_6EDT]
M9=56\EGU>2!9!,MDX0PK(.C`[=_'7;NVYYQ1]D:UDU.YT\7D=UJ-S%/*SHI5
M=JQQD*,'@I'W[D\CC!9AH5Y#K::P+0KH^VZ$IB5+5W:U51\KR'>/,!.`0`F"
M<`G&:R5UG6(-*NKNX;2YHVO1:6DUOI,Q8[=PD?R!(SRC<I`"D<*6Z5L:?I4N
MGZG<7O\`:FN7`G9F>">*`KSG`#",/A<\#=@4#1+5-$TS38?[3B;3`OV6["(T
MR,$*;SN4J6*LV<KCYCQ19AH6M'NDU7PU'?R00I*Z/NV1[<%21]T\J>.5/*G(
M/(K3M[>!K:(F&,DH"25'I6=900:7I+V<$%T03)(\DJ#+R.Q9W;&!DLQ)P`.>
M`*N07>VWC7[/<'"`9"<'BGK8-"S]F@_YX1_]\"C[-!_SPC_[X%1?;?\`IUN?
M^_='VW_IUN?^_=*S#0Q?&FH7'A_PGJ&J:;IMK<W%M"\N)B%1`JDEFQR>G0=2
M1R.HTM5@=-.EDLY+&TDC&\S7-J9D51R<JKH>GO4.LV\&N:)?:5<P7J07D#P2
M-$@#!6&"03D9Y]*AU"W?5H=2L;Q;LZ=>6X@$21@,N=P?G'\0('.>A]:+,-#F
MCK7B*.QTM[FWL(/M4<T\MW'HEQ<1QIN00JT:291F5F9B6(7:1[UH0^(A=>)G
MLH/L(M(;E;9]]G*?,)C1]PF7,:'YP`C#+8R#S6MJ=JVHF/R[G5[)54HZ6RIM
ME0]58.K`?5<-[U771+..]66)=1BMA(DQLE1?):1`H1SD;P0$7@,!QD@FBS#0
MH^(==GTKQ!%:06UK]F6**23-E),7+R,A#2(0MNJA<[Y,ALG&-IJ:XU#4;7Q'
M_9S6VF-]ICE-G&T$D:[E5B@:<@J[-M)*(NY0"?F'))M"_M"-6U&;42\]NL&H
M1111^7>*,X5\IG'S,/DV9SS[27&AI<W#2R7NN$*\DMLAV,+65U=3)&64MD"1
M@`Q95S@``"BS#0GT.34)=2O[#5(M.N/LJQ$7=G;F)"[;BT91F<AE`0YSR''`
MK7L0%%P```)F``_"LK0K&31('@-[J]_&<;1=0PC8>23F.-"22<DMDD_CG5L&
MW).V",S,<'J.E/6P"_\`,5_[8?\`LU<1HT;SWFF&YU'4#_:VGW4M]"U_+A&5
MX\,GS9BVEBOR;>O/(%=G-YW]I#R=F[R>=^<8S[5BZ:-!34-3_LL>'%O>3J'V
M78).I)\W;SUSG=[T-`8-D+J'0+.:RO=29M6N3?Q1SWTTK0VT:&1%!D);#;8]
MPSR9&!XXK3T"">.X^SV>K7DGVO2X;EI;FX:YV2,Q^=0Y(7<,\#Y?EZ=:U+2]
MTZYM;?4;.YT.6WC_`-%@N89%9$W,J^6K#@98(-H/)"CTJ+P^-''VL>&_^$?_
M`-9_I/\`9VS[_P#M[._7K2L%S+M+B\O=&\.V!UBYAED@FN+N[WCS3$B%=VXC
M:#ODC;D8^4\8J`V4\<D<5MJ.J'0KZ[M[=#+?3-*<+(SR),6\P(Y\M1R/NDCA
M@3T;06<E@-\6C-9S1&`94&-XSU3T*GGCI6+:VW@P:'>3VD'@_P#LARHNY(DA
M\ABIRHD(^4X)XST)HL%S!DEN9M,UA)-9U&./2+2\DLKE;Z126CGE4&0AOWNP
M(B_/N!YSDFM@7>H1>)(9V%Y++-?)`TBWP-LD9CR8O(W\2#!8DH#WW8XJY<KX
M5^S:0UT/"GV<<:69?*V]1_J,\==OW?:KZ_V9_P`).VW^PO\`A(/)^;&W[5Y7
MO_'MZ>U%@N:^G?\`'A%^/\S5JLZR^U_9$\KR-G.-V<]:G_T__IV_\>IM:@BU
M157_`$__`*=O_'J/]/\`^G;_`,>I6"YQ\<EPOB"SOS?7BW$VM3V3VS73F)H5
MCD(`B)V@@(K[@,]><&I=>,K:IJ-V+Z\AFT_[)]FBBNG2-M[\[HP=K[CE?F!Z
M<8-:$2Z*/%,WDKX>_P"$A9,R[`GVLI@?>Q\^,8Z]L5'<VV@6>JZ;;W4'AN#4
M8E":?'*D:RHHZ"('D`>BT6"YC:9<Z@OB!KFXFG>SOY[V&)VO))"Q0N55K<CR
MX5548!E.6PNX98UWMM_QZP_[B_RKGXO[)_MC4OLG]A?VQY?^F_9]GVG;CC?C
MYNF,9]JUX/MOV>/9]GV[!C.[.,4[:`7J*J_Z?_T[?^/4?Z?_`-.W_CU*P7(=
M:CMI=-=;R]GM+?<N^2"8Q.W/W0R_,,GCY2&.<`U5T?3IAH,EG?2WGER-)Y?F
M7+^?'$2=H,H._<!WSD>IQFIM0TW^U;0VNI66FWEL2&,5S%YB9'0X8$51L-&L
M;06M[IMMI-O;0P2K%]EC5(MDA1F(VC'.Q3Z46"YAZ=97/_"%:OJMAJVH0+>I
M)/;/)>RW9C@56\LQF5FVLXPQ//WL=@:K^*[[5;2TGOK9[NYDMM'6>UBM;P(8
M9\/F2:/>IE5CL`&U^588&<UOC7]"M]"B==7\.1:01]FB87*+;D`8\M>=O`'W
M1VJ.;4/#E[+I5W/>>&)Y"6&FS/)&Q)!VMY))[$`';W%%@N3^+X!/HB-NO$O'
M=(;<6U[-`!+(0H+>4ZEE&<G/8&L"]MY]/EG==5U+SM+NM/MK8R7TA$Z.T8;S
M$+;9"Y=URP)XXP175/;+IUO<75RU@D*RM=R2W!PL;8Y;)X7`'7]:IWJZ+_PD
MEHU\/#W]O%0+4S[/M6WG&S/SX^]T]Z+!<S]",JZMIMY]NO)9;_[7]IAENGDC
M&Q^-L9)5-I^7Y0.O.375P?\`'_=_\`_E6+IHT<:[??V7_P`(_P#VO_R^?9=G
MVCK_`,M-OS=?6M.+[7]KN-OD;_EW9SCIQBFD!HUS/BNT^V*(;;4+^+57B864
M%K=M$%?_`)ZN%^\BDC._<N.-I)P=S_3_`/IV_P#'JQ]9T32]0DBN=<TS0;EP
M5@CEOK=7.6;"H"X[LV`.Y/O2L%R"Y:_C\?Z5:RZA*]G<Z;=EK=!Y:AD:W&[(
M.2WSMSVSQW);X1L$6\U348+O47LVF:TMX;J_GN%`B8J\@\UB06<,..-JKCJ<
MWOMUE_;<5C]JT;^UH8F$<'F#STC;!("_>"G:I../E'I4<#66N:?-::?=:5<6
MT,P\U;.17"2*X?!QD`Y&3WYSUYHL%S(LH9AKDG]I32W$6JW%S!!<6.M7++&H
MWD*8AM2(JB8WJ<ALCODY,<=_'I%A<:9+?7$&NZEL2.?6+DA+412M&5F)9X]Y
M5&++S\VWGBNBLM1\-MX@N%L;SPP=:G+).()8_M$A4'<&P=QP%.0>F/:IFN]$
MN/#DB-<>'9=#@402`NC6T87`V'^$`<#':BP7)_#EP;CPD-S7!>'SX'\^8S,&
MC=T(\P@%P"I`8C)&">2:VK;_`(]8?]Q?Y5GPAQI2BS%B+(0_N_L_W-F.-N.,
M8Z5/!]M^SQ[/L^W8,9W9QBG;0"]157_3_P#IV_\`'J/]/_Z=O_'J5@N9_B.&
MTFMHDNKN_CRQ$5M8W3027#XX`*%6)&"?O`8R6X'#/L5S_P`(K9V&JZG(+TQQ
MQRSQ7'D--)Q\HD`!&XC&5`/IBH/$D&CO:Q3^*(O#[6\;$1R:FJ%%8^ADX!./
MTI)M+TRQTZZGN8=&BTN2WCBE2956V6),[1@C;M^8]?:BP7./O?$.JZ;X>72Y
MIM42XM9W-Q>06L]T-HF.R!9U0YPN`7?#$+R,MQUUQ:?:?$,,^GZEJ#78E22=
M&N'\B"#`S&T7"AF'3(WY).<#%6[;[&-"A^R_V,-'V+Y7E8^S[<\;<?+C.,8J
MC)8^'CXH4R6OAD^(3B8;HX_M?'1_[_;K[46"Y0\8>(;FSUO3K./^T[:WBO+9
MI9(+&9UN=T@!C\Q4*@`9)&<DD#ID&D_B>:Y^(`@N[G4M+L/[/OH]LMK+#''Y
M;18N"[IY9XWD,<JH*@\O@]9'9KIVG6EG+]@$$3HD/G_W\_+CH-V>F._2I9L&
M_B$_]F&]\B3RP_\`K/*ROF8SSMSLSV^[GM18+F9X8:XM-9U;29WG=8EBN(#)
M=O=`QN74'S'^8,3&24Z+D8)%;UE_R\?]=V_I67H(L!9.?#PT3[(9#N_L_;LW
M]\[.,^M:=ANV3[\;O.;..F>*.@"_\Q7_`+8?^S5YR+*XOK&"Q32KU[BQTN\M
M;QYK22)79WC&$9@/,+;6<;21QU&1GT*:+S=2"^8Z?N<Y0X/6N=3Q38EY?.CU
MB"'R)+BWF<H5ND1@K>7M8G.67`8*3NR.,X;`R;>QO-1NGMX?[4G@N)VO#?7]
MF;>25HX!&JNNQ`N',97Y5)V-UP36GH%O!JMQM;3KNWMH]+AL[A+FUDM]SAB=
M@W`;@.>1E?FZG)J[_;4$5H9;N+5;2=9XX'M97C,B;SPQ*,RE0,L2&/"GC(Q3
M=/UZVO$G>XCU;3Q%"MPOVHI^]B8D*RA&;N,;3AN1QS2T`R[?3E&C:%:7^DSO
MI^G64]S-;BV+!CL,2Q>7CYB4DD^7'8<57\^"\NO^$A73]4CD2ZM?M-N=*N59
M8$$HC`4Q@R,&D+,4!V\=@"=[^W;$Z7I^H*^K.E^&,,21EI<+&TAR@YSA",=<
MD#&35,^*85D-K+8:Y%JFZ()ISO#YT@D#E2I\SR\8BD)RX(V'(Z9-`.<DMY8=
M.U<2Z/J,D.KV=['96R6$C$-)/*P#@+B+?O1OGV^^"#C9%IJ"^)(;"$W`B6^2
M\FWZ>V#B/#.+G<4*GA0F`_X59F\6V46GI>1V^M3QK#)/=+"T9:T2-RC^8-_)
M#*XPFX_*<9K0CU:"75#:*NIFW$OD?;MZ>29<`[!\V_//7;MSQG-&@&SIW_'A
M%^/\S5JLZRM?,M$?SYUSGA7P!S4_V+_IZN?^_E-VN"+5%5?L7_3U<_\`?RC[
M%_T]7/\`W\I:`<=''*WB"UL38WINK?6Y[U[DVD@B6%HI,$2D;6R'5,`D]L8!
MPNK2_:KR]C2PU"1]36S>TD^P2[5"OGYV*_NBI^;#[3SQS6FNMV[:VFG&/5EC
MDG:UCO2R>0\RJ6*##;P<*W)4#((SFG:CK$.G:C]D:+5IHT\OS[F%D,5OYC;5
MW98,>?[JM@<G%&@&%IEG>0Z^Q"7PV3WKW%M+;%+:W64NXDBE\L>8S';D;V`W
MMPN`!WMM_P`>L/\`N+_*N<MM:MKZ]ELT74D!2<P3S,GEW'E-LDV@,6&&('S*
MN>V:VH+3=;QM]HN!E`<!^!Q3TL!>HJK]B_Z>KG_OY1]B_P"GJY_[^4M`)+NT
M@OK62VN4\R&08=,D!AZ'';V[URGADQ6?P\T32-2TZ>:X;1U,FGO;Y,BHB*Z,
M&PN?F`VL1G)]#73_`&+_`*>KG_OY3#IT9E68S3^8JE0Y;D`X)&<=#@?D*-`.
M/B?4%L=>GTR/4G&H2P1V]S-9M#<(\C>4Q\MD7"1+L8,5Z!LYQDS>(TTBTMSX
M>_L>]$%U9K;W%W;:7/<`6X+#RP\2,2_+8R?EW%NO!N1^((+RPN+S2[?5]1BM
M[EK=S!+%']U0Q<&5T!3D8.>>HXYI&\26,.B:7J5T-5M?[2GB@@MI2OFYDD"*
MS!6("_,&SGH1W.*-`&^/+*W\0^`->M8;62\F@MY1%`L;EC,J';A?XCD@C@\X
M(Y`JEKD4K:OJ%A]AO)KB]O;">VECM)&B1(WC+$R@;$VE';!(//`)-;VI2QZ0
ML:00ZA=W-PS%+:T=`[XY9OG95X[Y/?N:SY/$EK'/`IM];\AS`LMPRJBVSS$!
M%D5F#@Y9<X4[<C.*-`*^@H[:MIMM]ANXI]/^UBYFEM'CC.]^-LA`5]QPWRD]
M.<5U<'_'_=_\`_E6)I^L0ZAJ8LQ%JT*/YGV>YE9/*N/+;:VW#%AU_B"Y'(S6
MI%:[KNX3SYQMV\A^3QWIJP&C7+^-M)74;;29TM'N+FTU:RDC*J6,:_:8][X'
M3"@Y;L,\X)K>^Q?]/5S_`-_*/L7_`$]7/_?REH!QUU`UQJDVEM87QN&U1KKS
MUM7$?E&+&1,1LS@[,;LY[8IWAJ6YM[M[V]:=+&ULXK)1)I<EJ5._"J5)8N0,
M9=?DYX[UJ3ZO%;:U%ILMOK"^?(T,%R=@BFE$9D*+EMV=JM\Q4+P1NS3=,U`:
MUJ%WIUSIFL6<EJL<C_;'@=,DY4`QNXW#;NQU'![C)H!2US3;_7%\4&.&998K
M,V%@LB85RT8>1TSC.XNJ9SC]V1QS6?.E]-#YT9U0VBWD4C:@=-$=[$%23.R'
MR?G`/EH,QM\KMUQD;(\26`%Q-.VIV]E$9@EY*R^7.8MWF!`&+\;&ZJ,XXSQ4
MK:N8[1I9=/UR*?SA#%:N8]\S$$C:V_R\8!ZL,=#@\4:`3>&X;BW\(B*YC=&4
MS[#(NUW0NY1W7`VNRD,5P,$D8'0;=M_QZP_[B_RK,M9(M1TC[;#-=A&5ODE;
MD%200<<=01P<5:@M-UO&WVBX&4!P'X'%/2P%ZBJOV+_IZN?^_E'V+_IZN?\`
MOY2T`R_$VJ1Z6MLXTVXNKF4O'%-#82W*VX(&YG$:E@#QP/O'`X&2*UM)I.G^
M&K;3X+:^G@L+>!E3["QFB4Y"2>6R9W`J3@*2"/N]JO:I+)IT<9AM=7U"5\XB
MM&3(`ZDL[*H^A.3V!J!+NUDT2+6K%-2NUND1HXX%Q+)G[H(;`&,\[B`.<D4:
M`<5>:'K\OAT16>GQWFF17$EU"MY-);W,TKS%_-DB$)YRQ('R8)SM&%`Z:YN[
M.\\11:;+I=[;F*ZCN99X]-G:.><`;2)ECV;1P"[$?=QTJ4^)=+308M6FN-0B
M22X-J(&(,HF5RC)@$@[65LD$C"DYQS4]QJB6NJK9S6^L+`TJ0"].T0F1L;5&
M6WGJ!N"[<\9S1H!B>);?6=8U'2M2L+&TOM.ANK:2UWSRQ21-Y@WNT?E'MQN)
M&T;N.35=].U^+Q^-1U/1;:_MI-/OXW:WG:3?#NB,<.QXU0,0,!2^&+2'<,8/
M3ZC=Z=H)TZTEN+I6NYTMK>&'MD@9QT51D9/N!U(!;<:O86VO?V,;C4)+L6<E
MXPB!<*B%`1QR6.\84`G\QDT`K^&%F;6M7N42[:PG6)HY+RU-O*)`7#1A"J_N
MU41[3MYR?F;K6_9?\O'_`%W;^E9NDW:ZJ9T9-3LYX"HD@N73<`PRI^1F'([9
MR.X%:-@NU)UR3B9AD]3THZ`([I'JF7=5'DXRQQ_%7'VV@:B8XK6Y;1Q:V%G<
M6MI_I#RF?>R[6D&U-F%3D*6.3D$8Y[!T235,.BL/)SAAG^*L&UU'4KSQ#K^E
MKI=A`;.VMY;(RG=YGF-,NZ3:.!^Z!"CG'4Y.%;L!F:?X6D^UB:]ELXXY#(\D
M8U"6Z=7$7E1GS)`&?Y7E)+8Q\H`.,UK:!;7\%VMQJSZ;&T-HEI$+2Y:3>%.2
M[;E7;GCY1G'/)JC+K5]802PW4.FW-RE\D"SP6K1QR($,LH"%F(945QG<1NQG
MH5JQI-]JKR/%?6FFW4TMDEY;):PF'&XD%&+LV<<?,,9Y^7U6@:BV6F7EA#9N
MEQ82SV-A+%;H\Y"-.[`Y8[<A0%`R`3\S<5GC3=<F:VU"YAT;^U;2\6[4C5'9
M+@F*2)E)\@&-563*@!N>O))-ZWU>^N],T0V^GZ:=1OXY998W)$:!$/0X)QYA
MC7..`Q.,X%49=7UNWU--%D31Y+N>YBMXM0CLF\E',4LKHT7F[BRK$O\`&,^:
MO`Q1H&I!_P`(WJMKI]Q%9RZ2T^I6UQ#>--=N%MVEFDES&!'^\`,SC!V9VCD9
M.-!O#QD\20W#-9+8P3)<+(E[+N9E7`!@/[L-GK(#D@8QWK._X275;G3+F:S@
MTI;G3;:XFO%FM6*SM#-)$5CP_P"[#&%SD[\9'!YJ\GB5/^$B6UD?3$BDN$MT
MT_R3]JVLH*S%MV-A.1C9C_:SQ1H&IU%A/"EE&K2HK#/!8#N:L_:8/^>\?_?8
MJM800O91LT2,QSR5![FK/V:#_GA'_P!\"F[7!!]I@_Y[Q_\`?8H^TP?\]X_^
M^Q1]F@_YX1_]\"C[-!_SPC_[X%+0-3DXM*OEUJ)#)IJZ5!J,NH+*+EC.[.C_
M`"%-@50&D)W;CP!QSP7UAJEY<S`?V2EOJ"VYO";QRT#(?F$8\O$@(P`24]<=
MJ6/5KYM;@8PZ<VE3ZC+IPB%NPG1D5SO+[MI!:,C;M'!!SQBGZOJ-]:ZC=-9Q
M::+&P\C[1'-;LTLOF-SM8,`N%P>5;)]*-`U(-.T)['5I[MDTR,[)M]Y;RYN+
M[?RHF&P8V]OF;H,8'%=7;W$"VT0,T8(0`@L/2N2TW7+J^UNZLY[:U6W*7/E[
M;1XS'Y;A5Q,QV3[@2QV`;,8/-=;;V\#6T1,,9)0$DJ/2GI8"3[3!_P`]X_\`
MOL4?:8/^>\?_`'V*/LT'_/"/_O@4?9H/^>$?_?`I:!J'VF#_`)[Q_P#?8JIJ
MD-MJFEW-BU^UNLZ%#+!(H=0>N,@C\P:M_9H/^>$?_?`JEK#QZ=HM]?16MO))
M;V\DJ)(0BL54D`L>@..O:C0-3F8O#-U!HNL::VLQ7B:C>QLWVHQJ/LW[M95Q
M'&HW%%=0,8^[TYJ3Q7X5.N7$=W8Z_-:3+):CR@T)B5(IUD)7=&S!N,C!P2J[
M@0*CL]?OY?#VK7*V%K=WMD,KYEE+8*1LW9:*7<X4=,C.[!QT.&:YXAO;,7DU
ME#IZQ:7I46IWB36I=IE<R?)&0Z[#B)^2&Y(]Z-`U+FO:<GB!H9Y-.TR]:REE
MB6TU*;;#.C!?G)V-@@J,#:1QUZ&J$?AW4K>-=/2[TV:RG:SDNKJ6Y<2JT)3<
M$CVD,"(U`)<$9)(..>A\0O=66EF[TZ&U'EC?(7LI+EB.P6*/#,2>^>.N#6`/
M$5_<1IJ%O;Z4+&!K..Z@\HR.QGV;C'*&"@*)!CY3NP>11H&IH:1IU];:C:K=
MR:<MC8>?]GDAN6:27>W&Y2H"8&<X9LGTK>AGA%[=,94"MLP=PYXK`TG4;ZYU
M.U:[BTUK"_\`/^SI%;LLL7EMQN8L0^1D\*N#ZUOPP0F]NE,2%5V8&T<<4U8"
MS]I@_P">\?\`WV*/M,'_`#WC_P"^Q1]F@_YX1_\`?`H^S0?\\(_^^!2T#4YV
M[LKB]\1VMU(NDI%:R;XKZ.8BY"8YAV[<;2>IWX/]W/-36"OHFE7,CM!=WUQ>
MO-((Y,;@\N%YQ_#'M'(_@Y/>LQ?$#/XIFM6_L^&PAN&MV66SERVU`Q;[0/W2
MMG($9&2!G=S@:6@:D=8O-2$NG16]O"T?V;<OSR1LN0S#MGJ!U`QGG(!H&ISM
M_P""5UB[O1=RV5O"?M!MI;>]F8%I59<^0QV1$!SN*-\YY^7.*F?PN\MHX-IH
M44+7"3/HZS;K2XVK(,NQBZEG1S\AYC7KUJ:RUZ_O->N[!+2P)W7*6R/:2QQ@
MQ-M4FXY24MU*H-R<@YVDU;AU6ZLDO;?4(+"]NXY$AM7M(#"MQ*REC'M9G*[0
M,L<GCGC&*-`U+^BVBZ1X;^PR7$#,OFLL<3`I$K,S+$G3Y4!"C@<*.!TK5M[B
M!;:(&:,$(`06'I63H%W_`&SX+TW5I[>W2XO+".X<1)A59D#';G)`R?6M:WMX
M&MHB88R2@))4>E/2P$GVF#_GO'_WV*/M,'_/>/\`[[%'V:#_`)X1_P#?`H^S
M0?\`/"/_`+X%+0-3%\12ZM/!##HSZ<R.Q%UY]ZUN^S'`1E1\$]SC('3!.0P7
M-X-/>PMK#2H6@@B"PO<$V[@Y#1!M@(``'S;3][[O:K6M0W<=KYFGOI=HJ!GF
MN+V`R*B@9^ZK)[Y)88QT-0Q27]YX5MKV*PL[/49H4DDCGB:1820"WR*`S$#.
M%^4GID4:!J<U/X)DN--/DZW_`&;/M*Q6-F\+VMNI<,50O"6`X'0*#@<`5N-_
M;,GB&)YTTJXTN!AY+M?LDHX`,C1B(JS]<#<`,^O(RE\5S_\`"-0W`TRVEU0S
M.DL?E&-8XDEV&5T/S1EA@B,G<"V#T)&S?/JEIK-OB'2Y+&>X6%+986,Y4C+2
M;]P4;>3MVG@?>R<4:!J9>HZ%/K\MGJ\>LW.GW+R6TDMIOA:-%C?<=I>(N#U.
M.`3C(IJ^%+JR\4IK&G^(V=5@O/W=YY3@33-&5!VHK-&"G.7##8@!QD5J:[K"
MZ=J%A9V5C;SO)=01W3N.((Y'VCIU8GH/0$GH`:YUU[GQ<NDZ?86<EJ;*ZD6>
M3@27$3Q+M!`.$!D()P>0<?=.30-2?P_I[6&I:A?W`T^R^V*@:SL9]\7F!G+3
M$E4^=]X!X_@&2:V[$AA<$$$&9B"/PK&\.7TE_=:C8WZ6;W-FZ@M%:/;[@V>?
M+D);;E6`?.UL$CI6S8@*+@```3,`!^%'0!DTOE:D&\MW_<XP@R>M9EUID5Q=
MZG=QOJMK<ZA:Q6KRVX4-$L9D*LF0<-^];DYZ#I6O_P`Q7_MA_P"S5S%NUT/%
MOBFUU#7)TM38VDD3AEB6U#O<*=F<@'"KECDD_0`-@6+'1$M&@-Q=ZO?I!')'
M''<0P*H#A0>(XTR0`<'_`&FZ\8GT;3$T>1I#/JU\_E+!&UVD9\J-<X5=BKGK
MU.2>,FN;2;5;`W6B?:;CSUU#[1$OVV2<Q6Z0B0+YK_.^YT&Y6Z"7;RN,Z>@0
M3QW'V>SU:\D^UZ7#<M+<W#7.R1F/SJ')"[AG@?+\O3K2T`OQ:/;V\`2!M4B=
M+-K.*953?$K')9<KC=D+U!'RCBJ47AHQV45NVK:](\$RSVT[06WF0.`P9E(A
M`8L'8,7#9R>Y)J"PGO+_`$SP_9/JUY"WV2>YN[Q74.553&I8D$9W2!QD8S'T
MP,52DL[E-0L+:VU#56\/ZC?10`R7TQE.V&>1I%FW^8J.RQ*.0#M..&&30#2F
M\)VDEFEK'=:U;HT,D-T85B#7BR.7?S"4."69SE-A^<XQQC2.FQMJR7KRZL\*
M.)8[)PIA20+M##C>.,_+NVY.<9YKB_M%[=:'J)NM3U"V&E6-Y+9W"7LD98Q7
M$R([G=^]PD<?W\@[B3G-;(N]0B\20SL+R66:^2!I%O@;9(S'DQ>1OXD&"Q)0
M'ONQQ1H!U=E=>7:(GD3MC/*ID'FI_MO_`$ZW/_?NC3O^/"+\?YFK5-VN"*OV
MW_IUN?\`OW1]M_Z=;G_OW5JBEH!S":)"NM#4#-JS1)<-=1V12,01S,A4N,+O
M)PS'!8C+$XZ8;/H:W-S'-+>ZTP*Q+<QA(@MV8SE6DPF0<]=A4'IC%9T<EPOB
M"SOS?7BW$VM3V3VS73F)H5CD(`B)V@@(K[@,]><&I=>,K:IJ-V+Z\AFT_P"R
M?9HHKITC;>_.Z,':^XY7Y@>G&#1H!>@TB&SG><2:E)%&LGV:VF1/*MB_WBI"
MACU/WF;`)QBMF"[VV\:_9[@X0#(3@\5QVCR:B-;-U<7,SVE\EX(R;N23S=K_
M`"[H6&R#8H*_(3NS\V#Q7=6W_'K#_N+_`"IZ6`B^V_\`3K<_]^Z/MO\`TZW/
M_?NK5%+0"K]M_P"G6Y_[]U7OO(U&PGLKFSN6AG0QN`F#@BM*J>J7QTW2[F]6
MVGN6A0L(8(R[N>P``)/X"C0#(MM*AAMKY+A]3O;B^A$$]W/'&)6C`8*OR*JX
M&]L?+W.<U7U/P[:ZFX)DU6WC>V6SNHH8XMMU"I)"2;D)Q\SCY2IPQKG-)U&Y
MUJ:/3K[4]5V3:W(DS[9[%F'V4R+$A(1U4,I.T$-A1G.3F:[NKH>%4U--2N9;
MO3(GEEA6_9'%NDD@$WE@?OG=8\`2$*<$@@@Y-`.HN;>]O$?=?:K9R"5C#):)
M'E8SCY2KHRMTZE21G@]ZH#PO9)-#Y,NL0V:>0TED@3RYVB(*,Y*ER<A<X8`[
M1D'G*>/]=NM-T&2&R6_BDN+>9S>6UI++Y`5,]45MK$D`%L`#<<\8.5<WD]UY
MFK+?:A!-:W&G1VT;3RQ*Z2&/<'A)`8L7=?F7/'&"*-`.@T_2(M/U'[6)M6GC
M3S/(MIDC\NWWMN;;M4,?;<S8'`Q6I%=;;NX?R)SNV\!.1QWKF]",JZMIMY]N
MO)9;_P"U_:89;IY(QL?C;&253:?E^4#KSDUU<'_'_=_\`_E35@#[;_TZW/\`
MW[H^V_\`3K<_]^ZM44M`.9N-$L[N^EEN$U"6RF8R2Z<\4;6\CE=I9@5W'(ZK
MNVGKC-1VN@:=HKWD_A_2ETVYNC$',%I'&H56&0`%[C/'J>HZU!JD-Q!XIL-0
MM=4N#;2736UWMO2X0F-@L0@QY8`;:Y?EQCN"<7O#MF8+ZXFL[Z]N=,>)`LEW
M=//YTN3N="Q.%Q@?+A2>@`&2:`5G\.V[/(5N=9C0-*]JB)$!9R2!@[Q'9NW'
M>_WBP&XX`I8/#FGG3A8:M!<ZY;JVZ)-2LK=Q$><E0D:C)R<DY/OUH32ENM<D
M^RZIJ<T!\U=0<WTFPYR%CCVL!&RGO&%(`Y))S6;I&FV<WAZ34KG6-8AL;ZY$
ML$2:M<2-)"-PB179C("^0Y"$$DA<D#!-`-[2+"S\/^&K?1M/M+B.VM8/*0M&
M`3QRS8`&XG))QR236C!=[;>-?L]P<(!D)P>*J:-;7UIX9\G4)I)9P)6!E;<Z
M(68HC-SN95*J3DY(SD]:U+;_`(]8?]Q?Y4]+`1?;?^G6Y_[]T?;?^G6Y_P"_
M=6J*6@'/:YI[:V+4"\UBQ%O)YF+6.(B0]MZR(X..HXX//4#`UO?312P2W^JA
M!'$(;B..-9ED7=N<X0(=V5^4J5XZ<U/XCAM)K:)+J[OX\L1%;6-TT$EP^.`"
MA5B1@G[P&,EN!PS[%<_\(K9V&JZG(+TQQQRSQ7'D--)Q\HD`!&XC&5`/IBC0
M#+NO!WA[4;1H]2T=K^[?E[^ZLXGN&.<_>VX'T``YX`JTFD/#KIU.+4=:C0[0
M+,0P&%4``V+F,NJG`)`8<UR-[XAU73?#RZ7--JB7%K.YN+R"UGNAM$QV0+.J
M'.%P"[X8A>1EN.NN+3[3XAAGT_4M0:[$J23HUP_D008&8VBX4,PZ9&_))S@8
MHT`@N?#&DZQ':3ZWHT=UJ<31/)>&SC,CE#D*6*\KQ@C`R/2B7PCX=?61JT.B
M/:7@AGB,MI;K"Y,N-TF]0&$@`(#`@C>WK53QAXAN;/6].LX_[3MK>*\MFED@
ML9G6YW2`&/S%0J`!DD9R20.F0:3^)YKGX@""[N=2TNP_L^^CVRVLL,<?EM%B
MX+NGEGC>0QRJ@J#R^":`=3IEDFG7,]W(VI7MY,B1/<7,:;_+4L53Y%48!=NV
M>>2:TK!MR3M@C,S'!ZCI6%X8:XM-9U;29WG=8EBN(#)=O=`QN74'S'^8,3&2
M4Z+D8)%;UE_R\?\`7=OZ4=`(YO._M(>3LW>3SOSC&?:H/+6:]NH]FF/=O"BW
M*XR[1$OL#CKMSYF,\?>QWJW_`,Q7_MA_[-7)_P!CZA9>)_%4VA6D<-Q>V5D8
MY[AF2.27S+CS#YFULLJE>QQ\@QC%-L#6M++3=)B1K.VT*SC@D-NAAC6,1O(R
M@H,8P68(,=SM[XJ/P^-''VL>&_\`A'_]9_I/]G;/O_[>SOUZUS.EZ/JHM5T6
M73!91K?7-T&ADDF1MJ87=(\:\F1U8'JVUCV-:^@6\&JW&UM.N[>VCTN&SN$N
M;62WW.&)V#<!N`YY&5^;J<FE<+&LT%D]D`T6C-:W,9MQE04E3DE/1E^\<=.M
M8D%OX)70[NXMX?!HTAW1;F2-8?(9@?E#D?*2">,^M1V6G*NEZ/;W^DRR:?IF
MG3S26QM"^YF!C6-4Q\Q\LRC;C.&''-4GFCO-7L_$J6&J1&&\A^UV_P#95TC)
M;K#<)$`ACS(P>7+;`=O']T$EPL;5VOA?[/I#7H\*^0`!I9F\K;CC'D9X_N_=
M]JO+_9G_``D[;?["_P"$@\GYL;?M7E>_\>WI[5Q1M;FUT748[O3-1N%U6PO8
MK*!+&60IYEQ,Z(_R_NLK)%]_:!M.2-M;0M-07Q)#80FX$2WR7DV_3VP<1X9Q
M<[BA4\*$P'_"BX6.KLOM?V1/*\C9SC=G/6I_]/\`^G;_`,>HT[_CPB_'^9JU
M3;U!%7_3_P#IV_\`'J/]/_Z=O_'JM44KA8YJ)=%'BF;R5\/?\)"R9EV!/M93
M`^]CY\8QU[8J.YMM`L]5TVWNH/#<&HQ*$T^.5(UE11T$0/(`]%K-CCE;Q!:V
M)L;TW5OK<]Z]R;201+"T4F")2-K9#JF`2>V,`X75I?M5Y>QI8:A(^IK9O:2?
M8)=JA7S\[%?W14_-A]IYXYHN%C5MQI/]JZI]A&A_VKL_T_[+L^T8_P"FF/F_
M[ZK7@^V_9X]GV?;L&,[LXQ7':/93Q:V2T=_NA2\\V&>V*6]J)7W_`+F38/,W
M$`GYGQSC;TKNK;_CUA_W%_E3OH!%_I__`$[?^/4?Z?\`].W_`(]5JBE<+%7_
M`$__`*=O_'J1FO44LQM0H&226P!5NLOQ);R7GAC5;6&W6YDFM)8Q"W23<I&.
M".N?447"QG@:/XATF>4#P_J6FO(99G&R:%G4#+,>5)``Y/3%5=3O/#&GW%C%
MJMSX6MIK:,26:73Q(T2=`T8;E1QP1Z5G6VE-J>A^(HYTU#4K6>!6ADU*U,$\
ML@C92AB$<>57"$97DL>N!6Y>VMQ>C0--:.06AQ->?NSM*QJ-L;'MERIP>H1A
MZT7"Q::!;&PO9;E[!;.4O-<O.<1[2/F+9XVX'.?QJE=IHB>(K/[8GAU=<"!;
M3S@@N=HS@1Y^;'WNGO4'CZR@\0^`M>M8K:2\GA@F$<*QL29PAVX7^(Y((X/.
M".0*HZY%*VKZA8?8;R:XO;VPGMI8[21HD2-XRQ,H&Q-I1VP2#SP"31<+&OIH
MT<:[??V7_P`(_P#VO_R^?9=GVCK_`,M-OS=?6M.+[7]KN-OD;_EW9SCIQBN;
MT%';5M-MOL-W%/I_VL7,TMH\<9WOQMD("ON.&^4GISBNK@_X_P"[_P"`?RII
M@'^G_P#3M_X]1_I__3M_X]5JBE<+'.21Z0WB0I*GA\Z[+`058)]I>(C!']XK
MU]JS]*T[PQ>+=VOA^/PTKJT?VH:6L6X;7W*'V#CE3U]#C!JM]CO(/%%TFV^D
M>:_:Y\D6*F`QF(*)1.4P)0%"@;P>,;<<U:\+S+H]F+6.75CHUG!%`@U&R,3P
M."$5%Q&I=<=6^8=]V*+A8L6-AX>BUZZ;3[3PRFL0Y:Y-O'&+B/=U+X&X9SSG
MKFFW!\.:CX?7[2?#%UHMBP0>9Y;V]N5&T#GY5(!QVQTK$\1:?<ZI->6VB6%Y
M#,+:[@DMYK/R88_,5B9(W"A9'D<)D;SPQ)VG-/G2^FA\Z,ZH;1;R*1M0.FB.
M]B"I)G9#Y/S@'RT&8V^5VZXR"X6.KLK:.TT58M+@TV'3O+9HTLTVQ[3DDJ%X
MYR3^-6X/MOV>/9]GV[!C.[.,5F^&X;BW\(B*YC=&4S[#(NUW0NY1W7`VNRD,
M5P,$D8'0;=M_QZP_[B_RIWT`B_T__IV_\>H_T_\`Z=O_`!ZK5%*X6.;\20:.
M]K%/XHB\/M;QL1')J:H45CZ&3@$X_2DFTO3+'3KJ>YAT:+2Y+>.*5)E5;98D
MSM&"-NWYCU]JG\3:I'I:VSC3;BZN92\<4T-A+<K;@@;F<1J6`/'`^\<#@9(K
M6TFDZ?X:MM/@MKZ>"PMX&5/L+&:)3D))Y;)G<"I.`I((^[VHN%BW;?8QH4/V
M7^QAH^Q?*\K'V?;GC;CY<9QC%49+'P\?%"F2U\,GQ"<3#='']KXZ/_?[=?:N
M4O-#U^7PZ(K/3X[S3(KB2ZA6\FDM[F:5YB_FR1"$\Y8D#Y,$YVC"@=-<W=G>
M>(HM-ETN]MS%=1W,L\>FSM'/.`-I$RQ[-HX!=B/NXZ47"QJQV:Z=IUI9R_8!
M!$Z)#Y_]_/RXZ#=GICOTJ6;!OXA/_9AO?(D\L/\`ZSRLKYF,\[<[,]ONY[5R
MWB6WUG6-1TK4K"QM+[3H;JVDM=\\L4D3>8-[M'Y1[<;B1M&[CDU7?3M?B\?C
M4=3T6VO[:33[^-VMYVDWP[HC'#L>-4#$#`4OABTAW#&"7"QU&@BP%DY\/#1/
MLAD.[^S]NS?WSLXSZUIV&[9/OQN\YLXZ9XK!\,+,VM:O<HEVUA.L31R7EJ;>
M42`N&C"%5_=JHCVG;SD_,W6M^R_Y>/\`KNW]*.@$<T7FZD%\QT_<YRAP>M84
MGB;28Y->7[7J!70[<7%W(`=I4^9PA/WB/*8''&>,Y!`WW=(]4R[JH\G&6./X
MJQ9]+:36]<OO-TZ:*^L;:WCAN/G4M&TQ;>O]T^8O0GOQZO4!QU7R=.6\O[/6
M+'?<)`L,\L+.VXCY_D=AM`))R<X4\'C,>GZ];7B3O<1ZMIXBA6X7[44_>Q,2
M%90C-W&-IPW(XYK.L_#;-<Q^=#I&G6699396,VY(Y3&8U9?W:`DAY"Q(&"%Z
M\D:6@6U_!=K<:L^FQM#:):1"TN6DWA3DNVY5VYX^49QSR:5V&@O]NV)TO3]0
M5]6=+\,88DC+2X6-I#E!SG"$8ZY(&,FJ9\4PK(;66PUR+5-T033G>'SI!('*
ME3YGEXQ%(3EP1L.1TS-9:9>6$-FZ7%A+/8V$L5NCSD(T[L#ECMR%`4#(!/S-
MQ6>--UR9K;4+F'1O[5M+Q;M2-4=DN"8I(F4GR`8U59,J`&YZ\DDEV&A9F\6V
M46GI>1V^M3QK#)/=+"T9:T2-RC^8-_)#*XPFX_*<9K0CU:"75#:*NIFW$OD?
M;MZ>29<`[!\V_//7;MSQG-<__P`(WJMKI]Q%9RZ2T^I6UQ#>--=N%MVEFDES
M&!'^\`,SC!V9VCD9.-!O#QD\20W#-9+8P3)<+(E[+N9E7`!@/[L-GK(#D@8Q
MWHNPT.BLK7S+1'\^=<YX5\`<U/\`8O\`IZN?^_E1V$\*64:M*BL,\%@.YJS]
MI@_Y[Q_]]BF[W!6(OL7_`$]7/_?RC[%_T]7/_?RI?M,'_/>/_OL4?:8/^>\?
M_?8I78:'.KK=NVMIIQCU98Y)VM8[TLGD/,JEB@PV\'"MR5`R",YIVHZQ#IVH
M_9&BU::-/+\^YA9#%;^8VU=V6#'G^ZK8')Q5.+2KY=:B0R::NE0:C+J"RBY8
MSNSH_P`A38%4!I"=VX\`<<\%]8:I>7,P']DI;Z@MN;PF\<M`R'YA&/+Q(",`
M$E/7':B[#0LVVM6U]>RV:+J2`I.8)YF3R[CRFV2;0&+##$#YE7/;-;4%INMX
MV^T7`R@.`_`XKF=.T)['5I[MDTR,[)M]Y;RYN+[?RHF&P8V]OF;H,8'%=7;W
M$"VT0,T8(0`@L/2GK8-!/L7_`$]7/_?RC[%_T]7/_?RI?M,'_/>/_OL4?:8/
M^>\?_?8I78:$7V+_`*>KG_OY45S;O!;22QM>W#HI*PQ2J&<^@W$+GZD#WJU]
MI@_Y[Q_]]BD-S!@XFBSVRXHNPT.6B\36XLM3NKZTUNP33V".LS12-*^W<5C$
M3ON(&,],9]CBU?ZU;6!BW+JDR-"MQ*\3)B",G`9LL">>,*&/M2Z?IIMO!1TJ
M6XL_M\UM)]H>-_W;7$@)D8'&<%V)Z9K)U[PP^JR1E6TN=A9):PS7,F'TZ0;B
M9X/D.7)*=T_U:\T78:&UJMPFB_98X+;4KV>\F9$@LWC5B=K.S$NR+C"]<YR1
M52XU^*UNXH)[3644M!'<3;XF2UDE("))AR<Y902H8#(.<<T_6(CK-KY<FDZ)
MJ*P2L@@U5\+(.,.K>6VWOQL.<=?7*3P]J4"_8$NM.FLKA[26ZNI;EA*K0E-R
MI'M(8$1J`2XQDG!Q@EV&AL:?K$.H:F+,1:M"C^9]GN963RKCRVVMMPQ8=?X@
MN1R,UJ16NZ[N$\^<;=O(?D\=ZQ-(TZ^MM1M5NY-.6QL//^SR0W+-)+O;C<I4
M!,#.<,V3Z5O0SPB]NF,J!6V8.X<\4U<-"3[%_P!/5S_W\H^Q?]/5S_W\J7[3
M!_SWC_[[%'VF#_GO'_WV*5V&A@1ZI]HUJ[TZUL]8N%LY/*GNDEA$22&-9`OS
M.')PZ]%(RW7KAFF:@-:U"[TZYTS6+.2U6.1_MCP.F2<J`8W<;AMW8ZC@]QF.
M721+XF2^%IH<*I*)1J,+;;MACF-ALY!Z%M_3^&K5@KZ)I5S([07=]<7KS2".
M3&X/+A><?PQ[1R/X.3WHNPT([S7=+L=1O;*6\OC)963WUPR994C7&1QU;!!V
MC)P1ZC-<^(8UM@7LM:6^:=;=-/,L'G.S(7&#YGEXV*S??X`-4)/!\\>H7,UM
MXHN3#/97,.)FAW+)*P;.4C5B..I;=P.<5%;^&+FS>"_L+70[">VNTN8M+M;K
M9:[A%+$[EQ""&991GY/^6:CU-%V&ATVGW$.K:+]O@ENU5@ZM%,XW(Z$JR-@D
M9#*0<$].M78+3=;QM]HN!E`<!^!Q6=H=F-*\.O:SSVYN99+BXE$4FY0\LCR%
M5)`)`+X!(!.*UK>X@6VB!FC!"`$%AZ4];!H)]B_Z>KG_`+^4?8O^GJY_[^5+
M]I@_Y[Q_]]BC[3!_SWC_`.^Q2NPT,O5)9-.CC,-KJ^H2OG$5HR9`'4EG95'T
M)R>P-0)=VLFB1:U8IJ5VMTB-''`N)9,_=!#8`QGG<0!SDBE\12ZM/!##HSZ<
MR.Q%UY]ZUN^S'`1E1\$]SC('3!.0P7-X-/>PMK#2H6@@B"PO<$V[@Y#1!M@(
M``'S;3][[O:B[#0KGQ+I::#%JTUQJ$227!M1`Q!E$RN49,`D':RMD@D84G..
M:GN-42UU5;.:WUA8&E2`7IVB$R-C:HRV\]0-P7;GC.:Y^?P3)<::?)UO^S9]
MI6*QLWA>UMU+ABJ%X2P'`Z!0<#@"MQO[9D\0Q/.FE7&EP,/)=K]DE'`!D:,1
M%6?K@;@!GUY!=AH6-1N].T$Z=:2W%TK7<Z6UO##VR0,XZ*HR,GW`ZD`MN-7L
M+;7O[&-QJ$EV+.2\81`N%1"@(XY+'>,*`3^8SDZCH4^ORV>KQZS<Z?<O);22
MVF^%HT6-]QVEXBX/4XX!.,BFKX4NK+Q2FL:?XC9U6"\_=WGE.!-,T94':BLT
M8*<Y<,-B`'&11=AH;NDW:ZJ9T9-3LYX"HD@N73<`PRI^1F'([9R.X%:-@NU)
MUR3B9AD]3TK$\/Z>UAJ6H7]P-/LOMBH&L[&??%Y@9RTQ)5/G?>`>/X!DFMNQ
M(87!!!!F8@C\*>M@$=$DU3#HK#R<X89_BKEKKQ'=6=]XGCN-)LXXM+M()[0%
MLM*9&F7+D`A03&.`"0.3R<#IYI?*U(-Y;O\`N<809/6LZ?3+*YO=2NI;>^9M
M0MHK:5<8"K&9"I7'(;,C<Y[#IW-0,:/Q#<1:9NE%A<W1O5A!73YK4^6$,DFZ
M&0[E.Q'VMN(/!]JMZ3?:J\CQ7UIIMU-+9)>6R6L)AQN)!1B[-G''S#&>?E]9
M;70X8;Q;RZGU>_N-DB.]RD8\S<%7D(BCY5!`P!]]LY)R)M&TQ-'D:0SZM?/Y
M2P1M=I&?*C7.%78JYZ]3DGC)I68:%.WU>^N],T0V^GZ:=1OXY998W)$:!$/0
MX)QYAC7..`Q.,X%49=7UNWU--%D31Y+N>YBMXM0CLF\E',4LKHT7F[BRK$O\
M8SYJ\#%;$6CV]O`$@;5(G2S:SBF54WQ*QR67*XW9"]01\HXJE%X:,=E%;MJV
MO2/!,L]M.T%MYD#@,&92(0&+!V#%PV<GN2:+,-#,_P"$EU6YTRYFLX-*6YTV
MVN)KQ9K5BL[0S21%8\/^[#&%SD[\9'!YJ\GB5/\`A(EM9'TQ(I+A+=-/\D_:
MMK*"LQ;=C83D8V8_VL\4^;PG:26:6L=UK5NC0R0W1A6(->+(Y=_,)0X)9G.4
MV'YSC'&-(Z;&VK)>O+JSPHXECLG"F%)`NT,.-XXS\N[;DYQGFBS#0T[""%[*
M-FB1F.>2H/<U9^S0?\\(_P#O@53LKKR[1$\B=L9Y5,@\U/\`;?\`IUN?^_=-
MWN"L2_9H/^>$?_?`H^S0?\\(_P#O@5%]M_Z=;G_OW1]M_P"G6Y_[]TK,-#F8
M]6OFUN!C#IS:5/J,NG"(6["=&17.\ONVD%HR-NT<$'/&*?J^HWUKJ-TUG%IH
ML;#R/M$<UNS2R^8W.U@P"X7!Y5LGTJ9-$A76AJ!FU9HDN&NH[(I&((YF0J7&
M%WDX9C@L1EB<=,-GT-;FYCFEO=:8%8EN8PD06[,9RK283(.>NPJ#TQBBS#0I
M:;KEU?:W=6<]M:K;E+GR]MH\9C\MPJXF8[)]P)8[`-F,'FNMM[>!K:(F&,DH
M"25'I6#!I$-G.\XDU*2*-9/LUM,B>5;%_O%2%#'J?O,V`3C%;,%WMMXU^SW!
MP@&0G!XIZV#0L_9H/^>$?_?`H^S0?\\(_P#O@5%]M_Z=;G_OW1]M_P"G6Y_[
M]TK,-"7[-!_SPC_[X%177V&RM9;FX2&.&)2SN5'`%'VW_IUN?^_=0W;6U_:R
M6MYILEQ;RC;)%-`'1QZ$'@T68:')OXBU273)Y4TF*VN%U,VH`T^6\\B$1"3?
M)'$0Q;&!@$`%@.<<VM2OM8@T9-4T\Z+=0Q6X)1K21)+R?<5\I%+_`+DD@*-V
M\[B00,<RVWA?3--AN4T6&^T9Y[C[09-/@BCVG;MV[2A1EQGAE."21@TR3PTJ
MS6TEEJ>NV(MU;;'!%;LAD=F9Y2)(F^=BS9(QU(&,FBS#0T-:ENTO;#3M*6P@
MNKI99#)=VQE150#(VJRG)++SGUZUSUKXGU&^LX=4BM-,CM(6LX[RV>!FD9IM
MF\I)N``7S`1E3G!Z5N7NGW.HLLDEYJ=G<0S.T$]I%%O6-A@H=Z,I!QGIG('/
M%5$\+643VR02ZQ%90BW#V:A#'.8<%&=BI<GY5SA@#M&0><EF&@_2=1OKG4[5
MKN+36L+_`,_[.D5NRRQ>6W&YBQ#Y&3PJX/K6_#!";VZ4Q(579@;1QQ61I^D1
M:?J/VL3:M/&GF>1;3)'Y=OO;<VW:H8^VYFP.!BM2*ZVW=P_D3G=MX"<CCO35
MPT+GV:#_`)X1_P#?`H^S0?\`/"/_`+X%1?;?^G6Y_P"_='VW_IUN?^_=*S#0
MYK5=5O='\16T<]K8OIEP7`5+9P\:K&S;S,3LW%EVB(#=SD$@&G>$M6FUKS#>
MK8',,<RQQ64T#1[LY7,G$RCH)%P"<_**MSZ7'=:@;BYFU::UW^9]@D5#"'QC
M</EW_P#`=VW/.*AM]+FT^)VM+K5)KC$<4+W21GR(5<$HN$&1C(RV6/'S=Z+,
M-"+5=>DTFXUI[G2[5+2PT\W<)+#?*06!W<85>!ZGN<=*HKKM]*MM90OIAOKR
M^%M%+)IDT0B7RI)27A=E8\1,%8-ALYXQBN@O+&SOYKF2YM;QQ<VOV21-N`4R
M3QCD'YCSFLZ7P_',@DDO-9;4%F26/4#%#YT94.J@#R]F-LCCE22&.319AH7-
M"O/[6\./=7$%NMU')<6\IBCVJ9(I'C9E!)(!*9`R<9K7M[>!K:(F&,DH"25'
MI6;86\.E:-]@ABNW4"1FEF0;G=R6=VP`,EF).`!STJ[!=[;>-?L]P<(!D)P>
M*>M@T+/V:#_GA'_WP*/LT'_/"/\`[X%1?;?^G6Y_[]T?;?\`IUN?^_=*S#0H
MZU#=QVOF:>^EVBH&>:XO8#(J*!G[JLGODEAC'0U#%)?WGA6VO8K"SL]1FA22
M2.>)I%A)`+?(H#,0,X7Y2>F13-<T]M;%J!>:Q8BWD\S%K'$1(>V]9$<''4<<
M'GJ!@:WOIHI8);_50@CB$-Q''&LRR+NW.<($.[*_*5*\=.:+,-#$7Q7/_P`(
MU#<#3+:75#,Z2Q^48UCB278970_-&6&"(R=P+8/0D;-\^J6FLV^(=+DL9[A8
M4MEA8SE2,M)OW!1MY.W:>!][)Q5&Z\'>'M1M&CU+1VO[M^7O[JSB>X8YS][;
M@?0`#G@"K2:0\.NG4XM1UJ-#M`LQ#`850`#8N8RZJ<`D!AS19AH.UW6%T[4+
M"SLK&WG>2Z@CNG<<01R/M'3JQ/0>@)/0`USKKW/BY=)T^PLY+4V5U(L\G`DN
M(GB7:"`<(#(03@\@X^Z<I<^&-)UB.TGUO1H[K4XFB>2\-G&9'*'(4L5Y7C!&
M!D>E$OA'PZ^LC5H=$>TO!#/$9;2W6%R9<;I-Z@,)``0&!!&]O6BS#0M>'+Z2
M_NM1L;]+-[FS=06BM'M]P;//ER$MMRK`/G:V"1TK9L0%%P```)F``_"LW3+)
M-.N9[N1M2O;R9$B>XN8TW^6I8JGR*HP"[=L\\DUI6#;DG;!&9F.#U'2GK8!?
M^8K_`-L/_9JXO4(9[4:A?:5J^HR6B6TD=W<2W;2(TI=0#&#\J%!YF2@502!@
MD';V$WG?VD/)V;O)YWYQC/M6!I>F>&?[1O8=(L?"_P!N1#%=I:11^8JMU60*
M,@''0]:&@,RY>YT^[N=%T^]O942[2=#->22R(B0^:R[V)8J66,%2>DA'0XJ[
MH$$\=Q]GL]6O)/M>EPW+2W-PUSLD9C\ZAR0NX9X'R_+TZUI65EIFE01RV-KH
M5G#'(T"/!&L:J[NJL@(Q@LZH".Y`'4"F>'QHX^UCPW_PC_\`K/\`2?[.V??_
M`-O9WZ]:5@N9=A/>7^F>'[)]6O(6^R3W-W>*ZARJJ8U+$@C.Z0.,C&8^F!BJ
M4EG<IJ%A;6VH:JWA_4;Z*`&2^F,IVPSR-(LV_P`Q4=EB4<@':<<,,]0T%D]D
M`T6C-:W,9MQE04E3DE/1E^\<=.M8D%OX)70[NXMX?!HTAW1;F2-8?(9@?E#D
M?*2">,^M%@N87VB]NM#U$W6IZA;#2K&\EL[A+V2,L8KB9$=SN_>X2./[^0=Q
M)SFMD7>H1>)(9V%Y++-?)`TBWP-LD9CR8O(W\2#!8DH#WW8XJ[=KX7^SZ0UZ
M/"OD``:69O*VXXQY&>/[OW?:KR_V9_PD[;?["_X2#R?FQM^U>5[_`,>WI[46
M"YKZ=_QX1?C_`#-6JSK+[7]D3RO(V<XW9SUJ?_3_`/IV_P#'J;6H(M455_T_
M_IV_\>H_T_\`Z=O_`!ZE8+G'QR7"^(+._-]>+<3:U/9/;-=.8FA6.0@"(G:"
M`BON`SUYP:EUXRMJFHW8OKR&;3_LGV:**Z=(VWOSNC!VON.5^8'IQ@UH1+HH
M\4S>2OA[_A(63,NP)]K*8'WL?/C&.O;%1W-MH%GJNFV]U!X;@U&)0FGQRI&L
MJ*.@B!Y`'HM%@N96@S7SZ@UU?/<YO5NPI_M%I48HY^4P%=L6T`*"AR<?-R:[
MFV_X]8?]Q?Y5R]IJ'AZ;5K[^SKOPY)J\R,+G[))&;EPHY#;3N.,=^E;\'VW[
M/'L^S[=@QG=G&*=M`+U%5?\`3_\`IV_\>H_T_P#Z=O\`QZE8+EJJ&N/-'H.H
M-;7$%M.+>3RIKB3RXXVVG#,V#@`X.:E_T_\`Z=O_`!ZF2_:S$_F_9/+VG?OS
MC'?/M18+G$-:ZAY(\/PNT5ZEQ'-.LWB&[/VF,I)M6.<KO5LQAF11@#)YS3M4
MO=WAP:I87=XDVE0L\]H=3DWQ1QO(KR!3\UP6,;*OFD*P&1@YSH+_`,(F/"[;
M?^$3_P"$?,OS8\K[*9,]_P"#=G\:NW8T7S-+:\'A[?D#3C-LSTX\G/M_=HL%
MR+Q8VH75SI>GV,3O'<B5W`OY++)4*5!EC!<=6.`.<<\9KG8[R>[LEU9=2U-9
MK6738K827A`E20QAO,12(Y"Y=USM[?+C%=-JUII5GID_]O\`]B_8)[CS7_M+
M;Y1D/3[_`,N>..])<+H7_"06+7(\.?VT8P+,R[/M&SG'EY^;'7I[T6"Y1T(R
MKJVFWGVZ\EEO_M?VF&6Z>2,;'XVQDE4VGY?E`Z\Y-=7!_P`?]W_P#^58NFC1
MQKM]_9?_``C_`/:__+Y]EV?:.O\`RTV_-U]:TXOM?VNXV^1O^7=G..G&*:0&
MC157_3_^G;_QZC_3_P#IV_\`'J5@N<QJJ36OBBQU*WU6?[(]TUO>?Z:65,QL
M%C$&/+4!MKES\XQW!.)?#<-SI_B._M'O9[FRFM8KBU,EX]UNY8-(6;[A;*_(
MOR`+D=2!9!TG_A*"`=`_X2'RL'[GVKR\?]][<?A4.GV6C7]G>0:(-"\HW"M=
M?V<$YE5@WS[?XLCOS]*+!<=;6,A\0M/INJ7TP4R_;'GN&EAW'(2-4R$4J<9V
M`'`PQ).:Q+JXUI-+M;"*XGOY;G7)[6:66Y:V)C"2L!YD8S$-R(,J.G`Y-:^G
MV7AV/Q#<?V;:^&5UN(LT_P!FCC%RF[J6V_,,YYSUS5V^^P?V3>?;_P"Q?[-W
MM]J^T;?)W9^;?GY<YZY[T6"XGARX-QX2&YK@O#Y\#^?,9F#1NZ$>80"X!4@,
M1DC!/)-;5M_QZP_[B_RK.MFWZ.C6#:>U@8?W)M3F,QXXV8XQCICBK$'VW[/'
ML^S[=@QG=G&*=M`+U%5?]/\`^G;_`,>H_P!/_P"G;_QZE8+F#\1'OH?`.LW&
MGZA+8S06DLWFP@;R%0G"M_#DXY'.,XP>1I^)#9Q^'[VXOWNEMK:)IW-K<20R
M$(,X#1D-VZ`\U%K-Y;6FG2?VY<Z1#8S#RG^W.%B<'^$[^#GTJ.[BM[:.\U2_
METU;6>&-9Y+A@(=BYVY)XQ\YY/M18+G,S:#JMI8Z;%)J,]RMO;3W-Y:RZ[<P
M3%W9""LBY=DC`=`&.#N&3GFI;74KV[\127\JW2645_#:P[;]T*K)%$55K?!5
MP2Y)9B&';@5OW,>FZY8V^H72:'J%G&PD@N90LL:G.`RL<@'/<42-IK>)(UD.
MAG7EAS&&*_:A'[?Q[>OM18+F%XLN=0BU^XN[::?[+IMK!-,JWDD/E`R/N9(D
M!%PS*N-KX`VC!RQQ->L]OXC@DAU>Z-CJ3W%H]U%?>;Y,P21L"(CRXQ'Y;#<,
MG=@..IJ_+8:/ILFDP7ZZ&+J#]W8-=A!+GN(\@'/LM).N@?;]3^T#PW]L^SG^
MT?,$?F>3CGS<\[,?WN,46"Y-X9LI+>ZO9;>\O9M(D2);5;RX>=F<;M\BNY+;
M&R@`SCY"1P03LV7_`"\?]=V_I7/>&3X=W7(\*?\`",[L+]H_LKR\]]N_R_\`
M@6,^]=!8;MD^_&[SFSCIGBCH`O\`S%?^V'_LU<OI,NGZWKH<:9J%@MI;36UM
M#)IL]L-CLN]C(4"C.U=JJV<9)YX7I)HO-U(+YCI^YSE#@]:PUUZ,7;V\UEKT
M+F%YK??&I-RJ$!MBJ2P/S+PX4\^QPV!B:;H]T-+AT6*RGMHEU34[I<PE4"+-
M+Y(R1@9,D;+ZA21Q6EH%O!JMQM;3KNWMH]+AL[A+FUDM]SAB=@W`;@.>1E?F
MZG)JTNO6ZVTCW4.KVD\5Q';R6TS1EU+XPV59E*A<L2&/"GC/%+I^O6UXD[W$
M>K:>(H5N%^U%/WL3$A64(S=QC:<-R..:6@&79:<JZ7H]O?Z3+)I^F:=/-);&
MT+[F8&-8U3'S'RS*-N,X8<<U2>:.\U>S\2I8:I$8;R'[7;_V5=(R6ZPW"1`(
M8\R,'ERVP';Q_=!/1_V[8G2]/U!7U9TOPQAB2,M+A8VD.4'.<(1CKD@8R:IG
MQ3"LAM9;#7(M4W1!-.=X?.D$@<J5/F>7C$4A.7!&PY'3)H!S9M;FUT748[O3
M-1N%U6PO8K*!+&60IYEQ,Z(_R_NLK)%]_:!M.2-M;0M-07Q)#80FX$2WR7DV
M_3VP<1X9Q<[BA4\*$P'_``JS-XMLHM/2\CM]:GC6&2>Z6%HRUHD;E'\P;^2&
M5QA-Q^4XS6A'JT$NJ&T5=3-N)?(^W;T\DRX!V#YM^>>NW;GC.:-`-G3O^/"+
M\?YFK59UE:^9:(_GSKG/"O@#FI_L7_3U<_\`?RF[7!%JBJOV+_IZN?\`OY1]
MB_Z>KG_OY2T`XZ..5O$%K8FQO3=6^MSWKW)M)!$L+128(E(VMD.J8!)[8P#A
M=6E^U7E[&EAJ$CZFMF]I)]@EVJ%?/SL5_=%3\V'VGGCFM-=;MVUM-.,>K+')
M.UK'>ED\AYE4L4&&W@X5N2H&01G-.U'6(=.U'[(T6K31IY?GW,+(8K?S&VKN
MRP8\_P!U6P.3BC0"2WMI;G6M9U*[@9/(7['9%U_Y9;%=W7C^)S@^OEK6Y;?\
M>L/^XO\`*N<MM:MKZ]ELT74D!2<P3S,GEW'E-LDV@,6&&('S*N>V:VH+3=;Q
MM]HN!E`<!^!Q3TL!>HJK]B_Z>KG_`+^4?8O^GJY_[^4M`+55=26)],NEGLC>
MPF)@]J$5_.7'*[6(!STP:/L7_3U<_P#?RHKJ(6EK+<--?2"-"Q2++NV.RJ!D
MGVHT`XZ#4%TR>_U,:7J=_'<7"-:7$^E3>='*496W1K$&2-5"*&"Y.XCGK6?J
M>FS"T$>FQZHL+Z>%M42P=1>SF21VBN%>,M!'NVX.8^)#\W`QT+>)(T(@;3]=
M&I&58ET[="93N5G#;A)Y>W:C')?MCJ0*9<>+;"&!)TCU>:%;<75T\;Q#['$6
M9=TH9P>"CYVAC\C4:`2^)9OM36<L<VH6\=K)*D]SIUH9YHGV@!1&8WRI#'+;
M3T'(S7.VUE<VVGQZ/-I-VMW,^F/;+%:2-%`D1CSF7!1"GENV"V>>,D\]GJ3K
MH]N)(;;4[LNS,R6A3CNS,6*J/Q.3VS6:_B:R$MN8TU>6TE^S[[Q"GEPF;'EA
MP6#Y.Y<X4XW#.*-`(-!1VU;3;;[#=Q3Z?]K%S-+:/'&=[\;9"`K[CAOE)Z<X
MKJX/^/\`N_\`@'\JQ-/UB'4-3%F(M6A1_,^SW,K)Y5QY;;6VX8L.O\07(Y&:
MU(K7==W">?.-NWD/R>.]-6`T:*J_8O\`IZN?^_E'V+_IZN?^_E+0#FKN[L;W
MQ$NG-I5_$EM<F<N-+EV74VPC(EV>6%P<%BPR0!TZLT62VM==U'54AOX;)[:"
MW87=BT!MRCL$BC4(NY!YC'<`P&?O$=-.75-/BU]=%:]O/M9MY+AB#\B(FS.6
MZ9^=3CT/;C+-)NX]?C.ZSU:W@*I/"]XJA9D)RKK@M@\`[6VL.,@4:`8NC6TD
MFI6-@UC>P36=Y?R74K6TD<;I*TF"LN`K;MR-\K$\<X(J&ZT6ZL]+M5LEN]/M
M+/7)[B3[';[Y!"4E4,D>UM_S.I^ZWK@XK6C\16TES+']GUH1*9EAG`5EN6B)
M#K&JL7)R#C*C."1D<U8M=8MI+>]DO1J>G262J\\%TZ%U5L[2/+9E;."``2<\
M8S1H!-X?2YC\*;;J'RY`9]N81$SIO<H[H``KLN&88'S,>!6S;?\`'K#_`+B_
MRK)TZXAUCP[;:M;37@@N[5;B-)F&X*R[@&`R,X//-78+3=;QM]HN!E`<!^!Q
M3TL!>HJK]B_Z>KG_`+^4?8O^GJY_[^4M`,OQ-JD>EK;.--N+JYE+QQ30V$MR
MMN"!N9Q&I8`\<#[QP.!DC+E%C9>&]+LK"&]FM]+:TE>$V<GG>3DA6\O:&)RI
M)4#(V]!P*V=4EDTZ.,PVNKZA*^<16C)D`=26=E4?0G)[`U`EW:R:)%K5BFI7
M:W2(T<<"XEDS]T$-@#&>=Q`'.2*-`./U;2]>U+2YIK'2H9=,:Z>[AMKF66VF
M\PRY#F+RF)``W`$@@L21D"M&[LM2?Q0]I:>?;I-J-O?W`:P9E?8(]Y6Z!V;-
MJ;-C*'SG^'%:I\2Z6F@Q:M-<:A$DEP;40,091,KE&3`)!VLK9()&%)SCFI[C
M5$M=56SFM]86!I4@%Z=HA,C8VJ,MO/4#<%VYXSFC0#"U<7=UKEQJ-FUY+!>V
MENEG"MAYD4[HTI*3%D/EKEE.3LZ]3C`O[9)O&-@]C8WL"P3S+=03V8C@5&63
M,Z2*N'=V$?&]OE8Y53DUI:C=Z=H)TZTEN+I6NYTMK>&'MD@9QT51D9/N!U(!
M;<:O86VO?V,;C4)+L6<EXPB!<*B%`1QR6.\84`G\QDT`F\,6\PT^74+Q'6]O
MY6GD$B%&122(T(/(VIM&/7)[FM&R_P"7C_KNW]*S=)NUU4SHR:G9SP%1)!<N
MFX!AE3\C,.1VSD=P*T;!=J3KDG$S#)ZGI1T`1W2/5,NZJ/)QECC^*N:MCXE%
MQ>WES;^'VOS"Z6DHU&1DC&0539Y(*@X!8AB20.P`7I71)-4PZ*P\G.&&?XJP
M%FUV/67L'M]&G:6UDGC6.)T%JP8!!(Y)WALM@A4/R'`/)#=@*MOI%]?2P?VL
MFEPJK333207S3O+,T?EHW,2``*SC';"X]KV@6U_!=K<:L^FQM#:):1"TN6DW
MA3DNVY5VYX^49QSR:RH/$EVEC.ES:V3WD.I"U5Q9O`)8A&)7?R78NGR+(H))
M!*AN0<5?TF^U5Y'BOK33;J:6R2\MDM83#C<2"C%V;../F&,\_+ZK0-1;+3+R
MPALW2XL)9[&PEBMT><A&G=@<L=N0H"@9`)^9N*SQINN3-;:A<PZ-_:MI>+=J
M1JCLEP3%)$RD^0#&JK)E0`W/7DDF];ZO?7>F:(;?3]-.HW\<LLL;DB-`B'H<
M$X\PQKG'`8G&<"J,NKZW;ZFFBR)H\EW/<Q6\6H1V3>2CF*65T:+S=Q95B7^,
M9\U>!BC0-2#_`(1O5;73[B*SETEI]2MKB&\::[<+;M+-)+F,"/\`>`&9Q@[,
M[1R,G&@WAXR>)(;AFLEL8)DN%D2]EW,RK@`P']V&SUD!R0,8[UG?\)+JMSIE
MS-9P:4MSIMM<37BS6K%9VAFDB*QX?]V&,+G)WXR.#S5Y/$J?\)$MK(^F)%)<
M);II_DG[5M905F+;L;"<C&S'^UGBC0-3J+">%+*-6E16&>"P'<U9^TP?\]X_
M^^Q5:P@A>RC9HD9CGDJ#W-6?LT'_`#PC_P"^!3=K@@^TP?\`/>/_`+[%'VF#
M_GO'_P!]BC[-!_SPC_[X%'V:#_GA'_WP*6@:G)Q:5?+K42&335TJ#49=0647
M+&=V='^0IL"J`TA.[<>`..>"^L-4O+F8#^R4M]06W-X3>.6@9#\PC'EXD!&`
M"2GKCM2QZM?-K<#&'3FTJ?49=.$0MV$Z,BN=Y?=M(+1D;=HX(.>,4_5]1OK7
M4;IK.+318V'D?:(YK=FEE\QN=K!@%PN#RK9/I1H&I!IVA/8ZM/=LFF1G9-OO
M+>7-Q?;^5$PV#&WM\S=!C`XKJ[>X@6VB!FC!"`$%AZ5R6FZY=7VMW5G/;6JV
MY2Y\O;:/&8_+<*N)F.R?<"6.P#9C!YKK;>W@:VB)AC)*`DE1Z4]+`2?:8/\`
MGO'_`-]BC[3!_P`]X_\`OL4?9H/^>$?_`'P*/LT'_/"/_O@4M`U#[3!_SWC_
M`.^Q5>^NI!8SFPDM&O-A\E;B7;&7QQN(!.,^@JQ]F@_YX1_]\"HKJW(M93:6
MULUSL/E"4;4+=MQ`)Q]!1H&IR266NG[)?O#HO]IVUT9V!U)V2X5HW0@OY(,>
MW<NT!6&!CJ<U0N/"E^+*]M;>;3'75]/^Q7[O=LA@S),[-$!&=_\`KW`#%?NK
M[ULPMK\PO+0-H?FVTBA]0-HXAP5)9?*\S)9?E!_>`8;/;%9%YXHU1+*ZNH[3
M38!I>FKJ5Y');-(;A"\H`B(==F5A9@6#??7T-&@:G0ZI)<:GI\UJFGZ3>6_F
M-$]IJ4Q6.=!@JV[8V.<\%3G`P1U.)'X>U.WC&GK>:=/9W#VDMU=RW3^<K0E-
MP5-I#`B-0"7!&22#CGIM8BNTLQ+ISZ7:(JM)-<7T!D5%`S]U63WR2PQCH:YF
M/Q#JTL,=\VGZ=;06[6<=[9RP,9=TVS<4?<`NT2`X*$G!!Q1H&II:1IU];:C:
MK=R:<MC8>?\`9Y(;EFDEWMQN4J`F!G.&;)]*WH9X1>W3&5`K;,'<.>*P-)U&
M^N=3M6NXM-:PO_/^SI%;LLL7EMQN8L0^1D\*N#ZUOPP0F]NE,2%5V8&T<<4U
M8"S]I@_Y[Q_]]BC[3!_SWC_[[%'V:#_GA'_WP*/LT'_/"/\`[X%+0-3#U335
MU'Q%8WOVJW6VAL+NUE'F?/F8PX('3`$;9Y[CKVR]#TV7PVLUPEEI<;;(K?RK
M&9C]J(8`S2908?!Z?-[OCD:5SJ$\?C&UT5=.MH[:XLYYTN7`9F>,Q#[HQA?W
MO<Y..W4Q^'GU6ZU34HM1?2KFRM66&.6VL7@9INKC#2."J@J,CON';DT#4SX-
M+UBUD18GT=H["6ZN+&1[MP97E+[5D79\H42$$AFSCH.E/31;W5+,#5;Z+3;R
M.X%R)].O4N/.?:0-XE@"A5R-H`.,`YR,E=&\0G5=7E5(K0VN^>..W^QR)(3$
M[+\LQ_=.3M)*#!7N34-UXFGM=(B>YL;6VOKG4Y;",16SW:Q;%D<$HF'D.V/&
M%QDGCBC0-36\-6#:%X(T_2+J_CN;FTLEA=U92"0N,+@+E1T&1G`&<G)K:M[B
M!;:(&:,$(`06'I6;I$ZZCX;CO)EM'G:-]SV\31KN!(^ZXW(>.5/*G(R<9K2M
M[>!K:(F&,DH"25'I3TL!)]I@_P">\?\`WV*/M,'_`#WC_P"^Q1]F@_YX1_\`
M?`H^S0?\\(_^^!2T#4Q?$4NK3P0PZ,^G,CL1=>?>M;OLQP$94?!/<XR!TP3D
M,%S>#3WL+:PTJ%H((@L+W!-NX.0T0;8"``!\VT_>^[VJUK4-W':^9I[Z7:*@
M9YKB]@,BHH&?NJR>^26&,=#4,4E_>>%;:]BL+.SU&:%))(YXFD6$D`M\B@,Q
M`SA?E)Z9%&@:G-3^"9+C33Y.M_V;/M*Q6-F\+VMNI<,50O"6`X'0*#@<`5N-
M_;,GB&)YTTJXTN!AY+M?LDHX`,C1B(JS]<#<`,^O(RE\5S_\(U#<#3+:75#,
MZ2Q^48UCB278970_-&6&"(R=P+8/0D;-\^J6FLV^(=+DL9[A84MEA8SE2,M)
MOW!1MY.W:>!][)Q1H&IEZCH4^ORV>KQZS<Z?<O);22VF^%HT6-]QVEXBX/4X
MX!.,BFKX4NK+Q2FL:?XC9U6"\_=WGE.!-,T94':BLT8*<Y<,-B`'&16IKNL+
MIVH6%G96-O.\EU!'=.XX@CD?:.G5B>@]`2>@!KG77N?%RZ3I]A9R6ILKJ19Y
M.!)<1/$NT$`X0&0@G!Y!Q]TY-`U)_#^GM8:EJ%_<#3[+[8J!K.QGWQ>8&<M,
M253YWW@'C^`9)K;L2&%P0009F((_"L;PY?27]UJ-C?I9O<V;J"T5H]ON#9Y\
MN0EMN58!\[6P2.E;-B`HN```!,P`'X4=`$=PFJ9(8_N?X5)_B]JQ;#PZ;'[4
M#X@UVX2YW%Q*D88,>C!TB5\C&!EB`.,8`K<_YBO_`&P_]FKBM32[LH=3U'1=
M6U&:&.TECN)YKHRH\Y90#&&RB&,!\E0JY(!!(.T8&Y;>'K6*^6]NK[4;ZYV.
MCO<1J/,#``9"1J/E`(&`/OMG).:FT;1H='D:0W^I7S^4L$;7:`^5&N<*NQ%S
MUZG)/&37->??V<3:/$]U%=K=B=D_M.2[V1)'YORRN!(0S*BLIS]\C[IJ_H$$
M\=Q]GL]6O)/M>EPW+2W-PUSLD9C\ZAR0NX9X'R_+TZTAFI%H5I;P!(+K4(G2
MS:SBF5/GB5CDLN4QNR%Z@CY1Q5*+PJL=E%;MKVM2/!,L]M.UO!YD#@,&92(`
M&+!V#%PV<GN2:IV$]Y?Z9X?LGU:\A;[)/<W=XKJ'*JIC4L2",[I`XR,9CZ8&
M*I26=RFH6%M;:AJK>']1OHH`9+Z8RG;#/(TBS;_,5'98E'(!VG'##(!KS>#K
M&2S2UCU+5K=&ADANC"B!KQ9'+OYA,1P2S.<IL/SG&.,:1TB!M62]>]U)X4<2
MQV3KF%)`NT,/DWCC/R[MN3G&>:X;[1>W6AZB;K4]0MAI5C>2V=PE[)&6,5Q,
MB.YW?O<)'']_(.XDYS6R+O4(O$D,["\EEFOD@:1;X&V2,QY,7D;^)!@L24![
M[L<4`==83*EE&I#Y&>B,>Y]!5G[0G]V3_OTW^%1:=_QX1?C_`#-6J;W$MB+[
M0G]V3_OTW^%'VA/[LG_?IO\`"I:*0SG4\/VRZT-0-]J31)<-=1V1C401S,A4
MN,1[R<,QP6(RQ..F&S^'HKFYCFEU75F!6);F,1H%NS&<JTF(L@YZ["H/3&*R
M8Y+A?$%G?F^O%N)M:GLGMFNG,30K'(0!$3M!`17W`9Z\X-2Z\96U34;L7UY#
M-I_V3[-%%=.D;;WYW1@[7W'*_,#TXP:`-.'0[:RF>X6[OI8XUD^S6TL:^5;E
M\[MI"!CG)^\S8!.,5LV\Z"VB!$G"#I&Q[?2N)T>341K9NKBYF>TODO!&3=R2
M>;M?Y=T+#9!L4%?D)W9^;!XKNK;_`(]8?]Q?Y4^@NH?:$_NR?]^F_P`*/M"?
MW9/^_3?X5+12&1?:$_NR?]^F_P`*KWRB]L9[59[NV,J%!/;H1)'D=5)4@'\*
MNU0UQYH]!U!K:X@MIQ;R>5-<2>7'&VTX9FP<`'!S0!@MX5+:6FGMXDUWRDD$
M@(M[<9X.58"WVL"3D[@<GFGWWA:WU'!N=6U5FDMQ:WA$,0^VQ!F8)+^YQCYW
M'R;>&-9UO9L;:XT&:XO+?4(F298_[?N66\+*^U?M#KYB?ZLLRQCC`Z@D&G=W
MMRWA.'5$U.[FO]*MR]W"+QHF5(WD5Y1$H_?%C&RJ)"%8#((.<@'2:EHT^KA!
M/K&I6@AN6EB6TA0@KQM#B2)@VT@D<<$]R`:CE\-0W%Y'//JVK2)F%[B'RXU2
MZDB(*N^V('.0N0I4':!C&<M^(<E]'\/]8NM.U":PFALY)O-A&),*A.`3]W)Q
MR.0,XP>1G:[)<#5;^^%]>03V-]8PVT:73I$Z2/&&#1YVONWNN2">!C!%`&UI
M^A6^GZC]K%]J,\:>9Y%M,@\NWWMN;;M0,?;<S8'`Q6E#,HO;IL/@[/X&]/I7
M,:$95U;3;S[=>2RW_P!K^TPRW3R1C8_&V,DJFT_+\H'7G)KJX/\`C_N_^`?R
MIH1+]H3^[)_WZ;_"C[0G]V3_`+]-_A4M%(9F365K/K=GJK&Y$]I!-`BB,[2L
MAC+$C;G/[I<<]SU[0PV(T[26L],EFC=KAIC+)$227E,DA/RX.=S=N_4=:Y^7
MQ#<W/CZVLV;4[2T4SVRQ?8)E21@O^M,A381D?+@D8Y/WAC6\.V9@OKB:SOKV
MYTQXD"R7=T\_G2Y.YT+$X7&!\N%)Z``9(!-:Z):6FHK=+<7SQ1R22P6KQCRH
M9'W;V7";N=S<%B!G@"B?1+.6W*)->0S"[>\AN$C!DAE8,"5W(5Z,PP0>":Y>
MRUK4+.XEUB]M;^<RS7D,4-M=R3&0QR2;4-L%*H`J##*=Q_B'-5;+6-1U+3+F
MR%U?W%]<:WY*B=;C3U*F'S#&)-F^)0%;&T%N%S][)`.ZM+2VTO2)+2W\]@?,
MD9Y$.YW=B[LV`!DLQ)P`.>U7+>=!;1`B3A!TC8]OI61X;NIKOPD&N'=YXC/!
M*78M\T;NA`8\N`5P&/+``G!-;=M_QZP_[B_RI]!=0^T)_=D_[]-_A1]H3^[)
M_P!^F_PJ6BD,P]<TH:V+4#4]3L1;R>9BUB0B0]MZR1N#CJ..#SU`P-97<T4L
M$NKZB$$<0AN(XU699%W;G.(PAW97Y2I7CIS3O$<-I-;1)=7=_'EB(K:QNF@D
MN'QP`4*L2,$_>`QDMP.&?8KG_A%;.PU74Y!>F...6>*X\AII./E$@`(W$8RH
M!],4`4+KP1X;U&T:/4M/6_NWY>_NK-'N&.<_>\O`^@`'/`%6DT/R==.IQ:SJ
MT:':!9B"(PJ@`&Q<PEU4X!(##FN,O?$.JZ;X>72YIM42XM9W-Q>06L]T-HF.
MR!9U0YPN`7?#$+R,MQUUQ:?:?$,,^GZEJ#78E22=&N'\B"#`S&T7"AF'3(WY
M).<#%`#;GPGHVL1VD^MZ=;W6IQ-$\EX;)3(Y0Y"EBG*\8(P,CTHE\&>&GUD:
MM#IBVEX(9XC+:6WDN3+C=)O50PD`!`8$$;V]:S_&'B&YL];TZSC_`+3MK>*\
MMFED@L9G6YW2`&/S%0J`!DD9R20.F0:3^)YKGX@""[N=2TNP_L^^CVRVLL,<
M?EM%BX+NGEGC>0QRJ@J#R^"`==IFF0Z=<SW<EU?7MY,B1/<7,0W^6I8JGR(H
MP"[=L\\DU=L3D7!&>9FZC'I6%X8:XM-9U;29WG=8EBN(#)=O=`QN74'S'^8,
M3&24Z+D8)%;UE_R\?]=V_I3Z"&N7&J?(JD^3_$<?Q?0U1LO#6CZ;<O<V'A[2
M+6=U*/+!`B,RGJ"0F2#Z5H?\Q7_MA_[-7"Z./!6K^(+J32YM)D@2VFBO(!*L
MDE]\REGE0DLZIM(#."3O.,#!88'86.BV&F",6&CZ;:"(.(Q!&L>P.06`PO&2
MJY]=H]*=I^D6>D^;_9NDZ?9><VZ7[,@CWGU.U1D_6N$L-(M(M$TV'3["VLKG
M696UB6VAB$85(D#1*%7@;&-N..,Y/4U=\(6^B75Q+%X?FAB@DTV$7SV#@$3[
MC]\CI+C=DGYNF>U(9V#:9;/`\#:78M%)%Y#QE05:/GY"-O*\GCIR:HQ^$M!A
MM9[6+PQHB6]P5,T2VT823:<KN&S!P2<9Z9KFK86<GA_P_8WMS+#IUK9SWMY)
MYK+^Z1#&-T@.X<R;@0<Y3.>*RHV\(RP27=A=:-'X=DN[5+NQCFB-O%$!)MDE
M0':A=V0$'J$7/.0`#T";P]I5PEFDV@Z5*ED,6JO"K"`<?<RGR]!TQT%6!IEL
M-3.IC2[$:@4\LW04>:5_N[]N<>V:\GN!H']D7B7SV?V,VEX?#WF$;M_GR;?L
MW?/^JV;.<;=O%=`H$?CB**(:;+J[7://,787RP^6-R%-H_<C`PP8J2<8SS0!
MW5@9A91[40KSR7([GVJSNG_YYQ_]_#_\346G?\>$7X_S-6J;W$MB+=/_`,\X
M_P#OX?\`XFC=/_SSC_[^'_XFI:*0S,31K&/5)-431].749!M>[$:B5A@#!?;
MDC``Z]JC_L#3/.M)O["TOS;)0EJ_E+N@4=`AV?*!Z#%<=`=+/C2W*-:?\)(N
MLS_:/+(^T"U\J3;YF.?+V^7C/RYV]ZV?$#0W6M^#M2M;UIH)M1VIY4H,+H;6
MX;<,<-G"\\]..IR`;7]EVEK+>WT&EV,%W<H?/N(D"R2<?Q,%RWXFKENT_P!F
MBQ'&1L&,N?3Z5P\2Z3%XW:71Y+:6>5;B._BB!%S$Q#-YEP68LR94*@(`&X;<
MKC'>6W_'K#_N+_*GT%U#=/\`\\X_^_A_^)HW3_\`/./_`+^'_P")J6BD,BW3
M_P#/./\`[^'_`.)I'$LB,CPPLK#!4N2"/^^:2\MA>6DEN9I8A(,%X6VL!WP>
MV>F1SZ8KC?#]Q'+\(]+M9-0%O=7&A!E?:99`/*4-((P=S[2RYQZCUH`Z`>'-
M)72VTL:!I(T]FWFT$">46ZYV;,9]\5--H]E</:O-I&G2/:?\>S.BDP_[F5^7
M\*XS3[73IO".O:?IC:=_9\=L91?:%&MO%<$HX*$H[$LH5=Q##.X=.14/C6ZU
M5;'1E32KV73H+C395EMY80)9?M$?R,&D5NF`.,%G!)`7-`'=C38_LUW;RVD$
M\%V[//%*=RON&""-N",=OSILVCV5SJ<6ISZ1ITNH0C;%=.BM*@YX5RN1U/0]
MS6+XQU+PHEI`FO-IMP7D>*WM[Z91"90!NW[CM&T8Y(R,\<D`\B8M&@E@@?4;
M._UN*331I-T)`\\T.8PS1')8H2)=Q!(VYW$B@#TFVTBSLKZ>^M=)T^"\N/\`
M77$2!9)._P`S!<G\:DA,WVVZPB;ODR-YXX^E<7X9&DGQ):-8FU_MG_2QJWE$
M>;]_CSL<]<;=W;IQ7<0?\?\`=_\``/Y4T(EW3_\`/./_`+^'_P")HW3_`//.
M/_OX?_B:EKDO'MJ)K/1[@SSKY&LV!$:2%4<FZB&6`^]@9P#QSG&0"$,Z.:#[
M009K2VD(!4%SG`(P1RO<<&LJ+PIH]K!+%8Z%IEB)2AD-I"D1?8P8`X3GD?X8
M/-<GJ68_&5Q'IHTV766N=YFWM]N6'R^4V%1^Y&!AMQ4D@8SS5KP$^G6!G,<V
MDG_1X1<SV@:,I-G;LN"SD-,2>6(5R3@CI0!V46G6\.H2ZA%IMC'>S*%EN%4"
M1P.@9MN2/K27&FVUW;3VUSIEC-!<-OFBD4,LC8`RP*X)P!U]!7G=C+/9>)KR
M[TJ"SO\`59)KP2V$05;R++,T;7$K2#='A0$4A<!T`)`R:J_;SI5U!=1-:6@U
MYFU*?6Q%-$4:U)/FJDA&WS/+XW!1E0#@'`!ZB8C;:>T$-M!#!'$55(SA54#H
M`%Q^%26[3_9HL1QD;!C+GT^E8OA8K_PA<2QP10Q1B:.,0[A&Z*[!7C#%B$8`
M,HR<*0!P*WK;_CUA_P!Q?Y4^@NH;I_\`GG'_`-_#_P#$T;I_^><?_?P__$U+
M12&9>IZ+8:TL:ZKHVFWZQ$F,74:R[,]<;E.,X%1)X?L%CGA_LNR-K/#'`]J5
M7R?+3=M79LQCYC5+QK'H\NDB/5[K3[7.?(FU.,O;(_'+`LJEN?ER0<\CH:R]
M0N(;KX=V-M<RQPE8[3[5]L;S%A3(^:X4[2T;;3N#;<@GD<X`.LBL(8+!+&+3
MK..S0!5MT`$:@<@!=N`*J-X<TE]4_M1]`TEM1WA_M9A0R[AT._9G/OFO.BF@
M+IBPZS+ITEDMM=_V9*0%@DE,F0;5<G;@$!`I)`'RD]:TK,RKXN674_L$NI"[
MA6""1&^V>28H@7C<,,1!BY9=K*2&R0>*`.[MM-2UT^WLA:P20V^TQB1LX*G(
M.-N`0>>`,=JFDMQ+.L\EG;/,J-&LC'+!&P64';T.U<CO@>E<5XNO[^YU/29;
M?3[RYTJ*]M)(+BSN(/*G=I`#NS(&(`X`P5R<D\#&*89Y-9OQ<SV::O/+J$#2
MVUNQU"S@(F,4S%'R\6U8PJ;.K*0=PH`]+L-.M]*A:'3M-L;.)F+E+=1&I8]3
MA5'-26.<7&0`?.;./PKC_`,GG:GJ4EA#I<6C&VMQ"-*F\VW:;=*9"&VK\Y!C
MW<>@R2#78V7_`"\?]=V_I3Z"&NI;5,!V3]SU7'][WK+B\4Z-++/&-5E3R8FG
M+RP-&CQKPSQLR!9`,C)0G&1ZBM;_`)BO_;#_`-FKDIXM8U\WYOO#MW:3FVE@
MM?/EMWA",1N&5D9B[@#DJ`N,>I88&Y#X@TV:S-T+^ZC19TMV2:U:*1)'("AH
MV0,,[E.2,8.>G-)IWB'2]56=K;49PL""60W%NT`\LYPX\Q%W(<'YAD<=:YVT
M\/7]S<^5_9]]9:?)))<D7UVL\PE$/E+YC^8[,#OR/F;'E]N!6KH-G>W5TLNI
MZ/)9QP6,5ILN)(I!*ZMDL-C-\HP,$X//04KC+[^(-)CTRUU)]8"V5T"T$S`!
M7`1G)^[T"(S9/&!55?%VCO;23"^OP8V13`UA*)\OG9B$Q^80=K8(7'RGT-5=
M/TW4[*'39)+!Y3IMA,R0+(F9;AB`%!)P"%##)X^?KQ6:UIJ]Y?6>O3^&]034
MK2\2:6%I+7,L7DS1B.(B8C"&8L2Y7.XXZX!<#=N/%NBVMG;W<NI70@GC,H=;
M1V\M`<,TF(_W8!X)?;CG/2KBZU8/JS::M]<&X5MA/V<^5OQG9YNS9OP<[=V<
M=JXQ="URQTN^CBT:>YEU>TNXVC$T*K:/+/+*HD)?D`38)3?]PX!R*U?["U'_
M`(2*"&.*_BL(KI+IG\^$VTA5>2!CS@Y.,J<IQG.>*+@=/81LUE&1,ZCG@!?4
M^HJSY3_\_$GY+_A46G?\>$7X_P`S5JF]Q+8B\I_^?B3\E_PH\I_^?B3\E_PJ
M6BE<9"T;*I9KF0`#))"\?I69I.N:?K;RI87URS1JKD2VS1$JV=K+O0;E.#AA
MD''6M*]@-S8W%NIVF6)D!],C%<WHBZJEU'=W>AW=L8+.&R\LS0LTC;_F=</C
M8HYY(8C.%S@$N!KR7]I+=7>G1ZAYEY!!YLL`VDHK9`W8'&<'WJW;Q.;:(B>0
M?(.`%XX^E9LFGO#KUY>1P*EO)8["ZX&Z3>Q.1US@CFM:V_X]8?\`<7^5/H+J
M'E/_`,_$GY+_`(4>4_\`S\2?DO\`A4M%*XRAJ%Y!I=FUU=W<R1`A?DCWLS$X
M"JJJ68D]``352*^TR[L5U];]_L\$4JF9UV>6H(\P,I4%6!3!!&001ZU?U.6X
MAL9'MK.2\?HT,4PC=E/7:Q(&[TR5^HKGM&>YT#2S81:1=//(MS>6MHTT9<`.
MI\N20N<NS29W98=<L3U+@:5KK^FW5C=7@U&>&&T7?<?:H#;M$N,[F61%8#`)
MR1S4%UXKT6S$#3:I.$FMUNMZVS,L<+?=DD8(1&IP>7VC@^AK&FTC6]>LYIFM
MFTN]:023QZC;Q3I<!5/EHHAGX5"<Y8\MSCL!XM=A\.:7H%YX?NM0MOL,<=]+
M9M;J'P,&#;+,.,##,"<C.,9RI<#H[VZLM!@:::XN@)Y"VV"!IY)&QR0B(S'`
M'88`'855/BK1OM%I$NJS/]K$312QV[-$?,_U>9`FQ2W8,03D>M4O$%H^KSVM
MW!9ZG/'8R36\MO8W8MI7W!<,KB1.`5Y&X'K[@YHTGQ`L;:?<V$UU)>RV,\U_
MY\7EQ&(Q^8&RP<MB/(VH02PZ<X+@=-9:]IVH:G)I]M?W+7";_O6S(C[#M;8[
M(%?!(!VDXJY#&QO;H><X(V<X7GCZ5@:+8ZFFI6%O<Z9-;P:=]H_TIY8V2?>W
MR[`K%NG)W!<8[UT<'_'_`'?_``#^5-")?*?_`)^)/R7_``K,U/6K#1Y(X[Z_
MGC9QN^6`N$7IN<JA"+G^)L#WK8KF_%]M>:CISZ?!I=U=K*O[N6WNUB$<O.#*
MK,NZ,<$CY\]T..5<9:_M[3O[7_LO[?<_:=_EY^SMY6_&=GF[-F_'.W=GVJ99
M;'5I;NP2^:=[21%N(U(^1N'4$@?0X_/K6/>-K>HZF+.72;N".WS]EU!6@DA\
M[80)G3S0Y523A`O/7/3$&@:9J7A274YM0DMKFUD,"QFTMC$\CD[68[YF).6R
M<\DY(STHN!JIXETE[J:W_M29#")"TDD!2)MF=^V1D"/MP<[2<8.::?$^EBSD
MN3>7VV.583%]AD\XLW(`B\O>V1D@A2,`GH*QM8M-7\3KJ5C=:'>67[B>&QN'
MEMVB4E2HD)60OEAP!L^4$YSFHVTO6$GLM1BTW4W@L;];A-/N;R.:X;,,T3LK
MO*5`_>J0N\<*>!G%%P.K@NH=2TC[;:74LEO+&S*6383U!!4J"#D$$'!%6;>)
MS;1$3R#Y!P`O''TK(\.Z?<:=X7ECNHC%---=731,03%YLLDH0E202`X!P2,B
MMNV_X]8?]Q?Y4^@NH>4__/Q)^2_X4>4__/Q)^2_X5+12N,R]4U2UT>.-KRZN
MLR9V1P6S3R-CJ0D:,V!W.,"H7OM+M[#^W5OW>"ZCC"S0IYIF4YV!%526)+'`
M49.:/$5[JUK!#'I6E7-X9F*RRV\D(:W7'W@LKJ&8]!S@=3G&#G7,7F:`FF:?
MI-_!-81V\L4230B:+DXVLQ>-I%"G(8[3GKSFBX%J?Q3I%M;PS27]YME5FVK9
MR,\84X8R*(RT8!X)<+CO4XU[36U4::FHSO<9492`M$&9=P4R!-@8J00I;."#
MCD5SR0Z]8Z4UFVC:I>IJ,LLUW*EQ;>?$K$`1G=(B[BO4H2%[=B'-H-]_PDZW
M,.GW41%U#/%<?:%%K'"J*C1O")/FEVAP'V-C*X;"@`N!M3ZOI.A7,&DR7MQ'
M($0A4@:01JS%5,CA"$#,"`7(R0>M2?V_I_VZZM#>7JM:!C/,UFX@CVKN;,QC
M\O@'^]6!J4.HZL]])9:5<RVFMV5O$LXEB'V8JS[BX+@D88$%-V>>G!,_]FZM
M;ZZUUIFF75K(D\\L_FZFSVEZC+)M4*6/EN7,3$^6-H!`+#@EP-_3-3M=8CD>
MSN[D^60'66W,+C/(.UT!P1R#C![59L1@7`))_?-R>_2L;P[97L6KZI?2VEU9
M6MV(R+>\G6:7S@7WN&#OA"#&%7=@;3@+6U9?\O'_`%W;^E/H(:Z))JF'16'D
MYPPS_%7.W7B&XTVXE34?#T,2-;2W%MY5PLCL$95*R#:`A)=>07'7)'?HG<)J
MF2&/[G^%2?XO:N?L]'UE#?\`V_6;6Y-W&R&5-(=9%Z[!\TC(44$C;L&<DDY)
M);N`2>(DM(9(K[3+)-0BN8H98(+CS$"N-Y8.44DB-7;:5'W<=#NJ33-:FN/-
M&H:#%`_V9+N!+67[0TJ,2,$;%VN#C(Y'/WNM5-,\'P64T<DLEL$`DWP66F&W
MBW,@C4HNYMN%,F>3DR$Y`&*T=#TN[TZX\_4-06\=+=+6$Q6+P[8U)/S99MS'
MC)&!QP!2U#0BCUY9M*TFZAT)I;G45=A:*\8:,+&SD%CA2<JJ]<9<<XYJE)XE
MO8+T:5<>'K)-7EDB2"-;LM;OO65^9?*R"JPN2-AZKSS5ZVT.2RB@-O?,+BVL
M9+6VD>S9A&[L&+E<\_=3C(Z'GFJ,?AW5O(@:;5[)[^VNA=P7(TB89D*/&YE4
MS'?E'(&"NW`QP``:AH1/XPD?3GNK30+6>2T@FGU"$W.PQ"*1XW6,^7^\.Z.3
M&=@.!R,UI1Z]&^IA#IMJNFM="S2X,P$K3%0PQ%LQMYZ[L_[..:S7\'W*6+6]
MGJR0/=P30ZA*VFNYE\V1Y&:,;P(SNDDQG>!D<''-\^&HG\2QZI(]NT43*\8&
MF8N057"H9QUC'7:5SG^+'%&H:&Y800O91LT2,QSR5![FK/V:#_GA'_WP*K6$
MRI91J0^1GHC'N?059^T)_=D_[]-_A3=[@@^S0?\`/"/_`+X%'V:#_GA'_P!\
M"C[0G]V3_OTW^%'VA/[LG_?IO\*6H:$<Z6MO;RSO#'LC0NWR#H!FL70]3FU&
MZ-OJ&C6UD[VZ74'E3^<'C8D?-\B[6'&0,CG@FMJ=H;BWE@=9=DB%&_=MT(QZ
M5@Z5I.I6#B:XU2&XGCABMH6&FR(JPJV6W#S#EV'&X$`'!VGD$U#0LC48I]7O
M],&F/$+>V$JW#JJB0DL/E'7`QU.,]L]:U;>W@:VB)AC)*`DE1Z52GMD_M*XU
M$/)\]G]G\LPL,8+-G/XU=MYT%M$").$'2-CV^E/6P$GV:#_GA'_WP*/LT'_/
M"/\`[X%'VA/[LG_?IO\`"C[0G]V3_OTW^%+4-`^S0?\`/"/_`+X%4]5N++2-
M)N]1GMT,5M"TK*J#)`&<#W-7/M"?W9/^_3?X53U:UM=9TB\TVY$ODW4+1.1$
M<@,,=QC\Z-0T,:RUF\U.RDDT[1M)NYEG\K=!J:/;@`$DM((RP88P5V'DCG&2
M*4GC"#[3IMNEEI%O+=IN==1OQ;D'S#&%CQ&WF$E6(Z9`'KQ8N=#UB:*9X];M
MXKNX9%G9=*E\IX4#`($$H93\W+!^<`#%37^C:EJ6EMIL^JPK9W-H;2[@BTME
M4H0P)A^?,9*L!\Q<?*,`<Y-0T+_B+5++P]HT]])9K/(JL8K=%`:9@I;:/3@$
MD]@">U9EWXB:"[S%HMM+80R6T5U-Y^V2)IBH&U-F&`WJ2=PX)P#C%/UCP];^
M);2>/41=P3HDUO:36\L\16-P!EU1P'Y`R&X..@R:@;PM*LRP6^I,FF.UL]S#
M+:2RS2M"5QB9GX#!$!RK'`.""<@U#0MZ9K,E]J<4,^CVT-E=>;]DN$GWN_EM
M@[TV#;D9(PS=.<5L0P0F]NE,2%5V8&T<<5CZ9HMQ8ZC%+/?B>SM?-^R0)8NC
MIYC9.]]Q#8'`PJ^^:V(9E%[=-A\'9_`WI]*:N!9^S0?\\(_^^!1]F@_YX1_]
M\"C[0G]V3_OTW^%'VA/[LG_?IO\`"EJ&AS*^)(9?$\ND0:?82+&[1D&]C6Y8
MJ@8LL)',8)V[MP.<_+@9JYI5]<W.HS6&IZ-:V<ZPK<((9Q.-C$C#'8NUL@\#
M(ZX)Q5>30YO[4DF@O4CLWN/MGDFP8R"?;M!\S<!LZ';MSU&['%)IMKKNEVT[
M3WUIJ-U*Z'S$TR2%F.X!F<F5@?ES@``#'`/2C4-!FD^)+75=9O[58M&2ULWE
M1F%\&N/W;%2S0^7A5RK<[ST_*"/Q6EY:@V.BQ&ZFU(V%K#=R>2)<1>;YC$(Q
M0%`Q`P3T!P3@6;WP\^LW'EZU?R7>GQN[P0Q6TMO*-RLI#R(PW`!B!A5/`))(
MS51/!L=D'ETW4+E+M=1^WV\E\EQ=K&?*,15@TF6RK/SN!Y']T4:AH;.E7L.L
M:`U[]CB@F!FBEC7YA'+&[1N`V!D!E.#@9ZUI6]O`UM$3#&24!)*CTK-TJQ31
M]`:R,C32DS32RB!D5Y)':1R`<[1N8X&3@=ZTK>=!;1`B3A!TC8]OI3UL!)]F
M@_YX1_\`?`H^S0?\\(_^^!1]H3^[)_WZ;_"C[0G]V3_OTW^%+4-#/U7[7;QI
M_9>D6EW*V2WGSB"-`/5@C')[87'J15(ZS%+X:T_5;72D::_$0@MYV$8#28QO
M<!L`9Z@'V!S3_$5EJ&K000V&H16D(8FXBN-/DG6X7'"G:Z$#U&>>AXR#'>VF
MHZGIUSIUU):%#%$!(VFEXI7!/F*\+,<H<+QN!Y//>C4-"K+KMW_9TMU;:%83
M?8S*+\M>A4B:/[RQMY9+G'(W!!ZD'BF+XKM7\4Q:-_9]G'YI1426X5;I]T?F
M;U@V\Q@9!;<,%6&.,U&/#6HVMI;6VGZG900J[2W$$FCR-#+(2""JK*I55Q@+
MENV<D9JX^@S2:D\KW_\`H4MU%?2PK9R"4SQA`,2;^$/EK\I4G&1G!HU#036-
M=.FZC<10:/;SVEE#%/>SO,(VC5V8#8FP[R`I)R5XQC)XJ.T\1QWVOZAIUO9Z
M1+]D\P+"E^OVN4IP<0E``-V5R7QQ4=SH>HZH[7$][';+?6T4.HVQL'?<$9C^
M[8/\A(<@YWC@8]3:N]&OKZ\CDN=9E,5M-)<631V&V:"1TDC&6Y1U593@%.PW
M%N<FH:%CP_JD>L_;8YK*RCFM)?*D^RSBXCW=UW[5^9>C#'![FM2Q`47````F
M8`#\*S=*TZ6TU.[U2_NA<WUS#'`S06;PIY<9<K\I9LM^\;)SZ<"M*Q.1<$9Y
MF;J,>E'0!?\`F*_]L/\`V:N1U'5-=T?4K^":]GD26T9[:66"(1B7<@_=!,MM
M4-R)3DG&,C-=8Y<:I\BJ3Y/\1Q_%]#68GA734-Q_H(99XFA9'O)71$;[RQJ<
MB,'`SL"]!Z"A@8USJFKZ4\^F?VE/>SI=QLES+#$'\D1&5U8*H7!\LKD*#\X[
MX-7-&GUM)S;R:G]OEN=/CNXFNHD187)PP'EJN5Y&`<GC[W/&A8^&K'3YUG@M
M&>90X\RXOIIF;>%#;BY);A%`SG`&!@$Y?I.@6NB&0V-LREU5"9KV68JJYVJN
M_.U1DX48'/2E89D66J:SJ&G:!;17\*:A=033W$[6X92J)M!V9&!YCQG&<D`C
M/>J$MYKL.J6VDIKMS/9WE[':QZF88!.DBQ3RS*H$?ELO[J-0=IP6<9)''3C0
M+06SVZV:K&]L;0[;J12(B22`1R#SU'/3G@53B\':=%8_8EBO3`"C(&UBZ9HB
MF=OEL7S'P2/E(R.#FBP'-+KNO7VDWS0ZO-;7&DVMU(9!!$PNWAGFB7S`4X!$
M.2$V_>X(Q6I_;>IQ>(83/+?A;BZCACLQ9C[,(74$/YVS)?.>-_\`P#O6E<>#
MM*NK6WMI;%S#!&T01=0G42(QRRR8(\T$\D/NSDYZFK:Z#:)JYU1;0"Y)W8^U
M2>7NQMW^7]S?CC=C=CC-%@+VG?\`'A%^/\S5JJ-@9A91[40KSR7([GVJSNG_
M`.><?_?P_P#Q--[B6Q+146Z?_GG'_P!_#_\`$T;I_P#GG'_W\/\`\32L,Y*+
M4M5.MVUY_:,ILYM6FT]K!HH_+5%23#JP7?NW1@\L1@D8Z&I-:O=434KZXM=2
MEMX-.^S_`.BK%&R7&]OGW%E+=#@;2,'GFM-?#EDNLG5A:DW>\R#=>S&-7*["
MZQGY%8KD;@H/)YY-,D\+V$US;W$MM*\D"QH"VHSD2!#E/,&<2D'G+[CFBP&/
M9:OJ0UDV=]-?R27(N!+!-9B."WV`E/*DV`N",9.Y_P#@/2NQMO\`CUA_W%_E
M61%H-GITMU>6]J$ED1\YNI'6/=RWEHWRID\G:!D]:T[=I_LT6(XR-@QESZ?2
MGT%U+-%1;I_^><?_`'\/_P`31NG_`.><?_?P_P#Q-*PR6HKI)Y+65+:989V0
MB.5DWA&[';D9QZ9HW3_\\X_^_A_^)JO?6AU&QGLKF%6@G0QR*D[H2I&"-R@$
M?@:+`<C<W6O6\3(FKZC<Z6MTJ/J5O8QS704(^X*B1%6'F!%W",X!;TW"-[_6
M-9TO2;BSUG4]/O+ZX>T6%+>W*;8WDW3.'B8@E$S@$#)4<9K<7P?IRV2VAANV
MC1UDB9]7NFDA8`J#&Y;='P2#M(R"0>*TH],AAEM)([2)6M(VB@Q,V%5L;N,<
MD[1R>?S-%@*6N/?3ZEINE6>I7%@;A)I'N8(XW?Y`N%PZLO)?)X[=JY:R\0:[
M?Z9%JYU)HC:M8136B01^5<&7R_,8DJ7&?,.W:P`P,YKJKOP\FI1E;\S28G::
M)H;Z:!H]PV[0R$-MQGC./;I49\):7]IM9ET\)]E6)(H4O)5A`BYCS$/D8KQ@
MD$C`]!18"EHU[JCZI87-SJ4L]MJ/VC_17BC58-C?+L*J&Z`@[BV2>U=)!_Q_
MW?\`P#^59]EX>L]/U&2_MK4K.^_[]Y*Z)O.YMB-E4R>3M`S5R$S?;;K")N^3
M(WGCCZ4T(O45%NG_`.><?_?P_P#Q-&Z?_GG'_P!_#_\`$TK#.=U675=/U9;F
M#5);A"6D?3A!&(HX%0DL6QOW;@`#NP<XV\$B+P?J&IW3L-4N;YY9K:.X6.ZM
MX8UY^\T1C.1'G`"R?..,DYJ^GAJSCU>75$BN5N9G\R4#4[@1.V-OS1;MAXXP
M5Q38O#<-G!,FGJ]N\K)^\-Y-(416#;$W'Y%ZC:N%YZ$<46`H+;ZW-XIO+>R\
M1WI@MH"[K<VUN\(ED#>6@"(CD(/F(+9.4&>M9@U?64OXO#TVJ7L-U/J2PBYE
MCM_M*0&"60/A4,6&:!P/ER!G."*Z[^R+;;J*M8P,NHOONU>5F$IV+'R"./E1
M1@8Z>M4CX5L#8FT:WG93(LGG-J=P9PRYP1,3Y@QDC[W0D=Z+`'AV_N=1\+RR
M7<AEGAFNK5Y2`#)Y4LD6\A0`"0F2``,FMNV_X]8?]Q?Y52@LETW2/L=M`D=O
M%&P4&9G;N226&6)))))R3U-6;=I_LT6(XR-@QESZ?2GT%U+-%1;I_P#GG'_W
M\/\`\31NG_YYQ_\`?P__`!-*PS.U])_L7FQZQ-I<4>3));PI)(QZ*J[U8=>,
M;222`,=\S4=1UNT\'Z<TRM'K%RT$,YMHT9D9B-^Q6)0-C(&XE02"<@<Z&KZ#
M;:XUJ]]#+OM6+PO;W\UNR,1@G,94]..?4^M-.@B2&:VG,LUJ\44:1R7LK-&4
M)(<2$[@^2/F!!^4'.>:+`<_>W/B1O";WFGZA?M?69E5H)+6V65I`?E$YR4**
M/O>5AF!ROI5LZGJ*^(TN[NXU"#1)9(8K1X1:FVF\Q5"E]V9@6D?:,8Z#.,\Z
M#^%-.D@AA-I(!%N^9=0G5Y`QRPD<'=(">H<D'O4X\/V:ZG]O6S"S9#%%NY!$
M6``#&(?(6``^;;G@<\46`K^(5U6*:.?3]7:*4[4MK!8$*SOG+>8S`MMQ_=*[
M<$DFN;N/B);R>+Y[6VUG3HK"WT^^)C>16?SX3&=S@?,`!YN%&"0C-R,8Z`>$
M;>2:"ZNGO9+Z*%83<1:K<P[U!)P0K`$9)ZY]R:T[K2H+Z[6YNK*"65;>6V&Z
M5B#%(5+J5Q@@[%ZCM[FBP&1X2U/4;FYO;+53>)<11Q3+%?"`3!7W#=^X^39N
M4@?Q?*<]JW[+_EX_Z[M_2JNFZ1#I1E:U@.^7&^2:[DF<@9P-SY.T9.%S@9.!
MS5FQSBXR`#YS9Q^%/H(7_F*_]L/_`&:O,M*E\-13QS33V:2KIUW_`,)$T#X8
M-YD?^O*<[MV\#/.-P'&:]+=2VJ8#LG[GJN/[WO67%XIT:6:YB&J3H;:-Y7:6
MV:-61&VLR,R`2`$@$H3R1ZBA@<C:G2+^-++PW<:;]GN;IKU;*PD1T@6",,IV
MH=JN93"Q`Z9'4\F+3I_!-M97$QDT\:-]@MQJ0B<"-[C?PLN#@N3D,&Y(^]Q7
M;P>(M,N+)KM-0N%C6X2V=9;9HY$E8J%5HV0,N=RGD`8.[IS4$/BW1I[:>X34
M;L)`$8A[.1&<.<(8U,8:0,1@%`<GI2&<S8?V%<Q0QQ7]J-$MTNM1N!8W@\FS
M4IY2QAHS\N%>1OE/##([&LK/A&:6WN[&YT5/#,E]`E]8I-";>*-8;CRY9D^Z
MA>4Q\'GY$SSD#T'_`(232%L4O9-6>&!W>/,\?ELK(C.X964,I"JS'<!@"H%\
M7:.]M),+Z_!C9%,#6$HGR^=F(3'YA!VM@A<?*?0T`>=S?V/_`&!*FKM9"'[!
M>?\`"/[RN[_CXE\HV^.=VS[/MV_-C&*Z!0(_'$440TV75VNT>>8NPOEA\L;D
M*;1^Y&!A@Q4DXQGFNEN/%NBVMG;W<NI70@GC,H=;1V\M`<,TF(_W8!X)?;CG
M/2KBZU8/JS::M]<&X5MA/V<^5OQG9YNS9OP<[=V<=J`+NG?\>$7X_P`S5JJ-
MA&S649$SJ.>`%]3ZBK/E/_S\2?DO^%-[B6Q+147E/_S\2?DO^%'E/_S\2?DO
M^%(8R_\`-_L^Y\C/G>4VS'][!Q^M<1X.N/#EI>F;2+C3XK5K&W2\:%U53<LY
M"AS_`,]220<_,20#VKI%U_36UH:0+^Y%V7,:YMF$;.%W%!(4V%@N3M#9P#QQ
M2WVO:=IVHQV%U?W*SR;/NVS.B;SM7>ZH53)X&XC-`%,6H@\8ZE+YT\C3::K$
M22$A?G?`4=%'T'/?-=#;?\>L/^XO\JQX]<T^^N+FQM[Z=YXTDX:!E238=K['
M*!7VDX.TG!ZXK4MXG-M$1/(/D'`"\<?2GT%U+-%1>4__`#\2?DO^%'E/_P`_
M$GY+_A2&2U3U2>\MM+N9M/M#=W:(3#`&5=[=AEB!^9%3^4__`#\2?DO^%1SD
M6UO)/-=R)%$I=V(7"J!DGI0!Y=%#%/HNH6^MS+IL$>N&6:37X([F&=S`/EDV
M2[%&XA@"P7[JKZ"75'L'MK&^>UT(75E9O]@TB[TW<MSMD?;]E;>%5I!&A`4.
M5!4D'(KO+77+&[TN?4A=WEO9VZEY);RT>V`4#);]ZBDC'<<5'=>)-*LK:UN9
MM1N/)N8UE1TMF<+&W1WVH?+7G[SX%`%/QA::;K.BI!+8V%]<R7"VD)N(8YOL
MSN0'8;@0&5<G'^R*Y?4['0M,UAM/1+.'5K:XT^/1H\C[0L`9`?+_`(MN1+NQ
MQC=NXKNKRYLM#4-+/=!KF4L$A@:>1V[G:B,V`,9.,`>E5Y/$^D1W=M;'4YV:
MY$9CD2W9HOWAQ&#($**6/`#$$Y&.M`'.>&1I)\26C6)M?[9_TL:MY1'F_?X\
M['/7&W=VZ<5W$'_'_=_\`_E6?9:]IVH:G)I]M?W+7";_`+ULR(^P[6V.R!7P
M2`=I.*N0QL;VZ'G."-G.%YX^E-"+U%1>4_\`S\2?DO\`A1Y3_P#/Q)^2_P"%
M(9PUU=:L_P`0+2:[TO4885^TP6SAX6A$87_6[5EWLQ(SRH(&`!G=E/`::/HT
M<MM97>BW<*01)/J5G;K!(T@(4)<-O8M*22><')/'-=?/?VEK?P6,^I;+J='D
MCB.W)1,;FZ<`9')JE8ZGI?B5)K>VO;B41;)'CDA:$E2<HX#(I9"5.&&5.",G
MF@#E],M=(_X2N\A9=$UB:^GN$OA_9ZI=VT9WMB8LY)CPJ1@%0#E2,@UFQ:5H
M%KH&CZO-8:3::+K&I+=7ZM;QPV_V8PR_9E=3Q@,8CS_$Q/>NU/BG2TU$V$MS
MJ<,X61LSZ;-&A6,9=@[1!2`!US@Y&,Y%+_PE.E_V>MZUSJ:1/*(8UDTV9)97
M(W`1QF+>_`)^4'@$]C0!!X.&/!(";?LWF77V39C;]G\Z3R=N.-OE[,>V*Z.V
M_P"/6'_<7^54;>\M]4TEKVSO7FMW5P#M`Y7(92"H(((((."""*M6\3FVB(GD
M'R#@!>./I3Z"ZEFBHO*?_GXD_)?\*/*?_GXD_)?\*0SF_&UYX9MK2U3Q&MA*
M9F9;6#4)%6%WQR6W?*`!_$02.W)`-'4!IT?@"TM6U:QU"WM([9II+F<M!<)D
M8\UP'VQM@_,P8<<Y&:Z/5-4M='CC:\NKK,F=D<%LT\C8ZD)&C-@=SC`J%[_2
M[:P_MX7[O;W,<>V:%/-,RG.P(JJ2Q.XX"C)S0!P<EQX8;0XX-:;0X)IWG&D"
M6<"VMX<@"2(M@84\JR@$C&W`Z6"D$?CQ+A+FSGO%N[=$A=0]]+`8D0RQR;_E
M@R2[*%()5SG+8':C7M+_`+'35CJK)9,XB#R)M(??LV%2NX-N^4J1D'@BD?7M
M.CU;^S&U"X%SO$9/V=O*#D9"&79L#D$';NSR.*`..\4SZ/=:Y?33364FHO8V
MS:'([J69_,DSY![MNV[MO.-N>,4X'2[/Q7>7`.FW\MS-<I?^18/'J5G$(Y#O
M+AC(4Q&J#:HW;@5/0'M)IK#0X+.WFOFMTFE2UMU;!+R-T4<$D]3GZDT7.K6%
MGJ'V"XU3R[G[,]V48+\L*$!G)VX`!8=>O..AP`8/@DV<6IZQ;Z4UC-I?[J6&
M?3E"P*Q+J8MH+#S%"J6;/)<9"UU-E_R\?]=V_I573-3M=8CD>SN[D^60'66W
M,+C/(.UT!P1R#C![59L1@7`))_?-R>_2GT$+_P`Q7_MA_P"S5R.D6.M6MQIZ
MMHLJC1[.X@62:XB`NV9DV[-K,0"J$G>%P2!CJ1U4T,<^I!9%W*(<XSCO7.:;
MK<-S>1?;M,AM-/N;::ZM;L7A?='&R@^8I5=A(8,,%A@')&*;L!3MO#]_=WL@
M_LZ[L;"XGEO&6[N$EE6;R?*&]E=RP.[*C<0HB`XX6K%I)K]K&;]?#5T;FVL8
MK-+9KF#,S;OF=2),;0.1N*D^@I\?B&RET@:@-+ECW7WV5(II2CE0<LY'8^6&
M?;UXP<<X6SU*^NDDC;PY"MX]O'<VL2:B65T=L?.Q0;"O!(`?@\;CQ2T#4+"U
MU$7*:B^BWB26T,\YAG>`275T^T`C9(RK\JE1EN`PR>*H-::O>7UGKT_AO4$U
M*TO$FEA:2US+%Y,T8CB(F(PAF+$N5SN..N!HIJY,<41T%Y-0-Q-;O;P7.Y<Q
MQERR.VT,"=J`D+RW.,&JLFNW4%Z-*N/#]LFKRR1)!&NH.UN^]97YE\O(*K"Y
M(V'JO/-&@:F<NA:Y8Z7?1Q:-/<RZO:7<;1B:%5M'EGEE42$OR`)L$IO^X<`Y
M%:O]A:C_`,)%!#'%?Q6$5TETS^?";:0JO)`QYP<G&5.4XSG/%5G\4%].>ZM-
M"BGDM()I]0A-\R&(12/&ZQG9^\.Z.3&=@.!R,UI1ZM`^IA#I\*Z:UT+-+@W9
M$K3%0PQ%MQMYZ[L_[..:-`U.BT[_`(\(OQ_F:M5G65E;RVB.\>6.<G<?6I_[
M.M/^>7_CQ_QINUP1:HJK_9UI_P`\O_'C_C1_9UI_SR_\>/\`C2T#4Y:+3M4_
MMJ"S.F3"UM]6FU`W[2Q>6R.DF%50Q?=ND"\J!@$YZ`KJ-MJUW<W4<>BW7E:H
MMLQE::$"T*GYQ(-^20!D;-P)[]ZD350VMQ6YTB/^S9KR2Q2[6[8R>:BLQW1[
M<!<HRY#$YQQ@YI^J:C]@U&6*#2(I[*U\G[7.UVR.GF-@;$VD-@<G++QTS1H&
MI3TS1;RTUB6XDL+F%HTN?/N9;A7@F\QMP\B,.?+R<%OE3..=QYKLK;_CUA_W
M%_E7(:=K]KJ6MWNF+90(T*3$>7>&2:+RV"_OH]H\O=G*<MN'/%=-!86SV\;-
M%EF0$G<?2GI8"]157^SK3_GE_P"/'_&C^SK3_GE_X\?\:6@:EJJ6KVHOM&O;
M0VXN1/`\9@,QB$@((*[QRN>F1TI_]G6G_/+_`,>/^-0W5G#!:32PV3W,J(62
M%)-K2$#A06(`)Z<D"C0-3D7\/:[J-I,EK))IMB"KQZ?JX-\[.`^<LMP<+DH5
M&X@%>G:J3>%->@M[6X473ZFVCVUE&]E<_9X[6>+S"KRKYO[Q!Y@!`W@[3\O(
MQ=_X2RTCL)'N+/38KI+MK7=_:A-H&6,R,6G*#`4`J?DX;CWK5DU."*WTB0Z3
M([:A*D;-%.'BA#'&XR`X8'MCDYYQS@T#4?K/VB_:WN;"TU!KBTG>!I;.2!9%
M!V[L"7*,AP`>0PQQS7/67AS6M,T]-#-A-="X>QEDOQ/'Y4)B,?F`[F\QC^[R
M,*<EADCDCIO$4T>B::U['9VKQ1_--+=WOV>*)?=L,<D\`8Y/4BLI]?&^*>+0
MP;!3:I=/)=,DT#3[<`1[2&V[U+?,.IP#BC0-2SHMCJ::E86]SIDUO!IWVC_2
MGEC9)][?+L"L6Z<G<%QCO71P?\?]W_P#^5<]IFH_;M3BAGTB*&RNO-^R7"7;
M.[^6V#O3:-N1DC#-TYQ6U%96[7=PACRJ;=HW'C(IJP&C157^SK3_`)Y?^/'_
M`!H_LZT_YY?^/'_&EH&IRY\.Z]#XRBU<7EA=0-)*S9M&21(]N(X]_FD8'J$Z
MECCFI;#[19:MJ&MW.DWEDMPD,,T<UQ',\LF_"F,ASMC&\_+E<Y)"`GF:ZN9[
M+5HHIM$3^SYIO(BG6\)F9]I;/E8QMX/._/&=N*K^%=;M/$LER@LK=/*2.3-O
M>&<)OW?NY?E79*NWYDYQD<FC0-2U<:3<7]UXCFO+'SDG@%E:PM=&,30>7N;#
M+DQ[G=U)Z_(I]*H6[Z_I5G<RZ?H6IR13-&D-E=7D4TUN?G\R4L\Y4K]P!`XZ
M'H#Q#/XIM;.":\NM*C2S9KF.R"WA,]P\`?<"A`"9\ML'<W;.WI5^#5(X8;Y=
M7TR.VO;3R_W%K=-.)?,!V!&*H2Q((QCJ.N.:-`U-/2+<6WAORQ8W%FQ65WBN
M3&9"[,S,[&-F7+,2W!_B[=*T[;_CUA_W%_E6+H\UMK/A6QUE;3R&O+-+D1^8
M6V;D#8SQG&>N*T8+"V>WC9HLLR`D[CZ4]+`7J*J_V=:?\\O_`!X_XT?V=:?\
M\O\`QX_XTM`U,_Q%>ZM:P0QZ5I5S>&9BLLMO)"&MUQ]X+*ZAF/0<X'4YQ@PV
M]T;32/[/L-$O`;2WA!M#/&D@1LC:KARID`4YRPZ@[N<U-JMO<6\:?V7I,-W*
MV2WGWA@C0#U8*QR>V%QZD56CNH[OPM;:Q8Z7NDN(4F6"XN1$J!@"2[\@*!R2
M`W`X!HT#4YBY\&Z]-HZBREMK:&-WDMM.OK?[1+$SR;F=I5F"F3!.2=YY;YB6
M)KI+B;5+S7X+2\T&\?3[>5'2ZB>#RI'`!$C*9=ZJISA0I.0#VQ6<OBG3CX9M
M-5_LUI)KF5HDMX)RZL%DV-*K\9BXW!\#(*\98"M*\GGL]5BCDT1/[.DG2W6X
M%V3*S-_$(@,;!W)8'@G;CFC0-3*UC2-9\076G:WIMU;"`RVSQVUU9[I($60,
M[!Q,%.<`D`$D*`#34\.>);#QNFLI<6.H1_9;W):`PL6=HC%"S^8V/N`!@F`$
M;*DMFMG6M0L-'N]/M19/<37EQ'$0CD"%&8+YC'TR0`.I/L"1!-J]D/%!T.VT
MV2YD6SFN&D27`+QF,>4,G!8B4$DD`9'J<&@:DWAVRO8M7U2^EM+JRM;L1D6]
MY.LTOG`OO<,'?"$&,*N[`VG`6MJR_P"7C_KNW]*Q?#]Y!K/VV.:SMHYK27RI
M/LMX;B/=W7?A?F7HPQP>YK9L%").JC"K,P`_*CH`R::.#4@TC;5,.,XSWKE(
M?#%K-Y=MJNJK<Z;;1/#:6]M#+;.BM(CC?*LA9B/+4`KL!YR#GCK_`/F*_P#;
M#_V:N(BU3Q,]I%<65\]Y<ZKIEU/;6DT42K;SJ4\H*P525^?!WELX!R.E-V`N
MV/AK3;&Z)&IW$UJ9+B4Q7#S3-OD4("'D=B,+O'OO[8Y2+2]3BM)-GB6U6]%O
M':V]PNF,!'$K9.Y?,^9FZ9!4#L!49UG4K*P6T-WJCZG]K5I%U".U,B1*AD;_
M`%(V;&$97/+#?V.,3Z>=;D+6DOB&9C=6,5V+F2VAW6Y+?.$`4+C'3>&QC)W=
M*6@:DEGI\]NHE?5K+[7#:2VUH\&GR)'$7()<JTK%SE5S\PS@\\FJD>C7_D0-
M-KNG/?VUT+N"Y&ERC,A1XW,JF<[\HY`P5VX&.``+%M>ZY.UEI\&IJTD[W$L5
MY/;*S26R(%1W1=H_UDB'C;N4<8SQ1EO-=AU2VTE-=N9[.\O8[6/4S#`)TD6*
M>695`C\ME_=1J#M."SC)(X-`U%?PRR6+6]GKL$#W<$T.H2M8,YE\V1Y&:,>8
M!&=TDF,[P,C@XYOG0[)_$L>J27-FT43*\8&G@7(*KA4,X/,8Z[2N<_Q8XK%7
M7=>OM)OFAU>:VN-)M;J0R"")A=O#/-$OF`IP"(<D)M^]P1BM3^V]3B\0PF>6
M_"W%U'#'9BS'V80NH(?SMF2^<\;_`/@'>C0-3I+*]MXK1$>3##.1M/K4_P#:
M-I_SU_\`'3_A1IW_`!X1?C_,U:INUP15_M&T_P">O_CI_P`*/[1M/^>O_CI_
MPJU12T#4Y&/2MNM).=7A_LV*]>^BM5LV$GFNC*=TF\@KEV;`4'..<#EMUIMQ
M=W)=]:M5AN5A%_&M@^96C.<QDR?NP>A!#\=#GFFQ:EJIUNVO/[1E-G-JTVGM
M8-%'Y:HJ28=6"[]VZ,'EB,$C'0U)K5[JB:E?7%KJ4MO!IWV?_15BC9+C>WS[
MBRENAP-I&#SS1H&HMKIHMKD-)J<4UK;+-]DA6U9)`9.6\R3<0_7C"KZG)%;\
M%_;);QJTN&5`"-I]*Y72]6U>XUJ47DT[6%RET(3(D(A<HWR>1M_>?<#;O-ZD
M?+Q79VW_`!ZP_P"XO\J>E@(O[1M/^>O_`(Z?\*/[1M/^>O\`XZ?\*M44M`U*
MO]HVG_/7_P`=/^%175[#-:RQ0WK6\KJ0DRQ[BA[$`@@_C5^J.M27T.B7TFF1
MK)?K`YMU89!?''&1GGMD4:!J<P^B-->+JT^KVC:W'(CQSK8.+==J2(,Q&0G.
M)6R0X/"]ABM)+&T32[*R%\<V]TMTS^4?G;>7(`[`DG'7`]:Q[+4=7U./4;&Q
MU+6F^Q+#-]IGT^&&[G#B3,:+*B(I!1?F=.A([AAFW/BC6;C2K^]BU1X9=%T=
M;Z>.".(I<S!YUDC?>A*@&W*_(1RQ]!1H&IUMS=ZC<I(;74K:SD25@@FLVFCD
MCXP64.ISUQAAUY'88L7AJ.V$5I:ZS&FF$VSW,+61:65H2I&V0,%0-L0$;#P#
M@C/'1ZZL[6`FCUB;2XD&Z22"%))&)P%5=ZL.O&-I))`&._+#5/$@A-[=W[6]
MQ82V,%S91PQF*8R^7YI)(+`XD(&UL`KW%&@:FKIFG&QU&*6?5H9[.U\W[)`E
MFR.GF-D[WW$-@<#"K[YK:BO;=;NX<R85]NT[3S@5A:->ZH^J6%S<ZE+/;:C]
MH_T5XHU6#8WR["JAN@(.XMDGM720?\?]W_P#^5-6`/[1M/\`GK_XZ?\`"C^T
M;3_GK_XZ?\*M44M`U.4DM;V?6YKJ?6[.2QD#(D!T]Q+#&5P0D@EP"3SN*$]N
MF*99V]UI@-Q_:%M=W,<45I;JEHT2K"'&=^7.YL9Y&`.R\X)J5Q=VGBL,/$=W
M%I]I`VH:C!)';F&*`!@J@^6)!DJS9+'B-AW&#P;XK7Q+J&K8U&PGC0QO;P6L
MR2&&-EZ.5)RV1SV!.!TR30-2C=^$M/U"]U&XN[VT+W*RB*XATY8KA2ZE09)!
MQ+L#$+E1QUW'FK7_``C]GJ#R7.O:B;J^9U9)K`3V(CVJRC&R0MG#OGYOXNE1
M:7XUCUGQO+I]CJ>G26HM)A#:K,IE::-U!9\990?FPN.BEN<X$5UX@UN#2[:W
MD>6>_N]7GL?,T^.-71525QY8ERF<1@9<XY)-&@:FSH-G9^'O"5EHD5Y)<&TM
M1#YKA\N0,$_,3M&>BYP!@#@"M6"_MDMXU:7#*@!&T^E4M#O)+[PLLLUQ+<3*
M)8I7FB2.0.C,C*ZH2NX%2#M.TD$C`(%:UM_QZP_[B_RIZ6`B_M&T_P">O_CI
M_P`*/[1M/^>O_CI_PJU12T#4YOQ$ESJT$$-AJ]M:0AB;B*XLGG6X7'"G:Z$#
MU&>>AXR"\W6I20R0#4K2"1(XC%<)9L4>3YMX,9<G9]W`#`\GYN]6]?2?[%YL
M>L3:7%'DR26\*22,>BJN]6'7C&TDD@#'=D4>M77A6V%Q<?8]6:%#</;Q(S!L
M`L$#DH&/(&=P!]:-`U.=NO!^D:A:S/=ZC<C4K@YEN+2:XMXB2^X@1))C&?4D
M]R36B(+Y?$*WO]MV<EC&0L5M-I\C21)@!@LGF@;CC[Q4GG'2N:O/']QIFAQ6
M-[JME::XDKFX-])$DB0K,54%00K2LF,[/D'S$<``]9=G4UURTEM-9,T=Q*I6
MP6&/RA;X&]RV"^[T;<%.0-O>C0-3-O/#^GZY]EU"_N;FUU/S();C[-<W"1MY
M;;@NQ9-H/49Y(SD$TG_"*:1!K\>K:=J=]9RI!=(%$\TH62=E8R*KL4&"&.S:
M5)()'RBE\5^-8-*URPTJ'5;"TE%S;F\%Q*@=HG?&U%8^F26[`>IR*\'C==6^
M("Z/IVL:>ENUI=Q)$61Y#<QM&`S+D-@9DPN06",>F"#0-3;TJW6TU.[U2_U"
M&YOKF&.!F@MFA3RXRY7Y2S9;]XV3GTX%:]@P=)V4Y5IF(/Y5C>&[Z^.IZII6
MHW-S+/:^7+&;J.)9'B<L`_[H;-A9&VC[P`^;FMJR_P"7C_KNW]*.@$<SR)J0
M,<7F-Y/3=CO61#X8T^":XE&DR.TZ/&PFOI)%178,RQJS$1@L`<(!T'H*V_\`
MF*_]L/\`V:O*(ELY+9AHSP?VTVEW:ZU]C;$@D\R,'S2GS!P?,VY^;&[;QFFP
M/0;/0K:QGCGBTZ>2:-702W%_).Y#[=V6=B6^Z`,YP,@8!.:@\'Z8+">R_LNZ
M,$P0,#JDQ8*ARBJV_<B@]%4@>U<S8BTN(5T?1VTB6)[IKU9-)C,=M((8PPV)
MO90RRF')4XSS@&FZ=/X)MK*XF,FGC1OL%N-2$3@1O<;^%EP<%R<A@W)'WN*5
MP.RAT"WA@GA%E>2">%H'>;5)I9-C=0'9RR_@15>+PG8Q6/V);+43`"C(&UFX
M9HBF=OEL9,Q\$CY2,C@YKG[#^PKF*&.*_M1HENEUJ-P+&\'DV:E/*6,-&?EP
MKR-\IX89'8UE9\(S2V]W8W.BIX9DOH$OK%)H3;Q1K#<>7+,GW4+RF/@\_(F>
M<@%P.VN/"FFW5K;VTNE3F&"-H@BZC*HD1CEEDPP\T$\D/NSDYZFK:Z-;IJYU
M1=,<7).['VMO+W8V[_+SLWXXW8W8XS7FDW]C_P!@2IJ[60A^P7G_``C^\KN_
MX^)?*-OCG=L^S[=OS8QBN@4"/QQ%%$--EU=KM'GF+L+Y8?+&Y"FT?N1@88,5
M).,9YHN!V]E+<+:($MMZ\X;S`,\U/Y]W_P`^?_D44:=_QX1?C_,U:IMZ@BKY
M]W_SY_\`D44>?=_\^?\`Y%%6J*5P.?70;5=9.K#39C=[S(-U\YC5RNPNL9;8
MK%<C<%!Y//)IDGARTFN;>XETZY>2!8T!;4I2)`ARGF#=B4@\Y?<<US4!TL^-
M+<HUI_PDBZS/]H\LC[0+7RI-OF8Y\O;Y>,_+G;WI=?N-"O=;FN))[";4Y%LY
M-%DWJTCJ7SF`]2"<[MO;KQ1<#IX]'M[*XN+R'3Y4D=''S7CO'$&Y;9&253/4
M[0,UI037(MXPMIN4(,'S`,\5P>@1VZ>*;F:*>SDNY4N_M4$*`74.7W+]J;<2
M^,;4RJX!P-W6O1;;_CUA_P!Q?Y4[Z`1>?=_\^?\`Y%%'GW?_`#Y_^115JBE<
M"KY]W_SY_P#D45#=(]]:36EUIJ36\R&.2-Y%*NI&""/3%:%-D4O&RAV0L"`R
MXR/<9HN!SG_"-6?V$6O]GW1"R>:LQU.7SPV,9$V_S!P2/O=#CI1<^&;"Z-OY
MFE3`0)L58[^2-77=NQ(%8"09R</GJ?4URVI6EI%X?2TN[FVCLDUR<RW.KDSV
MP`$F//5F7>"Q&`6`#;3V`-6]E\+3:'I]CK%W86FN/:&&"[O+E8C;1"1U%Q#N
M;";L;D"_,1L!.%R"X'9WOAY-4='U""\E>&=YX&AU&6`Q%AC`,;@],_F<8S0W
MAJRDO+>ZDTZZDE@$>WS-2E=7,9RC.I?;(RGD,P)R!SP*SOB!=W\WARZMM-M;
MF[LS;SB]GLYH@T6U.$.YU(R3DE<G"D8^8$8-[)IT^HJ]['!!XB,VFMID4K(;
MI(\Q[@FTD[<^;NVDC&<\47`[6RT2VT_49+^VTV59WW_?O7=$WG<VQ&8JF3R=
MH&:O12W`N[@BVRQV[E\P?+Q7'>&1I)\26C6)M?[9_P!+&K>41YOW^/.QSUQM
MW=NG%=Q!_P`?]W_P#^5-,`\^[_Y\_P#R**//N_\`GS_\BBK5%*X&='"\5[/>
M)IV+B=421_.^\%SM'H,;F_.J]S932_:'@MGMY[AHVDE2<@D(1@<$8X!'X\@]
M*R-76>T^(6G7=N+B[E?2;]DM/-"JS(UOM5<X4$DGD^O)P.*_@^[NX-5UV36;
M:\LYG:"266]EAV!V&`B;)&"KT"CZ9R2<EP.G,3M?I?'3_P#24B:%7\[HA()&
M.G51^55IM+BGM);9]-=8Y)FG)CNV1Q(3DLKJ0RGD]".M<-/!8QW^M);7FG7-
M_>"\6ZN;73V34+!2'8&0AS(4PJ(H"@G*D=J99W?AN/3KR?6K?P_%X<,L"V5I
M8W(>REN<2;AN(1'X*DAE"J1D\KD%P/088#8:8;2WL/*@56_Y;;CSDEB3RQ))
M))Y))J>":Y%O&%M-RA!@^8!GBLSPS%:P^#HULKZ"]MR)G22WF$L2[G9O+1AU
M5,[![*.G2MRV_P"/6'_<7^5.^@$7GW?_`#Y_^111Y]W_`,^?_D45:HI7`P=7
MT:'7&M7OK&YWVK%X7M]0DMV1B,$YC93TXY]3ZTQM%,L4MO/#=2VS1Q)&C7\A
M>,INPZR;MX<Y'S`@\#FJ_C:\\,VUI:IXC6PE,S,MK!J$BK"[XY+;OE``_B()
M';D@%G_$A3P1;6.HZM:7]E#;PB2YEE,D3C'R/)AN8R5_B.T@<FBX&G'ID4>E
MG31IK-;$Y8/=%F<YSEG)+,<]R2358>'[==9DU9+.^2[E=9)-FJS+&Y48&8P^
MPC`Z%<5P=P^I0^#X[&SLKN]T>WF>9;W3I84AGS/N1$5I0RPKGA5W#`4;B`<]
M'=7'A6[\:P0QW5A;:^EQ&]Q)+<(+D$*"(%R<D,,95?EZ]S1<#H8[&5M.M+2\
MMGNC;LD@D><Y+H=RMG))Y'<GWS3KW38=1N!/>:2D[BVEM</+E3%)MWJ5Z$'8
MO4=O<UR_BZ_O[G4])EM]/O+G2HKVTD@N+.X@\J=VD`.[,@8@#@#!7)R3P,4Y
MKR_;XCI-K6E:E;V[:9J$8\N1'5;=7APZ"*0R;B!SA0^74`$*2"X'9Z;IJ:3Y
MAM;"4O)@/)/>-,Y`S@;G).!DX&<#)Q5ZP)*3EEVL9FR,YQTKE_!)LXM3UBWT
MIK&;2_W4L,^G*%@5B74Q;06'F*%4LV>2XR%KJ;+_`)>/^N[?THZ`1S)(^I`1
MR^6WD]=N>]9$7B?3I9KF(:PZ&VC>5VELWC5D1MK,C,H$@!(!*$\D>HK;_P"8
MK_VP_P#9JXB#1-5N+>VLKC19ECTRPN;=99+F)?M3LR;#&5+%1A-V7`P=HP><
M-L#HHM<MI+(7?]I311^<D!6>Q>*17=@J@QLH89R#DC&.>G-5H?%>FSVT]PFK
M3!(`C$/I\J,X<X0QJ5#2!B,`H#D]*Q[3P_K-]>^9?)J"Q3L\K/?30&162(QQ
MAUA.SDR,P"<?NP3@G%6[237[6,WZ^&KHW-M8Q6:6S7,&9FW?,ZD28V@<C<5)
M]!2N%C3_`.$BT];%+V36EA@=WCS/;F-E9$9W#*P#*0JLQW`8`J!?%FG/;23#
M4[H&-D4P-IDPGR^=F(2GF$':V"%Q\I]#5>PM=1%RFHOHMXDEM#/.89W@$EU=
M/M`(V2,J_*I49;@,,GBJ#6FKWE]9Z]/X;U!-2M+Q)I86DM<RQ>3-&(XB)B,(
M9BQ+E<[CCK@%PL;%QXKTRUL[>[EU>403QF4.MA(WEH#AFDPO[L`\$OMQSGI5
MQ=8@?5FTU=2D-PK;"?L;>5OQG9YN-F_!SMW9QVKD5T+7+'2[Z.+1I[F75[2[
MC:,30JMH\L\LJB0E^0!-@E-_W#@'(K5_L+4?^$B@ACBOXK"*Z2Z9_/A-M(57
MD@8\X.3C*G*<9SGBBX6.DLHKAK1"ESL7G"^6#CFI_(N_^?S_`,A"C3O^/"+\
M?YFK5-O4$BKY%W_S^?\`D(4>1=_\_G_D(5:HI7"QSZZ[:MK0T@:I(+LN8US9
M.(V<+N*"0KL+!<G:&S@'CBEOM<MM.U&.PNM3D6>39]VR=T3>=J[W52J9/`W$
M9K+BT[5/[:@LSIDPM;?5IM0-^TL7ELCI)A54,7W;I`O*@8!.>@*ZC;:M=W-U
M''HMUY6J+;,96FA`M"I^<2#?DD`9&S<">_>BX6-*'6;>_EN;6#49)'C5\[K1
MT23;PP1R`KX/!VDX[UI00W)MXRMWM4H,#RP<<5R]CH^HIK322PWUO8V0N#$D
MT\+PG?P!%L`<C&2?-Y&<#(KL;;_CUA_W%_E3OH%B+R+O_G\_\A"CR+O_`)_/
M_(0JU12N%BKY%W_S^?\`D(5'.)K:WDGFOPD42EW8Q#"J!DFKU4M7M1?:->VA
MMQ<B>!XS`9C$)`005WCE<],CI1<+&,/$UG_9ZWIO;Y(GE$4:/I,ZRRL5W82,
MIO?Y03E01@$]C3[KQ'8V=O;W$VK/Y,ZAU=+)W"*3C<^U3Y:YXR^`,'TK!FT;
M5)X4D_LS5QID=PDBZ:VH`WJL$D5F2?SR%7+Q_*)%X5AT.TU'\):W:@3P+>F\
MDL$M+1K:\\I;-XY)FB:?]X/.4+*@;[^XJQ(.[-%PL=K=&+1+"[O[K44MK6/=
M//*\8P/4G\AQ]`*JW'B"SM=0@LIM5D668QA6%DYC!D.$#2!=B%CP`Q!)Q6?X
MLTO4_%&F3QZ9<PQ_95GB:VN;;S%N)=F%96$J@8R<;L@$Y(RHJI+I.N*9-/?3
MWN?MLMC-+?1M''!#Y1C\P%&D+YQ'D`!@2PY')!<+&[9:Y;:AJ<FGVVIR-<)O
M^]9.B/L.UMCLH5\$@':3BKT45P;NX`N<,-NYO+'S<5AZ+8ZFFI6%O<Z9-;P:
M=]H_TIY8V2?>WR[`K%NG)W!<8[UT<'_'_=_\`_E33"P>1=_\_G_D(4>1=_\`
M/Y_Y"%6J*5PL8!URW&KRZ8-0N&N(3B9DT^1HHCL#X>4+L4[2#@L.H]13++4;
M/Q&LMM!?ROL"2%)K-X"RYRK+O"ED)'494U4DTZZ@\2S75AI-]!(\_GS727^;
M>Y78%(,1D'[PA54$I@8'S4_3-0O5DN=5UC0=0LKEECA"O+;NH4O@(FR4D\MD
MD@$]AP!1<+#G\4VD>H&Q>ZU-;G$A5#HESAP@RQ4^7AOP)SD8SD46_BFQN8KM
MTO[Y3:LB2QR:3/')N8$JJHR!G.!G"@G&/45?L+.Z/B+5]2NX&7_5VUG^\#!H
M50,6`S\I,CL#G!.Q>V*YV?PU?7'AK19KFVNC?P7C:C?VMM=;)GDDBE5T27>H
M!4R@`A@-J8!'%%PL=);7/]IZ2+ZUOS-;2(Q&8-A.,@@@X*D$$$$`@@U9@AN3
M;QE;O:I08'E@XXJGHUO?6OAGR=0:0S*)2HED\QTC+,8U=\G<P3:"<G)!.3UK
M5MO^/6'_`'%_E3OH%B+R+O\`Y_/_`"$*/(N_^?S_`,A"K5%*X6,;5-231XXV
MO+^;,F=D<%D\\C8ZD)&&;`[G&!437EG;Z>=>&J(UM<QQ;9XXO,\U2<1JBKDL
M27P%49);IDU)XBO=6M8(8]*TJYO#,Q666WDA#6ZX^\%E=0S'H.<#J<XP<J^L
M_MFA0:58Z;?6YTX6T_V43HDI3)_=K('(\P!3SN'./FYR"X6)YO%FF06D5U+K
M$JQ2;R?]`DW1!#AVE7;F)5/4N%`[U<.KQ_VQ_92WMS)=<;C%I\CQID9&Z55*
M*<<X+#J/45B7>GZE<^%VTJZT74[JWNC($0ZBIFMU)^19F:3]XO//S29'!#5*
M-)U&+7DE@L;J&[>:&6YU%+XM:SHJHL@:`R##E4*C"$#@[LY%%PL7I]5L-!EB
MTV74I(BB*?EM'D2)2<*9)`"$R0<%R,\]:MSZG!:ZD-.GUB-+LVSW?EF(<1(0
M&<GH`"PZ]><=#C+U'4[_`%<6T$7AS4+G2+B-9)98I+;+Y)_=D/*N!P"2,Y!P
M/6LB[\)^*%\3S7\%_I]R)K#4(Q/)9E2CR&+RHVS*=P&P<A<81@1E\@N%CJ],
MU%-760VFH2DQD;TELVB8`]#M<`X.#@XP>U7K`$).&;<PF;)QC/2L'PGI-SIU
MY?2?9+RTLI(XD2&_NOM,QD3>&;?YCX0@H`N[C#'`SSOV7_+Q_P!=V_I1?0".
M:&.?4@LB[E$.<9QWKG7UZU6_U^V.CW"?V5!#*C2R;/M)D:10%'\*YCQN/7.<
M8P3T4TT<&I!I&VJ8<9QGO6)?:7:7E]K-U_:.PZC9P6RCR2?):)I6#_[7,HXX
M^[UYX>O0-"LVM"T@E34=(A@OHKN*!H8;UI$9&7>75RBDX0.<;1RF,X.:6SU*
M^NDDC;PY"MX]O'<VL2:B65T=L?.Q0;"O!(`?@\;CQ1!H_FZC]NU75X+J1A)Y
MB0630J28Q&I7+L1A3)GDYW]@,&.+2]3BM)-GB6U6]%O':V]PNF,!'$K9.Y?,
M^9FZ9!4#L!1[P:$R:N3'%$=!>34#<36[V\%SN7,<9<LCMM#`G:@)"\MSC!JK
M)KMU!>C2KCP_;)J\LD201KJ#M;OO65^9?+R"JPN2-AZKSS5NST^>W42OJUE]
MKAM);:T>#3Y$CB+D$N5:5BYRJY^89P>>352/1K_R(&FUW3GO[:Z%W!<C2Y1F
M0H\;F53.=^4<@8*[<#'``![P:$3^*"^G/=6FA13R6D$T^H0F^9#$(I'C=8SL
M_>'=')C.P'`Y&:TH]6@?4PAT^%=-:Z%FEP;LB5IBH88BVXV\]=V?]G'-9K^&
M62Q:WL]=@@>[@FAU"5K!G,OFR/(S1CS`(SNDDQG>!D<''-\Z'9/XECU22YLV
MBB97C`T\"Y!5<*AG!YC'7:5SG^+'%'O!H;UE96\MHCO'ECG)W'UJ?^SK3_GE
M_P"/'_&H+*]MXK1$>3##.1M/K4_]HVG_`#U_\=/^%#YKB5@_LZT_YY?^/'_&
MC^SK3_GE_P"/'_&C^T;3_GK_`..G_"C^T;3_`)Z_^.G_``H]X>AS::J&UN*W
M.D1_V;->26*7:W;&3S45F.Z/;@+E&7(8G..,'-/U34?L&HRQ0:1%/96OD_:Y
MVNV1T\QL#8FTAL#DY9>.F:9'I6W6DG.KP_V;%>O?16JV;"3S71E.Z3>05R[-
M@*#G'.!RVZTVXN[DN^M6JPW*PB_C6P?,K1G.8R9/W8/0@A^.ASS1[P:#K/58
M[JX"3:=#;P70F^Q.MV7D?RR0Q>/:`G3(PS>^#7006%L]O&S199D!)W'TKG+7
M1+6VUJZU22ZLY9'$IB,.GB"5B_>60'$A`X!PO&<Y/-='!?VR6\:M+AE0`C:?
M2CWK"T)/[.M/^>7_`(\?\:/[.M/^>7_CQ_QH_M&T_P">O_CI_P`*/[1M/^>O
M_CI_PH]X>@?V=:?\\O\`QX_XTV2QM(XV<PL0H)(4L2?H!UIW]HVG_/7_`,=/
M^%']HVG_`#U_\=/^%'O!H<]'K-E_8%WJDVE7$+PSR01VA<&65U)"J,'`+8]>
M.YX-9UWXLL(3IT4-I8_:KJUM[IK>ZU(6[;9LA4B+#$CY5OE)7H.1FM"YT'1[
MZVEBN[NX+FYFN(I+>::W:,R9R,QL"W!QR>?2L]O"EFFFI96NJ[%ETU-,O9)H
M9)9)85W_`.K8OF-LR/@G<!P,<"CW@T-OQ"TFD::][9Z?9W$<*L\WVF\DAP`.
M-NV-RQ/3'';K62VMW$+QM/X?A2&)[:*_(OV+V\DQ4`*NS#A=ZDG*\$X!Q6O=
M;-5@6"\F2.*&]29%$9/F1QL&4'G^\`?PZ51U'2OMNJS2Q:M##I]S-;SW5N;-
MFE=XB"-LFX!00B`C83@'!!/![P:#],U'[=J<4,^D10V5UYOV2X2[9W?RVP=Z
M;1MR,D89NG.*VHK*W:[N$,>53;M&X\9%8NF:<;'48I9]6AGL[7S?LD"6;(Z>
M8V3O?<0V!P,*OOFMJ*]MUN[AS)A7V[3M/.!0N86A/_9UI_SR_P#'C_C1_9UI
M_P`\O_'C_C1_:-I_SU_\=/\`A1_:-I_SU_\`'3_A1[P]#&FOK2+Q3!H8TRX9
MI;66X$Y;:C>68P57)Y/[Q>>`/7KB#0-135]2U'3[K3(;>XLA&S^1>&X5=^["
M.P"[9!MRRC(`93DYJY=P6UUX@L=56^,9M+6XMP@B))\TQ'=D],>5TP<Y]N:<
M*7MK/+J$VI6U]?[$MXBEFT*^5O!8N-YW-@DY!`'9>Q/>#0KZEK,FC-/+J'A_
M9:[)GMS%>;Y7\M2WSK@*@;'!W-U&<4IU.YAM;Y;K1;*&^L]CS!M3(MHXF4MY
MCS,@(4;6!PA.?;FHY])O;YM3CU#7[.:WOHI(5*::Z30HV=@5C*5^4D'[GS8Y
MJQ#::A$9[O\`X2"U&J3.FZ5--80M&BL`C1F0MU8MD.ISCMD$]X-#2TYK74]`
MBU)+;RO.A,BKO+8Z\@]QW![BKL%A;/;QLT669`2=Q]*S]+@L](T62RCN/-=W
MFF=MA4&25VD;`_A&YC@9X'>M""_MDMXU:7#*@!&T^E'O6%H2?V=:?\\O_'C_
M`(T?V=:?\\O_`!X_XT?VC:?\]?\`QT_X4?VC:?\`/7_QT_X4>\/0S]5M[BWC
M3^R])ANY6R6\^\,$:`>K!6.3VPN/4BLZXUFPB\)6FNK8A/M:Q&.&YN/*53)C
M[[\A5`))89X!(!X%3^(DN=6@@AL-7MK2$,3<17%D\ZW"XX4[70@>HSST/&08
M[M;C4;<VUS=VBO;^1-;7"6C;//4DL3&7)V<+QN!Y//0T>\&AF7WB3[#X;AUO
M^R+&6VPS2/'JRM&^#A5@8*3*[_PJ0F>A(-7(]9M;CQ=+H<,&F@0%5D\[4BEP
M6,8<[(=AW`!ER=PZGTY5K"[%@]O%KMJINC(;T/IQ:.3?]XQKO!0XX&YG'J#4
MLE@TL]O`^LAM)@DAECMVMF$RM$5*CS0P!7*@D%23DC=@X![P:$FMSSZ4[31:
M(EQI\**TTQNRDAR<8CC`.\CC.2O48S4-QK6GQ>)6T:'3Y;@QV4]T\L;G[\9C
M_=*.[8E!ZC''7)Q%,FLW]S97DFL:=`L2*S6<VFR2JLH)RX*S+S@X`.X`C(R>
M:J77@K09]4>[AO[^WCDM+RWDA6ZN&!:X*EG7<Y5<88[0N"2#U44>\&AH^%M6
ML?$L-S)'#9LL+*/,LKTW,1W#.W?A<.!C*XXR.36_8*$2=5&%69@!^59&DP+9
MZA=:A?:C%<74\4<'[BV:&-8XRY7Y2S9;YVRV>>.!BM>P8.D[*<JTS$'\J-;:
MAH+_`,Q7_MA_[-6'INH:S+XO\0V%S+;/%;VMM-90HI54WM./G;&23Y:YXP.@
M'4G8F>1-2!CB\QO)Z;L=ZBCMC%J5QJ":=BZN(XXI9//^\J%BHQT&#(_3U]A0
MT!R]OXBUA_#T;2SH^H'5KJ!WAB`7RK>64L,'.`5BV9Y/S]<\U9T\ZW(6M)?$
M,S&ZL8KL7,EM#NMR6^<(`H7&.F\-C&3NZ5K6^CVUK.LT.E;75KAQFY)&Z=]\
MIP3CEN?;D#`)%4!X/TP6$]E_9=T8)@@8'5)BP5#E%5M^Y%!Z*I`]J5@N0VU[
MKD[66GP:FK23O<2Q7D]LK-);(@5'=%VC_62(>-NY1QC/%&6\UV'5+;24UVYG
ML[R]CM8]3,,`G218IY9E4"/RV7]U&H.TX+.,DCC>AT"WA@GA%E>2">%H'>;5
M)I9-C=0'9RR_@15>+PG8Q6/V);+43`"C(&UFX9HBF=OEL9,Q\$CY2,C@YHL%
MSGUUW7K[2;YH=7FMKC2;6ZD,@@B87;PSS1+Y@*<`B')";?O<$8K4_MO4XO$,
M)GEOPMQ=1PQV8LQ]F$+J"'\[9DOG/&__`(!WJ[<>%--NK6WMI=*G,,$;1!%U
M&51(C'++)AAYH)Y(?=G)SU-6UT:W35SJBZ8XN2=V/M;>7NQMW^7G9OQQNQNQ
MQFBP7-/3O^/"+\?YFK59UE+<+:($MMZ\X;S`,\U/Y]W_`,^?_D44VM03+5%5
M?/N_^?/_`,BBCS[O_GS_`/(HI6"YR\6I:J=;MKS^T939S:M-I[6#11^6J*DF
M'5@N_=NC!Y8C!(QT-2:U>ZHFI7UQ:ZE+;P:=]G_T58HV2XWM\^XLI;H<#:1@
M\\U>70;5=9.K#39C=[S(-U\YC5RNPNL9;8K%<C<%!Y//)IDGARTFN;>XETZY
M>2!8T!;4I2)`ARGF#=B4@\Y?<<T6"YF66KZD-9-G?37\DER+@2P368C@M]@)
M3RI-@+@C&3N?_@/2NQMO^/6'_<7^58D.C6VGS7-W;Z<\<DJODM=LZ1ACEMB$
ME4R>2%`SCFM*":Y%O&%M-RA!@^8!GBG;0+EZBJOGW?\`SY_^111Y]W_SY_\`
MD44K!<M53U34[71M+N=1O9!';6Z%Y&/84[S[O_GS_P#(HH\^[_Y\_P#R**+!
M<X2P\2:WX@TF[.F7J7D\>J;)6T:6U=K>V\K>H0RG8QW?+N/7YB,`<;4FK7[Z
M?HD^GWHDMGO$MKN2Y13/(PD,;H=@"*0P8$@$<8`'6KEUH=M>)*LFF2JTD_VD
MR0WKQ2"3:%+*Z,&7*C!P0",^IJR+%!:6]J-,_<V\BRQKY_1P<@D]2<\G.<]Z
M+!<I>++S485LK73'O!<3LY*6`@\\JJ]5\_\`=X!*YSSR,5S\&NZW=V2:JNJE
M?LCV$4UM%;H(;DR^7YI.Y?,4_O"!AA@J,@\BNDN=':^CD2]@NI"9FEC>&^>%
MX@<?*KHP8#CD`X/I4+>&=/:[M[G^R'4VXB$<27KK#^[.8R8@VQBIY!*DC`]!
M18+E;1KW5'U2PN;G4I9[;4?M'^BO%&JP;&^7854-T!!W%LD]JZ2#_C_N_P#@
M'\JRK+1+;3]1DO[;395G??\`?O7=$WG<VQ&8JF3R=H&:O12W`N[@BVRQV[E\
MP?+Q32"YHT55\^[_`.?/_P`BBCS[O_GS_P#(HI6"YQUYX\MSXO\`[.M-4T[R
M+=;B*6W,R&>6=%SC;G*@$$=,DY[#G4\.SZFFH+;W^J2WZ7%A'=@RQ1IY3DD,
MJ[%7Y>1C.2,=36M-"]Q/#/+IP:2$,$)F'&X8/'0Y'K65;>'8M/MI8M.M;FW>
M3RP9&OY)65$;(12S$JO4;1@<]#THL%SGI?%^JV]GJ.K2->I&%O$M8);>(V[O
M$T@4(5/F[L)D[OE;G;BM>TEU2ZM+VWGUZ_TZ2VD6::6[M;;STA(;[K+F(*2O
M!920`01D@C1_L*S^TSSMI!<SAP\;W3-%\^=Y$9.Q2V3D@`G)SG-5IO"MA<6@
MMI=/O643+/YG]JSB7>N=O[P/OP,G`S@=A18+E_1I-1E\,[]4;=<D2X8IL9H]
MS>6S+@;6*;2PP,$G@=*U+;_CUA_W%_E6=!!)8:8;2*WG,2JWSW%XT[\Y)R[D
ML>O<^U6()KD6\86TW*$&#Y@&>*=M`N7J*J^?=_\`/G_Y%%'GW?\`SY_^112L
M%RGKZ3_8O-CUB;2XH\F22WA221CT55WJPZ\8VDDD`8[YFHZCK=IX/TYIE:/6
M+EH(9S;1HS(S$;]BL2@;&0-Q*@D$Y`YMZOHT.N-:O?6-SOM6+PO;ZA);LC$8
M)S&RGIQSZGUIIT=I(9K:>"YFM7BBC2.2^=FC*$D.)"VX/DCY@0?E!SGFBP7,
M2]N?$C>$WO-/U"_:^LS*K026MLLK2`_*)SDH44?>\K#,#E?2K9U/45\1I=W=
MQJ$&B2R0Q6CPBU-M-YBJ%+[LS`M(^T8QT&<9YMOX9L9((83IEP!%N^9=1E5Y
M`QRPD<-ND!/4.2#WJ<:);+J?V]=+=9LABBWC"(L``&,0.PL`!\VW/`YXHL%Q
MGB%=5BFCGT_5VBE.U+:P6!"L[YRWF,P+;<?W2NW!))KF[CXB6\GB^>UMM9TZ
M*PM]/OB8WD5G\^$QG<X'S``>;A1@D(S<C&-L>%XI)H+JZBU&2^BA6$W$6K3P
M[U!)P0L@!&2>N?<FM.ZL([Z[6YNM*665;>6V&Z;(,4A4NI7H0=B]1V]S18+F
M;X2U/4;FYO;+53>)<11Q3+%?"`3!7W#=^X^39N4@?Q?*<]JW[+_EX_Z[M_2J
M&FZ:FE&5K6PEWRXWR37C3.0,X&YR3M&3A<X&3@<U>L"2DY9=K&9LC.<=*+:`
M+_S%?^V'_LU<;Y6FZ=XL\92ZM=S&P?3;*6YDGF;"H7N<J,?=7``POZDDGKID
MD?4@(Y?+;R>NW/>L\ZW9"YU*W_MR$RZ9&DEZHC!\D-NV[CZG:>.O3CD9;`X^
MU.D7\:67ANXTW[/<W37JV5A(CI`L$893M0[5<RF%B!TR.IY,6G3^";:RN)C)
MIXT;[!;C4A$X$;W&_A9<'!<G(8-R1][BNR@\06=Q9-=IJLBQK<);.LMD\<B2
ML5"JT;*&7.Y3R`,'=TYJ"'Q7IL]M/<)JTP2`(Q#Z?*C.'.$,:E0T@8C`*`Y/
M2E8#GK#^PKF*&.*_M1HENEUJ-P+&\'DV:E/*6,-&?EPKR-\IX89'8UE9\(S2
MV]W8W.BIX9DOH$OK%)H3;Q1K#<>7+,GW4+RF/@\_(F><@=Y_PD6GK8I>R:TL
M,#N\>9[<QLK(C.X96`92%5F.X#`%0+XLTY[:28:G=`QLBF!M,F$^7SLQ"4\P
M@[6P0N/E/H:+`<!-_8_]@2IJ[60A^P7G_"/[RN[_`(^)?*-OCG=L^S[=OS8Q
MBN@4"/QQ%%$--EU=KM'GF+L+Y8?+&Y"FT?N1@88,5).,9YKH+CQ7IEK9V]W+
MJ\H@GC,H=;"1O+0'#-)A?W8!X)?;CG/2KBZQ`^K-IJZE(;A6V$_8V\K?C.SS
M<;-^#G;NSCM18#2T[_CPB_'^9JU6=917#6B%+G8O.%\L''-3^1=_\_G_`)"%
M-K4$6J*J^1=_\_G_`)"%'D7?_/Y_Y"%*P'`P'2SXTMRC6G_"2+K,_P!H\LC[
M0+7RI-OF8Y\O;Y>,_+G;WI=?N-"O=;FN))[";4Y%LY-%DWJTCJ7SF`]2"<[M
MO;KQ73KKMJVM#2!JD@NRYC7-DXC9PNXH)"NPL%R=H;.`>.*6^URVT[48["ZU
M.19Y-GW;)W1-YVKO=5*ID\#<1FBP'*:!';IXIN9HI[.2[E2[^U00H!=0Y?<O
MVIMQ+XQM3*K@'`W=:]%MO^/6'_<7^58D.LV]_+<VL&HR2/&KYW6CHDFWA@CD
M!7P>#M)QWK2@AN3;QE;O:I08'E@XXIVT`O455\B[_P"?S_R$*/(N_P#G\_\`
M(0I6`M52UB2QAT:\DU.7RK%86-P^]DVICGE>1QZ<T_R+O_G\_P#(0H,%T!DW
MO'_7(46`\R#>#IC:7"3Z,OAJ2_`GLXY8FM82()?+:55.Q"[<X;C(3^*MJWM/
M,\.>&K@SS^7#J""WC20B-HS,1&2!][Y-N,Y'?&>:VI/$FGQV"WJZSY\#W#6L
M9M;5IVDE7.514!9B-K'@'A2>@J*X\6:7;+"\FM-LEA%QO2R=UBB)(#R,%(B7
M((R^W[I]#18"MXNGT&;4-+'B";36T96GCF^VNGE"<*NP'=QNQYF`>?QKCK+[
M";6P747A_P"$C']EG2_./^E^3F/.T'Y\?ZS?[;MW%>BWUS#H,)EFO)AY\A;;
M!9O/([8Y(1`S$`#TP!5=O$^G+<VD(UEG^U")HI8[1WB/F_ZO,H!12W8$C.1C
MK18#"\,C23XDM&L3:_VS_I8U;RB/-^_QYV.>N-N[MTXKN(/^/^[_`.`?RK*L
MM<MM0U.33[;4Y&N$W_>LG1'V':VQV4*^"0#M)Q5Z**X-W<`7.&&W<WECYN*:
M0&C157R+O_G\_P#(0H\B[_Y_/_(0I6`YC689XOB#I\UO/.\TVDW^R)G^165K
M?;M7IG+'GKSZ8K/\!/IU@9S'-I)_T>$7,]H&C*39V[+@LY#3$GEB%<DX(Z5V
MS17**6:^"JHR28P`!6597UKXBADB@OI9$7:Y66T>'>N<JR[PN]"1]X94^IHL
M!P;_`&#9>?8`C>("=374UMI-EWL/F!"Q^\`#Y>PGH,;>*9`NEPPV\%Q-H5SX
M8&IQ/=W-I#'#IQ4P3`(4+NN1*L18YP2Z<#!KO$\1V,EU-;C5V5H1(2[V;K&V
MS._9(1M<K@Y"DXP<TS_A)[/^SUO6OKY(GE$,:R:3.DLKD;@(XRF]^`3\H/`)
M[&BP#?!PQX)`3;]F\RZ^R;,;?L_G2>3MQQM\O9CVQ71VW_'K#_N+_*LVVNAJ
M>E&]M-1$]LZN,B+;RI(92#R""""#R"#5F"&Y-O&5N]JE!@>6#CBG;0"]157R
M+O\`Y_/_`"$*/(N_^?S_`,A"E8#`\;7GAFVM+5/$:V$IF9EM8-0D587?');=
M\H`'\1!([<D`L_XD*>"+:QU'5K2_LH;>$27,LIDB<8^1Y,-S&2O\1VD#DUIZ
MIJ2:/'&UY?S9DSLC@LGGD;'4A(PS8'<XP*B:\L[?3SKPU1&MKF.+;/'%YGFJ
M3B-45<EB2^`JC)+=,FBP'G]P^I0^#X[&SLKN]T>WF>9;W3I84AGS/N1$5I0R
MPKGA5W#`4;B`<]'=7'A6[\:P0QW5A;:^EQ&]Q)+<(+D$*"(%R<D,,95?EZ]S
M6G-XLTR"TBNI=8E6*3>3_H$FZ((<.TJ[<Q*IZEPH'>KAU>/^V/[*6]N9+KC<
M8M/D>-,C(W2JI13CG!8=1ZBBP'-^+K^_N=3TF6WT^\N=*BO;22"XL[B#RIW:
M0`[LR!B`.`,%<G)/`Q3FO+]OB.DVM:5J5O;MIFH1CRY$=5MU>'#H(I#)N('.
M%#Y=0`0I(ZB?5;#098M-EU*2(HBGY;1Y$B4G"F20`A,D'!<C//6K<^IP6NI#
M3I]8C2[-L]WY9B'$2$!G)Z``L.O7G'0X+`8O@DV<6IZQ;Z4UC-I?[J6&?3E"
MP*Q+J8MH+#S%"J6;/)<9"UU-E_R\?]=V_I5#3-135UD-IJ$I,9&]);-HF`/0
M[7`.#@X.,'M5ZP!"3AFW,)FR<8STHZ`+_P`Q7_MA_P"S5B0:;=Z=XIU[4K33
MXVAGLK58%5UC$LJ/<,X]C^\4Y(P2W7KC7FACGU(+(NY1#G&<=ZP[;41?ZSK6
MEVFC,L^G0PR1/=SM$MP9#(.,!BJ@Q'YB"3GIC!+=@,RV\/W]W>R#^SKNQL+B
M>6\9;NX2659O)\H;V5W+`[LJ-Q"B(#CA:L6DFOVL9OU\-71N;:QBLTMFN8,S
M-N^9U(DQM`Y&XJ3Z"FV^O.-/ENK[1;6+%^+.$V^H-*DP',KJ2BGY`LG&.2AZ
M#!J:SU*^NDDC;PY"MX]O'<VL2:B65T=L?.Q0;"O!(`?@\;CQ2T#4+"UU$7*:
MB^BWB26T,\YAG>`275T^T`C9(RK\JE1EN`PR>*H-::O>7UGKT_AO4$U*TO$F
MEA:2US+%Y,T8CB(F(PAF+$N5SN..N!HIJY,<41T%Y-0-Q-;O;P7.Y<QQERR.
MVT,"=J`D+RW.,&JLFNW4%Z-*N/#]LFKRR1)!&NH.UN^]97YE\O(*K"Y(V'JO
M/-&@:F<NA:Y8Z7?1Q:-/<RZO:7<;1B:%5M'EGEE42$OR`)L$IO\`N'`.16K_
M`&%J/_"100QQ7\5A%=)=,_GPFVD*KR0,><')QE3E.,YSQ59_%!?3GNK30HIY
M+2":?4(3?,AB$4CQNL9V?O#NCDQG8#@<C-:4>K0/J80Z?"NFM="S2X-V1*TQ
M4,,1;<;>>N[/^SCFC0-3HM._X\(OQ_F:M5G65E;RVB.\>6.<G<?6I_[.M/\`
MGE_X\?\`&F[7!%JBJO\`9UI_SR_\>/\`C1_9UI_SR_\`'C_C2T#4Y:+3M4_M
MJ"S.F3"UM]6FU`W[2Q>6R.DF%50Q?=ND"\J!@$YZ`KJ-MJUW<W4<>BW7E:HM
MLQE::$"T*GYQ(-^20!D;-P)[]ZD350VMQ6YTB/\`LV:\DL4NUNV,GFHK,=T>
MW`7*,N0Q.<<8.:?JFH_8-1EB@TB*>RM?)^USM=LCIYC8&Q-I#8')RR\=,T:!
MJ5+'1]136FDEAOK>QLA<&))IX7A._@"+8`Y&,D^;R,X&178VW_'K#_N+_*N6
ML]5CNK@)-IT-O!=";[$ZW9>1_+)#%X]H"=,C#-[X-=!!86SV\;-%EF0$G<?2
MGI8"]157^SK3_GE_X\?\:/[.M/\`GE_X\?\`&EH&I:IKHLB,CJ&1@0RL,@CT
M-5_[.M/^>7_CQ_QILEC:1QLYA8A020I8D_0#K1H&IS4FF:EISVEY;Z9)=?9M
M5N)S;021J[0R(ZJR[F5>"R\$CC/<8-62#6(-&M]$F\-WUW8W"22WAMYK8DB2
M1F,!$DJ\8;!89&.!UR+XUBW/AR^U8Z'=[[:2:,6@<&1MA/).=JY`SR>/KQ57
M5O$MAI]]:V4-M8O=2PPSM#=:B+9F60L%6+<,2.2C?*2O0<C-&@:EOQ!%)JX@
M>+3M0NK>TFDCE@LKD6\[/M`#)()4^498$;AGTXK'AT/7+:U&DOIC3"Z>PD>\
MCDB6"W$1C#J1D,2!%QM3!+#ISCI-6=;.XM+2RT^&XNKG>RB>Y:&-43&XE@K'
M/S#`QSZBL.+Q1!=QP7MEI$<VE[K9+B<WA$D33E0-J!2KA=ZDG>."<9Q1H&I>
MT6QU--2L+>YTR:W@T[[1_I3RQLD^]OEV!6+=.3N"XQWKHX/^/^[_`.`?RKGM
M,U'[=J<4,^D10V5UYOV2X2[9W?RVP=Z;1MR,D89NG.*VHK*W:[N$,>53;M&X
M\9%-6`T:*J_V=:?\\O\`QX_XT?V=:?\`/+_QX_XTM`U)IXQ-;RQ,@=70J58X
M#9'0GM7&Z';ZAI5Q+J>I0ZFL4,$=E%!=302-S(!\GE8!094`MASSD9QG0N]3
ML;/Q''I$FG3A6LYKHW+$A,1^7E5[L?W@YZ=N3G#=#O'U&Z-OJ&D163O;I=0>
M5=M,'C8D?-\J[6'&0,CG@FC0-2M=IJ.NW5[!J7A>\^SK%/#;![J%(G#*5+%T
MD,BEU.T83Y03ZY#+=]?TJSN9=/T+4Y(IFC2&RNKR*::W/S^9*6><J5^X`@<=
M#T!X-/UV'4]3U*VL[+3IQ9F9$ABU3-U(T;%.8BH"J6##<7[5834G@M-2-_H+
M"]L51C!8W!G67<"0%=E3!XYW``<<\T:!J:FD6XMO#?EBQN+-BLKO%<F,R%V9
MF9V,;,N68EN#_%VZ5IVW_'K#_N+_`"K.MXK:[T:*^6W\MIK<3!=Y.W*YQGO5
MB"PMGMXV:++,@).X^E/2P%ZBJO\`9UI_SR_\>/\`C1_9UI_SR_\`'C_C2T#4
MS_$5[JUK!#'I6E7-X9F*RRV\D(:W7'W@LKJ&8]!S@=3G&#E7UG]LT*#2K'3;
MZW.G"VG^RB=$E*9/[M9`Y'F`*>=PYQ\W.1JZK;W%O&G]EZ3#=RMDMY]X8(T`
M]6"L<GMA<>I%9UQK-A%X2M-=6Q"?:UB,<-S<>4JF3'WWY"J`22PSP"0#P*-`
MU*=WI^I7/A=M*NM%U.ZM[HR!$.HJ9K=2?D69FD_>+SS\TF1P0U2C2=1BUY)8
M+&ZANWFAEN=12^+6LZ*J+(&@,@PY5"HPA`X.[.15:^\2?8?#<.M_V18RVV&:
M1X]65HWP<*L#!297?^%2$ST)!JY'K-K<>+I=#A@TT"`JLGG:D4N"QC#G9#L.
MX`,N3N'4^G)H&H[4=3O]7%M!%X<U"YTBXC6266*2VR^2?W9#RK@<`DC.0<#U
MK(N_"?BA?$\U_!?Z?<B:PU",3R694H\AB\J-LRG<!L'(7&$8$9?(W];GGTIV
MFBT1+C3X45IIC=E)#DXQ'&`=Y'&<E>HQFH;C6M/B\2MHT.GRW!CLI[IY8W/W
MXS'^Z4=VQ*#U&..N3@T#4=X3TFYTZ\OI/LEY:64D<2)#?W7VF8R)O#-O\Q\(
M04`7=QAC@9YW[+_EX_Z[M_2N?\+:M8^)8;F2.&S9864>997IN8CN&=N_"X<#
M&5QQD<FM^P4(DZJ,*LS`#\J.@#)IHX-2#2-M4PXSC/>LZ*"WAU_4M52^PU[:
MP6X3R3^[,1E.[/?/F]./N^_&K_S%?^V'_LU<K<:UKEMJWBV&6YM%6TL+>?3T
M6,E8V=IU&X]68E$]AP`.I+=@+4&D6,-IH]FU_P"9;:=:O"5:)BTLC($\S<3P
M<&3/7._KQS4BTO4XK239XEM5O1;QVMO<+IC`1Q*V3N7S/F9NF05`[`56BUW6
MK:TDLYI;P7JWJE!>)`;A;=8O-;S/*'E8;8Z`KR`PZ-TN:>=;D+6DOB&9C=6,
M5V+F2VAW6Y+?.$`4+C'3>&QC)W=*6@:DEGI\]NHE?5K+[7#:2VUH\&GR)'$7
M()<JTK%SE5S\PS@\\FJD>C7_`)$#3:[ISW]M="[@N1I<HS(4>-S*IG._*.0,
M%=N!C@`"Q;7NN3M9:?!J:M).]Q+%>3VRLTELB!4=T7:/]9(AXV[E'&,\49;S
M78=4MM)37;F>SO+V.UCU,PP"=)%BGEF50(_+9?W4:@[3@LXR2.#0-17\,LEB
MUO9Z[!`]W!-#J$K6#.9?-D>1FC'F`1G=))C.\#(X..;YT.R?Q+'JDES9M%$R
MO&!IX%R"JX5#.#S&.NTKG/\`%CBL5==UZ^TF^:'5YK:XTFUNI#(((F%V\,\T
M2^8"G`(AR0FW[W!&*U/[;U.+Q#"9Y;\+<74<,=F+,?9A"Z@A_.V9+YSQO_X!
MWHT#4Z2RO;>*T1'DPPSD;3ZU/_:-I_SU_P#'3_A1IW_'A%^/\S5JF[7!%7^T
M;3_GK_XZ?\*/[1M/^>O_`(Z?\*M44M`U.1CTK;K23G5X?[-BO7OHK5;-A)YK
MHRG=)O(*Y=FP%!SCG`Y;=:;<7=R7?6K58;E81?QK8/F5HSG,9,G[L'H00_'0
MYYIL6I:J=;MKS^T939S:M-I[6#11^6J*DF'5@N_=NC!Y8C!(QT-2:U>ZHFI7
MUQ:ZE+;P:=]G_P!%6*-DN-[?/N+*6Z'`VD8//-&@:C+71+6VUJZU22ZLY9'$
MIB,.GB"5B_>60'$A`X!PO&<Y/-='!?VR6\:M+AE0`C:?2N7LM7U(:R;.^FOY
M)+D7`E@FLQ'!;[`2GE2;`7!&,G<__`>E=C;?\>L/^XO\J>E@(O[1M/\`GK_X
MZ?\`"C^T;3_GK_XZ?\*M44M`U*O]HVG_`#U_\=/^%']HVG_/7_QT_P"%6J;)
MO$;&,*7P=H8X!/;)HT#4PDMK1=*U.R^VY^VO.^_RC\GF9[=\9]LUF:IH-K?>
M:(-2C@^UV":=>LULSM)"N_'EG</+;]XW.&[<<"I5U#7CX2U><75H=2MIKE1,
M82(T5"<83/S8``Y//4^E)XBO]6L-&M]:AO9UMH(%EN(XH(BH4#=))*6^8H%'
MW8QNSZCH:!J2ZI"VM6XBFFT]5AN2T<=W8?:8W08VDJ6!#@Y(8$>X[5G1>&8;
M18K*SUB.+2LVS7$+V;/-*T)7!$FX!0VQ`1L/0X(SQL^*&UEX;'^QC?\`EF4M
M<MI_V;SBFTX"_:/DY8J3WPIK";6M2G1M1L=8NFM;&:R@,$L$.+I9#'YC2$("
M'Q(?N%0"O0CBC0-33TS3C8ZC%+/JT,]G:^;]D@2S9'3S&R=[[B&P.!A5]\UM
M17MNMW<.9,*^W:=IYP*PM&O=4?5+"YN=2EGMM1^T?Z*\4:K!L;Y=A50W0$'<
M6R3VKI(/^/\`N_\`@'\J:L`?VC:?\]?_`!T_X4?VC:?\]?\`QT_X5:HI:!J<
M_J%I9:AK=IJ#WF$@L[FU:+RS\XF,1SGMCRNF.=W;'-"PMKW3%-Q)JEM?W20Q
M6L`6R:%5B#C<6RYW,0>H(''"]C/JNKZI8>+[>VW0?V?)IMW<+&JY=GB,."Q/
M0?O",#ZD]@OAV?4TU!;>_P!4EOTN+".[!EBC3RG)(95V*OR\C&<D8ZFC0-2&
MZL[VZN?.;Q#$#;M))8/]@;?"[HR9DPX655#G`VKT&22,U8TF&:TTRZM-0U.S
MN6F#8EM[*2$DL#N9]TC[B>.XQC'3&'(-8@\1"--6-\CB22>V>%(XK=<'R@K*
MNX$G`.YFR`Q`&,50-WXDNO#TPBEFFOTU*2*233HX$=(E8\()R4S@!?FR><_0
MT#4W+>6VM-&BL5N/,:&W$(;81NPN,X[58@O[9+>-6EPRH`1M/I531[Y-0\-^
M:L]U,Z"6&5KM8Q*)$9D=7$8"9#*1\O!QD9'-:EM_QZP_[B_RIZ6`B_M&T_YZ
M_P#CI_PH_M&T_P">O_CI_P`*M44M`U.;\1)<ZM!!#8:O;6D(8FXBN+)YUN%Q
MPIVNA`]1GGH>,@QW:W&HVYMKF[M%>W\B:VN$M&V>>I)8F,N3LX7C<#R>>AK2
MU])_L7FQZQ-I<4>3));PI)(QZ*J[U8=>,;222`,=\S4=1UNT\'Z<TRM'K%RT
M$,YMHT9D9B-^Q6)0-C(&XE02"<@<F@:D36%V+![>+7;53=&0WH?3BT<F_P"\
M8UW@H<<#<SCU!J62P:6>W@?60VDP20RQV[6S"96B*E1YH8`KE02"I)R1NP<#
M-O;GQ(WA-[S3]0OVOK,RJT$EK;+*T@/RB<Y*%%'WO*PS`Y7TJV=3U%?$:7=W
M<:A!HDLD,5H\(M3;3>8JA2^[,P+2/M&,=!G&>30-0F36;^YLKR36-.@6)%9K
M.;39)564$Y<%9EYP<`'<`1D9/-5+KP5H,^J/=PW]_;QR6EY;R0K=7#`M<%2S
MKN<JN,,=H7!)!ZJ*VO$*ZK%-'/I^KM%*=J6U@L"%9WSEO,9@6VX_NE=N"237
M-W'Q$MY/%\]K;:SIT5A;Z??$QO(K/Y\)C.YP/F``\W"C!(1FY&,&@:G1Z3`M
MGJ%UJ%]J,5Q=3Q1P?N+9H8UCC+E?E+-EOG;+9YXX&*U[!@Z3LIRK3,0?RK!\
M):GJ-S<WMEJIO$N(HXIEBOA`)@K[AN_<?)LW*0/XOE.>U;]E_P`O'_7=OZ4=
M`(YGD34@8XO,;R>F['>JLNFQ37-Y<2Z4'EO84@N"9_OHA<J,=!@R-R,'GV%7
MO^8K_P!L/_9JXBYL5B\1>-U-[<`3:79RO)*SOM!>YRH"C*I@8PHZ9/)));`Z
M&RT&UL)TGBTV9YT5U\VXOY)W(?;NW,[$MPB@9S@9`P"<U!X/TP6$]E_9=T8)
M@@8'5)BP5#E%5M^Y%!Z*I`]JY6PD&H?\2[3(=*ALI;C[7;P:7)YEO^XCW,8V
M"J&Q,T&2%`!SW%.TZ?P3;65Q,9-/&C?8+<:D(G`C>XW\++@X+DY#!N2/O<4K
M@=E#H%O#!/"+*\D$\+0.\VJ32R;&Z@.SEE_`BJ\7A.QBL?L2V6HF`%&0-K-P
MS1%,[?+8R9CX)'RD9'!S7/V']A7,4,<5_:C1+=+K4;@6-X/)LU*>4L8:,_+A
M7D;Y3PPR.QK*SX1FEM[NQN=%3PS)?0)?6*30FWBC6&X\N69/NH7E,?!Y^1,\
MY`+@=M<>%--NK6WMI=*G,,$;1!%U&51(C'++)AAYH)Y(?=G)SU-6UT:W35SJ
MBZ8XN2=V/M;>7NQMW^7G9OQQNQNQQFO-)O['_L"5-7:R$/V"\_X1_>5W?\?$
MOE&WQSNV?9]NWYL8Q70*!'XXBBB&FRZNUVCSS%V%\L/EC<A3:/W(P,,&*DG&
M,\T7`[>REN%M$"6V]><-Y@&>:G\^[_Y\_P#R**-._P"/"+\?YFK5-O4$5?/N
M_P#GS_\`(HH\^[_Y\_\`R**M44K@<^N@VJZR=6&FS&[WF0;KYS&KE=A=8RVQ
M6*Y&X*#R>>33)/#EI-<V]Q+IUR\D"QH"VI2D2!#E/,&[$I!YR^XYKFH#I9\:
M6Y1K3_A)%UF?[1Y9'V@6OE2;?,QSY>WR\9^7.WO2Z_<:%>ZW-<23V$VIR+9R
M:+)O5I'4OG,!ZD$YW;>W7BBX'3PZ-;:?-<W=OISQR2J^2UVSI&&.6V(253)Y
M(4#..:TH)KD6\86TW*$&#Y@&>*X31!$GB>:&Q&FO*@NCJ%Q;NQNI1D[/M*E5
M*$$X4,6R`2N!7HEM_P`>L/\`N+_*G?0"+S[O_GS_`/(HH\^[_P"?/_R**M44
MK@5?/N_^?/\`\BBCS[O_`)\__(HJU39%+QLH=D+`@,N,CW&:+@9@M`MK<VPT
MW]S=,[3+Y_WB_P![GJ,Y[54N]!L[Z:.6?2G+)$L)"7;()(QG"2!2!(HW-P^1
MR?6N5N+?2K6RLH-;DC?14UVZ%RVHR;XF.R79YK/P1NQC=QNV]\50NW\)RZ'8
MV6J7VGVVK36SK975W=+&;.U,K^7-$7.%;;C!7YF(7/"Y!<#N;C1C?(XO+>Y=
MO-:2.2&^>!X@V/E5T8,%X&0#@^E1OX:L'O+>Z.D2*UN(PD27KK#^[.8RT0;8
MQ4\@D$C`]!5'Q;/H$U]I0U^?37T96GCE^VNAB\\*NP'=QNQYF!_6N/LOL)M;
M!=1>'_A(Q_99TOSC_I?DYCSM!^?'^LW^V[=Q1<#T.RT2VT_49+^VTV59WW_?
MO7=$WG<VQ&8JF3R=H&:O12W`N[@BVRQV[E\P?+Q7'>&1I)\26C6)M?[9_P!+
M&K>41YOW^/.QSUQMW=NG%=Q!_P`?]W_P#^5-,`\^[_Y\_P#R**//N_\`GS_\
MBBK5%*X&7-:_:-0@OI=-#7,$4D,;F;HDA4N,=#G8O7T]S6;;>'8M/MI8M.M;
MFW>3RP9&OY)65$;(12S$JO4;1@<]#TKH;E2]I,JR-&2C`.@)9>.H`ZFN"\#W
M%G!>SM:G1X-/CMHXYY;"8E)+@O@-*65<3$=5(+#(!)R*+@=!8>'[?3-0DO;2
MSODEDD>1T;59GB+-]X^6SE,_AQVJ6ZT:WN[<P2Z6X7SVN0\=VT<B2MD%U=2&
M4D,PX(X)'0UC:Y:M!J?B*2-[V:6?13A4G(9?FD`$>/N8]0,]^37+0+I<,-O!
M<3:%<^&!J<3W=S:0QPZ<5,$P"%"[KD2K$6.<$NG`P:+@>E10M9:<UM!8>5"%
M8_ZW<<G)9B3R22223R2:G@FN1;QA;3<H08/F`9XK%\'#'@D!-OV;S+K[)LQM
M^S^=)Y.W'&WR]F/;%=';?\>L/^XO\J=]`(O/N_\`GS_\BBCS[O\`Y\__`"**
MM44K@8.KZ-#KC6KWUC<[[5B\+V^H26[(Q&"<QLIZ<<^I]::=':2&:VG@N9K5
MXHHTCDOG9HRA)#B0MN#Y(^8$'Y0<YYJMXVO/#-M:6J>(UL)3,S+:P:A(JPN^
M.2V[Y0`/XB"1VY(!SM56V'@&PL(=7L[ZV@%K]KNII/-B:#(^>3#9,1V\Y;!4
M$$XR:+@:K^&;&2"&$Z9<`1;OF7495>0,<L)'#;I`3U#D@]ZG&B6RZG]O72W6
M;(8HMXPB+``!C$#L+``?-MSP.>*X?4+;P_=>#$MI;K2+2<>>NFW(1Q;O\WWK
M0,Y5)"<;"I8K_"".*TLV<?C9+]_[+N]7FEMU%A<68^WVL;(BEHY&?)1<N[$+
M@_,,Y!HN!M#PO%)-!=746HR7T4*PFXBU:>'>H)."%D`(R3US[DUIW5A'?7:W
M-UI2RRK;RVPW39!BD*EU*]"#L7J.WN:YGQ1>^#KW5+>&XU'2X]6FBC:"\FND
M5K:+<</$S'AB<CY.3QG@5E:G?:ROCF6YO-$U0/\`V/J:6\<,\.#&K0E3'MD+
M;F(&25!S(HP0I(+@=SINFII1E:UL)=\N-\DUXTSD#.!N<D[1DX7.!DX'-7K`
MDI.67:QF;(SG'2N2\`+%!=:E;VL^G7=L(X7^TZ7"(K;S#O#IM#O^]&T,QSSN
M7(&.>NLO^7C_`*[M_2CH`LUM(]P)HYO+;9M^YGOFD\B[_P"?S_R$***+A8/(
MN_\`G\_\A"CR+O\`Y_/_`"$***+A8/(N_P#G\_\`(0H\B[_Y_/\`R$***+A8
M/(N_^?S_`,A"CR+O_G\_\A"BBBX6&QVEQ%&$2[PHZ#RQ3O(N_P#G\_\`(0HH
MHN%@\B[_`.?S_P`A"CR+O_G\_P#(0HHHN%@\B[_Y_/\`R$*/(N_^?S_R$***
M+A81K:Y="K7F588(\H4+;7*(%6\PJC`'E"BBBX6%\B[_`.?S_P`A"CR+O_G\
M_P#(0HHHN%@\B[_Y_/\`R$*/(N_^?S_R$***+A8/(N_^?S_R$*/(N_\`G\_\
MA"BBBX6(X;":#S/+NMID<NY\L'+'O^E2>1=_\_G_`)"%%%%PL'D7?_/Y_P"0
MA35M+A9'<7>&?&X^6.<4447"P[R+O_G\_P#(0H\B[_Y_/_(0HHHN%@\B[_Y_
M/_(0J*>PFNH3%-=;D)!(\L#."".A]1111<+$OD7?_/Y_Y"%'D7?_`#^?^0A1
M11<+"-;7+H5:\RK#!'E"A;:Y1`JWF%48`\H4447"POD7?_/Y_P"0A1Y%W_S^
M?^0A111<+!Y%W_S^?^0A42V$J7,EPMUB6155V\L<A<X'X;C^=%%%PL2^1=_\
M_G_D(4>1=_\`/Y_Y"%%%%PL16]A-:VZ00W6V-!A1Y8/ZDY-2^1=_\_G_`)"%
@%%%PL'D7?_/Y_P"0A4EM`8$<,^]F<L3C'6BBBX['_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>graph2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 graph2.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`$?`4P#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#TCQ+XEU3P
MIKB1L4OK?6"L&FQR,D8@NL@!&;@F-@=V>2"I'.5%+XMCUS2?#D-]!XGOTNHY
M;6WD$=O;>7(9)TC=\-$2#AS@`X&!P><Z5UX-L]6O-4N=9D^VM>1?9X1MV"UA
MZ[4Y.&+`,7&"2%Z;13[SP[=ZEX3@T>^U7S[F.6WD>\,&#)Y4R2#*[NI"8)SU
M.<=J`&;]0TOQ#HNFOJMS?17*7+RO<QPAFVA-H_=HH`&3T'?G-=%*XBB>0JS!
M5+849)QZ5C:WHU_?:EIVH:;J%M:7%F)5Q<VC3HX<*#PLB$$;?6M"RBOULO+U
M"[@FN3G,UK;F%0.V%9WY'N3]*`.*/CG4-4\%:SJ]E:6UN(M*N+NWN(+U+AH)
M%0E4FC*@I(#R5PP!4@GIG4TOQ5J$MY;6&H:.8[JYTYKZV6*Y5VD";`R."%5'
MRXZ%EZ_,*IW?@"XU-[^;4=4M'NI]-N-.2XMM.$,A648+S'>?,(QD`;!DMQSQ
M?U?P8NKSQN^H20JNDW&F'RDPW[W9\X;/!&SI@]>M`&7=_$:739M1@O=-LFN+
M;2YM3CCL]2$VY8R`4D_=CRV.1C&X=>>.9]2\>R:4;6VO[;2;*_N86N%CO=7$
M$2Q`@#,C1YWG)^4*0-I^;&":MU\.+J^CE%QK%G&7TJXTT):::(8U$NSYPOF$
MY&P9&<'C&W'/1:AH-X^I6VIZ5J45G>Q6QM7\^V,T4L9((RH=#D$$@ANYX-`'
M/P^,]1UC7-'?P]#!=VE]IES.UO-<"-!)'-&A8RJCGC+J-H()(/3D:-MXQNM6
MMM/_`+%TA9[NZM#=R175UY*0J&V[2RJY+%MP&!CY3R*TK?09D\066KW&HM<3
M6]A+9ONA"F0O)&^_C@8\O&,=^O'.99^#KW2+:P.E:Q%#>6UL]J\D]GYL<R%]
MXR@=2"I)P=V.3D&@#/?QZ3J-I>JDPL&TBZGEL<)YGVF.XBB";O[P9G3K@YSZ
M5)<>,-3TC5;]]?LH[.UL]*%V88+A94D<R;1B1E0@]%(.`,@Y[U.?AW:[(8A?
MS;(]/GM6?8OF-++,DQGST#!TSC;CGVQ3YO!E[J<U[-K>MBXDN;`60^R6OD"(
MA]XD4%W^;.#SQD#ITH`HCXGV:V.KR,NFW-Q8637RQ:;J:W2R1*0"&8*-C`D<
M8(Y&"><7;WQEJ%A?V^FSZ781:C-";A89M3\I94R1MB=HP'EP,E>`,C+8.:LZ
MCX:UC6O#VJZ5JFO0R"]M6MD:"P\M8\C[[`NQ9OHRCVJSXAT&\UM6A2^M!9RQ
M^7+:WM@MRG?+I\RD/@XY+#@?+UR`;L;%HU9D*,0"5)&5/IQQ3JJZ;8QZ9I=I
M81/(\=K"D*M(VYF"@`$GN>*M4`%%%%`!1110`4444`%%%%`!3)3(L+F)%>0*
M2BLVT$]@3@X^N#3ZANYI8+.::"V>YE1"R0(RJTA`X4%B`,^YQ0!S.G^-1J8L
MK2VT\G6))FBO;!IL&R"$>8SMCE1D;>/GW+T!)#])\<6%_IU[>W,5Q:I;W\UD
MB&VE+RE'95V+LW.Q"Y*J"5Z'D5EV/AS7='U>#Q*O^F:IJ+K'K-JDH""(_<\K
M=@?NNG;<"QZXJC<>$]38*7L+J5;'7+N_"6]X+=[F*?S"#$Z2*59?,`(8J#R,
MX-`'6S^,M"M[.UN9+N0)=3-!"@M93(90I8H8PN\-@'Y2`>W4BI#XLT4:7#J`
MNV:&>4PQ(D$C2O(,[D$07?O&ULKMR,'(KBY[1]"U7PY<6OAZY6XNM6GE:VGU
M#[3<2?Z(XW%Y'*A]JXQO*X'WN>-"UT76;*^C\0_V;)+/+J%Q=3::MQ'YD<<D
M21KM)(0N/+4D;L?.V&/<`[+3-4LM8L5O+"<30,2N=I4JP."K*0"K`\$$`CO5
M!/%FDSSRV]O.[S(LA3=!(B3%`2PCD9=KXQSM)Q4?A;3KRTCU.\OH?L\VI7S7
M?V;>',"E$0*2.-V$R<$C).">IYVVT76[;5/*TRPO]-LF><WD,U]'/:2JRMCR
M`6+H2Y4XPB@%N#Q0!N>'/&^E>(;.Q=7>VNKJS6[\F6-U7&U2X21E59-A8`E<
MX[XJ:T\:Z!>R%(;R4$P/<1M+:RQK-$HRSQLR@2*`0<H3P1ZBL.P\/ZS:Z;X,
M2.W2*YTS29()RSJ5BF,"*`<'YOF4],]*R_["\27VH6-S<V&I,\5C=6\\M[?0
MMNEDBP"B1MM"%AC.`>1D`"@#L(O&>ASZ:E_%/<R6\D@CAVV4Y><D9S&FS=(,
M<[E!&,G/%0W?C;2[9]*>-FGM=0:9%DB1W=7C&2@B52Y;((*XR,'BLC6/#-X\
M'A>Z2SO;@:9:M;7%E87YM9<.B#<CJZ`[3&!M+`$$^@!LZ7X?FM[_`$*YCTJ6
MSCAFNIITN+TW,J-(N`S.S$ECWP6`]3UH`V&\6Z(NF6VH"[>2&YD,4*16\DDK
MN,[D$2J7W#:V1MR,'.,5%'XNL;G5=+MK-DGM;^WNIOM._;Y7D&,,K*1D'+G.
M<%=O(].;T[0=:T:\M]6&FRW30:AJ9:SBGC#M#<3;TD7<P4D!5X+`X8]Q@PS^
M#=8U*\9YXA:+?V^K+*R2JWV4W'DK&/<D(6.W(SGGID`Z.V\<Z;?^(;+2[(22
M)<6T]PUQ+')"%6,I@J'4;U;><.#CY3U[6(_&F@20W4WVUTCMK>2Z=I;:5-\*
M#+21[E'F*..4W#D>HKE[W1->\2WEG!=:1)I446BWNGRW)N(G`EE6)04VL6*?
M(2"0#UR!QFN_A:^N_#NHVO\`PCNIQ:BNCW-K%->:X]Q&TKQ%-L*M*PVL>[A,
M#''7`!UH\<:"T,<JSW;"7<8U33[AF=5"DR!0F3'\R_O,;>1S6[:W4%[:0W=K
M*DUO,@DBD0Y5U(R"#Z$5R6OZ/.\.ERP:1J4MU;6QA6YTJ]C@G@)"_*1(RHR$
M@'DMRH^4]:Z+0H]2BT&QCUB5)=26%1<NF,,^.>@`_(#Z4`:%%%%`!1110`44
M44`%%%%`!1110`445#=W4=E9SW<V_P`J"-I'V(7;:!DX4`DGCH.:`)J*BM[B
M&[MHKFWD66&5`\;J<AE(R"*EH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`(I;6WFFAFE@BDE@8M"[H"T9(*DJ>Q()''8D5+110`4444`%%8FGZO/JVN
MW:6?EG2K+=!),5),MQD9"'.-J#()YRQ(XVG.W0`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`<OIA_P"$:UXZ(^%TR]9IM-8G_5R<
MM)!].KJ/3<!PHKJ*SM<TA-;TJ2S:5H)<B2"=/O0RJ<HX]P<?7IWJ'P]K#ZM8
MR+<QB'4;24V][`#G9(,'(_V6!#+[,*`->BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`*P/$>H7+/!H>ER%-2O@<S+@FUA'#S'/<9PH[L1V!QI:OJ
MMMHNF37UT3Y<8`5%&6D<G"HH[LQ(`'<FJ'AS2[BVCFU/4U3^U[_#W)4Y$2C[
MD*GNJ`GZDL>]`&GIVGVVEZ?!8VD>R"!`B+U/U)[D]2>Y-6:**`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HJA::WI-_<SVUGJEE<W%O_KHH;A':+_>
M`.1^-26&JZ=JJRMIU_:WBQ/Y<AMYED"-_=.TG!]J`+=%4I=8TRWU&'3IM1M(
M[Z;_`%5L\ZB5^_RJ3D_A2G5],&J#2SJ-H-0*[Q:&=?-*^NS.<>^*`+E%4HM8
MTR=+MX=2LY%LR1<E)U(@(&2'P?EP/6K@(8`@@@\@B@!:YKQ!')HVH1>)K96:
M*-!#J4*#/F09XDQW:,DGW4L.3BNEI"`P((!!X(-`"1R)+&LD;JZ.`RLIR"#T
M(IU<OH?_`!3NK'PS)D64BM-I38.!&/OP9]4)RO\`L$#^$FNHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`***YKQ!<2ZK?)X8L)61YD$FH3HQ#6]L<C`(Z.Y
M!5?0!F[#(!'8?\53K@U5PW]DZ=(R6*,/EN)A\K3^X7E4]?F;G*FNIJ.WMX;2
MVBM[>-8H8D"1HHP%4#``K*7Q=X:>_%BOB'23>&7R1;B]C\PR9QLV[L[L\8ZY
MH`V:*HVFLZ7?WD]G9ZE9W%U;G$T,,ZN\?;YE!R/QIU_J^F:6T*ZAJ-I:&=MD
M0N)UC\QO1<D9/L*`+E%13W5O:JC7$\4*NZQJ9'"AG8X51GJ22`!W)J--1L9+
M^2PCO;=[V)0\ENLJF1%/0E<Y`]Z`+-%,AFBN(EEAD22-AE71@0?H13Z`"BBB
M@`HHHH`****`"BBB@`I"`00<8[YI:1E5U*LH96&"",@B@#@]3TNP\3V4JZ=-
M#INB65A<VL=[$HC3+IL(3H/*0#)/0D#'W<U;TF35)/'42W,=A%!'I!#I9S-*
M.95\HEBJ]0),#''/)S6S9^$?#6GW2W5EX>TFVN$!"RPV4:.H((."%SR"1]#5
MF#0='MK&>Q@TFQBL[C/G6\=NBQR9Z[E`P<^]`'+^-X()-*N[FP>Q86EW!<ZE
M;0Q@W%Q)&T;QIY@;Y'PJCYE)(*@%1S5#0Y]2M$6YU".QN(9?$$\)@>W8W"2&
M=U24.6P-J;<#;]P9W=J[F71=*GU&+49M,LI+Z'B*Y>!3*G^ZQ&1^%._LC3/[
M4_M3^SK3^T-NS[7Y"^;M]-^,X]LT`>;7^D_\(Q=20+<'4%CM;:.2(*8PMNL[
M"".5MS$L\LC;I,8V1OE?7T#P]K)US3&N7MQ;S17$UM-&LF]0\4C1MM;`W+E3
M@X'T%7I+*UF6=9;:%UN%VS!HP1(,8PWJ,>M+:VMO8VL=K:6\5O;Q+MCBB0(B
M#T`'`%`$U%%%`&5X@T@ZSI9ABE^SWD3":TN,$^3,O*MQU'8CN"1WI=!U<:QI
MOFO$8+N%S!=0'K%*O#+[CN#W!![UJ5R^MC_A'-6'B6(8LI0L.JJ#P(Q]R?'J
MA.&_V"2?NB@#J**0$,`000>012T`%%%%`!1110`4444`%%%%`!1137=8T9W8
M*B@EF)P`/6@#.UW6$T733<>4T]Q(XAMK=?O32MPJC^9/8`D\"F>']';2;*1K
MF1)]1NW\^]N%7`EE(`X'90`%4=@!6;H:/XAU0^);F-EMD#1:3$Q/$1^].1V9
M\<=PF.A8BNHH`*Y6X635_',D97=;Z+:++$#@@W4NX`_5$7C_`*ZFNJJ-+>&*
M:6:.&-)9B#(ZJ`7(&!D]\#B@#S[PL(SI_P`/&0+]J%A()B0-^/)'F9SS_K`N
M??K4VM)?CQ1XCN`VG-:Q:5`9(-0B:5)H1YQ=`-RA0QX+'<.GR^O86VAZ39W5
MQ=6NEV4%Q<Y\^6*W17E_WB!EOQI)M!T:XAM(9])L)8K/;]E1[9&$&.FP$?+C
M`QC%`'G'C'6H;NYTJ2XL]4MX+'4M.>WB739VC9C+&SL'5"K$*=BJ#DG<`"2*
MV-?TB73M3:Y@OVW7;7$D44<.)80Z+Y\A?/S`*@"C:,,RY)X`[J>V@ND5+B".
M94=9%$B!@KJ0589[@@$'L12F"%IQ.8HS,$*"0J-P4D$C/ID#CVH`PO"6L#4K
M%K;^SXK+[)'"$BAF\U!&\89,-M7G:1D8X[$C!KH:K66GV6FPM#86=O:Q,Y=D
M@B5%+'J<`=3ZU9H`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`*;)&DL;1R(KHX*LK#((/4&G44`<SX?E?1=1D\+W4C,L:&;3)7(S);@X,
M?J6C)"^ZE#R<UTU9'B+2'U6QC>T=8=2LY!<64Q'W)`",'_98$JWLQ[XJ;0]6
M36M*BO%B:&3)2>!_O0RJ<.C>X.?KU'!H`T:***`"BBB@`HHHH`****`"N6UA
MQXFU=_#D+9L+?:^K,,X8$96WSZMP6_V,#^,5H^(=7ETRTBALHUGU2\?R;.%C
MP7[LWHBC+$^@QU(JQHFDQZ+ID=HLKSRY,D]Q)]^>5N6=O<G\N`.!0!?`"J%4
M``#``[4M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%<OJ8'AG7O[<3Y=,OF2'4E`XCDX6.?Z=$8
M^FT\!3745POC?PYXNO;::3PQX@""12LNF7T,<D,RGJH8J67(XP3^(H`W=/\`
M$4>H>,-9T./:?[,@MG=@>=\OF$C\%"'_`($:W:^?O@C_`&WI?Q(UO2_$4-U%
MJ,U@LC&YY9A&RH#D_>&&X(.#BOH&@`HHHH`****`"N5N/&-I8>.K[1+V=(8+
M?2$U$R.<!0)'#Y_#8:ZJOG/QEX8\7^,OC-J4V@P20V]HT,(O9/DA0*JL02?O
M_/GY0#VR.]`'M/AZTGO[J3Q)J4!BNKE/+M('ZVUMG(4^CO@,WX#^&NCKF_#'
MAO4M)B$NL^(K_6+TCYF=O+B7_=C7C\3G\*Z2@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*X?QOXD\2:9XC
M\-Z'X:CTIKK5_M67U)9"B^4BOU0Y&06['MTKN*\_\6_\E>^'7_<3_P#2=:`#
M_B[_`/U(W_DW1_Q=_P#ZD;_R;KT"B@#S_P#XN_\`]2-_Y-T?\7?_`.I&_P#)
MNO0**`//&A^+33),T7@,RH"%<K=;E!Z@'MG`I_\`Q=__`*D;_P`FZ]`HH`\_
M_P"+O_\`4C?^3='_`!=__J1O_)NO0**`//\`_B[_`/U(W_DW1_Q=_P#ZD;_R
M;KT"B@#S_P#XN_\`]2-_Y-T8^+XZ?\(-_P"3=>@44`>?_P#%W_\`J1O_`";H
M_P"+O_\`4C?^3=>@44`>?_\`%W_^I&_\FZIZMJ7Q9T;1K[5+A?!3065O)<2+
M&+HL512Q`R0,X'J*],KG_'?_`"3SQ+_V"KK_`-%-0!<\-:E-K/A72-4N%C6>
M]LH;B18P0H9T#$#))QD^IK4KG_`G_)//#7_8*M?_`$4M=!0`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!7G_BW_DKWPZ_[
MB?\`Z3K7H%>?^+?^2O?#K_N)_P#I.M`'H%%%%`!1110`4444`%%>!>.`_AKQ
MM<>%-)U:"QT[Q;)')=J3@V;,VV1EP.!(!C_`5K_&'P#X9T[X<W>JVVF"._T^
M"WMK:82N-D?FJN-N=IX9N2,\T`>S45XIXM\):'X5\/\`A!=%L?LHN_$=A)-^
M]=]S;'Y^8G'7M7M=`!1110`4444`%<_X[_Y)YXE_[!5U_P"BFKH*Y_QW_P`D
M\\2_]@JZ_P#134`'@3_DGGAK_L%6O_HI:Z"N?\"?\D\\-?\`8*M?_12UT%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%>
M?^+?^2O?#K_N)_\`I.M>@5Y?\2-;T[PY\1_`.K:M<?9[&#^T?,EV,^W="BCA
M02>2!P*`/4**\_\`^%V_#S_H8?\`R2N/_C='_"[?AY_T,/\`Y)7'_P`;H`]`
MHKS_`/X7;\//^AA_\DKC_P"-T?\`"[?AY_T,/_DE<?\`QN@#T"BO/_\`A=OP
M\_Z&'_R2N/\`XW1_PNWX>?\`0P_^25Q_\;H`>/A?97FG>(H];O3J-_K;DR7A
MA"&!1_JU1<G`0X[\U;UGP3>Z_P##1O">H:X)+EDC1M1%K@L$D5@2F_J0H!.[
MKS[51_X7;\//^AA_\DKC_P"-T?\`"[?AY_T,/_DE<?\`QN@#1\9^"I_%6AZ5
M86VK_P!G7&FW<5W%<_9A-EHU8#Y2P'5L\YZ=*G\.:'XJTS47FUSQE_;5J8BB
MV_\`9D5MM?((?<AR<`$8]_:L?_A=OP\_Z&'_`,DKC_XW1_PNWX>?]##_`.25
MQ_\`&Z`/0**\_P#^%V_#S_H8?_)*X_\`C='_``NWX>?]##_Y)7'_`,;H`]`H
MKS__`(7;\//^AA_\DKC_`.-T?\+M^'G_`$,/_DE<?_&Z`/0*Y_QW_P`D\\2_
M]@JZ_P#135S_`/PNWX>?]##_`.25Q_\`&ZQ_%GQ?\":GX-URPL]=\RZNM/N(
M84^R3C<[1L%&2F!DD=:`.X\"?\D\\-?]@JU_]%+705S_`($_Y)YX:_[!5K_Z
M*6N@H`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`.:\"?\BR__82U#_TLFKI:YKP)_P`B
MR_\`V$M0_P#2R:NEH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@#FO`G_(LO_V$M0_]+)JZ6N:\"?\`(LO_`-A+4/\`TLFKI:`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`YKP)_R++_]A+4/_2R:MG5+
M=[G3IHDN9;?(RSQ'#%1U`/;/3(Y'8@\UC>!/^19?_L):A_Z635TC*'0JPRK#
M!%`'EWAVUMM:L_`>F:K;17E@_A^2Y,%P@='E7[.H8@\$@.V/][-)HMC;ZY*;
M#5[5+JSL-(W6;W`+E#]HG3>K-GY@D<?S=1USS7<R>%-'DTNQTX6\T5O8(([7
MR+J6*2)=NW`D1@^,<')Y[T7/A/1;JWM8'M9(X[6+R8E@N)(?W?&4;8PW*<<A
ML@T`</:VFIOIGA_Q7<"WFN'LK-PS,PN/-,>WR$&,;9'=2QR,8R0<#'5>#]5M
MIH#IRI<?:55KA[B55"W99V#RIAB0N\-@-@@8XQBMY].M)#:%H1BS;=`H)"H=
MI4''0X!(&>E0:?H6FZ5<W%Q9VYCEG/SDR,P`R6PH8D(,DG"X&23C-`&C1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`'->!/^19?_L):A_Z635TM<UX$_P"1
M9?\`["6H?^EDU=+0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4453U+5M-T:W6XU34+2Q@9P
MBR74RQ*6P3@%B!G`)Q[&@"Y17/\`_"=^#_\`H:]#_P#!C#_\51_PG?@__H:]
M#_\`!C#_`/%4`=!17/\`_"=^#_\`H:]#_P#!C#_\51_PG?@__H:]#_\`!C#_
M`/%4`=!17/\`_"=^#_\`H:]#_P#!C#_\51_PG?@__H:]#_\`!C#_`/%4`=!7
M(^,/%[^"KFRU#4(6ET&X;R+B6-27M9.JN0.J$9![@@8SG%7O^$[\'_\`0UZ'
M_P"#&'_XJLOQ'KW@7Q-X=OM&O?%6A>3=Q%"W]H0DH>JL,MU!`(]Q0!S/@_Q[
M;WTMIX7\/$75[/?7US<W(&8[6W-U*^__`&F8,NT=/F!/H?6J\-^"L7ACP=I.
MH76J>)="34[J=HB/[1B^6*-B!CYNC'+>XVUZE_PG?@__`*&O0_\`P8P__%4`
M=!17/_\`"=^#_P#H:]#_`/!C#_\`%4?\)WX/_P"AKT/_`,&,/_Q5`'045S__
M``G?@_\`Z&O0_P#P8P__`!5'_"=^#_\`H:]#_P#!C#_\50!T%%<__P`)WX/_
M`.AKT/\`\&,/_P`51_PG?@__`*&O0_\`P8P__%4`=!15/3=6TW6;=KC2]0M+
MZ!7*-):S+*H;`."5)&<$''N*N4`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`5YW\6X(;JW\'V]Q%'-!+XHLDDCD4,KJ0X(
M(/!!'&*]$KS_`.*?_,E?]C78_P#L]`'0?\()X/\`^A4T/_P70_\`Q-'_``@G
M@_\`Z%30_P#P70__`!-=!10!S_\`P@G@_P#Z%30__!=#_P#$T?\`"">#_P#H
M5-#_`/!=#_\`$UT%%`'/_P#"">#_`/H5-#_\%T/_`,31_P`()X/_`.A4T/\`
M\%T/_P`37044`<__`,()X/\`^A4T/_P70_\`Q-'_``@G@_\`Z%30_P#P70__
M`!-=!10!S_\`P@G@_P#Z%30__!=#_P#$T?\`"">#_P#H5-#_`/!=#_\`$UT%
M%`'/_P#"">#_`/H5-#_\%T/_`,31_P`()X/_`.A4T/\`\%T/_P`37044`<__
M`,()X/\`^A4T/_P70_\`Q-'_``@G@_\`Z%30_P#P70__`!-=!10!S_\`P@G@
M_P#Z%30__!=#_P#$T?\`"">#_P#H5-#_`/!=#_\`$UT%%`'G?PD@AM;?QA;V
M\4<,$7BB]2..-0JHH"```<``<8KT2O/_`(6?\SK_`-C7??\`LE>@4`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`5Y_\4_^
M9*_[&NQ_]GKT"O/_`(I_\R5_V-=C_P"ST`>@4444`%%%%`!7,>)O%_\`PBVK
M:3'?6!.E7\OV>34!+Q;2G[@=<?=;^]GC!S73UYO\4KMM<6S\`Z<L,NHZPP:9
MG3>+2W4Y,I'8Y&!TY]Z`'2_%RQ@T'6]??3R='L;E;2RG6X&_4),X;RU(`P.3
MD$\`G'!KLG\2:)#IUKJ$^L:?#:76!#.]T@CD/HK$X8\'IZ5X?K#2'X->(/!6
MHV,?]M^&FB9`L0^>#S5Q<)Z90MDCG!.>IJOXR_LR[U_2M2CU"+2_"T^DB+3I
MSH2WD!D#MNC6)U_=N>N0`3CTH`]^N]:TJPDA2\U.RMWG1GB6:=4,BJ,L5R>0
M!R2.@J2WU.PN[`7]M>VTUF06^T1RJT>!WW`XKY_N;.PT>Y^&4/B*.[O],B@O
M'>*\L/WBQ8!0/"K/PORG&3P.1QBB6QEO-`UW4="L+@>#YO$%I<&UAMV3SK55
M_?%(\9V$E#P.B]L4`>_:=JVG:O`9],U"UO80<&2VF610?3*DBKE>3>"6T;5/
MB;+JW@JT^S>'UTOR;N2&V:W@FGWY4*A`!91G)Q_/GUF@`HHHH`****`//_A9
M_P`SK_V-=]_[)7H%>?\`PL_YG7_L:[[_`-DKT"@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"O/_BG_P`R5_V-=C_[/7H%
M<OXX\)W'B[3M.AL]5_LNZL-0BOX;C[.)\/&&"_*2!U8'G/3IS0!U%%>?_P#"
M)?$/_HI__E`M_P#&C_A$OB'_`-%/_P#*!;_XT`>@45Y__P`(E\0_^BG_`/E`
MM_\`&C_A$OB'_P!%/_\`*!;_`.-`'H%%>?\`_")?$/\`Z*?_`.4"W_QH_P"$
M2^(?_13_`/R@6_\`C0!Z!17G_P#PB7Q#_P"BG_\`E`M_\:/^$2^(?_13_P#R
M@6_^-`'2ZCX7LM3\4:/X@FEN%N])$P@1&41MYB[6W`C)XZ8(K;KS_P#X1+XA
M_P#13_\`R@6_^-'_``B7Q#_Z*?\`^4"W_P`:`/0**\__`.$2^(?_`$4__P`H
M%O\`XT?\(E\0_P#HI_\`Y0+?_&@#T"BO/_\`A$OB'_T4_P#\H%O_`(T?\(E\
M0_\`HI__`)0+?_&@#T"BO/\`_A$OB'_T4_\`\H%O_C1_PB7Q#_Z*?_Y0+?\`
MQH`/A9_S.O\`V-=]_P"R5Z!7+^!_"=QX1T[48;S5?[4NK_4);^:X^SB#+R!0
CWR@D=5)XQUZ<5U%`!1110`4444`%%%%`!1110`4444`?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>graph3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 graph3.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`%L`BP#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V?Q%J%_IM
M@L]E%:;5+-<7%Y-Y<5O&JEB[=SR`./7)X%<S<>/YBVA*JV6GMJ&G+?3?;V?$
M6XJ%3*CCJW)P.*ZW5K74[F*(Z7J45E*CY;SK83QRK@C:R[E;T((8=.<CBN=F
M\$WG_",P>'+;7/+TO[%]CN8Y;0.SJ?O-&P9?+8@D<[@!C`XY$#)#XNNO^$A\
MC[)!_98U,:49=Y\WS?)\S?C&-N3LQU[].*7Q-XMN]*U.73M-M(+BXMM-EU2X
M$[E1Y2$`(N`?F8[N3P-O/6G+X,9-;6X74!_9HOQJ7V0P$R>>(O+_`-;N^YP&
MQMSG^+'%5K[P?J.K8OY-3CM=3GL)=-O)#;>8LD#N2-JAP$<>N6')R&XI.]M/
MZT_S&K:W_K7_`"*@^(TT^K9MM/C?1X]0MM.DG:4B3?,@8.%QC:"RJ1UYS4_A
MWQ])K>MV-M)91QV6J17,UA,LA+E89-AWJ1P6'S#'3IS0OPYBAU3=;:DT>EO?
M0:A+9F'<[2PJ`H$F[A?E4D;2<CJ!Q4V@>`(M#U>SNOMYFM=.BGAT^W\K:8EF
M?>V]]QWD=!PO'7)YIK?R_P"!_G^`GM_7?_([*BJ]Y8VNH0B&[@2:,-N"N.A]
M?UK/\+JJ>'X44859)@!Z#S6H`V****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"LGPU_P`@*+_KK-_Z->M:LGPU_P`@*+_K
MK-_Z->@#6HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**RM>\
M06?AVTBGNX[J9II/*BAM8&FED;:6.%49X56)/H*S[WQWH=DFG2-+<30W\*W$
M<L%N[I'$Q`620@?(I+`9/OZ4`=+16$?%NECQ,-!S<_:M_E>;Y#>3YNSS/+\S
M&W?L^;;Z4>(?%NE^&6A6_P#M+-*KR%;>!I3'$F-\C[0=J+N&6/K1<#=HKG9O
M&^AP>)(M":>4W4CI%YBPL85D=2R1M(!M#E1D#TJ73/&&CZOK=SI-I-*;J`.0
M7A94F"-L<QL1APK?*<=Z-P-VLGPU_P`@*+_KK-_Z->M:LGPU_P`@*+_KK-_Z
M->@#6HHJAKDC1:!J4B'#I:RLI]"%--*[L)NRN7Z*X7X8R.VE7J,[%$F&U2>!
MD<XK8U&/QDNK/)IEQH<FG95E@NH95E(`&Y?,5B!D@X;8<9Z''-U8>SFX]B:<
M^>*D=%17/?VCXJB8>=X<L)%(X-KJI<@^^^%/TSTID_BB^LH6EO/"6N+&G#O;
MB"X&>GRI'*9&&?\`8SCD@#.,RSI**X__`(65H$7RWT.LV$O4176D7*L1_>&$
M/'4?@:UK;QAX8O)#':^(](G<#<5BOHV('K@-[T`;5%1P3PW,*S6\L<L3?=>-
M@RGMP14E`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`8?BB\N;/3`(M'O=3@G)AN$L)O+GC0J?F
M3E<\X'#`C.>U>>W/AWQ!;:%%I[:3-<3:IX?ATEF@\O;9NK/S)R!@+)R5!Y0^
MHKUZB@#SE='U1/%(TS^S;@VO]N#5_P"T?E\GRA`%V?>W;]XVXQTYS577HM6O
MKUO$-EHEY=#5=#FTH6T93=;RF0E'<D@;#DY89Q@=<UZA12:NK?UM;\@3M>W]
M:W_,\AB\)ZY8:P=%73I9[6XUBSU+^TE*B)(X43>I!.X/NCP!CD-G/:K?@SPO
MK%AXCT:WN[&6"V\/VUY`;MRNR[,TNY#&`2<;>3D#!XKU.BFM'?\`K:WY!=VM
M_7<KWMJUY"(UNKBV(;=O@8!C[<@\5G^%UV^'X5W%L23#)ZG]ZU;%9/AK_D!1
M?]=9O_1KT`:U<[XY<IX.O\-M)V#@XSEUR/RS715ROQ!&_P`-")?]9+<1H@]3
MSQ^E:T5^\CZF=7X&5OA^NS^V5QMQ=D8QC'6NSKE/!_\`R$O$?_81D_F:ZNG7
M=ZC%1^!!1116)J%07-E:WJJMU;0SJIRHEC#`'VS4]%`&'/X,\,7$S3R>'],\
M]NLRVJ+)Z<.!N'X&H_\`A"]%7_4KJ%L.XM=3N8`?J$D&?QKH**`./?P7JD+^
M9I_CCQ!"^>%N##<(%],-'].22?YU;M],\76<6Q?$EA?`'.Z]TO$C?[.Z*15`
M]]AQ[UTM%`'/>=XQB8_Z!H5TI'!^VS0%3_WZ?/;TJC+XJ\1V<I%YX%U%X58J
MTMC=P3[O=%+*Q4GN0IQU`/%=?10!D^'?$%KXETQKVVBG@,<\EO-;W`42PR1L
M596"D@'C/7H16M7-B>/2/';6[MLCUR`21#'!N(1A_P`6B\O\(CU[=)0`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!63X:_Y`47_76;_P!&O6M63X:_Y`47_76;_P!&O0!K5RGC
MC]['HUHO$DVHQ[2>@ZCG_OH5%X@NI%\=:!`DS!?F9D5L=<C)'O@C\ZM^(HEN
MO$?ANU8E0;B2?</6-0P'XUT4X<LHR?9O\S&<N:+7R(?!_P#R$O$?_81D_F:Z
MNN4\'_\`(2\1_P#81D_F:ZNHK_&_E^15+X$%%%%9&@4444`%%%%`!1110`44
M44`8/BZQ:YT1KRWA\R_TUQ>VF.&+Q\E`?]M=R'V8_6M/2]2MM8TFTU*S8M;7
M<*31$C!VL`1D=CSTJW7+^')O[-U_5_#;0^5%$_VZQ/9X96)=1_N2[A[!TZ=*
M`.HHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`*FHZII^D6WVG4[^ULH-P7S;F98UR>@RQ`S5>\\1:'IT=M)?:SIUJETN
MZW:>Z1!,..4)/S#D=/45S_Q$\2Z?X7T^PO9[:"?4GN/)T[[1($CCE92ID=CP
MJ@$Y/H>V<UR%TT/AG3-+FT[Q4#J-IH@CL(X(HI(-1D,@+(C$'<&8*-J88#!S
MBA`SU;^UM-_M0:7_`&A:?V@4W_9/.7S=OKLSG'OBB_U;3=*$)U'4+2S\Y]D7
MVB98][>B[B,GV%><B4'Q<+!RJZRWB<7GD[@9!;_9`#)_N;<IGIGCK4/B[5K&
MYU:YU6:X5]'O_#%W:V+2`J);@R#=&JG!WL`F!U.WCI2;LK_UM?\`X`TKW_KK
M;_@GICZMIL6I1Z;)J%HE_(NY+5IE$K#U"9R1^%+;ZII]W>7%G;7UK-=6QQ/#
M',K/$?\`:4'*_C7C$44\&O2:;?JQ\02^(M.N80W+M$D*;Y!ZH%$BD]`3CJ:O
M>`X[@^+/#]NP8ZCI]GJ*:QSDH[W.5#GU9LL/4<CBFM[?UM?_`('J)[7_`*_K
MJ>R5D^&O^0%%_P!=9O\`T:]:%PUPL8-M%%(^>1+(4&/J%;^59WAC/]@0[@`W
MF39`.1_K6H`X[Q/.S?$S20N5,;0)D'J#(2?_`$+%=!>3_:?B%I,'RF*"SDGC
M9>Y?*GZC"C'UK&U70'\2Z]KJ1,@EAEMEBE<G"C8=X&.O7.*K^!I?M7B*W+KS
M!IA103]TB3']3^=>@TG3NMTOS1QIM3MW?Y,WO!__`"$O$?\`V$9/YFNKKE/!
M_P#R$O$?_81D_F:ZNN2O\;^7Y'12^!!11161H%%%%`!1110`4444`%%%%`!7
M-^*Y5TI]-\0LZQQ:?/LNG(Z6TN%?/L&$;G_<Z5TE0W=K!?V<]G=1++;SQM%+
M&W1T88(/U!H`FHKG/!=X9-&DTN61Y+O1YCI\[..6V`%&]]R%#GU)]*Z.@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"F10QP1".)`B#H!3Z*`"BBB@`K)\-?\`("B_ZZS?^C7K6KD?".M0KI^H07MQ
M'$+2[=07(4;7)(&>Y)W548.2;70ER2:3+GA?][>Z_<=-VHO%M_W`!G\<U8T'
MP[;Z')>2HWF37,S.9",$)GA?PYYXSGV%4O`(E;PND\Q+//-)(78Y+G=@DGUR
M#UKIZTJR<92BOZL132<5)_U<Y3P?_P`A+Q'_`-A&3^9KJZY/P>RG5/$BY&X:
M@Y(SR!N;_`UUE*O\;^7Y#H_`@HHHK(T"BBB@`HHHH`****`"BBB@`HHHH`YR
M[6/2O&UG>\)%JL)LYCG`,J9>(GMDJ95]3\H]*Z.L?Q1HB>(/#]S8GB;Y9;=Q
MP8YD(:-@?9@/PR.]3:!K$&O:):ZC;LI$J?.H_P"6<@X=#[A@1^%`&E1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`5Y-J_AF[N--_M:T`,&)GN1NYRDC@''?Y?RP:]9K'\.HLGA]$=0R-)
M,&5AD$>:_!K2E5=.7,B*E-3C9D7@V)8?".G*I)!C+<^I8D_SK=I%544*H"J!
M@`#``I:F<N:3EW'%<J2.=T?_`)'/Q+_VZ_\`HLUT5<[H_P#R.?B7_MU_]%FN
MBJJOQ?)?DA4]OF_S"BBBLRPHHHH`**XFT^(KW]G!>6O@SQ3+;SQK+%(MM#AT
M89!'[WN#4W_"=77_`$)'BK_P&@_^/4`=A17'_P#"=77_`$)'BK_P&@_^/4?\
M)U=?]"1XJ_\``:#_`./4`=A17'_\)U=?]"1XJ_\``:#_`./4?\)U=?\`0D>*
MO_`:#_X]0!V%%<?_`,)U=?\`0D>*O_`:#_X]1_PG5U_T)'BK_P`!H/\`X]0!
MV%8.D6+Z3K^K6T4#+8WCB^B=1\HE;B5<]B2%?WWGT-9O_"=77_0D>*O_``&@
M_P#CU'_"=77_`$)'BK_P&@_^/4`=A17'_P#"=77_`$)'BK_P&@_^/4?\)U=?
M]"1XJ_\``:#_`./4`=A17'_\)U=?]"1XJ_\``:#_`./4?\)U=?\`0D>*O_`:
M#_X]0!V%%<?_`,)U=?\`0D>*O_`:#_X]1_PG5U_T)'BK_P`!H/\`X]0!V%%<
M?_PG5U_T)'BK_P`!H/\`X]1_PG5U_P!"1XJ_\!H/_CU`'845Q_\`PG5U_P!"
M1XJ_\!H/_CU36/C;[5J]CI]SX:U[3C>R-%%/>0Q+'O6-Y,$K(3]U&[4`=511
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`<QXZEL;?0TGU/6[[2[..4%_L,ACFN&((
M6-67YLD\X7DX],UP]_J/B)-($NH7][9ZAHN@1:D(DEV^=.7<;9@.'XC4$=,L
M:](UWPSI/B1;0:I!+*;283V[1W$D+1R#HP*,IR.Q[5'<^$=&O1:_:H+B8VRA
M%:2\F9G7<&VR$OF49`.'W"@'L<BNI:B_BH:H;^[4_P!NC2?L/FGR/(,`;/E]
M-^X[MW7''2I/&U_?W'B.YTV'4;O3X=/T*;5HI+64QF2=7VJ'_O(`.5/!W<]J
MZ\^&]).N#63;-]N#>9N\Y]F_9Y>_R\[-^SY=V,XXSBJ1\#Z'-I-GI]U;-+':
MQO&I2:2/*.<NAVL"R$@91B0<#.<4FM+?UM_GJ"ZW_K7_`"T.`A\2ZU?:R=:?
M4;B%[?6;+35TY&Q"\,R)ORG=LN6#=1MXXJWX*\1:O>>(]$N+F^GF37[:\GN;
M61MT=LT,NU/+'\`"_*1W/)YKO9?">AS:VFL26"F^1UE#B1PI=5*JY0':6"D@
M,1D#@&I+'PSH^FZK/J=I9B.\F#!G,C,%#-O8*I)"!F^8A0,GD\TUO?\`K;_/
M4.G]?UY&A<3_`&>,/Y4LN3C$2[C6=X8.[0(3@C,DQP>O^M:M>LGPU_R`HO\`
MKK-_Z->@#6HHHH`YW1_^1S\2_P#;K_Z+-=%7.Z/_`,CGXE_[=?\`T6:Z*M*O
MQ?)?DB*>WS?YA1116984444`<OX4NQ8?"O1+PIO%OHD$NW.-VV!3C/X4NG>,
M!>3Z7!/9"UENX9Y+E6F!^S-$$)4G'S`B0$-QQ@XYIOA6T^W_``JT2SW^7]HT
M2"+?C.W=`HSCOUI+GP1;7>KPWDMRQ@_L^2QN+<+@2[U5"X(/RG:H!ZYPO(QR
MGL[#5KJ^QJIXDTIVA4W#QF8HL?FPO&'W\+@LHR">,],D#J1D;Q)I2QR2?:'9
M(VE5V2"1@OEMM<G"\`'(STX//!J@/#%Q<6DT6HW\5S(L(@M)$MO+\D*0RLPW
MG>X94)(VCY1@#FJNI>!;2_BT[,>F3R6D7DN=0TY;I7!(+,JEAL<MDYR1R<@\
M8H1M/XATU+EK<RS-(LOD_);R,"^S?M!"X)VG/!JO-XFM(KVV7]XUK-:S3F1(
M)&9?+9%(*A<C&XYR!@BGIH*QW:S).%5;[[8$$>`!Y'E;.OXY_#'>J<OAF]01
MFQU6."15N8W:2U\P%)I?,.!O&&&,`\CN0>E3J!J/KFG1SK$9R2S*H=8G:,,P
MRH+@;02",`GG(]12V&M6>JZ.NJ6!FN+5X_-C(A93(N,C:&`)R*Q/^$'L8_$"
MZE#!IA7";FN-/66Y5DC"+Y<Q8;!A5XVGO@C/&MHVD2Z)X5L='@ND>:SLTMTN
M)(CM+*H4,4#9QQG&[\>],%T*-QXHD@\.#5#8I%(;J2V\NYN!''%MD9-TLJJP
M1?DZ@$9('/6M+0M4.M:-;W[6S6YE!^0MN!P2-RM@;D.,JV!E2#@9Q6(/"VJR
M:6MO=:KITT\-\;ZW<Z:WE!R[N0\9F)<`N2N&4J54\XK0T'1KC0HX+*.9'LT2
M627";09G?=B-<G9&OS@+DX#*,G!-,":;5+RUUV"TGLH18W):.&X2X+2%PA<[
MH]@`7"L-P8G...>,T>,#!`+F^L!#!<PB>P\J8R/.K.B*'4J/+8M+&,98?,<G
MBK2Z-JG_``E4FJ2:G:2V;(8TMGLW\R*,@957$NT98`DE"3C'0#%/_A#C/8?8
MKZ^66*WA$&GF*`HT"*Z.I<ECYC`Q1\X4';TYJ=1JU]1+WQ==:;8O]MT^UAOT
MN%@<->'[)&&7>KO.8P54@;<E/OD#H<ULZ/J_]J:=8W+VTL$MU"9=FUF5<8!^
M?`&#D%<X+#D#@XQ[OPG>7J174^HVCZK'<BY\QK(FV8A#&`83)NX4D@[\AB3T
M^6M31M'DT:RLK.*YC-M!$ZO$D.U6=F#`IR=B+\P"<X!`S\O-"-:BBBD`4444
M`%<_XA_Y#GA/_L*R?^D5U705S_B'_D.>$_\`L*R?^D5U0!T%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`5D^&O^0%%_UUF_]&O6M63X:_Y`
M47_76;_T:]`&M1110!SNC_\`(Y^)?^W7_P!%FNBKG='_`.1S\2_]NO\`Z+-=
M%6E7XODOR1%/;YO\PHHHK,L****`.1\/7[:7\(-)U!%5FMM"@F`?H2L"GGVX
MK1DUIH4M=M[:79G>50]O%\AVQL^,^8<=.O/I@=:I^%+*/4OA7H=C,SK%<:+;
MQ.4(#`-"H.,]ZW+[3(=0FMI96D5K<N4V$`'<A0YX]&-3*]G;<<;7U,6S\5[T
MM!/!)+/<16I$5O&!AY4=_O,_(^0^F/?/$I\86AL'NXK&^E$0F,T:B,-%Y4AC
M?.YP#\P/0G('TJ>#PM8V\]K*DMP6MA`$!9<'RD=%SQZ2'/OCI6/?>%I[:Y=]
M.C:8L)I8'E$+"*XDE:0EMZG"988V#=A><\52WU\Q=/N_X)NZAK\=AJEMIPLK
MNYNKBWEN46'9PL90-DLPYS(N/QJN_BRP6/SDAN9;94A>::-%*PB7&W<,[NA!
M.`<`@FKTVD03ZU:ZK(\GVBWMI;954@(5D*%B1C.<QKCGN>M4!X1L$B\E)[I(
M'2!)XE90)_*`"ESMST50<$9`QTI:C5NI0MO&,DLEM]IMVM%EU6YL?F02!EB6
M5LY#C8<19)PWH!SN&C_PE-J--MM0EM+F&"[*?9C,8T\W<I<=7^7Y5)^;;Z=>
M*:WA'3WGBD:2X,<5[+?+"679YDB.C@\9*GS&.,]<8XXJ6#PXEO96EJFHWQ6R
M*FU9C&6AVJR8!V?-E6(.[)[]>::VUWT_X(2MS.VVO_`'GQ%9#18=3199(YI5
MACCC`9VD9]@48./O=\XP"<XYJA<^);I]8T[3[2QDB>6Z>&Z$ZJQC"QA^,2`<
MAE.03@9&,\#6OM)BU&PBMKF><M%*DR3J560.C!E;@8ZCIC!&1BH8O#]O'J$-
M\]Q<2W,<KS%W*_.S1B/D!0,!5`&,=.]-6ZDN_0L3:I'%J<>G1PRSW#1^:XCV
MXC3=M#,6([YX&3P>*R!XI^SVCW-Y&2L<5U*T<$>2RQ3>6,$MUP1QCD]QC!UI
MM*BDU5-2CFE@N1&(7,>W$J!MP5MP/`.>F#\QJG-X6L9[9X&EN`KQ3Q$AESB6
M02-VZ@CCV]:G6WW_`/`*TN0W7B>.WO[*WDCEM6DO6MI5FB5SQ;O-G<LF%&%Z
M_-T(P,Y%VRUEM0TZ.^M],O3#*B21!O+5I%89!`+\<8X;!YZ=:BO?#5C?ZA#>
M3M,6BN3<A`1M9C"T.",=-KGOU_*HAX6@.FVNGO?7DMM:E/)241/M"JR@'*?,
M,-_%DY`.<\TUUN)D^FZS_:=^4C3;;-90W*;UPX+LX(/..-@_7DU1T_Q6]S;/
M)/IEPLAU*:PB2(H2Y1G&?O<<(<^_MS6GIFB6VDF,P/*VRUCM1OQ]Q"Q!X`Y^
M<^W3BH[?P]:6TP>.6<*+U[Y8R1M61PP;MG!+L<$]>F!Q26_]=_\`(;M;S_X#
M_6Q%/XA2RT6\U2:WGFM[22<3&&-042)F!."_.`IZ<GT&<4NAZQ-JFHZY!(L8
MBL;Q8(2@(+(8(I,MD]<R'ICC%5]4\&:=JUC):3S7"QR?:=VWRV_U[;FQN4@$
M'H1R/6M'3-&M]*N-0F@>5FOIUGE#D$!A&D8`P!QB,=<\YIKS$S1KG_$/_(<\
M)_\`85D_](KJN@KG_$/_`"'/"?\`V%9/_2*ZH`Z"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`**P?%WB&?PUH<M]:Z9<:C<`/LBBP%7:C.6=CPJ@*>?7`')%86L
M^/FT[4=%LM]G;-?V:W,DMRDK(A9E55R@(49+?,V`,=:%J'F=W17('Q?=_P!O
M^3]CA_LP:F-*,F\^;YOE;]^,8VY.W'7O[4[Q)XMN]+U:73=-LX)Y[739-4N/
M/<H#$K;0BX!^8G=R>!COFE?2_P#7?\@M_7X?F=;17`)\1IKC4C);:=&=(CU"
MWTZ65Y2)M\RJ0X7&-H+J",Y/)J?P[X_DUO6=/@DL$BLM6AN)K"59"7"PR;")
M%Q@%A\PP>.G/6GUM_7?\@\SN*R?#7_("B_ZZS?\`HUZTY)8X5W2R(BDXRQP*
MR_#)!T&(@Y!EFY_[:M0!KT444`<[H_\`R.?B7_MU_P#19KHJYW1_^1S\2_\`
M;K_Z+-=%6E7XODOR1%/;YO\`,****S+"BBB@#C=%N[BP^#.F7EIM^T0:!#)&
M6/`(@!ST/\JTQX@CT_5M/T6]N;5[ZYX$9NT,YX9MWEA5RGRD;@!SV[U#X.MH
M;WX8Z!:W";X)]&MXY%R1N4PJ",CGH:UCHUBVH?;C')YYE$QQ,X4N$V!BN=I.
MWCI0!@1^*6M_L]Q+YTUM/;V`1&V!P\\S1[B0`.ZD@<<<"M(^(M^L_P!F063R
M2^=)$7+A578D;ECWQB4#@$Y]N18?PYI+VPMVM,Q".*)1YC958FW1X.<@JQR"
M.<]Z?:Z%IUE<_:8(7$^YW\QY7<DN%#$[B<Y"+^5"V!^12T;Q/'K=RBP6-XMM
M-$TT%TT+B-E5@.6(`!.<J`3D9Z$8K2.IVXN/)\N[W[MN?LDNW.<?>VXQ[YQ1
M9:5::<3]D22)#G$8E<QKDY.U"=J\^@%7*`>^A@ZQK-Q`TT-E"28)+=99=RY7
MS)`,!3U^7J>.HQD]'KKTLK8BL1^\NY+.#?-C>Z;]Q.`<+B-N>3GC'>KESH]C
M>7!GGB<NVS=ME=5;8VY<J"`<'U%*^D6+PB+RF51.UPI21E99&+%F#`Y&=S=#
MT)'2@#/_`.$C>0K'!8-).(YWD0RA0IA<(X!QR23\O`R.N*M7NJ1I86%W$\HC
MNIX%0H%!(D8`9W`\<\]_0BJ\WAFTFOK=_P!XMM%;S0M&D\BLYD=68E@P)R5.
M<DY)K4GL+:XAAADB!CA=)(U!*A60@KT]"!QTH`SM,UXZC/"IM#%%/Y_E.9`2
M3$^QLC'&>HY/'7%16-_>:OJ>IB&=;:#3[H6JQ[`YE(57=G[@8<!0".F3G(`T
MK?2[.T,)@AV>3YGE_,3CS&W/U/<\TTZ19?;9+Q(WBGE8-(T4KQB0@8!8*0&.
M`!D@\`#M26VH/R,MO%:QV'VV2QD$,EE)>VP$BEI(TVD@CHI(=2.3P><8Q4X\
M0,MW+!-9%/)N8[:5Q(&`,@4H1QS]\`],=LU.OAW2U@>`6[&)X6@V-,Y"1MC*
MJ"?D'`X7'0>@JP^E64DDTC0Y>::.=SN;ETV[3U[;5XZ<4P*-KK_VB:,-9O'%
M,\\43EP2SQ,P(([`A20<]CG'&:ECXPMM2B!L/LMZ[7@M`]I=K+"6,1DSY@'0
M`8/&1Z'O8LO"]E%:RQ7:M<-*UP&W2N5"3.S,`I.%.&QD8/7UJ[#HMA!(LBQR
M-(LPG#23NYWA"@.6)_A)&.E`&6?%@50K:?*)73]RGF+B243"%TSVP[)R>H;/
M8BI;C5IM$DA34YHV^V74@CED<1Q1+N`2(-MY<@C`;&3N&[IFQ<:#;RWNF2QH
MJ1V5Q+<X))+,X;(^FY]WU5<=!BY?Z;:ZG&(KM9'C'5%F=%;IPP4@,..AS^M"
M\P>Y;KG_`!#_`,ASPG_V%9/_`$BNJZ"N?\0_\ASPG_V%9/\`TBNJ`.@HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`*>KV']J:-?:?YGE?:K>2#S-N[;N4KG'&<9K
M#U;POJ&I:.NCQ:TL.G260LKJ)K0.77&"T;;@48C(YW@<<9Z]110!RB^#&36U
MN%U`#31?C4OLA@/F>>(O+'[S=]S@-C;G/\6.*K7W@[4=6"7\FJ1VNJ7&G2:;
M>2&VWJ\#MN^50X"2#L<L.3PW%=I10U<%H<./AS%#JN^VU)H]+:^@U"6S,.YF
MEA4*H$F[A/E4D;221U`XJ;0/`$6AZQ9W7V]IK73HIX=/M_*VF)9GWMO?<=Y'
M0<+@=<GFNRHHZW#R&211S+MEC1U!SAAD5E^&0!H,0`P!+-Q_VU:M>LGPU_R`
MHO\`KK-_Z->@#6HHHH`YW1_^1S\2_P#;K_Z+-=%7-Z.ZCQMXD0GYB+8@>PCY
M_F*Z2M*OQ+T7Y(SI[?-_F%%%%9F@4444`<MX5GGM?A9H,]M`9YH]'MF2,=6/
MDK^?T[U0N?$M[#)J.J6TD=Q!::1]J>*19(0S))+N7RVYC8A<$GE2!P>VIX+@
MCN?AOX<BE7<C:5:YP2"/W2D$$<@@\@CD5J#0],%O/!]D0QSQ-#,&))D1BQ8,
M2<G)=B3U))H'IU*+^(/^)K!;Q-%+'*S1,J*Q,3B-I/F?[N<+C9UY!SVJB/$N
MHFQLW%O&]U<6(O1##!+(""%Q&"O0DD_.<`<?*:VX]"TR*]:\2S19V8N6!/WB
M@0MCIDJ`">I`'I3I=&T^:.WC>V`6WC,,6QBI6,XRF002IVKE3P<#/2CJ(2^U
M!K(64SHJ6\LFR=I#CR@5)!_[Z"K_`,"K&OO%,UE8:==F*)GN&M_-M@KED6:0
M(I+`83&<_,/F*D#&,UT%]86NIV,ME>P+-;2C:\;=&'6H+S1--U"=)KJT25T*
M%<YQE&W(<=#M))&>F3CJ:.HU;J<OH'B"Z@T6^>9FN'B?59P\TA)Q#=,JID_P
M@$#V`%:MOXBN;N^$4-J66.2&.55AD8_.B.6WXVJ%#C@Y)P>G%7I?#>CS6YMY
M+",PDREDR0&\UMT@89Y#-R0>#4ZZ-IR7@NTM42?:BEE)&\)G9N`X;;DXSG':
MA;:DO<P?$-[>6&KSW\<GF1:?IS3Q6N]T5W9BOS[6PW08RIQSCFKEUK%]:&\)
M^S2+8)&\X",IEW$G"\G;A<8SG<>/EK7N=/M+OS?M$"2>;'Y3[OXDSG'YTV?2
M[.YNEN9H`TJ[>=Q`;:=R[@#AMI)(SG!.10ALR$UG49[J%$6U2.XO+BT0LK,5
M,9<[SR,Y$9&WCJ#GM3K_`%>XE\`SZO;-]FN7T\SHR@-Y;%,\;A@X/J/PK76P
MM4:-E@0&.5YD/H[9W-]3N;\Z#I]H=._L\P)]D\ORO*_AV8QC\J70.IR#^(]6
M6#68)V$%]ING2,X"J0TJD[95R/NLNUL=!DCJ#6Q'?:C;>+&L[];@6=R3]BFC
M\LPL0F3&PQYBN`K-G.T@=0>*U)M*L+B>XGFM8WEN(!;3.1R\0)(4^V6;\S2I
MIEHEY]J6(^;DL,NQ52>I52<*3SD@`G)]33#JS(U[4KO3=6TQEDN(K&6XCBGE
M98V@^8E53`_>;V8J`?NCN>Q9>:CJ6G2^(GDNHY1:Z>MU;H(=JQDF?@\DMQ&N
M>><'`&<5KOH^GR7OVQ[5#/O$A)S@N!@.5Z%@,`-C(`'/%`TBR%W-=%)'EF79
M)OF=E=>?E*DXQ\S8&,#)HZ!U,W3KR]C\67FDS7;W=O'8PW*R2(@969Y%(^4`
M8(0$<9Z\^E(>)=2_LZ.\:*T`DTU]1"`,<!`N4)SR6W#YNW/#5T5AI=EIB,EG
M`L08*"<DDA1A1D\X`X`Z#M2?V38>0L'V6/RE@:V"XX$38ROT.!^5#\@+:L&0
M,.A&:P/$/_(<\)_]A63_`-(KJMJ*U@@EEEBC57F(,C#^+`P,_@`*Q?$/_(<\
M)_\`85D_](KJ@$=!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%9/AK_`)`47_76;_T:]:U9/AK_`)`47_76;_T:]`&M1110!S=BBKX^U4J,
M%K6(M[GI_("NDKG;/_D?=3_Z](OYFNBK2KNO1?D9T]GZL****S-`HHHH`XK2
MY)X?@E82VLIAG3P]$R2#.5(MP<C!!!]#GBKNK:[J6F6^IS)]EF;38(Y6A\E@
MUR6R0J?.=N<;1PWS9^E3^!E#?#OPVK`$'2;4$'O^Z6ME;"S0PE;2`&#(B(C'
M[O/7;QQ^%-;@<[XCN-2M]?TVYL'E=;:TN+B:S#D+<(&B!&.A<!B5SW&,@$UD
M:'>W^KZ18"#5)-]U8WQ29YF(9OM"*ASUZ'`/4`\5Z!L4N'VC>`0&QR`>H_0?
ME47V.V\KROL\/E[2FS8,;3U&/0]Q1?2W]=16UN9^A7+36ES!/`\%Q:S&&=3=
M-.N[:K961L,1AAU`P<\"N9N;F=8FNK:[O+?1[R_M+:.5[EW9E\PAW5F)*(YV
M("#R/F'W@3V\=M!#;BWBAC2$`@1JH"X/7CI44.F6%NDB06-M$DHVR*D2J''H
M<#GJ:2W3'T,%+^XTW1O$<UO,9Q8S2?93<2-*.(D8J23D@.7'7C&.U/.M:E#?
MW,4S6CQ6]]!;'9"REQ*$P<ES@@O[YQVKH5@A6`0+$@A"[1&%&T#TQTQ2F&(D
MDQH2S!B=HY(Z'ZC`H!BHZ2+N1E89(R#GD'!'YTZFHB1KM1549)P!CDG)/YTZ
M@`HHHH`****`"BBB@`HHHH`*Y_Q#_P`ASPG_`-A63_TBNJZ"N?\`$/\`R'/"
M?_85D_\`2*ZH`Z"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`Q_$WBC2?".COJFL
M7/DP*=J*!EY'P2%4=R<'^N!5+4?&VGZ:(6>UO)8VM$O9WB5,6L#'`>3+`XSG
MA=Q^4\5H^(M-.J^']0M8XHWN9+:6.`N!\KM&R@@]NN,^A-<CK/A'6+BWF@M(
MX'74=$ATJX9Y=OV<J6R^,?,,2-P.<@>M"_K\?^`'3^O(Z+_A+['^W?[,^SW6
MS[5]C^V83R/M'E^9Y?WMV=O?;MSQG/%+KWBVRT&Y^S/;75W.ML]Y-':A"8;=
M"`TC;F7C)Z#+'!P#@UB+X6U1-=$(CA.F_P!LC5OM7F_-@0A/+V8^]O'7.-OO
MQ5?5=%US5[R37;.Q@$^H:-+I4MM+<8$!9R4EW;?F7!.1@'IC-)WMI_6G^>G]
M7&K:W_K7_+4V6\?:1_;"V$<=U+$;F*T:]C13`DTB[D0G=NR01R%(!(!(-2Z1
MXWTK6M633[9+A3,DLEI/(J^7=+&^QS&0Q/#?W@,CD9'-<K#X!UBSOVL(6MI=
M,FU:TU)[II"'1853*;,<DL@P<XP35CPKX'U71]:T;[6UO]BT.WNX(94<EKGS
MI-P.W'RX7KSUZ9'--;^7_`_ST$[6_KO_`)'HU9/AK_D!1?\`76;_`-&O6A<6
MR74821I5`.?W4K1G\U(/X5G>&`%T"%1G`DF')R?]:U`&O1110!SMG_R/NI_]
M>D7\S715SMG_`,C[J?\`UZ1?S-=%6E7=>B_(BGL_5A1116984444`<_X$_Y)
M[X:_[!5K_P"BEKH*Y_P)_P`D]\-?]@JU_P#12UT%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%<_XA_Y#GA/_`+"LG_I%=5T%<_XA_P"0YX3_
M`.PK)_Z175`'04444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M63X:_P"0%%_UUF_]&O6M63X:_P"0%%_UUF_]&O0!K4444`<[9_\`(^ZG_P!>
MD7\S715SMG_R/NI_]>D7\S715I5W7HOR(I[/U84445F6%%%%`')Z3H7BG1M&
ML=+M]?T9H+*WCMXVDT>4L510H)Q<@9P/05<^Q^+_`/H.Z'_X)IO_`)*KH**`
M.?\`L?B__H.Z'_X)IO\`Y*H^Q^+_`/H.Z'_X)IO_`)*KH**`.?\`L?B__H.Z
M'_X)IO\`Y*H^Q^+_`/H.Z'_X)IO_`)*KH**`.?\`L?B__H.Z'_X)IO\`Y*H^
MQ^+_`/H.Z'_X)IO_`)*KH**`.?\`L?B__H.Z'_X)IO\`Y*H^Q^+_`/H.Z'_X
M)IO_`)*KH**`.?\`L?B__H.Z'_X)IO\`Y*H^Q^+_`/H.Z'_X)IO_`)*KH**`
M.?\`L?B__H.Z'_X)IO\`Y*H^Q^+_`/H.Z'_X)IO_`)*KH**`.?\`L?B__H.Z
M'_X)IO\`Y*H^Q^+_`/H.Z'_X)IO_`)*KH**`.?\`L?B__H.Z'_X)IO\`Y*H^
MQ^+_`/H.Z'_X)IO_`)*KH**`.?\`L?B__H.Z'_X)IO\`Y*J,:+KUUJVEW>J:
MQILT&GW#7"Q6NFO"SL89(L%FG<`8E)Z=A7244`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4451U/6M*T5(WU74[*P20D(UU.L08CJ!N(S0!>HJA_;>DF]M[+^
MU++[5<H)((/M";Y4(SN5<Y88!Y%2:AJNG:1`L^I7]K90LVQ9+F98U+>@+$<^
MU`%NBJ4^L:9:WEO9W&HVD-U<_P"H@DG57E_W5)RWX4L>JZ=-J4NFQZA:O?Q+
MNDM5F4RH/4KG('([4`7*R?#7_("B_P"NLW_HUZUJR?#7_("B_P"NLW_HUZ`-
M:BBB@#G;/_D?=3_Z](OYFNBKG;/_`)'W4_\`KTB_F:Z*M*NZ]%^1%/9^K"BB
MBLRPHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`*X#XB7%K87^G:E)J][IU_;VURNG
M>3;+*D\[!<1G<C98X`"C!()P>#7?T4`>0M=7\VKBSU.`VWB/4=0TN]BMU!.(
MXTC\XJ>1M4K,#SW]ZW/%6N:7_:.E:U<3[M%2'4+*24QMM%QE8PI&,Y.R51V/
M;J*]"ID4,<";(D"KN+8'J223^))-#U5@6AXE%!J&G0S:5JZRKK&HVFBIIB."
M6=H=ID"GL4?<S>F<]ZV=*4O\0]-LA%(=4LM6U.ZO#L/R6TJMY9)Z8;,6/]WV
MKU>BE:[N%W:W]=B&X6X:,"VEBC?/)EC+C'T#+_.L[PQG^P(=Q!;S)LD#`_UK
M5KUD^&O^0%%_UUF_]&O3`UJ***`.=L_^1]U/_KTB_F:Z*N;M)%'Q!U&,GYVL
MHV`]@>?YBNDK2KNO1&=/9^K"BBBLS0****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***J:GJ,&D
MZ=+?7.[R8L;M@R>2`/U(II-NR$W979;HK-T?7;#789);&1F$9`<,I4C/2M#S
M$\SR]Z^9C=MSSCUQZ4.+B[,$TU=#J*AN[F*RLYKJ8XBA0NY'H!FN4L-?\3R6
M:ZG-H\5Q8S`ND4!*S(,X!P?O#`SP.=P/3BJC3<E=$RFHNS.QHK,T?7K+6[9Y
MK<O&49E>*8!70C&<C/N*DU+6=/TBTCNKVX$<,C!48*6R2,]L\8%+DE?EMJ/F
MC:]]"_161=^)]&L[%;M]0A>-_N"-@S-]`.?\*GTO6].UB%9+*ZC<D9,>X!UY
M[KU'2APDE=K0.>-[7-"BF&:)91$9$$C#(0L,D?2EDD2)"\CJB#JS'`%24.HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*R?#7_("B
M_P"NLW_HUZUJR?#7_("B_P"NLW_HUZ`-:BBB@#FDB6/XE2,"<R:5N.?7S`/Z
M5TM<=K-_+I'C^PNFMV:VN;9+-I3D*I:0G[W3(P#CTKL:UJIVB_(SIM7:\PHH
MHK(T"BBB@`HHHH`****`"BBB@`HHHH`**:[K&C.[!44$LS'``]32JRNH92&4
MC((.010`M%%%`!1110`4444`%%%%`!11427,$LKQ1S1O(GWD5P2OU%`$M%%9
M@\1:+YCQ_P!K609.N9U`_//--1;V0FTMS3HK%_X2W0/^@I;_`)FK!\0Z*`3_
M`&O8<>EPG^-5[.?87/'N:5%4+;6]+O$WV^HVK@=<2C(^HZBK]2TUN--/8***
M*0PKD_&(-UJ/A_3LX2>\\QC[)C]<,:ZRN5+)JGQ%"X;9I5J3GC!D?'YC:WMR
M*UHZ2YNR9G5U5NXTS'3?B5Y?S>5J=J">R^8F<'WX7'_`JS9],N-:\=ZM):W\
MEK-9QQK%-&H8#*#*G_Q[OZ^E=7K6A6>NVR17(97C;=%-&</&?8_EQ[#TJ#P_
MX>&A_:Y&O);N>Z<,\LO4@9P#R<GD\UJJL5'F6]K?U\C-TVW9[7O_`%\S)L-#
MO]?EBOO$DNZ*)B(K!5*)E?EW,#@G)!./0CG'%=>JJBA5`50,``8`%+16$YN?
MH;1@HF+JOA;2M7E\Z>`QSD_-+"=C,.A!/<$<?2FP>#]`MKM;J+3D$JDL,NQ`
M/^Z3C]*W**/:SM:[%[.-[V,ZVT#2+.X\^WTVUCESN#B,94^WI^%17GA?1+\D
MW&F6Y8DL6C7RV)/4DK@FM:BESRO>X^2-K6.8O/`VE26B)IRMI]S&X>.XB)9@
M?<DY(Y]1T%.M_`>@Q1@36SW,O.Z665MS$YY."!W]/UYKI:*OVU2UN9D^RA>]
MCB;DZGX)=6MS-JFF2Y2.V8G=`1R`&P>,9]*TO#_C"WUF6:"ZA73[E&55AEF&
M9-W3;D`D\=,=QZUTE9VJZ)8:S`T=W`I<KM695`D3G(VMC(YJO:0DO?6O?_@"
MY)1?NO3L:-<[%XTTE]9FTUY/*,1(\^1T$1P/[V>N<C\*JMX)=5,<'B'5HX2,
M&,S9!]>F!^E;5OH&EV^GPV1LH)H8E"CSHU<GW.1USD_C2M2BM7<+U'LK%VWN
M8+N(2VTT<T9Z/&X8?F*EKF;CP#H%Q</-]GDCWG<4CD(4?0=A[5%_P@5E_P!!
M75__``('_P`32Y:?\WX?\$?-4[?B=717*#P#8CIJFK#_`+>%_P#B:/\`A`=.
M;B:_U.:/O')<`J?KA:.2G_-^`<T_Y?Q-'7/$=GI.E3W,=Q;RSJO[J'S1ESD#
MIG)`SDX[5B6>I^,SIIU"2TM62-`IMI8I%G<KU8`#JV?IQP!SG=L?"VAZ=(9+
M;3H0Y((:3,A!'H6)QU[5L4^>$5:*OZBY)R=V[>AP2?$ZU$2"73IQ-C]X`PP&
M]O:GQ_$ZQ+-YNGW2QX^5E*L2WICC`Z<Y_"NUAM;>V+F""*(N=S^6@7<?4XZF
MG20Q3;?,C1]IR-R@X-5[2C_)^(N2K_-^!Q__``LS1?\`GUO_`/OVG_Q==DK*
MZAE(92,@@Y!%0?V?9?\`/I;_`/?L?X58K.;@_@5BX*:^)W"BBBLRPHHHH`**
M*\]T_P`2:S+XOL&DO=^FW^I7VG_8S$@$7D!MCJP&[),;YR2/F&`,4KH#T*LG
MPU_R`HO^NLW_`*->KU[?6^GPB6Y9U0MM!6-G.>O103VKGM!U[3K;2(XI9)0X
MDE.!;R-UD8CD+Z&F!U-%9/\`PDNE_P#/6?\`\!9?_B:/^$ETO_GK/_X"R_\`
MQ-`#M>T9=<T];<S&"2.59HI0N[:P[X[\$UGR:1XG$;F/Q2K2`':K6$:@GL">
M<#\#5[_A)=+_`.>L_P#X"R__`!-'_"2Z7_SUG_\``67_`.)K2-225OT1#@F[
MF4&\<M^YV:2O;S_F_/'O]*#_`,)M9_O3_9M^#C="F4*\]B<?K^5:O_"2Z7_S
MUG_\!9?_`(FFKXHTA\[9Y6P<'%M*<'T^[3]K_=7W"]GYLK:;XEEFU*+2]4TV
M:QOI0QC&0\;A1SAA]#^77FNAKE-9G\/ZV;9KFXO8WMV+(\,,JG!ZC[O0X'OQ
MUJCY&E_]#-XE_P"^Y?\`XW3?LY:IV!<ZTW.ON]2LM/,8O+N"W\PD)YL@7..O
M7_/(]:M5P<-CH+7DDNI:C?ZG'Y8CA2[MY6,8ZD[MO)STZ8''-/\`[*\#?\^<
M_P#WQ<TG&EW?W?\`!0)U.WXG<T5PWV#PL.$NM41!]U%\_"CT'R]*3[%X6#!1
M>:HN1D*//Z>WR_2ERT^_X?\`!'>?;\?^`=C?ZA:Z9:/=7DPBA7`+$$]?8<FL
M;_A._#?_`$$O_($G_P`36;;6GA."Y2X?[7<2QG*&XBG<+^!7'YUJ_P!K>'O^
M>(_\`9/_`(BG^Z7=_A_F+]X^R_KY#/\`A._#?_02_P#($G_Q-.'C;PX8C)_:
M2[0<8\M\_EC-+_:WA[_GB/\`P!D_^(IAU#PRTJRFUC,BC`<Z>^0/KL]Z+TNS
M^]?Y!:IW7]?,R-9UV[\3V$EAX?L[B6"4B.6[.45>1E?ICK['WK3@\.:Q8P);
MV'B::*W085)K5)2H]`3VQCBKX\2:4``)9@!T`M9?_B:&\3Z2JEFGF"@9)-M+
M@?\`CM-UK+EBK+[Q*E=WD]?N,E?^$ZC40'^RI3P/M!SGZXX_]!IWV3QPI.-1
MTMP>?F1ACCH,+TS6K_PDNE_\]9__``%E_P#B:/\`A)=+_P">L_\`X"R__$T>
MV_NK[A^S\W]YE?8_&\99$U/3)4!.V22,JS#/!("X!I6L?&5M'')%J]G>/C,D
M4T`0`\<*5'(Z\G'^&I_PDNE_\]9__`67_P")H_X272_^>L__`("R_P#Q-+VS
M[+[@]FN[^\R/.\=$N/L^E+NX!R?D^G/X\YIPN/'(`'V+23[DM_\`%5J_\)+I
M?_/6?_P%E_\`B:0^)])!`,\P).!FVEY_\=I^U_NH/9_WF97]H^-0/+.B61?.
M/-$PV?7&[.*3^T?&NY9?[$M-H&UH?/7<3_>SNQCMBM?_`(272_\`GK/_`.`L
MO_Q-'_"2Z7_SUG_\!9?_`(FCVJ_E7X_YA[-_S/\`KY&0^K>,'!MUT"&&:3[D
MQG#(GJ3@_ES^=1V/@'3Y--B.JH\NHN2\\RS-EF))QUP>O7OBMO\`X272_P#G
MK/\`^`LO_P`31_PDNE_\]9__``%E_P#B:/;-*T%;T%[)/XM?4SO^$-41?9EU
MO5A9E=C0&<$%<8"CCA<<8]*O#PGH`B2/^RK?:G0E>?Q/4_C3_P#A)=+_`.>L
M_P#X"R__`!-(WB?254LT\P4#))MI<#_QVI=6;ZE*G!="5?#VBJH4:18X`QS;
MH3^>*@'A/0`0?[*M^/5:?_PDNE_\]9__``%E_P#B:/\`A)=+_P">L_\`X"R_
M_$TO:3[CY(]B&Z\'>'[MMTFF1(?^F1,8_)2!5%M%UK0H]VA7QNK=2,6%U@X7
MOM?C'TX_&M3_`(272_\`GK/_`.`LO_Q-'_"2Z7_SUG_\!9?_`(FFJLUHW=>9
M+IQW6ACQR^._+PUOI>7YW,3E,CIP<<?C^-/%QXY``^Q:2?<EO_BJU?\`A)=+
M_P">L_\`X"R__$T?\)+I?_/6?_P%E_\`B:KVO]U![/\`O,ROM/CC_GRTC_OI
MO_BJO>'-&NM-:\O-0FCDOKUP\HB&$7&<`>O7_/6I5\4:0ZADGE93T(MI2#_X
M[3O^$ETO_GK/_P"`LO\`\32=5M622!4TG=NYK45D_P#"2Z7_`,]9_P#P%E_^
M)H_X272_^>L__@++_P#$UD:&M163_P`)+I?_`#UG_P#`67_XFC_A)=+_`.>L
M_P#X"R__`!-`&M16/_PE&D;]GGR[L9V_9I<X]?NT[_A)=+_YZS_^`LO_`,30
M!K45D_\`"2Z7_P`]9_\`P%E_^)H_X272_P#GK/\`^`LO_P`30!K45D_\)+I?
M_/6?_P`!9?\`XFC_`(272_\`GK/_`.`LO_Q-`&M160?$^D@@&>8$]!]FEY_\
M=I?^$ETO_GK/_P"`LO\`\30!K45D_P#"2Z7_`,]9_P#P%E_^)H_X272_^>L_
M_@++_P#$T`:U%9/_``DNE_\`/6?_`,!9?_B:/^$ETO\`YZS_`/@++_\`$T`:
MU%9/_"2Z7_SUG_\``67_`.)I%\3Z2RAEGF*D9!%M+@_^.T`:]%9/_"2Z7_SU
MG_\``67_`.)H_P"$ETO_`)ZS_P#@++_\30!K45D_\)+I?_/6?_P%E_\`B:/^
M$ETO_GK/_P"`LO\`\30!K45D_P#"2Z7_`,]9_P#P%E_^)K51@Z*Z]&&1QB@!
M:***`"BBB@`KGK;P;IEKXF;74>Y:;=))%;M)F&&20`22(N.&;'))/4XQDUT-
M%`!4%I:165LMO`"$4D\G)))))_,FN8\>>,7\)65KY$=F;JZ,GEM?7'DPJ$0N
M06P?F.`JKQDGKQSI>&/%FE>++![G3)][0D1W$11E:&3'*$,`>.>W:@#<HHHH
M`****`"H+2SBLTD6+=^\E>5BQS\S,2?YUA^-O%`\(^'O[0$,<DLD\=M%YTGE
MQ(SMC=(V#M0#))QVQQG-4_`?C^P\;Z8KH$@U%%9I[12S!%#L@97*@,IVYR.F
M<=10!U]%%%`!1110`5"UNC7D=R2V^.-XP.V&*D_^@C]:FKS?0_BNM[JNG0:O
MIB:=:ZO*\&FS)<B9FE1PICE4`&-B67@],X-`'I%%%%`!1110`5#=6Z7EG/;2
M%@DT;1L5Z@$8.*FKB?&'C;4/#VHO;:=HT>HK:VT=[>9N1'((7=D`C4CYFRI[
M^@P2:`.VHK.T+7+#Q)HEKJ^F2F6SN5+1L5*G@D$$'N""/PK1H`****`"H9K=
M)Y;>1BP,$AD7'<[67G\&-35YS:?%"X;5&DO]#%MH)U*32Q?K="22*=6('FQ;
M0R!OE_W<\GD4`>C4444`%%%%`!4-U;I>6<]M(6"31M&Q7J`1@XJ:N)\;^.;O
MPQ>0V6G:3%J%P;.:_F$MV(`D,17=@E3N)!;N,;<\]*`.VHK+\/Z]:>)-)34+
M-)XU+M')#<1F.6&13AD=3T8$8-:E`!1110`445@^*M>N]"M+,6%A'?7U]<_9
M;>&2X$"E_+=^6(/:,@#N2!QF@#6L+*/3K&&TA9VCB7:I<Y)^N*L5S7@OQI8>
M--):ZM5,%U`56ZM'<,T+$9!!'WD;JKCAA]"!TM`!1110`4457O[R/3M.N;V9
M9&BMXFF<1KN8A02<`=3QTH`!91C4FOMS^:T(A(S\N`2?SYJQ7GGA'XG'7=<M
M-(U;38].N=2LEO\`3?*N?/6>(AB5)"C:Z[&X/H>F!GT.@`HHHH`****`(9+=
M)+B&<EMT6[:!T.1CFIJ\]7XG+;:\D>K6,=IHEW=RV-G>B;>_GQOL*RQ@93<<
MX].-V,\>A4`%%%%`!1110`5%;0):VL-O%GRXD"+DY.`,"N;\7^*+W0YM.TW1
M].CU#6=2,OV6WEG\E66)-SG<1C/*X'&<GD8JYX2\3V_BS0DU"*"2VF5O*N;:
M4'=!*`"5S@;AA@0>X(/'2@#=HHHH`****`"BBB@`HHHH`****`"N7\3>.]+\
M+W1MKJ"\N9H[;[9,EI&KF&WWA#*P+`[0Q&<9.,G&`2'^,-9N=/LAI]DXM[_4
MX9K>PNI/]6MUM'EQDX.&;YB">/D([@'S^_TN"#Q6NBGQ1JI\26]XKZ/?L@N;
MF..6/,JRKPK0`@GD#;G`XR"`8B7+74^G:27O]1U"^F6"_MY1-<6FIVLH`:\A
M;D0N$922-NW)!'!%>TZ)X?BT4W,IO;N^NKDIYMU=LAD8(NU5^15&`,]LDDDD
MTGAG0AX=T46`ECD8SS3L8HS%&#)(SE40LVQ1NP`#V]2:V*`"BBB@`K%\0^);
M;P\ELKVMW?75R7$-G9*KSR!$+NRJS+D`#MSEE`R6`,GB#6O[#M+>X:!GBEN$
M@DESA+<-D"1_1`VT$]MV>@->.ZHFHZ3/:V?B[6-3GU.]L$U&#[.JS75KJ"S(
MOEVH7"X97(9`"/E)!Q0!7U3Q"9A=:I;W&HC4+N5[K2YVAENK74(MS'[#+"-R
MI(G*]`1L#;AD&O7_``_X/LO#L_FP7=[<E(!:VZW4BL+:`'(C3"@[>GWLGY1S
M3?"7AN708[^XN[\7M[J,RSSRQP&W1F$:IN\K<55VVEF(P6+<\``='0`4444`
M%5[^^M],TZYO[R3R[6UB::9]I.U%!+'`Y.`#TJQ7D/C#6=6;P_>>.X[RZMK;
M3EMX5T7SAL=_/V7,=U'M()PP`(/3G`[@$?BWQ5#X@O;97TS7X[6SA>2YL5+0
M7+1N4V7EOY;$2B,@@@DX#G(X-6O`GA2V\0^'9)=0F1U%]^\N[.S2V_M:-&26
M-Y=T0E4AA@@%<E2<MG<=#P;X=M[N[M-3TO7'N]!TV_G?3H)[%M\(,;Q&.*=F
M^>#Y\C`(^51G*FO2*`"BBB@`HHKC_$US?ZOJZ>%+.34-+,R)</J,#*GF0`L)
M%B?G#@[.V?F[#F@#-\;^.+&&QUK18KK4M/GC3[,VKP1@PVL[H&C5W&67=N"[
M@O&3AE(R.5\-V%KK7BJWT@Z;J-LL5D\TL&I0&2;2+E2H\R"6<.&CD+$A<MRN
M_BKVD:3%K-V]I8^(`=?C%_8:K)/:BZ2[MTF>&(7:JR@2;-I0D@D!NHXKU+2=
M/32-&L=-CDDE2TMX[=9)#EF"*%!/N<4`0Z#HEIX=TB+3;+S#%&6<O(07D=F+
M,S8`&223P`.P`'%:5%%`!117EGCW4?$%UIVI:[I&KR:7::!',ODPR?OGNUE`
MQ,A4JT1BVNHR#\X)!XP`5O%7B^+Q)+8P6NE:M+;1Q/>O9R,;8ZE:M$#YMLZM
M^\=`X<(2#U&`P^4\%^&++Q9IU_-?3"Z1;H1KJBZ?'!/?P;5;RY_,BWDCHSJ1
MNS]XXH\+>'K/Q3(+O2M8D.AV>J07T=I-9F1(9T`D=;68O@1EF*D;3@J<8!R?
M7*`"BBB@`HHKE_%5[?SW%MX?T]KNRGOMCKJ$90*$65/.C0G.)?*+L,K@@'&2
M#@`I^-/&MEHUO?Z:7OH9OLP$NH6L`F33S*L@CDD4'=_RS8\*<8&<;AGSS2H8
MM6\0Z5HTMG?(;CS([^PU&`W2PR".1A>VL\@9`"R]OE;(^4BM+1K"6^\0W&FQ
M^)[E_$&EZC-9Q37-N+IIM.$:/Y=T`5W(79@&8@[B=O/3TWPMH$?A?PS8Z+%<
MRW*VJ$>;+@%B6+'@<``D@#L`!SB@"70]$@T*TFAAFFG>>=[F>:?;ODD<Y9CM
M55_("M.BB@`HHKG?%VKWECHL\.D#.IW`>VM9/E*Q7!C+1AL\`L=H&[Y<E<GD
M9`'^(?%EKX>E2%[*]OIS!)=/#9(CO'"A4-(0S`D`NHP,D\X'!QXY9W<<QTBU
MO[JZU'4[VZAWQ7`EN;+7;220#S@KY$,D8(/.W84QCG`V]2\/BWUQ-(U;Q?JK
M:O`+.[TBZPL]Q%<3-.DRJ`H+P_NU9EX`50.`.?1O!_A=/"FEW5J)XYI+J]FO
M)##"88U:0YVHFYMJ@``#/:@!WAOPCI_AA[N6UDFFN+L1K++*$7Y(P0B!(U5%
M503C"CK[#&_110`445'/(T-O+*D;2LB%A&O5B!T'UH`KZMJ=OHVDW>I79;R+
M6)I7"C+$`9P!W)Z`=R17DGB7Q&-8\0W,MW'K.GZ?91+:W4(=UNM,G#L5NO)C
M=DEA8,%)PV0..#\R^)Y]:O!%XEO[^;_A&+K4[:T>T,H2V&FS(HD>9``RR!SM
M)9LJ=PP!C.]X(\.27\^B^)I-6O;FWLH)X+,:A8F&[>)R`#+)O_>)A2R?*.'S
MUH`@\#>"=.U70-%U>_MEMYX;@7+V]K:I:PSSPO(D=P0(DDY!+!20OS?=ZUZ?
M110`444R6:.",R32)&@(!9V`&2<#D^YH`2>>.VMY;B9ML42%W;&<`#)/%>/^
M+_%L/B*ZTR/[%K$5G%:O?7&F%O)GO;:10%G@,;D,T?+;&(.">/E.-/QAJVI:
MAHM]XGT[5I[2ST6)@UA%*%9KM)"LL=PA4ADV;,#(ZYQR#2^$/#]CJDXET/67
MN?#FF:J9;*.ZLB[1L%^9;:<N/W.YBOW3]TC)^\0"#PQX.TCQCX?O'NA)]GDO
MW'VU+:..?4[8/'*@G9XO,X8!3MV[BA.3D&O5Z**`"BBB@`KG?$GBVV\.EDEL
M-2NMD'GS-91+(8(MVW>06!(!.3M#8`)(P*H^.+[7);2;0_#<GV36IX%GL[F7
M9LD"R`2HI)X8*0>01AN/4<3)ID<'C2;03XEUAM;L9K:;2;Z8?:9RLH;SHY0H
M7=`-H8Y(`R!D=&`,'P_+%<WN@:?<W%UK,EU=#[7;7\,EU::G"S?+>1-*2(W1
M2H<<'(*D`@J?:O#GABQ\,6UQ#9&1VN)`\DDBH&.U%15`154*JJ``!^I)I?#.
MA'P]I<EHUPD\DMS+<N8X?*C5I'+%43)VJ,\#)/O6S0`4444`%%%%`!1110`4
M444`%8>M^+='\.:EIMCJMS]F;4/,\F5Q^[!0J"&;^'.]<$\>]0>(?%$VD:G8
M:58:3-J6HWJ22QQ"184V1[=_SMQN^887\RN0:Y[1H=-UUDL-8TY;G3=9LGO]
M+>[<.YAF,<L\#=PR2;'4Y/&W!S&30!2'A?7M"0Z%/->:OH6MR-YTT+GS])N7
M;<)(SU,8?!_V2"W<@]YI&EM;I#?ZA#:-KLMK%#>W5NF!(RCD`GG;DG'3M[`2
MZ)IAT71K;33>3W:VX*)-<$%RF3M!(ZX7"Y[XR>:T*`"BBB@`K%\2^*=,\)V=
MM=ZJTJ6\]P+</'&7V$JSEF`YV@(Q)&<4[Q%KC:'9V[0V;7EW=W"VMM`'V*\C
M`D!GP=HPIYP?UKDM+O8VUFVOM2M(X-*U:ZF@%M=,C_8]30R0.JL.JRJLBCKD
MC`QYF*`.<U:U_P"$1UC3=:O+JXUF77IKZVN5MY&F%_;2*S6T0!R%.?+`*!0-
MQ'(Y/>^$?#7V32-&NM8M2VLV-L\$4EQ*)IH(W(/EM(/E=@`%W`#OC`)S;\.^
M$-/\-6[VEHTDEDERUS9V\V'%D64AA&3R,[G[_P`9'<YZ"@`HHHH`*@O;R#3[
M"XO;EPD%O$TLCGHJJ,D_D*GKRR]\1ZCXL:W-CH\=O?16CZG8++<><MY:Y$<L
M3JH^1V5^%Y(8`9'.`!^KW5SXX\0:9/H%Y=:/JVDVMQ=PV]]"T9N0YB$?&=KP
MMA@Q!)7(R`3BM/2M'N?%$=[+KFDBSM-3A\G6-,N`P;[3$55'BD4C<C+U;)^X
MF#]ZJ'A[P,9]5\/ZS8^(9+GP[IP:XTNWFC8W$*21[3#YFX'RQQPP)`&P],GT
MR@!D,,=O#'##&D<4:A$1%`55'```Z`4^BB@`HHKAO&/CFUT5]1L[K2;JYTVT
MA@_M.X5S%Y4=PS1J4!`,G0Y*'CIG((``OC'Q-I<D=UX=GNKNQ\V6.TGU!480
MP,^Q]CR`_*61L#H.>HZCF[.QMK'5M2\(^&HYAJ6D:JM[I_G-*\-E&UI&?WCD
M_P"K=FD0H"6PY8`[:=+X0UG4KK5-.CU>WAU=HEM=3:ZMTECU.TPX@G*X#"10
M2I((&Z,]0!GTO1=(M="T>TTRTWF&VA2%7D(+N$4*"Q`&3A1^784`2V>FV6GF
MX-G:Q0-<2M/,R*`9)&.2S'N?KVP.@JU110`4V21(HVDD=41`69F.``.I)IU>
M:W_B74O%$]O9:9;#3KEWGN]$OC<^8EP]LVR1)HUQM5@[+@EL9S@$8H`BU[4=
M'^($,%I_:FH:26T^>YL8KE)+=;IFC4QSJZD;Q&-Q*#D[LD8',V@Z=-XJUK6K
MV_,%U92H=,NIHK5K>'4+<QA@44R,ZR1R.Z%LX*G@[E^7.\-^"X-:;1-3T/5W
M@\,6=[]OM]/EA?S[:=6998`Q(*H6SD'/(XX.3ZU0!!96=MIUE!96<*0VT"".
M*-!@*H&`!4]%%`!117*>*O&$F@330PZ/<7Z6UDU]>-',(O*@&060MP[#!)4$
M$#GJ0"`6=7\::3HE^]K>"Y"1>7]IN4BW0VPD)"&1OX02.O09%>7:!HOB6*SM
M_#>D"YN-/LKR:2WO[N#;';3QM(;=D<."T4BA"^%8#>0,EL+L)X3DO-4F@T_5
MD35X[`1VLMW`KQ:CI4A&(YD(W,4QL+9!QL)^^`/1/"^@Q^&/#&G:+'.]PMG"
M(S*XP7/4G&3@9)P,G`XH`FTO2+73GN;M+2WAOKYEEO9(0<22!`N1GG''`]R>
MI).C110`445SWB3Q-+HEYI>GV>F2:AJ&IO(EO$)!$G[M"[;G((!P.!W_``-`
M#?$?C#3?#\ZV5R+UKB2V>X/V2#S&BB4@-(>V!NST/0\5Y?H>DZA#HL.G-JEG
MJ5MJVHJC?9XVDGU*W:3F\:8,S1R+G(!("^2W4FM@Z='?:GI%UI$T^EWFJ1-J
MFA7LA\T1M(HEN;:92WS*V?,`YP6D(("X/>^$?#O_``C.A_8F-MYLD\EQ(MI#
MY4*,[9VQID[5'`&3VSQT`!/HND-:0V]WJ*V\^LK:K:S7B`EI$4D@9//).3[G
MZ5KT44`%%%5-4OX]*TB]U&5'>.T@>=E099@JEB![\4`-U;5;31-+GU&]<I!"
M!G`R220JJ!W))`'N:\<\2:\VH?$6QU8"Z@AL(4CE@N;622XTER23-]F4[7#A
MU3S!NP<'JJYW-<E_X20WMYJ>C/:2:7:C[=`DXF6\TR?<6*LN/F4Q;QM)YCP"
M<UN^&_"&HV/B&'5K[7(]4@MK62VL;DQ8NI89&5@L\H;$@7;QQR6+<=*`(_!V
M@S7VDWLVM0PR66J3"[>PD@94\]96S*JN-RI($BEV-DAF;.,XKNZ**`"BBB@"
M.>>&UMY;BXECA@B0O))(P544#)))X``YS7F6LOI/Q*?["VI7EL\E@USH]C-`
M]L))=I*70?(\W&5(7(P-Q8>A-XSO/%DMA:Z7ID=GJ3Q/JFBSSSK,DC1DQLDB
MH1LW*TB$9RN3G!&*D\.^#YKZ;1+^QU>2+PU9W!OK.P>%ENK63:R/;^9D'RPS
M-E2#P-O3F@#=T_2[?Q'YFK^2L%IK6GM::Q8R1,DCR)E,9!!5EW2HQR<A4`Z`
MUUL,,=O#'##&D<4:A$1%`55'```Z`4^B@`HHHH`*X3QQXPT^WTK6M'%W=6-P
M(3:MJ*QMY-K-)'F,2.H+(#N7Y@O&>H-6O%/CP>&[JZC32Y+V.P@BNKXK,L;1
MPNS+NC5A^\(*G(!`[9SQ7'6OA<WFL7EMHNHI;:Q%:I')]N3S8-5TN0,(C(AP
MS,HQ$6SG]WS]X8`,G1M(O;Q4\*R0%[2YU&Y:X%O#<&;26C4"-H;F5L-%(L>`
M?E.)2,G)%>TZ?IXA*7MU';MJLEM%#=7$*;1(5R>,\A=S,0/>FZ!I0T/P[IND
MB8S_`&*UCM_-(QOV*%SC)QG'3)QTK1H`****`"BBB@`HHHH`****`"HKE9GM
M9DMY!'.R,(W(R%;'!QWP:EHH`\5\+SZQH/C#3+*YN;^74PYLM2TVXGDN!.I"
M_P"G02.#\APK,,C&",=!7H?@KP=#X1TM(7NY+Z^,20R7<O7RT&(XU'\**.`!
MU.3U-=/10`4444`%%%%`'B>MZEJOACQA=SB[U(ZQ'=R3V^GN\LMOK5J[95(<
MAA'+&K;,*O0#&<DUWWAOP+!H>OZEK=S>RWUY<W$[VPDX2SBEE:0I&.Q);YF[
M^@YSUU%`!1110`4444`>:_$BVO$UNPO+N[U2U\/-:R037>G74D9L+@L#'<.J
MGYEQE<D8&3G'%5--\.S_`!(L-(U#6;R5(+`W%E<36Z^6-:M]\91R0<B-C'DK
MZ[L8ZUZK10`V.-(HUCC141`%55&``.@`IU%%`!1110!S_C>QUC4O!>J6GA^Z
MDMM5>+-O)&^QL@@E0V1M+`%<Y&,YKS*ST\>+[/5?"-KJ.IQVFJ6GGS6E^7FE
MT6YADC/ELTARR.3P,Y^7(ZDU[;10!F:%H=KH.GBUMVDED8[Y[F9R\MQ)W=V/
M4G\AT``XK3HHH`****`.'^)$4WV73;B0ZG_9*3LE\VF3R1SP!AB.<!.7$;@'
M&#V.#@BN8TG1;WXC:=;17NL7/D:+=R6JZI`K1OJ=HZ*3\V<C<`H8\@_G7K]%
M`$-K:6]C:QVMI#'#!&-J1QKA5'L*FHHH`****`,OQ)9:AJ7AK4K+2KS[%J$]
MNZ07&2/+<C@Y'(^HY'4<BO*_#JRWK7/AJ*?5(6U;3;BSU+3;]GE;39PC+YRR
M/RT;G>0`2"6R,<@>T44`87A?PO;>&-+CMEN)KVZQF:]N3NEE)`'7^%0%4!1P
M`HZXS6[110`4444`%>)Z5>ZUH'BBRB=M275X[E;;4]/GFDFBU6-V"&\MF<$*
M02K,`44!0#C&#[910!RG@GP6/"FG)'=:A)JE\J+"ES,N/*A082)!D[5`S]22
M3V`ZNBB@`HHHH`*\Q^(ZRPZ['<WEWJEAI[V2K:ZK:M(T.GW*NQ+31J=I2171
M"64C`QQDD>G44`>=:9X;O/&FHZ3XKUYVM(3:1K/HZ`F*XEBEE,4K$X)3]YO5
M".XR3CGT6BB@`HHHH`*\_P#B7'=K)I5Q(=2&B#S8;Z33IY(Y+1FV&.Y(1AO$
M94G!!`R3@\5Z!10!Y%IOAJ[^).G:1=ZQ?[(-)GN+*66T0QC5[4B,JX8-E%<*
M-P'JP&WI7K%M;06=M';6T2101*%2-!@*!V%2T4`%%%%`!63XGM-1O_"VJ6FD
M7+6VHRVSI;RJ=I5R.,'^'/3=VSGM6M10!X=9/-XA:[\*:8^I6]CK5G.MU8:E
MYDLFC7,8'_+1V),<C<XY.>1MY`]9\->'H/#>C06$<LES*@S+<R\O*Y`RQ].@
?`'8`#M6Q10`4444`%%%%`!1110`4444`%%%%`'__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>graph4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 graph4.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`%H`F\#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`*@O+G[)`LFS=NECCQG'WW5<_ANS4]4-8_X\H_^OJW_P#1R4`7Z***`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"L74]?:PUNRTU;42-=#B0R;0ISC
MI@YK:KBO$K^7XWT(XSED'YOC^M<V*J2ITU*+ZK\SJPE.-2HXR71_D=#IVLBZ
MN#8WL!LM252S6[MD.HZO&W\:].>",C(!XK3!#*"#D$9%5-1TRUU2!8KJ/.QM
M\<BG:\3=F5ARI]Q6/8ZI=:+;6T&ML'M615BU)1A>G"S#^!O]K[I_V20*Z#FM
MI<Z2B@'(R**8@HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"N5US4]?L/$NDV=G=:=)!J%T$%N]C(98X
M53=*YD$P';`^3JZCGOU59CZ+"VOG6O-<W:VIM80X!CB4MN)`P#DD+GGHHZ4`
M<[XF\97FCW^J"VCM_LNCV<-Y>":-F:99'8;4(8;2`A.2&SD#`ZUDW/Q%U2SB
M@OI+:RDL]1^TI8Q(KK)$\4JQ*9&)(8-NR<*NWI\W6N@;P'9S>2UUJ.H32&WC
MM[TM(I%\J,742;@3PS-]T@X."2*1OA[I$CS":>^EMV$P@MWE&RU,KAW,>%#9
M+`$;BV,<8'%`%SPSK-]J%UK&G:E]G>[TNZ6!IK:-HTE#1I("$9F*G#X(W'IG
MOBK6L7UIMCM/M4'VG[5;_N?,&_\`UJ'[O7IS3M%T*'1%NF6XN+NYO)O/N;FY
M*^9*VT*,A%50`JJ``!T]<FFZQ8VFV.[^RP?:?M5O^^\L;_\`6H/O=>G%`&M1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`5P_BK_D=="_ZZ1_^C*[B
MN'\5?\CKH7_72/\`]&5Q9A_!^:_-'=E_\;Y/\CN*KVR+)I\*.H9&B4,I&01C
MI5BJVGL7TVU8]3"A/Y"NSJ<?V69'V*\\.D-ID;76EC[UAG]Y`/6$GJO_`$S/
M_`2,;3KV&H6NIVBW5G,)8F)&0""I'56!Y4CH0>1WJS61?Z-(UW_:.EW`M+__
M`):9&8KD`?=D7^3###U(R"R37HK+TS65O97M+JW>RU&,9DMI"#D9QO1APZ'U
M'K@@'BM2@`HHHH`****`"BBB@`HHK$N_$%Q#J%Q:6GA_4]0^SE1)+;/;J@8J
M&Q^\E0]".V.:`-NBN?\`^$AU3_H3-<_[_67_`,D4?\)#JG_0F:Y_W^LO_DB@
M#H**Y_\`X2'5/^A,US_O]9?_`"11_P`)#JG_`$)FN?\`?ZR_^2*`.@HKG_\`
MA(=4_P"A,US_`+_67_R11_PD.J?]"9KG_?ZR_P#DB@#H**Y__A(=4_Z$S7/^
M_P!9?_)%'_"0ZI_T)FN?]_K+_P"2*`.@HKG_`/A(=4_Z$S7/^_UE_P#)%'_"
M0ZI_T)FN?]_K+_Y(H`Z"BN?_`.$AU3_H3-<_[_67_P`D4?\`"0ZI_P!"9KG_
M`'^LO_DB@#H**Y__`(2'5/\`H3-<_P"_UE_\D4?\)#JG_0F:Y_W^LO\`Y(H`
MZ"BN?_X2'5/^A,US_O\`67_R11_PD.J?]"9KG_?ZR_\`DB@#H**Y_P#X2'5/
M^A,US_O]9?\`R16EI.I#5;'[3]DGM&$CQ/!<;-Z,K%2#L9EZCL30!>HHHH`*
M***`"J&L?\>4?_7U;_\`HY*OU0UC_CRC_P"OJW_]')0!?HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`*X?Q5_R.NA?]=(_P#T97<5PWBQMOC+0VQG
M#QG_`,B5Q9A_!^:_-'=E_P#&^3_([FJNF?\`(*L_^N"?^@BK55-*8/H]DZ]&
MMXR/^^176_B7]=CD7POY?J6Z***H@I:EI5KJL*)<*P>-M\,T;;9(F_O*PY!_
M0C@Y!Q6=%JEUI$J6NNLAB=@D&HJ-J.3T60?P/VS]UCTP3MK>IDL4<\3Q31K)
M&X*LCC(8'J"#U%`#Z*QX_#5G"@CAN-1BB7[L:7TH51Z`;N!Z#M3O^$?M_P#G
M]U3_`,#Y?_BJ`-:BLG_A'[?_`)_=4_\``^7_`.*H_P"$?M_^?W5/_`^7_P"*
MH`UJ*R?^$?M_^?W5/_`^7_XJC_A'[?\`Y_=4_P#`^7_XJ@#6K)TO_D,ZY_U\
M1_\`HF.KUG:)90F))9Y`6W9FE:1OS8DXJCI?_(9US_KXC_\`1,=`&L2`"2<`
M=ZS['7=(U2XFM]/U6QNYX.)8[>X21H^<?,`21R#UK`^)GG?\(5-LW?9?M$'V
M[;_SZ^8OFY_V=N<^V:K^,S"4\,'1C&=0_M*W^Q_9\?ZC_EKTX\OR]V<\=.^*
M`.WI&8(I9B`H&22>`*\YT37]?DET*:^U9+C[5K%YIL\*6R1QLD8GVN.K!LQ#
M^+&#@@GFO1Z`*FGZII^KVWVG3;ZVO;?<5\VVF61<CJ,J2,T0:II]U?7%C;WU
MK+>6V//MXYE:2+/3<H.5_&N%LKQ_#>JO<V\8DAUJZO+=(QT-ZD\ICS@<;TW`
MD]/*%1:3C18/%,$6I2VLS:Y%&9X+8332R/;P%MJD$!F8L<D$#))&!0!Z517F
M5AXFU=-&T_7;_5YULK+4I[/4XVB@!,(E>..63:AP00N[80N,D=.>\T1;P:7'
M)?7$TT\Q,N)E16C5CD1_(`/E!`SWP>:`+D]S!:H'N)HX4+!0TC!02>@Y[TEQ
M=VUH(S<W$4(DD6)#(X7<['"J,]220`.Y-<[X^M+.X\-++=PPNT%[:R0O(!F-
M_/C`*GL><<=<D=ZA\?VMM+9:+<2P1/-!K=@8I&4%H\W,8.T]LC@XH`ZZD)"@
MDD`#DDTM1744$]K)'<A6@9?W@8X!7OGV]:`(+'5M-U2%YM/U"UNXHV*N]O,L
MBJ1U!()P:6UU73KZS>\L[^UN+5"P:>&971=OWLL#@8[^E<1XGT]/[/\`$.M(
M(X4OH+:&2-N/,M(I?WTC#W21QS_"%Z9Q5'Q3YO\`PDFI?9=XTO&CB]\O_5X^
MU-OSCC_5;-W^SC/%`'H::SI<FEG5$U*S;3@I8W8G4Q`#J=^<8_&I[2\MK^UC
MNK.XAN+>0926%PZ,/4$<&N#O+"ZO/$FNW&FSV<<%A=V=VR3OLAEG6)Q*LC`'
M;\C0'.#@JIQ6IX#>YO(M:U5U1+/4-0::T2-BR%!&B%T)`RK.K,#@;L[N]`'7
M5D^'_P#CTN_^O^Y_]&M6M63X?_X]+O\`Z_[G_P!&M0!K445QMSXS5?&DNC_:
MH+2VM9H;>9YK*67S99%#*@E4A(N&4`OG<3@#B@#LJ*XKQ-XRO-'O]4%M';_9
M='LX;R\$T;,TRR.PVH0PVD!"<D-G(&!UK)N?B+JEG%!?26UE)9ZC]I2QB176
M2)XI5B4R,20P;=DX5=O3YNM`'I=4-8_X\H_^OJW_`/1R5G>&=9OM0NM8T[4O
ML[W>EW2P--;1M&DH:-)`0C,Q4X?!&X],]\4[6-:T_P"TQZ7]H_TW[5;_`+K8
MW_/1&ZXQTYZT`;U%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!7">+
M_P#D;]%_WD_]&5W=<!XM)_X3C21DX`A./^VC5P9B[4?FOS._+E^^^3_([^J&
MA_\`(OZ;_P!>L7_H`JY*2(G(X.TU3T/_`)%_3?\`KUB_]`%=;_B+T?Z'(OX;
M]5^I?HHHK0S"BBB@`HHHH`****`"BBB@`K)TO_D,ZY_U\1_^B8ZUJR=+_P"0
MSKG_`%\1_P#HF.@#6(!!!&0>U9>FZ3H-A=W;Z5I^FV]RQQ<M:PQHY)YP^T9[
MYY]:J>,KG4;3PW+-I=U%;7'G0IYDD1D&UI%4X`9?[W7/^(Y9[O4?#%_K][;)
MI[`ZE8K>@0.OGO,L,3L@W_N^6W<E\\@\\D`ZZ+PAX9@,)A\.Z1&8)/-AV648
M\M^/F7"\'Y5Y'/RCTK990ZE6`*D8((X(KAK3Q5XFU77)AI>A++I,5W/9/+,T
M:;6C++OW^<6QO4#;Y6<'.3T-6#QGXBG\.Z%?Q6UI/=ZZH-M;00#,&(V=LF2=
M!)P!QE,<]:`.UL-$TG2H?)T[2[*SB\SS=EO;I&N_&-V%`YQQFJH\)>&A'<1C
MP]I.RY(,Z_8H\2D'(W#;\W///>I]!NM3O-'@FUBP^PWYR)8-ZL!@D`C:S`9&
M#C)QG&36E0!D7.AI(HM;46=KITK%[N".U^:9B0?O!@!G!#94D@]16O110!3U
M+2--UFW6WU33[2^A5MZQW4*RJ&P1D!@1G!//O4=_H6D:I;0VVH:58W=O#_JH
MKBW218^,?*""!QQQ6A10!232[1-6.IK$HNC`+?>$4'8#G&0,D9Z`D@<XQDYL
M7-K;WMM);74$4]O*I62*5`RN#U!!X(J6B@#-T[P]HFC^;_9FCZ?9><-LOV:V
M2/>/1MH&1R>M2VFD:9I]@UA9:=:6UFV=UO#`J1G/7*@8Y[U=KS[5O%^O:/\`
MVB)WTTM8:C"L@^RN-UDZJQE_UO!4>9R>"4QCF@#L1H6CC3XM/&E6/V*)@\=M
M]G3RT8'((7&`0><U)?:7::@UH;B)6^RS+/%E%.UUZ$$C(_#'&1T)%<IJ_B#7
MK'2WNX[[1H]TER\"RV<TDDD:<1JL:29<G!)<$8!7Y.>)H_%]P=1TI;H165IJ
M$$#0M-;R,LLDFTE1,#M5AG`5AEB1@]J`.QK)\/\`_'I=_P#7_<_^C6K6K)\/
M_P#'I=_]?]S_`.C6H`UJY_4/"-E?ZI)?M/.ADDBFEMQM,,LL6/*=@1NRI`X#
M`'`SFN@HH`Y1O`=G-Y+76HZA-(;>.WO2TBD7RHQ=1)N!/#,WW2#@X)(I&^'N
MD2/,)I[Z6W83""W>4;+4RN'<QX4-DL`1N+8QQ@<5UE%`&7HNA0Z(MTRW%Q=W
M-Y-Y]S<W)7S)6VA1D(JJ`%50``.GKDU+K'_'E'_U]6__`*.2K]4-8_X\H_\`
MKZM__1R4`7Z***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"O/O%C9\=
MZ6/00C_R(:]!KSKQ:VWQSI[==HA./^!FO/S+^"O5'HY8OWS]&>A2_P"I?_=-
M4/#YSX=T[_KW3^0J_+_J7_W35#P]_P`B[IW_`%[I_(5UO^*O1_H<:_A/U7ZF
ME1116ID%%%%`!1110`4444`%%%%`!63I?_(9US_KXC_]$QUK5DZ7_P`AG7/^
MOB/_`-$QT`7-1TZUU;3YK&]C,EO,,.H<J>N00RD$$$`@@Y%8LW@/P].EZDEM
M=;;V6.:X5;^X4.\>-AX?C&%QC'W5]!B_XBUR/P]I1O7@EG9I4ACBB1F9W=@H
M&%#-WSP">.`>E<Q-\0KVTTB/5;WP]+:6$5P8+Z>X::+R!@;9%5X5=XR2%SM4
M@]L9-`'0_P#"):,+RZND@GBENAB?RKN:-9&QC>55P/,P!A\;@0#G(IB>#-!C
MT.VT9;.065H_F6R_:I2\#<X*2;MZXR1P1P<55'B/6FAM+9="MO[:GMGNFLVO
M_P!U'&K`8,HC.6.X8`7'7G'-4;KQ_-#JZV$'A^_N'A>&.^6**61[=Y%5L`QQ
MM&VU7!;,B].,T`=A:VT5G;K!"&V+W=R['W+,22?<G-35QQ\;7:1?:Y=$\FQ3
M43ITSO=`R)(9!&K;%4@J6(!.[(ST-5=%\5ZE>Z=IDVLZ-:R-=ZO/:1RV\X=(
M2DLBAB&4'(V$`C.<9.W.*`.[HKDHO&<\CV5R=)_XE5]<M:VMRER#(S@L%+(0
M`JN4PIWD\C('8T?QA?:H^FO+H9MK?4(IC%NNE:421D_*5`V@$#(;=[$#K0!U
MM%>7^*_$DNM^$/&&DWMG'9WEAI@NL6FH&7;NW85V4+M<%/F7D$$<D&O3H_\`
M5)_NB@!U%8/C75K[0O!FK:IIT<+W5K;/*@F8A1@=>`<D=<<9Z9'6J=IXEUJZ
MUZ_TDZ!`DNGP0S3L+_(D\P28$7[OYN8\?/LZD\8&0#JJS;OP_I5]=75S<V4<
MLUW:?8IV8G]Y#DG8>>GS'WYKG+;Q\QN-2LKO3X%U"T>UC6&SO/M"N]PQ5$9M
MB[&!4[N"`.<FL>WU5]%U#Q+-J&CR7'G:M8Q30_:!+%"TB1@.K.`60.RD87()
MZ`#@`[6;PKHL\5C&UF52P@-O;K'*Z!8B`#&=I&Y2%7Y6R.!4<7A#1(%LUCM9
M1'9LK11FYE*%EQM+J6PY7:""P)!&1SS63+XYN([N^5M$=+:QU6'39Y)+E=Q\
MTH$D15!!'[Q"02,`^N0$E\:Z@VM6EI:Z+;O:7.I2::)I[UHY5>-69F,8B;Y<
M(2OS<Y7.`<T`=G63X?\`^/2[_P"O^Y_]&M6M63X?_P"/2[_Z_P"Y_P#1K4`:
MU%%%`!1110`50UC_`(\H_P#KZM__`$<E7ZH:Q_QY1_\`7U;_`/HY*`+]%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!7FWBW_D>+;_`+8_^A5Z37F?
MBIBWCJ$'^%H0/S!_K7G9I_!7JCTLK_C/T9Z3+_J7_P!TUG>&VW>&]./_`$P4
M?D,5HR_ZE_\`=-9OAG_D6M/_`.N(KL?\5>C_`#1QK^"_5?DS5HHHK4Q"BBB@
M`HHHH`****`"BBB@`K)TO_D,ZY_U\1_^B8ZUJR=+_P"0SKG_`%\1_P#HF.@"
M76]%M=>TUK&[,JIO25)(7VO'(C!E=3V((!JG)X:^T?9/MFL:C=+!O+I,(2EP
M67:"ZB,#@=-H7GKFK/B#6QX?TMM0>PN[R-&"R+:^7N0'^([W4;0<9YXSGIDB
MO>^)HK"Y>WDT^\:7?'%`J&+-S*REO+3+_>"J2=VT`<YQ0!GVG@.&QM[(6^O:
MPMU8H\-O>;H#(D+[<Q$&+8R90$94D=B!Q5Y?"L,.L2:E;:EJ-O).B+=QQR+L
MNBHVAGRI(;&!N0J<`>@K)O\`7SJDFBSV4U[9O#K`M+VR?:K;O+9BDF,Y_A(V
MM@YZD5<L_'-G>#2S_9NHQ#4;JXLU,BQGR98=^Y7"N3SY;XV[AQVS0!G>'_#5
MS=7=_/K$&HVL']JR7L5E-+`\,IW;HY#L+,"I`.-P&0#@FM'_`(0BU2.UC@U7
M4X(K;4'U".-'C(WLS,5^9#\N9']_FY)P,1V?Q`TZ_%BUOIVJ%+Z6:"V9H`F^
M:(MNCPS!E.$8Y8!1@Y((Q5:]^*'A^PL+:YN#+&\QDW6TDD,4D7EN4?.^10Q#
M*1A"Q/8$4`:-IX+LK*X#17U_]ECN'NK:R9T,-O*P;+(-NX\LQ"L64$Y`&!4%
MMX%AMH=.A&N:N\=@)@BLT(WB7(8,1&#W.",$9KI+.[@U"R@O+619;>XC66*1
M>C*PR"/P-3T`<2WPRTUM,N+`:KJB1W%BFGR-&8$)A5F(7`B"CAV'3OGKS786
ML+6UI#`\\EPT:!3++MWO@=3M`&3[`#VJ:N:UCQ=I6AW>I/=Q:B7TZS6XF\J%
MV0QLV,J.C$'.6`X`.2,4`;&L:5;ZYHUYI5WO^SW<+0R;#A@K#!P?6LB'P=#'
MJ&J7<FKZI.=3LUM+A))(P-JA@&5E0,K#>YR&_B/'"XNZ7XAM]4U*[L%M;JVN
M+>**?;<(H\R.3=M=<$\91AAL$8Y%:]`''_\`"N=+:*99+[46DE@MX1*KQQM&
MT#L\4B!$`#J6],>HY.2\^'MK>I=^9KFLB>[FMYYYA-&2[0XV?*8RB\JK':HR
M1CIQ785D^)=7FT+0+G48+*2\DB`Q$C*.2<9.Y@,#/KF@#&NO`$-U_:&[7]83
M[??17\FS[/\`+)'MV;<Q=!LCX.?N#U;.;IWA[5(O%<VI&UU""\:=F:[E6Q>!
MXB^=@DVFYQMZ*<`$8X&*%\33Z+XJ\17>I1ZK)8I96-PUL[1,+!6,P<D!MN/E
M!.TLQQQD#C6O/B'X?L?$BZ'-<C[29UMF82Q?)*P!52A?S#G</F"E1W(H`ZNL
MGP__`,>EW_U_W/\`Z-:M:LGP_P#\>EW_`-?]S_Z-:@#6KBM9-WI'C*UU.[2>
MXT^\N8+2W$.J3H89&!7)M@/+=<\DDD@<XXKM:H-HFE/J3ZD=-M!J#IL:[6%1
M,5QC'F`;NGO0!Y_XKUZZEU#7+G3M0D8:9IMK=:<MK<D1S2/+(K;@IVR`[`N#
MD#MS6+?>(-7M+.TU&WU6[-UJ/V]+U&N"R0)'<)&&1#\L9121E0/4Y/->KIX?
MT9/L.-+LRU@NVT=X59H!_L,1D=.W6I4T;2XKFZN8]-LTN+L;;F58%#3#T<XR
MWXT`8'@Z6=-3\2Z:;FXN+.POUBMFN)FF=5:&-V4NQ+-AF/4G&<=,5>UC5/\`
M28]/^PWO_'U;_P"D>3^Y_P!8C?>S^'UK5L-.LM+M%M-/L[>TME)*PV\2QH"3
MDX4`#K4.L?\`'E'_`-?5O_Z.2@"_1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`5YCXH8-X\0`\J\(/Z&O3J\J\4,4\=S,.JRPG_QU:\O-7:E'_$OU
M/4RE7K2_PO\`0]2E_P!2_P#NFLSPP0?#.GD'/[D"M.7_`%+_`.Z:R?"?_(K6
M'_7,_P`S7<_XR]'^:.%?P9>J_)FS1116QB%%%%`!1110`4444`%%%%`!63I?
M_(9US_KXC_\`1,=:U9.E_P#(9US_`*^(_P#T3'0!?O+2#4+&XLKF,26]Q&T4
MB,,AE88(_(USC^#YFT;3(?[69M7TZ87$6HR0[M\@0QDO&&&04.T@$>Q%:GB3
M78_#NBR7[PM/)O2&&%3@RRNP5%SVR2.>PJ*V/B2"6%[Z32[B%Y/WJP1O$;=,
M$\,SL)#G:.B<9..U`&7+X-O6>"YAU6VCO3J2ZE>2M9,RSNL8C"JOF#8H48ZL
M??KF)/`EU'<6C1ZZT4%EJLVI6Z):KNS+O+([,3N'[Q@"`IP?7!&K%XU\/2K*
M_P#:2QQQP&Y\R:-XD>(8S(C,`)$Y'S*2.1ZU$/'OAMD=DOIGVVZW0$=G,QDA
M;_EH@"9=1W*Y"]\4`9-AX&UBR_L?.O64G]FZC<7_`!IK#S/.W[E_UW&/-DP>
M?X>.#N71_`^L:+=)>V_B&U-WYLYFSIS>5+%+(92I7S<AE=FVL&Z'!!ZUKS^.
MO#4!N`=423[-''+.8(GE$22#*NY13M7'.3P`1G&15B3Q9HD6KII;7;&Y9UCR
ML$C1!V7>J&4+L5BO(!8$@CU%`&Q&K)$BO(9&``+D`%CZ\<4ZL&R\:>'M2DMD
MLM1%P+EI$@>*)V21D!+*'"[2V`3MSD@9`(IUGXMT>_M+6ZMI;J2&ZNC9Q'[#
M."91D,""F5`VMEC@#:<G@T`;E<?XE\'ZEKUUJKPZS:VMO?Z;_9QC>Q:1D4DD
MMN\U<GYF[<<=<<[2ZI)IUNG]L./.EG:.$6ULY++G@E%+D8'5LXQR=O0:<4J3
MPI-&VZ.10RGU!Y%`'/Z5X?U*R\37&KW>J6MPDUC!:-#%9-$08RQ#!C(W4N_&
M.A49X)/1T5GW.N:?::DFGS3,+EE5]JQ.P16;:I=@"$W,"!N(R0<9P:`-"L[7
MM,;6=#O-.2X^SO/'M2;9OV-U!VY&>1TR*Q-$\4*M]=:;J]^);TZG+:P&*V81
M@!0R(S`%4;:>-S9;M5V/QKX>D:Y']H>6+>%KAWFADB0Q*=K.C,H#J"0"5)ZC
MUH`QM6\#ZMJK>(-^OVJIK-C%9OG3B3$$+?,")0#GS).,=UZX.[5TSP_JFF:G
M<W,>LQ-;WLBW%W`;0_Z[8JLT3%SL5MH.U@^,GGO4S>+]&6S%WYEVT3#*!;"=
MFD7`)9%";F4!AE@"!GDU9A\1:5<301P71F$\:2QR11N\95R-OS@;03D8!.2.
M>@H`U*R?#_\`QZ7?_7_<_P#HUJUJR?#_`/QZ7?\`U_W/_HUJ`-:BBB@`HHHH
M`*H:Q_QY1_\`7U;_`/HY*OU0UC_CRC_Z^K?_`-')0!?HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`*\F\3DGQM<9_YZQ_^@K7K->2^)&W>-+DC_GL
M@_(**\K-_P"%'_$OU/6R?^++T_5'JEW_`,>4_P#US;^59GA/_D5K#_KF?YFM
M.\_X\I_^N;?RK(\&,6\)V))R<./R=J[I/]_%>3_-'"E_L\GYK\F;M%%%;G.%
M%%%`!1110`4444`%%%%`!63I?_(9US_KXC_]$QUK5DZ7_P`AG7/^OB/_`-$Q
MT`,\4:"OB/0Y+#S_`+/,)$GMYMN[RY48,C$9&1D#(]*A2VU_4[.XLM72PLXI
M(FC:6QN'E>0,",X9%\OL>K>F1UK<EEC@B>6:1(XT&YG<X"CU)/2L#6?&>C:;
MX7EUR#4]/N+?=Y4$@ND\N23^Z&!P3P20.<`^E`&/'X9\12V5FE[_`&4T^F6,
M]I;-%+(HN2Z*@9_D_=C:,E1OY(YXHM-`\36\EFS6VD-]GT,Z<<7LG,O&&_U/
MW?E'OSWQSTV@7%_=:=Y]]=:;>!VW6]SIP8131$`AL%FP<Y'#,"`#GG`TI)$A
MC:25U2-`69F.`H'4DT`>/Z!;ZM;ZUJ'A:WGT-M3B\/V-A<@W;,$""5#(J[,N
M0K(Q0A?O@;NA/3WWA/7Y;RTCAO+9['3[BUDLEDN)$VI&%#*Z*N&;AF#%CG@8
M7&ZM74O%D(M-.O=%N]-OK*:_BM;BX2X#K&K'!*E<@GZD8Z\]*UDU[1Y=*.JQ
MZK8OIRYS=K<(8A@X/SYQU]Z`.,T_POXGMAHPF@T?%EK5SJ,Q2]E.4E\WY5S"
M,D><W7`.P?WCMU?#EM!=>)=3U73;^&[T64B6`PR"1/M+C$Q5AQC")T_B>3/-
M;RZ[H[M:*FJV+->(TEL!<(3.JC+,G/S``9)'2J9\8^'/M.GP+K>GNVHEA:E+
ME"LN#M^4YP?F^4`<D\=C0!'XKT6XUFRC6UAB>XA)>)VNY+5XWX`*R1JQ'&<C
M:0>!6MID%U:Z59V]]=?:KN*!$GN-NWS7"@,V.V3DX]ZM5S_BK7M0\.V<=]:Z
M0NHVP<"=4N"LR@D<QIL(<@9.-RGC`SF@#H*Y;7_#E[J&NVFIZ<T=K<Q^6C7<
M=S)%((U8LR,@!293G`5L8R2#S5B77[^ZGT]M#LM/O["^MFGBN9;YHN0,XVB)
MN#E><YY/''.1:>/+V?2+&YFT>T@N]0U"6PM8CJ!\O=&9`QDD,0V@F)@`%8G*
M^O``/H/B5B3]GTG/]MC4!_ILG^J'&/\`4_>_3WJD_A/Q7-J+:G<W.GW%ZVF7
M5A(9+J41L9&0HRJ(\1CY3D`$],LW4=U87-S<QR_:K,VLL;["N_>K?*#N4X&5
MY(Z#IR`>!;H`X+4/!=[J$/A^[N]-T34+O3;1K2>QO6+V\@;9\Z.8R58;!_!T
M8CWJU<>%+^/6--NM*2RTU8'C65[2:2)?(4@F(P!2D@(W*"2I7((STK3U'Q!>
MZ;?VYETG.F374=I]I$Y\T2.P16\K;]S<0-V[/?;CFI(==FO?$5QIUA'ITUO:
M,$NG:^(GC8J#Q$$.1RO)9><^G(!N5D^'_P#CTN_^O^Y_]&M6M63X?_X]+O\`
MZ_[G_P!&M0!K445YCXJ?5#\1?#]Q=:1=_98=5C@LIDEA,;H;>4R-@N&#$GD$
M8VQ<$D@$`].HKR'Q9J4&K:IJ-S;2I+<S:;;/X<:1"K-/YL@D,.0&W?<W8YVX
MSP:QKHRE`VG[_P"V@+\:^80WG>5]H3:)>_W,[,_PYV\4`>[U0UC_`(\H_P#K
MZM__`$<E<S\/Q:_:/$?]D^3_`&%_:"_V?]FQY&WR8]_E8^7;OW9V\;MW?-;^
ML/=[8U\B#[-]JM_WGG'?_K4_AVXZ_P"U_A0!K4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%>1^(?^1SN?^OA?Z5ZY7C?B%S'XIOG&,K<$C/UKR,X
M=J4?7_,]C)E>K+T/7KS_`(\I_P#KFW\JQ_!?_(I6/_;3_P!&-6Q>?\>4_P#U
MS;^58O@EL^$[,>AD'_C[5W2_WF/^%_G$X(_[M+_$OR9T%%%%=)S!1110`444
M4`%%%%`!1110`5DZ7_R&=<_Z^(__`$3'6M63I?\`R&=<_P"OB/\`]$QT`5_%
M^F7NJ:(D=AM>>"[M[KR6;:)UCE5S&3T&0N.>*YG5-)UB>PU^_M=!NEGU=[95
MTX36X=#'G=,Y\S9E@%7Y68X5??'?W-S#:0-/<2+'$N,LWN<`?B2!6?I6LMJ6
MI:O9O926YTZX6'<[`^:"BN&&.V&'OZX/%`&A;RO/;12R026[NH9H92I9#Z':
M2,CV)'O5378IY]!OXK:RM[V=X'5+:Y`,<IQ]U@>"#Z'%:%%`'FRZ!KS2:A>2
MZ9+*TE_9Z@(I7@1Y?+50T8"'8&&T]6QP/F/:9_#VLIJX\20Z<1G5?MSZ0)4$
MC+]F\C);=Y?F9^;&['OGFO0Z*`//(O#NJV5]I>K0:8[*NLW%^^GI)$'MHYK=
MH\`E@A.]M[`,?O'&>[_#FB:_I<FCF[TR+$%WJ`?R;I6V1SR^:KMD#W7"[C]T
M\9.WOI&*QLRH78`D*",L?3GBLWP[K#:_H5OJ36K6C3%P8'<,4*NRX)'&?E[?
MK0!J5B^(IKV*.R-EI%WJ)6X61UMY(5**OKYCKG/;&?PK:HH`X^V\.WN@>*I[
M[34\[1989[@V*8#QW+;21'N8*%?!.#@!N<C)K-T?2+^7P4VDZWX3-Q#]KNI9
MK.XE@9I%>9Y4,9#E=PW@?,5P0>>F?0J*`.:\&:7?Z3IUU!=&YCM6N"UC;7<X
MFFMX=J_(S@MGYMQ'S-@$#/%=+110!S-Y=ZI-KZH_AO49K6VD'V>5)K81,Q&/
M-?,N_`R<#:3U."<`/NK6XU;7K25M'ELWL+C<NH221'S(\,"J;6+$-D9#!0,Y
MY(%='10`5D^'_P#CTN_^O^Y_]&M6M63X?_X]+O\`Z_[G_P!&M0!K4CHLB,CJ
M&5A@J1D$4M%`#8XTBC6.-%2-`%55&`H'0`4ZBB@`JAK'_'E'_P!?5O\`^CDJ
M_5#6/^/*/_KZM_\`T<E`%^BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`KQ;Q`YD\1:B2/^7F0?DQ']*]IKQ36R#K^HD=#=2_^A&O%SM_NXKS/:R7^
M)+T/9;S_`(\I_P#KFW\JQ/!'_(J6O^\__H1K;O/^/*?_`*YM_*L/P.0?"ML`
M>C.#_P!]&O1E_O,?1_G$\^/^[2]5^3.BHHHKI.4****`"BBB@`HHHH`****`
M"LG2_P#D,ZY_U\1_^B8ZUJR=+_Y#.N?]?$?_`*)CH`H^.]/BU+PG<12Z>+X1
MR0R^2(/.8A9%+;5P23MW<#D].]</K-M`RZS+:>']3BEM=1TXV`CTN;]W&AA$
MAA"J0`$613M[#'((SZY10!Y?<:??76H76=,N4\3#5DFM-3%LX0V7G*VWSL85
M1%N4QD@[@>#G-5;?2)--O-&M+?P[=M)IWBBZD4P6>U(;643%2CG"[,&/.TX!
M4`\[0?6J*`/+(K*6QTS5[.;0)=4M&".["RFMYI&:1"1,%S]H('+,F[<$*D'.
M*SK33'M]2T>UGT;4$M8=>N'\NUT^XCM5MI(/^>8R`F]D^]ZMT&\#V2B@#R31
M8':'3(=0T/49?#UO=WZ"SETV7]VS3AK9C$4R4$9(!`PI/.,<=AX$>6S\-V6G
M7=C?VEP&N"JW$+'Y1*2"SC*@D,,!B"><`XKJZ*`"BBB@`HHHH`****`"BBB@
M`K)\/_\`'I=_]?\`<_\`HUJUJR?#_P#QZ7?_`%_W/_HUJ`-:BBJLFI6$6H1V
M$E[;)>RJ6CMVE42.!U(7.2*`+5%5+G4]/LKFWMKJ^MH)[@[8(I9E5I3Z*"<L
M?I34UG2Y+NZM$U*S:YM%WW,*SJ7A7KEUSE1]:`+M4-8_X\H_^OJW_P#1R5-8
M:C8ZK:+=Z=>6]Y;,2%FMY5D0D<'#*2*AUC_CRC_Z^K?_`-')0!?HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`*\1U?_D-7_\`U\2?^A&O;J\/U(EM
M5O&/4SN3_P!]&O#SOX(>K/;R3XY^B/:KSBQN/^N;?RK`\"?\BO%_UT?^=;-^
M2VC7+'J;=S_XZ:QO`G_(KQ?]='_G7I2?^TQ]'^://BO]EEZK\F=+11174<@4
M444`%%%%`!1110`4444`%9.E_P#(9US_`*^(_P#T3'6M7/1:E!INMZNMTMRO
MFS1NA2VD<,/*0<%5(Z@T`=#163_PDFF^MW_X!3?_`!%'_"2:;ZW?_@%-_P#$
M4`:U%9/_``DFF^MW_P"`4W_Q%'_"2:;ZW?\`X!3?_$4`:U%9!\2Z8H)+78`Y
M)-E-_P#$4O\`PDFF^MW_`.`4W_Q%`&M163_PDFF^MW_X!3?_`!%'_"2:;ZW?
M_@%-_P#$4`:U%9/_``DFF^MW_P"`4W_Q%'_"2:;ZW?\`X!3?_$4`:U%9/_"2
M:;ZW?_@%-_\`$4?\))IOK=_^`4W_`,10!K45D_\`"2:;ZW?_`(!3?_$4?\))
MIOK=_P#@%-_\10!K45D_\))IOK=_^`4W_P`11_PDFF^MW_X!3?\`Q%`&M63X
M?_X]+O\`Z_[G_P!&M1_PDFF^MW_X!3?_`!%-\-MYFG3R[)$62\N'3S(V0E3*
MQ!PP!YH`V*X7Q-;3S>*])EMEO7^S7T=Q-!+;A;01A2KSF95^^JM@*SGE1\O>
MNZHH`\IU]=0UZ;5I[33]14:[I5K%IKM;,PB=)9&;>1E8\;D?+$`]LD8K,O=`
MUB\L;2P@TJ]%UIIOWO7:W*+.LEPKA4<\2;U!.%)]#@U[310!R?@Z&9]2\2ZF
M;:XM[34+]9;9;B%H795AC1F*,`RY93U`)QGH16MK"7>V-O/@^S?:K?\`=^2=
M_P#K4_BW8Z_[/^-:U4-8_P"/*/\`Z^K?_P!')0!?HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`*\-OF#ZA<L.AE8C\S7N5>%77_'W-_UT;^=>'G?P
MP^9[F2?%/Y?J>T7O_($N/^O9O_036)X!)/AKZ3/_`$K8N"3X>E).2;4_^@5C
M^`/^1;_[;O\`TKT)?[S#_"_T."/^ZS_Q+]39UC5(]'T]KN1"X#*N`<<DXJ_7
M->.R!X8DR>LJ8_.N@MI/.M89,YWHK?F*VC4;K2AT23^^YC*FE1C/JV_T):**
M*V,`HHHH`****`"BBB@`HHHH`****`"BBB@"KJ3^7IETV<$0MCZX-6JI:O\`
M\@B[_P"N3?RJ[4KXF6_@7S_0****H@****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"J&L?\>4?_7U;_P#HY*OU0UC_`(\H_P#KZM__`$<E`%^BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`KP4DDY/)KWAVVHS>@S7@]>!GG_+O
MY_H>]DG_`"\^7ZGL[,6\+ECR399/_?%8WP]<MX>E!Z+<L!_WRI_K6I`YD\'1
MNW5M/!/_`'[K)^'?_(OS_P#7TW_H"5Z#=\12?]U_H<-K8:JO[R_4F\?_`/(M
M_P#;=/ZUKZ!)YOA_3G)R?LZ`GW"@5A?$3_D7X/\`KZ7_`-`>M+P?+YWA6Q)Z
MJ&7\F(I0G_MTH_W5^?\`P0G'_88R_O/\C<HHHKT#SPHHHH`****`"BBB@`HH
MHH`****`"BBB@#.U]BGA_4&!P1`Y!]\5HUE>)O\`D6M0_P"N)K5K-/\`>->2
M_4U:_=)^;_0****T,@HHHH`****`"BBB@`HHHH`****`"LRY\0:9::I!IMQ<
MF.YN'\N,&-MC/C<$WXVAB.0I.2.<5IUQ^LC4KWQ?8BYT&_ET?3I%GAGMY("L
MDQ4CS'4R!]J!C\H4DGD`X&0#<U'Q%I6E7D=K>7)CED`;B)V5`3M#.R@A`3P"
MQ`)XJL/&7A\W-U`=156MDD>1GC=4(C(#['(VOM)`(4D@\'FN/U?0]?UZ34Y?
M[)DMQX@TRWMF(N$S8,CN27R0Q^5P1M!.000.M4KOP5X@OK.TT[[$(AI)NY([
MA[A"EX9)UD15`)8<*0VX+@],CF@#TO2M9L-;@DFL97812&*5)8GBDC<`'#(X
M#*<$'D#@@]#1K'_'E'_U]6__`*.2LCPII]]#?Z]JE]:/9G4[Q9H[:5T9XT6)
M(_F*%ER2A.`3QCOP+&L:7_I,>H?;KW_CZM_]'\[]S_K$7[N/Q^M`&]1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`R8@02$G`"G^5>$5[I>?\`'E/_
M`-<V_E7A=>!GF\/G^A[^2;3^7ZGK]DQ;P3"3_P!`\#_QRLOX=L/[!N%[BY)_
M\=6M#3W!\"QLV`!8G)^BFLWX=?\`(%NO^O@_^@K7:G^_H_X7^AQR7[BM_B7Z
MB_$4G^Q+8=OM`_\`06JQX!E$GAH+G_5S.O\`(_UJI\1F/]E6:]C.3_XZ:/AS
M)G2[R/\`NS!OS4?X5DI6S)KNC5QOEJ?G^IV=%%&1G'>O7/'"BBB@`HHHH`**
M**`"BBB@`HHHH`****`,KQ-_R+6H?]<36E$28D)Y.T5D^*R1X7O\?\\Q_,5K
M1?ZE/]T5BOXK]%^;-FOW*]7^2'T445L8A1110`4444`%%%%`!1110`4444`%
M%%%`!1110`50UC_CRC_Z^K?_`-')5^J&L?\`'E'_`-?5O_Z.2@"_1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%5B^-36/^]"6_(C_&K-).XVK!1113$%%%%`!1110`4444`5M08IIM
MTPZB%R/R->'5[?JK!-'O7;HMO(3_`-\FO$*^>SM^]#Y_H?0Y)\,_D>IV3;_A
MPQQC_0)1^2L*J_#H_P#$FNAW^T?^RBIM+D$GPUD([6<ZG\-PJM\.?^09>_\`
M78?^@UUTW>O1?]W]#DJ*U"LO[WZC?B._^@V*>LK'\A_]>JWPVDQ+J,>>JQM^
M6[_&L;Q'JPU2)Y`<JU[*8_\`<"(H_/K^=7?AW*5URXC[/;D_B&7_`!-<:K1G
MF,9QV_X!VNBX9<X2W_X)Z74/_+Y_VS_K4U4MW_$[*Y_Y=LD?\"KZ%L^>BKW+
MM%%%,D****`"BBB@`HHHH`****`"BBB@#&\6?\BM?_\`7,?S%:=IS90?]<U_
ME61XR8KX3OBIP<(/S=16O9_\>4'_`%S7^58)_OY+R7YLZ&O]GB_-_DB:BBBM
MSG"BBB@`HHHH`****`"BBB@`HHHH`***RIM?MH?$MKH30W/VBYADF27R\1XC
MV[ADGD_.O0$>]`&K16#J_BVPT:^>UFAN)?)C2:ZEA"E;6-V*JSY8'!(/W0QX
M)(QS5%_B%I$4LOG0WL5N%F-O<O&OEW1B8(ZQX8MD,0!N"Y[9'-`'650UC_CR
MC_Z^K?\`]')4.B:[#K:W:K;7%I<V<WD7-M<A=\3;0PR49E(*LI!!/7UR*FUC
M_CRC_P"OJW_]')0!?HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`,F60KXLMDR=K64G&>,[TK6KG;V;9X
M[TR,GA[:0#CZG_V6NBK&E*[GY/\`1&]:-E#S7ZL****V,`HHHH`****`"BBB
M@"AKG_(OZE_UZR_^@&O%*]H\0$CP[J./^?=__037B]?.9W_$CZ'T62_PY>IW
M7A>[\WP3K5J3DPQ2L!Z!D/\`4&J6AZ@=.\%:M*AQ(\@B0^A88S^635#PU=^2
MFK6Y/RSZ?-@?[2J2/TS5:.5E\*7$8)PU['Q_P!__`*U90Q#Y(26ZC)&\J"YY
MQ>SE%F<TF;9(N?E=F_,+_A70>!I?+\4P+_ST1U_\=S_2N;K8\*R>7XHL&]9-
MOY@C^M<6%FUB(/S1UXJ-Z$UY,]BK,$@_X2AHN_V(,?;YS6G6(C`^-Y5SR-.7
MC_MH?\:^PJ.SCZGR-)7YO0VZ*:SJA4,0-QP/<TZM3$****`"BBB@`HHHH`**
M**`"BBB@#!\:?\BE??\`;/\`]&+6IIG_`""K/_K@G_H(K)\;,1X3NQZE!_X^
M*UM,(.DV9!R#`G/_``$5RQ_WF7^%?FSJE_NL?\3_`"1:HHHKJ.4****`"BBB
M@`HHHH`****`"BBB@`KEM7TS7)O&VDZQ:6MA+8V,$T+A[MTE<2F/<57RRN5\
MO@%AG/)6NIHH`\]U'P?KVMF[>\.GH-:T^"TU)5=U-OY;NV8QA@^5<KRRX(SD
MYQ5:X^'6J7D$-C+<V,=KIQN7L)4+L\KRS+*OF*0`H7;@X+;LYXZ5Z710!S_A
MK1KW3[K6-1U+[.EWJETL[PVTC21Q!8TC`#LJECA,D[1UQVR;6L6<6V.YW3^9
M]JM^//?9_K4'W,[?T]^M:U4-8_X\H_\`KZM__1R4`7Z***`"J=C=?:IKX;LB
M&X,0]L(I_F35RN:\(W!N)-9)/)OW;KZ__JK&<[5(Q[W_`"-H0O3G+M;\SI:*
M**V,0HHHH`****`"BBB@`HHHH`****`"BBF3-L@D?.-JDY_"@%J*CAT5U.58
M9!IU5[!M^G6KXQNB0_H*L4D[JXY*S:"BBBF(****`"BBB@`HHHH`X_6)MGQ$
MT=>PBZY_O;Q785P/B:;R_B!I+#^$0@_0R-G]#7?5Q825ZE5?WOT1W8N-J=)_
MW?U8455:[`U2.S!&6A:4COPR@?S-6J[$TSB::W"BBBF(****`"BBB@#+\1MM
M\-ZB<?\`+!A^8Q7C->R>)O\`D6M0_P"N)KQNOG,[_BQ]#Z/)?X4O4DAF:"0N
MO4HR?@RE3^AJP'QHIC_O7`;KZ*?\:ITXN3&$[`D_GC_"O(C.R:/7E&[&U<TE
M_*UFQD_NW$;?DPJG3D<QR*Z]5((I0?+),<ES1:/>*YR-@?B',!_#IN#_`-]B
MMVUNH;VV2XMW#Q/G:PZ'!Q_2N/U#4/L/CFYE!((M8X_KF1/\:^PQ4THPETNC
MY#"TY2E./6S_`$-S7+S[/?Z-#NP9;L9]QM(_FPK:KA/&-YM\5Z-%S^X9)?S<
M?_$UW=.A5YZM2/9K\B:]+DI4Y=T_S"BBBNHY0HHHH`****`"BBB@`HHHH`Y[
MQO\`\BI=?[R?^A"M+0_^1?TW_KUB_P#0!67XY;;X6G&/O.@_\>!_I6GH1#>'
MM-(.?]%C'_CHKC7^^/\`PK\V=DO]SC_B?Y(T****[#C"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`JAK'_'E'_U]6_\`Z.2K]9VM.L>GJ[L%5;FW))Z`
M><E`&C65H.J#5K:YG!RJ7+QK_NC&/T(IFNZI%;>&KJ^@E5PT>V)T.02W`(_/
M]*Y_X<7`^QW]N3C8ZR?F"/\`V6N.>(2Q$*2ZIO\`R_4[(8=O#3JM;-+_`#_0
MZF[U6&UU.RL#S-=,V!_=4*3G\P!^?I7+?#Z?S9]6`.0SHX/KDM_]:N>36Y+[
MQG!J$C84SJJ`]%3.!_//YT[P5JG]GZ\D3MB&Z'E-[-_"?SX_&O-^OJIB(2Z7
M:_!)?B>E]0=/#3CU:3^=V_R/5Z***]X\$***A-S&MXEKG]X\;2#Z`@?^S"DW
M;<:3>Q-117,VFM9\=7VG,W[MHE6/G^)1D_S/Y5%2K&FXJ75V-*=*512<>BN=
M-1116AD%%%(2%&20!G'-`"T444`%5=2?R]+NY,@;87.3VPIJU6=K[;?#VHG_
M`*=I!_XZ:BH[0;\BZ2O-+S':&V_0-.;))-M'DGUVBK]97AIQ)X:T\@@XA4<>
MW%:M*B[TXOR0ZRM4DO-A1116AF%%%%`!1110`4444`>:^-91'XPM9,_ZM(R<
M]L,37I5>6>/2#XF;VA3^M>H0OYD$;_WE!_,5YF"E_M%9>:_4]3'1_P!GHOR_
MR.:2[\SXCR0@G$=EY9'OD/\`U%=17FVF7XD^),L[L`C22J6)X"JI`/\`XZ*]
M$M[F&[@6:WE26)LX=#D'MUK7`U544W_>9CCJ3IN"_NHEHHHKN.$9++'!"\TK
MA(T4LS'H`.II]<GX]U/[)HRV:-B2Z;!]D')_H/SK6T#6+?5K!/*DW2Q11B8>
MC%<_XUSK$0=9T>J2.AX::H*MT;_K\36HHHKH.<QO%G_(K7__`%S'\Q7CU>N^
M,7*>$[XCKA!^;J*\BKYK.G^^BO+]6?2Y*OW$O7]$%%%%>.>N%%%%`'H7A?Q)
MI^E^%XEO)BK)*Z*B@LQ_BZ>GS5ROB#6$U/79;VU#I&0H7>!DX`ZCZBL>BNRK
MC:E2E&ELE;\#DI8*G3JRJK=_J;WBR],_BFXE0C$914[]`/ZYKUM6#*&'0C->
M$RR--*\KG+N2Q/N:]LTN87&DV<RD$/`C<?05ZV55?:5:LN^OYGDYM2]G2I)=
M-/R*FLZ@UC=:4`V%FNQ&P]058?S(/X5K5Q?Q`NC;?V4RYRLS2C_@.W_&J$OB
MXWOC&R>)RMA%+Y:@\;MWREC^?Z5U3QL*564)OJOQ1RPP,ZM&,X]G^#.UNM9L
M+*^BL[FY2*:5=R!^`1G'7H*O`@C(Y%>1^,KEKGQ1=9;*Q;8U]@!S^I-=]X2O
M%F\,6&]L,,Q#/<@G`_(4\/CO:UYT6MMOEH&(P/LJ$*J>^_YF]1117H'G!13)
M98X8FEE=4C099F.`!ZFE1TD0.C*RD9#*<@T7Z#MU'445GW>MZ=8O.EQ<JCP(
MKR+@D@,<#@=?_KBIE*,5>3L.,)3=HJYE>._^17E_ZZ)_.E\$7\=YX=BA#9EM
MB8W'H,DK^G\C6%XC\4V.M:)=6ULLBLCH5+@#>,\D#/T_.N<\.ZT^AZHMQAFA
M8;94'=?\17B5<;"&-C-.\6K/[V>W3P4YX-TVK23NON/9**SM"U/^V-'AO2H1
MGW!E'8@D5H;ANVY&>N*]N$U.*E'9GB3@X2<9;H6BBBJ)"BBB@`HHHH`****`
M"BBB@`HHHH`*R]?UE-"TO[6T1FD>:*WABW;=\DCA%!.#@989.#@>M:E9/B/1
M!K^D&S%P;>5)HKB&;9O"21N'4E<C(RHR,C(SR.M`!H&M'68+L2P)!=V5RUK<
MQ)+YBK(H!^5L`D$,I!(!YZ5G^,[ZT_X1Z^M/M4/VG]W^Y\P;_OJ?N]>G-:&@
MZ+_8UO=&2=9[N\N6NKF5(_+5Y&`'RKDX`"J`"2>.M/U+1;2_&\V=JTYEB9I)
M(@2RJZDC.,\J"/TJ91YHM=RHRY9)]CRR?69I_#]KI."(X9&<M_>ST'X9;]*?
MH6L_V0M^"C-]HMVC4K_"_8GVZUZI_8>D_P#0+LO_``'3_"C^P])_Z!=E_P"`
MZ?X5YBRRTU/G=UI^%CTWFEXN'(K/7]3Q5258,N00<@T*65@RDA@<@CJ*]J_L
M/2?^@79?^`Z?X4?V'I/_`$"[+_P'3_"LO[%A_.S7^VI_R(XK4/'#2VVE_9RZ
MRHRR78`QDKCY1['D_E6R?B!I`GV+'<E,']X4`'3TSGVK<_L/2?\`H%V7_@.G
M^%']AZ3_`-`NR_\``=/\*]&-&K%M\^]NG8\^5>E))<FU^O<R9_'.CP6\4FZ2
M221`YBB7)7/8DX&:YX^-(7\3Q:BUO,MLEN82@P6Y.<]<>GY5U&B^&;2RTF"W
MOK*RGN4W;Y/*#;LL2.2,]"*O_P!AZ3_T"[+_`,!T_P`**E&I.WOVMY"IUZ<+
M^Y>_F8UGX[TJ[N_)=9K=""1),`!QVX)K@&U61/$C:JA)/VDR@=,C/3\N*]8_
ML/2?^@79?^`Z?X4?V'I/_0+LO_`=/\*RKX.5914I[.^QK0QD:+DXPW5MR&#Q
M+HMQ]S4K=<#/[QMG\\5*VNZ0HR=4L_PG4_UI?[#TG_H%V7_@.G^%']AZ3_T"
M[+_P'3_"NU7ZG$[7T(;;Q)H]U#YJZC;H,D;99`C<'T)S6+XRURS;0C%97T,L
MSRICR90Q7!W9X]P*V7\/:<=0AE73K(0K%(KIY*\L2A4XQC@!OS]ZG_L/2?\`
MH%V7_@.G^%14INI3<&]T:4ZBIU%-+8PM$\;6-S:V\5_+Y-V<J[$83@?>)Z#/
M\ZU)?%6B16ZS-J$15AD*N6;\5'(_&K/]AZ3_`-`NR_\``=/\*/[#TG_H%V7_
M`(#I_A1",XQLW=A.<)2NHV(O^$DT7R!-_:=MM(SC?\W_`'SU_2N4\0^-;:[@
MFL;.-I8)8F5I6!4[CTP#V_QKL/[#TG_H%V7_`(#I_A1_8>D_]`NR_P#`=/\`
M"IK4Y5(\JE;Y%4:L:<N9QO\`,\R\.>)KC09BC*TMH_+19Z'U'O780?$'2I%8
MS0W,1'0;0V?R-;O]AZ3_`-`NR_\``=/\*H:+X9M++28+>^LK*>Y3=OD\H-NR
MQ(Y(ST(K"AA9T8\L9Z>:-J^*A6ES2AKY,S!\1=.\P@V=WL]0%S^6?ZU8M?'V
MD3MMF6XM^>&=,C_QW)K:_L/2?^@79?\`@.G^%']AZ3_T"[+_`,!T_P`*V5.J
MGK/\#%U*37P?B9;^.-$2)'$TK;F*[5C.1CN1Z&H[CQUI$2P-$TDPD<JX"D&,
M>I!Z]OU]*V/[#TG_`*!=E_X#I_A1_8>D_P#0+LO_``'3_"J<:G\WX?\`!)4J
M?\OXB?V[I&W/]J66,9_UZ_XTT^(='#*IU.URW3$H(_'T_&H[[P]IT^GW,5OI
MUE',\3+&_DJ-K$$`Y`R.:G_L/2?^@79?^`Z?X5J9'.>*_%$$"V<5A<QS?OEE
ME:%PPVJ00O'J?Y5L7GBO1;-`S7T<I)&%A.\_I5O^P])_Z!=E_P"`Z?X4?V'I
M/_0+LO\`P'3_``K)4Y*4I*6]OD;.I%QC%QVO\SS+Q?=07WB"2XMI5EB:-,,I
MXZ5?\/\`C*XLIIAJ,KRVYB_=J!G:R@8`]`0,?K7??V'I/_0+LO\`P'3_``H_
ML/2?^@79?^`Z?X5QK`.-9U8S:;=_(ZWF"E25*4$TE8\7\Q][/N;<V<D'KGK6
MI8^)-3T[3&L+241QLY?>!EAG'`/;I7JG]AZ3_P!`NR_\!T_PJA_PC-I_;_VO
M[%9?8OLOE>3Y0_UF[.[;C'3C/6L892H.\:C3-IYLYJTJ::.?MOB)Y-M;QRV+
MS2+&!+)YF,L.X&#5^#XA:=)%(TUO/$ZKE5^]O/IGM^-=!_8>D_\`0+LO_`=/
M\*/[#TG_`*!=E_X#I_A7=&C6C_R\O\D<4JU&7_+NWS9Y+K.L7.MWYNKC`P-J
M(O1%]/\`Z]&E:W?:,939.J&7;N)7/0Y_Q'XUZU_8>D_]`NR_\!T_PH_L/2?^
M@79?^`Z?X5Q?V5[_`+3VCYNYV?VK[GL_9KE['(:GX]D;3K-]/"QW+$^>CKD+
MCM]#G]*=H_Q`+2>5JT2JIZ30J>/J/\/RKK?[#TG_`*!=E_X#I_A4%QX>TZ2>
MU:/3K)4CE+2CR5&Y=C#'3GDJ>?2NOZO5Y^?VC]+:')]8I<G)[->O4Y#Q-XQM
MM5TC[%9PR#SB#*9!C:`<@#GKD"N*KVO^P])_Z!=E_P"`Z?X4?V'I/_0+LO\`
MP'3_``KFQ&6?6)\\YZ^ATX?,O80Y(05O4\4HKVO^P])_Z!=E_P"`Z?X4?V'I
M/_0+LO\`P'3_``K#^Q*?\[-O[:J?RH\4HKVO^P])_P"@79?^`Z?X4?V'I/\`
MT"[+_P`!T_PH_L2G_.P_MJI_*CQ2BO7-+\,VEK]L^UV5E+YMT\L7[H-LC.-J
M\CC'/`XJ_P#V'I/_`$"[+_P'3_"C^Q*?\[#^VJG\J/%*U;'Q%JFFV+V=K<E(
MF.1QDKZX/;->K?V'I/\`T"[+_P`!T_PH_L/2?^@79?\`@.G^%7#*%3=X5&F3
M/-W-6G!-'E&H:G)?Z5I\4TCR2V[2AF=LD[B"#_GTK+YKVO\`L/2?^@79?^`Z
M?X4?V'I/_0+LO_`=/\*)Y1&;YG-]/P5@AF\H*R@O^'U/&;B>6ZN9+B9BTDC%
MF/N:TM-UZYL(;:W'^HANUN>/O<#!'T(KT7_A&;3^W_M?V*R^Q?9?*\GRA_K-
MV=VW&.G&>M7_`.P])_Z!=E_X#I_A3AE*A+FC-W%+-G./+*"L<['\0;*::1!;
M21H(G97D8<L!D+@>OUJCI'CY+?3A%J4=Q/<JQ_>(%PR]L\CGMTKL/[#TG_H%
MV7_@.G^%']AZ3_T"[+_P'3_"NWV-6Z?M/P1Q>WI6:]G^+.'O?&W]HZ3J=K+"
M8WEP+?;S\I(!!]\9-8&DZ]>Z.EPEN[;9HR@&[A&/1A[BO5_[#TG_`*!=E_X#
MI_A1_8>D_P#0+LO_``'3_"L)X"4YJ;J.Z.B&/C"+@J:LSSRU\>:S;JJR>1<`
M<9D0Y/X@BN=N[F:]NY;F=MTLK%F/N:]E_L/2?^@79?\`@.G^%06/A[3H-/MH
MKC3K*29(E61_)4[F``)R1D\UG4RQU8J,ZC:1=/,U3;E"FDV>-T5[7_8>D_\`
M0+LO_`=/\*/[#TG_`*!=E_X#I_A6/]B4_P"=FO\`;53^5'E5MKUU::#+ID+.
MF^82"1&((&.1^.!^M1Z/J\VD:JM^H,K`,&5F^^".Y^N#^%>L_P!AZ3_T"[+_
M`,!T_P`*/[#TG_H%V7_@.G^%;?V7K%^T?N[&3S2ZDO9KWMS@-,\::N^KP"YN
MH_LTLRB0.@"HI(!P>V!ZFO3JH?V'I/\`T"[+_P`!T_PJ_7;AZ,J2:E)R]3BQ
M%:-5IQBH^@4445T'.%%%%`!1110`4444`%%%%`!1110`5CVOBK0KW7)=%MM4
MMY=1BSO@5LD$?>&>A([@'([U@>,O&K:7':Q:-?Z5YCW?V6ZN;DF6*S8H2@D"
M,"NY@JY/`SFO.8/#6J>(M5O;?3;0Z??6\LT=_:KJLD::?<3;66ZAV8WQLJY"
M'J?SH`]]HJ."-HK>*-Y&E=$"M(W5B!U/UJ2@`HHHH`*RM4\2Z-HMW:VNI:C!
M;3W1Q$CGEN0,GT&2!DX&2!3/$.NQZ/IETT#P2ZF+:66TLGD`>X95)"JO4].U
M>,ZA/J'C"_M9I4MY[S5;.-+&]L+J2WM+^..42R6LJY+1R`"0`Y!_H`>_45SO
M@K2=1T;P^+?4YI'F:5Y$A>X:X^SHQR(_,89?'J?7'05T5`!1110`4V61(8GE
MD8)&BEF8]`!U-#NL:,[L%11DLQP`*\T\6>-+J^U!M'T!M)U"VN;#S4@DD;.I
MABZR10RJVT.J@'').X=,<@'9>'O%V@>*HY7T35(+SR3B14R&7G&2I`.#C@XP
M>U;=>0>%_"EY=>(]#\46%W<WD6P*]_</'#(D"K(C6LD2*-[AB`7;G*=L#/K]
M`!1110`445B^)?$$>@Z3=S1".XU&.VDGM[+S`))R@SA1U/X`T`-UWQCX>\,W
M5I;:UJD-E+=DB$2@X..I)`PHYZG`K:1UD171@R,,AE.017B-Y_:?C34[>WOM
M1A3^U=-DCL[S2U4VVI0CYGMV64,895Y(;)P`>XKTGP#H=[X=\)P:=?,P9)96
MB@,OFFWB+DI%O_BVK@9_+@"@#IZ***`"BBN4\;>,(O#6CW,EK-:R7\/EM)$Y
M+FWB9@IF>-3O**,GC&<=:`+U[XS\.:;X@BT*]U>WM]2E4,D,A(SGH-V-H)[`
MG)[5NUX1/I-WXUO-7M;B4/?745O>SV-G+&+758EVJD\,KJ6BP%56`]AD9->Q
M>&=/O-*\,:9I^H71NKRWMDCFF)SO8#GD\GZGDT`:M%%%`!1145Q<06EO)<7,
MT<,,:[GDD8*JCU)/2@!E]?6NF6$]]>S+#:P(9)9&Z*HZFJ6@>)=&\46/VW1=
M1AO(`<,4)#(?1E."I^H%>:^+_%6K:N_B/288;2XTJVB1G@MI&2]DMV17^U0/
MDHX4Y^4#^'K6AX+\)7]MXRC\2QWQN;6ZLLW.HB1%&IEUC,;>2J@1[<-W)/RG
M)):@#T^BBB@`HHHH`*PM-\9^'=7UV[T2PU:"?4K0D30+D$8ZX)&&QWVDX[U@
M^+O&MQ97FGV>@WNCGSYI+>>ZNG,D4,X4&.%]C#8SY/S'ICH<UPNC>$KW5842
MQ-W#>Z7J;`6<MPD8TB0N)'*R!=\T;J6P.F&]<L`#W6BBB@`HHHH`*RM?\2:/
MX7L$OM:OH[.W>01*[@G+'H``">Q/L!5R]U&QTY8VOKRWMED<1H9I0@9B<!1D
M\D^E>*ZCXEU+Q'=V%QJDT6GI:W[P1WUA$6ETJX8F,17$;DJZ.IQOX&3V'4`]
MKL;^TU.QAO;&XCN+69=T<L3;E8>QJQ7$?#3PM=^$],O;*6&2VLVF5K>VDNA.
MRX0*[[@`!O8;MHZ>V<#MZ`"BBB@`J&[N[>PLY[RZE6&W@1I)9'.`B@9)/X4^
M66.")Y9I$CC0%F=VP%'J2>E>:^+O$ESK$]QH^E?V;J>FW-CYAM%9O-U")MPD
M-O,K;-R`#Y<$\_2@#M?#_BG0_%5FUUHFI0WD2G#[,AD/^TI`8?B*V*\G\'^%
M]3_X2K2_$MM=3W5K/`3<:E<%(I)X"A"0-`J\LK;"9"<DK^`]8H`****`"BBN
M?\6>)HO#VC7DT!AGU**W,\=H7&]D!`9]H.XJN<G'8<<T`.UCQKX;\/ZO::5J
MVK06E[=KNBCDS@KG&2V,*"00"Q&<&MT$,H92"",@CO7B-S;ZAXNUJ6"[O;=Y
M]0TX-']@5?LNM6R,Q"*9`Q@E4R<D$D`Y&.M>F^!='U#0?"%EIFI2!YH-RHH?
M?Y4>X[(]V!NVK@9]J`.BHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"N)\6^-;W29+B+2=*CU&&TL'O[R8W)B"Q*S*0A"D,_ROQD8P/6K?C/Q)JN
MC6>E3^']-_M:6XO?+EACYW0K'(S[6S@,-@QGKR,9K)MI+7Q+INI6VDRL='\1
MVL\6]8CNL;HHPD60?P[LEL'&&#<_.*`.-LO!.I6MSIUC%HGGI"\<'V^%H_)O
M=/=QNCND)!#JC9!`.2..U>M^'O"^D^%[62WTJW:,2D&1Y)&D=\#"Y9B20!@`
M=@*A\)^%++PEI(M+9I)[B3#W-W,=TMP^,;F)_(#L*WJ`"BBB@`K$\3:\^AZ:
M9+2U%[?/+##%;!]OS2/L5F(!*KG/..QJWK&H2V&EWLUE;B\O8(MZ6JMAG)SM
M!QD@$@]NQKAVU?5=/U2[N=:GT][_`$RYBAC^S!H_MEO,NXQ!6))D7!*@=2N.
M-Q-`'.ZII>L^(K^ZU&_\/&5;B86EU!9W"FZT^YA_U=S;R'!*$$$KQUSZUVW@
MCP=!I=E::OJ-@L/B">%7O=KY03E<.X0'8KL/O%1SS5S2_!=E9^*]0\23S2W5
MW<2%K99<[;12JA@BGHS;>3UZ#USU%`!1110`4R::*WA>:>5(HD!9W=@JJ!W)
M/04LDB11M)(ZHBC)9C@#\:\_\6^,KC2M<BC?31JGA*73R^HS01%S`K.4W[@<
M.N/O*HR!R>PH`I>+/$UQJ]S?>&+G3UMM(O;Q=&BU'S\O]I>(2QDQ[<%"2%ZG
M/.?2LG1?`VH:GKJP:OHS6-@QDGU`6TZK;M=J$6.XM60AT9OGW#@#'/:M2/PT
M_BSPT?#$M_.MOI]S;WNEZS`"WFVV3L*R=/,5=R9SGA6QS7H>D:18Z#I<&FZ;
M;K!:P+A$'/N23U))Y)/))H`FL;&WTVRBL[2/RX(AA5R3[DDGDDGDD\DU8HHH
M`***QO$FN-HVCWL]E`M]J4,#2PV".!)+CT7J?7@9XXH`J^+_`!0?#>F"2TM4
MOK^2>"!+;S=@4ROL5G(!*KG(SCD\5Y=);ZIXGOM2U@:?-/YMXVGW]M:RJUSI
M=Y;_`');:1MNY.A*\?>/7FM)M?U:/7]1N]1%K)KOAR>WBE%I&8UO[6X02>2J
M,6)D4J64>J@#J:Z[PKX!M-"\0ZOK[7<]U+J-W)=P12J56U$O+X7^\>A;KA0/
M7(!)X,\'VNEV=IJM[8"WUV:%9+M5E)C2=EQ(RH#L5CSDJ/6NPHHH`***P_$&
MJWL%D\&A"VN=5:2./RW;=Y*LP#2,H.2%!)QQG&*`*WB?Q+>:6;*VT6Q@U*_N
MKHVWE/<>6L1$32'<0&P2%X!`ZBO+;FVU+Q7:1>(=)TJ6X_M&%[_3KNT>+[18
MWFTQR02E\>9`6&"2.!QTQC7T;Q1>Q^.+":YTJ_M]2N[81ZO;_8RB3*'\N.YC
M&6/RL=C`X.UL\A<UU/@#X;6'@6V8BYDO[X[HTN9A_JHBQ81HN3M&3DXZG)]`
M`#7\->#M(\,(7L+;RYW7:S&1F"@G)5`3A%SSM&!70444`%%%1SW$-K"9KB:.
M&)>KR,%`_$T`.DECB4-(ZH"P4%CC))P!]22!7CFO>(];\:I8V-OIL.G+<7<T
MVE2W$I=+B2V+;H[B,I@*R!F')`*COR-SQUXIET?59$U2))_"-Q8Q>;-"P$UO
M*TC@2)_>P0G3D'!'0U8@T>/XB:/HMQJCW,*6+,+B-4,:WJLBXP1QL92"0I(Y
M9<\&@#%\*>`DU2X=M:T&ZT^Q@5)K.![G:UK.Q<3QPO&VXPD!2`3CYN.]>KV]
MO%:VT5O!&L<,2!(T48"J!@`?A2Q11P1)%$BI&BA411@*!P`!V%/H`****`"O
M/?&7CR>PEO[+3],%]96VG+>7UREUY;""0LN8<`AF`!/)'M4OCGQI<:+-I"Z>
MS/97-T8I[FS5)W\P8*6X!X5I#D;CTP>_(SM.+>+-(\1^'4M+S3(;X31%+B(,
M;"?"L\9VG!0^8LBG/.]QQ@"@#!T[P#?0ZE9Z7<Z$C+$R6-]=VSK]EU&Q"D*9
M4R"DRX3!`)SWQR/6-"\/:;X<LFM=-A9$=M\CR2-(\C8`RS,23P`.O``%,\-^
M'+'POI2V-EYCLS&2>XF;=+<2'[SNW=C_`/6'%:]`!1110`5E>(];C\/^']0U
M-HQ,]K:RW"P;]IDV+D@'G'N<'%7[B[@M=@FEC1Y#MC5G"EV]!GJ:\>L?B#>^
M(H,W=E()XKY(X+B.UV)IUTS%%@FRY9U8'8S!0,/Z]`!NISZKXRUV[:Y\.V=Q
M?:'&MM?Z6UR&CN;:Z02*8G91ME!0>GU[5T'@CP*CQKJ7B+39?MUM=.MD]Q+F
M62V0@P&X"G:[KC@G)&!W%7XO!%CKOB^/Q???:$62"$G2Y055;B,L`\@Z,5SA
M>,#DC.17=4`%%%%`!3)98X8FEE=8XT&6=S@*/4FB6:*")I9I$CC7EG=@`/J3
M7FVL^(=;/B.SNM1MX+?P9<7;:4\;%9&NA*A"SEE)"QE]J@>A).,C`!%XFUK4
M?$[W?AI[)-.M;N]>RL+XR[V:Z@Q*I>,ICRV*8[Y'UK.\/>`I]6UR5]5T:?3;
M`AYYH(KO$:WF5`EM7C.Y59=^X''8=AC<N?"=QXIL8O#NIW5]:2:%?K)%?PJR
MFZMBC!0)/[^UMKX.<KG&&%=[I^GVFE:?!86%NEO:P($CB08"B@!]K:P65I#:
MVT8C@A0)&@Z*H&`*FHHH`***P_$VNR:1I%U)811W>HQH&2V#98+D`N4'S%5!
MW$*"2!Q0!7\5^*)-#BMH-.LTU#4KFZBM4A,VQ8C)N*M(0"57Y3CCDUYH\6J>
M)YYM>BTRYG2[N"K+9O']KTF]@`BS&[$!X3CD>C'CDY=I?C6XN]=T_6'M;B75
M(_/@G-O9O%%J=FDQ0O$C$L98_O[2,X+CKT[[PCX!LO"^H:CJ/VF:\N;NXEDB
M:7@6\<C;BB+VR<9/?`]*`)?"7@S3="A@OQ8K;ZI-"#<)'*S112L`9!&A.U`6
M'\(':NJHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"N.USQQ902%-
M'U"TO+FPFWW]DAW2O`N5E\O'5DR&(&?ND<9J3QMXDU/0IM'M=,6P2;4;AH%G
MO]PA#A"R1Y4Y#.1M!Z=>O0\3I'VFX&BQ^&M$:WU:PN;RWU&'4&+#3Y)EW,Q/
M\<9)W*%P&XZ<F@#IM)\/W_A26RN?#,[:GHUZX:\M'E'!<Y^T1,3P.<LF<$<C
MFNTM=.LK&6YEM;6&![J3S9VC0*9'P!N..IP!5?0](AT'1X--MW9HH=VW=T&6
M+84=E&<!>P`':M&@`HHHH`*QM<\2Z1HQ6UO=7M+&[G0F'SVX'.T,1_=W$#)P
M.U3>(]5.A>&]1U4('-I;O-ALXX&><<X]<5Y9J\]SK6F^((+S3X+O5M8T;&G7
MNFAGMKZ*/<X"J<E9`7S@D]!CW`-B'1]4\0W%SXGL+\6'BZQ"64EJ^3;AH]Q:
M*0`_-')O#JW!`*D=Q73Z-X=@N=6C\6:GI[VVMW%M&KV\DHD6U8##;,<9/3=U
MP.W-/\+Z7J2RW&N:XL,.JWR*LEM;$^7%&I)13S\[@$@OQGIT`KI*`"BBB@`J
M*YN8+.UEN;F5(8(4,DDDC85%`R22>@`J6O,_&_B?4;C6=5\*VVG6MU;+IX>Y
MM))&CN;R&17#FW/3*`#@@DD\=.0!OC?6;/Q;H;6.DZM93Z;<LD$TBD'R)RZO
M`9`?^63E=AX_C!Y%-\"V&I6/BZYCB\-76B:9/:G^T+23:;07(*[6ML,>&5FR
M,`<#N*I0Z?J?B3Q;<3:)!`_A?7=+M#<WMTA;$*"13"JYYD.>2?N]>N*]9MX1
M;VT4`=W$:!`SG+-@8R3W-`$.G:;9:18QV.G6D-K:QYV0PH%5<DDX`]R35JBB
M@`HHK(\4ZM/H7A?4=5MK87$UK"9%C.<''4G'.`.3CG`H`CUSQ)I>DN+"?5K.
MRU&YC/V87!XW'Y58C^[NP.HSTKQZ6QO-?N-3U/4=$N=0OI-EI>?8`HO=*OHA
MM62')4^2XVOC=CDGUJ_XCN+G7]-UBSOK"VNM9U?1E.F7.GL6M]0AB?S/D1LE
M9%W9QDGIBN^\':%J,=Y=>)=<BBM=7U&&..2TMV.R*-/N!SGYY.>6[=!QU`(?
M"O@J.WU*/Q7K*M)XDN[.!+L%LQQRK&$+*.@8@`$_7&`3GM:**`"BBN9\=>([
MGPQX?COK5+<-)=0V[SW()AMU=MIE?!!VC([]Z`)=:\36D4MUHNG:G9)XA\K_
M`$>VG;@R%2R*?3('UQS@XKR*;3K^Y@N-;T;0;RZU"[O'O=-U.R""XM+@MF6U
MNN5RBL&7)R,<5L:I)JU[::I##HQ7Q=;:G8:I/:VTY:&\52J+)$QQM0A.<],'
M->A^$/#]SHEK>W-_+$VI:G<?:[M+<;8(Y"H4A!]`,L>6.3QT`!;TGPY8:9=S
M:C'#)]ONA^^DEN))BN3N*KO8[5W$G`P*V***`"BBB@"KJ.HV6DV$M]J%S%;6
ML(S)+*V%4=.M>4^,]8E\4:G96%C/IU_IEQ,DVF;TW0S74(;S;6XSD`LK97.,
M%1WJQXM\1WFH7>L6][86UQHNB7<4EW;0LZ7T2*4D6Y4GY63AN`,X!Y](]"\*
MWNO:_P"(8+JT6W\-7&J)JMM=1G;)/(55D:$C[H[LW4YQZT`3^`?"B2ZS<75]
MX=NK/3K('^SK74P&:UED_P!>L6"0T7RKM)'<XZG/J444<$211(L<:*%5$&`H
M'0`=A3Z*`"BBB@`K@?%?CJT2QE;0]2M+S[$Q?5+:%@9OLG*2/'ZE"0>,_=Q5
MOQKXCUG2=4TC3-(AL#)J`F(:^WA)70*1"K*0%=P6P3Q\O0UQ&BQWMQ+X<@\(
M:0\)M;.\TN__`+3)?^SF+Q.WF?W^^U>`=W8`X`'>%M`N8=?TA;32)K5&B,5W
MJ.EJB:?J5GY9,<IPP9)LD8*C.2><'CU;1-!T[P]9O;:=$Z)(_F2-)*TKNV`,
MLSDD\`#D]`!2>'M"M?#>B6^E632FW@W;/,<L1DDX&>@&>!V%:=`!1110`5G:
MQKVE>'[9+C5KZ&TB<E5:0_>(&3@=3@`D^@%:#-L1FP3@9P.IKRW0_$4FOZYH
M6M:Y96<EK<Q2VUG<6A?%G/(%#VUPK=6^7`;@$\8Y%`&3KUM-XB\0'4+[3E\1
M6UM:O&;2UVAI+.9]\5W:\_ZP8V-@Y^3CK70>"/`=C<6%AK.OZ1(-:MI6\J:X
M)2:1$?\`<O.JMM:0*%.3GD=<U)\.=`US^S-&OO$5M%82Z9:"TL[:/_6^7M"L
M96[[B%8(.FU3G->BT`%%%%`!4-W=V]A9S7=W,D%O"A>261L*BCJ2:FKRSQEX
MMO+O4M=\/C3(KNQL8D:\LA(T5Y-`P5FG@/W6"\C'7(ZCB@`\<:BGB^PCLM'U
M#3[JQGEB1/,7>D=Y&_F)%.O]R4#;SC!"]=U1^%/#LNH7FM:/=^&KS2O#-]:C
MS]/N]NR&ZW<FV96/R$'=G`P0,5.FD7WB+Q/JRZ?!$GAC6H;:\GU!B2\H\K:J
MP\_*WRJV[^$@<9KT]1M4+DG`QDG)H`2-!'$D8)(4``L<DX]33J**`"BBL#QI
MKUQX9\)7VKVMLMQ+;A3M?.U5+`,[8YPH)8X]*`&>(O$UA8>9I$.LV-EKMS$1
M9)<'(\QLA,CW(XSUQWKR&:UNM<?4M;'AV[NKV[D&;C3MGV[2-1C41M&W(+0G
M"D<X`/(YS6SK#7VLVVNV-W81/XDGM;6]LY;)RUMJ$,$P<-$#RCX)4C)ZCJ*[
M_P`):#?6-UJ.MZL88]4U4H\]M:Y$,0484?[3X."_?`XH`;X3\)V6FP6NKW&G
MK!K<]N&N@LKLD4K@-*(U+%4RW)VXSBNJHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@"CJ^CZ=KVF2Z=JEI'=6DH^:.09'L1Z$>HJMX?\-Z?X
M:M);>P$Q\Z3S)9;B9I9)&P%&68DG```]`***`->BBB@`HHHH`1E#*58`J1@@
M]#7.:)X%T+P[J3WNF03PDAPD'VAVABWD%MD9.U<D#H***`.DHHHH`****`"L
M/Q!X2TCQ*UO)?PR+<VQS!=6\K1319ZA74@@'THHH`TM-TZVTG3;?3[-"EO;H
M$C4L6.!ZD\D^YJU110`4444`%(RJZE6`92,$$9!%%%`'-:3X!\/:'K*ZGIUI
M)#*@<0Q"9S##OQO\N,G:N<#.!VKIJ**`"BBB@`J&[M+:_LYK2[@CGMYD*212
M+N5U/4$444`8WA[P;H_AB:6334N09$$0$UP\HCC!)"(&)VJ">@K?HHH`****
M`"BBB@#F_$7@70/%%PMSJ-K(+D1F%I[>9H7>(]8V*D;E.3P?6N@MX([6VBMX
M5"11($11V4#`%%%`$E%%%`!1110!G:YH.F>(]-?3]6M$N;9B&"MD%6'1E(Y4
MCU'-)HFAV7A^P-G9"4JSF1Y)Y6DDD8]69F)).`!]`!110!I4444`%%%%`!7/
M-X)T,^(O[<2"6*Z,@FD2*=UBDD'1VC!VLP]2***`.AHHHH`****`"N?\0^"]
M$\37-M=7]O(MY;<175M*T,RJ<Y7>I!P<GCW-%%`&Q86-OIFGVUA:1B*VMHEA
MB0'.U5&`/R%6***`"BBB@`IDL4<\3Q2HKQNI5T89#`\$$=Q110!SVA^!-!\.
MZF;_`$V">-PCQQ1O<N\<"N0S"-"2%!*CIZ5TE%%`!1110`4444`%%%%`!111
80`4444`%%%%`!1110`4444`%%%%`'__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>graph5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 graph5.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`&G`I`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBF2RQP1-+-(D<:#+.[
M``#U)-`#Z*SO^$@T7_H+V'_@2G^-'_"0:+_T%[#_`,"4_P`:`-&J.LWDFG:+
M>7D*HTD,3.H?H2!WQ34UW1Y'5$U6Q9F.`HN$))].M0^)_P#D5]3_`.O=_P"5
M`!Y7B'_G[TO_`,!9/_CE'E>(?^?O2_\`P%D_^.5K5R-U?^)Y_&5_H^GWVD0P
M0V4-W$;C3Y9&.]I$VL1,HX,><@?Q=..0#8\KQ#_S]Z7_`.`LG_QRCRO$/_/W
MI?\`X"R?_'*R=*\<VLNGSG6(FL]0L[F2UNK>!)+C#)M)==JDF/:Z-N(`&X9Q
M6J_B?1TOK:S^UEY+@J(WCB=X\L-RAI%!12PY`8@G(QUH`7RO$/\`S]Z7_P"`
MLG_QRCRO$/\`S]Z7_P"`LG_QRJLGC?PY#%++-J2PQQA6WS1.BR*QP&C+*!(I
M)`W+D>]*/&>A-+Y*WCB47(M2KV\J;)6QL5R5^0-D;2V`V1@G-`%GRO$/_/WI
M?_@+)_\`'*/*\0_\_>E_^`LG_P`<K&\,>-X-3LH8]8:*TU-Y+H,D<<GD8AE=
M"%E8;6(5`2,@XYV@5>/CGPZF1)?/%)YR0B&6VE25V?.S;&RAF#;6PP!!P>>#
M0!;\KQ#_`,_>E_\`@+)_\<H\KQ#_`,_>E_\`@+)_\<J#6-=>WLM,^P@)<:K<
M+;6S7<#@1L49\O&=K<*C?*=IS@<5-X>U.ZU&UNH[Y(5O;*Y>UG,`(C=E`(90
M<D`JRG&3C)&3C-`"^5XA_P"?O2__``%D_P#CE'E>(?\`G[TO_P`!9/\`XY53
MQ-J.MZ5;R:C8QVDEG:[6F@EC9I9U)&[RV#`*0#P"K;CQ\O4U+GQ/>P7LEWLM
MQH\&HQZ;("K&9G<JGF!LX"B1PI7:20"<CI0!K>5XA_Y^]+_\!9/_`(Y1Y7B'
M_G[TO_P%D_\`CE<];^,-4,-MJ+6UK<V.J0W$FF6]N&$Q:-&D168G#&1%8\!=
MIX^;K5CPQXIO=36YGNS;7EBL,4L=WIUO)A7<L&@*9=BZ8!)&/O<JN*`-GRO$
M/_/WI?\`X"R?_'*/*\0_\_>E_P#@+)_\<K6HH`R?*\0_\_>E_P#@+)_\<H\K
MQ#_S]Z7_`.`LG_QRM:B@#)\KQ#_S]Z7_`.`LG_QRCRO$/_/WI?\`X"R?_'*U
MJ*`,&^N->T^T:ZDGTV2.,KN1;=U)!('!WG'7TK>K+\1_\@&Y_P"`_P#H0K4H
M`****`"BBHY[B&UA::XFCAB7[SR,%4?4F@"2BL[_`(2#1?\`H+V'_@2G^-'_
M``D&B_\`07L/_`E/\:`-&BL[_A(-%_Z"]A_X$I_C1_PD&B_]!>P_\"4_QH`T
M:*SO^$@T7_H+V'_@2G^-'_"0:+_T%[#_`,"4_P`:`-&BL[_A(-%_Z"]A_P"!
M*?XT?\)!HO\`T%[#_P`"4_QH`T:R;VZU)M72RL7M8QY'G,T\;/GYL8&&%7;7
M4+*^+BSO+>XV8W>3*K[<],X-5/\`F:_^W'_V>@!OE>(?^?O2_P#P%D_^.4>5
MXA_Y^]+_`/`63_XY6JV2IVD!L<$C(S7#Z/XY^RZ9<7/BB]M5<7EU!&+*QFXC
MMY"CR.`TA"\`EC@+N`)[T`='Y7B'_G[TO_P%D_\`CE'E>(?^?O2__`63_P".
M5!+XR\/PWTEF=15YXGBCE6*-Y!$9/N;V4$*#ZD@<CU%*GB[1));6,7,H:ZN)
M;6+?:RJ/-C!+HQ*X4@`GYL9P<9P:`)O*\0_\_>E_^`LG_P`<H\KQ#_S]Z7_X
M"R?_`!RJ,7C[PQ+;O.-3"1JT2CS89(R_F9\LH&4%PV#@KD'!P:FA\8Z/.EZR
MF_0V4:RW"2Z;<QNJL2`0K1@MG!Z`]#0!8\KQ#_S]Z7_X"R?_`!RCRO$/_/WI
M?_@+)_\`'*FU(ZI+;*ND/;0S,-WFW<+2(OH"@96R<^O&#UZ5Q]YXWU7[#I,D
M45E93WEE)<[;F*29;B5,#[/$59?F/)!Y)'13S@`ZKRO$/_/WI?\`X"R?_'*/
M*\0_\_>E_P#@+)_\<K2@=Y+>-Y(S'(R`LA.=I(Y'X5SEUK6KZ3K4']HQVCZ7
M<I.RK#&PFMO+0N-[%BK@J#T"X)`^;K0!H^5XA_Y^]+_\!9/_`(Y1Y7B'_G[T
MO_P%D_\`CE<Y+XTU'3+>-]3M[0S7]D+JPACW(%<O'&(9&);)W31_,`.I^7CF
M1_%&JVNI+X=N7T\ZU+<QQ17,<#B`1O%)(':,ONS^YD7:'Y(!R,X`!O\`E>(?
M^?O2_P#P%D_^.4>5XA_Y^]+_`/`63_XY3-#UJ2_@\J\B*7L<\UO+Y,;F(M&<
M%MW(4$8(#'/..<5LT`9/E>(?^?O2_P#P%D_^.4>5XA_Y^]+_`/`63_XY6M10
M!D^5XA_Y^]+_`/`63_XY1Y7B'_G[TO\`\!9/_CE:U%`&3Y7B'_G[TO\`\!9/
M_CE'E>(?^?O2_P#P%D_^.5K44`9/E>(?^?O2_P#P%D_^.4EK=:E'K*V-\]I(
MLEN\RM!&R$%648.6.?O?I6O63+_R-UK_`->$W_HR.@#6HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`K)\2\Z(ZGHTT"L/4&5`1^1K6K#\6
M3&'18B`#OU"QB.>P>ZB0G_QZ@#7^S0?\\8_^^11]F@_YXQ_]\BI:*`(Q;P@@
MB&,$=]HK-\3_`/(KZG_U[O\`RK6K)\3_`/(KZG_U[O\`RH`UJ\UU'Q(NG>.]
M4U"#6/!YS:1V`AO->\F2-HGD8EU$38.9"-N>-O7G`]*KA-9\4:EI_C2XT:37
M_#^FP?9(KFV^VVCM)*7=T*#]^FX@QY^4?Q`8]0#DGL?"J7<&JW'B/P9KNH2/
M<27L&I7L26\CRF/YH^)-FT1*HX.1GG)-;FF:UH.C7E];67B3PB-)U&1990FJ
M1Q-:D0I$5C0`JRXC7&2N,]ZWM5\57&GZ7/+!-I]Y=VEU9VE[$@=5A>5T1L')
MW??!`XP.I-7%\8Z(EY<0RZS:R-]L:SAABC;>)412\?!.]@3GY0,;@N,CD`\V
MMX_#VG>%Y=*L-1^'T=XD$=O'J*:E'%+<HK*29=L9*DA`2,MN/.1BK.I:G;74
MVN20^(_!?^GZI97T8?7@-JP"+*G$9Y)A7_OH^G/HDWC/08--M[]KR1X;A9&C
M6*VEDDQ&<2$QJI==IX;(&T\'%:NGW]OJFGP7UJ9#;SJ'C,D31L5/0[6`(_$4
M`>2RQ>'M3TIM#U+QEX933H9[VX@GM]4C:61K@3##(<!0GGMT9MVT=.13X;[0
M[2PM8["[^'=C<Q7=O+/)9ZJD0N$B;=D[8\@GLIR!DG=V/L%8<7B_09[\V4-^
M)9ENC9L8XG9$F`SL9P-JGTR1DY`Y&*`,7Q%XI\):KI8M4\0>&[AC*K#SM96#
MRL'[ZO&2P8=L%?\`>%0:7XM\*:!]CT^W\2:'<QW#RS7=TVJ)N$A^;=@DY!/'
M+Y``^]R1NR^--#B:[07$TDEM#)/L2VD_?+']_P`H[<2X.`=A..^*+#Q;IE^G
MG_;%MU2S%U/;W$#Q21*3@,V\#`X.,KSP1QU`,#6O&VG3W\0LM:\'W5E'MD`N
MO$"PL90<@E5C<$#@CGKSV%4;C5/#MQ>R6C^+_#1T>;4(]2<_VG&)1(C*_EA<
MX*ET#;BV>2,'K77IXQT22RDNDFNB(Y?)>$6,_GJ^T-@P[/,^Z0V=N,'/2M>S
MO+?4+*&\M)DFMIT$D4B'*LI&010!Y=!=Z*L%OI__``FOABUM-+AN(]+N+?44
M:96D1DC9E)`7RT8C@MN//R]*L^'M;T31[R^OCXA\(P23PPQ?9+;6E\J9TR#.
MQ*C:Y4@8"G[HRQZCT^LB;Q1H]OJG]G37FR?<$+&)_*#D9"&7&P/CG:6S[4`:
M<$\-U;Q7%O+'-!*@>.2-@RNI&001P01SFI*Q=*\6Z'K<\,.G7PN#-&\D3K$X
MCD"-M;:Y&UB#U`.>0>A%;5`!1110`4444`9?B/\`Y`-S_P`!_P#0A6I67XC_
M`.0#<_\``?\`T(5J4`%%%%`!6+K[![K1;,QEUN;\!L#(4)')+D^V4`^I%;58
MUV[2>+M+@"9CCM;B=FR/E8&)%&/<._/M[T`:GV:#_GC'_P!\BC[-!_SQC_[Y
M%2T4`1?9H/\`GC'_`-\BC[-!_P`\8_\`OD5+10!%]F@_YXQ_]\BC[-!_SQC_
M`.^14M%`$7V:#_GC'_WR*/LT'_/&/_OD5+10`U(XX\[$5<]=HQ6;_P`S7_VX
M_P#L]:E9?_,U_P#;C_[/0!+K6H#2]'N;TW%E;F)?EDOI_)A#$@`._.T$D#.#
MUKR^:\T\Z"VF0^-O#"0WIOI;V--86/;+.[.FUU^9U3<5(^3=U_V:]5U+[9_9
MTYL)H(;H+E'GA,J#!R<J&4GC(^\/7GI7'6?BW6=4\.Q^7]AT_7[>XMH;ZWN+
M=Y8]LSJBR1@2*=C;MP.3]TJ>02`#G;W6;69-42'Q%X+Q=06<<9?7@,&$Y;=B
M/OD@?0>N`7%_8R7L#VWC/P?`EMK,FIQR2:BLI821NK*4!7!!<X.[G@\8P?03
MXNT5;M[0WC/.HD`V02%96C!WI&V-KNN#E%)88/'%4]'\;:7K:V$T5ZEKY^G-
M?R6EU"R2K%E0)-Q(`0?,,X(;(*G`.0#S:>?SUN)Y?%WA"YO;J.P$[S^(01OM
MKAIF(Q'@!OE`4*H7)X.,MV.J>)O"EWXCTJZC\6:(@VLMX%OXBCQJ0Z#=N&")
M-N/4%^/3I(_%^BRP32I/<9BD$9B-G,)68J6&R,IO<%02"H((!/8T[4?$^GV'
MA.Y\1H9+JR@@:;]PA+,!VQV.1@YQCG.,&@##U_QQH\UHD.D^)/#$N]L3_:-;
M2W/EXZ*RJY!/3..!G'.".?UW5=&UFU@CDU[P8\1M6MWLWUH".T;<"LL3A<EE
M`'9#QP17567C6W.J75OJ6+6$S01VA\B8-B51M\W<H\HECM&X`9XR35N7QKH4
M<U["MQ-+-9QRR.D=M*=XB.)!&VW;(5)`(4G!ZXH`SM+\?>'4:2RN_$^ANMK'
M$B79U./-P=OS$@X`.1V+#D<@Y`S!XNTN]U2X&I:UX/\`L4R26_GQZ^KR)"P/
M"QF,#+$+N^?\\`5T=[XMMK7P<GB!;:<B4(L-O)&\3O*[!%3#J"`6(Y(QCD9%
M6+9_$%M)$^I2Z9+;L[&8P1/%]G0(Q'+.V_D*,X7Z>@!P$L^@ZI;(NJ>,O"XN
M+&S%K82QZBCAF#QR":125P=T,?R`GH?FYXEGU30=1%W>ZCKWA!]0O)H>(M=*
M+:1Q*VQDE7:[.&=SQY?#D9XR>S_X3GPVL%Q-+J0@2WV%_M$,D1*N2$90Z@NK
M$$!ER#ZTX>--`,OE&]='%R+5P]O*OER-C:'ROR!LC:6P&R,$YH`S=!U_PMIJ
M6>DZ;XCT2Z,\KF1O[41I9)I&S\JY8L69B,;N.`,UV-<_9^-_#E^\8MM2$B2I
M))'-Y4@B<1D[]LA782,$X!SCG&.:;'X[\-O"LK:@8-UPELJ7-O+#(TC@%`$=
M0QR#D'&/>@#HJ*Q+7Q9H]Y<6<$$MRTEXTB1`V4RX9,[U<E,(PP>&P:T--U&V
MU:PCO;3SO(DSM\Z!X6X./NN`PZ=Q0!;HHHH`****`"LF7_D;K7_KPF_]&1UK
M5DR_\C=:_P#7A-_Z,CH`XSQQ>Z!>>+]*TAKVQLM7@GANY;^YN%C>WB#9\N,L
M02TF-NU>,$ENP,.E)8:/\0G.GR:#K#WEY=R7DUM:K]LT[(9L22AV^7(V;2%/
M/MBO3ZBN;>.[M9;:8$Q2H4<*Q4D$8/(P1]10!X]XIU"SUK4-9OX)!-<W.DVL
MOAAV4K(TA9RQ@#`$-G9NQSC&>*@:.]>]1]/Y\7QZEJ/VID(\\6^R;R@^.?+S
MY6T'C.,<U[5##%;01P0HL<4:A$11@*H&`!3Z`/+OAV+0^(;9]#V?8?["B&I^
M63_Q^[Q_K/\`IMC?NS\W3/:O2KE+M]OV6>"+&=WFPF3/IC#+COZU/10!F>']
M1FU70[>]G5%EEW9"`@<,1W)]*TZP?!G_`"*=C_VT_P#1C5O4`%%%%`!1110`
M4444`%%%%`!1110`5A^*XFGTJUB0@,=3L7R>F%NHG/Z*:W*R=?YMK-1R3?V^
M!])%)_0&@#6HHHH`*R?$_P#R*^I_]>[_`,JUJR?$_P#R*^I_]>[_`,J`-:N:
MBTG5#X\OM4N+>P;2[BQBLQ_I#-+\C2/DH8]O)D(QNXVYYS@=+7.WGC*QL;[4
M8);.^$.FHLEW=-&J11*59@<LP+#Y<?*#R?K@`QM?\.>(]2?6DM8M*\J[NK*>
MW,MW(K8@='(8"(X)V`#&>M5W\,>*3XE-\+;1OLO]N#5!F^EW[!;?9]N/)QG'
MS=>O'O6II_Q#T_5[&6?3-.O[^:*80R6UH8)F3*%PQ=9#$%P#SOZ_+UXJ_I_B
M^QU1K8V5O=30S6L5UYRHN(TD^[N4MNZ9)(!`P<GID`X.\LM2T./3[34;K1=/
MO7GOI%F_M,P*\<\PD\H2R6[`DEB"H7/R*P9>E>EZ"%30;&-+1+1(X5C2"-BR
M(JC:`I(!*X`P2`<8X%8TOC_2;?0(]9N8YK>UG*BU,\D,8N-P8KM=I`@R%)PS
M*0,9P>*=I'CO3-=-K_9L%W<B:+S',8C(@'F&/YL/\WS*PRFX8&<X()`.HK@I
M/#?B5K[4I%M](\JZUN#44)O9`PCC5%((\GAB(@>N/F//&3L3^+;5M)FO/LVI
M0VPD$4=Q%$DF_+A`RX+`#)YW@$8.0.,D7C6QFU&2T2RU#;#J']G2SO"$2.8J
M"N=Q#%6W``@'J#P""0#&LO!&I+INGZ3>269M-'BFCL+B*1C)+OB>)?,3:`NU
M'.<,VX\_+TI]QX8\0WV(YCID"_V7';B6.:20K/'('7Y2@W)D`'D$^@K5M/&M
MO?:]:Z7#I6I;;L3-!>,(A"ZQ$*[#]YOP&91]W)SD#'-=-0!Q.N>&]6\0G2[_
M`%'2]!N;JQ:16TZYE::VE1P`6WM%E7!52/D./F&><CK-.M5LM/@MDMK:V2-=
MH@MEVQQC^ZHP.!]!]!TJU10`5Q=SX5U2:>\L"]G)I%QJ2:FLIE99T=760Q;=
MA!!=/O[@0&(P<9K>\4:R_A[POJ6L1VK73V=N\PB#!=V!GDGMW/?'0$\5@1>+
M;RQUK4!JEK=FT"V;)$D,8^Q"4LI\Q@Y#_,!G:6QD<8R:`$T70?$5G=:(UW;Z
M4L5F]VTYAO)&;$S%EV@Q#.,X.2*[:N7L?B!H&H>)O[!M[E6NR\D:$2QD.\>=
MZ[0Y=<;3RR@''!-=10`4444`%%%%`&7XC_Y`-S_P'_T(5J5E^(_^0#<_\!_]
M"%:E`!1110`5CVY>7Q??L0/*ALH(T/?>SREA^0CK8K&T57?4M=N&8%9+T)'@
M=%2&-2/^^@Y_&@#9HHHH`****`"BBB@`HHHH`*R_^9K_`.W'_P!GK4K+_P"9
MK_[<?_9Z`+E\+AK"X6TCBDN#&1&LLA1"V.,L`Q`]\&N6O/"5YJ%MH%VTL-EJ
MVGR6ZW'D2%XIX$D1FC)*@G[@93@$'O@DGJ;^[2PT^XNY5E:.&-I&$,9=R`,_
M*H!)/M61I/B*&\-I:PQ7]T3:PR274BQ`C>H*^8%(PQ!R2J[1R,C@4`9-GX2U
M-#:Z?=RV;Z=87\U];7"%O.;?YN$9-N!M\TY8,=P'09-9+>`M=N=/TS2;F33E
MLK?0)M'FGBF<R`N(P'5"F#_JE."P^^1_#ENC\3^/]#\)74=OJ4W[TQB5T66)
M6CC)(W[7=6?D'A`S<=*%\;V[ZI<Z<NCZHUS;S*C(JQ,6B92PG4"3+18'4#.3
MMQNR``4M:\.:QXDL]/?5;#1)KC3KGSDM))&EMKH&-D;?NC^0_-D`*VT@<GMH
MWOAQKSP!?>'[:UT_3)+JTEA6&T7$$+.#TPJY&3R=HSR<573QG%JEDHL+>[M)
M+VRDN+"ZN[<&*0J,D;0^[(R#AMN1G!.#532?'<<7A;2;O48;RZ<:9;76IWD,
M:>7;&2-6W.,@\\G"*<#D@#%`%75O#GBO4(=25;;1=UU=V4Z$WLHVB!E<@_N3
MR2@'XD]L&R_AGQ#?:J]WJ%S:/^ZO+=2MQ)@12@>7B/8%!7`!Y)/7=VJS?>.+
M-K/6##::RD-A(UM/>P6R$QR84@JKDD\."&*%,#).,9M1>-;&;49+1++4-L.H
M?V=+.\(1(YBH*YW$,5;<`"`>H/`()`%OO#MQK/@J+2+V:&WO4CB9)8,R)%-&
M0R,,X+`,HSP,C/2BYTW6]>T:^TG65L;2"YMY;=Y+*9Y6D#H5SAD79C.<9;Z^
MK;3QK;7VLV]A;:5J4D-Q+-%%?8B$+F$E9.LF_A@1]WG!(R.:T9=>@BU::P^S
MW#B!`\\Z[-D6>0&&[=TR<A<<=<\4`<EJ/A/Q'JEAYMPFD_VG!9+80%+F012(
M9(W>1OW>5)\I<(`V.?F-)JGAGQ+/)KLT<.CA;[4[*_3S+Z1=B0"+(;]R>3Y(
M_P"^CZ<V[;XI:)?6U[-8V]U>&T196CMY;=V:)FV^9Q+A0#C(<JP!R5%7M<\>
M:?X>FFBU"TN(BK*D323V\:SDIO8(SRJ,J",[MO48SD4`<IX3L[WQ+H%O/IE]
MIJPZ;J>HW%I.DIE8SN]PJ"1`,!0)@_#$L"O`')U%\+>)DE:?&GS337=E=2F?
M496(,))<`^5WPN,!1R>!CYMBQ\=Z=JLZ1Z99:C>@VL=XSQ0!0L,@;:WS,"W*
MD80,<\8X.,_5_%]])IJR65K=:5=6^IV4%U!?PQL[PS2*ORE'91D-UY(VD8'4
M`$<^GW<-K-9WEQI]KK4VJ-?:8MM,99`&8*S;653PKL&(R`&/-=S;P1VMM%;P
MKMBB0(@]`!@5)10`4444`%%%%`!63+_R-UK_`->$W_HR.M:LF7_D;K7_`*\)
MO_1D=`&M1110`4444`%%%%`&#X,_Y%.Q_P"VG_HQJWJP?!G_`"*=C_VT_P#1
MC5O4`%%%%`!1110`4444`%%%%`!1110`5EZW_P`P[_K^B_K6I63K7_'UHP_Z
M?Q_Z*DH`UJ***`"LGQ/_`,BOJ?\`U[O_`"K6K)\3_P#(KZG_`->[_P`J`-:N
M8O?"EQJ5YKQN]23[)JEO'"D<-N4DMRF=KARY#'+$_='0>^>GKDVOM1\0^*M5
MTFQU*;2[321$LTUO'&TLTLB;\?O%90H4K_#DD]1CD`=>>&]:U2RLH-1UVUG,
M$P:95L&2*XCVE2KIYO)YSR2N0/D.*IV?@*>UMO#\+:G;,VCI%&+E+'9.RQXP
MJOO.U6Q\X(8$'C;UK1N?$4NA(]K>Q7.K7L2/<S#3X5#16^]MCLK,,\#&%R6*
MD@>D$OQ"TA/-DB@O[BUBDMTDNHH/W8$^/+89(+J2RC*@]1VR:`*B_#XQ74M]
M;:A;VM\+F.ZMVM[+9$LBJZL\D8?#LZR,&(V9&W@$9K0U'PO=:O+I\][?6;W%
MK(DAF2QVNA5B3Y+;]T>[@')<8!]:C/CZQ%^FG?V7JO\`:+W,EJ+40IN\Q(A+
M@OO\L;D((RW?G&#AQ\=6GV"WOH])U66U<E;B18DQ9L)/+99,N.5;.0FX@`GI
MC(!5O/`]U.FI&UU.SM)[T1AI(]/P&*LK%Y%$@#N2,!AMP#C!ZTS_`(0W6_M%
MY,VO6)-SJD.I,JZ8PP8U1=@S/T(C3GZ^HQH1^-K.:]:WBTW4V"WCV)E:`1KY
MRIN"_.P;##H<8]2,C,MCXG&L0V:VVG:A"]X;A"S-!NM3$VQC(`[?Q<#`;!Z@
M4`<UX.L[M=?:]:"197:03PW.EW,#6P=BQ"2/*83E@N[R5PQP?>O1JPXM8:QO
M+31;E+J^OQ;)+<3QK'A06V!F'RDY(/W%P,$D*,5N4`%%%%`&=KVDIKOA_4=)
MDE:)+VW>`R*,E=RD9QWZUSM[X0UN\;4S_;]FIODMTR=-8^7Y3;O^>PSDDCV&
M.IY/9T4`<_H>@7VA3201:G$^E-++.ML;8^8KR,78"3>1LW,Q`VYY^]70444`
M%%%%`!1110!E^(_^0#<_\!_]"%:E9?B/_D`W/_`?_0A6I0`4444`%8WAA6_L
M7S6?>;BYN+@-_LO,[+^`4@?A6C?7(L]/N;H](8FD/X`G^E5M`M/[/\.:99DD
MF"TBC)8Y)(4`DGN:`-&BBB@`HHHH`****`"BBB@`K+_YFO\`[<?_`&>M2LO_
M`)FO_MQ_]GH`MZA!-=:=<V]O*D,TL;(DCQEU4D8R5!&?ID5S5AX,N+=]$DNM
M0M9YM,C2/[2ECY4SJJA0H<.=JG!+*0V<\;<5T6JZE!HVDW6I7*RM!;1F6011
MEVVCK@#K6,?&UA&\D=Q9:A;RA(7@CDB7=="5MB>7ACSN(!#;2N<G`YH`GOM!
MO#XA_MG2M0BM+B6!;:Y2>V,R2QJS,N`'7:PWMSR.>0:HWGAW51J*:S_;4*W5
MM.S[TT]W9K3'_'N563YCD9W`<G&%%3P^-+.=_LZV%^+];@V\UBPC$L3!5<D_
M/M8;65OD9L@\`G(J=O%-O_I^++4#'9*?-ECB#X8(7*A%)?(&!RN"2`"><`'-
M>%=!U/4?#EA/<WK6[6UI+#:6USIKQ/;R.-K-(&8,^!D+C8,$_>X-6;/X>W-I
MI(TO^VHWLKC3XM/U",VA'GI&GEAHSYG[MBF%).X'`(`J*W\8WFGZG>R77VW4
M=)BTBSOXS';QB:%'\P222X8!C^[W$(.^%7C-3ZWXKF-O/+HMY(C6NL65G<K<
M6PP4E:,$1YP<$2*VXY]NH(`)9O!>IR:;XELX]:M8AK,XEC==/8_9@$6/&#+\
M_P`D:8/'.3@@X#!X-UO[1=S-K]B?M.JPZDP&F,,&-479_KNA$:<_7U&)I_&7
MV>YB2TLM1O?M.LMIQ61(XO)98MYVABI*D*S`MDG+<XV@LNOB-H>F:6+R>>X<
MS7-Q%'#<-#;R9B?:X`E:,84\8)W'W-`&?X9M+Y/$LEV8W\QYI3+!<:5<PF!'
M=FRLK2F`GA<F-,MQGN:Z'5_"J:QK$%Y-+`J1[E)6VQ/L*@&,2AAA#SD$'.1C
M&*?I'BZPUVX5--AN9[=HXG^U!5"+YB>8H(W;Q\I!R5QDXSG(K+\5:YJD'B2P
MT6R-U8P36L]U+J$:0.J",H.5D;.P;\M@!CE=IZD`&II&@7MIH[:1JFIQ:E8K
M`;:,?9?+<QXQB1MQ#MMXR`HZ\>E,^$;R.#2[BWUA1K-@7S>S6N])U<!75XPX
M."$3HP(*#W%,E^(.GV=I)+>V&J0,+?[3"C6ZEKJ+(7S$"L<#++D/M*@C(%=-
M9W$EU;"66TGM&)(\J<H6`!P#\C,.>O7//.#Q0!S[>&=6DUW4M3;78T-YIJV*
M^19[)(2I=A(K%R"0TCG&WIM&<@DY$OP\OS9SQ6^LV,$D]Q:7,KC36(:2!MV?
M]=D[B$SDD\'GD;>_HH`!TYZT444`%%%%`!1110`5DR_\C=:_]>$W_HR.M:LF
M7_D;K7_KPF_]&1T`:U%%%`!1110`4444`8/@S_D4['_MI_Z,:MZN?\(2)#X.
MM))'5(T$C,S'`4!VR2?2MR"XANH5FMYHYHFSM>-@RGG'!%%NH$E%%%`!1110
M`4444`%%%%`!1110`5@^()'75_"\:MA9=497&.H%I<,/U4'\*WJQ-;A\[6_#
M9W8\F_DEZ9S_`*-.F/\`Q_/X4`;=%%%`!63XG_Y%?4_^O=_Y5K5D^)_^17U/
M_KW?^5`&M7/WOA^]36YM7T34HK*YND1+J.YMC<0S;`0K;0Z$,`<9#<@`$<"N
M@K%N/$D,.K_V?#87UWY<L<-S/;1J\=L[@%1(-V[H0254A003@<T`4;SPK>R:
MG_:5CK/D7<UK]DO&GM_-6:/<6!4!EV,I9\'D8;D-69=?#Z\:SO;&QU>UM;.9
MK+[/&U@SF%;8J44GS1NSL7)P.]:#_$#2HE\Z6UOUM)89)K2Z6(/'>*@W-Y6U
MBV<`L`P7(!(R`35?4?B%%:V-Q);Z1?O<Q"T=(9!&ADCN)/+1QE^F[(P<'/4`
M<T`8FK:)K.F^--/NX[SSY+_5VNQ+#H\TD5I_HC6X\PJY!4_NAR4Q\QZ?=T[S
MX=27%L;=-70Q,KR,EQ:>8!<M*TIF4!U`)9L8.3@#!4Y)T7\:V%M<7"20:J\J
MW\5@T'V7/E2NBD#(_APP.XD@YX)&*EM_&<%S-%`NDZD+B1+G$+"(,)("`\1/
MF8W'(P<[3G[PH`J-X5U=;B2<ZW:>6=5&IE!IKDX"[?+_`-;SP!SCKV[5I:#9
MQMJ&I:M$ES'#>.K11W$;1E?E&Y@C`,FYNH('*Y[UC/\`%7PW&NF-(\D8OX(I
MP))(5:%)#A-R&3<WOL#XZG`I]YXJN[CQ;X?M=.65-+N+V>UGF>%2EPR12DA&
MW;AM:/!RHW=B0#0!JZ]X:_MN_LKDSV\7V61)%=K;=,FTDGRY`P*%N`<AA@=.
M:WZ*K7]V;&QEN1;7%R8QD0VZ!I'/0!02!^9`'<@4`6:*YR/QA#+9+)'I6I-?
M-/);C3@L7G[D^]SO\O`&#G?CD#J<5E7OCS;/J4$NEZO9VL&G6]T+J.%#-&9B
MZ@&-L[2-O\2D`JV[`QN`.XHK!G\3^3/JL(T;4I)-/,0VH8<W'F'"F/,@R.OW
MMO0@9/%9S^,V6[TV*TT[4+M;_5);%_-6.)H"D;,<*Q4D?(3SS@-R3M!`.OHK
M"TWQ.NII:%-*OXGN)YH'CE\K=`8R0Q<"0\9&.,GD<<UNT`%%%%`!1110!E^(
M_P#D`W/_``'_`-"%:E9?B/\`Y`-S_P`!_P#0A6I0`4444`8OBU8I?"U_:SD"
M.\069R<9\YA%C\=^*VJQO$)CD;2;.3!^TZC%M![M&&G'Y>5G\*V:`"BBB@`H
MHHH`****`"BBB@`K+_YFO_MQ_P#9ZU*R_P#F:_\`MQ_]GH`9XJ9AX2U<)#-,
M[6<J)'!$TCLS*0`%4$GDBN<@\)76MZ;!?7NK2I>K#;_876R,#6PC<2#>CDLS
M$@!L[00.%7K78:E?Q:7IMS?SK*T5O&9'$49=B`,G"CDUS<WQ"L((+J5],U4+
M;6D=_)^Z3/V9\_O?O]!M;*GYOE.%-`"W?@V6_L[L7=W97%Y>2++/)+8;H@RJ
MBJ8T\S<A55.#O)RV>>E)<^#+F35$OX-3MXIH[9X!*;+,TI*%`)G#CS$&=VW`
M.X`[L<4ES\2O#UMKSZ099)9UWKF`I(3(J%R@C5C+G`/.S:3QG/%31>.(+C3;
M.]M]&U27[=%Y]I"HA$DT0169QF0``!@/F()/0'B@"G#X&O8K:.$ZXA,NEQ:5
M>N+/!EBCW[6C^?\`=OB1LD[AZ`5%?>`]2G.IK:ZW:017FH6M[&C:>S^5]G"!
M4SYPW9\J/)XZ-ZC$R_$72SI+ZU+;:O#;)IRWY@-LK9B=L*P*DY.!DX;"@_-@
M]-)O&%JBW:OI^H+<P311);%$\R<R_P"K*?/@`\_>*XP<XH`H_P#"':@]V]S+
MK41<:P-4@V66WR_W1B:,Y<[OD.0W&&YP1\M0V7@?4K"=;Z#7+8:E'=W<T<K6
M#&/R[AQ))&R>;EOF`(8,",#KSG9T?Q5:ZKHU[JLUK=:;;64DT<YO3&"IB)$A
M^1V``*L.?3TP:H3^/]/M(+E[W3M4MI(8%N8X7@5GN(2P7S$V,1@$C.XJ5R-P
M&:`+,GAB2?Q%8ZQ-=VYFMLDR):;)G&W!3S`W^KSD[2&[<\4FK^&KK5O$EMJ#
MW]NMC'9SV<EH;5B\B3;=Y\SS``?D7'RG'/7/&E+JTL&D/?R:3J'F!MJV:(CS
M.2VT8"L5`.0<E@`.6Q@XRU\:VTMI&]OI>I3WS&8'3D2,7"^2P20G+A,`D#AC
MG(QF@#-NO`FHWFE?9KC78);F&S:QM+E[$YCA8H6+J)`'D(C4;AM''W>:[6(2
M"%!,RO*%&]D7:">Y`).![9/UKGKKQKIUK*5:WO6B22*&:981M@FEV[(W!.X,
M=Z]L#(R02`6KXVM#+9QOINHI]IOI[#)2,^7+$&8A@KDD,$;&T'ISC(R`=-17
M)VOC>TE>QMK:QUB]GN[5[Q/]&1&$0D"MDDJN5W#Y1EL8XR1ED7CRQ$5M'#9Z
MQ>SSV,FH(OV948Q*^&!)*H&&1\N<XQGDC(!U]%<IJ?CVQT^-)8=-U*_A*V[/
M+:K$%C\\A8@WF.O+$CID#/.*ZI22H)4J2.AZB@!:***`"BBB@`K)E_Y&ZU_Z
M\)O_`$9'6M63+_R-UK_UX3?^C(Z`-:BBB@`HHHH`****`/-M1NOL_P`)[6+9
MN^TS>5G.-N)&?/O]S'XUT_@3_D3-/_[:?^C&KSS5V-WHFA6,*,TT,%S<-T`V
M;V)[]0(V/Y=:]#\"?\B9I_\`VT_]&-79./+AEYO_`#.:+O7?H=%1117&=(44
M44`%%%%`!1110`4444`%9.I#=K>BJ.HFE<_3RF'\V%:U95\1_P`)!I*YYQ,<
M>VT?XB@#5HHHH`*R?$__`"*^I_\`7N_\JUJR?$__`"*^I_\`7N_\J`-:L%=!
MO+77[R_L-1BAM;]TDO+>6V,C,ZH$W1OO`3*JH.58<=JWJXS5_&/]C:YJD9T:
M\F:U%C%O%TH219Y'17"%L+A\J3C<>,_*`:`&1^`KF+3(]-75X6M+&.6/2Q)9
MEFMO,5D^<^8/,VHS*O"]>=QJ*Y\!:G>3327&NVIWV5G;1B/3V7:UM*)D<YE.
M06W97C@@`C&3?B\7W<\L]A%I,9U:._>R$)NL0_+$LV\R;,A=C*.$)W'&"/FK
M/U3Q!JND:Q-J,MO(P324FDTR6Z`CB;S@K%653EL'OUQVH`L3>#-7?4+^ZCUZ
MU'VK4;:_P^G%BODHJA21*,Y$:9.!_%QR,20>$-4BODO#K=N9TO+B<%;`@>7,
M`&3!D/S`@$-TXY4U8N/%LUO?WVG_`-GQ->1WD5G9I]I(6X9X_,!8[/D`4,3P
MWW>,UCZ+K6HPS06U]9ZA>7+ZE?!'^V*`K1HQ6/`*AP1D+N`4<,<,!0!<\/>!
M]0\,):QZ=X@W1+:QVUTMS9AS($)V,FUE",%.WD."`,@G)+XO!-W%>6!7766R
MT[47OK6%+5?,`</OC=R2&7]XP!"@@'J3@BM;_$;?IL>HW&C2QVT^CR:M;K%,
M))'2,J&1EP`#\ZD$$Y&<XQ6UX?US4]4U#4;34-,L[3['Y8WVU\UP)"ZAN,QI
M@8(_PQ@D`Z"L_7-/N-5T>>SM;YK*:3;MG5=V,,"00""00"#@@X)P1UK0HH`X
MVU\$W>G!9=.U2UMKJ*[DN(2+#,0615$D;()`6!*[@0RD$#.><NUKP;?ZH=3E
M@UN.VGU&QBM)G:S\P#8SL&4;QC_6,,$GHO)Y!["B@#&FT-[C6;+4I+I0T4(C
MNHTBPMP5.Y#R25"MN('/WNM94?A&^6YBN9]8B:2WU6348O*LRNT/&\;1D%SD
MX<D-Z]CTK3\8:I>:)X.U?5+!(GNK2UDFC$Q(7*C.3@<XZX[],CK7.KKNLZ1K
M>JSW=NUU"$L6GB^UYCM1(61A#^[!?G!.X+D9YX`H`W-"LXI=9U'6H8[J*"[V
M".*XB:([MH#N$<!EW;4!!`SY><<Y/0UR6D^./[7\0?8+?2+TV32S0I?"";8'
MB+*VYC&(PI*D`AV.>"`:ZV@`HHHH`****`,OQ'_R`;G_`(#_`.A"M2LOQ'_R
M`;G_`(#_`.A"M2@`HHHH`QK]EE\4Z/;$$E(KBZ!QP-H2/K_VU/ZULUCQ,9O&
M5TNT[;:PBPW;,DDF0/?]VN?J/PV*`"BBB@`HHHH`****`"BBB@`K+_YFO_MQ
M_P#9ZU*R_P#F:_\`MQ_]GH`L:M9RZAI%Y903I!+<0M$LKQ^8$W#&=N1GKZBN
M.N_`.JW5O?0G7K-?MFBQZ.Y_LUOE52V7'[[J1(_';CK@Y[>[EE@LYY8+=KF9
M(V9($8*9&`X4%B`"3QDG%<A;^.KR5S;G18I+M=02PD^RWZ2PHS1APQ<JI[X(
MVY!!Z\9`+.F^%]9TF&\@M-<M!!=%IF1]/)V3N,NRGS>$9LL4.3R<,.V%J^AW
MFD^'O#FB2W4LL=A"T1O;;2KF4':H5%*6\HE4E<Y.[:>01R`.FM/%L+>$[_7=
M0MC:C3VN4NHHW\S#0.R-M.!N!*\$@=>@K,O_`!U?Z/,MMJ/AYA<2/`8A;7:R
M(8Y9!&&9F"D,'905`/WA@D9(`(+WP=K.M:;-%_:EAI\5SI9TQH$TQL+'N.'4
M>=\N5Z*<[<\YQ4'B/0]7MX;JZN;U;M+YK2*3['I,SFW\K<?,VQS>:06/\!#+
ME3G`)JW??$"XL)IM.ET8MK4<[1BUADFG1XPBOY@:*%GQAU'^KX8X/'-6]+\8
M:EK&I2VD'AN>W,%I!=R+>SB*7$JOA53:?F#1E?F*]STQD`ET+1EN_!UUHU]$
MILKE)(MR6TMLTJ2#YV9)7>0.2S9+'<3DFJ=UX(U*^TN:&ZURWEOOL?V"WNS8
M$>7"64MN42?,[;%RP*CC[O6J\WC76YX)(;33=+74+?4;6UF1=2,L6V7!QO$6
M0W\)!7@<C/`J_!XGF$UQ;V^DR_VE<:G+:QP7-Z3&2D(<N6PWEH5`^50>3G&2
MV`#9UG3+W5-#-G%J(M+HF,M/'$=K%6!92NX':V""`P.#UK!L_`]SI4\5WI6I
MVUO>0O<;"UB6A\J9U=T,8D4\,H((8>^:AC\?WEU<_8[7P\_VQ;6ZFD6XNEC1
M9+>01R1A@K$]00VW!#+[[>PT^\34=-M;V-2J7$*3*&Z@,`1G\Z`//_%^A7^E
M65Y<VUU=7EOJ&I6-S/9V^G/-+YL<D6]PR9VILAR05Z@`-SM.O-X+NY[Z&YBU
MLP0PZJVJP1BS&\,Z,K(Y9N0=YZ!2`2.N".RHH`XO1O!VLZ7J>F7<NNV5PMC:
M3VH0::R%Q*ROG/G'&"B=N@/KD06G@?7;62S?_A(K!S:V-S9+G2V&1,P8L?W_
M`%!1/P!]<CNZ*`/+)=$O[;7+6TEW3S6%O;PP%]&N7@O#$NY6+QS")<-T\[)5
MAD8!%>I+G:-P`..0*6B@`HHHH`****`"LF7_`)&ZU_Z\)O\`T9'6M63+_P`C
M=:_]>$W_`*,CH`P/%;7%UXATJQT:_O5U@3Q3R)%.PA@M0W[QI4'RD,`57<"2
M>F`"1@:;JNIOK6D:C)?7?VFZUV]L;NV:9_)6WC$NT>43M7;L0[@`>>3@UW]Y
MX9T#4;X7U]H>FW5V,8GGM(WDXZ?,1GBI)M"TZ26[N(K2"WO;J(Q27D,*+/@C
M'W\'..V<T`>=>*==N;B]\2W^GZM/LTO2[6[TK[)<L(I7D:3+%5.V4,55<-N'
MI@FJ<^N:Y`EOK-O=WDFIRZGJ-K+:&1VB\J))BBB$G:,%(SN`!.>20:].A\-Z
M+!'IZ+I=FQTZ,16CR0JSP*!CY6(R.G:K$>DZ=#J$NH1:?:I>RC;)<K"HD<>A
M;&30!PW@J\NU\16-M'J5W?VE[X?AU"Y>XN#+MN&<`,N2=@<%_E7"C9P!7;:E
MJG]F^5_H-[=>9G_CUAW[<8Z\\=?T-/L-)TW2A,-.T^TL_.??+]GA6/S&]6V@
M9/N:N4`>1:#I,MQK5FE[<&.#4+"YCL&!+8<;E=2.P`9V[`DCG.17:?#VZ2X\
M)01H&#6\CQOGN2=_'MAA^M8S6TH^'%AJUFF;_2G>ZA((&5$C>8K'@[2F<@$9
MP/I5WX8,&\,SL.ANV(_[X2NCG<J33Z6_4QY5&HFNMSM:***YS8****`"BBB@
M`HHHH`****`"LF[_`.1HTO\`Z][G^<5:U8%XQ_X6!HR9.W^R[YL9XR);0`_7
MD_F:`-^BBB@`K)\3_P#(KZG_`->[_P`JUJR?$_\`R*^I_P#7N_\`*@#6KDM:
M\!0:UJEW?R:[JUL;H6X>&#R-@$#^9'C=$QX?+=><D=.*ZVN2U;QE=:7/JS-H
MQ-EI/EO=3O<A6,3#)>-`&W8P>"5/!^A`%'@2`75U>#6]6%Y/>B^2X#0AH)-G
MEG8/+VE2F%(<,,*#P<FI[WP9;ZC<337>JZE+YUD;*1"T0!4MNW\)D-NYX.!T
MQCBH!XTD,\5PNEE]'ENY+&.Z2;,OG(S)S%M&$+(5!#$YQP`<U6_X6!&-%MM2
M>'3TBFN%@:4ZA^XMR=Q(E?9F-@%`P5QN8+GO0!;;P'8O-<74FI:H]_-+%.+Q
MIUWQRQIL#HNW8"5)!^7!!(QCBF#P%;QW<=U;:[K5O.ES-=[EFC<&61"C'#HP
M`P3A0`.>G`QB^)O$%Y+=3I;1W^GW5G-I,C&.[5H[J.><H4"@D`<N"PVLVT9R
MH&=H>*;B2]2PO=(>*ZCU..TE-O>9C0,GF))NPK,I'&W;UR#QR0#/G^'SZ;I4
M`TO5M7GFL=.DT^VA:6!,Q2$;OF\H?,-JD'(Y10>"V=7P;I5SI5O+&8;RVM&.
MY;:[BLXW5R3D@6JA,'CDDD^V.<71->NXY;"RNUO+^2XU[4;6*[>Z\M8S$9MB
MN%^\"J$8V[1C/4+5S1?%>NRQZ2^KZ9IL-KJ#2J+J*_<[64,P4H80!D*<?-T!
MYS@$`[:BJ6D75W>Z3;75]:QVES*F]H(Y3*$ST&XJI)QC/`P<CGK5V@`HHHH`
MIZMIEOK6CWFF7>_[/=PO!)L.&VL,'!]>:P+KP,EV;XOX@UA?MJ0K)M,''E'*
MXS$<<DD_7'`P!U=8FKZW=VFHPZ;IFG+>WTEN]R5EG\E%C5E7[VUOF);@8QP<
MD4`&E^&XM'O));34+U;61WE-B3'Y(D<Y9QA-PR23C=MR>E;=>?KJ&H>,->TE
MK?S[/2)K`7J-%J$EO.C%E^^BH58@Y78S%2"3UP*]`H`****`"BBB@#+\1_\`
M(!N?^`_^A"M2LOQ'_P`@&Y_X#_Z$*U*`"BBB@#&T=GFUC7IG3:JW:01MD'<B
MPQG/M\SN/PK9K&\,^8^ES3S;=\][<R#;G[GG.$Z]]@7^G%;-`!1110`4444`
M%%%%`!1110`5E_\`,U_]N/\`[/6I67_S-?\`VX_^ST`6=4T^+5M*N].G:5(;
MJ)HG:)]K`,,'![&L$>!X$EBD36=31TN(KEBH@`=XTV#(\K`!'4+@>F*ZFB@#
M`TSPG9V&AW^D7%U=:C:W\LTD_P!L\O),I)D'R(HP26/3C/'&`.?\3>$[N'0/
M+T_^U=:O7N;159YH%D@@BF64A2VQ?X3R<L25R2!D=_10!S!\$VKA+D:EJ4>J
MB<W!U(/'YY8H$((V&/;M51MV;>`<9YJ0>#X3J&J7<VK:G,=2LA93(SQJ`@W8
M92J!@P+N>N/F/&``.CHH`Y>+P/:11,@U/422ULX?]RI5H&RI`6,`9Z$8QCH`
M>:;_`,(+:^9--_:^J?:6OOM\-P7BWVTI3RSL^3!4I\I#!@>O7)KJJ*`.4?P)
M;?;8[N#6-4MY%MYX&\LPG?YS;I';=&3N+!3UP-H``&0=K1]).CV4-HM_=7,$
M$$<$:W`C^4(",Y5%))&`<\?*,`<YT:*`"BBB@`HHHH`****`"BBB@`HHHH`*
MR9?^1NM?^O";_P!&1UK5DR_\C=:_]>$W_HR.@#6HHHH`****`"BBB@#!\&?\
MBG8_]M/_`$8U<]\)YXAH=_8AOWT%T7*X/",HVG/3G:WY5T/@S_D4['_MI_Z,
M:O/]!5=`\;^;"TGV=;\Z7+DAF=9"WE\8&,-'ECGTP.N=8QO"3[6_K\C.3M-(
M]>HHHK(T"BBB@`HHHH`****`"BBB@`K&GB5_&MA,<[XM.N57Z-)`3_Z`*V:R
MG&[Q;$?[EB_X[I%_^)_6@#5HHHH`*R?$_P#R*^I_]>[_`,JUJR?$_P#R*^I_
M]>[_`,J`-:N-?P_<ZOXKU@WT.H6VES+`/EEA\F\"`Y5@"S@9/^SD9!XXKLJ\
MYU>XFTWQGXFGMX(;H/8Z<TL-W(S1X:65&(7D#@#Y1@$C/4G(!TL7@^R@OGGB
MN[U+8SO=+9*Z"%)VSF1?EW9RQ.-VW)SC/-(OA&-)+^9=7U(75[M$D^8B0BA@
MJ;?+V,`';EU9CQDG`QGW'B36FO&FM8M/&G#5%TS;(',P.]5,N0<==P"8Z8;=
M_"8+'Q1KUQ#I)*:;)+>6UZ73RWC4S0MA2&W-M0]QAB/7M0!97X=:8KS!;[45
M@>UMK:.W5XPD(MV#PLAV;MRMD\D@[CD$8`NR>#X95@8ZKJ*W*7B7LMR#%YEQ
M(JA5W_N]H7:`,*%%<3JFO76M_#>\M-/@M-/CM_#$>I7"0HZ!?,C<I'#L8;`I
MC)YR",+CDXWO^$GU.V\0Z9I45QI<EO=2"U6..*226W/V8RJ\C[@@.5/[O`)4
MA@W7`!>M_`4%M<6<RZYJQ-KJ,VI*K&##2RYWAL19VG>_`Q]\\\##[CPV@TR'
MP\D%Y<V3SK.UU-*FV%5D#^7P5;D9484C!^8GG/-:3XSU&ST+0]3UJ&TOA-H=
MWJK3Q1E9E\L1L8P"2!D..<C..@Q5^_\`%OB32F\F6VTN[EN+1+VWDC$D21IY
MJ(Z/RVXCS%(88!PW`P,@'H%%87A[5;Z^OM;L-0%NTVFW:PB2W1D5U:))1\I9
MB"-^#SSC/'2MV@`HHHH`*Q]5\/0ZGJ%KJ*7EW8WULCQ)<6K*&,;E2R,'5@02
MJGID8X(K8HH`P+/PI!IVKVM]::A>Q0VMJ+2.R'E&'RP.A)3?G.&SNSGVXK?H
MHH`****`"BBB@#+\1_\`(!N?^`_^A"M2LOQ'_P`@&Y_X#_Z$*U*`"H[B9;:V
MEG?[L:%S]`,U)61XJ#/X5U.%'9))[=K='7JK2#8"/?+"@!_AN"6U\,:5#.P:
M=;2+S6`QE]HW''US6I2*H50JC``P!2T`%%%%`!1110`4444`%%%%`!67_P`S
M7_VX_P#L]:E9%Y'?0ZVEY:V:W,9MO*8>:$*G=GO0!KT5E_;]6_Z`W_DTE'V_
M5O\`H#?^324`:E%9?V_5O^@-_P"324?;]6_Z`W_DTE`&I167]OU;_H#?^324
M?;]6_P"@-_Y-)0!J45E_;]6_Z`W_`)-)1]OU;_H#?^324`:E%9?V_5O^@-_Y
M-)1]OU;_`*`W_DTE`&I167]OU;_H#?\`DTE'V_5O^@-_Y-)0!J45E_;]6_Z`
MW_DTE'V_5O\`H#?^324`:E%9?V_5O^@-_P"324?;]6_Z`W_DTE`&I167]OU;
M_H#?^324?;]6_P"@-_Y-)0!J45E_;]6_Z`W_`)-)1]OU;_H#?^324`:E9,O_
M`"-UK_UX3?\`HR.G?;]6_P"@-_Y-)45M'?W&O1WMS9K;11VKQ#]\'+,S(>W^
MZ:`-FBBB@`HHHH`****`,'P9_P`BG8_]M/\`T8U<KIVC1:]/XTL)(HGD>X)@
M,F0$EW2[6R.1@^G;(YSBNJ\&?\BG8_\`;3_T8U9/@S_D9/%7_7Y_[/)6]/\`
MAS^7YF4_CC\_R-?P?K3:_P"&+.^E96N-ICGPP)WJ<$D`#!/#8QP&%;M<AITK
M:%X\OM*=-EEJV;VT(W$><!^]7..IP6ZX``_O8KKZP-0HHHH`****`"BBB@`H
MHHH`*R@0?%C`=5L1GVS(<?\`H)_*M6LF(_\`%7W0_P"G"'_T9+0!K4444`%9
M/B?_`)%?4_\`KW?^5:U9/B?_`)%?4_\`KW?^5`&M7/:CX)T+5KZ\O+R"[>:\
MC2*<I?W$:NJ'*C:K@``\\`<D^IST-%`''ZYX/#75M>Z)9VWVS[?!=7!NKR5%
M;R\98*`X,A`"EL`D=2>E7SX'\.M,)CI[&53,T;_:)<PF7_6>6=W[O/7Y<8))
M&"370T4`<T?`/AHZ?#8&QE^S16SVBK]KFR86SF-CORRC)P&)V]L8%2VW@CP]
M97,,]K8-`8)EN(4BN)5CCD5#&"L8;:N5)!P/F[YKH**`.?M_!/A^TN+*:"RD
M1K))(X%%U+L5'^\NS=M*G`&""`%4#A0`T>!O#XTV33UM;E;638-@OIP553E4
M5M^40'D(I"^U=%10!C6/A?2].OKB]M1>+<7,XN)F:_G<2.%*@D,Y!&TXQC'"
M\?*N-FBB@`HHHH`****`"BBB@`HHHH`****`,OQ'_P`@&Y_X#_Z$*U*R_$?_
M`"`;G_@/_H0K4H`*K7UC#J-NL$^[8LL4WRMCYHW5U_#*C([CBK-9-QKT-OXE
MM-$:&0RW$+2B08VC&<#_`,=;].N>&HN6PFTMS6HHHI#"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@#!\&?\BG8_\`;3_T8U9>B,+3XC:]8PHJPS1I
M<-U)WX4GOT)D8_ETK4\&?\BG8_\`;3_T8U9.F_\`)5]8_P"O-?Y15O1VFO+]
M495-X^I;\>6$LVBQ:I:1Q-=Z3.M[&'4'<J<LN<@@8PQQUV@=<5OZ;J%OJVF6
M]_:MNAG0.O()&>H."1D'@CL0:M5R?A:-="UC4_#)+>6C?;;'+%AY#G!4#G`5
MACDY)).*P-3K****`"BBB@`HHHH`****`"N?L_\`DH>L_P#8*L/_`$;=UT%8
M]HB_\);JLN/G-I:H6_V0TQ`_-C^=`&Q1110`5E>)@6\,:F%5F/V=\!1DGCTK
M5HH`R_\`A(])_P"?O_R&_P#A1_PD>D_\_?\`Y#?_``K4HH`R_P#A(])_Y^__
M`"&_^%'_``D>D_\`/W_Y#?\`PK4HH`R_^$CTG_G[_P#(;_X4?\)'I/\`S]_^
M0W_PK4HH`R_^$CTG_G[_`/(;_P"%'_"1Z3_S]_\`D-_\*U**`,O_`(2/2?\`
MG[_\AO\`X4?\)'I/_/W_`.0W_P`*U**`,O\`X2/2?^?O_P`AO_A1_P`)'I/_
M`#]_^0W_`,*U**`,O_A(])_Y^_\`R&_^%'_"1Z3_`,_?_D-_\*U**`,O_A(]
M)_Y^_P#R&_\`A1_PD>D_\_?_`)#?_"M2B@#+_P"$CTG_`)^__(;_`.%'_"1Z
M3_S]_P#D-_\`"M2B@#+_`.$CTG_G[_\`(;_X4?\`"1Z3_P`_?_D-_P#"M2B@
M#F]:UK3[S29K>WG:2:0H%18VR3N'M72444`%>;:QJ<T?Q7L\+'^Y>*V7(/*N
M.2>>O[QL?05Z37CGC.>6U\>75Q"VV6)X71L`X8(A!YKKP<>:;7DSFQ,N6*?F
M>QT445R'2%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`',:SK^J:=XPT#3(K.W_L[4)7BE
MN)')D+")W`11TQL&2?7`'>JFD^)]0G\63Z9JL\%F&N9XK.UDTN>-KA$^ZR7#
M/Y;G;\Q"KG&:T]9\+C6=8T_4FUC4;5]/<R016X@V!RK*6.^-F.58CKCTP>:;
M=^&9)KPZC)J-U?7=OYLEA#=&-(K:1E*\>7&&Q@XRVX@>]`&-XE\9ZEI6HZV+
M*&T-IH5G#=W:S(S27`D+?*C!@$PJ$Y(;)(&!UJE+\1+^U,6JS6ULVC37EY9K
M`J,)T,"R'>7W%2&\IAMVC&0<GI6NOP^LYK>%;[4M0N)'LXK34"TBL-06/)'F
MEE+=2WW2I(."2*M)X%TE;UII&N);;SIIX[*0IY,4DH82,H"ALD,W!8@9.`*`
M*?AGQ1JE[K5MIFKI9>9>Z4NJ6YM49?+4L%:-MS-N(W+\PQGGY175W-]:66W[
M5=00;\[?-D"[L=<9^HK'T'PG9Z!/Y\=W>7<JVZ6D+W3JQA@0DK&NU1QD]3EC
M@9)Q6_0!@^#/^13L?^VG_HQJR=-_Y*OK'_7FO\HJUO!G_(IV/_;3_P!&-63?
M?N?BOIOE?N_/LSYNWCS.)/O>OW5Z_P!T>E;T?M+R9E5^R_,[2N.\9+)HVH:?
MXLMPQ%HPM[U%/^LMW..FX`D,>!ZL">%KL:BNK:*\M)K6X3?#,C1R+DC*D8(R
M.>AK`U'12QSQ)+$ZR1NH9'0Y#`\@@]Q3ZY;P;>RP)=^'+^XB>^TM_*C`4*SV
M^%\M\`D=#CCIQGDY/4T`%%%%`!1110`4444`%95D,^(M6<]0D"?@`Q_]F-:M
M96G'=KFLL.BO$GXB,'_V84`:M%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!7D6OVJ:OJ'BC57+1M8211)&.=Q
MW"/)/IA2<>XYXY]=KS:R@BN8_'J2KN4.[@9(^96E93^8!KKPKY;R]/S1SXA<
MUH^OY'>://+=:)87$S;I9;:-W;`&6*@D\5=KFO`EXESX4M(_M*RSPAED7?N9
M!O;:".H&!Q["NEKGJ1Y9M&T'>*84445!04444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110!@^#/^13L?\`MI_Z,:L/7;NWL?B?I%Q=2K%"MKM+MT&?-`SZ#)'-
M;G@S_D4['_MI_P"C&J[J>@Z7K.TW]G',RXP_*L!SQN&#CD\=*UI3C&7O;-6,
MZD7):%V"XANH5FMYHYHFSM>-@RGG'!%<YXOU^YTV&&PTM))-4NN8Q$H=D53D
MG;@YS@@<=B<\52F^'5I'-]HTK4KRPG#DJP.X(I!X7&&'7&23QZU9\->%KW3[
M]]2UF^^VWH3RH27,@C7J3N89SU''0$]<\:1C2C[][VZ6(;J/W;6\SE)?%L_]
MH0:[);>1J%A_HVI0K&<26K2#D!F^5E<@8ZDL#G`('J<4L<\22Q.LD;J&1T.0
MP/((/<5Q?CO2XX/)UZ*W5_+/DWJ`[?.A<;"">QP2N0,_,/[HH^'.LB>PFT2:
M?S)K`@PLS#=)`W*D@,W(S@@<+E1UJ*L4TIP6C_!E4Y.[A+=';T45'<3Q6MM+
M<3-MBB0N[8)PH&2>*Q-3C]7\9RZ=XUM],"QBR79'<&3"X9\'>&ST4$>G\7L1
MVE>3VNAOK?A76M=G"QW,D[7,?R;1A<L^"<DJ=S#'J@R:[SPCJPUCPY;3%F::
M(>3,6)8EU`Y)/4D8;\:ZZ]*,8IQZ:,YZ-23D^;KJC<HHHKD.@*Q])=7UG7@K
M`[+J-&QV/D1''Y$'\:V*Y_P]_P`ASQ9_V%8__2*UH`Z"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`KB?`T::
MA+X@U$HK6E]=%1'(,G'S,0PZ8Q(!W[UVU<7\,O\`D6[C_K\;_P!`2MZ>E*;]
M#*?\2/S"\\"-:7/VWPW?R6%P,?NW<E&&1QGDXX)(.X$^@JO9>.[O3)FL?$UA
M)#,B$B5$P7P,#Y>AR0WS`XSC@#FN\J&ZL[6]B$=W;0W$8.X+*@<`^N#WY--5
MN96J*_YB=*VL';\CB?#/C+4-4\2FVO8MEK>(S6J!/N;<_P`7&0=K`GGD<8YK
MO*X/QW:1:9<Z+K4$$>VTF2(QJ2N54[T4#&`!M;\QU[=U'(DT221NKQN`RLIR
M&!Z$'THKJ+49Q5D_T"DY)N,G=H=4-W=V]A:275U*L4$0W.[=O_K^W>IJ\^OC
M+X^UR6PMY/)TK3]VZ97!\R0@A6`!P1D<>V[D9`J*5/G=WHEN54GRK3=G?QR)
M-$DD;J\;@,K*<A@>A!]*=7!^$-;BT3[3X>UFXCMY;68B%Y,JK*<D\D#`[@D\
M[QBMOQ=K2Z;X4GN[>=0\ZB."122#N[@CI\NX@Y["G*C)3Y.XHU4X<QI6&MZ9
MJDLL=E>PSR1$AE5N>,9('=>1R./>K]>.G3_#MOX=L;X^(K>UU3`8B&0R_-\S
M+E4RR$?*">@QT)/-_0_B+>6$##4K>ZU*P27R4OX8SU"_=RP&XG@\X;DDYJJE
M*&OLY7\A0J2^VCT+7M3_`+&T.[OPNYHD^08R"Q("YY'&2,^U8O@GQ%<ZO;36
MNI-_I\.)`2@0R1,,JV._7J`!@KZUQ?B;Q3>>,+JUTO2M,G\KS-R*[KOE;'!(
M&=H'S?Q8P<G&*T-3\(>)?$,D=VUCHNF$`HL*N^\(#A0Q4%20`,$8X^@`I1A&
M'+4T;\MB7*4I<T-4O/<[[3]>TO5;F:WL;R.:6'[ZKGIG&1G[P]QD<CU%:->6
M6WA'Q;X>D74K*33FEMT.Z.W:1VG&<D%2`#QV&/NC'S<UU.@:QJGB&P%Q;ZGI
MJ2+@30FP<M&W_?[D'L>_UR!G4IJW-#5&D)OX9[G545RW_%??]2U_Y'I@U'QO
M92LESH.GZBK*"KV5WY(4\Y!\SDGIT`'U[8FAUE%<ZGB'58+*2XU'PKJ$;*WW
M+26*Y)'`!P&#9R>@!XYSZ00^/]'%V+748K[29FV[%U"W,>\$D9R,@#(ZG`_7
M`!U-%4K/6-,U"4Q66HV=S(%W%(9U<@=,X!Z<C\ZNT`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`&#X,_Y%.Q_P"VG_HQJWJP?!G_
M`"*=C_VT_P#1C5O4`%%%%`#9(TFB>.1%>-P596&0P/4$>E>-:U9W7@GQ-;7D
M0N)DMG#6LDC@*\'S>9'T(!^<C(QC)./F&/9ZBGMH+J/R[B&.9.?ED4,.05/!
M]02/H36D)\J<7JF1*%VFMT</'XM\2Z];JVAZ%Y2.C'SY6W*>P*LVU<@YX.?I
MP:6?1/'6HV#076K6:QS(!)'PK`'JI*I^!P<'W%6-`\WPMXED\,R_-I]YYEUI
MLGSG9SEH><C@`GK[GE\#M*T]NE\,4OQ(]E?XI,I:1IL6D:3;6$1RL*8+<_,W
M5CU.,DDX]ZY#PSYGA_QKJ&@R?N[6YS-:I\Y'J-I/^SD$^J8SQSWE<AXSL)K>
MYL/$=G'))-8.//2-B"T0.3SV`^8'`/#'/`HHRYFXR^U^?0*D;)273\CKZ*J:
M9J-OJVG0WUJ6,,PR-PP1@X(/N""*MU@TT[,U3NKH*R=%`%WK1QR;\Y_[]1UK
M5E:(/GU-_P")KZ3/X!0/T`I#-6BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@".XGBM;:6XF;;%$A=VP3A0,D\5
MRGPV@EA\+L\BX6:Y=XSD<KA5S^:D?A6]X@_Y%O5/^O.7_P!`-9W@3_D3-/\`
M^VG_`*,:MXZ46^[7ZF3UJKT9T5%%4M1U?3M(B\W4+V"V4JS*)'`+A>NT=6/(
MX&3R*P-2MXDT?^W=#GL5,:RMAHG=<A6!S^&>1D=B>O2N2\.>+[C2KM-!U^);
M<0`0I,1C9CH'[;<8PP]B<YR-*+Q?JFO6J/X:T&=E=@#=:@1'$@W8R`&RXX;.
MTY&!UZ5'=^![WQ!+%+XDUMKA$5BEM:0+$L3-@D!CDLHQ@9&>`?7.T*B47"2N
MOR,IP;ES1>I5^(/BN&T']@13I'+.%^T3;B1$A/0A<G)')X^Z>ASPN@:MJ":7
M!9>'/"\_D>4A-[?L+=6D8?ZS;R77@'Y6)QP,<5J>%_`MAX;F:Y++=7?(CE:/
M;Y:D<X&3R>><]...<]52G/W>1;#C'7F>YPDW@G5=>NWN?$&H6<(9\M%IMLH8
M@)M'[UANZ]CD<?3%,_"BVCU>WE2[,]CO#3)<9,FT`?*"N`<\C/&/>O1Z:[I&
M,NRJ"0,DXY)P!^).*E5)(IPBRO9:9I^G;_L-C;6OF8W^1$J;L=,X'/4_G5B2
M-)HGCD17C<%65AD,#U!'I3J*@HJ6NEZ?92F2TL;6WD(VEHH50D>F0.G`JW11
M3;;W$DEL%>?:_H%WX:OSXA\/#9&N3<6P&55>_'=#W'\/4<?=]!HJZ=1TW=;$
MS@IH\QD\7^*-2\_5=,M?*TVUV^9'M5QQR<D@,??;C`QTZUV&D>+M+U:PDN!+
MY,D$)FN(6!+1J.I''S#CJ/49`)Q6U!;PVL*PV\,<,2YVI&H51SG@"N/UCX<Z
M??W(FL9OL&<F1%CWJQ)SD#(V_0<=,`=]^>C4T:Y>S_S,N6K#5._]=#*/BKQ1
M),^M6]I)+H@F8+%Y2C,8!Y)&6'`Y;E0?RKJ=`\8:9KS+!&S07A&3!)WP`3M/
M0CKZ'@G%;5I:6]A:1VMK$L4$0VHB]O\`Z_OWKG-=\":9K$LES$6L[MSN:2,9
M5R<9++Z\'H1R<G-)SHST:MV:_4.6I#5._E_D:]]X>T;4FE>\TNSFDE7:\K0K
MO(QC[V,@XZ'.17):CH^C>%)\:?XDOM%FE_>16ZDW$(X"EFB(.<@'ECUZ=,5;
M_P"$,UK_`*'"_P#R?_XY5*\^'$LMM>7$NK7%[J!3,)90-S`=&+,<YP`#D8]Z
M4*=&_O3_``'*=6WNQ-B*;QGI5NZSVECKF'VQO#/]FE*Y)W."NST&`>/?K4MM
MXYT=[A;:^^TZ5<ODK%J,)A)7'WLGY0.".3U%.\#ZG_:?A>WRNU[7_1FP,`[0
M,$<_W2N??-/UK6_#"@6NK3V5P%<_NGC\_8R\'(`.T\D<X[^]9.E)2<$KM&BG
M%Q4FS?KD/&WB:[TCR;#3!_ILJ&9W";C'&O.0",'.&R>P4\<@C"@?1Y[>[U+P
MWK%[H+VI:>:T(5XI,@@LL1;:2254<X&%&!D&F:%?:C;7=[XA\1Z)++::C&$-
MU`@=8XN^Z+.?+VJ/F(/"CKNYTA#V;YJBV_,B4N=6@]ST33+Y-3TNUOH]H6>-
M7*JV[:2.5SZ@Y'X5;KB_ASJ4-QIM[IT-R;B.RG/E2[-H:-R2O'4$D,<'ID?A
MVE95(J,VEL:0;<4V%%%<MJ?C[2-+U&:RDCNI9(3M9H51ESCD9W#D=#[@T0A*
M;M%7"4XQ5Y,ZFBH;.Z2]L;>[C#".>-9%#=0&&1GWYJ:H:MH5N%%%%`!1110`
M4444`%%%%`!1110!@^#/^13L?^VG_HQJWJP?!G_(IV/_`&T_]&-6]0`4444`
M%%%%`&%XJ\/+X@TKRXG6'4(&$MG<G(,3@@\$<@'&/;@X)`IOA#7O[=T5#<-M
MU*V_<WL+##I(,C)7`QNQGI@<CL:WZXOQ+82Z!K2>+]-CED/RQ:G"JA]\'&7&
M2""`J]..`3@!L@':457L;ZVU*RBO+.99K>5=R.O0C^A[$=0:L4`<'_R(6O\`
M_+PV@7O_``(02_J3@#V)!_B*UWE4M5TJTUFP>SO(]\;<@CAD;LRGL1_GBN:\
M(7UYIMW)X9U?<+F$%[:1F!62/^ZIZD#DCKQD<;<5T2_>QYOM+?S\_P#,Q7[N
M7+T>QV596@G=#?/_`'KZ?CTPY7_V6M6L;PS*L^GW<B9VG4;Q>?59W4_JIKG-
MC9HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHKD/$_CS3-'$UC;3/<:BT<BI]G"N(9!D#>2<`Y[<D8Y'3+2N[";LK
MG)ZAXPN_[:UN%Y_.T^Y2:W1$.Y0-I5&3GC/!..#DG'3'0^'?$^E:%X6TZSO)
MV-\X<I:1(7E<ERRC:.A8,NW.,Y%8?A[P5JVN>'534-1^QZ;,YN(K:.(%R^&4
M,Q(&!C:<`D,#VZUWOA_POIGARU1+.VC^T;`LMSM^>0X&>220"0#M!Q737JP<
M>2*M_P``PHTY)\TF9*W'BWQ#LELUBT"QWL-US%YETP&<'81M4'C@\C&<D8SH
M:7X/TK3;B2ZD674+UW5_M5^1-*I487:Q'&,=1S[\#&_17*=`4444`%%%%`!6
M1XF`_P"$?N)&&1"T<_3_`)YNK_\`LM:]9GB2S74/"^KV3#*W%E-$><?>0C^M
M`&G14-I,+FS@G'22-7_,9J:@`HHHH`****`"BBB@`HHHH`****`.-O\`X?V]
M_K%S=-J$T5I<2>;);1KU?!YW$D9R6/3C)`K4L?!F@6."FGQRN$V%IR9-W3G!
M^4'CL!6]16KKU&K7,U2@G>QR6I_#_3+_`%2"[AVVL2D>?;QQ_)*`1P,$;21D
M''UZYSU<<:0Q)'&BI&@"JJC`4#H`/2G45,JDI)*3V*C",6VEN<;K7@"+4=;_
M`+5T^_;2[@C+/;QD,7.=S9##!(.#^)[FL'4M!\8:3,'.L:GJ%A_%+9N[3+P.
ML1<9Y..">`2?2O4**:JRCL)TXO<\W\.^.(;.WU*VN]2&HQVR&6TG;<K3<_<.
M[YLDD=CCYN<`5T/@739;/0!=7)W75^_VAW;!8J?NY;)S_>_X$?>F^*?!%IXD
M>*XCF%C>(Q+3QPAC*,`8?H3C`QD\<^M0OKVM>&G)\26\5SI@V(NI62'*DG&9
M4)R,C!)48!(`SGBYU4XV2U>Y,:;4M=EL=?1116!J%%%%`!1110!B7_BG3]/\
M2:;H,BW#WM^6"&.+,<>$9OG8\#(1L`9/MCFJUOXVTVXUF&P2"Z$4]Q+:07I5
M?(EGC!+QC#;LC:W)4*=IP<U#XDTK7=0\2:#>Z?;:<]KID[3L;B\>-W+1O&5"
MB)@,!LYSSC&!UK(C\(:AILT#R-#+INE7]UJMOY)=YYFD$A$9C"XX,AY#$MQP
M*`-[6?&FG:+?SVLT%W*MI"D][/"JF.TC=B%9\L"<X/W0Q`!)Q4(\>Z0-0$$B
M7,=J\TUNFH,J^0\L0)D0$-NR`K<E0IVG!S6#=>$/$.M07LMVVGPR>(-,M[;4
MPKNIM73=DQ+AM^0Y&"RX(SD]*<_P[O+I5TNYN+==)AO;N\BE21C,YG60;&4J
M``OFL<ACG`X%`'2Z#XNLM>NOLT=I>6DSVRWD*W2*OGP,<+(NUCQGLV&&1D#-
M=!7'>&?#&J66KVVI:P]F9K+2TTN`6KNPD4,&:1MRKM+;5^49Q@_,<UT6I:+I
M^K^5]NM_-\K.SYV7&<9Z$>@H`H>#/^13L?\`MI_Z,:MZL'P9_P`BG8_]M/\`
MT8U;U`!1110`4444`%%%%`'#64W_``@>M/IUV95\.WK@V,[ON2UD/+1L2,J"
M<D9..,\_.1W-5=2T^WU;3+BPNEW0SH4;@$C/0C((R#R#V(%<KH&LRZ!J<7A+
M7)8O-1%&GW:X59XNBJP_A;C`]<8Y."P!VE<EXYTB:XM(-9L0JWNG'S=W'*#Y
MNXY*D9`/'WNI-=;6=X@_Y%O5/^O.7_T`UI2DXS31%2*E%IAH.I_VSH=I?E=K
M2I\XQ@!@2&QR>,@X]JH^#E*Z)<;@1G5-189'4&\F(/T((-,\"?\`(F:?_P!M
M/_1C5KZ;9?V?9?9S)YG[R1]V,?>=FQ^&[%*JE&;2[A3;<$V6Z***@L****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***YO5/&FGV.IQZ591
M2ZGJ<NY5M[4J0KCC:[$X7D'/7:`21Z@'25S>L^,K33WDM--@EU?4TY:TLP7*
M`'#%V4$+@\8ZY(XYS6>^B^)?$^[^W+[^R=/;(^P6+`R,OS##R<CH1D#(([*:
MZ32M$TS0[<PZ;9Q6Z'[Q499N21N8\G&3C)XH`YZ?0O$GB-F&M:DNFZ<Z_P#'
MCI[9=@0V5DD(ZC(!`RK8Z#K61XP@TS0M+A\/:)9B&XNW1Y$BCW-(@9MH+'+,
M=_3DG@C@<'JO%7B6+PY8*X3S+J;(@C(.W(QDL?09''4Y^I&/X6\+7#W?]OZ_
MNEOY3YD<4@_U?HS#^]Z#^'Z_=Z:,5!>UGMT\V859.7[N/S\CL+.U2RL;>TC+
M&."-8U+=2%&!GWXJ:BBN9N^IOL%%%%`!1110`4444`%(RAT96Z,,&EHH`Q_"
M9E_X1#1UG</.EG$DK`8RZJ`QQVY!XK8K&\+N[:,Z.A1H;RZA"DY^5)Y%4_BH
M!_&MF@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@#!\&?\BG8_]M/_`$8U;U8/@S_D4['_`+:?
M^C&K>H`****`"BBB@`HHHH`*Q?$WAFR\3Z8;6Z&R5,F"=1EHF_J#W'?V(!&U
M10!PWAGQ->Z?J8\+^*#LU!,"UNF.5N5Z+\W<GL>_0X8<]O)&DT3QR(KQN"K*
MPR&!Z@CTK'\3>&;+Q/IAM;H;)4R8)U&6B;^H/<=_8@$8'AGQ->Z?J8\+^*#L
MU!,"UNF.5N5Z+\W<GL>_0X8<@$OPR_Y%NX_Z_&_]`2NTKB_AQ_H^FZCITORW
M5M>-YL?7;D!>O0\HW3TKM*WQ/\61E0_AH****P-0HHIKR)$H:1U120H+'').
M`/J20/QH`=1110`4444`%%%%`!1110`4444`%9VNZK_8FBW&H^3YWD[?W>[;
MG+!>N#ZUHUQOQ+D=/#,2H[*KW2JX!QN&UC@^HR`?P%:48J=119%67+!M$<?C
M?5YHDDC\)7KQN`RLK.0P/0@^7TIW_"9ZU_T)]_\`F_\`\;KL+>"*UMHK>%=L
M42!$7).%`P!S6#JOC/2]/EEL[9VU#5%4[+*T4R.S#(*DJ"%(P20>0!TZ9MU*
M?2'XLGDG_-^",F?QWJ=K"TUQX5O(8EQN>1V51SCDF.M"X\>Z-%]ECMQ<WUW<
M(KK:6<?FRJ""?F`.`1CD9R/3'-47T_Q5XJ`>^NET72;B)=]E#\]P1D9#,5&T
ML,]^!@%3S61I5MK/@.74+&UT:345GVM%<Q1DC@$`M@$G_=R,<XZY+Y8U5:"L
M_7_,5W3=Y.Z]#9?1?$OB?=_;E]_9.GMD?8+%@9&7YAAY.1T(R!D$=E-=/I>D
M6&B60L].ME@@#%MH)))/4DGDGZ]@!VKD@OCW68F??:Z7$T8`3[I;.>>C,K?B
M,<=\TY/AO#/-+-JFKWEW*^,.H"MP,<EMV>WITI>RA'XIKY:A[23^&/WZ'<52
MU?4HM(TFYOY1E84R%Y^9NBCH<9)`S[UPNJ>&+SPA+'K6@3S2QPC_`$B.7#';
MW)``RGKW&,^XK:UXFE\8VFGZ581-!/<3D3Q$LV,8VG<!RG))XXVY[9.D,,I-
M.+O'KY$RKM)IJS+OAS1+CQ3??\)'KK++"Q(@M_X3@D=.R`YX[G)/^UZ'4=O!
M%:VT5O"NV*)`B+DG"@8`YJ2L:M1U)7Z=#2G!07F%%%%9&@4444`%%%%`!111
M0`4444`8^A2H;C6K93S;:@RL,="\<<O_`+4!_&MBLC3@(O$&LQ@8,C0SGCKE
M-G_M.M>@`HHHH`**Q]0GU%]:MK&RN8+=&MY)G:2`R$E60`#YAC[QIWV37?\`
MH+VG_@"?_CE`&M163]DUW_H+VG_@"?\`XY1]DUW_`*"]I_X`G_XY0!K45D_9
M-=_Z"]I_X`G_`..4?9-=_P"@O:?^`)_^.4`:U%9/V37?^@O:?^`)_P#CE'V3
M7?\`H+VG_@"?_CE`&M163]DUW_H+VG_@"?\`XY1]DUW_`*"]I_X`G_XY0!K4
M5D_9-=_Z"]I_X`G_`..4?9-=_P"@O:?^`)_^.4`:U%9/V37?^@O:?^`)_P#C
ME'V37?\`H+VG_@"?_CE`&M163]DUW_H+VG_@"?\`XY1]DUW_`*"]I_X`G_XY
M0!K45D_9-=_Z"]I_X`G_`..4?9-=_P"@O:?^`)_^.4`:U%9/V37?^@O:?^`)
M_P#CE'V37?\`H+VG_@"?_CE`&M163]DUW_H+VG_@"?\`XY3+6;4H-=2QO+J"
MXCDMGF!CMS&5*L@_O'(^;]*`-FBBB@`HHHH`****`,'P9_R*=C_VT_\`1C5O
M5@^#/^13L?\`MI_Z,:MZ@`HHHH`****`"BBB@`HHHH`*S]9T:RU[3)+"_BWQ
M/R".&1NS*>Q'_P!8Y!(K0HH`\H\.:VOA+7]>BOHKVZL#<A'OMID,1$C*#*??
M<3GKD<`YX]2MKJWO+=;BUGBGA?.V2)PRG!P<$<=17':#%';^./$FDRHL\=TO
MGN7'&#R4*\Y'[W'X=.>);CP]JGAZ]DO_``LZO:RRK)/H[X5'/(8QL?N'H<<#
MCN`%K6LK2T[+\C.D[Q^\[&BN;T?QKIFI7`LKH2Z9J8VAK.\78VXA<!2>#DMP
M.">N*Z2LC0*X?XGSQ+HEG;EOWKW.]5P>552"?_'E_.NXKB_&?_(R>%?^OS_V
M>.M\-_%3_K8RK_PV7?!&OMK>CF.<YNK3;'(<DEUQ\KDGN<'/)Y&>,UT]>>>)
M(W\*^,+77[=&^R7)VW"H.,_Q#`P,D?,,GE@3VKT&.1)HDDC=7C<!E93D,#T(
M/I17BKJ<=F%*3UC+=#J*AFO+6VEBCGN88I)CMB61PI<\<*#U/(Z>M35A8U"B
MBB@`HHHH`**S]5UO3-#MQ-J5Y%;H?NACEFY`.U1R<9&<#BL#_A*M7U>[^S>'
M]#E$3IO34=15XH",]0`,L",8P0><XP#0!UDLL<$3RRNL<:*6=W.`H'))/85Y
MEXX\1Z9?:UH\>G[=5DM92TD$`WK)DH0N<$-G!'&??TKH5\%2ZJD#^*=7N=3D
M3!-O&1#;@X/\*@$D$M\W!(P,=JH?9+*#XJ6,&F6D4,=O;L9TMX=BHQ5^3@8Z
M,G/N!6U"_,VNB9E5M9)]6BT^B^)?$^[^W+[^R=/;(^P6+`R,OS##R<CH1D#(
M([*:Z32M$TS0[<PZ;9Q6Z'[Q499N21N8\G&3C)XK0HK$U"BBB@`HHHH`*S$\
M/:5%K!U6.S5+TDL9%9AR1@G;G&2">W?/6M.BFI-;,32>X4444AA1110`4444
M`%%%%`!1110`4444`<Q?:II&@>,)[K5=2L[`7MA#&C75PD0?RI)3@;B,D>=V
MJ?\`X3OP?_T->A_^#&'_`.*KH**`.?\`^$[\'_\`0UZ'_P"#&'_XJKVF>(=$
MUJ22/2M8T^_>,;G6UN4E*CU(4G%:5%`&3+_R-UK_`->$W_HR.M*X:9;:5K:.
M.2<*3&DCE%9L<`L`2!GO@_0UFR_\C=:_]>$W_HR.M*XD>&VEEC@DG=%++%&5
M#.0/NC<0,GW('N*`.9T+Q%K^L0VEU+HFFP6L\CHVS5&>50K%6(0PJ&P1G[W3
M\JE\0>*8K30M2NM$NM.OKRPV^=";@-Y62`=P7)SCH#C/J*S/!OAB.VT::>Y\
M.II&N/\`:(VN2(3)(LCE@2\3-N'*_>.<K]#6-I_@BY/A6>SDT:Z@UF/3OL7V
MBXU5YX)<%21$ID;:K%<X*KB@#T&+7=(GAGFAU6QDBMY/*F=+A"L;_P!UB#P?
M8\U7C\6^&Y8+F>/Q#I+PVN/M$BWL96')VC><X7)X&>]</XF\/ZMK7VK58O#$
MHFF-A%'9-+;^:/(G,KR,?,V#Y247!+?-S@'C2\6:+K%[>:[-8:6]P-6\.FP3
M][&GE3#S2`^6[^:`",C(Y('-`'7R:WI,5_!82:I9)>3@&&W:X022#U5<Y/X5
M6N_%OANPE\J\\0:5;2<C9->QH>#@\$^M<9J^C^*+\6D8T:*'[-=:==-]EEA*
MW'E,AD#R/AR5PV`%'`'S'.VM#PSX=FG\'ZSH^J:3+I"75[=31*)(B4221GC9
M3&S!2@*^F"O'%`'90ZA97%W+:0WEO)<Q*KR0I*I=%;[I*@Y`/8]ZHPZU+)XI
MGT5].EB2.V%PET\BE9AD`A5!)&"<'=CIP".:@\(K?RZ#!?:J8CJ-XJR3F$DI
MPH4;<\X(&['JQJ-_[0'CY)AI-RUA]A,!O1)%L#[M_P!W?OQQC[O4^G-`#X->
MO_[>M;&]TC[/;7J.UK<+/O;*C)65-HV$CD8+#C!(-;]<S87>I76N^?>^&[^W
M(W113S36YBABSDGY)6<LVU?X>P'&"3M:7J`U33X[L6\UN'R/+E*%A@D=49E/
M3J"10!<HHHH`****`"BBB@`HHHH`*R9?^1NM?^O";_T9'6M63+_R-UK_`->$
MW_HR.@#6HHHH`****`"BBB@#!\&?\BG8_P#;3_T8U;U8/@S_`)%.Q_[:?^C&
MK>H`****`"BBB@`HHHH`****`"BBB@#B]-_Y*OK'_7FO\HJ[2N)O9$T[XIVT
MB.L,=S9,UTS'@@*_))Z`>6O3'3ZUV%K>6M[$9+2YAN(P=I:)PX!],COR*WKI
M^Z_)&-)[KS95U71-,URW$.I6<5P@^Z6&&7D$[6'(S@9P>:P&\/\`B#1$G?0-
M9\^VCRUOIE['O7&`-@E+;@!CY1P.`#W-=?16!L<@/&=WI=O'_P`))H%]9/\`
M+YEQ;J)K=02!N+`_+SGY>3C'7-8M]K^BZOX\T6Z_M*%].CA+[I)3&L<@+D$A
ML;3E4Z]>.HQ7I->>ZAI5KXG^)D]IJ,2/;65J/D&09!@$`L""/FDSQZ8K:C>\
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MG+8D_>J`<\`<'TY)/]:?9^'/&.DVJV.FZQ8QV<1;RE,8S@DG)RAP3G/4U"IQ
MEM)+[_\`(MSDMXDFI^-=66WW:=H#6V_A)-7GCMCN!&[$;,"PP1R".3[<VW\/
M^)-5:-]5\2-:Q[MSVNE1^4%(!`VRGYB.A(((S^!JB?`=YJ[3W7B#56EO6`2%
MK?&Q`!QD%1QGL,=^<GAL&B>.M.L%@M=6LVCA0B./AF('1063\!DX'L*KV,&K
M*:O^!/M)WUCH;^G>#?#NE2^;::5`)-RL'DS*5(Y!4N3M/TQV]*W:X7_A,?$&
ME2R?VYH#"!"NZ:W#!4!ZG=EE8\C'(YX^FC:_$+P_<1%Y+B:V8'&R6%B3[_+D
M8_'M4O#U%JE?TU&JT'N[>IN:KJMIHU@]Y>2;(UX`'+.W95'<G_/%<EX.%]J_
MB._\2SVZP6UQ&88QD_-@J./4`)@GCGIW`H2.WC[Q<L:'_B3V/S9,9&]21D9'
M.6(XY&`,XR#GT>.-(8DCC14C0!551@*!T`'I5R2HPY?M/?R1,;U)<W1?B.HH
MHKF-PHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`,F7_D;K7_`*\)O_1D=6]2M;"]TZ>#4[:WN;(KNEBN(Q(A"G=RI!!P0#^%
M5)?^1NM?^O";_P!&1UJ2.(HVD8,0H+$*I8\>@')^@H`X**R\!"ZN;?4/!>FZ
M6T%L]X#>Z;;J)(%(#2#;NP!D9#889&0*(;+P";:\FO/!FGV!M8!=-'<Z5#N>
M$YVNH0-G)4C;]X'`(&1EFJ8\9Z3K=O;VFHPZE>Z=+;6RW>FSVZ0(1G#22(`6
M9MN0I/08!VEC'K=C>^*YKC4K.POX!9V"(D,T1@:>47$<S1@/C.!`%W?=/F<$
M\X`)OL?@*.VN&N_!>FVEU`\2&RFTVV,S&5ML6T+E3O/`YZ@@XP:OZ3X<\%ZJ
M+A/^$+TNTN;9Q'/;7.FP!XR0&'*AE(((Y4D=1U!K.OK&W\0:AJNNW=MJT&GM
M:V=O;&*SE2[$\4TD@D6(H6&UG3!*X.#GY1DZ.B:3)!!?ZEXBBGNWO[B#9#<6
MRSRHL>!$76)2N[<2Y*@!<]L9H`T?^$$\'_\`0J:'_P""Z'_XFC_A!/!__0J:
M'_X+H?\`XFN@HH`Y_P#X03P?_P!"IH?_`(+H?_B:/^$$\'_]"IH?_@NA_P#B
M:Z"B@#G_`/A!/!__`$*FA_\`@NA_^)K4TW2=-T:W:WTO3[2Q@9R[1VL*Q*6P
M!DA0!G``S["KE%`!1110`4444`%%%%`!1110`5DR_P#(W6O_`%X3?^C(ZUJR
M9?\`D;K7_KPF_P#1D=`&M6=!X@T6YU-],@U>PEU!"P>UCN4:52.H*`Y&._%:
M-<!:&[TOQ8W]CW&JRZ7)=7-QJL-]8^5##D,VZ&1HT+'>`!AG&"3Z&@#L[K5]
M-L;NWM+S4;2WN;DX@AFF5'E/^RI.6_"A-7TR34WTQ-1M&U!%WM:K.IE5?4IG
M('(YQ7EVM)>^(!KMW::5J)_X231K-=,+V['RW4N2)&7*Q$;U;+$`]B34<WA[
M6KN&'28+6ZCU*VU34;M[MXG6,QRQS"-EE(VL3O08!R,<@8H`]5L=6TW5#,-/
MU"TNS`^R7[/,LGEMZ-@G!]C5RO.O!5C<OX@L+U-.NM/MK+P_#IUQ'<6S0[IP
MX.U=P&X(`WS#*G?P3S7;:E::A=>5]AU/[%MSO_<+)OZ8Z],<_G0!0\&?\BG8
M_P#;3_T8U;U8/@S_`)%.Q_[:?^C&K>H`****`"BBB@`HHHH`****`"BBB@#D
M/$O@Z;Q#XAM;IKB.*R2%8Y<$^8<,Q^48QW`R3QZ'OGR^#]:\/RRW/AC4&99`
M%>"7;N/3')&TG[QR0,#@9S7?T5O'$324>G8Q="#;?4X<^,M<TO<-;\/2!$<>
M9/!D(JG'?YE)Y_O#GCBK]K\0O#]Q$7DN)K9@<;)86)/O\N1C\>U=36=<:!H]
MUYIFTNS9I<[W\E0Q)ZG<!G/OUHYZ4OBC;T_X(<M1;2OZENTN[>_M([JUE66"
M4;D=>_\`]?V[5R.B_P"E_$K7;R#YX(H5@=^F'^08P>>J-STX^E5+O3M7\%W<
ME[HH:YT4GS9[5CGR^QZ\XP?O#T^;('+_`(>77V[4O$%YLV>?,DNS.=NXR'&>
M_6M53482G%W5OUZD.?-.,9*S_P"`=Y1117&=(4444`%%%%`!1110`50DT/2)
MI7DDTNR>1R69FMT)8GJ2<=:OT4TVMA-)[D-K9VME$8[2VAMXR=Q6)`@)]<#O
MP*FHHI-WW'L%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`9,O\`R-UK_P!>$W_HR.KU]91:A9R6LSSI&^,F"=X7&"#P
MZ$,.G8\].E49?^1NM?\`KPF_]&1UK$@`DG`'>@#FCX6T070M3J.L"X9#((O^
M$@O-Y4'!;'G9QD@9]ZE_X0W2_P#GZUS_`,'M[_\`'JX_5M1N(?$.G^+ETB^%
MI%>"%]0#0&%K"0",8Q)YFW>5ER5]>U7==UK6H;[Q9]GU^.V&D6<-]:0):H0P
M*R'9(6#%E8ICY=K=,8[@'1_\(;I?_/UKG_@]O?\`X]1_PANE_P#/UKG_`(/;
MW_X]7)3^(_$8MO$]V=31;C1[F(V]BENBB99(HW6%]VYB27V`J0=PS_LBW_PD
M>L2+_:\5X_R:U_9DFCF)"!'YWE[L[=X?;^\^]MQVQS0!W=F(X[=8(O.*0`1`
MS%RQVC&2S\O_`+V3GU-3UYY_;WB!CIL)U2W#S^(;C3)Y$M0,QJDC+M!)VD>7
MWW<GVP:CWNIW>H^&UN/$=RHAUN^M))HUA42K%'/M,@V;=V%VG``Y)`!P0`>G
M45YE8:[XDF_LA[C6T+W6MW>E3+%:(L>R/SL.H.6#_NAC+$<\AN\$/B3Q5J-S
M!H5CJ%O]M$VH(+N>1('G^SW`C7_EC(A.TY8!5SG((Q0!ZI17EVI>(?%-G%XF
MN+C6+57TC2[.^2&RA0Q-(1+O0NX+,K&/K\IP1C&#GJ-#6?\`X37Q"9=7NID5
MXECM)/*V*IC1LC"!N"2.N.3G)YH`ZFLN^\1:7IVHP6%U<E+B=E10(G959CA`
M[@%4+'A=Q&3TS7):MXAUC=XAOK2]:!]#O$ACTSRD9;R,I&WS$KOW.795*L!D
M#(/-:6@6=Q'X]\2S/JMW,G[C_1Y%AV#<A('RH&^4<#GIUW'F@#KZ***`"BBB
M@`HHHH`*R9?^1NM?^O";_P!&1UK5DR_\C=:_]>$W_HR.@#6IDT,5Q!)!/&DL
M4BE'C=0RLIX((/44^B@!``JA5```P`.U+110`4444`8/@S_D4['_`+:?^C&K
M>K!\&?\`(IV/_;3_`-&-6]0`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%0VMG:V41CM+:&WC)W%8D"`GUP._`J:BBX!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`&3+_R-UK_`->$W_HR.M&XMH+RVEMKF&.>"52DD4JAE=3U!!X(
M]JSI?^1NM?\`KPF_]&1UHW/G?99?(=$FV'8SIN4''!(!&1[9%`%(^'M$;25T
MEM'T\Z:IW+9FV3R0<YR$QMZDGIUK&L?!-O:^)[G4IH]*FL3'$EG9C354V9CR
M%*/N('#,#A1VQC!SS^A^)?$T>B>'[G4M2TMX-5TV2:.9K&3?'.(Q(JM^^P^5
M\P\!?N<8S5JT\<ZD?#B:O>)9JT,*07=N(F79>M.8-N_><(K`YX/&"#S0!LZ9
MX.CMO$^IZWJ)TZ^FNKD7%LQL`LEH0BQX61G8\JBYP%YR>^!KS6.BVFH_VO/:
MZ?#>MB+[9)&BR'/`7>>>?3-9VCZOJ1\17N@ZM]EFN;>UBNTN;2)HD='9UP49
MF*D%#_$<CTKE?&=W=ZW82S&*Q_L_3M=M+>(/&6G$BW$2M(&SA?O,NW:20<[A
MG%`'7P>&_"CRNEOHNC-);7&]UCM8B8IL*V3@?*^"ISUP0?2K=OX=T2T0);:/
MI\*B87&V.U11YHXW\#[WOUKD[OQCKT:7J16>FI+;^(8-*RSR.HBE\K#XP-S?
MO>GR@>^.72^)_%3:_-INFZ3'J(TV:&&_E2..))"ZH[%"]QNCPKY`VR9(QD4`
M=%%X/\,0^3Y7AS2(_)D\V+;8Q#RWX^9?EX/RKR/0>E.3PEX;CM/LB>'M)6V\
MSS?)%E&$W]-VW&,^]9-KJ_B'6+*74]/ETJ+3V^TQJDL3O-$T;.BN2'VOEDY3
M"X!^\2,'-\.Z]XBO]'T"PCO=/DU.YT:/4I;FYMG(92$"IL$@RQR=SY`&!\G.
M``=3/X5\.W4T\UQH&ES2W"A)GDLXV:1000&)'(&U>O\`='I5RUTS3[&026EC
M;6[B)(`T4*H?+3[J9`^Z.PZ"N5T;Q/KFOWUE'#!864,M@MW)YBO,Y82;'08*
M`#@X;GL<=JN^$/$EWK9N+?4A%;:C"BO-8FWDADM]Q/!WDB1>,"1>&YX'2@#<
MFTC3+C48=1GTZTEOH!B*Y>!6DC_W6(R/PJ*UT#1K'49M1M-)L+>^FW&6YBMD
M263<<MN8#)R>3GJ:YN_\5ZC9^,+33(YM+N8+F[:T\B))#)"?):16DESM5B5_
MU>W.""":BTWQ=K1MM.U'58K!+.ZM[IY(+579XVARP(<G#`JI&-HP>YZ4`=JU
MS`MRELT\8G=2RQ%QN91U('4BI:\[L#?77Q%\.:IJ,=@MQ>:/=.IM8R"J;H&$
M;.2=^TL<-A1\Q^4=_1*`"BBB@`HHHH`*R9?^1NM?^O";_P!&1UK5DR_\C=:_
M]>$W_HR.@#6HHHH`****`"BBB@#!\&?\BG8_]M/_`$8U;U8/@S_D4['_`+:?
M^C&K>H`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@#)E_P"1NM?^O";_`-&1UK$9&#TK)E_Y&ZU_
MZ\)O_1D=:<K,D3ND9D95)"*0"Q]!GC\Z`,F#PIHEMIUII\5BHM;2=;B"-I&;
MRW'0@DYP!P!T`XQ@8J5?#FCK;ZG;_8(C#JDC2WJ-EA,S*%)(/3(4=,>O6L+3
MO%4UW8:;#HFAP_:+BT:\-K)<B%((P^W&Y4;+$YP`,<')'&8X/&MO?7UG/!H$
M\DTFCSWT,K-$)!M=%D@&3P=VW.2!E1UQP`=+I6B6&C(ZV4<H+@!I)IY)I&`S
MM!>1F;`R<#.!DXJA?^"?#NJ7-U/>Z<)C=%&N(S*XBE92"K-&&V%AM`W$9QQG
M'%8B>/-0N=(%S'I$$$]SH1UBS62[+`JH3<KX3C'F+C&=PZ[:O:WXBU/1/AI>
M:]<6UN-2@LS*(XI#+'O/"DG:A(Y!(P,<CWH`FE\`>'9_M.^WO<7-TEY+MU*Y
M7,R_=<8DX(XQC'W5_NC&A<>&M)N=7&J26[B\*"-WCGDC$JCHLBJP60#)X8&J
M=EX:DBM()?[<U62]8Q23W#W3,LVT@LHC)V(&P1\BJ<'K7)Z+9227M["UIXKN
M%BU66".^77)3#$@DP,H9RS;1ZQD'OQDT`=O;^&=)M;^:\@@EC>9G>2-;B3R6
M=OO-Y6[9N/=MN>3S5?\`X0K0!;6,"6<D2V`*VSPW4L<D:D`%=ZL&*X`&TDC`
M`QP*Q]*\WQ?K7B(WUY?P6^FW_P!AMK>TNI+?;M16,C&,@L6+GALK@#CJ3H>"
M=6O-2L]4M;Z1IIM+U*:P%P5`,ZI@JQQQG#`''<&@"_;^%]'M-3AU"VMI(9X;
M86D:QW$BQI".B",-LQ^'7GK5C3]$L-,GDFM8I%>10F7F>0*HZ*H8D(O^RN![
M5H44`84W@_0[B]>[EM96E>?[3_Q]2A5EVE2RKNVJ2&(.`,]\TRU\$Z%9FP\F
M"Z`L"YMU>_G=5W_?!#.0P/H<BN@HH`P+#P5X>TR[M;JUT\":SW_96DFDD^SA
M\!A&&8A%XX"X`R<`9-;]%%`!1110`4444`%9,O\`R-UK_P!>$W_HR.M:LF7_
M`)&ZU_Z\)O\`T9'0!K4444`%%%%`!1110!@^#/\`D4['_MI_Z,:MZL'P9_R*
M=C_VT_\`1C5O4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110!DR_\C=:_P#7A-_Z,CJ[?W4UG:--
M!8W%]("`(+=HPY]P9&5>/K5*7_D;K7_KPF_]&1UK4`<AIO@LQ:9HKR7UU8:K
M8VQA>:R=/G1CEHV#JP9<]#C((R"*F;P+:+=VL]IJ>I6:VMA)I\4431,HC?&X
MDO&S%B0K9)ZJ/4@]310!R-I\/[2U^PJVL:I/#9Z;)I20R&':]N^`0VV,'(VI
M@@@_(,YRV=Z'1[=="&D7327UL8?(D-T0S2J1@[L`#D>@`K0HH`PM.\,C3D2'
M^V-4N;.+'DVUQ(C+'CI\P0.V/1V8<#TJA!X(FMH+FWC\6:\(;J5YIT'V4%V<
MY;YA`&7/^R1CMBNLHH`P;GPK`VH37VGZA?:5/<*JW!LC'MF"C`+*Z,`<8&X`
M-@`9XJY8:);Z5:VMKI\DMM!#(TCHNUO/+9+&1F!8DL=V00<]\<5I44`%%%%`
M!1110`4444`%%%%`!1110`5DR_\`(W6O_7A-_P"C(ZUJR9?^1NM?^O";_P!&
M1T`:U%%%`!115'6KFXL]!U&ZM%W7,-K+)$N,Y<*2!COR!0!>HKSKP5>7:^(K
M&VCU*[O[2]\/PZA<O<7!EVW#.`&7).P."_RKA1LX`KOKE[M-OV6""7.=WFS&
M/'IC"MGOZ4`9'@S_`)%.Q_[:?^C&K>KEO"4FHKX8LQ!:VKQ?/AI+ED)^=NP0
M_P`ZVO.U;_GRLO\`P,?_`.-4`7Z*H>=JW_/E9?\`@8__`,:H\[5O^?*R_P#`
MQ_\`XU0!?HK%L-6U'4/M/DZ?:K]GN'MWWW;#++C)'[OIS5OSM6_Y\K+_`,#'
M_P#C5`%^BJ'G:M_SY67_`(&/_P#&J/.U;_GRLO\`P,?_`.-4`7Z*Q;#5M1U#
M[3Y.GVJ_9[A[=]]VPRRXR1^[Z<U;\[5O^?*R_P#`Q_\`XU0!?HJAYVK?\^5E
M_P"!C_\`QJCSM6_Y\K+_`,#'_P#C5`%^BL6PU;4=0^T^3I]JOV>X>W??=L,L
MN,D?N^G-6_.U;_GRLO\`P,?_`.-4`7Z*H>=JW_/E9?\`@8__`,:H\[5O^?*R
M_P#`Q_\`XU0!?HK%M]6U&YU&\LDT^U$MIL\PF[;!WC(Q^[JWYVK?\^5E_P"!
MC_\`QJ@"_15#SM6_Y\K+_P`#'_\`C5'G:M_SY67_`(&/_P#&J`+]%8MOJVHW
M.HWEDFGVHEM-GF$W;8.\9&/W=6_.U;_GRLO_``,?_P"-4`7Z*H>=JW_/E9?^
M!C__`!JCSM6_Y\K+_P`#'_\`C5`%^BL7^UM1_MC^S/[/M?.^S_:-WVMMNW=M
MQ_J\YS[5;\[5O^?*R_\``Q__`(U0!?HJAYVK?\^5E_X&/_\`&J/.U;_GRLO_
M``,?_P"-4`7Z*Q?[6U'^V/[,_L^U\[[/]HW?:VV[=VW'^KSG/M5OSM6_Y\K+
M_P`#'_\`C5`%^BJ'G:M_SY67_@8__P`:H\[5O^?*R_\``Q__`(U0!?HK%_M;
M4?[8_LS^S[7SOL_VC=]K;;MW;<?ZO.<^U6_.U;_GRLO_``,?_P"-4`7Z*H>=
MJW_/E9?^!C__`!JCSM6_Y\K+_P`#'_\`C5`%^BL6XU;4;;4;.R?3[4RW>_RR
M+ML#8,G/[NK?G:M_SY67_@8__P`:H`OT50\[5O\`GRLO_`Q__C5'G:M_SY67
M_@8__P`:H`OT5BW&K:C;:C9V3Z?:F6[W^61=M@;!DY_=U;\[5O\`GRLO_`Q_
M_C5`%^BJ'G:M_P`^5E_X&/\`_&J/.U;_`)\K+_P,?_XU0!?HK%O]6U'3_LWG
M:?:M]HN$MTV7;'#-G!/[OIQ5OSM6_P"?*R_\#'_^-4`7Z*H>=JW_`#Y67_@8
M_P#\:H\[5O\`GRLO_`Q__C5`%^BL6_U;4=/^S>=I]JWVBX2W39=L<,V<$_N^
MG%6_.U;_`)\K+_P,?_XU0!?HJAYVK?\`/E9?^!C_`/QJCSM6_P"?*R_\#'_^
M-4`7Z*Q;_5M1T_[-YVGVK?:+A+=-EVQPS9P3^[Z<5;\[5O\`GRLO_`Q__C5`
M$-_87\FJV]]8W-M&T<#PLL\+."&93D888^[^M)Y7B'_G[TO_`,!9/_CE3^=J
MW_/E9?\`@8__`,:H\[5O^?*R_P#`Q_\`XU0!!Y7B'_G[TO\`\!9/_CE'E>(?
M^?O2_P#P%D_^.5'J>K:CI6G2WL^GVK118R$NV)Y('>,>M6_.U;_GRLO_``,?
M_P"-4`0>5XA_Y^]+_P#`63_XY1Y7B'_G[TO_`,!9/_CE3^=JW_/E9?\`@8__
M`,:H\[5O^?*R_P#`Q_\`XU0!!Y7B'_G[TO\`\!9/_CE'E>(?^?O2_P#P%D_^
M.5'J>K:CI6G2WL^GVK118R$NV)Y('>,>M6_.U;_GRLO_``,?_P"-4`0>5XA_
MY^]+_P#`63_XY1Y7B'_G[TO_`,!9/_CE3^=JW_/E9?\`@8__`,:H\[5O^?*R
M_P#`Q_\`XU0!!Y7B'_G[TO\`\!9/_CE'E>(?^?O2_P#P%D_^.4MU?:I9V<]S
M)8692&-I&"W;9(`R<?NZ+6^U2\LX+F.PLPDT:R*&NVR`1D9_=T`)Y7B'_G[T
MO_P%D_\`CE'E>(?^?O2__`63_P".5/YVK?\`/E9?^!C_`/QJCSM6_P"?*R_\
M#'_^-4`0>5XA_P"?O2__``%D_P#CE'E>(?\`G[TO_P`!9/\`XY2W5]JEG9SW
M,EA9E(8VD8+=MD@#)Q^[HM;[5+RS@N8["S"31K(H:[;(!&1G]W0`GE>(?^?O
M2_\`P%D_^.4>5XA_Y^]+_P#`63_XY6E"9FA4SHB2]U1RX'XD#^524`9/E>(?
M^?O2_P#P%D_^.4>5XA_Y^]+_`/`63_XY6M10!D^5XA_Y^]+_`/`63_XY1:6&
MH?VNM_?W-J^R!H42"%D^\RDDDL?[M:U%`!1110`4444`4[#2=-TH3#3M/M+/
MSGWR_9X5C\QO5MH&3[FKE%<UXC\2VENESHVG:I:#Q"\?[BS$R><21GY58XW;
M<E0V`3CM0!T,,$-M"L,$211+T1%"@=^@J2O-OAKXTU+5IAHVK!KJ5HIKJUOQ
M+$QDA6;RPLJQ\(XX]C@]P:])H`***YGQ3XHMM/MKK2]/U738_$<D#?8K6XG4
M,TA'R@@GOVSUH`Z**"&#?Y,21[W+OL4#<QZD^I]ZDKS3P'XUU"XU--!U>.YN
M7FDN1:WLA0RYA8+(DR1C$>&SANC`J.O7TN@`HHK%USQ+IFCXLYM5L+;4[B,_
M9(+F8(7<Y"Y'7!;C-`&M%!#!O\F)(][EWV*!N8]2?4^]25Y7X$\<ZM)KC:%K
M4<US]HOYX(;F6:`RPO%&K/%)'%D`!M^&R>H!QQ7JE`!1161K/B+2]':.UN=4
ML;6_N01:Q7,P4R,>%XZXS@9H`TXH(8-_DQ)'O<N^Q0-S'J3ZGWJ2O+O"'B_Q
M!!XD_L77XYKDSW(MGED:)7MKGR#,R"-,[H2H^5LY&"#7J-`!1167KGB'2?#U
MLLNIZE9V1ER(?M,PC#L.P[]QG'3-`&@D$,<TDR1(LLN/,<*`7QP,GOBI*\B\
M.^._$%CXHN;#7T:Z$UW:VDL(FA#64TH9@8T0$R0LI0AB<C:<CK7KM`!116=J
M^OZ1H$"3:OJ5K8QR-M1KB4)N/H,]:`+J00QS23)$BRRX\QPH!?'`R>^*DKR6
MP\:>)](\7R0ZU$;JQN9X8F02P*(%FF9()8`I+21D*`V[!R<^M>M4`%%%4=5U
MG3="L_MFJWUO96^X)YD\@4%CT`SU/6@"UY$/VC[1Y2>=LV>9M&[;G.,]<9[5
M)7CC_$;6]"\4W\NIB.ZT\Q"X%LES"%%NTH2&6V(RTN1G<IP<D8]#[&#D`T`%
M%%4]4U;3M$LFO-4O8+.V!"F6>0(N3T&3W]J`+'D0_:/M'E)YVS9YFT;MN<XS
MUQGM4E>/:Q\1M?L-5EU:V#7.C6LS-);BW"P7%F54K/%<'`:3K\@//(QQFO8%
M8,H8`@$9Y&*`%HHJGJ>JZ?HMDUYJ=[!9VRD`RSR!%R>@R>_M0!8\B'[1]H\I
M/.V;/,VC=MSG&>N,]JDKQCQ/\0_$]E>2:IHTB7FF6]R94BBMPUM<V0BW,YN>
MBN&##8,'..#T/L<$AF@CE*E"ZAMIZC(Z4`24457OKZTTRREO+ZYAMK6(9DFF
M<(BCIR3QUH`D>"&2:.9XD:6+/EN5!*9X.#VS4E>1^)_'^NMJBW/A:9+G3H2D
ML;+`KVMY&%8RA[@\1,I7&,CJOK7J&D:@-6T:RU%8)8!=0),(I1ATW*#@^XS0
M!<HHJ"\O+;3[26[O+B*WMHEW22RN%51ZDG@4`/>"&2:.9XD:6+/EN5!*9X.#
MVS4E>2>)?'^LW&HR2^$KQ;JUC\C[+Y%H)[>Z8L5E268?ZK:"I_AZ=3NKTKP_
MJRZ]X>T[5DB:);RW2<1MU7<H./UH`T:**9--%;P23SR)%%&I=Y'8*JJ.223T
M%`"2P0S[/.B238X=-Z@[6'0CT/O4E>5^+_'FI7<D2^"K\7$14!+FTMENHFG#
MC,,K=(E*$-O)'&[TKNO"6NR^)/"]EJT]FUG-.I\R$G(#*Q4E2.JDC(/<$4`;
M5%%-DDCAB>65UCC12S.QP%`ZDGL*`&RP0S[/.B238X=-Z@[6'0CT/O4E>4^,
M/B!?7,VSP;JBSPQVSR>?8V@O%:X5@1%(1D1JRY^;WSD!37<^#]<N/$/AFWO[
MRW6WN]\D%Q&ARHEC=D?:<G*Y4XH`W:***`(Y8(9]GG1))L<.F]0=K#H1Z'WJ
M2O.O%WCDSVWD^$]729D61;BXTZ`7SP2X'E*4&0%8AQN/`('K6_X%\0WWB/0&
MFU2R6UU&UG:UN5C8-&\BXRR,,@J<^IP<CM0!TU%%%`$<T$-S"T,\22Q-U210
MP/?H:DKSWQ7XX698[3PQJHF<.\=W<Z;;B^DM&V'RR8U!RI<8)QZ#O6I\._$N
MI^(]!F.M6B6^J64_V>X\O&QSL5U88)QE77(['TZ4`==1110!'-!#<PM#/$DL
M3=4D4,#WZ&I*X;Q7XUC@G33=#U*&2[25EO\`[)']KGM$"M\WDKRV'V`^@/2I
M/AIXDUCQ!HMW%KL&W4-/G%O)-M"F8%%=691PC;6&5'0^G0`':T444`-=$EC:
M.1%=&!5E89!!Z@BA$2*-8XT5$4!551@`#H`*XWQ7XUM;-6L-(OTN-3BG1;N"
MS47%Q;Q$X=Q$,DE<@D8X&:@^&_BK5M;CU#2M<C+:AIVQOM7EB+[1$Y?8S1]8
MW^0Y4@=N*`.[HHHH`:Z)+&T<B*Z,"K*PR"#U!%"(D4:QQHJ(H"JJC``'0`5R
MGBGQC:Z:LVGZ;>VTVLQM&9;2-A)/'$2"[+%G+,$.X+U(YP>AR?AKXH\0:M?:
MOI.OQM(]HPFM;QX1`\T#NZH7B'W#\A(!P<8R.Y`/0Z***`"BBB@`HHHH`***
M*`"BBN=USQ!Y<]UHFD7=K_PD:6RW<%K<`XF3<<J/<A&''W<@XH`A\6>,+3P_
M9L(KW3Q=K+%'*+B;Y;99#A9)%7Y@N<#/OU`R:\UEL-;\6ZAX@MH=/M%OEN(Y
M+BSDN2KV5V$`BO;:;;DQLJ)E2`?E_.YJ&BV]W:>']:\-:,-7N]1O[QKD7R#Y
M?.BD5H[@XSLC;`(;)^3`YQ7I'ACPGIGA>V=;&V6.>94$[+([`[0<*N]F*H,G
M"YP,T`6]'T2RTB%G@LK2&[G`:ZEMX%C\Z3'+'`YR<G\:TZ*YWQ'XA6TE?0].
MO+>+Q'=6DDVGQ7*G9(R]L]"?;.>"<8%`%?QIXQA\,:1--;R6LU[$\8DA>3)A
MC9@IE=%^;:H.>*\_N](U7Q%K6LM:VMA=O?Q1'4M.DN3Y,R["+>\MI<97[N#Q
MD;2.>#5J[CBOO["\6Z-X?;4;^\U&;[=;R`;HI'MFMVBD8@E8U91GMQG'-=]X
M3\'Z9X4LR+.UBANID47#1,YCW#+$1J[-L3<SD*#_`!4`7M'T:WTZ/[2UK:KJ
MD\48O;J&$(UPZCEF(Y/.>OK6I17.>)_%NFZ$%LIK]+:_NEV0.T+2I"[?*CR!
M?NKN(')&>>:`#Q9XOL/#&CWER]S;O=VZ*_V8OE\%@NXH,MM&<D@=`:\RN4U3
MQ=XFU"VGM--O7N=/A,]B+C_1]1M06,=S;2X+1NC.<@Y'S=?30OK!;C2;KQ/8
M:0]YXG.M6OVVS"@O#(FR*2$,1D1LFXY/&V3/2NY\'^$K3P[9BX-A9VVI3I_I
M"VA?R8\G<4C#$[5R2<#`)R<"@"7PIX<CTC3+2>^M;1M=-LD=Y>QQKYDI`Q\S
MX!;H.3UQ7145@>)?%6F>'HTM[J^%O=W*-Y'[EI=G;S'"]$!(R3@>]`#O%/B6
M'P[H]W<(89[^.!I8+(R`/+CN%ZD#J<`\`UYQ<KJGB;7H;Q;?2[FZN;%0UKYQ
M>RU>Q#D_(6&8Y8V?.#G&X<U9UNU&KZ<OB6/1WO/$]GJ>GPW=G'\S0R03`E8R
M?NJP?.[IM8$UV7A7P=9:)(^J26%K;ZM<AVG6U=_)BWL"5C5B0/NKD@#<5S@<
M``%GPUX>33K&RN=0M+5M:CMA!)=*`\GE@_*AE(#.``HR>N,UT%%8OB+Q5I'A
M:U6XU6Y:-6R0L<;2-M'WFVJ"=H[GH*`)M:UVRT2QN9IYHC/%;R3QVV\>9*$4
ML0J]3T[5Y3=:KJOC/6-*N+:#3YWFT^;R4#E[/4[=BAF@;*[H95*KR<\@?2GZ
ME'_PD7AKQ/J;P_:/%]C;0V^R",-CRY&DAN(!RP$@8-P>HQVKN_"7A6WTZ676
MKG2;33]5O&=W@M7;RX58CC&=N\A5W,H&2/:@!G@GP=%H6DV;:E:6<FJ6X>.&
M<('D@@W$I%YI&Y@JX&:Z^BLO7?$.G>';-;G49)%5CM1(HFE=SU.%4$G`Y)[4
M`2ZIJ]II4&Z>>(3NK&"!I55YV"D[4!/)XKRV]U/4_%-]HU[&NE?:V69=.E61
MWM;K<H,UG<(P!1\+D>Z'@8Q3=<T^#Q?X>\47E[!]NU^UTSR((HDWH\19I8KB
M!<9^<%<X[H1VKLO#OA2WDU5_%.J:/;V.L7$AE6"&1R(05*@N-VQI<%LL`,;L
M#/)(!+X4\,)9V-M-JNE6,=Y:RR&Q48F:RA;I&LA`.!D].@..<5UE%9NMZ_IW
MAZQ%WJ,Q1&;;&B(7>1L$X51RQP">.P)H`GO]2M--C5KJXBC9\B)'D56E;^ZN
M2,GV]Z\<U#Q1JOC0>'+NT%K97#W<HL9`6DB2?8ZM:W497(+)N&X=B<#O6E.N
MF_$1]6%\1<W,.F7#:4T<>%N+6?:R2*K`D2(R;#T.1R.:U_`GA)9YH_%6M:);
MV.J2*A@C1WW@"/;YDPW;#(=S'[N0&QDG-`%[P7X*M]-TU7U;1=/BN8[N6XLH
M!B<6*OC*1N5!`W!FXZ;O:NWHK/UO6]/\.Z5)J>J7`M[.-D5Y"I(4LP4=/<B@
M"Q>7]GIT2RWUW!:QLX17GD"`L>``2>I]*\FU;Q9?:[?:9O%K9XU%XK"\B<N;
M.["L@@NXV'*R*S#<IZ-QZUNW]G:^)_$=U9:TD=TUM9SSZ7&H#0W=O,%&\`Y_
M>(1MR#T<'^*JG@/P<-5TW1];\3:%#:W]G;6T5HN^03,(D4!YQD*S;EW*",J,
M9YZ`&SX7\)YL9D\0:!I<,0N1<6UBA%Q%;R;?G>/<OR!FR0HZ=>]=M1535-3M
M=&TJZU*^D,=K:Q-+*P4DA0,G@=:`)+N]M+"#S[VZAMHLX\R:0(N?3)KQ[6?$
MVH>+XE39;V$FGZR(H+B.1O-T^X!*0M.C##QR;L97@;N^*ZF]2R\7^(;6TO)X
M;BS,3:CH\D85HKA#$89$8'.XJSA\\<./0UC_``Y\$&\TK3=0\2Z'':W>GQ1V
M]N#(XEE\ILAY0K!64,%V*0<;,YY``!M>%/!C@:L_B'1=-BAOIH;C^SXR)X!.
MJD/,H884N2..P7W-=[1574M0MM)TRZU&\<QVUK$TTK`$X51DG`Y/`H`DNKNV
MLK=[B[N(K>!/O22N$5?J3Q7E'B[QG+J'V^S=8(]+L[Z&.2[MI<W.GN&5X+ID
M/RO$6VGCM[\#=O+FQ\4^)-*M=0GAN=$NG74-(DC`,5RR1E7@E#9#$%O,'`/!
M'!4U@>!/`::KIQB\1>'8;:UL9)K>W8L\<]ROGR,0^TC,(!4!6SG&>F,@&OX1
M\%ZA%J>L-X@TS21IMX8Y#:P?O8)[E6.;A48?N\C;\O/(S7I`````P!0!@8%1
M7-Q%:6LUS,VV*%#([8)PH&2<#VH`6XN(+2!Y[F:.&%!EI)&"JH]R>!7DWBWQ
M<VO0:_I+1P#3K*2%VDMYV%RD0*.MXG!5XU;!('9<Y[5JW6N6WBO7-+M);F*?
MPWJPBN=,N84_Y>('WO#+N!&6`Z$`C:1U&:SO"W@-=2DN-/U[0H8M.TJ[NXK6
M0,T4DRR3,X5=A'[G8QRK9R6QP%.0#6\->$M0N;Z^D\3Z;I$]O=VZ)<F+$D>H
M2HQ*3F,C"-M//J3VP*]`AABMX(X((TBBC4(D:*%55`P``.@`IP`50J@``8`'
M:F3SPVMO)<7$J10QJ7>1SA54=23V%`!/<0VL#SW$T<,*#+22,%51[D]*\Q\:
M>,_MJZSH]O#:7VEK8AKE8)S]HDMY%(:>''RNJ'((Z\=N\NM>(-)\97D>E37!
M?P_+=0VTS-`T;Q7:.)8U<.,-%*H"C(QD#KN&*^F>#8=8\0:KIE]X;AM='LKZ
M>2*[&Z&60R`'9"R%2J8)W=0=V,<'``[PGX7U6]UT:IJ<6EW>F7^G>7>7<+93
M5P=IBD>$C"N%W9.3G->GP016T$<$$210QJ$2-%"JJC@``=!3;2U@L;."TM8E
MBMX(UBBC48"*HP`/8`5([I%&TDC!44%F9C@`#N:`"21(HVDD=411EF8X`'J3
M7FWB;QB-4O\`4/#MI!9W^GSZ<S%([@B:]C8,)1;N`4+(/X2<D^G6C6/&5AX@
MNX+.*<3>&;X_V?>2&!T>*63F&3+##0O@H#C!)ZFJ>F^$(]1\2ZWHD_AV.WT:
MWU=K]+SYX6R\$85;<H5(.Y268'&!C&3P`3>$?#%_=:C:WU^FG:EIDEDUO_:6
M[+:C:,%,22Q8P67'+'L,<Y./2K.SM=/M(K2RMXK>VB7;'%$@55'H`.!19V=O
MI]E!9VD2PVT$:Q11KT55&`!^`J<D`$DX`H`:[I'&TDC*J*"69C@`#N:X#Q/X
M\D35DT;0EL;^2:Q:Y53/@W:[F5HX'&5\Q0I;!]N/2OXF\7:3XA@N])MKUGTH
MHUMJKI$RO%%-\D=Q&Y&UD#`@D9&&ST',#^#UN_%MYHL>@VXT,/;7;7C@Q[&6
M/;^X*%2)257+`C`'.<@4`9/@?PYJ.H2>'-6LY+&[TN&$P#4B=LTUCL*_9)H@
M,,R,%&[/1?S]>L;"STRSCL["UAM;:,82&%`BKWX`XI-.T^TTG3X+"P@2"U@0
M)%$G10*LT`!.!DUQ&O>,YUUFVTO0?[)O?.BD),]X46>12`8$=00LF#NY_+J1
M2\1^-]*U)+K3[6\:33D5[?57B1T:.%_W9FB?&&6-^'(R`"3VK)_X0B-O%VI:
M!:>'[5M"N[.P>>\D4HB^5YH/E[,$RL",$$;>ISP&`(_!?AS43<Z5=6$4$NDP
M,5ANKE]MW:P_,LME*H'[S##`R>",]@*]3T[2]/T>T%IIME;V=N&+"*WB"+D]
M3@<4FEZ79Z-I\5A81&*WCR0I8L222S$LQ)))))).235R@`KB_$OCN+3+[2K+
M2I].N9K^66)7FN,1>8@4B(NN=CMN`&>.#[4[Q3XNAMM/NWTR9+H:=(&U2%%.
M\6W*R,C="R9W'&?ND'!-<E<>";,W6G:)HNBVU_I%]I,,<]].N(L1OD2L4VEI
M2K';@@_-G.`:`*'AWP]K^N3V&HV*01VT&J2W$5S<G9=Z8WFM]IMR`,2JQ+`<
MCJ<XKV2PTRPTJ%X=/LK>TB>0R,D$80,YZL0.Y]:9I.DV6B:='8:?$8[="S`,
M[.Q9B69BS$DDDDDD]ZNT`%<CXE\9)ITMK::5=Z5)<S7!MWDNISY4,@7<L;E,
ME&;H,_KP">(O%T4"RP:/<)=WEDQFO+2-&,DENAVS"-AQYB[@<`DY&,#-<.?"
M$,&MZ/9^'])@U;2M2T)[>>_N1^Y?,R2>=*5P6;&2`""2PY`!(`)M.TG6M3N2
MVFV-I&;?4GE<7$V+C2+HR!Y0K@?OHI%8L`<9#@'CIZI8:1INEM<-I]A;6K7$
MAEF,$2IYC_WFP.35;0/#NE^&-.-CI5N882^]MTC.S-@#)9B2>`!UX``K5H`*
MX_Q;XXM]#^RP65S8//-=K;32SRYBM"02/-V\KDC:,\9.3TJUKGB8"WU"ST">
M"ZURS&\6A!(D*89XMW0.4XZY&X'%>>77ARTNK70M4\):;'JZ:PMXD[78`BVS
ML),SE0"1&P(`SG*@9SB@""'1M=\4ZAK<<-A"C'4UFF2XGQ+IEZHCQ/#(%_>1
ML@4@8'0#IS7LUKIEA8W%U<6EE;P3W3A[B2*,*TK#H6(ZGKU]:H^'/#FG^&-,
M%G80[-Q#RL9'<NX4+G+LQQA0`,\``5L4`%%%%`!1110`4444`%%%<WXH\7:;
MX>N;+3+N[6TO-529+.>4?NED4+C>>V2X[4`/\3:U/;6E_IFD[FU]]/DN+&+:
M/WC#Y1C=P2"5)'H17*KI<7C"2]T[7(/[+\:V<,+"\MB2OR%C'/`QQE"78,O4
M9P>QKA[2^\52^*DT-IXGUBVU&22WCGN)YIH62$9E\Q@!]FE((VX&-_`RM?0*
MKT9E428P2.?PS0!F:#HPT>TDWR+)>7+B:[E12J23;%5G5,D+G;G`[DFM6BN:
M\5>,K+PN$BG@O9I)(9)W-K")/L\*%0TS@D?*I=>F3[4`/\2^(A8B71["3_B?
MW=A<RZ;&RC;++&F0H)X)R0<>@)-<C;VL/BZ_DT'QE8M9>*[>V5X;JU8[&5&R
MMQ;M_"RLW(]\'(X'&QZ9XG@O+'1I[FR_MN747O(&+L]PT@#L+LL#@1.$\LQX
MX5AT)%>_HI(1Y%7S0N"1V]0#Z<4`97A[0QHMI*995FO[MEFO9T78LTP14+A,
MD+D*,X[\UL45SGBGQA9^&'MK>:WO;FZNDD>.*SA\UE1,;W(R.%W`X')["@#0
MU75H;&6"R+LEY>I*MI\N0TBKNVY/&[&2`>N#Z5YI`-=U/1[W2->TJ"#QK>:=
M$T%T?]3>I&P<*Q'RK(C,0P&.N0<=,.>\BMTMHY-7U'7-1\06,=Q:&Q=G'VY)
M25EB#8$848R#@84@CJ*]PT\7;Z=:/J4<*WPB4S"(Y19,?-M)YQG-`&1X7\.W
M&CF[O]3OC>ZOJ!5KN55V197.U40=``<9.20!D],=#16'XG\46OA:RAGGM;R\
MEG<I#;6<8>60JC.V`2!PJL>O:@"UJ>NV.D7FFVU[(T;ZC<?9H&V_+YFTL`3T
M&<8'J:\Q235]4L9-`\:Z9#!XHU+29[73=0CYBF#IN,3XX5U8`D=/ER/?G;S6
M=2\16]I,U[/)9:G>>4JM=QN)B9@(I;:/)>*2+<&92`/DP3S7NNF)>?V59?VJ
M(6U!(E\]HA\OF8PQ7/0'G\Z`.?\`!7AG4='^U:IK=ZMQK%_'$LZ0C;#"L8(5
M$'?`)RQY-=;16/XG\2V/A+16U?4EF-I')''(T2[B@=@NXC/09YQD^@-`%K4]
M7L](6U:]D:-+FX2V1]I*AVSMW'^$$C&3QD@=Z\VBN]6_MF?3?%^F+]OOXKNU
MT35`N%9),G[/*%^57PJD'H0.N<D\IXCU?4TU[64G*7%MJX+6"8GN8M4MVQY<
M<!3Y87`&2V,AL'IU]M\/0:G#H-I!K4D<]]""C2K_`,M`I(5SZ,5P3CH2:`,'
MP5X1O=)D_MG7;E)];EM([1EMQMA@A3[J`?Q'/)9LG/3`KLZ*R/$?B.R\,Z?'
M=7:RRO-,EO;6\(!DGE8X5$!(R3]:`+.IZM::/%!+>N8XIITMP^TE5=SA=Q[`
MG`R>Y%<#)JFI6NO^1XUT]5LKC4+F'1M2AR3`'9HTCE"\#<ARI.0<C//3%\2Z
MU)=^$[KQ)'J<=U8:D;BU72]2$J^;\R@0I$/NRC9*-W/..O;T[PU!J</A^UM]
M:=)KN+*^9U+J#\C-QPY7!..^:`.6^'7@G5M"CM;_`,0W<3W]M8C3[>WMN(XH
M0V?F/5V)`.>@[5Z#16;KNM6^@:6U]<Q3S#S$BCA@3=)+([!411D#))`Y(%`$
MFKZM::'I<VHW[LEK#M\QU4MM!8+D@=AG)/89/:N%O=4U+2O&<-SXFLA=>'Y;
M[_B5:A&OS6$K+Y860+U1]QPQS][GJ,<?XC\;ZA?SW\RWL]G;7MLKZ:DBB2`X
M7$EG=1<[)&(8!LYY`![5ZCX#TS5M*\*0:?K$B2F$E;8YW.(."BO_`+2_=^@%
M`&)X+\":AIVHP:KKUTCSV*RV^G6MM\L<$3L22Q'WF/IT'UZ>A453U;4[?1M(
MN]3NM_D6L32N$7<Q`&<`=S0`:KJ=MHVF3ZC>,RVUNNZ5E4MM7."<#L.I]`#7
MEOB37M7EUK5(KVWCU+2[2[@F.CO&J/);*R,EQ!)_RU^<'<AR,8'&<G"\0^,'
MO?%D^JI/<V,4*)9M#?1RR)8R;7#I-;1D[Q)N4*_(X]0*]$\!Z-/+X4TY=>TR
MV(MRDVG13Q[I+5&0$(=PRI0ED'?:HSS0!9T+P+#HNIEUNVET^UG,^F6Q!#69
M=661`^?FC.[(4\`@>E==145Q,+:VEG96<1H7*H,DX&<#WH`9?7<>GZ?<WLJR
M-';Q-*ZQJ68A020`.IXZ5Y3XCUG5=5U#4%FN;6\\/21)<1:455/MUEM5S-!-
MGYI`V[<AXP%!X;)MS>(Y-?M3XSTGQ/#9Z7!Y$9M;UG58'W,)4F1>I;<@!.<8
M)''-7/AQHL^H>%R=>TRSETV:<7FG6T\(;[/NR6"JPX3=EDS\P#8.,4`:FC^"
M;2TUY=6L[AETEV%];:>R$?9[EU8.Z'.55E<Y3&,_E79T`8&!5>^O;;3;"XOK
MR58;:WC:661NBJ!DF@!]U<+:6DURZNRPQM(5C7<Q`&<`=S[5Y%XH\4ZWJ>L7
MUG9O:7&D7.G":ST^4!8]5MF3]\4GZK*N1A>F.<&CQ)XWGUAWNK237]&L[&`-
M-(L!5[1Y,M#/+&,B6%E5@1R5[@'!&O\`#2QDUSPQY^L:=9SZ9<2?:K6*:,.(
MYM["0QJPXC9E$B^GF$#@"@#0T;P9:SW<.KV[RVVCWPAU(:2Z[6MKO*N'1@?D
MR,AE'!R>U=W0````,`4V218HVD<[40%F)[`4`)+*L,3R.2%4$G`R>/8=:\J\
M3^*]7U46UYH5W$^C7UD&M[29!&FHYW":'SL[HY@N-HXZ-UP<1:_?2?$2UGO-
M+;48CH\4&IV6F20B+[82Q=)2P9MRLJ%57@@Y)[8Z7PMHUCJ%OJ$T<-M>>%M8
M"7\%I<IO\F=L^:FQA@+D*V.S%J`(-!\,:1KEEINL:>LD&BWD,%V=/<%2L\90
MQ2J0?D8!2K8X88^M=_38XHX8EBB14C0!511@*!V`I6940LQ`51DD]A0`M>2>
M*_$^JZQJ=G!I=U:+H>H6;Q107MN#%>709EDM9G)!B;;G`'4CKQ5F[\<VWBV>
MU33-9N-!B^S7$]L]ZAA%XR[?+D0C[T:E9-R$@D8X(I?`JR^*=0UZZNK?3+[P
M_>7+K*J1L;>:9`FV6-)`?O*2K]MT8(ZF@`L/#VH^,KI[V1UT[PSJ-O;236J#
M-Q+)&NWR]_\`"JD`[AR<#!KU$#``ID44<$210QK'&@"JB#`4#H`!T%/H`*\P
M\4>+K[5DLQX;U.&TM99+BT=KRV!CDNT8*+>8MS&'&[!X))'(Z%/%'C,ZU%<Q
M>'IKR5]#U!X]8L+63R;IX5W(6B(^\`V&P.N,'%0?#F&76M4U>_6>'5-#O,PW
M,TT6U;MU5&CE\O`4/L=HY!C[T8/M0!3L?#^H^.VM+BT`T709=.CTS4K7.^=7
MMII,Q1L<\9/W^N!ZU["BA$5!G"C`R<FH[2SMK"UCM;.WBMK>,;4BA0(BCT`'
M`J:@`)P,FO,O&_BS47N;2'1]02PTY;J:QU&ZGM1(L-P-OEI,&P5B?)^<=0RD
M'D9NZWJ%MX[U/4O!EGK4VE3V3%;^#RP);F(H"IC?=PF6&[C)''&>9M%TZ74K
MBTU`P0*[PG3=?L)N49HT^5@".2#@#^\D@/84`<]I>@:SXA73TLX[70]/ALGT
MG5(XQYK8CDYCB+9!5A_$<X!/>O4[&SBT[3[:R@+F&WB6)/,<LVU1@9)Y)XZT
MMG96NGVL=K96T-M;QC"10H$11[`<"IZ`"O/_`!=XMN9(Y;70]2.G-9WXM-1N
MWMA)]F+1[HV*M_RS9BH+XX&<>H76_&>GZ]-JGA'3_MZ7EQ%<V<&H11_N5NHX
MB[1AP<[U&#T'3&<US'P_7Q9JWBBWU:[M3+I;VIMI;^YA\IM1M_FV.R9/SJPP
M,CYE<G/3(!'9:)K?BE;&VTZ"TT*[TLW>EZRZ#S4*2^7+NAR3D-DD`_=WGVSZ
M_IFGQ:5I5IIT#2-#:PI"C2-N8A0`"3W/%.L-.L=+MOLVGV=O:0;BWEP1A%R>
MIP!C)JS0`5P/CKQ9>6<$T&CW,MLUA=1+JLZVPE>VMY$)$RHW#(&P"1TVMZ9#
M?$OCNSDUF7PM:75S87`N(8)M2:/%NA8JS1"0'*2,A(!(QD]<BN;TF/Q)>?$K
M3UM;[2]133('MM3NHM^YHC(P\B9FSO<##*1SD-GAN0!K>%9O&N@)HT5AIMG<
M6D^RXU*WN'*F.1UG,MN!D$2#.58C:3]*]7T71[/0-'MM+L%9+6W7;&K,6(&<
M]3[GZ5+8:98:5;FWTZRMK2$L7,=O$L:ECU.`.M6J`"N-\9>*);/3M0MM*EFB
MOK*2`W<D=OYKV]O(?FF1#PX`#>N"#P<8IWBGQ7;P:A-X4L[Q;7Q!=V7VBQ,I
MV)(2S*$#\X8[#CCN.O2N(T'4+[5?'MK'I-U?R7=C'FZMM55EEM(RZK+;RR8_
M>*0PDC;YCF,\X)H`K_V=J7C2POO#1M=*?6[&59_[72>1(GBG82+<Q"/.)"8P
M2IP,]."17L&CZ1:Z'IL=A9*5@1G8*3G!9BQQZ#).`.`.*?8:3IVE^=_9]A:V
MGGOYDOV>%8_,;^\V!R?<U<H`*Y'QGXANK6TN],T662/6%@CN=RP>:RV_F[)7
MC4\2.@R=ONO7(%.\6>)[>PO[/P[_`&BVEW^JH1;7[PAXT(8`KR1B0@G;GC.,
MYZ'EH?"=U82?V/I<[KK>C7O]HZ;>7CEOM5O,P\Y7?'/)96'7A#W%`%!=(OO%
M&CW>DQV^D7NI2YNEUF*YDCAF252@N$5,[9E*+E3@'!P>2*],\->';7PSI`L+
M5WD+.99I'/,DK8W-CHN2,X&!S5VRTO3]/DGELK"UMI+AM\S0Q*AD;U8@<GW-
M6Z`"BBB@`HHHH`****`"BBB@`K.U+0=*U@2?VAI]O<F2!K=FD0$^6Q!*YZXR
MH/U`HHH`;H&BQ^']'ATV*ZN;J.'<$DNGWR!220N>X`.!["M.BB@`K&\3Z&->
M\/:G8Q^7'=75E-:QS.N=@<?GC(4GZ444`-\+Z3?:5I*+JM^]]J4I\RXE)^16
M(`VQKT5``!@`9QD\DUMT44`%8GB7PS:^([:WWRR6M]:2>=9WL./,MW]1G@@]
M"IX(ZT44`,\/>%K70XA(ZV\]\7D=KA+<1!3(07"+D[%)4'`/6MZBB@`K+U[0
MK;7[&.">26&6&59[:XA($D$J]'4D$9Y(P0002#P:**`*7A?PLGAPZE*UPD]Q
MJ%U]JF,<`AC#;0ORH"<$XR3GDDUT-%%`!4-S:6]XBI<PI*JN'4.N0&'0T44`
M9F@>&;#PTMU#IOF1V<\OG):%LQV[$?,(Q_""><=,DXZULT44`%0SVMO<M"T\
M,<IAD$L1=0=CX(##T.">?>BB@#E?!?A&_P##[WDNI:F]SNN;AK6VC)6&&.24
MR9(_B<Y!R<[>@[D]A110`4V2-)5"R(K@,&`89Y!R#]00#110!SVC>$XM)UZ]
MU3?;9F3RHHK>U$*QQ[B^&P3O;)/S<=>E='110`56U#3[75=.N-/O81-:W$9C
MEC)QN4C!'%%%`'-:'X$ATCQ`NK2W\MY+!:FSMC)&!(L.00LCC_6D;<`D#`ZY
M/-==110`4R6*.>%X94#QR*5=3T(/!%%%`&/%X5TRV\1MKEI&UM<RPF&Y2$[8
M[D<;3(O0E<<'KR16W110`5%<VT%Y:S6MS"DUO,ACDCD7*NI&"".X(HHH`Y&7
MP=>S_$"36/[2>VTC[/;C[':L8VFDB,FT.1C]V`_W1PV<'@8/9T44`%(0&!!`
M(/!!HHH`XV?P1(/&EEJ5A=_8-)BLHK>6TMOW9?RG+1H"/NI\W('7:!T)KLP`
M``!@"BB@`HHHH`XA?AM8PZS;SV]SY>E07JZA'IQA#+#<#G=$^<HI/)4`@D#&
M.<]L``,```=A110`M%%%`'.ZGX*TC4+ZPOXHVL;ZRN3<1W-GB-V+,6D5N/F5
MR3D'U-="``,``#VHHH`6BBB@#$U'PGI.H%91;BUNTNA>)=6P"2K+@`MN'7*@
M*0>HX-;>***`"BBB@#DO%7A2\U:ZTB71;R+3)+>^DN+B=$!?:\+QLRC&"Y#8
MR>G7G&#T]I;)96<%K$TC1PHL:F60NQ`&.6.23[FBB@":BBB@#C_$/@&UUC4;
MG4+.Y6QN;Z'[-?AH!-%=Q=!N0D#>O\+]1[CBNKMH$M;:.!"2(T"Y8Y)P,9)[
MGBBB@"6BBB@#(UWPQI'B*SN;?4;.-S<(J-,HQ(NPL4*MU!4LQ'ID^IJ[IMD=
M.TVVLS<37+0Q+&9YR#))@8W,1U)HHH`M4444`9NL>']*U^QN+/5+&*YAN(Q'
M(''.`21@]0022".0:FTNP&EZ7;6(N)[D6\8C$UPVZ1@/[Q[GWHHH`N4444`%
2%%%`!1110`4444`%%%%`'__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>graph6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 graph6.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`$3`?P#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V6Y\16]OJ
M4MBL,LLL;Q1$K@#>ZN^"3P,*F<G^\H[U+IFOV>KLBV8D?,"3N<#$8;[JL<XW
M$9.!GCGH1G*MM(N8M;\3QB"*1-1DM[F)[B,M%_JUB8'LQ7RMVW_:'3.:-/\`
M![Z=?Q7*:O<2A95F<R+^\<[-K+D$`*QRY7;UQC`"@`&[I=^-3L%N1$T1+O&\
M;=59'*,/S4U<K%\*QR+HIFDAEA:ZNKBY$4J%'59)G=0RGE3M(R#T.:VJ`"BB
MB@`HKR27Q5XN?XFZQI]C=VTUA9Q3>:IB?R;51#NB+GRP=^_&=KMD'`7C(TOA
MUXIU>]\.2W.N7+.MQ<"+3+F>-CYY,>X](TRN0<':.XR<"@#TFBO/?A/X@UOQ
M%I5_>:K<?:H/.7[/<!"JN<'>$S&AV`XQD'&<;CCCT*@`HHHH`****`"BF--&
MF_=(B[!N?+`;1ZGTZ&DAN(+E2T$T<J@X)1@P!_"@"2BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`*-UK&FV6H6U
MA=7]O#>76?(@DD"O+_NCJ:B3Q%HTNLW&D)J=LVHVT?FS6XD&^->.2/Q'YBHM
M=T=]4FTN6$0A[2^CN&:3KL7.0"`>>1QTKG9O!%_=:U>&6ZM8]-<W4T,D2L+@
MR7$>QE?L57)(YR<+P,4`=9I.LZ9KMG]LTJ^@O+?<4\R%PP##J/K5ZN9\(>'+
MS0SJ5U?S6S75_*CO%:*5AC"1K&NT'G)"@GW..V2[Q!$4UO0`EQ=QK>Z@T,ZQ
MW,BJR"UG<``-@?-&AXQT]SD`Z2BL_P#L:U_YZWW_`('S_P#Q=']C6O\`SUOO
M_`^?_P"+H`T*IVNJZ??7EU:6E[;SW-H0MQ%'(&:(G.`P'3H?RJ,Z-:D?ZV^_
M\#Y__BZ\ST/X'#1_$E[JJ>*]7B\TDPO:N$FP>6\QF#!_RYZT`>N45P\_@+5V
M4_9_'_B*,]C(T3_R04^/PCXD@B54\7-.PZM=03$M_P!^YT%`':T5PUUHWC.%
M1]EFTF[/?S+Z]@_+#O[50N)O'%F`?^$-^W<X/V7Q/*IQZ_O,?Y-`'I%%>>+K
MM_"N;WP/XM3_`*]M1$_\IQ6@-;T=%!N;+Q7;9_OV]\^/J4W#]:`.>T'P+J\'
MQ!U?6;RV:/2DENS%;R20ROJ`F_O%5!V<<+(3C@<#)/<>$]"CT'1!"($AN+B1
MKJY5%4!9'.2HV\87A1[**XKQ/\2O!WAJ&+-QJ]U<R2*/LZSW4;JF?F<[R.@S
M@=S@>I&S;^+O`-S$DB>+8%#@$"36)$(^H9P10!W%%<U:7_A74!FR\117(SC]
MSK3OSUQQ)6E'IEC,N8KF[<8SE=0F/_L]`&G16?\`V-:_\];[_P`#Y_\`XNC^
MQK7_`)ZWW_@?/_\`%T`:%<GXY\3ZCX8LXKFRL4EA$<LL]Q*DC1QA%!"G8"5+
M9.&/RC!SU%;G]C6O_/6^_P#`^?\`^+K.U7P1H&N?9_[5M)KP6[^9$L]W,X5L
M8S@OB@"O!XBO9/$-C;W!L[2RO8U-O'*K&:9S$795(.`5XSD=*ZFN;_X0/PX=
M=&N&QE.J!=HNS=S&11C;P=_'!(X[5J?V-:_\];[_`,#Y_P#XN@#0HK/_`+&M
M?^>M]_X'S_\`Q=']C6O_`#UOO_`^?_XN@#0HK/\`[&M?^>M]_P"!\_\`\71_
M8UK_`,];[_P/G_\`BZ`-"HC<P"$S&:,1`X+EAMSG'7Z\5G76B0/9SI'+J`=H
MV"[-0F!SCC!+8!^M>/6?PMUFU^'][97.C37=U>WL4J:>NJHGD`)@R,VP1L>@
M("DXY#9Y`![O16/8:%'#IUK%/)=B9(D601W\^W<`,XR^<9JQ_8UK_P`];[_P
M/G_^+H`T**S_`.QK7_GK??\`@?/_`/%T?V-:_P#/6^_\#Y__`(N@#0HK/_L:
MU_YZWW_@?/\`_%T?V-:_\];[_P`#Y_\`XN@#0HK/_L:U_P">M]_X'S__`!='
M]C6O_/6^_P#`^?\`^+H`T**S_P"QK7_GK??^!\__`,71_8UK_P`];[_P/G_^
M+H`T**S_`.QK7_GK??\`@?/_`/%T?V-:_P#/6^_\#Y__`(N@#0HK/_L:U_YZ
MWW_@?/\`_%T?V-:_\];[_P`#Y_\`XN@#0HK/_L:U_P">M]_X'S__`!=']C6O
M_/6^_P#`^?\`^+H`T**S_P"QK7_GK??^!\__`,71_8UK_P`];[_P/G_^+H`T
M**S_`.QK7_GK??\`@?/_`/%T?V-:_P#/6^_\#Y__`(N@#0HK/_L:U_YZWW_@
M?/\`_%T?V-:_\];[_P`#Y_\`XN@#0HK/_L:U_P">M]_X'S__`!=']C6O_/6^
M_P#`^?\`^+H`T**S_P"QK7_GK??^!\__`,71_8UK_P`];[_P/G_^+H`T**S_
M`.QK7_GK??\`@?/_`/%TR;3;"VA>:>ZNXHD&6=]0F``]R7H`O7%Q%:6TMS/(
M(X8D+N[=%4#)-9=CXLT'4[R.SLM4@GN),[(T)R<`D_H#7-WX;Q)%)I^@0WDU
ME<1M'-J5Q>3^2@(P=BEOWG?V^M4_#WPI.BZY;ZA+JYF2'=F.*-HF.5*\,'R.
MO]*PE4FY)05UU9S2JU'-*FKQZL])HK/_`+&M?^>M]_X'S_\`Q=']C6O_`#UO
MO_`^?_XNMSI-"BL_^QK7_GK??^!\_P#\76A0`4444`%<_P"(?^0YX3_["LG_
M`*175=!7/^(?^0YX3_["LG_I%=4`=!1110`4444`%%%%`!1110`4444`8WB#
MPGH7BF*&/6]-AO!`VZ,N"&7D$@$<X.!D=#4TOAO0I[<6\VBZ=+"JA!'):HRA
M1T&".E:=%`'-O\/O!L@PWA;1A_NV4:_R%5A\,?!2S"9/#MG%(#D-$&0@^V",
M5UM%`'.?\(-H2@"--0A`Z>1JEU'C_OF04A\&VRKB+6/$$7O_`&K,Y_\`'V:N
MDHH`XW_A!M1C.;?QWXE4_P#362"0?D8ZI7_@_P`<F%QIOQ'N$8JP"W.FP-GT
M^90"OUP:[^B@#QWP!X2^*&AZ?=BXURRA#SNR6M\C7()))+AE8%0Q).,^Y&:[
MBV'CZ-?])/ANX.>/+$\/'X[ZZJB@#G?MWB^,G?H.D2CL8=5D!/X-`/YU5G\1
M^*K>0+_P@UQ.N,EX-2@(Z],,5/Z5UE%`'(/XSU2$`S^!?$(_ZY?9Y/Y2U8@\
M:))&'G\.^([4]UDTYG(_[]EOKQ73T4`<Z/&^B@$RKJD&.OGZ3=1X_P"^HP*Y
MVX^-7@ZW\2P:0;UC&ZGS+PHRQPOV1LC.?4XP.,]\>B5S^I>!_#&L:RNKZCHE
MG=7HC,9>:,,&'^TIX8CL2,B@#=BECGB66*19(V&59#D$>QI]<J/AYH%LDG]D
MI=Z-)(2=^F7<D&">^P'8?Q4U5M]#\<:1<'['XGM-6L\C;!JMKMD5<=/-BQD^
MY4_2@#M**XZ[\7ZWHSC^V/!]\T'`:YTJ47B#WVX63'_`:T-/\<^&M2PL>KV\
M,Q_Y871\B4=ON/@_I0!T-%-1UD4,C!E/0@Y!IU`&;/XAT>VUNWT6?4;>/4[A
M=\5JSC>PYYQ^!_(TZPUW2=4N[FTL-2M;FXM6VW$4,H9HCDC#`=.01^%8FH:#
MJTWBY-2M$TQ;<O;EYY"WFJD9?<NS;AB0[`,6&W/`/>SH&C7FFZOJ$K6EA9V,
MQ+)%;3-*TDC.S-*Q9%VD[ON@L/>@#HJ***`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HK-U?7=/T2#?=S?O&XC@C&Z64^BJ.360+;7?$C127CR:/IA
MY:TC;_2)1Z.X^X#Z#GW](<TG9:LB51)V6K+EYXHMTN7LM+@DU2_0X>&V(VQ_
M[[GY5^F<^U5HO#EWJL[W'B:Y2ZC)!BT^+(MXO][O(?<\>WIN:?IMEI-H+6PM
M8[>`'.R-<#/J?4^]6J7(W\1/(Y?']W3_`((U$6-%1%"HH`55&`!Z"G445H:A
M1110`4444`%%%8:>+=+?6+[33]J1[*-Y)IWMG6$!0I8"0C!(#*2!ZT`;E<_X
MA_Y#GA/_`+"LG_I%=5:T'Q'IWB2UEFL&F!A?RY8IX6BDC)`895@"`5((/<&L
MOQ-J5A!X@\,1RWMM&\6J.TBO*H*`V=S@D9XZC\Q0!U5%9_\`;NC_`/05L?\`
MP(3_`!JI>:E9W]UI]K9ZG&QDN#YBVTXW%1$Y['.,A:`-NBL%I--5BIU.]!!P
M?WLE)YNF?]!.]_[^R4`;]%<[?W6EZ9I\5]<ZAJ7D32B&/RO.E=W)(`"("Q/!
M[5`-6T(Z7/J+:O?I!!((I5D:9)4D.,(8B`^X[EPNW)R,`YH`ZFBN6O-6T2QL
M+&]EU34WAOG\NV\@3S/(V"V`B*6SA6ZCC!K0T^.RU2T%S9ZA?O&25(:61&4C
MJK*V&4CT(!H`V:*YRTO=)O[_`.QVNI:E*Y#;95,WDN5ZA9<>6Q'/`8G@^AJ_
M':6DHD,>I7+B(E9"MV3L(Z@\\4`:E%84LFD0PPS2:Y(L4\@BB?[:<.Y.`H.>
M35B*TM)Y)(X=3N9'C.'5+LDJ?<`\4`:M%<[J-YH^E221WFK7J21QK*Z++([!
M6;:O"@GD]!U.">@.$2]T>6*ZEBU>\EBM;=+F:2.:1E6-E+*=PX)*C.!DX(..
M1D`Z.BL\:7&P!%Y>D'D$7+5D^%O$EG<^$-$N-0U:U-[-I]O).9)D5B[1J6)&
M>#DT`=-16?\`V[H__05L?_`A/\:/[=T?_H*V/_@0G^-`&A16?_;NC_\`05L?
M_`A/\:/[=T?_`*"MC_X$)_C0!H45G_V[H_\`T%;'_P`"$_QH_MW1_P#H*V/_
M`($)_C0!H45G_P!NZ/\`]!6Q_P#`A/\`&C^W='_Z"MC_`.!"?XT`:%%9_P#;
MNC_]!6Q_\"$_QH_MW1_^@K8_^!"?XT`:%%9_]NZ/_P!!6Q_\"$_QH_MW1_\`
MH*V/_@0G^-`&A56_TZQU2V:VU"S@NH&&#'/&'4_@:A_MW1_^@K8_^!"?XT?V
M[H__`$%;'_P(3_&@#G[?X;Z+IEP\^A7&HZ*[G++871$9/J8WW)^E2G3O&UG/
MNM=>TW4(,_ZN_LC$^/\`?B./_'*V_P"W='_Z"MC_`.!"?XT?V[H__05L?_`A
M/\:`.*\5?$C5_!FFRW.K^$)RHPD=Q:W:RV[.>@+8#*/JM7_`7Q+TGQQIHD&V
MQOT(62TFD7)./O)SEEZ\X[5T%UJ>@7UI+:W5_ITUO,I22.2="K*>H(S65JFF
M^!M9TF'2]071Y[.!!'#&94!B4#`",#E>/0B@#JZ*\_32X=&M3'X:\=_9@#E+
M;4;E+R`=/E&X[U&..&QWQ26_C[4=(MF_X2.QLKH1];O1+M)E8>IB9A(/PW4`
M>@T5S.C_`!"\*:ZA-GK=JLB\-#</Y,BGW1\&M;^W='_Z"MC_`.!"?XT`:%%9
M_P#;NC_]!6Q_\"$_QJCK&OZ6FE7$B>)+.Q\M=[3I)'(54<G"G(/'M0!O45YE
M<>,)]-CT*74/%MDD<D8-W%%Y+W$DCR*$4)C[JJ6#%>1C-=[_`&[H_P#T%;'_
M`,"$_P`:`-"BL_\`MW1_^@K8_P#@0G^-']NZ/_T%;'_P(3_&@#0HK/\`[=T?
M_H*V/_@0G^-']NZ/_P!!6Q_\"$_QH`T**S_[=T?_`*"MC_X$)_C7F_Q+\9W>
MG7]D-$UE$A,+&7R'1QG/&3SBLZM14X\S,JU54H<[/4KJ[MK&W>XNYXX(4&6>
M1@H'XFN=CUG5O$.]=#M_L5F&Q_:%Y&?W@]8H^_U;CVK`\'SZ7K6DZ;K?B#7(
M[R_0N8HKBX14A(<@$(,?-@`Y.>U=O_;NC_\`05L?_`A/\:46ZB3V0HN51*6R
M?W_\`@TCPY8:1<3W<8DGOKC_`%]W.VZ23^@'L`!P*UZS_P"W='_Z"MC_`.!"
M?XT?V[H__05L?_`A/\:T225D:QBHJR-"BL_^W='_`.@K8_\`@0G^-']NZ/\`
M]!6Q_P#`A/\`&F,T**S_`.W='_Z"MC_X$)_C1_;NC_\`05L?_`A/\:`-"BL_
M^W='_P"@K8_^!"?XT?V[H_\`T%;'_P`"$_QH`T**H#7=()`&JV))[?:$_P`:
MOT`%<LWA">?6]1NKO6));&\AEB^RK`J.!(H4AI.K``?*,#'J:ZFB@#!\->&O
M[!-]<3WTE]?W\BO<7#($W;$"(`HX&%4?4Y/L&^(?^0YX3_["LG_I%=5T%<_X
MA_Y#GA/_`+"LG_I%=4`=!6?J/_']I/\`U]M_Z)EK0K/U'_C^TG_K[;_T3+0!
MCRZ%>O,[!4P6)'S4W^P;[^ZG_?5,O?B=X+L(IWF\16+-`#NCCDWN2.P4<DUD
M^'OC3X.UVVEDFOUTN6-]IBOB$+#LRGH1^H_(D`W-5T*^O-*T>VA?RY;748[B
M1U895%+$D9!!/([5@7WA#6;S3+_39T22WN]4,U].DB":_MMF%_AVI(I$8P`H
MPF01FNDO?%D#Z+::CH)M-56[NTM8C]I\N/<S8R7"L1C'H:FO?$)T324O-<MD
MMW"N\PM93+%&J\D^8ZIDXP<8R><`X)H`Y:Q\.>([?2O#$5Y;PRR:-J)D*6YC
M3-N(71,#Y1N^89'KG!Q76Z/I]Q$FJ37:B*34+II_+#;C&OEI&`3TSA`3C(R>
MIKGI?B/%'XLGT7^SBT45W!;_`&D3?>62V>??MV]MFW&><YR.E7U^(6@O&'5[
M@@Z:FJ#]R<^0[;%/USVH`?X1T_5=!T'3-!N;6-ULXS"]Y'*`C(N=C*O+;C\N
M00`.>3@9YIO`FI74<B7%K!Y*Z`NDR0+=F(WD@<-YA=5;:``<$J3EV!&.O82^
M*]/M]0%E<K/!,IB64N@*PM*Q6-68$C+$<8)QD9QD5#KWB&_T[7](T;3M-MKN
MXU&.>0-<7;0)&(MF>5C<G._T[4`8MCX:UJ*U?[0(Y`NL07D6](DN'B4*&,IC
M"HS\'![@#)SQ5CPSX<U31M=#C*:8(9@T5Q(D[H[R!P(9`@?RS\Q(<]<8'>HV
M^)=C;Q:;<7MH]M:75M=SS3,Y;ROL[*I"@+\X8G@\9&..>+FM>/++1+6RN[JT
MN(;::]-K.]RIC\D")Y"Z\$2#"X!4D'/!R,4`9PT,7/C[Q9%J<#7-MJ%E936B
M"4H2(MX90P(*D.5/7^+WIL>EZWH5C>"X:T71Q8/+/!"!@2>6VY1D;L`[%7G&
MU<=<5TU_XB@L?"4WB%[>X\E+;[0L#ILE;(RJ[3T8Y`P>YK''CKRM4O\`3[S3
MTMY[2&,A#<Y:29Q'M0#:/E9I0BOW*OP-M`&[X:L;C2_"VD:?=OON;6RAAE;.
M<LJ`'GZBJ?@3_DGOAK_L%6O_`**6KR:I(/$']E36RIOM/M,4JR;MY#;77&!C
M;N3![[NV*H^!/^2>^&O^P5:_^BEH`Z"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@"CJNBZ9KMF;35;"WO+<_P3QA@#ZC/0^XKG;?P
M-)H=HT/A?7M0TU`,1V\["[MT]`%DRP'^ZPKL**`.-LM8\9Z4DB^(=!@U&-,D
M76B2`DCGK#(0V?\`=+>PJ[H?CWPYK]VUE:WXBU!3AK*[1H)P<9QL<`G@]LUT
MM4=2T72]8B,6I:=:7B$8Q<0J^/S%`$\-[:W%U<6L-Q%)<6Q431*X+1[AD;AV
MR.14]>'6WPZE^%GBE_&:WMSJ&C0,XN(8L^?'"RXWMVD"MU'H`W;%>V6US#>6
MD-U;R"2"9%DC<=&4C(/Y4`2T444`%%%%`!7*:&5\1>(;KQ!)&?L]H6M-/)[@
M<22?B>!["I?%.LH"OAVRG*ZOJ*B./;G]TC9W2$]L*K'USBM^RLX=/L8+.!0L
M4$:QH,=@,5G\4K=%^9D_?G;HOS_K]">BBBM#4****`"BBB@`HHHH`****`"B
MBB@`HHHH`*Y_Q#_R'/"?_85D_P#2*ZKH*Y_Q#_R'/"?_`&%9/_2*ZH`Z"L_4
M?^/[2?\`K[;_`-$RUH5GZC_Q_:3_`-?;?^B9:`+$UC9W$3Q3VL$L<@(='C#!
M@>H(/6LOP]X/T+PO926NE:?%"DDAD<D;F8GU)[#H!6!XM\6ZW8>'[V:UT6^L
M)(RH2\D,3JOS@9VY/4<=.]8?@7QUXCU&2^%W:W.L;`A40)%'Y6=V<_=SG\>E
M8/$04U#6[.:6+@JBIZW?E_3/1-6T2VU>VM;>8*(8+F.XV;`5;:<[2#V-4=<\
M)V^KQQI#,+,):7%H!'$I54FV[BHZ!AL&#[GCFJNNZIJ<NDZ48#=Z-/>:C%;2
M?+$\B(=V<;@Z\X':LA?&&K6.K?V'A+V1=:33%O+@!69&M_.+L$`4LO3`"@C'
M2MT[G0G=7+O_``KBS;7Y-6>_G+R7$,[1A0!F.V:#&?<,3]:@M?AC;6XPVJ3R
M*NDQZ2F8U&(DDWJ3ZMV/:KDGC*>+4=/MFM(RESJ=W9.P)R%A1V##W.S]:K>&
M?&^H:YJ^CV]S8VL-OJFE/J2&.5F>/#JH0Y`SPP.[C)R,<<@S5OO!]I>Z[+J;
M/'F9H&E22UBE.8CE2K.IVYX!Z]`5VGFI]8\+6&N:WINHWRK,EC%/$+>2,.D@
ME"@DY]-GZUS7B+Q5JUGK6J^&;&Y5=7NFM7TIF124BE.R1@N,-Y?ER-SG[PZ]
M*#X\O9=0O=/ABB:,6%[/;WL62`]NVS'S`;CGD_*%!X!<<T`:8\!ILTM7U2=S
MIMI/9PL\2.3')M`#!@0Q4(!R.>]57^%VCSV:V<[!K0ZB;][5(@L.3$8]B)_`
MO.[J3FFZ3XWO+CSH)K>-WM[G3K4R9P7^T1QLS$#@$%SP.*O^&_%EYK=]&DNE
MS16MPDTD4RPR;(_+DVA7<@*68?,,=,$<]:`)M5\.7+_#R;0+6Z>YNHK01V\U
MR>9'3!3>?<JH)^IJ]>:2NNV5LVH1O!(('S#D$Q2.FTL",C<H+`$9')KGM2UW
M6]1\0>)=(T4R+)I5O:;5B6+S'>5BSE3+\N0BX&>,DY[8CT_Q5=S6US:7^J6L
M.M-9`6\%O'NC,JQN6D#$$?,T<FU2?NQYQR:`-G3-%N++Q%"YB`M+2RECCE7:
MJO)/,)'54!)55\M,9[-@9P:D\"?\D]\-?]@JU_\`12UH:%J8UOP_INJK&8Q>
MVL=P$)SMWJ&Q^&:S_`G_`"3WPU_V"K7_`-%+0!T%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`!`(((R#7GH23X:ZQ\
MB22>$M0F:261W^72I2>P[1,2/93G)YKT*H[BWANK>2WN(DEAD4H\;J"K`]00
M>HH`>"&4$$$'D$=Z6N"T>YN/`FKP>&]4GFN-&NWVZ3?2#/DL>EM(?_0">O3L
M*[V@`J"\NX;"RGN[APD,*&1V/8`9J>N4UL)XC\0VV@13'[/9,MWJ&WH<8\N(
M_P"]R2/1:F<K+3<B<N5:;C_"NFR7&_Q%JEH(M6O2S!6ZP1'`5!^"@^N2:ZBB
MBB,>56'"*BK!1115%!1110`4444`%%%%`!1110`4444`%<=+\0;>+7]0TXZ;
M=+;V4<I^UN"J3O&A=TCXPQ`'.2#Z`@$UV-8P\*:)_:<^H&RW3S[S(&E=HR77
M:[",G8&*\%@`2.,T`0^&O$CZ[)J-K<V7V.]T^1$FB6;S4P\:R*0V!GAAGC@@
M]>M5/$VH0P^(/#",ER3'JCEBEM(P.;.YZ$+ANHX&>_H:V='T+3=!@DATVW\I
M97WR%I&D9S@`99B2<``#G@``50\0_P#(<\)_]A63_P!(KJ@#0_MFU_YY7W_@
M!/\`_$53O]12:2SE@ANF:WF,A62SG4$&-UZB,_WA6Y10!AMK<K##:?(0>Q@N
M/_C-(NLR)G9ISKGKB"X'_M&MVB@#F[Z\CU**..ZTR5UCD$J$1W2E7'1@1$"#
MS4"_8E^SXT0DV\YN8V,-R6$I!!<DPY+$$C)SUKJZ*`.0\G3_`.T%OQH9%TDK
M3))Y5S\DC+M9@/)P"0<$XY[US_A?P[+X>UF/4Y_]*E@M9+.W$.FS6X$32!_F
M"Q$$@C`VA%Y/RY)->GT4`<O-+:W&K6VJS:*'O[562"X,%SNC5A@@'R>_-54L
M]*CN9+E/#R+-(DJ,PM[GE9#EQ_J>`QR2/4D]37944`<CY6G><DHT$!T,3*1!
M<]8^(SCR>JC@'KCBGVGV*PNVNK70Q%.=_P`ZP7/R[VW/M_<_+N;DXQD\FNKH
MH`X^,"'Q'>ZQ%92*U[;)!<QB"Y^<H6V-GRN"`S#\O2H;FQL7M66TT6.TN%M#
M:03I:7&84VLJX`A'W0S`>@8CN:[:B@#G[;539VL-M;Z:\<,*+'&@AN<*H&`/
M]3Z4WP[/#HWAG2M*E%Y))96<-NSK83X8H@4D?)TXKHJ*`,_^V;7_`)Y7W_@!
M/_\`$4?VS:_\\K[_`,`)_P#XBM"B@#/_`+9M?^>5]_X`3_\`Q%']LVO_`#RO
MO_`"?_XBM"B@#/\`[9M?^>5]_P"`$_\`\11_;-K_`,\K[_P`G_\`B*T**`,_
M^V;7_GE??^`$_P#\11_;-K_SROO_```G_P#B*T**`,_^V;7_`)Y7W_@!/_\`
M$4?VS:_\\K[_`,`)_P#XBM"B@#/_`+9M?^>5]_X`3_\`Q%']LVO_`#ROO_`"
M?_XBM"B@#/\`[9M?^>5]_P"`$_\`\11_;-K_`,\K[_P`G_\`B*T**`,_^V;7
M_GE??^`$_P#\11_;-K_SROO_```G_P#B*T**`,_^V;7_`)Y7W_@!/_\`$4?V
MS:_\\K[_`,`)_P#XBM"B@#/_`+9M?^>5]_X`3_\`Q%']LVO_`#ROO_`"?_XB
MM"B@#/\`[9M?^>5]_P"`$_\`\11_;-K_`,\K[_P`G_\`B*T**`,_^V;7_GE?
M?^`$_P#\11_;-K_SROO_```G_P#B*T**`,_^V;7_`)Y7W_@!/_\`$4?VS:_\
M\K[_`,`)_P#XBM"B@#!UDZ1KVDW&F:A:WTMK<+M=?L,X([@@[."#@@^HKGO#
M?BFXT:\'AKQ"+YW3*Z=J4MM+F_3KM(VY\Q1U]<9KOZQ_$GA^#Q'I+6LCF"Y0
M^;:7:#Y[:8?=D4^H_49'>@`O_$UAI]C-=3+=JD:D_/:2H&/9<E<9)P![FLSP
MQ+%8Z>UU?6UXNJ7S>?>,+"8G<>B9V]%!VCZ5A:5=7OB36K/PYKTB&ZT0F:\9
M7`6^=<"-PHQ@<[F&."0*](K./O2OT7],RC[\N;HM/\_\OO,_^V;7_GE??^`$
M_P#\11_;-K_SROO_```G_P#B*T**T-3/_MFU_P">5]_X`3__`!%']LVO_/*^
M_P#`"?\`^(K0HH`S_P"V;7_GE??^`$__`,11_;-K_P`\K[_P`G_^(K0HH`S_
M`.V;7_GE??\`@!/_`/$4?VS:_P#/*^_\`)__`(BM"B@#/_MFU_YY7W_@!/\`
M_$4?VS:_\\K[_P``)_\`XBM"B@#/_MFU_P">5]_X`3__`!%']LVO_/*^_P#`
M"?\`^(K0HH`S_P"V;7_GE??^`$__`,16A110`4444`%<_P"(?^0YX3_["LG_
M`*175=!7/^(?^0YX3_["LG_I%=4`=!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!69X@U4Z/HMQ=QIYMQ@)!$.LDC'"J!WY/\`.M.N
M6#CQ#XQV[&-AHASO[271&,>X12?Q-1-V5ENS.I)I66[*=QX$-WX;M5^U&W\1
MV[M=Q:E%]Y;EOO$_WE/W2.ZCMQ6KX5\3+K]M/;W40M-8L7\F_LBV3$X_B7U1
MNJMW!]0:Z"N4\5^'KV:YB\0^'7C@U^T0H`P&R\ASDPR>W'!_A/UJDDE9%QBH
MJR.KHK'\.^)+'Q-IHN[02Q.K-'-;7";)H77JKJ>01D?F*6\\2Z98ZS_9<\Q6
MX%I)>.=ORI&FW<6/8_,#CT_"F,UZ*P/#GBZQ\3-*EM;W=O)'#%<!+J,*7BE!
M,;K@D8(4^XQR!6_0`4444`%%%%`!1110`4444`%%%%`!117!ZCXVU&'Q5?:7
M;Z3?K##87+P2R6,FR:>-5;=O(`V?P@@\DCU%`'>5S_B'_D.>$_\`L*R?^D5U
M69\/_$%WKL>K"74%U.TM9XTMM05%7SMT2.X^4`?*S$=/8\@U9\374T?B#PPJ
MZ?<R!-4<JZ-'A_\`0[G@9<'N>H'0^V0#JJ*S_P"T;K_H#7W_`'W!_P#'*/[1
MNO\`H#7W_?<'_P`<H`T**S_[1NO^@-??]]P?_'*/[1NO^@-??]]P?_'*`-"B
ML_\`M&Z_Z`U]_P!]P?\`QRC^T;K_`*`U]_WW!_\`'*`-"BL_^T;K_H#7W_?<
M'_QRC^T;K_H#7W_?<'_QR@#0HK/_`+1NO^@-??\`?<'_`,<H_M&Z_P"@-??]
M]P?_`!R@#0HK/_M&Z_Z`U]_WW!_\<H_M&Z_Z`U]_WW!_\<H`T**S_P"T;K_H
M#7W_`'W!_P#'*/[1NO\`H#7W_?<'_P`<H`T**S_[1NO^@-??]]P?_'*/[1NO
M^@-??]]P?_'*`-"BL_\`M&Z_Z`U]_P!]P?\`QRC^T;K_`*`U]_WW!_\`'*`-
M"BL_^T;K_H#7W_?<'_QRC^T;K_H#7W_?<'_QR@#0HK/_`+1NO^@-??\`?<'_
M`,<H_M&Z_P"@-??]]P?_`!R@#0HK/_M&Z_Z`U]_WW!_\<H_M&Z_Z`U]_WW!_
M\<H`T**S_P"T;K_H#7W_`'W!_P#'*/[1NO\`H#7W_?<'_P`<H`T**S_[1NO^
M@-??]]P?_'*/[1NO^@-??]]P?_'*`-"BL_\`M&Z_Z`U]_P!]P?\`QRC^T;K_
M`*`U]_WW!_\`'*`-"BL_^T;K_H#7W_?<'_QRC^T;K_H#7W_?<'_QR@#0HK/_
M`+1NO^@-??\`?<'_`,<H_M&Z_P"@-??]]P?_`!R@#0HK/_M&Z_Z`U]_WW!_\
M<H_M&Z_Z`U]_WW!_\<H`T**S_P"T;K_H#7W_`'W!_P#'*/[1NO\`H#7W_?<'
M_P`<H`T**S_[1NO^@-??]]P?_'*/[1NO^@-??]]P?_'*`-"BL_\`M&Z_Z`U]
M_P!]P?\`QRC^T;K_`*`U]_WW!_\`'*`*_B75)=,TAOLFTW]RXM[-&_BE;@?@
M.2?I4^@Z7_8VB6UB7\R1%S+)_P`])"<LWXDFN8TZ];Q'XCDUO^RKV6UTYFMK
M-0T0Q)_RT<Y<`]@""1P>]=1_:-U_T!K[_ON#_P".5G#WGS?<90]Y\_W&A16?
M_:-U_P!`:^_[[@_^.4?VC=?]`:^_[[@_^.5H:G-^)_!C2ZJWBSP\#%XH@C58
M]TA6*Y4<&.0="".,\8(4YXK+\/>$_`_BO5&\86=K/_:!:>&]AEN)"4F8;9%D
M5B<%02`!A<-T/RX[C^T;K_H#7W_?<'_QRO*OBEJ'B'PE/'XI\,:5=6!E'E:G
M*PB>*3D;&>-2WS9)&_CKCN*`/1?#?A#3_"YE:TGNYY)(8K</<R!BD,0(CC7`
M```8^Y[DUT%<AX*\7WOB7PE8ZG-I,S7$BE9OL\D6T.I((PS@CIT(XS6__:-U
M_P!`:^_[[@_^.4`:%%9_]HW7_0&OO^^X/_CE']HW7_0&OO\`ON#_`..4`:%%
M9_\`:-U_T!K[_ON#_P".4?VC=?\`0&OO^^X/_CE`&A16?_:-U_T!K[_ON#_X
MY1_:-U_T!K[_`+[@_P#CE`&A16?_`&C=?]`:^_[[@_\`CE']HW7_`$!K[_ON
M#_XY0!H45G_VC=?]`:^_[[@_^.5H4`%(44N'*C<`0#CD`]1^@_*EHH`9%#%!
M&(X8TC09(5%`'/L*PO$/_(<\)_\`85D_](KJN@KG_$/_`"'/"?\`V%9/_2*Z
MH`Z"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*P?%6I26NG
M+86<H74]1;[/:#/()X9_HH.<_2MZN5\/DZ_K5WXBG@Q#$3:Z<3SF,$[I1_O'
MC/H*B;^RNIG4;^%;LZ#3K&'3--M[&W&(H(PB\8S@=3[GK5JBBK2MH6E96044
M44#"D(##!`(]#5>6_M8)#').BN.H-,_M2Q_Y^8_SH`Y?7=$NM`U.?Q7X9M3-
M=./^)CIJ'"WR<?,HZ"5>H/\`%R#UKH]#URQ\0Z7'J&GR[XGRK*PP\;C[R.O5
M6!X(-2_VI8_\_*5RFLZ5<6NHS^*/!P@?4PF+ZQ.1'?IU&<?=E&#M?OT/'0`[
M>BLW0M=LO$.F)?63MC.R6*0;9(9!]Y'7JK#N#6E0`4444`%%%%`!1110`444
M4`%%%%`!7/\`B'_D.>$_^PK)_P"D5U705S_B'_D.>$_^PK)_Z175`'04444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`444R6:*",R32)&@ZL[``?B:`'T$@`
MDG`%<[?>--*M28[07&J3#K'I\9FQ]6'RC\ZB?4/$.J6C"WM;#2PXQNO)_-DQ
M_N)P/Q;\*CVD=EJ9^UCLM?0K:]K]KK,=MH6A:Q;M>:A)Y;2V\JN8H@"SMP>N
M!@#KS[5U5I:Q65G#:P($AA01HH[`#`KR[P?\.]3\/^*;+5+N^TQX(-^Y8IF+
M'<C*,94#J1WKU031$@"5"3T`85G0<Y7E-69EAW.:<ZBL_P!!]%%%;G2%%%%`
M'(:U_P`A>?\`X#_Z"*PEU:V;4I-/`N/M"(9,&!PK`8SM8C!QD=#W^M;NM?\`
M(7G_`.`_^@BN5@T&=/%,VM3:G)*C1>5%;+$J*H_VF'+X[9Z9..M`&AIVHPZG
M;-/"LJ*KM&RRH48$'!!!YKJO#7_+U_P#^M<KI]C]A2X7S-_G7#S?=QC<<X_^
MO75>&O\`EZ_X!_6@#-U_PY?V%]-XC\)>7%JI^>\LFXBU)0.%;^ZXYVN._!R*
MV_#_`(@L_$>G&ZM1+%)&WE7%M.FR6WD'5'4]",_0]1Q6M7)>(O#=U%J8\3>'
M"L6LQX%S"6(CU"%1_JW'3=C[K8X/M0!UM%8_AOQ)9>)]*6^LQ+$P)2:VG79+
M`XZHZ]C_`/KK8H`****`"BBB@`HHHH`*\Y\0:C/#XREM=/\`$&JB_P#(E=;/
M[,SV[$PL(XE(3:K;@'+,<]!WX]&HH`XGX=7-_=V^JR2R:C)IGVA!8MJ(<3$>
M4GFYW_-CS-V,^^.,4[Q7!KS^)/#C6FI:;%`VIL+=)=/>1HV^QW&2["90XP'P
M`%QD<G!SVE<_XA_Y#GA/_L*R?^D5U0`?8_%__0=T/_P33?\`R51]C\7_`/0=
MT/\`\$TW_P`E5T%%`'/_`&/Q?_T'=#_\$TW_`,E4?8_%_P#T'=#_`/!--_\`
M)5=!10!S_P!C\7_]!W0__!--_P#)5'V/Q?\`]!W0_P#P33?_`"57044`<_\`
M8_%__0=T/_P33?\`R51]C\7_`/0=T/\`\$TW_P`E5T%%`'/_`&/Q?_T'=#_\
M$TW_`,E4?8_%_P#T'=#_`/!--_\`)5=!10!S_P!C\7_]!W0__!--_P#)5'V/
MQ?\`]!W0_P#P33?_`"57044`<_\`8_%__0=T/_P33?\`R51]C\7_`/0=T/\`
M\$TW_P`E5T%%`'/_`&/Q?_T'=#_\$TW_`,E4?8_%_P#T'=#_`/!--_\`)5=!
M10!S_P!C\7_]!W0__!--_P#)5'V/Q?\`]!W0_P#P33?_`"56O>WL=C")95<J
M6V_*.?\`/%4?^$CL_P#GG/\`]\C_`!H`K?8_%_\`T'=#_P#!--_\E4?8_%__
M`$'=#_\`!--_\E59_P"$CL_^><__`'R/\:FM=:MKNY2"-)0S9P6`QP,^M`%#
M['XO_P"@[H?_`()IO_DJC['XO_Z#NA_^":;_`.2JZ"B@#G_L?B__`*#NA_\`
M@FF_^2J/L?B__H.Z'_X)IO\`Y*KH**`.?^Q^+_\`H.Z'_P"":;_Y*H^Q^+_^
M@[H?_@FF_P#DJN@HH`Y_['XO_P"@[H?_`()IO_DJC['XO_Z#NA_^":;_`.2J
MZ"B@#G_L?B__`*#NA_\`@FF_^2J/L?B__H.Z'_X)IO\`Y*KH*9)+'"NZ6147
MU8X%`&%]C\7_`/0=T/\`\$TW_P`E4?8_%_\`T'=#_P#!--_\E59N?%.A6F1)
MJELS@9\N)_,?_OE<G]*QY_'\`F\JTT35[@D95VM_*0CZN1_*H=2*ZF;JP74O
M_8_%_P#T'=#_`/!--_\`)5'V/Q?_`-!W0_\`P33?_)5>?_$+4-7\0Z5:1+I#
M1QI-OV12F9\[2.0%P!^)IO@.REBT*ZM=2N-6LHGN"WD6X$._Y5Y+$;NV."!Q
M67MW[3D43'ZRW5]FH_,[:]N]>TX$WOBOPU!CM)I4@)^@^U9-8R>(?&E]<&+1
MS97B`X^T2:)+!"?HS763^`KHO#>D>'[,ROI>FB*52"TTHW2'.?XB2>U='6MI
MO=V_K^NAM:;W=O3^OT.1DTOQOJ-LJ7.OZ=ILF.386;29/_`VR/PJBO@75V9)
M+S5=&U"9?^6E]I<\Q_)KK:/P`KO**%3CUU]05*/77UU.9>P\36]FZR:MHAM4
M0[XH=(DC)7'(4_:"%..^#CT-8LLL<$;2RR)'&O+,[8`'U-=Q??\`(/N?^N3?
MR->=ZQ:O>:;)'%:6=U,"&BCO,^5O!X)P#TZ]*LT)Q?6C-$HNH"TPS$!(,N/5
M?7\*MP"9KB-;>2..<N!&\B%U5L\$J""1GMD?45Q=OX:N8)-,"Z+I");NLDSB
MZ;S-RL2I#>2,@9+8^7DXX`Y[BQ_Y"%M_UU3^8H`UOL?B_P#Z#NA_^":;_P"2
MJ/L?B_\`Z#NA_P#@FF_^2JZ"B@#G_L?B_P#Z#NA_^":;_P"2J/L?B_\`Z#NA
M_P#@FF_^2JZ"B@#B;U+R.[D6_G@GNAC?)!"T2-P,84LQ'&/XCSSQTJO6AK7_
M`"%Y_P#@/_H(K/H`*OZ;#K$OF_V5?6-KC'F?:[-[C=UQC;*F.^>N<CICFA6_
MX:_Y>O\`@']:`$^Q^+_^@[H?_@FF_P#DJC['XO\`^@[H?_@FF_\`DJN@HH`\
M]U7P=XK.LCQ'I6LZ+'K4<>Q@FG2PQW:#I'*3.X(]"%R,#D5-X8UWQ'XHLI)(
M-:T>WN[=_*N[.;19A+;R=U8?:OR(X-=Y7,>(?#5S<:G%X@T&>*UUZ"+R0TP)
MAN(LY\N0#G&>01R#0`MU_P`)-8P&>[\2^';>$$`R2Z3(BC/3DW6*BGNM>M;N
MWM+CQ9X9AN;GB"&33)%>7_=!NLM^%4SJD/Q%\$Z[I5O!]BU;R);.>SO1AK>8
MJ0I.`<KGD,!R/<$5:UCPWJ-[J<<EO]C-O+#:PSR2NPDA\F8RYC`4ABV<<E<8
M!YQB@"[]C\7_`/0=T/\`\$TW_P`E4?8_%_\`T'=#_P#!--_\E5T%%`'/_8_%
M_P#T'=#_`/!--_\`)5=!110`4444`%<_XA_Y#GA/_L*R?^D5U705S_B'_D.>
M$_\`L*R?^D5U0!T%%%%`!116+HGBG3/$%S=06)GW6V"3+`T8D4EE#H6'SKE6
M&1QQ0!M4444`%%%%`!1110`456O]0M=,MA<7<HBB,B1!CW9V"J/Q9@*LT`%%
M%%`!139)8X4+RNJ(.K,<`5@7OCGPU8MLEU>W=R=H6#,ISZ?(#4RE&.[)E.,?
MB=BUXC_Y!\?_`%U'\C7%7VHM8W5E$;9Y([F7RO-#`!&P2,CJ<X/2MG5_$J:A
M8(+32M4D42C#O;>4IX/0N17$>);?6M8L%AATWRO+E616%P-^1GL.._K4RJI*
MZU,YUDHMI7]$;%GK#W>L7=B+&6-+9MIG=U`<X!RJYR1SC.,9!%=)HG_(7@_X
M%_Z":\L\.>%-9@U:74;B>2WN%39&]P?.`#?>"KNP.@KO]&T_4GU.%6UN9&.[
MYHK>,$?*>FX-2A4<E?E84ZKG&_*U]QZ%16))X=EF4K-K^L-GJ5F2,_\`CB"H
M!X.L2,2W^L3?]=-1E_HPJKRZ(KFGT7XG14R2:*%=TLB(OJS`"L./P5H,;;C:
M22'_`*;7,LGZ,Q%2OX7T"*&1DT6PWA#\QMU+=/4C-%Y]OQ_X`TY]E]__``"2
M7Q1H$!Q+K>G*?0W*9_+-<%>?&:.WOKB"'1EGBCD9$F6\P)%!(#`;._6KALK*
M%2XM(5"C/RQ#/\JY*8>$+C33K(L;F=)[AH@D4<WF/+D[@(\@C&&/3L:RJQKO
MX&D85HXB27LY)?U\ST^/Q>MU'NL=)O9,]#.T=NO_`(^P;]*C\WQI?NK11:-I
M]NPSEY'N']B,!5-8MM<17EI#<P-OAFC$B-CJI&0:[NQ_Y!]M_P!<E_D*UY&]
MV;<C>\F9(T/4[B'9J'B*\;(Y%I&EN/S`+#_OJH(_`7AX3BXN;22]GQCS+R=Y
M2?P8X_2NEHH]G%[JX>R@]U?UU_,AMK.VLHA%:6\,$8Z)$@4#\!7/>(_^0A'_
M`-<A_,UT]<QXB_Y"$?\`UR'\S5FECEFU?9XBCTA[:13+`\\<^X%6"E01CJ#E
MQ2Z1JKZK'+(UF]LJ-M`=U+'KU`.5^A]:G?3X)-4@U%@WVB&)X4.>-K%2>/JH
MJ#2]%M]*DN)8IKJ:6X(WR7,[2M@9PH)Z`9/'O0!V'AK_`)>O^`?UK?K`\-?\
MO7_`/ZUOT`%%%%`%>^_Y!]S_`-<F_D:XFNVOO^0?<_\`7)OY&N)H`*L6/_(0
MMO\`KJG\Q5>K%C_R$+;_`*ZI_,4`=M1110`4444`<CK7_(7G_P"`_P#H(K/J
M_K?_`"%Y_P#@/_H(JA0`5O\`AK_EZ_X!_6L"M_PU_P`O7_`/ZT`;]%%%`!11
M10!R/C+000?%.FW"66N:7;NT5Q(Q$4D0^9HY@/O(0#[@\CI6)X%^,FB^--6.
MDFWEL;Y_]0DAW";";FP0.""&X/4`'O@>DG&.>E<?X(B\&SS:KJ'A:TBCEDN-
MMVX@>-M^`V`'`(4@@C''-`'84444`%%%%`!115/5K1[_`$>^LXI/+DN+>2)7
M_NEE(!_6@":UN[:^@$]I<17$))`DB<.I(.",CC@@BL7Q#_R'/"?_`&%9/_2*
MZK.\`Z%J.DQZI=ZC96^G/?3HZ:?;2!XX`D:QY!``RVW=^(SS4OB+P[JNI:[H
M]W::WJ4,$-Z9)(XEMMMLOV:9-Z;XBQ)9@I!+??)P,`J`=917/_\`"/:I_P!#
MEKG_`'YLO_D>C_A'M4_Z'+7/^_-E_P#(]`&[++'!"\TTB1Q1J6=W.%4#DDD]
M!7'>%;;2K'5%$?B;3M1E6V%G9PP,@=859GPV';>W3D!1A>G4U:U/PMJMWI5Y
M;)XMU:5IH'C$<\5H(W)4C#%;<,%/?!!QTKA]#^%&MVFLV\]W?I;0(6WRV-PR
MS+E2/E)7UX/L36%6I4C)*,;HYJU6K":4(W3/8J*XJ;X;P3@A_$_B4Y];U3_-
M*@C^%MG&,?\`"1:VX_Z;"UD_]"@-6G-]/Q-%*H]X_C_P#MI;JW@!\ZXBCQUW
MN!_.LV?Q9X>MF*RZW8!AU47"DC\`:PXOAQ:P_P"KUB[3W&GZ?G_TFINB^#]3
M_L>QFO\`7M0M=1>WC:ZBAM+#;'*5&]01;G@-D=3TZFG[_D-^T\OZ^XNO\1O"
MJRB)=4\V0]%B@D?/Y+6;+\1`9G%M8W4T88A2ME)DC]*VE\-ZB@POC#6U'M!8
MC_VWJG)X'EED:1_%>N%F.XG99\G_`,!Z5JG=?=_P1<M3K)?=_P`$\G^)VLZE
MK^J6`%U?Z:EO$'2.)C%EB_WB,G)^48/;%=_I_C+Q/=Z;;21Z9IWSQ*?-EG;Y
MN.N!G'YUI2?#N.9MTOB36';&,M%9D_\`I/4B^`F50J^*=;"C@`)9X'_DO41I
MSYFW+0SC2J<[;GH7;1?$FJ6"3/J=C9;P>+>T+L.<=7;';^[43>#I;F0/?^)-
M:N,=42<0H?P0"I(/"^H6T*Q1>,-<5%Z#RK(^_P#S[U)_PCVJ?]#EKG_?FR_^
M1ZT=.+W-72B]]?F36WA'0;8#&F03,.CW(,S?F^36I!9VUJ,6]M#$/^F:!?Y5
MS[:!K8O(E7Q?K1MS&Y=_*LLAP5VC_CW[@MV[#\9O^$>U3_H<M<_[\V7_`,CT
MU%+9%*$8[(L^(O\`D'Q_]=1_(US%;%SX4OKN,1S^+]<=0=P'E60Y_"WJM_P@
M;_\`0U:Y_P!\6G_QBJ**%:&B?\A>#_@7_H)I/^$#?_H:M<_[XM/_`(Q4D'@J
M>VF66+Q9KBNN<'R[,_\`MO0!U=%<_P#\(]JG_0Y:Y_WYLO\`Y'J&[T#6TLYV
MM?%^M/<"-C$C166&?'`/^CCO[T`=-4<__'O+_N'^58?_``CVJ?\`0Y:Y_P!^
M;+_Y'I&\.:FRE3XRUP@C!_<V7_R/0!A5ST?AN>UM%6TU!$N8]0FO8Y9(-RCS
M"^5*AAD8<C.1R`?:NP_X0-_^AJUS_OBT_P#C%'_"!O\`]#5KG_?%I_\`&*`,
M?3K-=.TRULD<NL$2QASU;`QG\:[^Q_Y!]M_UR7^0KF/^$#?_`*&K7/\`OBT_
M^,5=3PWJ4<:QIXQUP*H``\FRX`_[=Z`.BHKG_P#A'M4_Z'+7/^_-E_\`(]4[
M/0O$3W6HK=^+-9C@2X"V;+%8YDB\J,EF_<'GS#(.W"CCN0#K*YCQ%_R$(_\`
MKD/YFI_^$>U3_H<M<_[\V7_R/5:Y\&W-W())_%NN.P&T'R[,<?A;T`95%7_^
M$#?_`*&K7/\`OBT_^,4?\(&__0U:Y_WQ:?\`QB@#0\-?\O7_``#^M;]<Q;>$
M;NSW^1XNUQ-^-W[NS.<?6WJ?_A'M4_Z'+7/^_-E_\CT`=!17)WFA>(DNM.6T
M\6:S)`]P5O&:*QS'%Y4A#+^X'/F",=^&/'<7/^$>U3_H<M<_[\V7_P`CT`;%
M]_R#[G_KDW\C7$UN2>&M2EC:-_&.N%6!4CRK+D'_`+=ZI?\`"!O_`-#5KG_?
M%I_\8H`H58L?^0A;?]=5_F*G_P"$#?\`Z&K7/^^+3_XQ3H_`\L4BR)XKUP,I
M#`[+/@C_`+=Z`.MHKG_^$>U3_H<M<_[\V7_R/1_PCVJ?]#EKG_?FR_\`D>@#
MH**Y/2="\13:-8RZIXLUF#4'MXVNHHXK$JDI4;U'[@\!LCJ?J:N?\(]JG_0Y
M:Y_WYLO_`)'H`H:U_P`A>?\`X#_Z"*H5IS^"I[B9I9?%FN,[=3LLQ_[;U'_P
M@;_]#5KG_?%I_P#&*`*%;_AK_EZ_X!_6L_\`X0-_^AJUS_OBT_\`C%6+;PC=
MV>_R/%VN)OQN_=V9SCZV]`'3T5S_`/PCVJ?]#EKG_?FR_P#D>H9M`UM9;<0^
M+]:9&D(F)BLOE3:QR/\`1_[P4=^M`'357O;G['://LW[,?+G&<D#^M8__"/:
MI_T.6N?]^;+_`.1ZCG\+ZA<0M%+XPUQD;J/*LA_[;T`2_P#"2_\`3I_Y$_\`
MK5B:!<SZ1/J%Q<^1/->RK(RVT?D1*0N,A"6^8]SGGT%6_P#A`W_Z&K7/^^+3
M_P",4?\`"!O_`-#5KG_?%I_\8H`UK77OM-U'#]FV[SC/F9Q^E;-<G%X(FAE6
M6/Q9KBNIR#LL_P#Y'JY_PCVJ?]#EKG_?FR_^1Z`.@HKF;O0-;2SG:U\7ZT]P
M(V,2-%989\<`_P"CCO[UTU`!1110`4444`%%%%`&4WB?0$O;BR?6].6ZMD9Y
MX6ND#Q*HRQ89R`!R<]*U`00"""#T(KS?4_`.HWLVL16FGZ!8V]]!>(94+R2R
MRS+A7.8P8^0-P5F#>G`J2\\)>+;G6Y+F&]LK:R-C/:K#%>3<%X%5"1LP=LBY
M!&.&R`"#N`/0A+&9FA$BF55#,@/S`'(!(]#M/Y'TI]<WH7AZ?2+^.9Q%+FPA
M@EF:=VD,J%RYY'(;>.21TZ5TE`!1110!6O\`4;+2K*2\U"[@M+6/&^:>0(BY
M.!DGCDD"BPU"RU6RCO-/NX+NUDSLF@D#HV#@X(XX((JCXDTO^U](-J+"TOCY
MB2"&[E:)"5.0=ZJQ!&.#@UR^F^$_$%KJ=A<W+V$EM$N#:VUW-;1P.9G=I%6-
M0LK%64'<%R03T)!`.ZMKF&[MH[BWD$D,BAD=>A'K4M<"G@_Q`-9T&ZEU:5H+
M&*-9HXKXHI978N=IB8R!@5!^9.!WIH\&>((A,8-7*F>VN(Y0;V;!=KA9(]O]
MP"/>I*X(+<9ZT`>@45P*^$M?;7=&O!>M:6%F%WV%OJ<CHA$C,QW/$6E#*5&"
M4Q@\D&N^H`*S-5\1Z)H4D4>K:M96+3`F,7,ZQ[@.N,GW%:=<AXE\/:EJ'B:Q
MU2SLM+OH(K&>TEM]0F9%/F,AW8$;Y&$((XZ]:`.G6^M7O!9K.C7#1>>$!R3'
MG&[Z9JQ7F=E\/=;TRQM;)-16\MH-+%J8S>RVVZ7[1YO!16VJ%^0=>!@C%;0\
M.:W]L@E\^),:>+=9%OYR;.78X+(A&)@2RG+D'Y>_&`#LJ*\_A\(^)(]$ND@O
MH+/4@T+VI%[/<1K(H*R2,7`/SJWW,8!`YSS5K_A$=83QI9:DFKW+:9:QQI'`
M+S8%"IM*M'Y3>9N/.=Z]>G`-`';45Q$GAS4K>71X8IYFDDOY9M1E$KNC6^2P
M7)(P25A4`#IN[9KMZ`"BBB@"%[NVCNX;1YXUN9E9XXBPW.JXW$#N!N7/U%%U
M=VUC`9[NXBMX054R2N$4%B`!D\9)(`]R*P->TO6)/$^CZSI4%C<?8[>Y@DAN
MKIX,^:8B""L;]/+/8=17,ZAX)\3ZK#K$5U<:?LNI8I+>,74I3]W<B4;@8\@E
M,J3EN@P`.``>ET5Q'AOPKKVE^*[S4]1U>:XMIC)LA%X6C"LV47RC$,;!P#O/
MT'2NWH`****``D`$DX`K#@\9^&;JVFN+;7=/GBA9%E:&=7V%V"KD`DC+$`5M
M2*6C91U((KRNS^$'V/P:MK]J$VO-%;0/<R2GRXHHYXY62,J@./DR,@G..0*`
M/5J*\UU/P9XO?2XK+3-4MT\J]GN(Y);V<.J&X$D2[MK9^0%3QD9X)&0UK4_"
M/B&\CU:.UNQ9BZG617CU68O*H<EE)>-EB&"!@*_0CH<``[J[N[>PM);N[GC@
MMXE+R2R-M5%'4DGH*FKD[_PUJ%Y\,KGPX;KS+^6R:W$UU.9!N(.-SA`2!Z[1
M]*ZL#``H`6BBB@#,/B+11J-SI_\`:MG]MMD,DUL)E\R-0,DE>N,$'\:T(I4G
MA26)@T;J&5AW!Y!KC9?`$5QK>L:S<3M+=W!E^Q1L_P"Z@+P"(M@+NW'Y@>2,
M'IFHAX3URSTVYM+.[BE64VVU;B\D.W9'MD(+*P!SM(!4KQT%`'=45PW_``C'
MB$K;[;N**\72Q:-?_;YG*2^45WK"5"M\YSN+?\!S@UI>"-`U+P]IEQ;ZG>SW
M4LDWF+YMZ;G:-H'#&*/`)&<8ZGJ>:`-^WOK2[*"WN8I=\2S+L8',;9VL/8X.
M#[58KG?#N@W6D/:&XDA;R=)MK)O+).7C+;B,@?+\PQW]JZ*@`K+N_$FB:?J<
M6F7FKV5O?3;?+MYIU1WW'`P"<G)&!ZUJ5Q6J^`(]=\;RZQJ-R_V#[/;HEK$X
M'FO&[O\`O`5S@%E(VL#G.:`.NM+VVOXWDM9EE1)7A8KV=&*LOU!!'X5/7!VO
M@?4+*]MKZWND2Z76+J\FQ=2A'MY3,5CV],YD0GCJ#R>]:V\(^*(]&O[>ZGM+
MF:XNH[B.+^TKB../$04KN1`2NX;MN.<\G<-]`'HM49=:TN"YDMI;^V2>)XDD
MC:0!E:0XC!'JQ!`]:Y?1/"VO67C&35K[59IK5HRHA%^S1@%0`GEM%G@@G<9,
MGKCDU!J_@G4K_P`2ZGJ44]H(;J[TN=%9V#!;:1FDS\N,D'CGZXH`[F&>*XC+
MPR+(@9D+*<C<K%6'U!!'U%25GZ+82Z=8203,C,UU<S`H21MDF>1>O?##/OFM
M"@"E+K&FPO>)+?VR-91B6Z5I0#"A!(9Q_",`G)]*KWGB;0=.OX;&]UFPMKN9
M0T<,UPJ,X)P"`3SD@@5R_BOP)>ZPNO76FRVD&I:A']G224N%>!H1&R28'9OF
M'!P0/4U)XB\*:GJD]_'#I^B7=O>Z?#:^9J$C$P.AD.X((SN^^"/F4Y6@#L9;
M^SAOH+*6ZA2ZN%9H86<!Y`OWBHZG&1FJFK>(]$T%HEU?5;.Q,P)C%S,J;\8S
MC)YQD?G7*W?@[Q%-XDTO4X=;MEM=+6WCCM9(`[7`0$2.TI&Z-F#N,+D$8R>>
M-'Q%X0EU_P`5Z/J1O7M[6QAF6186&^1F:,A2&1@4(0YZ'IB@#;EU[2H5E:2^
MB58@Y<Y^Z$"EOR#+^=:-<)JWA#7+V/6#;W\,<MR+P6CF9P8O-2%4Y"_+@QL3
MCID8S2WGAG6K9KS4(=0G:0K>MLBN9&)5X\1JB=-P8`_ER:`.ZHKAOA;<Z[>>
M';FY\0:;<:==R7.5@D1T14"*!L1F)4$@DYQEF-=S0`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`8_BK6G\/>
M&;W5HXDD:V56"/G!RP'8$]^PK#L/'WFZ;:7-WIEQFYN)(D:%&5#&@#-+B4(P
M0`DG(_A.,\5U=_86VIV4EG>1^9!)C<FXKG!!'((/4"BXT^UN[B">>(/)`'$9
M).!N&&XZ'(]:`.3MOB38W6@S:HFDZF72>*".S5(VEF:3&S;M<KCDYRV1M/XW
MHO$]Q)K%I;26;6T=P(#Y4RCS8R\=PQ#88C(\E>F>I_`@^'GA.VT*]T6'18%T
MZ]?S)X=S?,W8YSD8[8(QVQ6C:>&='L1:BVLQ&+546`"1L($5U4=>PD<<^OL,
M`&/8>.H=5M//@T^\M!YEGM^V1!?,BN)-H=0&SCAN3CIG!%0/\2+-=!GUO^R-
M1%@A=H9G\I!<1JCOYB9<$@A#@=3N''4CHD\/Z7&D:):X6-+>-!YC<+`Q:(=?
MX22??OFLB3X:^#IH;B&30;9H[BY^UR)N;!EP1D#/`Y/`P.>E`%CPUXCDU[4M
M:CV1K;6DL`MR%(9DD@CE^;DC.7/3'%=%69HWA[2O#T4D>EVOV=)!&''F,V1'
M&L:?>)Z(BCWQD\UIT`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!114%
M[>6^G64UY=2>7!"I=VP3@#V')/L.30!/15.UU6RN[*"\BN%$,^-AE!C).<8*
MM@@YXP1G-2O>VD<32O=0K&OWG:0`#DCD_4$?44`3T5`+ZT+,HNH"5<1D>8.&
M/1?K[5(\T:0O*SCRT!+,.<8Z_P`C0`^BJ/\`;&G_`-G?;_M2&V\OS=PR3MP#
MG;UZ,#C&>13[;4[.[B\R*==N2N'!0@@L#PV#_"WUQD<4`6Z*S[S7-/LM.6_>
M=I;9G$:M:Q/<%F)P`JQAB>?05)::K8WT,$D%RA$ZEHU;Y'('!^5L,""""",@
MCF@"Y14"WMH[1*MU"QE_U8$@._Z>O0_E57^W=-\RU3[0=UW<26L'[MOGDC#E
MQT["-^>AQP3D4`:-%8-CXST+4KFW@M+J:1KB-)(W^R3",AUWIERNU25Y`)!]
MJO:3K>G:[:M<Z;<B>%6V[PC*#[C(&01R".".02*`-"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"LS6]>L?#]K#<7QGVS3"&-8('F=G*LV`J`GHK'IVK3K!\3Z-<ZRVCK;SR0"
MVO\`SY98G"NB>3*F5R",Y=>WK0!4O?B%X=L]-L+Y;B>Y2_+BWCM;9Y)6*#,F
M4`RNT9W`XQ@U?N?%>DVWA^TUQI9I+"[$9@:&!Y'?S/NX0#=D^F*X:]\*>*TT
M32+"QL-.E2W2;[0DMQMS=,W%R6*L74@N60]=Y!!%:\VG>+9?"UFEU96=SJUE
MJ$5R$2ZV1S*K;B%.SY%'11@G`&>:`.HT7Q%I?B".5M.N2[PMMFADC:*6(^C(
MX#+[9'/:L\>//#W]N/I#WDD=TEQ]ER]O(L9FP#Y8D*["V".,]ZJ^&='UH^)]
M5\2:[#:6D]W!%;06=M*91'&A8Y=R`&8ECT'`%4+#P"T^M:I>ZO<3M;G6SJ=G
M9HZ>46$:*DC87?N!!XW;>`<4`=;H>LVGB'1;75K!G:UN4WQEUVG&2.1^%:%>
M8>&?!&O^'_#0MTD+WC:-);/$]XXB$^_Y`NW&T;<_,N#SUJP?#OB27P=<V=U8
M,\\FH^>EI!K3Q$0E!\OG+&,8;/RXQQUH`]'HKRZ[\)^,)M<T6Y2XG6&VMK9`
M(=8=%MW7_6[E:-S-NZ9//K7J-`!1110`4444`%%%%`!1110`4444`%5[ZT2_
ML9[24D1S(4?Y5;*GJ,,"#D<<@U8HH`XR'X8Z%!;K#'-?A5M)++_7C'DNS,R@
M8POWR`5`(&`"*T[3PA8V9?9<73JTJ2JKLI"%9FF`'RYQO<]<G'>N@HH`Y2\^
M'VD7SAIY[WB0O^ZE$3%2SL49T4.R9D;AB>ON<]#>V;7EH]O]KGA#D[GC";BI
MS\OS*1CGTS[U:HH`YJ/P1IL7VA8[B[6*:-HS%N4A0R1H2#MSG$*=2>],M_`>
MF6TA9+F\*MN+QLR%7),QY^7/'GOW].O?J**`.>D\'6,_AU-$N[J]O;5)A*&O
M9%N'.&W!6,BL&7/8@\4P>"K$6=K9F\O_`+):I*D<"RJB8D5U/"J,860A0,!0
M!@<5TE%`&#H'A'3O#DC26<EW+(RLK274YE=LD$DLW/8>W%377AVUN8=-03W$
M,FG2&6WFC*[@Q1D).Y2#D.W;J:V**`.2L/AUHFFZA:7ML9A/:1PQ0NRQ,ZK&
MFP`.4W@$=0"`:T]`\+V/AV:_ELWE+WT@EGW!%4N!C<%154$]R!S6U10`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
I110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>graph7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 graph7.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!V`K(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#VN[OIX;IX
MT*[1C&1[5!_:=SZK_P!\TW4?^/Z3\/Y"JM`%S^T[GU7_`+YH_M.Y]5_[YJG1
M0!<_M.Y]5_[YH_M.Y]5_[YJG10!<_M.Y]5_[YH_M.Y]5_P"^:IT4`7/[3N?5
M?^^:/[3N?5?^^:IT4`7/[3N?5?\`OFC^T[GU7_OFJ=%`%S^T[GU7_OFC^T[G
MU7_OFJ=%`%S^T[GU7_OFC^T[GU7_`+YJG10!<_M.Y]5_[YH_M.Y]5_[YJG10
M!<_M.Y]5_P"^:/[3N?5?^^:IT4`7/[3N?5?^^:/[3N?5?^^:IT4`7/[3N?5?
M^^:/[3N?5?\`OFJ=%`%S^T[GU7_OFC^T[GU7_OFJ=%`%S^T[GU7_`+YH_M.Y
M]5_[YJG10!<_M.Y]5_[YH_M.Y]5_[YJG10!<_M.Y]5_[YJGJGB8:/ID^H7DF
MV"%<L5C+$\X``'4DD"BN5\?^*-/\+^''GNUMYKF4@6EM,`P>0$$-MZX4X8GM
MQW(I-C2N;$7Q"M9-'N-2*W,:V\P@DMY;5EG$AV[4$9&23O7`[YIT?Q!L#X>F
MUR:Y^S64#,DOVB(H\;J<%2IYW9XQUKR-/%6D16>@:Q-K27ZQ7\EWJH9D2XDF
M\K9&RPY!V*<`<<``^M79IO#U[X%GAU?5=$?5+V]DF$8O(IOLQGE`)&#C*H<E
MNV#S1JW;^NG_``0TLG_77_@'H^H?$W3=,TJQU"YFDV7T)G@BC@+R-&%W%BHZ
M`+R2>E;]KKCWMI#=6\J203(LD;@<,I&0?RKP_P`7ZOI(\6+<V&N1'&D_9-,>
MQU%%2&XWG_6%7&U<;?O?*??%>KZ-J]AJEJ%M-4LK^:%$$[6LZR!6(ZG:3C)!
MQ]*K2UR;N]C>_M.Y]5_[YH_M.Y]5_P"^:IT4AES^T[GU7_OFLK7?&L'AV""2
M^=V>XD\J"&"!I))6ZX55YZ59KSOXF^,=/\.R6%H8H3JLN6ANGB#M91M\K2+W
MW$9``X..>F"F-'53?%'28M+L-0CN9+B._#FWCM[9GD<)]\[0,@+CFKFH?$#3
M-,L;.\N=1@$=Z%-JJC+3;L8VKU(Y'/09YQ7E,GB+PGHCP)I5Q!)'<:/]DT_]
M^C&*5W8OYQ+?N\EHR2V.C>F*M:O<>$A+X.TN'5M'G>TDB\Z^,\3>7#`N[:7S
M\NY\<<9Y]*MI?C_G<FYZ)K'Q&AT.]^S7EGJ6-Z1B=+%VA9FQ@!^A.3CZUT7]
MIW/JO_?->:W>O>%]8\9PRWFOZ6]CI<*R0))>1^6]RQ/SCG#%%48/8OZUVEAJ
M=AJL#3Z=?6UY"K;#);RK(H;`.,J3S@CCWJ5L-[FM_:=SZK_WS1_:=SZK_P!\
MU3HH`N?VG<^J_P#?-86M_$"UT"Z2WO/M#N8C.Y@M6D$48."[D#Y5Z\^U:->4
M>-O&^BMXKCT%KZ.WM2!%JMS#&&DE4$XM]_\`"O+;CGC)'7-'5(.EST36?B+I
M^@W<=M?3N&95>1HX&=848[5:0CA03P":MW7C2UM-:LM'DNHVU"\R8X$`+!0I
M8LP[#`/)Z]J\4U'4;#4=0\1Z,VJ:<)=7OX7:_P#ML7DI8QXV@.6QO&"-G7G/
M3FNRBUGP5%X\6[M]1T6-TLY))KO[1%^]DD90!YF>2%1N,\!AZT1>B;_K3^D$
ME;;^OZ_(ZRR^(^GW^MMI4$LWG>;)"LK6S+%))']]%<C!(Y_*NA_M.Y]5_P"^
M:\.\%Z]H/]O1376M1JT/VB:XCO;B*.WMYY'S_H_(W9RXW9(QSQGGV*&:*Y@C
MG@E26&10Z2(P964C(((Z@CO1I9"UNR__`&G<^J_]\T?VG<^J_P#?-4Z*!ES^
MT[GU7_OFN<F^)FEP:_\`V-)<O]H$RV[2"W8Q+,PRL9?&-Q';_`UKUX];>-?"
M>N>.S;3_`&:QTRUN#<0MA8TNKH9_?ROP,`#Y<G))R>P`OBU![-GI]K\1-/O=
M=?2()W:=9'A\SR&$32H,M&'Q@L!R14]OXZT^[U6\TZVOX);BRC,ESL&5B`."
M"W3/7([8YQ7EGACQ#X>N;G0K>34[2S_L7SYKN2>Y2-)KB0%?D);YP2TC9''W
M?6G:7JGA"%O&5S]JT^*RN2+.&TMIX8I)8D0AG3++N+,S$,3S@=:):*Z[?U_7
M8:WU/2]!^(5CXCGEAL)9/,CC64+-;M$9(V.!(NX#*G'6MW^T[GU7_OFO#?AS
M?:;:ZW-K&H^++*2TBL4T^P%W+#;R^4I!.Z,,2N"N`3R>OI7LU-I+81<_M.Y]
M5_[YH_M.Y]5_[YJG12`N?VG<^J_]\U@6'Q%L=1U9M.A>99,2&.66V9(IA&<.
M4<C#`'KBK.I:E::1IT]_?SI!:P+NDD<X`]OJ3@`=R0*\/D\4:3XBT_7&M+^*
MRO%M98=+L92EK!;PLRAP&R`97&3[9QTI-O6Q22=K]SU^V^*6CW*WCB[:*.U@
M-RTDMNRK)"#M\R/CYUSQQUHMOBEH]QI=]J#73V\5B$:X2XMV1U#\H=I&3NR,
M8ZYKRQ/$WAJ/[5X@G6SN=-MM*BTRQTF22-I9\,&)>(DE5#`<D=!G'3+K/Q/X
M:FT6WUV]O89;Y]3BN-4BW!7(1&\M8HB<E$9HP..Q)JK+K_6O^1+VNOZT_P`S
MV?1O%R:[:/<6AD7RY#%+%/"8Y(W'.&4\@X(/XUH_VG<^J_\`?->?^"-8T:Y^
MV2PZM9/>ZM>27:6@NHVE5,`*"@.0=B`D=N<]*[2AB1<_M.Y]5_[YH_M.Y]5_
M[YJG12&27_B'^S+"XOKR9(K:WC:25]A.U0,DX')_"L2T^)>FW>F7U^99K>*Q
MC66=+BV:-PC#*L%(R0W;'6H/&6MZ;H'A:\O=4AAN(-NQ;:7!%PYZ)@]<]3P>
M`3VKS.R\6:1=>'5UJ\U.T>_?4H)=1@W"-_)C.Y(XHR<LJ$KVY^;K1W'8]77X
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M;_9F\\S_`///R\9W>U8/Q)\6Z7X:TN!+J"&YU"9]]FDL8<0NO28@]-N<C')/
M`[D<1#X@\+Z1?Z'K%O>_;8A'=.S2RK]H:]D*CS)$+90,%(!/`&/:A=?Z_K_A
MO,;6W]?U_P`/Y'J5Q\4])AL+"[2:>Y2^1Y(4M[5Y'VI]\E0/EV]\_P!*EU#X
ME:=IRVSM)//'/;B[$EM:O(L<)_Y:.0/E7W/I7D-SXETCPOH.A^'H-0LIKJ2%
M_P"T-5M-MPT$;N6DBC9>['([8`!ZD$:GB3QIX:76+'P]8WUO;Z0($AO;FT42
M&6(?=MQ(#PN"=QSQD^]4TKV7?^OZ_P"`3_7]?UV/;1JEP0"&4@^U']IW/JO_
M`'S6/IVJZ;JL3-IE_:7D<9"L;:99`I]#M)Q5RI&7/[3N?5?^^:?#J-P\\:$K
MAF`/'O5"I;;_`(^H?]\?SH`Z*BBB@"I/I\4\S2,S@GT(_P`*S;!M)U.:[BL[
MIY7M)3#,`"-K#J`2.1G(R,C((Z@U=UJ^_L[2+FY5E$H7;"&_BE;Y47\6('XU
MP@;5_""0K?V5E9V-Q9O9FXM;UYV-U\SQNY:./:69I.><LR].ZNOZ_K^KC2OH
M=Y_94']^3\Q_A1_94']^3\Q_A7)ZN9[.W6&"]OE65=/W,;J0MEKI58AB<C*D
M@XQFJZZN=$\;3+?:G/#H\5Q-;JUS<,T8D:"VD1"6/))\TJ#ZD#KBB32=F5&#
ME'F_K9/]3M/[*@_OR?F/\*KP6]A<SW4$,\C26L@BF'3:Q57`Y'/RLIX]:\\?
MQ)=+X6TG.HB.\?28;GS+B^E\^0_,28X%P93\OS,S80<D$`@]?;2,DGC22-RK
M+.&5E."#]CAP0:3=BE3NVOZW1N?V5!_?D_,?X4?V5!_?D_,?X5RNJ/<:=:LT
M%Y>".."RN9G>Y=MJ+<`RL2QX&P-N[8!S5*QU/^WO'\L4.IW<NF,]P8Q!<R)&
MX$%F05*D97+L01P=Q(ZTV[.Q,(<RO?\`K1_J=G<6-G:VTMQ-+(L42%W;K@`9
M)X%2?V5!_?D_,?X5YW%=71\-Z3)-?7TOV[P[>RW.^9Y-[JL6&"DG##<V,#O6
MIJFJ33Z1JT_A&^;48HDM]S17CSA3YI\U5<;V#>7U"@L,@@9(R^HW3:W.P_LJ
M#^_)^8_PH_LJ#^_)^8_PKSNQU:\U36;-(M4@;39;^"$KINJSW:;O)N&<>>R)
MUQ%E`3C:"0,C/9>(KRUTY]/?4;Q[/2][+-<>>\2J^WY-\@(VJ>1EB`3M'4@$
M(:M;TO\`G_D6+B*PM;RUM)'N3/<[O+5(F<87&2Q52%'(Y;`R0*M?V5!_?D_,
M?X5SGAM9[F_L;NZEN9,I?&V:25OGM_/3RB1G#?(1@GDC!/-4-5N+J.\\0727
MUXCVNK6$4*K<.$1'%N&79G;@[VSQWI7*C#FV_K6QV7]E0?WY/S'^%']E0?WY
M/S'^%<'I&K:I>^(+/3I+NUANEGE6_A74YYK@Q[7'S0&(+"-Q1@^X+]T*QW#+
M[2]U35)[(07UWB_F6U9MSKL2V9/..,_*S,)UW#!.5ZX%59W_`*_K^O(AV1W/
M]E0?WY/S'^%']E0?WY/S'^%9/B+4=+L-8T_^V-5.GVCV\^&>[:WC9PT6,L&`
MW8+8!/<UER:FMFUI_P`)'J,MI;R:9$;8_:'ADFGRWF+A2"[X\K"\DDG`ZU+>
MG]>?^17+_7SL=)%:6,T\\,5PSR0$+*JL"4)`(!XX."#]"*F_LJ#^_)^8_P`*
M\REN]2TRXU)TD(N?MUG-J:3WDD&V`VB@NS*&9$\T8+*N`%()"@XW_#UU=ZM'
M$TU^DME+JC+`;&^GE3RQ;ME1.50RKO!.1D`\9^7`:U5_ZZ`XI.USI)HM.@G:
M!IY6G54=HHU+N%9MJL54$XSGGIP3T!JU_94']^3\Q_A7FU_<-8Z]=NM]<QW4
MB6L4+-=/ND1-1=&`R?FPA4'V;G[QSK7/B/R_&D%K]NM8534/*FC;4G><JRE5
M#6X`2-"S)M<ELY3N_"A[Z5NO^=AU(\E_ZZ)G7P6-G<QF2*61E#LA/3E6*D=/
M4&I/[*@_OR?F/\*YG7[E[3P'=S)<7-OC4L-):EO-"F]PVW;R202,#KG%4+C7
M%@_M&]L=1%QH.;:.&XN-2:&W$V7\S-SAV"8\L<9&_P"7@[J<=5<4HV5SLGT^
MTC:-7E=6D;:@)'S'!.!QZ`G\*2"PMKB".9#.%=0P$BE&`/JK`$'V(S7*:)J4
M-_::3/=ZC'))%J\T0:.[=D&Z.1HU#,<R`J4VL?O`@@`-BL,Z]JMI8:-<:A=6
MXTZ?18&2XOM7FLE:XY,GSI&V]R-A"L<G!(!^;";:=OZVN-1O%OM_FT>E_P!E
M0?WY/S'^%,CT^TF0M'*[*&9<@CJ"01T[$$5P%K=:L-)O[N\U*\?4+>\TN(LL
MLL:?.EMYG[M@N-Q=\@J#ST!JWJ&H6^EZ?%+%JL")%>7L<L%[J<MK&[>:2`9P
M&VR`8(0_>#,<<9`W9V#DTO\`UM<[?^RH/[\GYC_"C^RH/[\GYC_"GZ5.+K2+
M*X$%Q`)8$<17.?-3*@[7R2=P[Y.<U;JFK.Q"*/\`94']^3\Q_A2'2[<`DO(`
M.I)'^%7ZR]=BN+FR2UCLS=6\[[+I%=0?*P<@!B`<\*1D<,3VQ2&C-.J>'_['
M@U5+^6:SN6*0-!&TK3$9SL15+-]UCP#P">@S5[R]+_LS^TOMJ_8?*\_[3YB^
M7Y>,[MW3&.<UQ/AVY@T>T\.ZE>E=/TBWCO[8M*56**1I@4R0<*,(Z@G`S@=2
M,Z^G%K?P,\,V]9O.EOQ:E29A:FZ:0?N_O?ZL@;<9_AQGBFK.-_Z_KJ2F[*YJ
MP7FC7&F3ZBDUXL$!Q(LMM)'*#@$#RV0.2<C``R<C&<T+=Z.VDOJ7FW@@1]C(
MUM()@V0`OE%/,W'(P-N2"".#6/)?V]]J>IZ]9:C!+HB+8*]S%*&BW13.\IR#
MC"JZ9/08.?NG"W-_;S7<&OPZC`VAQ:N)9;I9083']E,6[?G!42$`GH"#Z&FX
MV_#]!K4Z*PAT[4[*.[LYY)(7R`<;2"#@J00"K`@@@@$$$$9JS_94']^3\Q_A
M53PY-'=V][>V[%K2YNWEMWQ@.F%&Y?52P8@]""",@YK9J0*/]E0?WY/S'^%0
MW=I8V-G-=W4[Q00H9)'8C"J!DGI6I7*^-;6:\TVZCFLY;G3H[.61HT*8:4#*
MEPS#A<9P,Y)']T9&!:U"XTC3+F&"ZFN@\HSF.W>18USC=(RH1&N?XG('!YX.
M+-_#IVF6;W=Y/)'"F!D#<6).`JJ`2S$D`*`220`":Q];U.VM'U*"]NDM;G4=
M.2*SMYI%5Y9/W@*(`?G;+KPN?O#UJ?Q-.D,NCW<ERHM=-OUDU`@Y$2&)U5G]
M%#.C$G@#DX`S3[`OT'R:CH,6EPZB;R=X)G,<:QQ.\KN,Y01*I?<-K;EVY7:V
M0,'"WFHZ#96]K<27TDD5VGF0M;QM/NC`!,F(U.$&1ES\HR,GD5S5C>16/BA_
M$MY="#P]<W-T+>YE.V'+QVRJ^3PJLT4VUCPVX8/SC,VAWL'AZV$VN3&S@OH[
MAK,7(*?*UQ+(L?/1RDD>$/S'!`'RG%..E_ZVV]1?U^.YV@TNW(!#R$'H01_A
M2_V5!_?D_,?X57\+VEW8>$]'L[_/VN"RACFR<G>$`//?GO6M2DK2:01=TF4?
M[*@_OR?F/\*IWPTO3#;"\NVA:ZG6W@!/,DC=%``]C^5;5<)XNAFDUC3;NZTM
MI/L^J6L=E,K(VU2P+D98%68\=.BCGG%1?5+NTOO=@EI%OLF;7VK1/[9_LG[9
M)]LSMV[3LW[=VS?MV[]OS;,[MO.,<U)JDFF:.D;7;WA,A(5+>WDG<X&2=L:,
M<#C)Q@9'/(KE2[-`/#PF8ZZNOB[,7\8@^T^;YO\`US\KY=W3/R=>*Z?4M:TS
M3=5LM0OM4M;:P>":%9I9E6,R;D.W<3C=\K<=?E/I56T3_K:__`']IK^MQNH7
MNB:7';R75Y,(IUWK)'&TB*G&79E4A$&1EVPHSUI;NZT2QU&&PN+UTN)=N`%)
M5=QPF]@NU-Q!"[B-Q!`R:P;>[BT&3S-;N/*BN]%MH+:&7[\LJ>9OC1.K.?,C
M&T#)[`XK.O%GLM$\1:%>2M_;6J01+IT1Y>8_9XXQL/?9(K%B/N#YC@$&G%7=
MOZ_('M_7D>A?V5!_?D_,?X4?V5!_?D_,?X5=&0HR<FEJ0*/]E0?WY/S'^%0M
M:6*7L=FT[BXDC:5(\C)52H8].Q9?SK4KD+.WN4\5Q7-U8SC4+FUN4>X+1E40
M/&41<.3M7/IDDYQR<)NP%_3[C2-4N)8+6:Z+Q\YD@>)9%SC=&SH!(N?XD)'(
MYY&2\NM$L-1AL+F]D2XEVX&TE4W'";V"[4W$$+N(W$$#)JCH>JV-W/IJ6^H0
M2MING/'?A9`3;O\`NAMDY^1LH_!P?E/I6/KTVR'Q=I33%M2UG:VDQC[TP:%$
M7RR.H5U9F(^X/F.`0:M+WK!T9TWVG1_[8_LH7,YNP=I"Q,8U;;NV&0+L#[?F
MVD[L$'&#1#<:1/JKZ;'-=?:$)&YH'6)F'55E*;&8=U#$C!XX.,2]N4E4Z!'=
MJ-<_MB&Y\@MMD:$3I*9`.Z>6"-PXR"O7BKMEJ%K-J%CI,=]%)J=KJ-Q-<6RN
M#+'&?.PS+U"G>F">#N'J*?+HG_705WK_`%W.@_LJ#^_)^8_PH_LJ#^_)^8_P
MJ]14#*/]E0?WY/S'^%9YGT03:C$VH*K::JO>;F`$`9=PW$C`^7GZ5KWLEQ%8
MSR6D*S7*QL8HF;:';'`)[#/>O,FM+J*Y\11BRN5F5M.N[V140M-LEWRG:C$D
MLJM@#/`QZ"CK83Z'<:8=+UBW::RGG8(VQTEC:*2-L`X9'4,IP01D#((/0BHX
M;C2)]5?38YKK[0A(W-`ZQ,PZJLI38S#NH8D8/'!Q4T2^MK[Q1JVL6EY%)I-Q
M#:VT,ZN/+FF4R;MAZ-PZ+D=P5ZJ0(K:_MY[RTTB&_B?5+;4+B6>W5P98D(FP
MS+U"G>F">#N'K5-6!,OVEUHU[?S6,-U/]HA#$B2)HPX4[6*,R@.%.`2I(!(S
MC(I=*N=%UHRC3[R24Q8)!4IN4YVNNY1N1L'#KE6P<$XKDF\W5/"%EX?TZZ$N
MO6.F307BQL"T,OD&,JYSA2TA!`)^;!(R!FMS2+VWUKQ;8WNE2^99VFER6]T5
M!`25GB*1,#T=0CY4\KD9`W#(HW=OZZ_\-_5ART7]>7^9T?\`94']^3\Q_A1_
M94']^3\Q_A5ZBI`H_P!E0?WY/S'^%9K7.BK83WRW<LL$$Q@<PHTA\P-M**JJ
M2QW<8`/-:>K"Y;3I$M4D:1RJD1.%<(2-Q4D@`[<XYZUQ%I'!I-K9SI`NE:3I
MNN3-<+(R*D<;1.@)(8@`.ZY/XGUJ;^];^MU_F.VG]=G_`)'66,6G:E8I>6EP
M[P/GYC\I4@D,&!`*D$$$$`@@@X(JE9ZCX?O[:ZN(-1/DVJ>;+)*#&HCYQ("R
MC=&<-AQE3@X)P:I32?VIX4U^/3;A1+JHN?[-^8*9OW07<F<9!8%@1P00W0YK
M+N[V#6M0@U#2'>:QT_3"EZ(HV)5O.A?R2O7S`L<F4QN7(!`W#.D8W>NGZ:7U
M_(EZ+3^M4=)!>:-<:9/J*37BP0'$BRVTD<H.`0/+9`Y)R,`#)R,9S5G3H]/U
M2U^T6LESLW%66:)HG4CLR.H93T/('!!Z&N>DO[>^U/4]>LM1@ET1%L%>YBE#
M1;HIG>4Y!QA5=,GH,'/W3CH=!NX-1DU.^L[F.YLI[D&&:)PZ.!$BDJPX(W`C
MCN#0XV!,M_V5!_?D_,?X4?V5!_?D_,?X5>HJ1F=-I]I;PR32RND<:EW9B,*`
M,DGBLNZU'0K*UM+F6[N#'=Q^;#Y4+R,8\`ERJJ2J`$98@`9&2,BIO%$-Y=6R
M6J6KSZ>\<AO!&R!G`7Y8\,1\IR2>>BXQ\QQA:5K%EI.F:3<:O*+*&YT:*&#[
M00`[J,LH()&Y@RD+U;!P.#AI73_KO_D2W:27]=/\SJ+BSLK6TDNIIG6"-"[O
MG.%`SG@<UGQZAH4FES:C]KG2"%_*D22%TE60XPAB90^\[EPNW+;EP#D9SY+2
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MR:9#'(KAI,J01DC_``JY14#%HHHH`2BLOQ*VWPMJ[;I$Q93'=$2''R'E<<Y]
M,5RM]>6T^F:K/X6N;6>P1+43FSE!C&)29_F7.&\H_-CYL8[XI7*4;G?45YLT
MUAJM]IJZ?>6LFG2ZQ$KQ:==M+`&%O,S+N`"X.$W(./4?,<UH+ZVL7==8GMQI
ML<]]!;-J%XT,*,MPXVAMI&\(%"#@@!MO>FM=/ZZ?YCE"T5+T_&_^1Z>)8S,T
M(<&15#,O<`YP?T/Y4^O.+L*E@B75PLFISV^DB:;RS#+.INMKL5(##.0""!C.
M"!TJ'Q/J:6^L-;6Y2VN;34[+"MEIA:YBW-&J`>7!@L&=B5)#J1R,*^M@Y+QN
MOZV_S/0X=0M;B;RX)#*=TB%HT9D5D(#*6`P""<8)SP?0XM5YCH3"#Q`UGIIB
MCNDEUG="F%P_G1F/<H_V6!&>QXJ1+JSN8'30;J1K:/1+I=2*RMYD<^$V>:2=
MZS?ZW[WS=<]J(NZOY7_"X3CRRMYO\['I5%9&GVT-EK=_!;1K%";>"3RT&%W$
MR`G'J0JY/?`KA].OK#3?#7A9]1:W$=W9/++/J5V(K>27"8$C,IWO@G:I(`"M
MZ##6NPN5VN>F&6,3+"7`D92RKW(&`3^H_.GUYU;W,ESX?TVXLI89-<;1;N&U
MD*A9#<)L&T!LD,"&^4DD8.>]:/AK5M(>\EFM+_38X(K11=);WC2JK[@%:4E0
MJ2?>!S\S=_NT=;?UU$TN6]SM**YWQ/<6-K=:9+K$R0Z4)'\UYFVPB3;\GFG[
MNW[V-W&[;WVUS/B'5['3K+6GANWCM;OP_MTW+MF9D\\MY8/S-@,AR/X<'IS4
MRERJY4(\SM>W_#I'I%%>:6ENEQ%IK2M([7'B:ZBE+.26C7[1B,_['RCY>G7C
MFFI=O'K,EE<W<-IKG]L;K<--(T[VWF?*J0JAS"8@02#L!W,<,I(M*_\`7I_F
M*<>7?^M6OT_$]%N?LMN3J%RRQBWB?=*[8"(<%B>V/E!S[5.I#*&'0C(KS?4]
M/C/@]MD3S376DWQDWDR-*VT,N<Y)P?NCMT&*Z/7;A+3PW8:Y92;K;32EV5MS
ME9;?85<`#[P",6`]56INDVO3]1N.BMY_A;_,Z:BO/-5N4TR[C37YK**Q?3$\
MF2]O#;XN"SF8HP4GS.8R,8(_A[UE^(-=%J[K-=K%J-M=6#-)<2LLY@!B,LD4
M>`8XB"^]B3T<,.@#6K):/5Z*Q="@A,E_=[0\[W<R^:WS$(&X4'LO&<#C/-;5
M,75E>]L;;4;;[/=Q^9%O23;N(^9&#J>/1E!_"K%%%(`HHHH`****`"BBB@`J
M.>>*V@DGGD2*&)2[R.<*J@9))[`"I*K:A;P75A-%<0QS1E22DBA@2.1P?>E)
MV38TKNQ3F\1Z5!I-KJC7#/:W:JUMY4+R/,&7<-L:@N?ERQ`'`!)P`::VMZ-]
MNL76X\V6\B'V>2%'D0QL1@EE!50QP`6(R>!FN0T6YATG2/`VL:A<QV^F1Z)]
MGDFE.$CD=(60LW101&PR<<D#J15K1]!>/1;;43-<6EW-<2LD!5565'N7E@65
M67<-F\-A2I'(.>E:U(*,FET=OS1-TU?R.YCE25I%1LF-MK<=#@'^HI]<CX<U
M>Y_X2&[T%HXFAM4<L5'[V%@P"M,<D,9@3(N`N`#UZUUU9]$^X^K04444`%9>
MK>(M,T22*.^FD6256=4BMY)F"+C<Y"*2JC(RQP!GK6I7+>*/$UCI5VFEO?Z?
MI]W=V[,+N^N4A2%,[00&.7;))"CCY3DKQD`U;SQ#IEC+;I--(WGJ'5X8))45
M"<!W=%*HI_O,0.#SP<2#5--36GT_S\7SH'*E6P0!T#8VY`YV@YP<XP<URMQ<
M:+H^FSZ=;ZC:I;W>D16VE(9@3<X6156,_P#+0_,G3)^8>M:&JZ3%%JHGMQ+-
M>SQN[0`J(QA`CR],[RNV,<XY''4TY*VWF*^GW?H=+;7,5Y:Q7,#%HI5#HQ4C
M(/0X/-2US?@_79M=LYY)+W3[Y8RF)[!"D:EE!,1!=_G7C/(^\.!724-6&@HH
MHI`%9MWK^FV6I16%Q.Z3RE0#Y+F-2QPH:0#8A8\`,02<`9S6E7&^);JRN+[[
M!]NDM=0BF2:+3BT:C5"-K*<#]XR@K@X*@;3N!44KI/4#=_X2/3CK#Z4GVR2Z
MC=8Y#'8SO$C%0P#2A"B\$'EN],L]=T@QWJ02O&EENDF\R"1!C<VYE+*-XR&Y
M7(S7-[K:TUJX;2KN];7Y=14SV%S<]8#(JO)Y*L%\L1\K(06X4$Y^6I-6M5T-
M;VZMKF>]:RC6?R;@H8K5"QV#"JI*+EI""2W[I>>E"=XI_P!;7![V7]?U_5SN
M`<@&BLOP]J,VK:';WDZQAW+`/%PDRABJRH,G"N`'`R>&')ZUJ535G82=U<**
M**0PJ%KN!+V.S:51<21M*D?<JI4,?P++^=35R=A8ZA:^+8KJ\@M7N+F&Y,DR
M7#,1&'BV(H*#`48XS@DLW4G()LU;3Q#INI_:$B^V+''&SO--93P1%1P2LCHJ
MM_P$GCGI4MCK6FWEK;26LQ,<LA@C0Q.K!P"2K*0&4@`GY@*YW0H-$NW?3-.O
MY=0MI;-XM2MY]0:X:!OE"HR;RL+<R`JH4<'CY0*I7E\WANW%Q;ZG:6\#3RQ-
MJ6K('$T@!+Y"-&,DH$7&/N'@Y%)=^@WT2/0:*JZ9=37NE6EW<6S6LT\*226[
MG+1,5!*GW!./PJU5-6=F).ZN%%%%(8$@#)Z5AVGBW2+VPN+^)[Q;.W@-P\\U
MA/$AC`SN5G0!^.?ES6CJ@)TF\"K<,3`X`MMOFGY3]S=QN],\9K@@NG-ILFGZ
M3>:A>Z`;,K?M!<"XDMY`\0"8<D1_(9-\8``5>%!P"KJ[3_K?_(>FAUA\1:5=
M::]Y)%J`@AD3Y9=-N4=GR"NR,H&?G'W0:T;;4[.[^S>1,'^TQ&:+"GE!C)/'
M'WAP<&N8TV&+4_MEOINK7#:)"D,UGJ<5V+ETFW2>:%EE\P.``H.<@;B/84X-
M5FT35M+M+.-9H=06-D:?F:Y0L$Q&01@HI,[Y!SN;`7J*6K274EZ*[.^HHHI#
M"BBB@"O?7L&G6<EW<EQ%&,MLC:1CDX`"J"2<D<`$U2_X2&P_LE]29+]+='$9
M633YTE+$@`"(IO;)8=%/Z&E\0K:-HDWV^::"T#1M--#+Y1C4.I+%\C8HQDL"
M"!D@@C-<W))H\VA@R:K=/X?COE,6H0ZF74*$R2]PSE]@DR,ALAL#@`TFQHW9
M=?T?RK&]N6N(1)*R0"XM)HG4]"S(R@JH'5V`49Z\UL),DDDB*<M&0&X/!(S_
M`"(KD3IUIJ6DK=">XN+:V=H[*1)A(UY;N$_=M(^[>CM@;LY(`.[N5L-8OK/Q
M9'HDD]G<M*SM/"BGSXP8Q)YY.[_5;B(@-H[?,<$4UJ2]&=A1110,****`*&J
MZS9:+##)>M-B:3RHD@MY)W=L%L!(U9CPI/3M56Z\4Z99QV;3+J&Z[1GABCTV
MX>4JN`Q:-4++C<OW@.HJCXLCT@W6FRZW>W=E:1&1A<QW7V:%'(``>4%70D$A
M=I`/S`YR`<AY+&1+*Y\4:A=:?.HGBLY3>&T69/-.S+*P9G*+&2A.&Z[<CA77
M4&=7)K.FP:C;V\LDD=S=HOE[X9`I'.U68C:K'YL*Q!.#QQ5VVNH;N-I('WHK
MLA;!`RI(.,]>01FN5DLKB^L=%O-4DGBU:XAA22RC*+&9PI;>W!;]WEVP&QP.
MO%6/!VN3:LMU#*+-%MMJBVMU(:T.YU,,GS'+J$!R`OWAQC!--6;1*;_(ZBBB
MBD4%%%%`"T444`17$$=U;RV\R[HI4*.N2,@C!'%2444`%%%%`!1110`4444`
M%%%%`!4<\,=Q"T4J[HVZKG&:DHH`****`"BBB@`JM>6,%^D:7`D9$</M65D#
M$=F"D;EY^Z<@^E6:*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@!:***`$JC::UI5_>W%E9ZG9W%U;DB>"&=7>(@X^90
M<CGCFC6S*-!U`P;O-^S2;-F<YVG&,<YK,FN/#<::!Y2VLFYP-(6UQG&S!,>T
M_<"'G'&.O:A!T.AHKSC^W-033-&OH]2E>_U![I;RU+JXCV12,P``^3RG54R,
M=?FR2#6K+;W<8G!U>_?R])%P<RXWS_-^\.`,=/NC"<_=Z4+57'R_U\['945P
MIO[F63Q!='594N+.>V6UA$F$!:&)@A7HPD9BO.>ORX/-5Y/$=U_PD^B""\D,
M-YJMU:2>=(J!TC60;$A&[A609<[6SCJ&P#K8;C97_K:YZ%437$"7*6S31B>1
M6=(BPW,JX#$#J0-RY/;(]:\]TB^UAM,T)_[4NKBXU#1KFYD,A!S*GE&/`Q@8
MWD<=0?FR>:W+2;^VM.O_`!%!+"K-',FEW,C;!'"50%B>@#/'NS@\8H"4>5V9
MU=%9&D2K]HN[?R[^&2-49HKN82XW9P5;<QYP1@GMT&>>)L=8UNST'2;V*]N;
M^\N]"N[MXY@'\R9!&8\*`,8WD<8W=\GFDVEJ.$'+8]-HKA+R]O[.R-[:W=S'
M##;Q7LR75PDADC1U,CH%8G#1E\CA<A<`<U9\-:C>W&MO875Z\Q4-J"`MD^3*
M%\M>`/E#&4#//R"J2O\`U_7](AW5G_7];?>=E17GNJZG?1W?C*:#69%N]-:W
M^P6>\;5=HD*J5_B$CG;@Y[[<'FI'U^Z.OZ.8KFX,=WK%Q92M*RHC(B2CRTC!
M/W609<[22!V;%"5QR7*K_P!;7.[$T3.J"1"[`D*&&2`0"?P)'YT^N(@N[O2O
M"\3Z:))IDTF[N(XF9I-\J%-O4YZDC`]:JZM>ZA;Z5FRO[VV^T):X>:>*63+7
M$2&2,9;AE=@<_+PN`,G,W5[?UU_R*4&[>9Z`64$`L`6Z`GK2UP]@9'\;W%I/
M=SR16-Q(MMOF;*JT$#E2<Y<;F8_-GKZ5KZ#,ZSP0W!N_M,EIYC.URLT$Y!4%
MT.XD<D8X4$-TXX?8EQ:.AHK&UB0MJFDV3W<EO;W#R;O+?8TS*F5CW#D?Q-P0
M3L],@\WK>N2:8NOK%J[-#;:!YUM,\BG]ZKS*6##@L"(P??'>E)\JN_ZTO^@X
MQYG;T_%I?J=[17'6[75S;P32:A=;Y]1,#;92`(@"2H`X&<?>^\,\$<5"VH7J
M7-R\,\PFMM4BM?\`2+I%@2+<B^607W%F1MP)!8LRX.,"KY>G]=/\R+_U]_\`
MD=L2`"20`.I-"L&4,I!!&01WKS_Q0DQ\(:E,]Y=.T_\`:,4BF9@I14G**%'`
MQY:CCD@'.<FNBU"^&B^&[+4!(_V6T\I[@EMW[DC:S$GDA0V__@-0FG?Y?B7*
M+BD^]_PM_F;]%<$VK:E>ZNMK.]]!!)I9OH!;O'$P9Y&^9B[#/EKY8V\K\_S`
M\8S[KQ/J/]EPWWVW?=17>G6\TL$B+;(9?),@0!CYNX2$@D8`/!!7)I*_]>=A
M-6_KRN>FT5D:,LDLU]<S7$TCBZEB16<[40-@`+T[=2,\XSBM>D+JT%%%%`!1
M16;K9NFLE@MK6XG\]PDI@D5&2/JQRS+U`VC!R"P/&,T`7H+B&ZB$MO-'+&20
M'C8,"0<'D>A!%16NI6-^)S9WMO<"WD:*8PRJ_EN.JM@\$=P>:XO0H[F/X/W<
M&EV\D%Q';7D=K&",A@T@7&">^!^%5-4^P&\M&TX6O]D#0E-[Y941?9O.B\O=
MCC;L%QCMC?[U4%S=?ZLW^A-_=3?];?YG=6^MZ5=Z;)J5MJ=E-81AB]U'<*T2
M!>6)<'`QWYXJ:QO[/4[1+NPNX+NVDSLF@D$B-@X.&'!Y!%<K>B;_`(274C'L
M_L__`(E@;D;/-\YMWX[/)_#;6]I?_(1UG&W9]K7&/7R8\T-6_KT&F:E%%%2,
M*J7^JZ=I21/J-_:V:RN(XVN)EC#L?X1N(R?:K=<?XFMY[OQ!&EG=6=K/'IEQ
MYCWB"17B9D#!5XP057+Y(&5RCY&T`ZZ21(8GEE=4C12S.QP%`ZDGL*J0ZQIE
MQI;:I#J-I)IZJSF[2=3$%7.X[P<8&#GGC%8.IS2W?@33KBWAF@BD-D\T5P?G
M2`R1F0/]$W;L^]9VK",^+(C&(?[/&K6HON1M\_R7V;O]K<;;&>^SVJFK2Y?.
MP+6/,=?-J^F6VF+J<^HVD6GLJL+IYU6(AL;3O)Q@Y&.><U=!!`(.0>A%><Z2
M!_PG99_*_L@ZA?"RR1L\_P`N#=L'3=N%WTYSYGJ:Z/P*&'A.#I]G,TYM<'C[
M/YS^3M_V?+VX]L4W%6O?M^(KZV.CHHHJ!A4<D\43Q))*B/*VR-68`NV"<#U.
M`3]`:DKE/$EG`?&'A&]*L;@7LL08N2`IMIB0!G`R0,G&3@>E.*N[`=0\T4<D
M<<DJ*\I*QJS`%R!D@#OP"?PJMJ.K:;H\"SZIJ%I8PN^Q9+J98E9L$X!8@9P#
MQ[5R=Z^HR^.-(N[S3[J.-;N6"U3S(BHC\E]SG#YRQ`.#T51W)!Z2XQ_PDEIY
MFSR_L<^-WKNBS^E+L).[:[%F[U33]/>W2]OK6V>Y<1P+-,J&5O[JY/S'D<"G
M3:A96]Y;V<]Y;Q75SN\B!Y55Y=HRVU2<M@=<=*XNP$:P7!UD0_V;_P`(Y;[?
M.(*;/WGG=>,8\K/_``'VK+NUG'AOQ8M_L_MDPVGV3>1YN[R4$&TGG/VCS-O^
MUG'-5%)NU_ZO8IJR_KR/4:*09VC/7O2U(@IID02",NN\@L%SR0.IQ^(_.G5@
MI86]IXR^U1+(9I[&3S&>5G)`D0@#<3@#<V`,#FCK_789HV6L:9J-Q<V]CJ-I
M=3VK;+B."=7:%LD8<`Y4Y!Z^AJ2;4+*WO+>SGO+>*ZN=WD0/*JO+M&6VJ3EL
M#KCI7,>&$NX[K26N9[::&73&-HL$.QH8\Q';(Q8^8>5^8!!D'Y>>,KQ`/]#\
M<B;R_P"T6:#[!DCS.8U%OMSR/W_F;?\`:SCFG%7=G_7070[IM4T]=373&OK8
M7[)YBVIF7S2G]X)G..#SCM21ZOILVJ2Z9%J%H^H0KOEM5F4RHO'+)G('S#J.
MX]:Y2Z#FPE6U\O\`M;^WX/-\LC?_`*U"<]_^/?\`\<]JT+8'&E?ZOSO[6NMV
M"/\`IOG^E5RV2=_ZT_S)OO\`UW_R.GHHHJ"@JE::SI=_#<36>I6=Q%;L5G>&
M=76(CDAB#P1[U)J#6JZ;<M?.B68B8SL[;5"8^;)[#&:XLZ;I3O<>(M3L;>T\
M/KIT=G;6@@(>>+>K+YD87/4*J18)PQR,MM"Z_P!?U_7D/M_7]?UW.TL-1L=5
MM%N].O+>\MF)"S6\JR(2.N"I(ID>KZ;-JDNF1:A:/J$*[Y;59E,J+QRR9R!\
MPZCN/6LO0-*G@U?5M:N(EMFU$Q!+50!L2-2`SXX,AR<GL`H[57A#^5I@3R_M
M']J76<$=<3Y_I5.R)6J-ZVU/3[RZN;6UOK:>XM2%N(8IE9XB>@8`Y7H>OI2V
MFH66H>=]BO+>Y\B0PR^3*K^6XZJV#PP[@\UY]<K=GP7HZ6>W_A(?[(N=VQOW
MN[ROWO/7_7;,_P"UCO6SI?V0^+]*.C^0+(:%^^\C&W87C^SYQVQYVWVW4TDW
M:_\`6O\`EH.6BO\`UT_S.QHHHJ0(KFY@L[:2YNIXX+>)2TDLKA511U))X`JH
MNNZ0^DG5EU6Q;31UO!<(81SC[^=O7CKUI^JR6L-@9+R$S1K)&5C"[B\F\;`!
MZ[MN,\5B(D=C%+>ZK8)]KO-1$]I91,&;S/+"(,\*7VH6)Z+SR0NZE<#H[:ZM
M[VVCN;2>*>WE4-'+$X97'J"."*CM=2L;\3FSO;>X%O(T4QAE5_+<=5;!X([@
M\US;:9JFG>`M;2-((M5N8KJX2&RR(XI'#%50X!)Z9;`RQ)P,UB:I]@-Y:-IP
MM?[(&A*;WRRHB^S>=%Y>['&W8+C';&_WJXQYG;^MF_TMYB;LK_UT_P`SNK?6
M]*N]-DU*VU.RFL(PQ>ZCN%:)`O+$N#@8[\\5-8W]GJ=HEW87<%W;29V302"1
M&P<'##@\@BN5O1-_PDNI&/9_9_\`Q+`W(V>;YS;OQV>3^&VM[2_^0CK.-NS[
M6N,>ODQYH:M_7H"9J4445(RKJ&IV&DVINM2O;:SMP0IEN95C3)Z#+$"H[[6M
M*TR."2_U.SM$G.V%IYUC$A]%)//X52UR?3X+W3S+9K>:J?,%A#MR<[?G;/1%
MQ@%CTSCJP!Q++2(=`T>UT2*SAU#7&LYE4B$"&%)'RPR>$A#,`%&2548!VG!T
M!Z':22)#$\LKJD:*69V.`H'4D]A52'6-,N-+;5(=1M)-/56<W:3J8@JYW'>#
MC`P<\\8K$UG3Y=+\%66GV\SS1VKV<,\DK<O`LL8D+?5`V?;-9>K",^+(C&(?
M[/&K6HON1M\_R7V;O]K<;;&>^SVIV5[)]1I>[=G7S:OIEMIBZG/J-I%I[*K"
MZ>=5B(;&T[R<8.1CGG-7000"#D'H17G.D@?\)V6?RO[(.H7PLLD;//\`+@W;
M!TW;A=].<^9ZFNC\"AAX3@Z?9S-.;7!X^S^<_D[?]GR]N/;%4XJU[]OQ)OK8
MZ.BBBH&+1110`E00V-I;S2306L$4LG+ND85F[\D=:GHH`A%I;+++*MO$))1B
M1P@RX]SWJ0Q1G.47E=IXZCT^E.HH`SK;1+&VU*ZOUA5[BXE$I=U4F,B-8\(<
M9`P@_,U:-C:&5Y3:P>8[*S-Y8RQ7[I)[D=O2IZ*!MM[E>6SB>W,47^CL(VCC
MDB5=T0/]W(('0=L<#BGPVT%O:1VL42K!&@C6,#@*!C'Y5+10(AMK2VLXS':V
M\4"$Y*Q(%!/K@4Y+>&/R]D,:^6I5,*!M![#T'`_*I**`*\%C9VWF>1:P1>;_
M`*SRXPN_ZXZ]34J0Q(VY(T5MH7(4`[1T'T&33Z*`,ZWT2RM]3N]0$?F7%S*)
M2T@!\LB-8_D.,@$(,U9.GV1F:8VEN97(9G,8W$CH2<=JL44#;N116T$!)BAC
MC))8[$`R3U/XX%1Q:=8PAQ%9V\8D(9]D2C<0<@GCD@\U9HH$0M:6SR"1[>)G
M#APQ0$[@,`Y]<<9JO)I%@]O/`MK#$EQCS?*C52^#GGCGO^=7J*`(Y[>"ZB,5
MQ#'-&>J2*&!_`TR2RM)5C62UA=8U*QAHP=@(P0/08XJ>B@!@BC``$:``[AA1
MP?6F-9VSW2W36\)N$&%E*#>!Z`]>Y_.IJ*`&&*,KM,:$9)QM'4YS^>3^=5KO
M3(+JP%CS#:\!HHE4*Z=T((/RGH<8/O5RB@"&XL[6[C6.YMH9D4Y"R(&`/K@T
MV6PLYY3+-:022%=A=XP25],D=/:K%%`"*BH"%4*"<\#'-+110`4444`%%%%`
M%9K&W,]O*$"FW+&-5``!88)_4_G4D5K;P*ZPP11B1BSA$`W$]2<=34M%`$$=
ME:16S6T=K"ENV0T2Q@*<]<CI3X((;:%8;>*.*)>B1J%`_`5)10`4444`%0W%
MI;7847-O%,$.Y1(@;!]1FIJ*`(C;QM+([*&,B!&!&00,\?\`CQIJV=JEJ;5+
M:%;<@@Q!`$P>O'2IZ*`('L[66U%M);0O;@`")D!0`=..E3]!@444`%%%%`!3
M6C1V1F169#E21DJ<8R/3@D?C3J*`&LB,RLRJ64Y4D<@].*K?V79-:K;2VT4T
M2N7"RH&&XDDG!'7)/YU;HH`BFM;>X:-IH(I&B;=&70-L/J,]#0]M!)/'.\,;
M2QYV2,H++GK@]JEHH`****`"DVKO#[1N`QG'.*6B@"J-.M$6X$-O%"UP")'C
MC4%LYY/'/4]:D%G;;X7,$;/"-L3LH+(,8X/:IJ*`(3:VYNA=&"+[0%VB78-X
M'IGKBA;.V2Z>Z2WA6X<8:4(`[#T)ZGH/RJ:B@`HHHH`;)%'-$T4J*\;##*PR
M"/0BJ:Z+I2JRKIED`XPP$"\C.<'CU`_*KU%`%)=(T^-0(;."$;UD/E1JN2IR
MN<#L:G6SMDNGNDMX5N'&&E"`.P]">IZ#\JFHH`BBM;>&626*"*.24YD=$`+G
MW/>B&V@MPX@ACBWL7;8H7<QZDXZFI:*`"BBB@".>W@NHC%<0QS1GJDBA@?P-
M5O[(TSR/(_LZT\G=O\OR%V[L8SC'7%7:*`*::79Q2V[PP1PBW+-&D:!5!88)
MP!Z?SJ>*UMX%=88(HQ(Q9PB`;B>I..IJ6B@"".RM(K9K:.UA2W;(:)8P%.>N
M1TI\$$-M"L-O%'%$O1(U"@?@*DHH`****`*]U86=Z5^UVD$^S.WS8PV,]<9%
M1-HVENB(^FV;*@PBF!2%&<\<<<U=HH`@2S@CW!8D"-&L6P*-NT9P,>GS&A;.
MU2U-JEM"MN008@@"8/7CI4]%`$#V=K+:BVDMH7MP`!$R`H`.G'2I^@P***`"
MBBB@!:***`$J&"[MKIYDM[B&5X'\N98W#&-\`[6QT."#@^HJ+5+S^S]+NKO`
M9HHV95/\38X'XG`_&N+M?[0\&RV=M/;0O]MLWA%Q%*9#)>('ERPV+S)ND/U`
M'<4!N=_17#RB/3?#`NK#6KV[FOX[=I99;UI3Y;R(LDZ`G$>%<GY,(...*G1(
MM$\8:;8P:K>26KPW;20W5Z\_EN%A*J6<EN@=AN)QEL8'%$O==F.*YE<[&BO-
M-.2YU;PC%J,FKZFMS;Z';W,$D5Y(H\W]Z2[`'$A.U<APP..G6M*\230O$6FV
M=O?WYM)+^W:07%Y+-]^.X4J6=B=I9(_ESC.,#-*^MOD6X;Z[7?W*YV_FQ^:8
MMZ^8%W%,\XZ9QZ4K.J8W,%R<#)QD^E>:6>LR20ZG<K>RRF:[:TBE60L=KW[Q
M*`V?E&#@,/NCD`X`JK"@O=6M+2>\N94T[Q-]GA"ZG-+L!M"Y0R$AGP^1\V2,
MLO3(H4KI/O;\_P#@@Z;3DNU_P5SU:HVGA6X2!I4$SJS)&6&YE&,D#J0,C/U'
MK7G6BWNMM8V&N'4K<W=ZDWVFUGOW82NJ.?*B@*@(\;*`0N"0&W;CR+FD6UK!
MXST*6WU>ZU`W6D7,[//<M,'R\'[Q<DA`W/RJ`O'`&*TC"[_KLW^A#T>IWM%>
M=ZK)?1ZQKFHQZI?(UCJMC#;P"=A"J2"!9`4Z,&#G[V<'E<$DF;5=5N%\)+)%
M?S+<?V3?N664A]\:@9SG.5;OV-9W]WF+5-N2CW.^J.&XAN%9H)HY55V1BC!@
M&4X8''<$$$=J\XU?3[BR_P"$@$&M:P/L6C1ZC!F_E.VX/G9<Y;E3Y:_NS\G7
MY:ATJ9[2*?4K75IY+YO$LEI]B$I,6Q[@[XS$.-VTM+O(W#'7:,4X^]+E7]:V
M!TVH<S_K2_Y6_K4]1HKAM$;4'OK#4WU*`F\N)HKF.?4I&#X#_NXH"H1'0H!\
MO.%?<2>:U=/%QI?@5KRS-S?7[V7VH"XN'E,DQC!P-Y.T$C[JX`SP!1)J*;?0
MA*[LC?N;F"SMI+FZGC@@B4O)+*X544=22>`*=%+'/"DL4BR1.H9'0Y#`\@@]
MQ7FGB;3K8:;#91:KJ-U!.+.ZE#ZC*Y#&YB17#;LJ'#/\H.W*`J`1FNJUZW2?
M5-$TV34KJTMYC*K)#<M&]QM0$)O!#YXW9!S\IYP30M1VT3.DJ&>ZM[9=UQ/%
M$,@9D<+R2%'7U)`'N17#F6ZU#1;>&]N)U2!;R03#49;/=#%+LCE:6,[F^3!Y
MX.=Q[5CW;R?VI_:Z7EVM[/IFD.SI=2!6WW6U_D#;<$=L8Y/]XY/M6_KK_D.,
M.97_`*W2_4]6I"0`22`!U)KB';4)=8NM234H(I+;4DM=EQJ4D<21%E'EF`+L
M+NK;E)RQ9UYQ@5F^*-.W>%]4O'O]2>2Y_M&*5#?2B/8JSLBA`VU<>6@X`)&0
M<@G*F^6-_P"OZU"G#GER^=CTE6#*&4@@C(([TM<`T1TV:"].IWEQ:V\UG;1+
M;:FY>WW^6H22)LK+N+Y+.2^U_EQM4UW]6U8S04445(PHHHH`****`"BBL;Q*
M]Y_9@@M=+NM06X<1SI:RQ(ZQ?Q8\QT'(^7@Y&[/:@#5@N(;J(2V\T<L9)`>-
M@P)!P>1Z$$5%:ZE8WXG-G>V]P+>1HIC#*K^6XZJV#P1W!YKA]"6ZF^#E]!8V
M,UI<"VO8[:'*@@[I-NW8Q`YX'(Z?0U%JTMI+J-E/8M"=,CT,2791AY8@,T)3
M=@XV[%GQGC`;WIP7,]_ZLW^@K^ZF_P"MO\SN+?6]*N]-DU*VU.RFL(PQ>ZCN
M%:)`O+$N#@8[\\5-8W]GJ=HEW87<%W;29V302"1&P<'##@\@BN5O5E/BC4I4
M/^A8TQ6.[Y?,$[EN_7:T6?;;6_I>?[1UD@C;]K7&#W\F/--JP7-.BBBI&%-D
MD2*-I)'5$499F.`![FG5@>+M,M+W1+FXN8O->VA=H@S$HK<$-LSM+`@88C(Y
MP1DT`C1O=9TO3;FWMK[4K.UGN6VP13SJC2G(&%!.6.2!QZU9N+B"TMI;FYFC
MA@B4O)+(P544<DDG@`>M8FN;K^:YT:RLT>YN[3;<W3X"P1-N5<]W.=Y5>G!R
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M]#T]*N5S.JPKK-U>:1IT%JA+Q-J%VR@E#P0H`'S2;`,$D;05//2I'T-QM2L$
MU)-.:]MEOG3S$MC*HE9/[P7.2.#SBFZCJVFZ/`L^J:A:6,+OL62ZF6)6;!.`
M6(&<`\>U<'IZZA;61O+R>.[F'B!X?[.DME(&ZY(63)!?S%C(=6!"A`/EXW5V
MEQ@>);0N5"?8Y\9/??%G]*?2_P#6UQVU:_KL6;O5-/T][=+V^M;9[EQ'`LTR
MH96_NKD_,>1P*=-J%E;WEO9SWEO%=7.[R('E57EVC+;5)RV!UQTKC-,*V\=S
M-JI06!\.VQ4RL-NU?-\WJ<=#'G\/:LFY2:/PKXNM[P_\322"V%L&?]X6:"-(
M=N3D'S@^/]K..:(I-V_K>P-67]>7^9ZE12#.!GK2TA!33(@D6,NHD8%E7/)`
MQD@>V1^8IU</IT^I'QNEU?Z!J4<\\%PBR/+;&..)6CVJNV4MC(R3C)9^F!\H
M#.U\V/SO)\Q/-V[MFX;MO3./2H9M0LK>\M[.>\MXKJYW>1`\JJ\NT9;:I.6P
M.N.E<?X9-V/&5S+?:+?VEY=6?F3SW+V[`GS/E0>7(QVJ#M''8D\DYI^(,C3_
M`!Y#*5^W2F+[$"WSG=$BP;><C]\'VXQ\V<<T0]ZU_/\`.P=SNFU33UU-=,:^
MMA?LGF+:F9?-*?W@F<XX/..U)'J^FS:I+ID6H6CZA"N^6U693*B\<LF<@?,.
MH[CUKE+P/)IDD%N5.I+X@@\P(WS_`.O1SGG/^HY_W?:M&VSMTD97S!JUUNP?
M^N^>_P!*KET3O_5E_F*^_P#7?_(Z:BBBI&%4X-7TVZ^U?9]0M)OLC%+GRYE;
MR6'4/@_*1@]?2J'C(7A\%:V-/W_:_L,WE>7G=NV'&,=_2N=:>QTNYB.KRVNJ
M6$NF&=IC9(?*`DB$<405<F-F;Y$8LV4^\QZ']?@W^@[;?UV_S_JYVEAJ-CJM
MHMWIUY;WELQ(6:WE61"1UP5)%,CU?39M4ETR+4+1]0A7?+:K,IE1>.63.0/F
M'4=QZUF:#IEPNJ:CKMW']FEU%(56SP,PH@.-Y!(:0ECDC@```G&36B#F'3%4
MKYW]J76<-[7&>_TIO02V-ZVU/3[RZN;6UOK:>XM2%N(8IE9XB>@8`Y7H>OI2
MVFH66H>=]BO+>Y\B0PR^3*K^6XZJV#PP[@\UY[=QW4G@31[6UR=;&CW(95?]
M[N$!63G.<^:4SS]['>MO3WM[CQGI,FF-&UHNAL93"PV[&>/R,X]EEV_\"Q1%
M)NU_ZLW^@Y+E5_ZZ?YG84444A%>^U"RTNT>[U"[M[2V3&Z:XD$:+DX&6)`')
M`JI;^(M#N]/GU"VUG3IK*`XFN8[I&CC/7YF!P.HZ^M3ZMJ,6D:-?:E,K-%:0
M/.ZKU(52Q`_*N-GTK5X;#PQ$=0EBN;G47GU&[C4.5=X92,!@1@,51=P(&$X.
M*$.W]>AW%I=VU_:QW5G<17%O*-T<L+AT<>H(X-,M=2L;\3FSO;>X%O(T4QAE
M5_+<=5;!X([@\USEU%>'P3XCM+1S/>1QW,45Q&BQO/)Y?WCL"C?N."0!RO;I
M6+JTMI+J-E/8M"=,CT,2791AY8@,T)3=@XV[%GQGC`;WJH+F?]=F_P!!/W5K
M_6R_4[BWUO2KO39-2MM3LIK",,7NH[A6B0+RQ+@X&._/%36-_9ZG:)=V%W!=
MVTF=DT$@D1L'!PPX/((KE;U93XHU*5#_`*%C3%8[OE\P3N6[]=K19]MM;^EY
M_M'62"-OVM<8/?R8\T-6%<TZ***D96O]0LM+M&N]0O+>TME(#37$JQH"3@98
MD#K4S2QI"9GD18E7<7+`*%ZYSZ5R_B<2S>(]`MK66*UO2;B6WN;A/,B!"`-&
M8\@NQ5F(PRD;"<D`@\Q<2W5SX!MK6VT;4+G28K>X,DD,UN1,49U5B6:/,9(\
MSY%P1M`&.":VN)W1ZA))'#$\LKJD:*69V.`H'4D]A52'6-,N-+;5(=1M)-/5
M6<W:3J8@JYW'>#C`P<\\8K*\2/<W'AB"802VY^TVDEQ%(R[HXA,AD#%6*X"[
MLX)&,]:QM7*'Q?;RH4^Q1:I;)>'<-HF,,H7=SC=N>WZ]RGM0M[%):7.NFU?3
M+;3%U.?4;2+3V56%T\ZK$0V-IWDXP<C'/.:N@@@$'(/0BO.=(X^(#SL5_LR2
M^ODM26&PS>5;@[1G&<I<].<A_>NB\"AO^$4B;_EB]Q<R6_.1Y#3N8L?[.PKC
MVQ5.*M>_;\27O8Z2BBBI&+1110`UXTE7;(BN,@X89Y!R#^=))#'*%$B*X5@P
M##.".0?K110!%'8VD/F^5:PIYW,NV,#?_O>O4]::-,L!;K;BRMA"K;Q'Y2[0
MWKC&,^]%%`$JV\*1^6L4:IMV;0H`V^F/3DT36T%PCI/#'*C@!E=`P8#D9SUH
MHH`;]CMC&\?V>'8X(==@PP/)R._4TGV&T\L1_98-@VX7RQ@;?N\>W;THHH`5
M;.V2Z>Y2WA6X<8:4(`[#T)ZGH/RI(K&T@E:6&UACD<DLZ1@$D]<D>M%%`#S;
MPMOW11G>P9LJ/F(Q@GU(P/RJ-=.LEDED6SMP\V1*PB7+YZY..?QHHH"Y*UO"
M^_=$C;UV-E0=R\\'U')X]Z8EG:QS><EO"LN"-ZH`V"<GGW/-%%`7!;.V2Z>Z
M2WA6X<8:4(`[#T)ZGH/RJ545%"J`J@8``P`***`(8["SA1DBM8$1V#LJQ@!F
M'.3[\=:CN],M;Z>&6YC$HB5E$;J&1MV,Y!'/0444`2R65K+Y7F6T+^208MT8
M.PC^[Z?A2-8VC%"UM"3&-J$QCY1D'`].0/RHHH`5K.V>Z6Z:WA-P@PLI0;P/
M0'KW/YU(88RNTQH1DG&T=3G/YY/YT44`0KIUDDL4J6=NLD2[8V$2@H/0''`Y
M-6<444`&*,444`&*,444`&*,444`&*,444`5FL+<SV\H0*;<L8U4``%A@G]3
M^=/BM;>!76&"*,2,6<(@&XGJ3CJ:**`&QV-I%;-;1VL*6[9#1+&`ISUR.E20
M6\-M"L-O%'%$O1(U"@?@***`),48HHH`,4UD5U*NH93P01D&BB@"M<:787<O
MFW-C;328QNEA5CCTR13_`+%`3<;T5UGP'5U!!`&,8[CZT44`*]E:RVHMI+:%
M[<``1-&"@`Z<=*6>TMKI46XMXI0AW*)$#;3ZC/0T44`38HQ110`8JG)I.G33
MF>6PM7F)R9&A4L3ZYQFBB@"?[+`;D7/DQ^>%V>;L&[;Z9ZXJ#^R[)K5;:6VB
MFB5RX65`PW$DDX(ZY)_.BB@"::TM[AHVF@BD:)MT9=`VP^HST-*]M!)/'.\,
M;2QYV2,H++GK@]J**`)<48HHH`,4W8I8-@;@"`<<@?Y`HHH`9-;I,DBL`"Z%
M"P`S@_6FBSMM\+F"-GA&V)V4%D&,<'M110`IM+<W0NC!%]H"[1+L&\#TSUQ2
M+9VR73W26\*W#C#2A`'8>A/4]!^5%%`$^*,444`&*JG3K$Q2Q&SMS'*V^1#$
MN';KDC')]Z**`(UT?3XU`ALX(1O60^5&JY*G*YP.QJ=;.V2Z>Z2WA6X<8:4(
M`[#T)ZGH/RHHH`6*TMX99)8H(HY)3F1T0`N?<]Z6&V@MPX@ACBWL7;8H7<QZ
MDXZFBB@"7%&***`&21I+&T<B*Z,,,K#((]"*26"*>)HIHTDC889'4$'Z@T44
M`0_V?;>;:NL:H+7=Y2(H"KD8_EG\ZDBM;>!76&"*,2,6<(@&XGJ3CJ:**`&Q
MV-I%;-;1VL*6[9#1+&`ISUR.E206\-M"L-O%'%$O1(U"@?@***`),48HHH`B
MN+:"[B,5S#'-&3DI(@8?D:>8T,?EE5*$8VXXQZ8HHH`8;>-I9'90WF((V!&0
M0,\?^/&FK96J6IM4MH5MR"#$(P$P>O'2BB@`>RM9;46TEM"]N``(FC!0`=..
3E38P,"BB@!<48HHH`****`/_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>graph8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 graph8.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`"[`E<#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#WZBBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BJL
M^HVEK<QV\TP220@*"#C).%!/09((&>I&!FJT?B'29(RZW\14;2"21N#9VLO]
MY3M;##(.T\\&@#3HJJ=1M!?"R,P%P>`I!P3C=M!Z;L<XSG'.,4R?6-/M9VAN
M+J.%D5F9I/E4`+N.6/&0OS$9SCGI0!=HJA%K>FS;0EVF]I!&(V!5]WR\%3R.
M&4].C`]"*LBZ@-X;02K]H6,2&/N%)(!_,&@":BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`H/3UHI",@C)'N*`.7/B6_MT6*[M;=;Z18,VT;[OLKRN$5)
M&!PV,DY&,[3@=#4E_P"(K_3[1"VGI/*M_'9SR1R;8T5Y$4/@_-DB13M&<'(W
M<9*V/A!;.TN+:;6]4O5F<2A[DP[TE4@K(&6-26&U<;BPPH&,<5?;0()=+6QG
MN;F8^?%<23NR^9+(CJX+84+R4`P`!C@8I/;^OZ[_`(%*U]=BFOB&5-6M89TA
M\B\O9;*%4),B-&C-N;G&#Y;<`<97KDXZ&L2+PM81^)9M>8M)=28*AHHAY9"[
M<AP@D;@D89F`R<`<5MU3M96)ZA1112`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`%%`HH`****`"BL34I[R+6;:*WO7)FV
M;+2.%<!5;][([G)V[2H&,<^N>*<&H:I+J4=M%<*6N[>[D3SH@R6[QRHB<+M+
M##G(+9.W@BFE?8#IZ*Y6&^U*XN;.RDU$QN8KUY)HHD#.8IE1<!@0!AN>,].?
M7HK"=[G3K6XD&UY8D=@.Q(!-+I?^OZT`L4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110!A:S::M>ZG91PVEC-ID;K)+YMV\<F\'@A1$P8+]X
M#<N6`Y&*S!HNOQ:1+"L.ER7$=O'90+]I=%>-#_K&;RR58\?(`0.?F.:["L]=
M;L/].,MPENEDVV9YV"*H_O9/&W.1GU!I>7]?UT$TF_Z_KH9$^DZU?ZY;WDLD
M6GJD)#RVUX\[!BC`JD4D?EJ0S;A+C<0H4K@D5#J.AZWJ%R;2<VEQ8);/#%>3
MW!\\.R$&1H5A"%OX>&7Y2WKBMY-<TB5[9(]4L7>Z4-;JMPA,P()!3GY@0K=/
M0^E,7Q#HKFV":QI[&Z<QVX%RA\UQC*KS\QY'`]15:_<#BFK/J94EIXC%M)<)
M8Z2][<7$<DL)OI$CC6/;@!_))<G;W5<9QSC)N6&CWMGK4EX]U!+#(LFX>4PD
M)9@0-V[!```'`X`XJ_<:MIMG:M=7.H6D%LBJS32S*J*&.%)).,$\#U-5;OQ'
M86-IJMU<L8H=,<),SLJ@DHCC!)`Y\Q1R1S^=2DD^9?U_5Q\MT:U%9\>NZ3(S
MH-2LQ)&L;2Q_:$+1B3&S=@\;LC'KGC-789HKB&.:&1)(I%#HZ,"K*1D$$=0:
M8#Z***`"BBB@`HHHH`****`"BBB@`HHHH`****`.6T_QI!K,C+86MS$(-5;3
M9_M<6PEE1B2F#[#K^5/TGQ5/J&F2WL^FK;C[%%>0HMQO+JX;AOE&T[E([\$'
M@Y`UM2U#3;!X#J4D$,8S(LUPRJD9&%SN8\$[\#ZT0_V.+B32X?L/GQVZK):)
MLW+#R%!0<A.3CC')I)-+7^M/\]2G;^O5F5=>*IK#5=+TV[L8C<W15;E;>624
M6Y<D(=WE@8)!Y<QYP=H8@@5;GQI<VMA%,^BS27+7$D<MI;K/-)$B8SD)"3O(
M9<`@(<@B3!!-UK[PI%-.[G2HX]/5?,NF\H1P'>P";_X6#`\<8)]:LN/#BRG3
M?+TMIH@)S:#RMRAB%#[#T!)`SWZ4TTU_7]=R&G?R_K_@"7?B`V6HI;2V9$<G
ME%9/,P=K;@Q*XXVD*#_O"N?'BW4+W688HD^RP[3F,@%CD6C`MD<$"=Q@?TKH
M;G5_#4[WD5WJ&DR-9H1=I+-&3`A(R'!/RC('7T%(;[PPUS;RFZT@SW<;3P/Y
MD6Z9`%)=3U8`1J21V0>@JH-)WEK_`%_7];7!V>JO_7]?@/U+5[FSOD@@LHYH
ME$;SR//L*(S%25&T[F&,XR`>>1QG,NO$FLJ8$MM*L#)=.KVHEOG`>$D`ER(C
ML?YEX&X<GGCG0MO$'AW4H;.XCU'3I!J&8[;=,A,Y4\JO/S$$]!G!I+5O#M]>
M7EC9PZ=<.A_TI85C<*X;[KXZ,#S@]*E-.Q$D[.QMC.!GK1110,****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`!10**`"BBB@"I)I>GS7HO9
M;&V>[`4"=H5+@`D@;L9X))'UJ6*SM8)I)H;:&.67F1T0!G^I'6LZ_P!7O+3Q
M%I>FPZ/<W%K>+*9KY"/+MB@!`;_>SCM[9YQAZ3K&K1:5)-/)<WD\PMWB%PD(
MV^:Y4[=FP;!C@,=V>IY%3S*]AV.IGTVQN8Q'/96TL88L%DB5@"3DG!'4DG/U
MJT!@8'2N=CUO4GUFTTY[1HY"@>XS;.RA?GY\Q28U/RK\I8GYN^.<F7QAJ5KI
MEU>>1;RQ6J["')#NWV,7&XD#'7Y<`=\\8P6K%1IRF[([BBN(U'Q5JMAJ8MS%
M;R2J=@16*QR%GM5!.06!'GL.#@XR1S@7[7Q#J%UJ4-@($$JS2),Z6TKQLJR,
MN=P^6,X7.&)R3@9QS25["E%QBI/9G445S^I:M?0B\-N]N@C9X8PZ%F#K"9=Q
MY`(XQMQTYSVK5TN`VVE6D+2O*R1*#([LS,<=26))_$FI4DVUZ?C_`,,2U8MT
M444P"BBB@`HHHH`****`"BBB@`HHHH`****`,?4?#6GZEKNG:U.LGV[3E<6S
M"1@HWC!RH.#67/X8N;*T5[3499[PB"(R7$"R`LLZN'8)M)`)<D9_B/(ZUTUY
M,UO93SHNYHXV<+ZD#.*XZ;QI+!HD&HF_TAX;B21([D21B'*@;4+^?L#$[NC$
MX'3K@273H-/4L6VB:F/%$C27,7DBUMWN)19D+,XGGD*QG?\`)ABN0=YP1WP:
MM1^%IX-,L=.@OX5MX[2.TNMUJ2\J)T,9#CRVR3R0W;TS3+S7]0L[:6[D^R^2
MK2KM$9S&$8`L6+@$`9)^[TZBJDWB.[OO#>HWMO/8RP1:=-<"2!BPEQY@&UXI
M3M^Y_"Q(.>0>E).]D5\;Y>]E]VA<U/PG<:A;7,":L\"SW/F?NT9"(OF)CW(Z
MMG<[D,".H!#`$&[!X?\`)M=2@^U;OMKH^[R\;-L4<?KS_J\]NOM51->GEL]8
M2SFM;C4;&!V2Q5&,D;`$Q^8=V?GP".A(/!.,U4C\:PW.KV\-O>Z<UI/<B"([
M_P!Y/E(SF(%@'4%VRR[L8'!YQ/PNRZDIWC?^NA-<^#GNB\,E]$;1;H7,$?V4
M;U)G6:0.V[Y@2N!@+@'G<0*ZJN=\.>(6UJ>\B:6U9[;`EBB=/,@<E@5=1(Q!
MX_B"G@\>D6@ZS?WLXCD^SBV26.`*$<N<VJ39+ESGEB.1G'?-.^@TFT_(Z>BB
MBD2%%%%`!1110`4444`%%%%`!1110`4444`9>KZ9<WSPS6=W#;W$*NJM-;^<
MN&P#QN4]`<<]3W&0:&F>%!IGB"34([QY+=H!$D$CS%D(5%R/WOE\A!TC#9_B
M[5=UW4Y]-M]UM$))!&\S*5R-B`9Y+*!U'.2?13SATVI3VT]^)HAL@@,T*XQY
MBJ/F.[)[\8*C\:+BT;.;N/A])/9P1_VN4FM%BCM)(HI(0J1B15#F*5'8[96R
M5=02`<`94W]/\)3V3E?MT"VPMX(5A@AE4$Q[/F;?,X8_)@'`;!`+-M%36VMW
M\^MMI0%D[QX:2X0L5VE5;`7^]\W3/0JW?;6-'XDU+57\-&&6TBEO62X*1,Q5
M%:"<[7&?F&4R.G*G^[FFO=_KU?\`F:1BY)OHBUHVGZA/J5X+R5GADE$T8>R>
M(VX2?S!'N)Q)G).X`8QWXJ_+X7FEU^TU#^TG%O;LT@MAY@!<N[9($@0C#D?,
MA.0"".E9<GCBZ73WNULXF"6KNZY(59EM_/V[C@D8P.%QR#NSE1KG7KJUT76K
MV\MX6ETV-I=D3D*X$*R8R1D=2N<=LX&<">5))_UW%K+3Y?E_FBG<>#IY[K3I
MAJ0"VC!7CQ.BRQ+)O08CF12P'!+AP3SM`R#J:1I%UI]P[W%Y#.BQB"!8[8QE
M(P25#'<VYN>2`H/H*Q]-US47\63:6SVDZO([O(DC$1JD5N=JKV),IXS_`+7?
M%3W_`(HGAM+?[/"'NIHHG$<<$DY5G1V`*Q\@90#<<`9R:2?+%?UW0G&^IU-%
M0B24-"C0NQ=?GD7:%0X[@G//MFIJH04444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`"B@44`%%%%`$-W<I964]U(&,<,;2,%ZD`9./RKE)O%
M&AZ?<BSN],%E;W$4DT^^%6SM$9R5CW;AB0DG/RA23QR.KN[9+VRGM9"PCFC:
M-BO4`C!Q^=9C^%]-(011FW5+::VVP*J`K*$#,>/O?NUP?YTE>[?]=?\`@%1M
MU_KL4)8_#Z:M+./-26PC20Q1VC%6`Z>40A+X)`*Q$\D`C)P=)M2TD7-O9/"X
M>[19%5K*0*`PVKYAVXC)`*@.03C&.U0IX6LDN)YO.F9YHFA;>L;_`"DJ>Z'=
MC:`-V0!P*E7P[9K>V]V2S2P1QQ@O'&Y8)G:22I(//\)%59+8A-]?ZV_X(Z"_
ML+V]$(MB92\R[GC7K$RAN<^NW'T[8I;S0+&^OH;J9#NB97"J``65MP.<9'/)
MP1GH<CBI+;1[>UNQ<H\I<-,^&(QF5@S=O51C^M:%1#F6KW_K]2GY$)M+8W#7
M!MXC,R[&DV#<5]">N/:I@,#`Z4450@HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`@O!$UC<"=2\)C82*.I7'(_*L.SN;30M,5H-+U$";?,WFSK-,X"@EW
M=Y"6XP!EB<`#&`*Z":)9H)(F)"NI4XZX(Q65!X;L(K>WMYD%S#;DF-)H8MHR
M,=%4#\<9Y-+76P=B2#7([I8Y8;2Z:U=U1;@A`N20.A;=U./NUJ5G#2%$I(N[
MD0&;SOLPV;`V[=UV[L;N<9_3BM&F]]!+S"BBB@84444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`&9K-[I5FD)U1%DY+Q)]G:9B1C)55!.0#G@<#)Z`
MU!/K.D:?+?2K%(9HX/M$S6]F[F5`!]UE7$A`8<`DC(S@&K&HZ?->7ML\=Q);
MHD<BN\6W=\VW`^8$=CVJ"#PS96\LSQR3`26QM@I*G8FU5P"1NZ(.I(Z\<T/;
M0&1V^O:#!*EI"?L[+$90AM'B"97>5.5`63;\WEG#XYQBJ6CZIX:M(M/T_2X9
M9%,GV:-X[*0E62,89VV\`HP(<\$-D''-77\*6$E[/=R,[S3\R.T418MY8CW!
MMFY3M'8@>W.*MIHL$=_]L2:=9?,$A`*X.(]F.G3`^N>].^G]?U_7R&V^G]?U
M_7<K?;]!_M&XMS"@GA4))(UHP0KD*5$A7:V-P!`)VYYQ4QUW2DODLUD9IIC@
MF.W=D!W%!O<+M7)1E&XC)&!FHI/"^GRR7C."5NU=90(XP=KG+C>%WX/(^]T/
M&,##8-`$%VJQW,Z6444*1Q`H0WEN[`$E<X&5`P1P.<U+VT%W(+#Q'X=:T>>S
M1D2WBC=EALG)02A&50%4Y9@R?*N2?3BG3VNBZM);6<4<B%X_M2-%9YC*MQEB
MR%`QST/S=<=Z=:^$=/M-(DTU))WA=H7S+L<@QI&B\%=IXC7.0>2?;%ZWT:WM
MKNWN(V93!#Y*HL<:`K[[5!]\9VY[5342IVO[NQ>AB2"&.&,82-0J@G.`!@4^
MBBD2%%%%`!1110`4444`%%%%`!1110`4444`%9%S>-::DQSE#C<OX"M>N>U;
M_C]?\/Y"KIJ[)EL;T<B31AT.5/>GUS5C?/:/C.8SU%=%%*DT8>-@RGO1*/*"
M=Q]%%%04`HH%%`$<QE!!1E"]\J3_`%%4;B_DMGVRLH]#Y1P?_'JTJK75JDT+
M1N/D/3_8/K51:ZB?D4?[97_GHG_?O_[*C^V5_P">B?\`?O\`^RK$O+62RF*.
M,C^%NQJONK7EB1=G1_VRO_/1/^_?_P!E1_;*_P#/1/\`OW_]E7-EP`22`!U)
MK-EUVV0MY<<\ZK]YXDRH_&KC1<_A5R95%'XF=M_;*_\`/1/^_?\`]E1_;*_\
M]$_[]_\`V5<E::C;7RDP2AB.JG@CZBK6ZDZ=G9H:E=73.C_ME?\`GHG_`'[_
M`/LJ/[97_GHG_?O_`.RKG-U&ZER(=V='_;*_\]$_[]__`&5']LK_`,]$_P"_
M?_V5<YNHW4<B"[.C_ME?^>B?]^__`+*C^V5_YZ)_W[_^RKG-U&ZCD079T?\`
M;*_\]$_[]_\`V5']LK_ST3_OW_\`95SFZDW4<B"[.D_ME?\`GHG_`'[_`/LJ
M/[97_GHG_?O_`.RKC9]8MX9&C199W7[RPINV_4]*=9:M:WY*Q/B0=8WX;\JM
MT)*/-;0A58M\M]3L/[97_GHG_?O_`.RH_ME?^>B?]^__`+*N<W4;JCD1=V='
M_;*_\]$_[]__`&5']LK_`,]$_P"_?_V5<YNHW4<B"[.C_ME?^>B?]^__`+*C
M^V5_YZ)_W[_^RKG-U&ZCD079T?\`;*_\]$_[]_\`V5']LK_ST3_OW_\`95SF
MZC=1R(+LZ/\`ME?^>B?]^_\`[*C^V5_YZ)_W[_\`LJYO=5.ZU6WMI!%\\LI_
MY9Q+N;\?2G&ES.T43*?*KMG8?VRO_/1/^_?_`-E1_;*_\]$_[]__`&5<9:ZU
M:W,OE9>*7.`DHVD_2K^ZG*ERNTD$9J2NF=)_;*_\]$_[]_\`V5']LK_ST3_O
MW_\`95SFZC=4\B*NSH_[97_GHG_?O_[*C^V5_P">B?\`?O\`^RKG-U&ZCD07
M9T?]LK_ST3_OW_\`94?VRO\`ST3_`+]__95SFZC=1R(+LZ/^V5_YZ)_W[_\`
MLJ/[97_GHG_?O_[*N<W4;J.1!=G1_P!LK_ST3_OW_P#94?VRO_/1/^_?_P!E
M7)W6H06:@RM\Q^ZB\LWT%58]>M6F\J59K=CT\Y-H/XU:H2:NEH0ZL4[-G;?V
MRO\`ST3_`+]__94?VRO_`#T3_OW_`/95S8<,`000>A%+NJ.1%79T?]LK_P`]
M$_[]_P#V5']LK_ST3_OW_P#95SFZC=1R(=V='_;*_P#/1/\`OW_]E1_;*_\`
M/1/^_?\`]E7.;J-U'(@NSH_[97_GHG_?O_[*C^V5_P">B?\`?O\`^RKG-U&Z
MCD079T?]LK_ST3_OW_\`94?VRO\`ST3_`+]__95SFZH;F\AM(O,GD"+^I^@[
MT*FF[)"<K:LZG^V5_P">B?\`?O\`^RH_ME?^>B?]^_\`[*N)_MZV#J)8KB%&
M.!))'A:T4E61`Z,&4C((.0:J5%P^)$QJ*7PLZ7^V5_YZ)_W[_P#LJ/[97_GH
MG_?O_P"RKG-U&ZIY$7=G1_VRO_/1/^_?_P!E1_;*_P#/1/\`OW_]E7.;J-U'
M(@NSH_[97_GHG_?O_P"RH_ME?^>B?]^__LJYS=1NHY$%V='_`&RO_/1/^_?_
M`-E1_;*_\]$_[]__`&5<YNHW4<B"[.C_`+97_GHG_?O_`.RH_ME?^>B?]^__
M`+*N8EN(X(S)*ZH@ZECBLYO$%JI!:*Y$3'B8Q':?Z_I5QHN7PJY$JJCNSN/[
M97_GHG_?O_[*C^V5_P">B?\`?O\`^RKEX+J*YB$L,BNAZ$&I=U0X);E*39T?
M]LK_`,]$_P"_?_V5']LK_P`]$_[]_P#V5<YNHW4<B'=G1_VRO_/1/^_?_P!E
M1_;*_P#/1/\`OW_]E7.;J-U'(@NSH_[97_GHG_?O_P"RK-OKA9Y?,5PQ/7Y<
M?U-9VZC=344MA-MDVZK=CJ#V<G]Z,_>6L[=1NIO41V\4J31+(ARK#(I]<CI^
MI/92]VC/WEKJX9DGB62-LJPR*YY1L:IW'BB@45(PHHIKNL:,[L%51DD]J`*M
M[;12V[I-@1=F/_+,^OTKD+F+[/.T8D20#HR,"#5[5]::Z9H83B`'J/X_K6-O
MS6\$TM3.3.>\6ZA+$D5I$2!("TF.X'05SZZ]>QP&!)BL9Z@5V4\J66KVFI2P
M+/!%E)D9=WR'N/<=:YOQI:Z+#=)=:->I-'/EGC4_<->IAJD5%12/.Q$&Y-LD
M\'[[_P`11VWF['E1MK=<-C(_E79J^Y0?45YWX2NY[365NK=<RHC!"1PI(QFN
M]B)2)5)Y`K#&2O-&V%3466=U&ZH=U&ZN4ZB;=1NJ'=1NH`FW4;JAW4;J`)MU
M97B"^>UTQA%N\V5@BE>H]?T!J_NJCJ88PI,B;W@<2*OKCM^615TVE--[$5$W
M%V.-M]8O+&-H89#&#]['>I]#N3-K]HLC$^;*J$]QDXS6IXQ&B7MM#J>FS1Q7
M#C$]J."I^E<UH4TB:S:S1IYC12!POJ1TS7K*JI0YMCRW3:=CU`Y1F0G)4E2?
M<4;JKH[E=SG+GEC[T[=7C'K$VZC=4.ZC=0,FW4;JAW4;J`)MU&ZH=U&Z@"MK
M-X]GI4\L9(DQA2.Q)Q7$6^LW=F6\N1E=CDL>N:[/5(WFL6"`%E(8`C()!S57
MQ"-$USP^-1CFBL]2MHPLMJ,+D_3T]Q7;A:D8JUMSBQ4&W?H<>VH2S7*S3,7(
M.3GO7ISQM;N8F;=@*P;U!`(_G7D-N?-N$3DY89`KU*&XFN`9IS\[XP/0`8`_
M(56,DFDA82+3;+>ZC=4.ZC=7`=Q-NHW5#NHW4`3;J-U0[J-U`$VZHY[A8+>2
M9ONHI8_A3=U1W"B:WDB/(=2"*$(X/^U[I+U[S<1)(<Y/;TJ*ZU6YO'W32ECZ
MFNUC&BZEX<.D:@T=E?68)CE*@&4#H<]SBO-Y&VSM&K!@&P".]>Q3JJ2T6QY4
MZ;3U/4-'XT2PEW9\Z,G'H5)!_I5[=6+H<TKZ9:QNNV."/8H/4DDDG]?TK4W5
MY55WFV>E234$F3;J-U0[J-U0:$VZC=4.ZC=0!-NHW5#NHW4`3;JX/5M2N3J\
MD_S;(G*1YZ#''%=MNK.L_P"RBNH:7K92"*8F2WN6'W6/)&>QKHPTU"3;.?$Q
M<HV1Q]WK=Y>J%GF9@.@KL?#DADT*";C!=XR/<8.?QS^E>>7RI;7LT4<HD16(
M5QW%=MX8DE_LB&(J5C1F<9_B+8Y_05UXJ2]G8Y</%^T31T>ZC=4.ZC=7F'I$
MVZC=4.ZC=0!-NHW5#NHW4`3;J-U0[J-U`'%^(=3GEU5T!/DP'"CMG')JC/KE
M[<0B&2<F,#`6NSTZXT[3M3O8-7B3['>CB9DSY;=.O8&N$U^WM+#5I8;"Z6YM
M@?DD!ZBO4H54XJ*6QYM:#YFV=3X,9IX;Y@^/(",1_>!.W'YD&NGW5Q?@Z2:.
M*Y1`0L^W>Q'55.<#\?Y5UVZN/%.]1G5ADU`FW4;JAW4;JYSH)MU&ZH=U&Z@"
M;=1NJ'=1NH`FW4;JAW4;J`)MU7M-U-[&89):(_>6LO=6UHND-=,)[A2(!RH/
M\?\`]:IDU;4$=3!,D\*RQG*,,BBG(JHH50`H&`!VHKG-0=E12S$!0,DGL*X[
M6M;-XYAA.(%/!&?G]S72:GIQU&-8S</%&#DA1][ZUE_\(E!_S]2?]\BKC9:L
MEW9RN_-&ZNJ_X1&#_GZD_P"^11_PB,'_`#]2?]\BKYT3RLY-L.I##(-9TNB6
M$S[WA&?H/\*[W_A$8/\`GZD_[Y%'_"(P?\_4G_?(I^T2#E.+MK*WM!B&,"K.
MZNK_`.$1@_Y^I/\`OD4?\(C!_P`_4G_?(I<Z#E9RNZC=75?\(C!_S]2?]\BC
M_A$8/^?J3_OD4<Z#E9RNZC=75?\`"(P?\_4G_?(H_P"$1@_Y^I/^^11SH.5G
M*[J-U=5_PB,'_/U)_P!\BC_A$8/^?J3_`+Y%'.@Y6<KNI"V1@UU?_"(P?\_4
MG_?(H_X1&#_GZD_[Y%'.@Y6<+<Z18W3[Y8@3]!4EKIUK9_ZF,#\!7;?\(C!_
MS]2?]\BC_A$8/^?J3_OD4_:(.4Y3=2[JZK_A$8/^?J3_`+Y%'_"(P?\`/U)_
MWR*7.@Y6<KNHW5U7_"(P?\_4G_?(H_X1&#_GZD_[Y%'.@Y6<KNHW5U7_``B,
M'_/U)_WR*/\`A$8/^?J3_OD4<Z#E9RNZC=75?\(C!_S]2?\`?(H_X1&#_GZD
M_P"^11SH.5G*;JI7.E6=VVZ6($_05W'_``B,'_/U)_WR*/\`A$8/^?J3_OD4
M^=!RLX:VTFRM&S%$`?H*O;L5U?\`PB,'_/U)_P!\BC_A$8/^?J3_`+Y%'.@Y
M6<KNHW5U7_"(P?\`/U)_WR*/^$1@_P"?J3_OD4N=!RLY7=1NKJO^$1@_Y^I/
M^^11_P`(C!_S]2?]\BCG0<K.5W4;JZK_`(1&#_GZD_[Y%'_"(P?\_4G_`'R*
M.=!RLY7=2;JZO_A$8/\`GZD_[Y%'_"(P?\_4G_?(HYT'*SC+FRM[M=LT8:JL
M6AZ?"X=(1D>P_P`*[W_A$8/^?J3_`+Y%'_"(P?\`/U)_WR*?M$'*<FNU%"J,
M`4[=75?\(C!_S]2?]\BC_A$8/^?J3_OD4N=!RLY7=1NKJO\`A$8/^?J3_OD4
M?\(C!_S]2?\`?(HYT'*SE=U&ZNJ_X1&#_GZD_P"^11_PB,'_`#]2?]\BCG0<
MK.5W4;JZK_A$8/\`GZD_[Y%'_"(P?\_4G_?(HYT'*SE=U07%O#=(4E0,*['_
M`(1&#_GZD_[Y%'_"(P?\_4G_`'R*.=!RLX%-"T^.0.L(S]!_A6D@6-0J@`"N
ML_X1&#_GZD_[Y%'_``B,'_/U)_WR*?M$PY;'*[J-U=5_PB,'_/U)_P!\BC_A
M$8/^?J3_`+Y%+G0<K.5W4;JZK_A$8/\`GZD_[Y%'_"(P?\_4G_?(HYT'*SE=
MU&ZNJ_X1&#_GZD_[Y%'_``B,'_/U)_WR*.=!RLY7=1NKJO\`A$8/^?J3_OD4
M?\(C!_S]2?\`?(HYT'*SD)8HYUVR*"*S_P"P=.W[O)&?H/\`"N__`.$1@_Y^
MI/\`OD4?\(C!_P`_4G_?(I^T2#D.0ABC@0+&H45+NKJO^$1@_P"?J3_OD4?\
M(C!_S]2?]\BESH.5G*[J-U=5_P`(C!_S]2?]\BC_`(1&#_GZD_[Y%'.@Y6<K
MNHW5U7_"(P?\_4G_`'R*/^$1@_Y^I/\`OD4<Z#E9RNZC=75?\(C!_P`_4G_?
M(KGM6M%T^]>V5BP7'S$>H!_K34D]@M8K;J-U0[JW="T-K\BYGRMN#P.[G_"F
MW85B31-%:\87%P&6`<K_`+?_`-:NP"A5"J``.@%"JJ*%4`*.``.!2UC*5S1*
MP"B@45(PHHHH`****`"BBB@`HHHH`****`"BBB@`K(\0WE_8V'VBRFLX$C!>
M:6ZB>48'1%1&4EF)`!&?H20*UZH:CI,6HSVD[S2Q2VCM)"R!#M8J5SAE(S@D
M9QGD^M`(Q[37M4N[M)FLX+:RCEAMKF"7)G661$;(8';A2ZJ1CGDY&`#-%K&I
M7BZY%%%;6DUC=+!$]P=ZJACC<R.`PS@.3@,.@Y%7ET*U%\+LR3F0NLLB^9A9
M9%78'91@9QCI@<`XR!A+C0;2X2]&Z5#>7$=Q*5(/SH$"\$$8Q&O!%#WT_K^M
M1QLEK_6O^1!9ZK<7FCXAN;&75&5MA'RQN`Y42A-Q;80-V-QR.`W.:RK?Q#K=
MZJ6EHE@]V#.XNWB=(+B.+8,HNXLNYGVALL!M+#<,`]#>:7'J&CS:;>3RS13(
M4D=@H9E)Y!`7:1CC&,$=:@GT"&Z6/S[N[::-7C2='6-Q&X`9/D`&#M';((!!
M!`H[B[$,>N33Z[IEFEJ%M;RQDNQ*S?-E3%A0/I)R3[8HT#4K^\N+VVU$Q&6!
ME_U=I);[<YRN)"?,`Q_K%PK9X`P:T&TRU:]MKK80]M`\$8!^4(Y3(Q_P!:;I
M^EPZ=_JY)9"(TA4R$'9&N=JC`'`R>3DGN31U8W:RMN7J***!!1110`4444`%
M%%%`!1110`4444`%%%%`$5TTZVDS6R(\X0F-7.%+8XS[9KG(-4UJ[@^S6EWI
M=Q=B23_3%MW$$B(J$A4$A.=SA,[R`58X.-M=#>VD=_87%G*SK'/&T;E#@X(P
M<53?1ED@C1KVZWQ9"2H41E0@`I\J@8X';(."#P,`%6S\0O?R:3)%:,EI?69N
MO,=AD?*K!0`<_P`1R3CMC/:OX7UZ^UHBYN1$EI=VZ7=D@@:-Q&WJQ=@_!7)P
MA'H00:VTTZUB:T,<>Q;6,Q0JIX52`,?D!4&G:+:Z65\@R%8XQ#"CMD0Q@YV+
MQTZ=<G@<\"F[7TV_K_@!T-&BBBD`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!5'5I+R*P9K&6U@E!RT]VI:.)!RS%0RD\#&-PZYSQ5ZJ6J:7#J
MUM'!.[JL<J3*5"GYE.5)#`@X(!Y'4`]J`.=M_$NKW<"7"6UO"EK;I<WB31N&
MFC9W4&/G,?RQEP&#'Y@IP<D:$6H:NVJWMLPL2WDR26]L@)>+:P5#*^[!$F=P
M`5<8(RV":MRZ%!<2B6:XN7D*JDS!@AG56+*K[0.`2>F,@D'()%-AT""**^A:
MYN98+UI&ECD93\S]2&V[N!@#G@``=!@>XU:W]?U_7R#P]J4^IZ<SW+1M<12M
M&Y2%X,XY!,3DO&2"#M8YZ'H16M52QT^&P$Q0N\L\GFS2OC=(V`N3@`=%`X`Z
M5;IL04444@"BBB@`HHHH`*X'Q0V-;G'^[_Z"*[ZN;N-";4?$<UQ.I%HNWO@N
M=HX^E5!V8I&9X?T$WS"YNE(MQ]T="Y_PKME544*JA5'0`8`H`"J%4``#``[4
MM$I7!*P4445(P%%`HH`****`"BBB@`HHHH`****`"BBB@`HHHH`*Q/$?B+_A
M'ETYO[-O+W[9>):XM4W&/=GYV]ABMNB@#E[KQ/-ID,LMQ;BXC^U2P(8F9G!!
M.`45"<8QTW'D<'-2VOB>2[:V1;)89)6&8KEI()"I<KE$>,,V`"W(7CVYJ*6]
MTC[9>RW?ATQ,^;0W,T$+?:XS,$=1M9F*[W!VL!G=P#S5:7P_X9GU+1I[<)9I
M:-FUMX+.)(E;<6(R8B8F+!LA60G!!SBBZ>H-/5FM'K5PUR\:VJ-"D@1Y&GPP
MW3/&,*$P?N9ZCKWZG,U'Q?<Z?IL-[-IZ`O%YZQQ7.0R^1-*`28^/]5CCU!SQ
M@Z[ZIHD$*S.\,:39D#-$5W*IW&3I]P%MV_[HW9SS4EW%IC'[-<6$,JQK$@5H
M590KEHP!GM@L#[,?4T;.[V-(N*E=K0R;GQ9=6]Z;#^SK=KW<0L8NFPX`B/RG
MR\EOWHXQT4G/II:MK+Z896%O')'!$DLI:;8V&8J`@VG<>#P2.H'>J&J>%]*\
M6?8KV;S8EB8OM2.+YSP,DLK%6`0`.A5@.C"MV;3[*YNK:ZGM();BV),$TD89
MXB1@[6/*Y'7%"VU,WY%;0IKNXTWSKUPTKRR$88$*NX@`85>@'?)]S6E38XTB
M0)&BHH[*,"G4`%%%%`!1110`4444`%%%%`!1110`4444`07MS]BL+BZ\IY?)
MB:3RXQEGP"<`>IQ7*V'C"XU/2M)UM;&>QLIA*;NWNTVR1H'5`^?0$[C_`+.3
M78UDZOJNFV)$5WY4DK^7$8F`/RRR",9[`,>`#][:0,XJ9.RN%KF(OC">UL+V
MZNK=Y2MR1#"D,I=8C$D@W!$<C&_!9@`"1DBIM9\27=A)83"*..V?4FM'/F9W
M@1R\O\GR*&56+#.`#GC.9Y+CP[J^F?;[G2XKI(T6_*R6:S%'V`@Y`*F3;MZ$
MG&.U7?[1TB:9H42.6>WE1GB\K#0O+@!B&`VL1(?<@MUY%:-KL.":NI>?Z_YH
MRIO%ES(]];VNGR"6W5\3-',(=RL`1YAB"'.3C:Q/'0<X+GQ9=VNIWMD-/CDD
MMDEE?==;5`CB@<A2(\G/G=_[OO@&BOX2U"WMKJWTK3K>XU"T2#8;15=XFCR(
ML[?F0+&1CE?DQVJY9S>'V\U++381'#Y<&Y+541DE5%`4D`%=H0$#LH&#@5+:
M6G7IZEQCRM\R+&FZVVHWLT:00BWC4DR"<EU(.,,NW"YP3U/`K-MO&$EZ\45K
MIX:26\%JIE:6%2#"\N_YX@Q&$QP"#G()J/3H?#FEZQ=:W!?,\M^PC4")0'!!
M8;-B!I00AVEB^`I"D#(K3SX;T2VMFC@T^TA.ZYA$,*J`,'=*`HX`#G+]`'Y/
M-#:Z$)-.S7]?\.16.ORZE?11QPI#$LZQ/F7+,3;^;@+MZ#<O.<\=,5T%8NDR
M:=J&HWEU;Z;%%+:N+1;DP;7=5'0$J/E!8@8)[],\[5);7%U"BBBF`4444`%%
M%%`!1110`4444`%%%%`!6/XHU[_A&?#]QJOV"ZOO)*#[/:KN=MS!>![9S6Q1
M0!@7.O7,%[!#%:K(UU<)#&DKF+R\PO(2Q"M_<QC'>IK36YKV#3Y(K6)?M,'G
MR>9.5$8!4'!VG=U]OUI]SJ&E1ZF(9DB,\6Z9I&C_`-453D[L=0K]N0&]Z8T>
M@WS6*OI\$S6\FZU1[(EK=UQR`5S&>1R<=11U'T_K^MC*B\;BX2[DM]/DFAMI
MHT>9!+L\MPQ$N#%N9>!\RJRX8-G`)&C9>(FOM:N=.CL)P(?,`F:&98RRG&-Y
MC"<_[+,?;KBC;#P=?VENO]DZ?L8+=B)K)'6)MIDW,5!0.`Y;KGY\_P`7-V"Z
M\,B\GUJWCLA=OB&:]2`>85PI&]P,[,;#DG;C:<XQ3L)IQ^+^OZ1EW/C:>*PG
ME;298V6V:5<3`D%87>0$[2!L90F>>6''KKZ-J%S=W]S'-)NC125&!Q^\=>P]
M`*&O]%<7,,]L%"2R6K)):D^:7^9U08^?=@L0,YP2>.:5-:T:.]M8;-[>22[D
M$:O!C!S&TH^8<$E1NQG.&ST.:%)*.O\`5RGK&UOZ_JYG?\)7-9:7!-=6OVAY
M(5=6MR\I8F14.Y$C+`Y;HH;H?2NBT^Z-]I]O=-#)`94#F.1&5ESV(8`C\0#[
M"LPP>'6AU!3IUJ4G"+=I]BS]H'W4RNW]X.,#J..*U[>"&VMHH+:%(8(T"1Q(
MFU44#```Z`#M1=$]26BBBD`4444`%%%%`!1110`"B@44`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`&6-#A4,PD<S-<"8NS,V!YHDVJ"<*#@#C'0&J<W
MAZ[DU6&Y74]MM$[2_9S&Y!<NS?WPN,/@Y4G(!R.E=!12Y5IY#O=6..E\%WKV
M=L%U:!+F$2Q%1;2K;>2^W,:Q+,&4#8N!YA`RW&"`O23:>)9F<2;0?)XV]/+<
MMZ]\X]JNT4WKN(KV5M]CLX[??OV`_-C&><U8HHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"L'5/#TU_JOVN'4/L\<BP+<1^2'+B&4R)M8GY02S!N#
MD$8VD<[U8%X)SXKA+R7:VH@CVK'',R,^]LY*$*/X<[@>*F72+ZC6S*VD^%;G
M3+>2V.H6[0&Q6T416K1LS!%3S)/WA5SA>,*I`P,G`J];:'-']LDN+R.2>[N8
M+F1HX2BAHUB4@`L3@F//4XW=\9//6=KX@BMM/N+_`.UI:R2HMU%!=3S2F,1R
M$2-E0R$N8P43H!U(SCJ-*69["=2]S&C2.(&ER953L3OR<YR1N'3'%4I.4>;O
M_F5*34M]_P"OT,.R\':A:VUDKZU%+/IR11V4GV+:L:JK(VY=_P`[,KD9R`,+
MP>=VA8^&WL[(6;7WG0[;;+/%AV:(C))!`PP5>`!@Y/.0!CZ+;ZMIILK4SWP0
M!)G)LT_TJ261O-,S+&`I48((V$DY);I70^&O[0;P[8RZI/-+?30I),)HUC9&
M*C*[548P<]>:E)3M-_U<'*5W+^NI1L?"\]L^GF?45F73Y5\@+;["84BDC56.
MXY?]Z26&`<#"BI[[0+F:.Q^QZB+6:WMVM'=K<2!XF"[L`D;7^0$$Y`YRK5NT
M53UW)OMY%'2]-72X9HDDWK),T@XQM!QQ[].M7J**$K*P@HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`P+SP[<7E[>NVH*EK<1N$B2$AT=D5"Q?=SC:"``
M,9/)XQ%;>'M3CELGFU6WW0RM).\%O,KS`[<*&>=\#Y0"&W9`XVD9IM_<ZRFH
M7QM9+MAY<BQP_9@8HP(MRR*VW+.7P-NXCGH,$U1U*75XOM-C#?7U^\?[DHUH
MA$J/&"S.Z(`&')4#;D\8;(PXK9H-[E32/#>L:=JLNF>3OTS[*(?MDG0D0)'O
M11,<-E<;3$.-Q\P\`[&J^%;F_P#M"P:K]G2Y8>:IB8@J(U3'RR+D_+GG(P2,
M'J,W4[GQ1:6LMM9O=S2I<!XYO*"`Q^6I,?$$F1N)`X4X&#(".=ZS_M3^V#-/
M<SM;.TT8MS"H1`K?(^0N[)'')P1CC/);=]>PI/G3YNOZ_P##%;4O#=[>R2O#
MJ<4!6Z%U:_N'S&Q0HXD*RJ74ACC:4(.,ENE-L?"L]E?V\JZBBVT<J7#V\=M@
M/*L'DG#,S$)M"D+R01RQ!Q4#KJT]W,8[W4$F=WBW?9%`MD,\:_NR8\-\@+9;
M?Z].*CU35=8LHFAC&HRM&)E>2*U7>V701E&91&7PQP.A/!':HW7W?H5L6E\-
MZHMKJ"-J\$MQ<&,12RV\S")48L"1Y^2_S=59`"`0M=+&ACB1"[.54#<W4^YK
M%T:XOY/"T4T4_P#:-_AL_;9$A._<<I(8H\*5Y4X4\K^-;:EBBEP`V.0#D`_6
MJVT)0M%%%(84444`%%%%`!1110`"B@44`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`5C7>NK8Z\ME<*J6S6^_SN<ASO(!]ML;<^N!WK9K)O+?1]0U-]/NXUENY
M($E:-@W,:/E3GIPQ^OX5+O=6_K0?1C;+6VDL%FO;9H9_+GE:)"&V+&^T@G/W
MN1[9S4$?B"8W<T,MJRQQYQ,H!4_OVB`QNST`_7Z5.MAH^N6T4\?F2PI+,%,<
MTD:L2Y$@8`C>I8'@Y7@$=J6[M-+M[NS$T3B2YE:&,*[X9B6G.X`X/*,03TR0
M,`FG:\DUM_P__`".UNO]7&S:\%'R6TL8\[RQ)*%*L!,L;D;6)[\9`H\/>*-+
M\3P23:9.DJ1A2VV6-\;@2,[&.T\=#@CTIUIX<L;6>>=O.FEFE:4[YY"BYD\P
M!4+%4YVYV@;B,G-6M.TJTTI)$LQ,L<C;O+>XDD1/9%9B$7T5<`>E-`[="[14
M0N(S=M;#/F*@D/'&"2!_(U+0(**:'!D:/#94`D[3CG/?H>G3MQZBG4`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`&7-KEO;W<L$L,J+&S)YS%`A81^81
MDMQ\N3D@#@\U1L?%-C>QB^LX/,LY(YI)KF*2)U'E;03N5R&X[C/;WQ;;PY83
M7]]=W`DE>[4H5\YPJ*453A0V`WR_?`#8XSQ4D6@:?"D"+',1#NQON9&W[AAM
M^6/F9P/O9Y&>O-`?U^'^9G67C;3-3ADDTY)+WRRX<6TL,@&U58_,)-IX8<`Y
MJS_PD<,-CJ%]>0M;VEI)M$SNBJX.,');Y>HY;`&?K5FTT*QLHO+C^U2#YQFY
MNY9V`8`,`9&)`^4<#@=NII1H=@%O%"3!;L*)5^TR;1M&`4&["-T^9<'(!SD`
MT^H=BI9>*]-U".Q>U9IDO7>.%XF21"R'YAO5BO`R>#T![\50O/%VG2:+!>75
MA<&SN(A/Y4L4;F2/R9)AQOP#B(]>^..<C:AT.QAB@CVSR_9_]4]Q<R3.OS;O
MONQ8\@=3T&.G%9EAX)TFUT2#3;E)+L1Q!'>2:3YCY31':-QV*5=_E'`W$CGF
MA6ZEPY4_>_K?_@#_`/A)M&TS4;312L=G<S*K1VOF0HPWL0,('RW(/W01^M:F
MDZI;ZSIZ7MK_`*ER0IWJW0X/W20"#D$=000<4VXT:TN;^*]<W23Q+M'DW<L2
ML.<;E5@KXR<;@<9J33M,M=*MC;VJR;2Q=FFF>5W8]V=R68X`')/``Z"CO<@M
MT444@"BBB@`HHHH`****``44"B@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"N
M?UG1+Z]OWO;"YBM[A8HHXG;)QAG\P$#J"K\?[0![5T%%)J[3[#OT.7N-#GCE
MTVRM52*U,LHN/+!`6#?YBJ.,=0JX]&;'2L:#P/JQLUM)9[6)HCL%W'+N:5?(
MFB\PQB--K9E4D%V)&?FX&?0:*J]G<(MQT1Q$O@^]O;*_,\&F6TUQ:RQ16UN6
M:&&0H%1P2@^8GDD*"!M`SC)34O"6KNUS%IYT]+:><R!&.TQ?NHEW+^[;!W(Y
MPNW[P.[(Q7<44U-H3UBX]-?Q.>US1;S4+]9+>.R:*2-(7>8E98!N),D9"GY@
M#P..3G(Q@X5YI&IZ3HFI-+:13DO"(S;$RM.HDR6DC6W)!Z9XF/)],UWU%2V[
M6#K<YNVT-;Q--EGLX$MD@@W6LR[BFV.48P5`X,B]AT/`Z5)HNDW]AJLTTR6B
M6Y@CC!C?S'E<*HW'**4`VXV[F!SGY>_044=;@W=684444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
(`"B@44`?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>graph9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 graph9.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`#Z`>4#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#U*"#5=9UW
M7U7Q)J5C!97J6\,%K%;%0OV:"0DF2%F)+2-W]*N?\(]JG_0Y:Y_WYLO_`)'H
M\/?\ASQ9_P!A6/\`](K6N@H`Y_\`X1[5/^ARUS_OS9?_`"/1_P`(]JG_`$.6
MN?\`?FR_^1ZZ"B@#G_\`A'M4_P"ARUS_`+\V7_R/1_PCVJ?]#EKG_?FR_P#D
M>N@HH`Y__A'M4_Z'+7/^_-E_\CT?\(]JG_0Y:Y_WYLO_`)'KH**`.?\`^$>U
M3_H<M<_[\V7_`,CT?\(]JG_0Y:Y_WYLO_D>N@HH`Y_\`X1[5/^ARUS_OS9?_
M`"/1_P`(]JG_`$.6N?\`?FR_^1ZZ"B@#G_\`A'M4_P"ARUS_`+\V7_R/1_PC
MVJ?]#EKG_?FR_P#D>N@HH`Y__A'M4_Z'+7/^_-E_\CT?\(]JG_0Y:Y_WYLO_
M`)'KH**`.?\`^$>U3_H<M<_[\V7_`,CT?\(]JG_0Y:Y_WYLO_D>N@HH`Y_\`
MX1[5/^ARUS_OS9?_`"/1_P`(]JG_`$.6N?\`?FR_^1ZZ"B@#G_\`A'M4_P"A
MRUS_`+\V7_R/1_PCVJ?]#EKG_?FR_P#D>N@HH`Y__A'M4_Z'+7/^_-E_\CT?
M\(]JG_0Y:Y_WYLO_`)'KH**`.?\`^$>U3_H<M<_[\V7_`,CT?\(]JG_0Y:Y_
MWYLO_D>N@HH`Y_\`X1[5/^ARUS_OS9?_`"/1_P`(]JG_`$.6N?\`?FR_^1ZZ
M"B@#G_\`A'M4_P"ARUS_`+\V7_R/1_PCVJ?]#EKG_?FR_P#D>N@HH`Y__A'M
M4_Z'+7/^_-E_\CT?\(]JG_0Y:Y_WYLO_`)'KH**`.?\`^$>U3_H<M<_[\V7_
M`,CT?\(]JG_0Y:Y_WYLO_D>N@HH`Y_\`X1[5/^ARUS_OS9?_`"/1_P`(]JG_
M`$.6N?\`?FR_^1ZZ"B@#G_\`A'M4_P"ARUS_`+\V7_R/1_PCVJ?]#EKG_?FR
M_P#D>N@HH`Y__A'M4_Z'+7/^_-E_\CT?\(]JG_0Y:Y_WYLO_`)'KH**`.?\`
M^$>U3_H<M<_[\V7_`,CT?\(]JG_0Y:Y_WYLO_D>N@HH`Y_\`X1[5/^ARUS_O
MS9?_`"/1_P`(]JG_`$.6N?\`?FR_^1ZZ"B@#G_\`A'M4_P"ARUS_`+\V7_R/
M1_PCVJ?]#EKG_?FR_P#D>N@HH`Y__A'M4_Z'+7/^_-E_\CT?\(]JG_0Y:Y_W
MYLO_`)'KH**`.?\`^$>U3_H<M<_[\V7_`,CT?\(]JG_0Y:Y_WYLO_D>N@HH`
MY_\`X1[5/^ARUS_OS9?_`"/1_P`(]JG_`$.6N?\`?FR_^1ZZ"B@#G_\`A'M4
M_P"ARUS_`+\V7_R/1_PCVJ?]#EKG_?FR_P#D>N@HH`Y__A'M4_Z'+7/^_-E_
M\CT?\(]JG_0Y:Y_WYLO_`)'KH**`.?\`^$>U3_H<M<_[\V7_`,CT?\(]JG_0
MY:Y_WYLO_D>N@HH`Y_\`X1[5/^ARUS_OS9?_`"/1_P`(]JG_`$.6N?\`?FR_
M^1ZZ"B@##\)7-W=:$S7MU)=SQ7MY;^?(J*SK%<RQJ2$"KG:@Z`45'X-_Y`=S
M_P!A74O_`$MFHH`/#W_(<\6?]A6/_P!(K6N@KG_#W_(<\6?]A6/_`-(K6N@H
M`****`"BBB@`HHHH`****`"BBB@`JO?V<>HZ==6,S,L5S"\+E#A@&!!QGOS5
MBB@#Y^T/X0>'XOBO>Z2MYJ9M],M[>]A8RQ[F<MG#'9@CCL`?>O0-2\:>(KK6
M-9@\,Z5I\]IH1VWSWT[1O,VTL4B"@@8&/F;@^G>NAM/#'V7QUJ/B7[9N^VVD
M5M]G\K&S8<[MV><^F!6)KOPV.I:OJ-[IGB"^TF+5T6/5+>!%=;A0NWY2W^K;
M'!(SQGCDT`59_'NLZO/X>C\*V-D_]LZ?/<K_`&BS((60J!N*9R`2<@#)XY'6
MND\):SJ>J6M];:W!:PZKIUS]FN?LC,87.Q'5DW<X*N.#7*ZWX.N!XN\+66A3
M7NEVVFZ;<1P7MO'YBPM^["A]P*MD9X;KS77>%?#TOA[3YX[O4I-2O[NX:YNK
MR2,1F5R`O"CA0%50![4`>;_$RTU[_A,_#%[?ZC%_9)\0V<5C8PKTZ%I)#W;.
M0!T`^IJY\2/#5UK'BU-5U/PW_:_AO3-,9BBWOD,9"^YR,,&)"+P.`3W].T\6
M^$_^$IFT.3[;]E_LO4HK_'E;_-V?P=1C/KS]*I^)_!.HZ]?3S67BS4M-MKR'
M[/>6:@3121X(;RPW^J8CC</RH`TM$N--NO`=G-HT;Q:8U@!:QR9W)&$PJG))
MR`,=3]:^9_"?A6XU#0]/U#PSIGBI?%'FEHKY4CCT\`.02)#@_=X(SUR.E?5%
MEI%KINA0Z/9*8K6"`01`G<54#`SZUF^"/"__``AOA&RT'[9]L^S&0^?Y7E[M
MSL_W<G&-V.O:@#F]6D\3I\1;Q/#L&F27[:':&274)'6),3SY^5!N8GG'(`QS
MZ%FI_$>_M?A]HVLQV^GP:IJ;^2(;EY&19`2IVI&&=_F`X'KU]>TCT;R_%=SK
MGGY\ZQBM/)V?=V/(^[=GOYF,8[=>:Y.^^&;S:1H,=CKLEEJVB22O:WZVRN/W
MC98&-C@\8'7M^%`&7:?$_5KSX9:GKZZ=:IJ^G:@EA)"X<12.9(U)`.'7B3H>
M01SGI4^K>*_'FF:]X?\`#XM?#LFJZJMTQ.9O)38I9/F^]P.OR\XP,9S5JU^%
M[6WA36=#;79)O[2U-=1-S+;#>K!XW((#`,3Y?48Z]*W]5\)_VGXYT#Q+]M\O
M^R4G3[/Y6?-\Q"OWL_+C.>AS[4`<5I/Q-\27NE:1K-UI&F1:;)?KIE[LF<RM
M,S[`\2XPJ`]0Q)/3MDIX[^*FL>%]=NTTZRT^\T_3_+%VA6=I<MC_`):(ICCY
M(&&)/MR*V[/X9_9/"EOH?]K[_)U==3\[[-C.)-^S;O\`PSG\*J^(OA,=<;7(
M8?$EY9:?JTJW4MFD".OV@8^<L?F*\`[01R.OH`=)XXD$WPT\0R@$!])N&`/O
M$U?.&B:'8R#2(?"\?BBR\9SQ13P27CP06KC@NZ$X9TQD@#.0.AYKZ>U;16U7
MPE>:&UR(VNK)[0SB/(4LA7=MS[YQG\:YO5?AM!J7@_0])34#;ZGHB1"RU2.'
MYXV0`$[=W1MHRN>P]*`#5?%NO7?BN[\.>%+#3Y[O38HYK^74)71/G`98T"C)
M8KSN/`I=%\>3ZY:>'-4CMHK?3]1FEL[N.3+20W`4[0K`X*ED89QSE>E2Z]X#
MN-3UI=:TOQ!=:/J<MNMK>2V\2NMQ$/\`9;[K>C9.*PO&WA#^S?AC8^#_``SI
MU[/.T\2VT\8!\F17#M+*_&W.&Y'<@#M0`^3XF7__``C>L^(8X]-73?MXLM':
M<NOGXR&D;:6+@D':J*#A3]1ER^+=:\2?#?QQ;:[:VL-S966Y'MK>>%)$D1L?
M+,`_!4\XP?PKJ;_X;6]WX&T7P];:A)97&CO%/:WD<8;;.@/SE3@$$L3CBFI\
M/+Q],\1V]_XEGOKK7;..">YFME'ENH<;D12`%PP^3L03DYH`X#X?77C.3Q$8
M-.FTN2*#P[9%(KII65%-N#'L`(`)?;OZ`CIS7>IXZO-3U+PGIND16SW>IP"]
MU$2J2+:W48?`#`AB^5&<\@YS1I7P_NO#>M6&KV.N2^7;:;!97MHMFK?;1#'M
M4J2<H3@'`SZ9K.^%/A.YTV]USQ'?6EQ:-J5PXL;2Z7;);VQD9PK+_"26Y7V]
MZ`&?'*UM[WP]H-K=P7]Q;RZS&LD6GH'N''E2\1@\%JP/#<%A\/O!7BGQ#X=T
MGQ':744<(\KQ+;+&KX8X*A-I(^8YY]*]5\0^'_[=N-%E^U>1_9FH)?8\O=YF
MU67;U&/O=>>G2CQ=X?\`^$J\*ZAHGVK[+]K0)YWE[]F&!SMR,]/6@#S[Q%\3
M_$7A?3=/.KVVAVE[JV9;5V:>2"VA"*3YNQ2S.6;`"#'O5BV^+CS^`X=5AMK2
M\U6;4UTF)8#(EO).P#!\N`ZIM.<$9SQ[UT_B#P2^K1Z/<V&L3:9K&D(4M;Z.
M)9!AE"L&C;A@0!QGBH;WP`=7\(?V/K&NWM[?BY%XNIL`KQ3@\-&G(11R-H[$
M^N:`,WP_XP\52>/[OPOXAL](B:VTDWWF6)D82/O51@L>%PQX(SD=<5=7QEJ!
M\/>"-0,-KYVNW-O%<KM;:BR1,[%/FR#E1C.:Y_PKX8UK2OC1J%SJMS?:K'-H
M>R34YK;RHI)/,C^1=HVKA5^Z"3U-:FG_``SO[6315N?%ES=V>BWBS65J]HBJ
MD2J5$9(.6;!'SDG@?=YH`YG5OCPFG^*+JW2"R&FV-T;::&3S?M<V&"M)'A?+
M`!W':S9(';-=1KWBKQ8?%5_H_AJVT62.UTV*^\V_,H/S,P(&SKD#C[N/4U.?
MAQ-!KEW<:7XFU'3=*OKO[9>Z?;*JF27@G;*,,@..0.O3(K:/A?\`XJS4M<^V
M?\?NGI9>3Y7W-I8[MV>?O=,#IUH`Y.+XFZAK.B>%1H6FVHUGQ$)_*6\D800>
M3GS"Q4;B,J<`8K2UOQ/XI\-^$K76=4TVP$EK>*FJK;EY%-N6VF6'G(Z@X8'`
MSFJEM\*?L7A70-.M->FM]6T)YGL]3BMUX\UF9@T;$@C#`8SV]\5;U#36\+^`
M-1MM136/%,]^\@NOLMOODD>4$$K$#A$''"].M`&AX;\3W?B/Q/KT5O';_P!B
M:;*MI'.%/F2W`&9.<XVKD#IWZUU=<UX`\/-X7\%:=ILV3="/S;DL<DS.=SY/
M?DX_"NEH`****`"BBB@`HHHH`****`"BBB@`HHHH`Y_P;_R`[G_L*ZE_Z6S4
M4>#?^0'<_P#85U+_`-+9J*`#P]_R'/%G_85C_P#2*UKH*Y_P]_R'/%G_`&%8
M_P#TBM:Z"@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`.?\&_\`(#N?^PKJ
M7_I;-11X-_Y`=S_V%=2_]+9J*`#P]_R'/%G_`&%8_P#TBM:Z"N?\/?\`(<\6
M?]A6/_TBM:U]0AN;G3KF"RNA:7,D;+%<&/S/*8CAMN1G'IF@"S17F6H7E_I=
M]J-AINH7LNDO<Z?8F>:Y:5XKB6?;.J2,2P/ELG?Y6/&*ZCPN;BVU37]*ENI[
MBWL[J,VK3RM*Z1O"C;"[99L-NY))P>M`'2T5CGQ9X;%\]B?$&E?;$=D>W^V1
M^8K+G<"N<@C!R.V*L?V[H_\`T%;'_P`"$_QH`T**S_[=T?\`Z"MC_P"!"?XT
M?V[H_P#T%;'_`,"$_P`:`-"BL_\`MW1_^@K8_P#@0G^-']NZ/_T%;'_P(3_&
M@#0HK/\`[=T?_H*V/_@0G^-']NZ/_P!!6Q_\"$_QH`T**S_[=T?_`*"MC_X$
M)_C1_;NC_P#05L?_``(3_&@#0HK/_MW1_P#H*V/_`($)_C1_;NC_`/05L?\`
MP(3_`!H`T**S_P"W='_Z"MC_`.!"?XT?V[H__05L?_`A/\:`-"BL_P#MW1_^
M@K8_^!"?XT?V[H__`$%;'_P(3_&@#0HK/_MW1_\`H*V/_@0G^-']NZ/_`-!6
MQ_\``A/\:`-"BL_^W='_`.@K8_\`@0G^-']NZ/\`]!6Q_P#`A/\`&@#0HK/_
M`+=T?_H*V/\`X$)_C1_;NC_]!6Q_\"$_QH`T**S_`.W='_Z"MC_X$)_C1_;N
MC_\`05L?_`A/\:`-"BL_^W='_P"@K8_^!"?XT?V[H_\`T%;'_P`"$_QH`T**
MS_[=T?\`Z"MC_P"!"?XT?V[H_P#T%;'_`,"$_P`:`-"BL_\`MW1_^@K8_P#@
M0G^-']NZ/_T%;'_P(3_&@#0HK/\`[=T?_H*V/_@0G^-']NZ/_P!!6Q_\"$_Q
MH`T**S_[=T?_`*"MC_X$)_C1_;NC_P#05L?_``(3_&@#0HK/_MW1_P#H*V/_
M`($)_C1_;NC_`/05L?\`P(3_`!H`T**S_P"W='_Z"MC_`.!"?XT?V[H__05L
M?_`A/\:`-"BL_P#MW1_^@K8_^!"?XT?V[H__`$%;'_P(3_&@#0HK/_MW1_\`
MH*V/_@0G^-']NZ/_`-!6Q_\``A/\:`-"BL_^W='_`.@K8_\`@0G^-']NZ/\`
M]!6Q_P#`A/\`&@#0HK/_`+=T?_H*V/\`X$)_C1_;NC_]!6Q_\"$_QH`T**S_
M`.W='_Z"MC_X$)_C1_;NC_\`05L?_`A/\:`-"BL_^W='_P"@K8_^!"?XT?V[
MH_\`T%;'_P`"$_QH`T**S_[=T?\`Z"MC_P"!"?XT?V[H_P#T%;'_`,"$_P`:
M`-"BL_\`MW1_^@K8_P#@0G^-']NZ/_T%;'_P(3_&@#0HK/\`[=T?_H*V/_@0
MG^-:%`'/^#?^0'<_]A74O_2V:BCP;_R`[G_L*ZE_Z6S44`'A[_D.>+/^PK'_
M`.D5K6MJ=C_:6F7-E]JN;7SXS'Y]JX26//&58@X/OBLGP]_R'/%G_85C_P#2
M*UKH*`.<A\(*FEOIUQK.H7=MA#"LL=LI@=&#*Z%(E^8,`?FR..E:&C:)#HR7
M)6XN+JXNYO.N+FY93)*^T*,[0%`"J````,=*TZ*`,_4?^/[2?^OMO_1,M:%9
M^H_\?VD_]?;?^B9:T*`"BBB@"C)K6E12-')J=FCH2K*TZ@@CJ",U8MKNVO(S
M):W$4Z`[2T3A@#Z9'UKR.S_UNI_]A6__`/2J6NL^''^J\1?]A4?^DMO775PO
MLZ4:M][?BB5*[L=M1117(4%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110!GZ[_P`B]J?_`%Z2_P#H!K0K/UW_`)%[4_\`
MKTE_]`-:%`'/^#?^0'<_]A74O_2V:BCP;_R`[G_L*ZE_Z6S44`'A[_D.>+/^
MPK'_`.D5K6\^_P`MO+VE\';NZ9[9K!\/?\ASQ9_V%8__`$BM:Z"@#A=.?6KW
MPKKUO]HNKR^_M2:V#PRB)TC\Q5.PEAM"J6(P<\=S6_X>-E"U[86RZBDUO(IF
M2_NY+AQN4$$,[OQCL#U!XH;PM8-I]Y9LTQ6YO3?;R5W13;PX9.,?*R@C(/3G
M-6]+TF+2Q<.)Y[FYN7$D]S.5WR,%"@D*`HX4<*`.IQDF@#%U;QAX8@U2P@F\
M1Z1'+;WCK-&]]&&B(BD4A@6XP>.>_%6O^$[\(?\`0UZ'_P"#&'_XJM#4?^/[
M2?\`K[;_`-$RUH4`<_\`\)WX0_Z&O0__``8P_P#Q5'_"=^$/^AKT/_P8P_\`
MQ5=!10!XSID\-TE]<6\L<T$NIWSQR1L&5U-S*001P01SFMSP3XET'1G\06^J
M:WIMC.VIAUCNKI(F*_9H!D!B#C((S[&L>S_UNI_]A6__`/2J6NL^''^J\1?]
MA4?^DMO7K8O_`'2'R_(SC\3-;_A._"'_`$->A_\`@QA_^*H_X3OPA_T->A_^
M#&'_`.*KH**\DT.?_P"$[\(?]#7H?_@QA_\`BJ/^$[\(?]#7H?\`X,8?_BJZ
M"B@#G_\`A._"'_0UZ'_X,8?_`(JC_A._"'_0UZ'_`.#&'_XJN@HH`Y__`(3O
MPA_T->A_^#&'_P"*H_X3OPA_T->A_P#@QA_^*KH**`.?_P"$[\(?]#7H?_@Q
MA_\`BJ/^$[\(?]#7H?\`X,8?_BJZ"B@#G_\`A._"'_0UZ'_X,8?_`(JC_A._
M"'_0UZ'_`.#&'_XJN@HH`Y__`(3OPA_T->A_^#&'_P"*H_X3OPA_T->A_P#@
MQA_^*KH**`.?_P"$[\(?]#7H?_@QA_\`BJ/^$[\(?]#7H?\`X,8?_BJZ"B@#
MG_\`A._"'_0UZ'_X,8?_`(JC_A._"'_0UZ'_`.#&'_XJN@HH`Y__`(3OPA_T
M->A_^#&'_P"*H_X3OPA_T->A_P#@QA_^*KH**`.?_P"$[\(?]#7H?_@QA_\`
MBJ/^$[\(?]#7H?\`X,8?_BJZ"B@#G_\`A._"'_0UZ'_X,8?_`(JC_A._"'_0
MUZ'_`.#&'_XJN@HH`Y__`(3OPA_T->A_^#&'_P"*H_X3OPA_T->A_P#@QA_^
M*KH**`.?_P"$[\(?]#7H?_@QA_\`BJ/^$[\(?]#7H?\`X,8?_BJZ"B@#G_\`
MA._"'_0UZ'_X,8?_`(JC_A._"'_0UZ'_`.#&'_XJN@HH`Y__`(3OPA_T->A_
M^#&'_P"*H_X3OPA_T->A_P#@QA_^*KH**`.?_P"$[\(?]#7H?_@QA_\`BJ/^
M$[\(?]#7H?\`X,8?_BJZ"B@#G_\`A._"'_0UZ'_X,8?_`(JC_A._"'_0UZ'_
M`.#&'_XJN@HH`Y__`(3OPA_T->A_^#&'_P"*H_X3OPA_T->A_P#@QA_^*KH*
M*`.?_P"$[\(?]#7H?_@QA_\`BJ/^$[\(?]#7H?\`X,8?_BJZ"B@#G_\`A._"
M'_0UZ'_X,8?_`(JC_A._"'_0UZ'_`.#&'_XJN@HH`Y__`(3OPA_T->A_^#&'
M_P"*H_X3OPA_T->A_P#@QA_^*KH**`.?_P"$[\(?]#7H?_@QA_\`BJ/^$[\(
M?]#7H?\`X,8?_BJZ"B@#G_\`A._"'_0UZ'_X,8?_`(JC_A._"'_0UZ'_`.#&
M'_XJN@HH`Y/5O&?A:ZT:^M[?Q+HTT\MO(D<<=_$S.Q4@``-DDGC%=96?KO\`
MR+VI_P#7I+_Z`:T*`.?\&_\`(#N?^PKJ7_I;-11X-_Y`=S_V%=2_]+9J*`#P
M]_R'/%G_`&%8_P#TBM:Z"N?\/?\`(<\6?]A6/_TBM:WW#%&",%8C@D9P?I0`
MM%>=/JFI1>';]&O[B223Q*FGM,6PZPO<1QL%(QM^4D`C&,Y'/-=#X:,]OJVO
M:6UU/<6MG<1?9OM$C2/&K0HQ4NQ+-\V3DDGYJ`-34?\`C^TG_K[;_P!$RUH5
MRNK>*-/AU2PA:WU<M!>.'*:/=LIQ%(/E81$/SW4G(YZ<U:_X3+2_^?77/_!%
M>_\`QF@#H**Y_P#X3+2_^?77/_!%>_\`QFC_`(3+2_\`GUUS_P`$5[_\9H`\
M]L_];J?_`&%;_P#]*I:ZSX<?ZKQ%_P!A4?\`I+;UQ^F3+<I?3H)`DFIWSJ)(
MV1@#<RGE6`*GV(!'>MSP3K]GI3^((+B'4G=M3#@VNFW%PN/LT`Y:-&`/'3.>
MGJ*];%_[I#Y?D9Q^)GI5%<__`,)EI?\`SZZY_P""*]_^,T?\)EI?_/KKG_@B
MO?\`XS7DFAT%%<__`,)EI?\`SZZY_P""*]_^,T?\)EI?_/KKG_@BO?\`XS0!
MT%%<_P#\)EI?_/KKG_@BO?\`XS1_PF6E_P#/KKG_`((KW_XS0!T%%<__`,)E
MI?\`SZZY_P""*]_^,T?\)EI?_/KKG_@BO?\`XS0!T%%<_P#\)EI?_/KKG_@B
MO?\`XS1_PF6E_P#/KKG_`((KW_XS0!T%%<__`,)EI?\`SZZY_P""*]_^,T?\
M)EI?_/KKG_@BO?\`XS0!T%%<_P#\)EI?_/KKG_@BO?\`XS1_PF6E_P#/KKG_
M`((KW_XS0!T%%<__`,)EI?\`SZZY_P""*]_^,T?\)EI?_/KKG_@BO?\`XS0!
MT%%<_P#\)EI?_/KKG_@BO?\`XS1_PF6E_P#/KKG_`((KW_XS0!T%%<__`,)E
MI?\`SZZY_P""*]_^,T?\)EI?_/KKG_@BO?\`XS0!T%%<_P#\)EI?_/KKG_@B
MO?\`XS1_PF6E_P#/KKG_`((KW_XS0!T%%<__`,)EI?\`SZZY_P""*]_^,T?\
M)EI?_/KKG_@BO?\`XS0!T%%<_P#\)EI?_/KKG_@BO?\`XS1_PF6E_P#/KKG_
M`((KW_XS0!T%%<__`,)EI?\`SZZY_P""*]_^,T?\)EI?_/KKG_@BO?\`XS0!
MT%%<_P#\)EI?_/KKG_@BO?\`XS1_PF6E_P#/KKG_`((KW_XS0!T%%<__`,)E
MI?\`SZZY_P""*]_^,T?\)EI?_/KKG_@BO?\`XS0!T%%<_P#\)EI?_/KKG_@B
MO?\`XS1_PF6E_P#/KKG_`((KW_XS0!T%%<__`,)EI?\`SZZY_P""*]_^,T?\
M)EI?_/KKG_@BO?\`XS0!T%%<_P#\)EI?_/KKG_@BO?\`XS1_PF6E_P#/KKG_
M`((KW_XS0!T%%<__`,)EI?\`SZZY_P""*]_^,T?\)EI?_/KKG_@BO?\`XS0!
MT%%<_P#\)EI?_/KKG_@BO?\`XS1_PF6E_P#/KKG_`((KW_XS0!T%%<__`,)E
MI?\`SZZY_P""*]_^,T?\)EI?_/KKG_@BO?\`XS0!T%%<_P#\)EI?_/KKG_@B
MO?\`XS1_PF6E_P#/KKG_`((KW_XS0!T%%<__`,)EI?\`SZZY_P""*]_^,T?\
M)EI?_/KKG_@BO?\`XS0!H:[_`,B]J?\`UZ2_^@&M"N3U;Q9IUSHU]`EMK(>2
MWD13)HMXB@E2.6:(!1[D@#O764`<_P"#?^0'<_\`85U+_P!+9J*/!O\`R`[G
M_L*ZE_Z6S44`'A[_`)#GBS_L*Q_^D5K705S_`(>_Y#GBS_L*Q_\`I%:UT%`&
M:=`TMK2XM3:@PW%Q]JD7>V3+N#;P<Y4A@",8P1Q4UAI=GIAN#:QLKW,GFS.\
MC2-(VT+DLQ)/"J/H*N44`9^H_P#']I/_`%]M_P"B9:T*S]1_X_M)_P"OMO\`
MT3+6/XD\47^C:C':6.EVUYF(2.T]XT&W)(``$;Y^Z?2JA"4WRQ5V!U%%<?X=
M\97^K^(5TJ^TBVM-]I+<I+!>M-]QXU*D&),?ZT'.3TKL*)PE!\LE9@>.V?\`
MK=3_`.PK?_\`I5+76?#C_5>(O^PJ/_26WKD[/_6ZG_V%;_\`]*I:ZSX<?ZKQ
M%_V%1_Z2V]>IB_\`=(?+\C./Q,[:BL_7=3_L3P]J>J^3YWV&TEN?*W;=^Q"V
MW.#C.,9P:X:^^).MZ?I]S>R^&]/:.WB:5PFK.20H)./]'Z\5YL*4YIN*O8N]
MCTFN&\=:IJUIK>CV6G:K/81SVUU+*88HG+E&@"_ZQ&P/WC=,5W->?>/?^1KT
M'_KQO?\`T.VJ\-%2JQC+8'L4],U/7TU:R\_Q'?7,37$:/#+!;!7#,`02L0;O
MV(KTVO+++_D)V/\`U]P_^C%KU.M\?3C3J)05M/\`,47='F.L:QK\GBO7+:V\
M07=G;6ES'%%##!;D`&WB<\O$S$[G;O6KX%U35KO6]8LM1U6>_C@MK66(S11(
M4+M.&_U:+D?NUZYK!U#_`)'/Q/\`]?T7_I);UK>`O^1KU[_KQLO_`$.YK2I2
M@L(II:B3?,>@T445YI84444`%%%%`!17'^(O&5_I'B%M*L=(MKO9:17+RSWK
M0_?>10H`B?/^J)SD=:/#OC*_U?Q"NE7VD6UIOM);E)8+UION/&I4@Q)C_6@Y
MR>E:>RGR>TMH*ZV.PHHHK,8445GZ[J?]B>'M3U7R?.^PVDMSY6[;OV(6VYP<
M9QC.#0!H45Y]_P`)[K__`$+FF_\`@VD_^1Z['0M3_MOP]IFJ^3Y/VZTBN?*W
M;MF]`VW.!G&<9P*TJ4IT_C5A)IFA11168PHHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#/UW_D7M3_Z])?_`$`UH5GZ
M[_R+VI_]>DO_`*`:T*`.?\&_\@.Y_P"PKJ7_`*6S44>#?^0'<_\`85U+_P!+
M9J*`#P]_R'/%G_85C_\`2*UKH*Y_P]_R'/%G_85C_P#2*UKH*`.?\:^8_A>>
MVBBMYGNI8;;RKB=8D</(JLI9O52>`"3T`).*3PJ+*V6_TVVT.RT>>UF7[1!8
MA?)=F16#*P5<\$#E0>.F,$[-[96^HVCVMU'YD+XR,D$$'(((Y!!`((Y!`(J/
M3M+L]*A>*TC9?,;?(\DC222-@+N=V)9C@`9))P!Z4`9VIZI;IJ.FH8[O*7;`
MXLY2#^YE'!"X/X5S/B>[CN]?W1K,H6UC!\V%XS]Z3H&`S79ZC_Q_:3_U]M_Z
M)EKD_&'_`",*_P#7I'_Z')77@?\`>(_/\F3+8R?#US':^/K-Y%E8'2[L8BA:
M0_ZVV[*"?QKT+^V;7_GE??\`@!/_`/$5P?A7_DH5I_V"KO\`]&VU>F48[_>)
M?+\D$=CQNP<2'4'4,`VJ7Q`92IYNI>H/(^AKI/`.H0VH\0I(ERQ.J`YBMI)!
M_P`>MOW52/PKG;/_`%NI_P#85O\`_P!*I:ZSX<?ZKQ%_V%1_Z2V]=>+_`-TA
M\OR)C\3+'C?5K:3P#XC18[P%M+N0"UE,HYB;J2N!]37G_B;_`)%36/\`KQF_
M]`->G>._^2>^)?\`L%77_HIJ\Q\3?\BIK'_7C-_Z`:C+_@J>G^8Y]#U[^V;7
M_GE??^`$_P#\17#>-+R*[\5Z'Y:3KML;W/FP/'U>VZ;@,_A7I->?>/?^1KT'
M_KQO?_0[:N3"?QX^I4MC*MY5AOK.1@Y5;J$D(A8_ZQ>@`)->C?VS:_\`/*^_
M\`)__B*\\LO^0G8_]?</_HQ:]3KIS/\`BKT_5DPV/)+J9;CQ;XEE02!6OH\"
M2-D;_CU@ZA@"*TO!=Y%:>*]<\Q)VW6-ECRH'DZ/<]=H./QJCJ'_(Y^)_^OZ+
M_P!)+>M;P%_R->O?]>-E_P"AW-:U?]RC\A+XCL?[9M?^>5]_X`3_`/Q%9R^.
M-`90RW-R01D'[#/_`/$5T->0VW_'K#_N#^5<N#P\:\FI/8J3L>C67B?3-1M1
M<V9O)H2[H'6QGQN5BK#[G9E(_"K']LVO_/*^_P#`"?\`^(K$^'/_`")D?_7]
M??\`I7-71WU_9Z99R7E_=P6EK'C?-/((T7)`&6/`R2!^-<LE:3117_MFU_YY
M7W_@!/\`_$4?VS:_\\K[_P``)_\`XBJ<'C/PM=7$5O;^)=&FGE<)'''?Q,SL
M3@``-DDGC%;E2!Y;XAN8[KQ]>/&LJ@:7:#$L+1G_`%MSV8`_C1X>N8[7Q]9O
M(LK`Z7=C$4+2'_6VW903^-3>*O\`DH5W_P!@JT_]&W-'A7_DH5I_V"KO_P!&
MVU>M_P`P']?S&?VCO/[9M?\`GE??^`$__P`16:OCGP^YD"W5R3'(\3?Z#/PZ
M,58?<[$$?A715X[9_P"MU/\`["M__P"E4M<>$H1KS<9/H5)V1Z7:^)=-O8V>
MV-Y*JMM8K8S\'`./N>A%9'C?5K:3P#XC18[P%M+N0"UE,HYB;J2N!]35CP1_
MR#+S_K[/_HM*F\=_\D]\2_\`8*NO_135A5BH3<5T8UL<-75^"-6MH_`/AQ&C
MO"5TNV!*V4S#B)>A"X/U%<I7<^!/^2>^&O\`L%6O_HI:]/-/L?/]"(&A_;-K
M_P`\K[_P`G_^(H_MFU_YY7W_`(`3_P#Q%:%%>2:&?_;-K_SROO\`P`G_`/B*
M/[9M?^>5]_X`3_\`Q%:%%`&?_;-K_P`\K[_P`G_^(H_MFU_YY7W_`(`3_P#Q
M%:%%`&?_`&S:_P#/*^_\`)__`(BC^V;7_GE??^`$_P#\16A10!G_`-LVO_/*
M^_\``"?_`.(H_MFU_P">5]_X`3__`!%:%%`&?_;-K_SROO\`P`G_`/B*/[9M
M?^>5]_X`3_\`Q%:%%`&?_;-K_P`\K[_P`G_^(H_MFU_YY7W_`(`3_P#Q%:%%
M`&?_`&S:_P#/*^_\`)__`(BC^V;7_GE??^`$_P#\15&3QOX3BD:.3Q1HJ.A*
MLK:A$"".H(W5I:;JVFZS;M<:7J%I?0*Y1I+6995#8!P2I(S@@X]Q0!'_`&S:
M_P#/*^_\`)__`(BC^V;7_GE??^`$_P#\16A10!G_`-LVO_/*^_\``"?_`.(H
M_MFU_P">5]_X`3__`!%:%%`&?_;-K_SROO\`P`G_`/B*/[9M?^>5]_X`3_\`
MQ%:%%`&?_;-K_P`\K[_P`G_^(H_MFU_YY7W_`(`3_P#Q%:%%`&?_`&S:_P#/
M*^_\`)__`(BC^V;7_GE??^`$_P#\16A10!@ZSJUM)H6H(L=X"UM(`6LIE'*G
MJ2N!]36]6?KO_(O:G_UZ2_\`H!K0H`Y_P;_R`[G_`+"NI?\`I;-11X-_Y`=S
M_P!A74O_`$MFHH`/#W_(<\6?]A6/_P!(K6N@KG_#W_(<\6?]A6/_`-(K6N@H
M`CGGBMH))YY4BAC4L\DC!54#J23T%1V5]::C:I=6-U!=6[_=E@D#HWT(X-8/
MCH2'0K78"8_[4L?.Q_SS^TQ[L^V.OMFF>%Q"/$OB_P"RL#`=1C+;<;1-]GBW
MX]_NY]\T`;.H_P#']I/_`%]M_P"B9:Y/QA_R,*_]>D?_`*')6EJVMZA'JEA&
MOA;5Y5BO'"2)+:;9<12#*YG!&1S\P''OQ6)KW]OZIJHNH/".K*@@6/#SV8.0
MS'M.?[PKIP<XPK1E)V7_``!2V(/"O_)0K3_L%7?_`*-MJ],KS#1;;Q%IOBF#
M5)O"6J-!'93VY5+BS+;G>%@>9\8Q&V>>XKIT\7W<FHS6"^$=<-U#%'-(GF6?
MRHY<*<_:,<F-_P`O<48R<9UI2B[K_@!'8X6S_P!;J?\`V%;_`/\`2J6NL^''
M^J\1?]A4?^DMO7,0:3XFB>\9O"FHXFO;FX7%S:<+),\B@_ONN&&?>MSPD^O:
M"FJK=>$-6<W=Z+B/RI[,X7R8H\',XYS&?PQ73B:L)8:$4]5;\B4G<Z'QW_R3
MWQ+_`-@JZ_\`135YCXF_Y%36/^O&;_T`UV6L:[J/BGP?K5CIOA/62]U;W=BC
MR2V:JLHWQ,#^_P`X#@C(!Z9&:Y?6-#\4:AHE_91>%-062XMI(D+W-H`"RD#/
M[[IS4X*K"$9J3M?_`((25['LE>?>/?\`D:]!_P"O&]_]#MJV;SQ?=Z?`LUUX
M1UR.-I8X0?,LSEY'6-!Q<=V91[9YXKG_`!,GB#6M;TR]MO".JK':VUQ$XDN+
M,$F1H2N,3GC]VV?J*YL-)1JQE+8I[%2R_P"0G8_]?</_`*,6O4Z\LM[+Q'#>
M6TS>$M3*Q3QR,!<6F<*P)Q^_]JZ^3Q1?Q/"C^#]<#3/L0>;9<G:6Q_Q\>BG\
MJWQ]2-2HG!WT_P`Q15D<9J'_`".?B?\`Z_HO_22WK6\!?\C7KW_7C9?^AW-9
M5UI_B2?Q!K%^OA/4Q%>W*2Q@W%IN`$$49S^_ZYC/KQBKWAE/$&BZWJ=[<^$=
M5:.ZMK>)!'<69(,;3%LYG''[Q<?0UI4JP>$4$]1)/F/2*\AMO^/6'_<'\J[:
MW\7W=W/=PP>$=<>2TE$,X\RS&QRBR`<W'/RNIX]?7-<;#IGB6.&-#X3U+*J`
M<7%I_P#'ZG+ZL*<FYNP35SK_`(<_\B9'_P!?U]_Z5S4?$;_D3)/^OZQ_]*X:
MS_"=SKFA>'TL+KPAJ[RBYN9<Q3V97$D\DB];@<X<9]\U!KNKZGXP\'P?V5X4
MU=H[M[2\AEEEM%5HUFCESCS\@E5X!'4C.*Y+KVE_,KH<_>?ZW3/^PK8?^E45
M>Q5Y%/I/B:5[-E\*:CB&]MKALW-IRL<R2,!^^ZX4X]Z[6X\7W=I/:0S^$=<2
M2[E,,`\RS.]PC2$<7''RHQY]/7%=./J1J5$X.^G^8HJR.;\5?\E"N_\`L%6G
M_HVYH\*_\E"M/^P5=_\`HVVIFM6WB+4O%,^J0^$M46"2R@MPKW%F&W(\S$\3
MXQB1<<]C1HMMXBTWQ3!JDWA+5&@CLI[<JEQ9EMSO"P/,^,8C;//<5I[6'U+V
M=]?^"*SYKGI]>.V?^MU/_L*W_P#Z52UW2>+[N349K!?".N&ZABCFD3S+/Y4<
MN%.?M&.3&_Y>XKBH-)\31/>,WA34<37MS<+BYM.%DF>10?WW7##/O6>`J1IU
M&YNVG^0Y*Z.W\$?\@R\_Z^S_`.BTJ;QW_P`D]\2_]@JZ_P#135C^';S6](L[
MB&X\'ZPS23F0&.>S(QM4=[@?W31KVK:KXA\):QIUEX1UD2W=I<6B/)-9A1(5
M:/G]_G`;T!Z=ZYJS4JDFN[&MCGJ[GP)_R3WPU_V"K7_T4M<1_9_B3_H4]2_\
M"+3_`./UMZ3KNH^%/`MC%JGA/6532=,C6ZECELV4"*(;V'[_`"1\I/3/M7;F
M%6%3EY'??]"8)H[RBN?_`.$AU3_H3=<_[_67_P`D4?\`"0ZI_P!";KG_`'^L
MO_DBO-+.@HKEW\7W<>HPV#>$=<%U-%)-&GF6?S(A0,<_:,<&1/S]C7":MX8U
M'5_$NKZK=^`9[@7DZ/$9S8NZHL,:8.9CCYD8X![U=."G*S=A,]CHKR_P;IVJ
M>%=6U2XC\#WT%M>06Z+':R62_/&TI8D>>!R)%Y]C[5U%OXON[N>[A@\(ZX\E
MI*(9QYEF-CE%D`YN.?E=3QZ^N:4XJ,FD[C.HHKG_`/A(=4_Z$W7/^_UE_P#)
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MG0C&+N]/R(BG<]!HKE[/Q?=ZA`TUKX1UR2-99(2?,LQAXW:-QS<=F5A[XXXJ
MQ_PD.J?]";KG_?ZR_P#DBO++.@HKE[_Q?=Z9IUS?WGA'7([6UB::9_,LSM10
M2QP+C)P`>E6/^$AU3_H3=<_[_67_`,D4`=!17/\`_"0ZI_T)NN?]_K+_`.2*
MCD\47\3PH_@_7`TS[$'FV7)VEL?\?'HI_*@#I**Y_P#X2'5/^A-US_O]9?\`
MR11_PD.J?]";KG_?ZR_^2*`.@HKFX?%%_<(7B\'ZXRAV0GS;(<JQ4C_CX]0:
M\RMO`MS%:0QR_#K?(J*KMML3D@<G/FUK2IQG?FE839[#KO\`R+VI_P#7I+_Z
M`:T*\ZCU35-`^&"V&H>%-70Z?HPAN)EFM&1?+APS#$^XC@GIGVKT6LAG/^#?
M^0'<_P#85U+_`-+9J*/!O_(#N?\`L*ZE_P"ELU%`!X>_Y#GBS_L*Q_\`I%:U
MT%<_X>_Y#GBS_L*Q_P#I%:UT%`$<\$-U!)!<11S0R*5>.10RL#U!!X(J.RL+
M/3;5;6PM(+6W3[L4$81%^@'%6**`&M&CLC,BL4.Y21G:<$9'IP2/QJK>:K96
M#LMU.L16![ABP.!&A`9L^VX>_-7*R=:T.QU=?]+EEB9HGMMT<FW*.1E<'(.2
MH[=J`+.G:G#J22&..:)XR`T4\91P",@X/8_T/H:LB"%;A[A8HQ.Z*CR!1N95
M)*@GJ0"S$#MN/K5:WMXXM3NI`DAE>.(-*S+A@-V%`'/'S'D?Q<$]!=H`R;GQ
M#:P7<UM'!>W4D&!-]EMVD$9(S@D<9P0<#)Y''-7[.\@O[2.ZMI/,AD&5;!'Y
M@\@]L'I5)M-ALY;NZBOIK-;B02389-I?`7=\ZG!("CTJ?2;6*STV."&&6%%9
M_EE8,Q)8DL2"1\Q);\>W2@`NI[#0M*N[V4);6=NLES,8X^`.7=L*,DDEB>Y)
M/<U!)K]A%J0L6:3>76(R",F-9&&51FZ!B",`_P!X>HJUJ5E:ZEI=W8WR[K2Y
MA>*9=Q7*,"&Y'3@GFLF;PY:01.0EY=B:^@NI8@Z99T,:JY)QPFQ&ZY.SOT(!
MN300W*!)XHY4#JX5U#`,K!E//<,`0>Q`-0:AJ-OIEL)[@OAG$:)&A=W8]%51
MR3_^OI5NJ>HV5O>11-.[1&WD$\<JL`8V`(SSQT)'/'-`$%EKEM>WALS%<VUS
ML,BQ7,)C+J#@E3T.,C.#QD>M:+1H[(S(K%#N4D9VG!&1Z<$C\:R;:WMY]5M[
MU;F:_>.*2-)A)&4A!*Y!"XR6P.Q^Z>G?8H`I7VJVNGHYG9RR[/D1"S,7)50`
M.I)!J2QOH[^`RI'+&58H\<R%'0^A!]B#]"*JW^DVM[?6\\L\L4R,C*J.`'*,
M6'!!]3TYP:MVL0BDN2"Y9Y=S,Y')VKC&.@``'//'XD`DC@AA>9XHHT>9]\K*
MH!=MH7+>IVJHR>P`[5D2^*+&-IF$%\]O"[)+<I:N8E*G#'..0"#DC(X/I6W6
M-<:7#!8S6XO[I+>8N!;J\8W%R244LN>23CGC/&*`-A65T5T8,K#((Z$55,EG
MI5O:VZHEO!N2V@CC3"KQA5``P!@8]!4ULBQVL2)&8E5`!&3RHQT_"H=0L;?4
M(8X[AG79(LD;(Y5E<="#0!!9Z[8WUXUM"T@;YMC/&567:<-L)^]@]<5>D@AF
M>%Y8HW>%]\3,H)1MI7*^AVLPR.Q([UF6NC0:?/8J@N9A;B41NS+MCWG))Q@G
MT&`<"M>@#/U'6+;3988)%GFN)@QC@MXC([`8R<#H!D<G`Y%.T[5;?4Q*(EFC
MEA8++#/&8W0GID'L>Q'!IE_96QNHM1DNGM)H8VB$RNH&QB"5.X$=5!Z9XINF
M6T,=Y=W4;37#SK'F[=T*R`;L*NW&-N3V'WNI[`%\00K</<+%&)W14>0*-S*I
M)4$]2`68@=MQ]:RY_$VG0W<MG&9[B[BF,+P00LSA@B2'MT"R)STRP'7BMBL9
M/#NGP^(9=7A:2.^E#F3#@@[EC0G!!QQ#'TX^44`:-E>P:C9QW=L^^&09!(((
MP<$$'D$$$$'D$5,D:1J51%4$EL*,<DY)_$DFJ&B6L-GIOD002Q*)YBPE969V
M,K%G.TD?,Q+8XQNZ`\#1H`QH_$EK(\9^RWZP2,%2Y>V98SDX!R>0"2.2,<UJ
MSP0W5O+;W$4<T$J%)(Y%#*ZD8((/!!'&*RI;"""""R>^N)(@4$5INB!<*00!
MD`D#`[YP*V:`(+B]M[1E$\HCW*S@GIA1EB3VP*K:;K%OJF_R8[B,JJN!/"8R
MR-G#`'G!P?>C5=)MM7B$5P\B':Z`QO@E6&&&#D$$>HI]K9);7*D"9RMND0E<
MKC"D\<<Y[GC%`%DP0M<)<-%&9T1D20J-RJQ!8`]0"54D=]H]*H7FNVUG>&S6
M&[N;A4#O';0,^Q3T+'H,X/&<\5IUEW5K:VUY)>G4'LGG"K(=Z!7V]/O@\X/:
M@"UI^H6^IVBW-LS%"2I#H496!P593@@@]C4T<$,+S/%%&CS/OE95`+MM"Y;U
M.U5&3V`':JNE6L=K;RK&LOSS-(TDK*QE)Y+_`"\8/8<?05>H`QI?$^GI$)8Q
M<W$6'+O!;LXC"L5);C(&58>^TUKQR)+&LD;!T<!E93D$'H161!H5G91WL=I-
M<()D(=%D#;<LSG;N!QDNW7CGM6AI\<<.FVL<,)AB2%%2)B"44`84D$@XZ<$_
M6@!3]DTK3N!%:V5K%T4!4BC4=@.``!^E4(/$5M-<0Q/:7]N)SMBDGMF5&/89
M_ASVW8].M7[^RM]2TZYL;R,26UQ$T4J$XW(PP1^1JA+:QF>&"6_N+MXI$D^S
M%H@>",,0`#@'GKV[]*`-5HT=D9D5BAW*2,[3@C(]."1^-4]0U>RTM"UW*5.P
MN%5"Q8!E7``')+.H`ZDFKU9>KZ%9ZR\#7+2J\+!D,;`?==''!!'#(A_"@"QI
M^I0ZBLNR.>&2)@LD4\91ER,C@]0?4<=?0U8C@AA>9XHHT>9]\K*H!=MH7+>I
MVJHR>P`[5!!;"*_NIB)6>54S(Y7&!NPBXYXR3R/XNI[6Z`,>;Q':QW$\,-M?
M77D-LE>WMF=$8=1G^(CN%SCIUK3MKF&\M8KFVE66"5`\;J<AE/((K,:TM-/E
ME2/57LOM$K2F+?'R['+$;E)Y/-7-)MHK/2;6VAMY+:**)46&1@S(`.A()!/X
MF@"7;;:?:RNL:0P)OF<1I@9)+NV!W)))]22:HR>(;"*>%&,WER*C>>(CY:;_
M`+@9OX2??U&<9K2FA2X@DAD&8Y%*,,XR",&L-]$LH-.FA26ZN(=\>^(2H2=F
M`%)...F><\8SVH`VYX(;JWEM[B*.:"5"DD<BAE=2,$$'@@CC%0ZAJ%MIEH;F
MZ9@@(4!$+LS$X"JJ@DDGL*M55O[&&_A2.5G0I(LD;H<,CJ<@CM^!R*`*UEKE
MM>7@LV@N[:X*%T2Y@9-ZCKM/0XR,C.1FM%HT=D9D5BAW*2,[3@C(]."1^-9<
M5M#)JT,QNI[Z6`.F2\>V`D<[@H!R<8Z'\*UJ`,R]U^PLKA[5VEDNE*`011EG
M8N&*@>O".?8*<U9L-0@U*V\^W+X#%'21"K(PZJP/(-5)="L9]=CU4/*MY$5)
M"2<-A75<@^SOTQUJ?3;1+3[6%BF5I+@R/)*5)E8A?F&WH,`#H#\O3N0"XD:1
MJ51%4$EL*,<DY)_$DFL<^)[3!D%IJ#6P.#<BU;R\9^]GJ5]P,8YZ5M5ARVUI
M%;/IHU68IY9C6S$D.XKC&P97/3CDY]^]`&Q/!#=6\MO<11S02H4DCD4,KJ1@
M@@\$$<8J2BB@#G_!O_(#N?\`L*ZE_P"ELU%'@W_D!W/_`&%=2_\`2V:B@`\/
M?\ASQ9_V%8__`$BM:Z"N?\/?\ASQ9_V%8_\`TBM:Z"@`HHHH`*QM7T"'5]0L
M9[B.WN((%D22WN8A(C!MOS`'HXVX!]&-;-<_X@AN&U&QF:WO;G3D2030V<I5
MO,.W8S`,I90`XQD\D<=P`1>%HEFO-3U."65K25_L<,<Q)>,V\LL;@G)RI;)7
MG.#CC%=+6'X?BD2:]=+>YM;!RGDPW))??@[V`))`.5X]03CG)W*`./U?P_+;
MWQOQ>12V4E\)Y+*>VWAY)$$*\[@-H)5N0>G%=%H^GMI>D6UDTOFM$N"P&!US
MA1DX49P!G@`"N6U9-2CUR1+J+4Y[*>]C<_90[HUN(F`0;2/+(E(8GC(QR>@Z
M/PZMRF@VJWDC/,`P)>0.P&X[59@3E@,`G)Y!Y-`"^(M+?6_#.J:5'*L3WMI+
M;K(PR%+J5R1^-0"R$6I06MG?7EJ(8UE>%-KQ.F[&W#@E>F/EQ6O,KO"ZQR>6
M[*0KXSM/8X/6N?TVVU^."";5]8ACE60)*JVZ!)/FP-ISD!N,#J,XZT`='6#X
MNCM6T='N[F&"..XC<?:(S)%(P/".HZ@G]<'M6]4<Y@\DBX\ORF^4B3&TYXQS
M0!R7AY;6Y\0_;$N+".9;=H_(L;9X@X)!W.S?>QC@8XW'UKL:S-(U0:@]VC2V
M[-%.RHL3@DQ_PL>3UYYK3H`YG7#HJ:]"VK-:LQM_W:O"S2QD-P\;CE>3R1@Y
M"U>\.E7MKJ2.^-Y&]P2DK(5;:$4`-D<D8Z]_K6C<1*1]H6".2XB1O*9E!()'
M0'J,X%-TZ2YFTRTEO(Q%=/"C31@8"N5&X=^AS0!9KSBYBTZ2]NHWUVSGBBBG
MMHXY;!V>VD=P2=P.,KSV!Z<\5Z/67>7MI8NLL#V:237*QSNS*"<=<G(R0,=>
ME`%^VV_98=LC2+L&';JPQU/O61XICLFTZWEU&:**T@NHY9&E4D8!X''0Y(P?
M6MRFR1I-$T4J*\;@JRL,A@>H(H`P=,OK"?556QUBZE5E.;60%E)]0S+N'TW8
M]JZ"JUN9ENIX3"L=M&J"$J,9X.1^'%6:`.0\6@G6-.>WM?M]W%#-)]DD@66,
M1_+NDP67#`X`(R2&(Q4OA/REU#5!&]JQE2"Y`LH]EOM<-M*C)RQVDEN,\<<5
MOW260GAGN1")H]QA=R`PXR<'TP,D>V>U9GA-89])AU-K:U@U.\@B;4%MB-HF
M"Y9<`D#!9O?GO0!O5Q,_]FCQ/JSR&X21IHX/[30*#9S&),1;LY"D%&P5V;F.
M<DXKMJS-5B>"RN)K&RAGN9WB25&3(D3<%8L.,X0M^0^E`&9X"61/##K-()91
MJ-^)'";`S?:Y<D#)P,Y[UTU5K#3[32[06MC`D$`=W$:=`68LQ_$DG\:LT`>;
M:9$T!FEU(#?*;5M/DEME61H(ROW7#L,XP<?*1DG;7I-8-XUA]ITW2U2S>RE9
MG*%A\I'*%>>/FR/TK>H`P/$6!>:;(ME/>RJTFR"!E1_N\L&9EVXQCKGD#UIV
MB7<4U]*D-]>S1F(-]GN=N;=@Q4J3C?N]0Q/;'6MB:U@N&B::)7:)P\9(Y5O4
M52TZ%GO+V\N+1(KCS6A615P9(E^Z3Z]3S0!I5P/B6X:T\4R7%OIL>HGR(HIF
MN+972W9F(C57+`C>3R`"!P217?5FZBUK:+=WB+;"_6V8C>0"P'W=W(R-V/S]
MZ`*7@^,0Z$8<;)([B5981&(UB?<<HB@L`H[8)X-;]5K".SBM$%@(1;DDJ8B"
MI)/)R.ISU-6:`/-2Q1-572;2[DNS+<3+?HJ+YT:N0ROE_P!Z`Q9!G!P.".#7
M<>'HUB\,Z5&DBRJMG"HD7.&`0<C/8U6U*S:.:QM;33H)+*\NV_M`%.%3RG;=
M@$=9%C!ZYW'CG-;2JJ(J(H55&`H&`!0!E^)X+.Z\*:O;ZC.UO9264R7$RXS'
M&4(9AGT&37%Z&+@WELT]@#MU1VN]0E@6.>.9\%(L!V.,.$+!B,$*!@Y7T:5(
MY(7295:)E(=7&5([@Y[5BI<6LOB..R(LVMX+=)+8[P7\T[@0!GL@4CCOUH`W
M:Y?Q/=6NG:E:7UU#>21QVLX=K1MK1)F,ER=P.,A1@9Y(.,`FNHJ-X(I)4E>-
M6D0%58CD`XR/QP/RH`R/#\UVSWEO>O>">-E81731,41AQM:,#(R".><@]N:V
MZS=#CE_LR*YN[2.VO[A1)=*@Q\_XDG]:TJ`/,M4O5T_5?$$=MI<%]*A:XF-Y
MIY9P"O'SY^>/L#P!@CM7?Z+!]ET2QM]]P_E0HFZX&)#@8RP]:I^(382Z6S7"
M6DV)!&OG,.#N`8`Y!!QGOVK9!!`(((/0B@".X7=;2KEQE",Q_>Z=O>O+8+F"
M?3;+2M*LYX;F8LD[Q67EQS")UW>8F<B3D$GJ#UR#7J]94MDI\4VMV+*,[;24
M-=`$,&+1X7K@@C<>0>G&.X!JUA>+62#1?MCR3Q?9)DG$D,'FE".Y7(RO//I6
M[3)98X8S)+(D:#JSG`'XT`<1X7E%QX@CC2RD@^P6P@FF2T\H7$C*K%G.X\8P
M0#DY).:[JL#P]]CCOM8C@BM(7:\)"P/DN@1!N*Y..<C@#ITK?H`XW5YH--\2
M:C<R1:BT\]E&\36:$;5C+[OFS@\L."#CCCFMOPW/-<Z/'-/->RESN5KR)$?!
M`('R``CWQ2>*;9[GPQJ0@L(KZ[2VD>V@E7(:4*=HX((R>,@@\]16I!&L-O'$
MBA510H4=@!TH`DKS5TG\J2RM]-TR>T%J+N>\^R@3Q)(258@L`TF%=BP/50<<
MUZ57,:B-.LM0TY;.UTT17]P8;Y_E4F)$D(Z$9Q*$7'/WB,<T`=/1110!S_@W
M_D!W/_85U+_TMFHH\&_\@.Y_["NI?^ELU%`!X>_Y#GBS_L*Q_P#I%:UT%<_X
M>_Y#GBS_`+"L?_I%:UT%`!1110`4444`%%%%`'-/_;9U74+L2W6VUE7[/8HB
M>5<0[5)^8C.\DOCYA@J,C!R='P[+>3Z+'+?K*L[2S<2IL;;YK;,C`Q\NVM2B
M@#-\0_VB/#>IG1\_VG]EE^R8V_ZW:=GWN.N.O%837.NSZD]U$EXFR^@AAM6C
MQ%);E4\UW)7A@6D((/\``H'4BNOHH`*RM>TUM2M(5BFCBN(9UFA\S)5F`(VD
M#GD%OH<'G&*U:Q]?TAM7_LU!M\N"\$TF6*G:$=<J1W!8$?2@"EHVD:A!=:9+
MJK6PEL;1[:%;16*L#LRS,0,<(,+]?PZ6LNPM-7M;LK<ZG#>66S"[[;9.&]V4
MA2/H@K4H`PM:T?3;O4K2_P!0N5CCB1XFCDDVK(#@CG(P01^I_#1TVULK2U,=
M@H$!;=D,6!)`Y!).:R=96"+64N9[73+G=;A%%W.J/'AB3M#*<AL\\C[HZ]K?
MAZ)([.X:.*SACDN&=8;.0/&G`'4`#)(W'CJW?K0!KUQ5UX=U1;V46]SIS6PA
MN86>16\R..9@Y^09#,".N1D=17:UPTNEV,=E?-'-I<&K^;.5G2Y"FX5R<K*<
M9Y!Q@YP0".@H`[2UC2*TACC+%$C55+=2`.,U5UG2X=9TN>QG=XQ*N%DC;#(W
M9A[@_G4VG1&'2[2)BI*0HI*G(.%`X-4?$4#RV5O)%<6T,EO<I,IN6VHQ&?E)
M[9H`;INCZ5I]S'Y"!KQ$VNZ,QP<<DC)"YYQFMFN-\.6)BO;*1YM,6Y1;DW)M
M+GS&G+OE<_*I;`Y)/0]*[*@#G_$.BW.HSK<6,UN+K[+-:M%<9VO')MR05Y4@
MJO.#QD>F+.DV5Q#?WUY>M']KN5B#I`K>6@4$`!C]XY+9/'&!CCFGK.GP3>(K
M6]N;V*T6.SDCCD\X)(LA="&7/!&%.<Y!S@@@U?T>:ZE687.IV-^%(V/:Q["!
MS][YV&?IB@#4K`U#1M$?5I+O4)(@\\:J(Y)BG*Y^8?,.H(!X["M^N)GDMH?%
M>IVTEI9ZE->2IY9N<J(CY2CR-Q0KV+A<Y^<\>H!UNGP6UM9K#:1M'"A8*K!O
M[QS][G&<\]^W%6:P?!J+%X;CB29)1%<7,9$8.R(K.X,:Y`)5""@.!D**WJ`.
M.M=$U2"ZF62;3WT]E@B>2,N9<0MQ\N"`2,`\\')]J[&O/H(;%M)0Z<8[.\01
M"[B,3QI=Q[U'FX*C<>A#@'K@GFO0:`,O7-$AURUAAEE>-HIEE1E)YP>5(!&0
M1D?CGJ*72['2K.68:<JACA9"DA<`CL<DX/M65XTDN8+.&6R8?:F26&./9*S,
M60\CRT<C&,YVD5)X:CM8Y(C:K:1(^GPY2U'R,RE@Q^Z.AXYYZY`H`Z2N7UO0
M;^ZOY+G3I;-S(]O+)%<EEVO"^Y2&4'@]"I'N"*ZBN-OUM+?Q1?RO>W%I>2+`
M4N+:%W$2X(Q,=I0*3V8^I!'6@#H-%LFL;6997#S2W$DTI5"B[F.<*#V]^_)K
M2K/TBYFN+:5;FX@GGAE:*1X86C7(_P!EB?YXK0H`YM_#N@QZG<M<NK2W+B18
M7G8%3C!VC=G!QG&.N:Z"!46WB6-2L80!58$$#'`.>?SKS>:YL[>#5]..EV>J
M7!FN)'NVBE;(W$EG(B;[F=ORD_<P,'@>A:8GEZ59I]H^T[8$'GYSYORCYOQZ
M_C0`FJ:?'JVD7FG3,RQ7<#P.R'!`92"1[\USNF:1JT&8[V33OL37PN@]MO:1
MV+`XY&%&[GJ<+\OO6[KL#77A[4K=;O[&TMK*@N<X\G*D;_PZ_A7'VTUI)+I\
M>B8@LYKF#[7:FWE2&&565_D)0!'.W!4@9R#PW#`'H%96L:);:K/9S7+X2V9B
MRDD!T(Y!P1CD*<^WN:U:XGX@9063&>!(W^299EDVM$)8I'W%$<!2$V'=@'>!
MG)H`Z;2K33;2-QIJKY;X8LCEU/4<$DC\JT*P/#K0/?:J]O:BSC,D8^S^4T9/
MR_ZPJ5&"P('&?N#G.0-^@#EX/#=Y;:XM]::G`]LDEU)]GEMR2'E.2-X8<!@.
M"I.,\ULZ+8QZ;H=C8Q/(Z6\*QAI%VL<#&2.WTKCXYK72[O4(8-4N+;57OIG`
M@M9)XIM[LRH5V[790<L$(8`<D`5VNFW/VS3+6Y\Z&?S8E?S800CY&<J"20/K
M0!9=%=&1AE6&"#W%<O8^&M"L&D@>7[5,DK.BF5FD12<A2`V3CUQTZ^M='=C=
M9SJ)#&3&PWJ,E>.H^E>90:AI$UGI>E6]MI$4^]62_MR[$;&&Z1"(@=QSW(^\
M<D]P#U.L[6[!]0L5$4R0S02I<1/(NY-R'(W#(R/QXZ]JT:Y_QE]G700]V\`M
MTN(GDCN"1'*H8?(Q`/!]QC.*`(M*TV_BNM,;4GM%^QPR16Z6F]MX(499B!CA
M>F.3SGM72UPND7-I<>++:UTR]6:QL_,*Q.KAH"Z`[%RN"G.1S\O3IC'=4`8^
MJ:)IEY>+?W^`L<11]TA53DC!)R,8Y'_`JN:;;6=I;&*Q0K#NSU8@D@<@GJ.G
M(XKC?$7V6T\:17-W=6;VI6.:YM9@Y<(B3*&"A2'^:3/.,%:WO"!B?29I[=HQ
M!/<O+%#$#LA4X^49`_WCQC+'K0!T%<8GA[6(+R=DDTY[.:Q%DTO[SS!$I<H0
M@!!;#G.#\QP>,8KLZX"#5K#3+*T33?$*PR_)!)"]N\\!E'#8Z,O(/0X]LT`=
M_1110!S_`(-_Y`=S_P!A74O_`$MFHH\&_P#(#N?^PKJ7_I;-10`>'O\`D.>+
M/^PK'_Z16M=!7/\`A[_D.>+/^PK'_P"D5K704`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`&?>:+8W^HVU]<0J\T"/&NX`JRMC(8$<\@$>GXFKD%O!;1
M^7;PQQ)G.V-0HS]!4E%`!65#X<TJ"\O+D6<+-=2"217C5E#XP2..,\9]3SU)
MK5HH`15"J%4`*!@`#@"JVI:=:ZMIT]C>Q"2WF4JRG^8]".H/8U:HH`IVFEV5
MDL?DVT0D10OFB-0YXQDD`<FKE%%`%#4M&LM6-LUW$&>VE$L;8!((ZCD=""01
M[_2K,%I;6H86]O%"&Z^6@7/Y5-10`5EOH%E*VIB12T6HLLDR9QB15"[U(Y#8
M1.>Q4$<UJ44`9?A_1AH.D"P%U)='SIIFFE`#,9)6D.<<=7-:E<;XA\:7&B^*
M+?2([2*3S1;&)&8B2Y\R5D?R_P#KFH#MUX/.WK72Z7>MJ%O)<X3RC,Z0E3G<
MBL5W'ZD$_0B@"E<>'8;G2K6RDG<O:,IAGV@,J@_=XZ@J-I]>O6MJN63XC^$9
M-3N]-&M1"[LS,+A'C=?*\K_6$DKC`]<X/.,TVP^)7@_4]/EOK/6XI+>*2.*0
M^7(K(SL%7*E0P!8@;L8]Z`-^\L3=7%I.EP\,EO)NRH!WJ1AE.1T/MSP*BMM'
MAM-9N=1A8J;A`KQ`?+N!R7'N>,_3/7-4=8\:^'?#\MU%JNIQVSVL:22AD8[0
MY8+C`.2=K?*,GCI63>_$73)O#5KK?AZ>'4;>;48;%B0R;"[A3D$`@@$'D<\4
M`=K6>=)C.IW-V96,5U"(I[<@%'QD!NF0<$CT/'I7.:?\4/#=]X@O-$>XE@O;
M?4#IZ*\#E9).WS!=JY97`!()V$UTFF:S8:S]K^P3^<+2X>UF.QE"RK]Y02!N
MQGJ,B@!FBZ3_`&-:RP?:I;GS)FE\R7&[G'!(ZXQU[UI444`8J^'8X;"[M+:[
MF@\]I"DH56>%9&W.JD@\$ECSG&?:M6UMHK.TAM8%VPPQK&B^B@8`_(5+10!6
MU"QM]3TVZL+I-]O<Q-#*N<95@01^1JH=%C)M@)F54F$\X5%'VF10`&?CL5!X
MQT':M2B@`JE>:7;W]PDEP`Z")X7B905D5RI(/XJ*NT4`4[2Q-O=W=T\[S27#
M#[P`"(OW4&.PR3D\Y)JY110!DQ:!!"]PZ2$EYWNK<NBL;:9U96="1WW,><]3
MV.*NZ?8P:9IUO8VP80V\8C3<<G`&.3ZU9HH`*Q4\.6\/B.+5K>0PJL<H>V5?
MD9W*Y<>A^7GUZ]>NU10`4R:&*XA>&:-)(I%*NCKD,#U!!ZT^B@#(T70_[&FO
MW^V2W`NI5=?-`S&JH$"Y_BP%')Y]<GDZ]%%`&7K>BKK%H46YEM+A598[B+JH
M88*D'AE/=3Z`\$`B]:0"ULX+<-N$4:INQC.!C-344`%8=WX9@FU6"^MKB2UV
MSK//`@!CG8=&([-_M#J.N>,;E%`!1110!S_@W_D!W/\`V%=2_P#2V:BCP;_R
M`[G_`+"NI?\`I;-10`>'O^0YXL_["L?_`*16M=!7/^'O^0YXL_["L?\`Z16M
M=!0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`9VN6VHWFFM:Z9<1V\LSJDD[YS'&3\Y08.7QG&>,G/;!P="\
M,:IHWB1I(KP1Z'%"8H;47,DFY<((QY;#9%L"L,H27W9;FNOHH`X#3O`-[!H7
MBRQGN+,3ZOK$VHVTBJ9%52RLBR`@9Y4@@<8)YK*OO!US=1:QKWQ"U'1+7S=+
M.G?\2\-'"B%PRNSR<E]P7`_GFO5**`/(?"VB>-;_`,%?\)!:WMO:>)M5N(Y;
MD7Z,J/;QJ42/Y?F3(^?(YY/3-7X/ASK4>BWMI+>V4MQ<Z]!JIDWR[=J^677Y
MMS9RK8R3QC)%>GT4`>4>)M!ET;2/%TVK:CIMO8WMZ-2TB0,WV@7@0%5VGAN8
MQA5R3\WT'=>#M+.D>%;""12+F1/M%T3U:>0[Y#_WTQX[5NT4`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`<_X-_Y`
M=S_V%=2_]+9J*/!O_(#N?^PKJ7_I;-10!5T?4K"S\0>*X[J]MH'.J1L%EE52
M1]CMN<$^U;7]NZ/_`-!6Q_\``A/\:T**`,_^W='_`.@K8_\`@0G^-']NZ/\`
M]!6Q_P#`A/\`&M"B@#/_`+=T?_H*V/\`X$)_C1_;NC_]!6Q_\"$_QK0HH`S_
M`.W='_Z"MC_X$)_C1_;NC_\`05L?_`A/\:T**`,_^W='_P"@K8_^!"?XT?V[
MH_\`T%;'_P`"$_QK0HH`S_[=T?\`Z"MC_P"!"?XT?V[H_P#T%;'_`,"$_P`:
MT**`,_\`MW1_^@K8_P#@0G^-']NZ/_T%;'_P(3_&M"B@#/\`[=T?_H*V/_@0
MG^-']NZ/_P!!6Q_\"$_QK0HH`S_[=T?_`*"MC_X$)_C1_;NC_P#05L?_``(3
M_&M"B@#/_MW1_P#H*V/_`($)_C1_;NC_`/05L?\`P(3_`!K0HH`S_P"W='_Z
M"MC_`.!"?XT?V[H__05L?_`A/\:T**`,_P#MW1_^@K8_^!"?XT?V[H__`$%;
M'_P(3_&M"B@#/_MW1_\`H*V/_@0G^-']NZ/_`-!6Q_\``A/\:T**`,_^W='_
M`.@K8_\`@0G^-']NZ/\`]!6Q_P#`A/\`&M"B@#/_`+=T?_H*V/\`X$)_C1_;
MNC_]!6Q_\"$_QK0HH`S_`.W='_Z"MC_X$)_C1_;NC_\`05L?_`A/\:T**`,_
M^W='_P"@K8_^!"?XT?V[H_\`T%;'_P`"$_QK0HH`S_[=T?\`Z"MC_P"!"?XT
M?V[H_P#T%;'_`,"$_P`:T**`,_\`MW1_^@K8_P#@0G^-']NZ/_T%;'_P(3_&
MM"B@#/\`[=T?_H*V/_@0G^-']NZ/_P!!6Q_\"$_QK0HH`S_[=T?_`*"MC_X$
M)_C1_;NC_P#05L?_``(3_&M"B@#/_MW1_P#H*V/_`($)_C1_;NC_`/05L?\`
MP(3_`!K0HH`S_P"W='_Z"MC_`.!"?XT?V[H__05L?_`A/\:T**`,_P#MW1_^
M@K8_^!"?XT?V[H__`$%;'_P(3_&M"B@#/_MW1_\`H*V/_@0G^-']NZ/_`-!6
MQ_\``A/\:T**`,_^W='_`.@K8_\`@0G^-']NZ/\`]!6Q_P#`A/\`&M"B@#/_
M`+=T?_H*V/\`X$)_C1_;NC_]!6Q_\"$_QK0HH`S_`.W='_Z"MC_X$)_C1_;N
MC_\`05L?_`A/\:T**`,_^W='_P"@K8_^!"?XT?V[H_\`T%;'_P`"$_QK0HH`
MS_[=T?\`Z"MC_P"!"?XT?V[H_P#T%;'_`,"$_P`:T**`.=\%2)+X?FDC=71]
14U%E93D$&\FP0:*Z*B@#_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>logo1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo1.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``^`,0#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^FEL>U>5
M_%+7?&'ABZM[_2+XII<HV./(1O*D]R03@]OI7$:+\7O$D>M6C:O?"?3O,`N(
MU@0$H>#@@=NOX5T0PTYPYXF$L1&,N5HL^+?B]K=QK,L6A7"VEE`Y1'"!FEP>
MIR.`?05Z'\,?'TGBZSGM+V(+J%HJF1UX6522,@=CQR*\HU_X:ZW%J4D^C63:
MAI=RWG6L]NP;*-RH/.>A^E:^G6^H?"GPQ=:G>;(];U91!:6XPQ@"Y+.W8]1Q
MSV]ZZJE.C*FE#?H80G44VY;'T`.E+7S/!\5/'5U<16\.I!YI7"(@MH\LQ.`/
MN^M=]XZ\1>+/!_A31&;5E?4YI'%S,($P>,@`8QQG&>]<\L).,E%M79NL1%IO
ML>M45\Q_\+<\:_\`067_`,!H_P#XFC_A;GC7_H*K_P"`T?\`\35_4:OD3];A
MYGTY17S'_P`+<\:_]!5?_`:/_P")H_X6YXU_Z"J_^`T?_P`31]1J^0?6X>9]
M.45\Q_\`"W/&O_057_P&C_\`B:]%^$OC/7O%&H:G%J]X)T@B1HP(D3!)(/0"
MHJ82I3BY2'#$1E+E1ZO12"EKE.@**XSX@:[J.APV+Z?/Y1E9P_R!LX`QU'O6
MGX-U*[U;PU;WE[+YD[LX9MH&<,0.![5N\/)4E6Z,YHXJ$J[H).Z5_(Z"BBBL
M#I"BJ&MW,MGH5_<P-MEBMW=&QG!"D@UP_@?Q1K&L:Y);WUV)8A;LX7RU'.1S
MP/>MZ>'E.G*HMHG-5Q4*56-*5[R/1Z*0<BEK`Z0HHHH`****`,W7M'M]>T2[
MTNZ7,5Q&4)[J>Q'N#@U\H:_HMUX=URZTJ[_UMN^W=C`=>S#V(YK[!KROXQ>#
M6U;31KUFH^TV*'SU`YDBS_->3],UV8.M[.?*]F<V)I<T>9;HK_"+QK!-X?FT
MC495B.F1&5)7/!@R<Y_W?Y$5Y=XY\3R^*_$]S>"1S9H?+M4;^&,=_P`3DUSL
M4\L&_P`J1E\Q&C;:?O*>H/L:W/!_AB[\6Z_%8P#$0(>XE[)'GG\3T%=RHPI3
ME59R.I*<53/1/@UX*9I/^$EU&W4Q@;;$..<YYD_H/QKT[Q1X/TSQ?;V\.I^=
MM@8NGE/MY(Q6Q965OI]E#9VL2Q6\*!(T7HH'058KRZE:4ZG/<]"%)1ARL\Y_
MX4GX4]+W_O\`_P#UJ\C^)/ANP\+>*ET[3A((#;)(?,;<<DL.OX5]1U\Y_&[_
M`)'Y?^O*+_T)ZZ<'5G*K9LPQ%.,872,KX9^&=/\`%?B>6PU(2F%+5IAY;[3N
M#*/_`&8UZU_PI3PGZ7O_`'__`/K5Y]\#?^1ZN/\`L'R?^AQU]#T8NM.-2R88
M>G%PNT?+_P`2O#-AX4\31Z?IPD$#6R2GS'W')9AU_`5UGP%_Y"NL_P#7"/\`
M]"-9?QP_Y'F'_KQC_P#0GK4^`G_(5UG_`*X1_P#H1KHJ-O"7?8QBDJ]D>Z#M
M2T@[4M>0>BCSKXK?\>VF?[\G\A6KX$NH+/P-;S7,J11(\FYG.`/G-97Q6_X]
MM,_WY/Y"N6T2RU7Q-##H\$OEV5N"[$CY022<GU//%>U"DJF"BF[)/5_>?/U*
MSI9A-Q5VTDE]QZ>?&OAT/M.J1Y_W&Q^>*UK/4;/4(?.M+F.>/IN0YK@'^%:>
M3\FJ/YH'5HQC\JY=)M4\$:^T>[YEY90?DE0]_P#/I6"PE"LFJ$[R[,W>.Q-!
MIXF%HOJO^'/:;DP?99?M&SR-A\S?TVXYS[5DZ4_AU[IO[)%CYX4EOLX4-M_#
MM3M0O(K_`,(7=W#S'+9.Z\^J$UY]\,>?$-Q_UZG_`-"6N>E0YJ,YMVY>AU5L
M5R5Z<$DU+J>M@\5EWWB31]-E,=WJ$,<@ZIG)'X"N;\=^*Y-(C73[)]MU,FYY
M%/,:^WN:YCP[X'N]>C%_>7!A@E^8'&YY!Z_2KHX2+I^UK2M'IW9G7QT_:^QP
M\>:2W[(]$B\9>'IV"IJD.2<#<&7^8K:61'4,K!E/0CH:\VU+X8".W9M.O69P
M"2DP'S>P(Z5F^$?%-UHFIC3-2:3[,S^7M<_ZE\_RJI82G4@Y8>5[;I[DQQU:
ME44,5&U]FMCUW-%-W#O17GGJCJY?QWXGM?#'ANZN)BC3RHT=O"W/F.1CIW`S
MD^U='/-'!$\LKA(T4LS,<``=S7S'\2/%I\5>)Y6A?=86N8K;T([M^)_3%=&&
MH^UGKLC&O4Y(^9Q[L7D9B`"23@#CFNT^&/BV/PKXD/VH?Z%>A896'\!S\K?0
M9/YU=^''P]/BJVU*\O%:.U$#16LA[S'^+W"_UKA]4TVYT?4KC3KQ=MQ;R&-P
M.A([CV/6O5<H5>:D<"4H6F?8RL&4%2"",@CO2UYI\)/&:ZYHRZ-=N3?V,8`9
MC_K(\X!^HX!_"O2P:\6I!PDXL].$E)70M?.?QN_Y'Y?^O*+_`-">OHROG/XW
M?\C\O_7E%_Z$]=&"_BF.*_ADGP-_Y'JX_P"P?)_Z''7T/7SQ\#?^1ZN/^P?)
M_P"AQU]#TL9_%88;^&?._P`</^1YA_Z\8_\`T)ZU/@)_R%=9_P"N$?\`Z$:R
M_CA_R/,/_7C'_P"A/6I\!3_Q-M9_ZX1?^A&NR?\`N?R.=?[Q\SW0=J6D%+FO
M)/0/._BM_P`>VF?[\G\A5_X:6R1^&3,`-TT[$GV'']#6?\5O^/;3/]^3^0K6
M^'$BMX2B1?O),X;VYS_6O5FW_9\?7]6>)32_M25^WZ(Z[`KSGXIV<?DV%Z``
M^YHF/J,9'\C^=>C9KSGXIW<?D6%F#F3>92/;&!_.N?+K_686.O-+?5)W_K4?
MX5N6N/AKJ:.2?)2>-<]ALS_6L?X7_P#(Q7/_`%ZM_P"A+6UX7M)+;X::B[C'
MGQS2K]-N!_*L7X7_`/(Q7'_7J?\`T):[7;V>(MW/-2?M<-?L9^OH=5\?W%NS
M<2720`^@X6O9K>".WACAB0+'&H50.P%>-:V_]E_$.:>13MBO%G/N,AOZU[-#
M,DR+)&P9&`96'0@UAF%_9TK;6.G*[>UK7WYO\R0@8KQKXA6(L_%<DB#`N(UE
MX]>A_49KV4FO'?B+>K=>*6B0Y^SQ+&?][DX_6EE=_;Z=BLYM]6UWOH>H:'>-
M?:%8W3@[I8%9OKCFBD\/VSV7A[3[:0?/'`@;ZXHKSZBCSNW<]2ES>SC?LCSG
MXQ^-!8V'_".V3CS[I<W+`_<C_N_4_P`J\6T72;G7=:M=,M!^_N)`BG'"^I/L
M!S7TY>?#_P`,:C>S7EWI<4MQ,V]W8DDFI](\%>'M#O?MFG:9#!<`%1(O4`]:
MZZ6)A2I\L5J83H2G.[>A=T'1[?0=$M-+M1B*WC"9_O'J3^)R?QKR[XT^$!+;
MQ>(K"WS*GR7FT<E<?*WX8Q]#7LF*ANK:&\MI;:=`\,J%'0]&!&"*YJ=64)\Y
MM.FI1Y3Y%T'6KKP_K5MJ5G(5DA<$@'[ZYY4^Q%?5N@ZU9^(-(@U*Q?=!,N1Z
MJ>X/N*Q/^%9>$/\`H"P9_&MW1M$T_0;1K33;=;>`N7*+TW'&3^@K?$UJ=6S2
MU,Z-*=/1O0T:^<_C=_R/R_\`7E%_Z$]?1E<_J_@W0->OA>:GIT5Q<!`F]LYV
MC.!^IK/#U52GS,NM!SCRH\7^!O\`R/5Q_P!@^3_T..OH>L'2/!V@Z!>-=Z7I
M\5M.R&,NN<[202/T%;XI5ZBJ3YD%&#A&S/G;XX?\CU#_`->,?_H3UPNEZWJ6
MBO(^FWLMJ\@`<QMC('2OJ36/!N@:_>B[U/3HKB<($#MG.T9('ZFJ'_"LO!__
M`$!8/UKKIXR$::@T<\\-*4W),^?/^$[\4_\`0<O?^_E'_"=^*?\`H.7O_?RO
MH/\`X5EX/_Z`L'ZT?\*R\'_]`6#]:KZY1_E%]7J?S'A6F:_JNM22+J5_/="(
M`H)6SMSUQ7=^&-=O/"TD<T\4CZ==+G`Z$\C(/KQBO0+?X>^%K1F,&DPH6'.,
M\UIOX?TR32TTYK1#:H<K&?X3G.1^=:2Q]&5-4W'3K_P#C>75O;.M&5GT_P"#
MY'/R_$O1A$2D=PSCHNS&?QKAYAJ/C?Q(9(HR`V%!_AB0>OZ_G7H7_"OO#^_=
M]GDSZ>8<5NZ;I=EI=OY-G`D29R0HZFL8XG#T+NBFY>?0N>$Q.(:CB)+E7;J4
MM1M(['P?=VL0Q'#9.B_0(:\^^%__`",5SS_RZG_T):]7G@CN;:2"50T<BE&4
M]P>#6=IWAW2M*G::RM$AD9=A9>X_R*QI8A1HU*;WD=%?"2G7IU([1.4^(/AB
M:_VZI91[I(TVS(HY8=B/IS69X7\>+I-FNGZG%(R1?*DB#)4>A%>I`"L'4/!^
MBZE.T\]FHD8_,R':36E+%4W3]E75TMK;HRK8*I&K[?#NS>Z>S,'4?B7IRVKB
MQAFDF((4NNT`]C7,>&?#U[XCU@:A>!OLPE$LLCC_`%IST%=Y%X!\/Q-N^R,^
M.<.Y(KI(88X(4BB1411@*HP!5?6J5&#CAT[O=LE8*O7FI8EJRV2'8QQBBGXH
&KSCUC__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
